0001493152-21-004781.txt : 20210225 0001493152-21-004781.hdr.sgml : 20210225 20210225074145 ACCESSION NUMBER: 0001493152-21-004781 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 100 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210225 DATE AS OF CHANGE: 20210225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Provention Bio, Inc. CENTRAL INDEX KEY: 0001695357 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38552 FILM NUMBER: 21676442 BUSINESS ADDRESS: STREET 1: 55 BROAD STREET, 2ND FLOOR CITY: RED BANK STATE: NJ ZIP: 07701 BUSINESS PHONE: 908-428-9136 MAIL ADDRESS: STREET 1: 55 BROAD STREET, 2ND FLOOR CITY: RED BANK STATE: NJ ZIP: 07701 FORMER COMPANY: FORMER CONFORMED NAME: Provention Inc. DATE OF NAME CHANGE: 20170120 10-K 1 form10-k.htm
0001695357 false Large Accelerated Filer 2020 FY --12-31 P7Y P7Y P5Y P5Y 0001695357 2020-01-01 2020-12-31 0001695357 2020-06-30 0001695357 2021-02-22 0001695357 2020-12-31 0001695357 2019-12-31 0001695357 2019-01-01 2019-12-31 0001695357 2018-01-01 2018-12-31 0001695357 PRVB:ConvertibleRedeemablePreferredStockMember 2017-12-31 0001695357 us-gaap:CommonStockMember 2017-12-31 0001695357 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001695357 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001695357 us-gaap:RetainedEarningsMember 2017-12-31 0001695357 2017-12-31 0001695357 PRVB:ConvertibleRedeemablePreferredStockMember 2018-01-01 2018-12-31 0001695357 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001695357 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001695357 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001695357 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001695357 PRVB:ConvertibleRedeemablePreferredStockMember 2018-12-31 0001695357 us-gaap:CommonStockMember 2018-12-31 0001695357 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001695357 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001695357 us-gaap:RetainedEarningsMember 2018-12-31 0001695357 2018-12-31 0001695357 PRVB:ConvertibleRedeemablePreferredStockMember 2019-01-01 2019-12-31 0001695357 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001695357 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001695357 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001695357 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001695357 PRVB:ConvertibleRedeemablePreferredStockMember 2019-12-31 0001695357 us-gaap:CommonStockMember 2019-12-31 0001695357 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001695357 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001695357 us-gaap:RetainedEarningsMember 2019-12-31 0001695357 PRVB:ConvertibleRedeemablePreferredStockMember 2020-01-01 2020-12-31 0001695357 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001695357 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001695357 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001695357 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001695357 PRVB:ConvertibleRedeemablePreferredStockMember 2020-12-31 0001695357 us-gaap:CommonStockMember 2020-12-31 0001695357 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001695357 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001695357 us-gaap:RetainedEarningsMember 2020-12-31 0001695357 PRVB:SeriesAConvertibleRedeemablePreferredStockMember 2017-04-01 2017-04-30 0001695357 PRVB:SeriesAConvertibleRedeemablePreferredStockMember 2017-04-30 0001695357 us-gaap:IPOMember 2018-07-01 2018-07-31 0001695357 us-gaap:IPOMember 2018-07-31 0001695357 PRVB:MDBCapitalGroupLLCMember us-gaap:IPOMember 2018-07-31 0001695357 us-gaap:IPOMember PRVB:SeriesAConvertibleRedeemablePreferredStockMember 2018-07-31 0001695357 2019-09-01 2019-09-30 0001695357 2019-09-30 0001695357 us-gaap:OptionMember 2019-09-01 2019-09-30 0001695357 us-gaap:OptionMember 2019-09-30 0001695357 PRVB:AmgenIncMember us-gaap:PrivatePlacementMember 2019-09-01 2019-09-30 0001695357 PRVB:AmgenIncMember us-gaap:PrivatePlacementMember 2019-09-30 0001695357 PRVB:AtTheMarketMember srt:MaximumMember 2019-08-01 2019-08-31 0001695357 PRVB:AtTheMarketMember 2020-04-01 2020-06-30 0001695357 PRVB:UnderwrittenPublicOfferingMember 2020-06-29 2020-06-30 0001695357 PRVB:UnderwrittenPublicOfferingMember 2020-06-30 0001695357 PRVB:UnderwritersOptionMember 2020-06-29 2020-06-30 0001695357 PRVB:UnderwritersOptionMember 2020-06-30 0001695357 2020-06-01 2020-06-30 0001695357 us-gaap:SubsequentEventMember PRVB:UnderwritersOptionMember 2021-01-01 2021-01-31 0001695357 us-gaap:SubsequentEventMember PRVB:UnderwritersOptionMember 2021-01-31 0001695357 us-gaap:SubsequentEventMember PRVB:UnderwritersOptionMember 2021-02-01 2021-02-28 0001695357 us-gaap:SubsequentEventMember PRVB:UnderwritersOptionMember 2021-02-28 0001695357 us-gaap:SubsequentEventMember 2021-02-01 2021-02-28 0001695357 srt:MinimumMember 2020-01-01 2020-12-31 0001695357 srt:MaximumMember 2020-01-01 2020-12-31 0001695357 us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001695357 us-gaap:USTreasurySecuritiesMember 2019-12-31 0001695357 PRVB:MacroGenicsIncMember PRVB:AssetPurchaseAgreementMember 2018-05-31 0001695357 PRVB:MacroGenicsIncMember PRVB:AssetPurchaseAgreementMember 2018-05-01 2018-05-31 0001695357 PRVB:MacroGenicsIncMember PRVB:AssetPurchaseAgreementMember PRVB:BiologicsLicenseApplicationMember 2018-05-01 2018-05-31 0001695357 PRVB:MacroGenicsIncMember PRVB:LicenseAgreementMember 2018-05-01 2018-05-31 0001695357 PRVB:MacroGenicsIncMember PRVB:AssetPurchaseAgreementMember srt:MaximumMember 2018-05-01 2018-05-31 0001695357 PRVB:MacroGenicsIncMember PRVB:LicenseAgreementMember 2018-05-31 0001695357 PRVB:MacroGenicsIncMember PRVB:LicenseAgreementMember PRVB:FirstIndicationMember 2018-05-01 2018-05-31 0001695357 PRVB:MacroGenicsIncMember PRVB:LicenseAgreementMember PRVB:SecondIndicationMember 2018-05-01 2018-05-31 0001695357 PRVB:MacroGenicsIncMember 2018-05-01 2018-05-31 0001695357 PRVB:MacroGenicsAssetPurchaseAgreementAndMacroGenicsLicenseAgreementMember 2018-05-31 0001695357 PRVB:MacroGenicsAssetPurchaseAgreementAndMacroGenicsLicenseAgreementMember 2018-05-01 2018-05-31 0001695357 PRVB:MacroGenicsIncMember 2019-07-31 0001695357 PRVB:MacroGenicsIncMember 2019-07-01 2019-07-31 0001695357 PRVB:AmgenIncMember PRVB:LicenseAndCollaborationAgreementMember 2018-11-30 0001695357 PRVB:AmgenIncMember PRVB:LicenseAndCollaborationAgreementMember 2018-11-01 2018-11-30 0001695357 PRVB:AmgenIncMember 2018-11-01 2018-11-30 0001695357 PRVB:LicenseAgreementMember PRVB:VactechMember 2017-04-30 0001695357 PRVB:LicenseAgreementMember PRVB:VactechMember us-gaap:ResearchAndDevelopmentExpenseMember 2017-04-01 2017-04-30 0001695357 PRVB:LicenseAgreementMember PRVB:VactechMember PRVB:FirstEighteenMonthsMember 2017-04-01 2017-04-30 0001695357 PRVB:LicenseAgreementMember PRVB:VactechMember 2017-04-01 2017-04-30 0001695357 PRVB:LicenseAgreementMember PRVB:VactechMember us-gaap:SubsequentEventMember PRVB:DosingOfFirstPatientInPhaseOnePROVENTStudyMember 2021-01-01 2021-01-31 0001695357 PRVB:IntravaccDevelopmentServicesAgreementMember PRVB:EuroMember 2020-01-01 2020-12-31 0001695357 PRVB:IntravaccDevelopmentServicesAgreementMember 2020-01-01 2020-12-31 0001695357 PRVB:LicenseDevelopmentandCommercializationAgreementMember PRVB:JanssenPharmaceuticaNVMember PRVB:FirstIndicationMember 2017-04-01 2017-04-30 0001695357 PRVB:LicenseDevelopmentandCommercializationAgreementMember PRVB:JanssenPharmaceuticaNVMember PRVB:SecondIndicationMember 2017-04-01 2017-04-30 0001695357 PRVB:LicenseDevelopmentandCommercializationAgreementMember PRVB:JanssenPharmaceuticaNVMember 2017-04-01 2017-04-30 0001695357 PRVB:StockOptionsMember 2020-01-01 2020-12-31 0001695357 PRVB:StockOptionsMember 2019-01-01 2019-12-31 0001695357 PRVB:StockOptionsMember 2018-01-01 2018-12-31 0001695357 PRVB:WarrantsMember 2020-01-01 2020-12-31 0001695357 PRVB:WarrantsMember 2019-01-01 2019-12-31 0001695357 PRVB:WarrantsMember 2018-01-01 2018-12-31 0001695357 us-gaap:FairValueInputsLevel1Member us-gaap:CashAndCashEquivalentsMember 2020-12-31 0001695357 us-gaap:FairValueInputsLevel2Member us-gaap:CashAndCashEquivalentsMember 2020-12-31 0001695357 us-gaap:FairValueInputsLevel3Member us-gaap:CashAndCashEquivalentsMember 2020-12-31 0001695357 us-gaap:CashAndCashEquivalentsMember 2020-12-31 0001695357 us-gaap:FairValueInputsLevel1Member PRVB:InvestmentsInCorporateDebtSecuritiesMember 2020-12-31 0001695357 us-gaap:FairValueInputsLevel2Member PRVB:InvestmentsInCorporateDebtSecuritiesMember 2020-12-31 0001695357 us-gaap:FairValueInputsLevel3Member PRVB:InvestmentsInCorporateDebtSecuritiesMember 2020-12-31 0001695357 PRVB:InvestmentsInCorporateDebtSecuritiesMember 2020-12-31 0001695357 us-gaap:FairValueInputsLevel1Member us-gaap:CashAndCashEquivalentsMember 2019-12-31 0001695357 us-gaap:FairValueInputsLevel2Member us-gaap:CashAndCashEquivalentsMember 2019-12-31 0001695357 us-gaap:FairValueInputsLevel3Member us-gaap:CashAndCashEquivalentsMember 2019-12-31 0001695357 us-gaap:CashAndCashEquivalentsMember 2019-12-31 0001695357 us-gaap:FairValueInputsLevel1Member PRVB:InvestmentsInUSTreasurySecuritiesMember 2019-12-31 0001695357 us-gaap:FairValueInputsLevel2Member PRVB:InvestmentsInUSTreasurySecuritiesMember 2019-12-31 0001695357 us-gaap:FairValueInputsLevel3Member PRVB:InvestmentsInUSTreasurySecuritiesMember 2019-12-31 0001695357 PRVB:InvestmentsInUSTreasurySecuritiesMember 2019-12-31 0001695357 PRVB:TwoThousandSeventeenPlanMember 2020-12-31 0001695357 PRVB:TwoThousandSeventeenPlanMember 2020-01-01 2020-12-31 0001695357 us-gaap:SubsequentEventMember PRVB:TwoThousandSeventeenPlanMember srt:MaximumMember 2021-01-02 0001695357 PRVB:TwoThousandAndTwentyInducementPlanMember 2020-10-31 0001695357 PRVB:TwoThousandAndTwentyInducementPlanMember 2020-10-01 2020-10-31 0001695357 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001695357 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001695357 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0001695357 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001695357 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001695357 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0001695357 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001695357 PRVB:StockOptionOneMember 2020-12-31 0001695357 PRVB:StockOptionTwoMember 2020-12-31 0001695357 PRVB:StockOptionTwoMember 2020-01-01 2020-12-31 0001695357 PRVB:SeriesAConvertibleRedeemablePreferredStockMember PRVB:PlacementAgentMember 2017-04-30 0001695357 us-gaap:IPOMember us-gaap:WarrantMember 2018-07-31 0001695357 PRVB:SeriesAOfferingMember 2020-12-31 0001695357 PRVB:SeriesAOfferingMember 2020-01-01 2020-12-31 0001695357 PRVB:MacroGenicsLicenseAgreementAndMacroGenicsAssetPurchaseAgreementMember 2018-05-31 0001695357 PRVB:MacroGenicsLicenseAgreementAndMacroGenicsAssetPurchaseAgreementMember PRVB:MacroGenicsIncMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-12-31 0001695357 PRVB:MacroGenicsLicenseAgreementAndMacroGenicsAssetPurchaseAgreementMember PRVB:MacroGenicsIncMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0001695357 PRVB:MacroGenicsIncMember 2020-01-01 2020-12-31 0001695357 PRVB:MacroGenicsIncMember 2018-05-07 0001695357 PRVB:MacroGenicsIncMember us-gaap:MeasurementInputOptionVolatilityMember 2018-05-07 0001695357 PRVB:MacroGenicsIncMember us-gaap:MeasurementInputExpectedDividendRateMember 2018-05-07 0001695357 PRVB:MacroGenicsIncMember us-gaap:MeasurementInputExpectedTermMember 2018-05-07 0001695357 PRVB:MacroGenicsIncMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2018-05-07 0001695357 PRVB:MDBCapitalGroupLLCMember 2020-01-01 2020-12-31 0001695357 PRVB:MDBCapitalGroupLLCMember 2018-07-19 0001695357 PRVB:MDBCapitalGroupLLCMember us-gaap:MeasurementInputOptionVolatilityMember 2018-07-19 0001695357 PRVB:MDBCapitalGroupLLCMember us-gaap:MeasurementInputExpectedDividendRateMember 2018-07-19 0001695357 PRVB:MDBCapitalGroupLLCMember us-gaap:MeasurementInputExpectedTermMember 2018-07-19 0001695357 PRVB:MDBCapitalGroupLLCMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2018-07-19 0001695357 PRVB:MDBCapitalGroupLLCMember us-gaap:IPOMember 2020-12-31 0001695357 PRVB:MDBCapitalGroupLLCMember us-gaap:IPOMember 2020-12-01 2020-12-31 0001695357 us-gaap:WarrantMember PRVB:CashlessBasisMember us-gaap:IPOMember 2020-12-31 0001695357 us-gaap:WarrantMember PRVB:CashlessBasisMember us-gaap:IPOMember 2020-01-01 2020-12-31 0001695357 us-gaap:WarrantMember us-gaap:IPOMember 2020-12-31 0001695357 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001695357 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001695357 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001695357 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001695357 us-gaap:OfficeEquipmentMember 2020-12-31 0001695357 us-gaap:OfficeEquipmentMember 2019-12-31 0001695357 PRVB:ClinicalEquipmentMember 2020-12-31 0001695357 PRVB:ClinicalEquipmentMember 2019-12-31 0001695357 us-gaap:ConstructionInProgressMember 2020-12-31 0001695357 us-gaap:ConstructionInProgressMember 2019-12-31 0001695357 PRVB:AccruedExpensesMember 2020-12-31 0001695357 us-gaap:StateAndLocalJurisdictionMember 2020-01-01 2020-12-31 0001695357 stpr:NJ 2020-12-31 0001695357 PRVB:NewJerseysTechnologyBusinessTaxCertificateTransferProgramMember 2020-01-01 2020-12-31 0001695357 us-gaap:DomesticCountryMember 2020-12-31 0001695357 us-gaap:DomesticCountryMember 2020-01-01 2020-12-31 0001695357 us-gaap:StateAndLocalJurisdictionMember 2020-12-31 0001695357 us-gaap:ResearchAndDevelopmentExpenseMember 2020-12-31 0001695357 us-gaap:StateAndLocalJurisdictionMember stpr:NJ 2020-01-01 2020-12-31 0001695357 us-gaap:StateAndLocalJurisdictionMember stpr:NJ 2018-01-01 2018-12-31 0001695357 PRVB:AssetPurchaseAgreementMember PRVB:ToleranceTherapeuticsIncMember 2020-01-01 2020-12-31 0001695357 PRVB:AssetPurchaseAgreementMember PRVB:ToleranceTherapeuticsIncMember 2018-01-01 2018-12-31 0001695357 PRVB:MDBCapitalGroupLLCMember us-gaap:IPOMember 2018-07-02 2018-07-31 0001695357 PRVB:MDBCapitalGroupLLCMember PRVB:DirectorsMember us-gaap:CommonStockMember 2018-07-31 0001695357 us-gaap:SubsequentEventMember PRVB:UnderwritersOptionMember 2021-01-01 2021-02-28 0001695357 us-gaap:SubsequentEventMember PRVB:LicenseAgreementMember PRVB:HangzhouZhongmeiHuadongPharmaceuticalCoLtdMember PRVB:ResearchDevelopmentAndManufacturingFundingMember 2021-02-01 2021-02-25 0001695357 us-gaap:SubsequentEventMember PRVB:LicenseAgreementMember PRVB:HangzhouZhongmeiHuadongPharmaceuticalCoLtdMember PRVB:ResearchDevelopmentAndManufacturingFundingMember srt:MaximumMember 2021-02-01 2021-02-25 0001695357 us-gaap:SubsequentEventMember PRVB:LicenseAgreementMember PRVB:HangzhouZhongmeiHuadongPharmaceuticalCoLtdMember srt:MaximumMember 2021-02-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares PRVB:Segment xbrli:pure iso4217:EUR

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 10-K

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM                TO                .

 

Commission file number 001-38552

 

 

 

PROVENTION BIO, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   81-5245912
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)

 

55 Broad Street, 2nd floor, Red Bank, NJ 07701
(Address of registrant’s principal executive offices)

 

(908) 336-0360
(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value   PRVB   The Nasdaq Global Select Market

 

Securities registered pursuant to Section 12(g) of the Act:

None

 

 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐.

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐.

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer ☒ Accelerated filer ☐  
Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in 12b-2 of the Act). Yes ☐ No ☒

 

The aggregate market value of the common stock held by non-affiliates of the Registrant as of June 30, 2020, the last business day of the Registrant’s last completed second quarter, based upon the closing price of the common stock as reported by The Nasdaq Global Select Market on such date was approximately $718.7 million.

 

On February 22, 2021, there were 63,374,738 shares of the registrant’s common stock, $0.0001 par value, outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE:

 

Portions of Provention Bio, Inc.’s definitive proxy statement to be filed pursuant to Regulation 14A within 120 days after the end of the registrant’s fiscal year are incorporated by reference into Part III of this Form 10-K and certain documents are incorporated by reference into Part IV.

 

 

 

 

 

 

PROVENTION BIO, INC.

ANNUAL REPORT ON FORM 10-K

TABLE OF CONTENTS

 

    PAGE
FORWARD-LOOKING STATEMENTS AND RISK FACTOR SUMMARY 2
     
  PART I 4
     
Item 1. Business 4
     
Item 1A. Risk Factors 53
     
Item 1B. Unresolved Staff Comments 86
     
Item 2. Properties 86
     
Item 3. Legal Proceedings 86
     
Item 4. Mine Safety Disclosures 86
     
  PART II 87
     
Item 5. Market for the Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities 87
     
Item 6. Selected Financial Data 88
     
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 88
     
Item 7A. Quantitative and Qualitative Disclosures about Market Risk 98
     
Item 8. Financial Statements and Supplementary Data 98
     
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 99
     
Item 9A. Controls and Procedures 99
     
Item 9B. Other Information 99
     
  PART III 100
     
Item 10. Directors, Executive Officers and Corporate Governance 100
     
Item 11. Executive Compensation 100
     
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters 100
     
Item 13. Certain Relationships and Related Transactions and Director Independence 100
     
Item 14. Principal Accounting Fees and Services 100
     
  PART IV 101
     
Item 15. Exhibits, Financial Statement Schedules 101
     
Item 16. Form 10-K Summary 103
     
Signatures 104

 

1

 

 

FORWARD-LOOKING STATEMENTS AND RISK FACTOR SUMMARY

 

This Annual Report on Form 10-K contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Annual Report on Form 10-K, including, among others, statements regarding the impact of the ongoing COVID-19 pandemic on our business; the timing progress and success of our ongoing and planned clinical trials; our planned engagements with regulatory agencies relating to, and the expected timing of regulatory review of, our product candidates; execution of our business plans; and our current expectations regarding the ability of our cash, cash equivalents and marketable securities to fund our projected operating requirements for at least the next 12 months, are forward-looking statements. The words “believe,” “may,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

 

These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

 

Some of the key factors that could cause actual results to differ from our expectations include the following risks related to our business:

 

  ● We are a clinical stage biopharmaceutical company with a limited operating history.
  ● We have incurred substantial operating losses in each year since our inception and expect to continue to incur substantial losses for the foreseeable future and we may never become profitable or, if achieved, be able to sustain profitability.
  ● We need to raise additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate certain or all of our product development programs or commercialization efforts.
  ● We have a limited number of product candidates and may not be able to acquire additional product candidates in the future.
  ● Although we have received breakthrough therapy designation and priority review from the United States Food and Drug Administration (“FDA”) for teplizumab and we may pursue such expedited pathways for other product candidates, expedited development may not actually lead to a faster development or regulatory review or approval process.
  ● Even though we may obtain or apply for orphan drug designation for a product candidate, we may not be able to obtain orphan drug marketing exclusivity.
  ● We may be unable to obtain or maintain governmental approvals to market our product candidates in the United States, European Union, United Kingdom or in other jurisdictions.
  ●

The results of our PK/PD bridging study for teplizumab, which we conducted to support and bridge the chemistry, manufacturing and controls (“CMC”) comparability assessment between the teplizumab study drug derived from drug substance manufactured by Eli Lilly and teplizumab derived from drug substance manufactured by AGC Biologics, who we plan to use for teplizumab clinical and commercial supply needs moving forward, may be unacceptable to the FDA or regulatory authorities, which may require further CMC development activities, additional clinical studies and information requests by the FDA and could affect the timing of the review of and decision by the FDA of our biologics license application (“BLA”) submission.

  ●

The FDA, European Medicines Agency (“EMA”) or comparable foreign regulatory authorities could require the clearance or approval of a companion diagnostic device for teplizumab for use in at-risk individuals, as a post-marketing commitment or otherwise, which may require substantial financial resources and could delay regulatory approval of teplizumab.

  ● Even if we receive regulatory approval for teplizumab or any of our product candidates, we may not be able to successfully commercialize any approved products, and the revenue that we generate from sales, if any, may be limited.
  ● We have never commercialized a product and are in the process of building and scaling the Company for potential commercialization of a first product candidate, including building our compliance, medical affairs and commercial organization, which, if we are not able to do successfully could negatively impact our business, including the successful commercialization of our product candidates.

 

2

 

 

  ● We currently have a limited commercial organization. If we are unable to establish satisfactory sales, marketing and other commercial capabilities or secure a sales and marketing partner, we may not successfully commercialize any of our product candidates.
  ● We are completely dependent on third parties to manufacture our product candidates, and our commercialization of our product candidates could be halted, delayed or made less profitable if those third parties fail to obtain manufacturing approval from the FDA or comparable foreign regulatory authorities, fail to provide us with sufficient quantities of our product candidates or fail to do so at acceptable quality levels or prices.
  ● We depend on rights to certain pharmaceutical compounds that are licensed to us and any loss of our rights to them could prevent us from developing, commercializing or selling our products.
  ●

The outbreak of COVID-19 has caused delays to our clinical trials. Moreover, the longer the pandemic persists, the more impact it will have on our clinical trials and other business plans and timelines, including our potential U.S. launch of teplizumab under the BLA under review by the FDA. In addition, this pandemic has caused substantial disruption in the financial markets and may adversely impact economies worldwide, both of which could result in adverse effects on our business, operations and ability to raise capital.

  ● Clinical drug development involves a risky, lengthy and expensive process with an uncertain outcome. We may encounter substantial delays in completing our clinical trials which in turn would require additional costs, or we may fail to demonstrate adequate safety and efficacy to the satisfaction of applicable regulatory authorities.
  ● We are generally a virtual company and may be unable to adequately protect our information technology systems from cyber-attacks, which could result in the disclosure of confidential information, damage our reputation, and subject us to significant financial and legal exposure.
  ● We may be unable to protect our intellectual property rights or may infringe on the intellectual property rights of others.
  ● If product liability or other lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.

 

The forward-looking statements included herein are made only as of the date hereof. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligations to update publicly any forward-looking statements for any reason after the date of this Form 10-K to conform these statements to actual results or to changes in our expectations.

 

We may from time to time provide estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information reflected in this Annual Report. Unless otherwise expressly stated, we obtain industry, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.

 

3

 

 

PART I

 

ITEM 1. Business

 

Our Company

 

We are a clinical stage biopharmaceutical company, focused on the development and commercialization of novel therapeutics and innovative approaches aimed at intercepting and preventing immune-mediated diseases. Since our inception, we have devoted substantially all of our efforts to business planning, research and development, conducting clinical trials, pre-commercial activities, recruiting management and technical staff, acquiring operating assets, partnering and raising capital. Our business is subject to significant risks and uncertainties and we will be dependent on raising substantial additional capital before we become profitable and we may never achieve profitability.

 

We have not generated any revenue to date and, through December 31, 2020, we had an accumulated deficit of $177.6 million. Since our inception in October 2016, we have financed our operations primarily through equity offerings. Through these equity offerings, we have raised aggregate net proceeds of approximately $364.2 million, net of underwriting discounts, commissions and other offering expenses. This includes recently completed underwritten public offerings in June 2020, which raised net proceeds of $103.3 million and in January 2021, which when combined with the partial exercise by the underwriters to purchase additional shares in February 2021, raised net proceeds of $102.3 million.

 

We expect that over the next several years we will continue to incur losses from operations as we increase our expenditures in research and development in connection with our regulatory submissions, clinical trials and other development activities, as well as costs to support our commercialization efforts to launch teplizumab, if we receive regulatory approval in the United States. If adequate funds are not available to us on a timely basis, or at all, we may be required to terminate or delay certain development activities.

 

Strategy

 

We preferentially source, transform and advance underdeveloped clinical-stage, or nearly clinical-stage, therapeutic candidates targeting the interception and prevention of immune-mediated disease. Our “predict” and “preempt” therapeutic focus is on identifying product candidates for at-risk individuals and intervening before the targeted disease begins, re-appears, exacerbates or progresses. We believe our experience and expertise in translational medicine, immunology, and the design and execution of rapid go/no-go clinical trials makes us unique in the field of immune-mediated disease.

 

We have access to relevant in-licensing opportunities from industry-leading pharmaceutical companies; innovative, development-stage biotechnology companies; and world-renowned academic centers. We have obtained exclusive worldwide rights to two product candidates from MacroGenics, Inc., the acquisition of teplizumab (PRV-031), a Phase 3 clinical-stage candidate for the interception, delay or prevention of type 1 diabetes (“T1D”), and the in-license of PRV-3279, a Phase 1 candidate for the potential treatment of systemic lupus erythematosus (“SLE”). We also in-licensed an enterovirus vaccine platform, targeting the prevention of Coxsackie Virus B (“CVB”), infections and the onset of T1D and celiac disease that includes PRV-101 from Vactech Ltd., a Finnish biotechnology company. Additionally, we in-licensed PRV-015, a Phase 2 clinical-stage candidate, from Amgen, Inc. targeting celiac disease.

 

Our Focus and Pipeline

 

Inflammation is a natural consequence of most infections, as it is the immune system’s first response to invading pathogens in the event of injury or acute illness. Most of the time, this response is beneficial and well-controlled; helping to repair tissue damage and clear pathogens from the body. In addition to directly damaging tissues and organs, an infection can sometimes result in the excessive release of toxic immune mediators leading to a potentially life-threatening acute pathological immune response. When patients have the requisite genetic predisposition, infections can also trigger chronic autoimmune responses that persist and progress long after the original insult has subsided. These sustained pathological responses have been linked to an increased susceptibility to chronic debilitating and potentially life-threatening diseases like inflammatory bowel disease, diabetes, celiac, SLE, cancer, and certain neurological disorders.

 

4

 

 

Our “predict” and “preempt” therapeutic development focus is on product candidates that intercept the underlying pathological immune and inflammatory responses in susceptible individuals. Our pipeline of product candidates in development includes:

 

  ●

PRV-031: a humanized, anti-CD3 monoclonal antibody (“mAb”) for the delay or prevention of clinical T1D in at-risk individuals and for patients with newly-diagnosed T1D. Teplizumab has been designated by the FDA, as an orphan drug for the treatment of newly-diagnosed T1D. Teplizumab was also granted breakthrough therapy designation from the FDA in August 2019 and PRIME eligibility from the EMA, in October 2019 for the delay or prevention of T1D. We currently estimate that the prevalence of individuals in the United States that have two or more auto-antibodies and dysglycemia and are at risk of developing clinical stage T1D to be approximately 200,000 people at any time. We currently estimate that there are approximately 64,000 new cases of T1D in the United States each year, approximately 26% of which are patients aged eight through 17;

     
  ● PRV-101: a CVB vaccine to prevent acute CVB infections and, in those patients at risk, to prevent the CVB-triggered autoimmune damage to pancreatic beta cells that may progress to T1D and damage to intestinal cells that may lead to celiac disease;
     
  ● PRV-3279: a humanized bispecific scaffold molecule targeting the B-cell surface proteins, CD32B and CD79B, for the treatment of SLE and for the prevention of immunogenicity of biotherapeutics such as those used in gene therapy; and
     
  ● PRV-015: a human anti-interleukin 15(“IL-15”) mAb for the treatment of gluten-free diet non-responsive celiac disease (“NRCD”), intercepting the effects of contaminating gluten in the most common autoimmune disorder without any approved medication.

 

5

 

 

The table below summarizes the current status and anticipated milestones for our principal product candidates:

 

Product Candidate / Indication   Status   Next Expected Milestone
PRV-031 (teplizumab, anti-CD3 mAb) for the interception of T1D        

 

At-Risk Indication – for the delay or prevention of clinical T1D in individuals at-risk of developing the disease

  

 

In December 2020, the FDA accepted and filed for review our BLA submission for the delay or prevention of clinical T1D in at-risk individuals. The FDA granted our request for priority review.

 

In June 2020, extended follow-up data from the at-risk study was announced which showed that a single 14-day course of teplizumab significantly delayed the median onset of T1D in at-risk individuals of approximately three years compared to the placebo. This data added one year to the two-year delay that was previously reported at the American Diabetes Association meeting in June 2019 and published in the New England Journal of Medicine in 2019.

  

 

The FDA indicated that an advisory committee meeting is tentatively scheduled for May 27, 2021. The FDA assigned a Prescription Drug User Fee Act (“PDUFA”) goal date of July 2, 2021.

 

In first half of 2021, we plan to file an application for the Innovation Passport and engage the Medicines and Healthcare products Regulatory Agency (“MHRA”) in the United Kingdom in a scientific advice procedure to discuss, among other topics, the Innovative Licensing and Access Pathway (ILAP) for teplizumab. The initial discussion with the MHRA will help us evaluate the possible regulatory path forward in the UK and the EU for teplizumab. We also plan further engagement with MHRA, EMA and other European stakeholders in 2021. 

 

Newly Diagnosed Indication – for the delay or prevention of clinical T1D in individuals diagnosed with early onset T1D  

We commenced a Phase 3 clinical trial (the PROTECT study) in approximately 300 pediatric and adolescent patients with newly diagnosed T1D. The first patient was dosed in the second quarter of 2019.

 

In March 2020, in connection with the COVID-19 pandemic, we announced a temporary pause in the randomization of patients with newly diagnosed T1D into the PROTECT study. In June 2020, we resumed enrollment of the PROTECT study on a country by country, site by site basis.

   We expect to complete enrollment in the PROTECT study in the second half of 2021 and report top-line results from the PROTECT study in mid-2023, subject to change for any potential COVID-19 related or other interruptions.
         
PRV-101 (polyvalent CVB vaccine) for the prevention of acute CVB and the prevention of CVB triggered T1D and celiac disease.  

We have completed manufacturing of a polyvalent vaccine at Intravacc, our strategic partner in vaccine manufacturing process development.

 

We commenced a first-in-human Phase 1 study in December 2020.

   We expect to report top-line first-in-human data in the fourth quarter of 2021.
         
PRV-3279 (humanized anti-CD32B and CD79B bispecific) for the treatment of SLE and for the prevention of immunogenicity of biotherapeutics such as gene therapy.  

We announced positive top-line results from our Phase 1b clinical trial (the PREVAIL study), which evaluated PRV-3279 in 16 healthy volunteers.

 

In January 2021, we announced positive results of pre-clinical experiments in support of the prevention of immunogenicity indication.

 

In February 2021, we entered into a License Agreement with Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”), pursuant to which we granted Huadong certain exclusive rights to develop and commercialize PRV-3279 in Greater China excluding the immunogenicity field (combination with gene therapies) to which we retained global rights).

   We expect to commence a Phase 2a study in lupus in the second half of 2021.
         
PRV-015 (anti-IL-15 mAb) for the treatment of gluten-free diet NRCD.   In August 2020, we initiated a Phase 2b clinical trial (the PROACTIVE trial) in approximately 220 adult celiac patients with gluten-free diet NRCD.   We expect to report top line results from the Phase 2b PROACTIVE study in 2022.

 

6

 

 

Recent Company Developments

 

PRV-031 (teplizumab, anti-CD3 mAb)

 

FDA Filed teplizumab BLA Submission

 

In December 2020, the FDA accepted and filed for review our BLA for teplizumab for the delay or prevention of T1D in at-risk individuals. The FDA also granted our request for Priority Review and assigned a user fee goal date of July 2, 2021 under the PDUFA. In its acceptance letter, the FDA has stated that it is currently planning to hold an advisory committee meeting, which is tentatively scheduled for May 27, 2021, to discuss the BLA. Priority Review designation is for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications. Under the PDUFA, a Priority Review targets a review time of six months compared to a standard review time of ten months.

 

At-Risk Study Data

 

On June 15, 2020, we announced that new data from the “At-Risk” TN-10 Study, presented by TrialNet at the 2020 American Diabetes Association Scientific Sessions on June 15, 2020, which demonstrated that a single 14-day course of our lead drug candidate, teplizumab (“Teplizumab Course”), delayed the median onset of clinical T1D, as compared to placebo, by approximately three years in at-risk individuals. These new data from the “At-Risk” TN-10 Study added approximately one year to the two-year median delay that was previously observed.

 

7

 

 

PRV-015 (anti-interleukin 15)

 

PROACTIVE Study Initiated

 

In August 2020, we, with our development partner Amgen, initiated the Phase 2b PROACTIVE (PROvention Amgen Celiac ProtecTIVE) study of PRV-015, an anti-interleukin-15 monoclonal antibody, in adult celiac patients not responding to a gluten-free diet, a condition known as NRCD. The placebo-controlled, double-blind, randomized study will examine the efficacy and safety of three dose levels of PRV-015 compared to placebo, administered every two weeks for six months. The study does not require a gluten challenge and patients are asked to maintain their usual diet. The trial is expected to enroll approximately 220 adults with NRCD across approximately 40 sites in the United States, Canada and Europe. The primary endpoint of the study is the efficacy of PRV-015 as measured by the CeD-PRO (Celiac Disease Patient-Reported Outcome).

 

PRV-101 (CVB Vaccine)

 

PROVENT Study Initiated

 

In December 2020, we initiated the PROVENT (PROtocol for coxsackievirus VaccinE in healthy voluNTeers) study, a first-in-human study of our polyvalent inactivated CVB vaccine candidate, PRV-101. We are developing PRV-101 for the prevention of acute CVB infection and the potential delay or prevention of T1D and celiac disease. PROVENT is a placebo-controlled, double-blind, randomized first-in-human study. The study’s primary endpoint is the safety of two dose levels of PRV-101 in healthy adult volunteers provided three administrations with 4-week intervals. Tolerability and immunogenicity will also be evaluated. Results of PROVENT are expected in the fourth quarter of 2021.

 

PRV-3279 (humanized anti-CD32B and CD79B bispecific)

 

Huadong License Agreement

 

On February 17, 2021, we entered into a License Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”), a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (the “Huadong License Agreement”), pursuant to which we granted Huadong exclusive rights for the purpose of developing and commercializing PRV-3279, a DART® (bispecific antibody-based molecule) targeting the B cell surface proteins CD32B and CD79B, in Greater China (mainland China, Hong Kong, Macau and Taiwan). We will retain exclusive worldwide rights to develop PRV-3279 for combination uses to reduce the immunogenicity of biotherapeutics, but Huadong will have the exclusive right to distribute PRV-3279 in that field in Greater China. In consideration of the license and other rights granted as part of the Huadong License Agreement, we will receive and upfront payment of $6.0 million and up to $11.5 million in research, development and manufacturing funding over the next three years.  If Huadong successfully develops, obtains regulatory approval for, and commercializes PRV-3279 in Greater China, we are eligible to receive up to $37.0 million in regulatory milestones and up to $135.0 million in commercial milestones based on aggregate net sales in a calendar year in Greater China. If commercialized, we would also be eligible to receive low double-digit royalties on net sales of PRV-3279 by Huadong in Greater China. The License Agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Huadong without cause upon at least 12 months prior notice to us and by us in the event Huadong challenges a licensed patent or in the event that our upstream license terminates. We may also terminate the License Agreement if Huadong ceases commercialization of PRV-3279 for a consecutive period of six months after first commercial sale.  We are generally responsible for the manufacturing of PRV-3279 at least through regulatory approval in Greater China and Huadong will exclusively purchase all clinical and commercial supply requirements of PRV-3279 from us until Huadong exercises its option to assume manufacturing responsibilities, which may be triggered after regulatory approval in China. We will retain all rights to PRV-3279 in the rest of the world. We plan to begin a Phase 2a trial of PRV-3279 in systemic lupus erythematosus in the second half of 2021 and expect a portion of such trial to be conducted in Hong Kong.

 

8

 

 

Preclinical Data Announced

 

In January 2021, we announced positive results of pre-clinical proof-of-concept experiments in support of the prevention of immunogenicity indication. A PRV-3279 mouse surrogate was tested in mice transgenic for human CD32B, which received gene therapy with an adeno-associated virus (“AAV”) vector AAV9 encoding for the enzyme acid-alpha-glucosidase (“GAA”) gene. Errors in the GAA gene cause the serious human glycogen storage disease type II (“Pompe disease”). In the study, the PRV-3279 surrogate reduced anti-AAV9 vector antibody levels in a dose-dependent fashion. Anti-AAV9 antibodies have been linked to reduced efficacy, safety concerns and the inability to re-dose patients, and thus, based on these and other study data, we believe PRV-3279 co-administration with gene therapy products has the potential to improve the safety and efficacy of this therapeutic modality. The PRV-3279 surrogate in combination with sirolimus increased skeletal muscle levels of GAA enzyme expression. Consistent with prior results from clinical trials in healthy human subjects, the PRV-3279 surrogate decreased Immunoglobulin M (“IgM”) production and was well tolerated.

 

Based on these data, we plan to look for opportunities to work with academic and industry experts to combine PRV-3279 with gene therapy and other biotherapeutic products to further our mission of preventing and intercepting devastating immune-mediated conditions.

 

Impact of COVID-19 on our Business

 

We are closely monitoring the continued developments related to the COVID-19 pandemic and are making every effort to ensure we remain focused on the health and well-being of our patients and our employees while maintaining business continuity. At this time, we are unable to predict what the long-term impact of this pandemic, and the associated economic downturn, will have on our business, including on our potential U.S. launch of teplizumab if approved by the FDA under the BLA under its review. We have experienced some level of disruption to three of our current or planned clinical trials. In March 2020, we announced a temporary pause in the randomization of patients with newly diagnosed T1D into our global Phase 3 PROTECT study of teplizumab. During the second quarter of 2020, we began enrolling patients in the PROTECT study on a country by country and site by site basis and as of September 30, 2020, all sites have been activated, with a majority of the sites actively enrolling patients. As a result of the delay, we now expect to report top line results from the Phase 3 PROTECT study in mid-2023, subject to change for any further COVID-19-related or other interruptions. In addition, we, with our development partner Amgen, collectively decided that, to protect the integrity and quality of the PRV-015 Phase 2b trial in gluten free diet NRCD, we would stagger study startup throughout the third quarter of 2020 rather than initiating screening in the second quarter of 2020, as had originally been scheduled. We initiated the Phase 2b trial in August 2020. Additionally, our plans to initiate the Phase 2a portion of the PREVAIL study in lupus patients has been delayed from the first half of 2021 to the second half of 2021, predominantly due to COVID-19 related impacts on our plans.

 

OUR PRODUCT CANDIDATES

 

PRV-031 (teplizumab; anti-CD3 antibody) for T1D

 

Our lead product candidate, teplizumab, is a humanized mAb that binds with high specificity to a cell surface protein called CD3. The CD3 protein is a co-receptor that helps activate T cells and direct different kinds of immune responses. Preclinical data suggests that binding of teplizumab to CD3 triggers events that differentially inhibit the activation of self-reactive T cells without affecting regulatory T-cells (“Tregs”). This restores the important state of immune tolerance and may prevent self-reactive T cells from attacking beta cells in the pancreas. When administered to T1D Stage 2 subjects, teplizumab delayed progression and onset of clinical T1D, and when administered to Stage 3 subjects, teplizumab slowed down the loss of beta cell function in all studies conducted to date. Therefore, we believe teplizumab has the potential to intercept the T1D disease process along the entire continuum, slowing or preventing the destruction of insulin-producing pancreatic beta cells.

 

In December 2020, the FDA accepted and filed for review our BLA for teplizumab for the delay or prevention of T1D in at-risk individuals (T1D Stage 2). The FDA also granted our request for Priority Review and assigned a user fee goal date of July 2, 2021 under the PDUFA. In its acceptance letter, the FDA stated that it is currently planning to hold an advisory committee meeting, which is tentatively scheduled for May 27, 2021, to discuss the BLA. Priority Review designation is for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications. Under the PDUFA, a Priority Review targets a review time of six months compared to a standard review time of ten months.

 

9

 

 

T1D Market

 

According to the International Diabetes Federation, 8.8% of the adult population worldwide has diabetes, among whom 10-15% have T1D. According to the Juvenile Diabetes Research Foundation (“JDRF”), it is estimated that 1.6 million people in the United States have T1D and approximately five million are expected to have T1D by 2050, including nearly 600,000 under 15 years of age. The annual economic burden of T1D has been estimated by JDRF to be greater than $30.0 billion in the United States and greater than $90.0 billion globally.

 

Moreover, the incidence of T1D is increasing worldwide and it is estimated that more than 90,000 children are diagnosed each year in the United States and the largest five European countries. In the period between 2005 and 2020, epidemiologists predict a 70% increase in the incidence of T1D in children in Europe, with the age of onset decreasing and the number of cases in children younger than five years old doubling.

 

Market Opportunity for teplizumab

 

Estimated Patient Prevalence of At-Risk Indications (all ages)

 

Based on our analysis of literature, we believe the following represent the estimated prevalence of At-Risk individuals:

 

Market 

Stage 1 / Stage 2

>2 Autoantibodies

  

Stage 2

>2 Autoantibodies

and Dysglycemia

  

Stage 2 Familial Direct Relatives

of T1D Patients who exhibit

>2 Autoantibodies and Dysglycemia

 
United States   300,000    200,000    30,000 
European Union   180,000-300,000    120,000-200,000    18,000-30,000 

 

If the FDA approves our current BLA for teplizumab for use in “At-Risk” individuals, our potential commercial launch of teplizumab would initially focus on familial direct relatives of T1D patients with two or more autoantibodies and dysglycemia, and then expand to other populations identified as At-Risk through potentially increased universal screening in the United States

 

Our commercial priorities are as follows:

 

Near-Term Focus

 

  ● Commercial Planning in the United States for the At-Risk indication
  ● T1D disease and risk factor awareness
  ● Health care professional (“HCP”) and key opinion leader (“KOL”) engagement
  ● Patient advocacy group engagement
  ● Increasing awareness of screening of familial direct relatives of known T1D patients

 

Mid-Term Focus

 

  ● Inform and support execution of our regulatory strategy and engagement with the MHRA in the United Kingdom and EMA in the European Union on potential approval pathways for teplizumab
  ● Commercial planning / partnership in European Union
  ● Planning for potential Newly Diagnosed indication

 

Long-Term Focus

 

  ● Market expansion with broader population screening
  ● Potential research efforts to support the addition of age groups and multiple courses of treatment for both At-Risk and Newly Diagnosed potential indications.

 

T1D Lifecycle Management and other potential indications

 

We are currently exploring and supporting research and lifecycle management programs for T1D beyond the current treatment regimen and patient population including repeat dosing and age expansion for at-risk individuals and newly diagnosed patients as well as subcutaneous formulations and combination therapies potentially with antigens, metabolic drugs, immune modulators and beta cell transplants. Other potential indications for teplizumab may include GI immunology disorders such as Crohn’s disease, Celiac disease and autoimmune hepatitis or rheumatology disorders such as psoriatic arthritis and rheumatoid arthritis. These initiatives may include new clinical studies sponsored by us or investigator-initiated studies, which are clinical studies initiated and sponsored by physicians or research institutions with funding from us.

 

10

 

 

T1D Background Information

 

T1D is the end result of immune-mediated destruction of the insulin-producing beta cells of the pancreas and is one of the most common and serious chronic conditions occurring in childhood. T1D patients require life-long dependence on insulin products delivered through multiple daily injections or continuous infusion pumps. While the disease presents in children and adults, the vast majority of T1D is diagnosed in children, with more than half of T1D patients diagnosed before the age of 14 years. The life-expectancy of individuals with younger-onset disease is on average 16 years shorter than non-diabetic individuals. Individuals diagnosed before the age of 10 years have a 30-times greater risk of serious cardiovascular outcomes than the general population resulting in decreased life expectancy, compared to healthy individuals. It is believed the loss of beta cells, which is more severe and rapid in younger individuals leading to increased glycemic load, is the cause of increased cardiovascular-related deaths. The disease is believed to occur in genetically susceptible individuals upon exposure to environmental triggers. In addition, because of a similar genetic predisposition, patients with T1D are at high risk of developing celiac disease. Celiac disease is characterized by autoimmunity in the gut and other organs triggered by consumption of gluten and can lead to malnutrition and other complications including a form of cancer called lymphoma. There is no approved therapy for celiac disease.

 

Lack of insulin secretory capacity has serious consequences, even when patients receive insulin replacement therapy. The complications of T1D include eye disease, nerve damage, kidney disease and heart disease. Diabetic retinopathy has a prevalence of approximately 80% among patients with T1D and is the leading cause of vision impairment and blindness among adults. Moreover, about 60% to 70% of people with diabetes present some form of neuropathy that can induce numbness, weakness and blood pressure dysregulation. In addition, diabetic nephropathy is the leading cause of chronic kidney disease and affects about 30% of T1D patients. Diabetes can also cause severe heart complications and adults with diabetes are two to four times more likely to die from heart disease than adults without diabetes.

 

In summary, people with T1D experience substantial morbidity and mortality owing to chronic complications.

 

Current T1D Treatment Options and Their Limitations

 

So far, no disease-modifying or curative treatment exists for T1D. Patients with T1D still need to use daily insulin injections to manage blood sugar to within a normal range. However, it is estimated that fewer than one-third of people with T1D in the United States achieve target blood glucose levels and insulin injections often cause hypoglycemia (low blood sugar). While insulin injections or infusion allow a person with T1D to stay alive, they do not cure the disease, nor do they necessarily reduce the risk of serious effects and long-term complications of T1D.

 

While pancreatic and islet cell transplantation offer the ability to normalize glucose levels and remove the dependence on insulin products, there are significant risks, resulting in a modest number of such transplants being conducted every year. There is risk associated with mandatory immunosuppression, which commonly results in the development of infections that may be life-threatening. Furthermore, pancreas transplantation may be associated with technical complications (vascular thrombosis, pancreatitis, infection, fistulas) as well as acute and chronic organ rejection. Islet cell transplantation can provide better glycemic control and protect patients from hypoglycemic episodes, but only approximately 50% of patients are insulin-free after three years of follow-up.

 

New approaches are still required and could significantly enhance patient care. In particular, there is a strong need for new preventive or curative treatments. Among the different possible strategies, primary prevention through vaccination and secondary prevention (interception) with a disease-modifying non-chronic immune modulator seem to be the best candidates considering the potential efficacy and safety balance that needs to be achieved.

 

Overview of T1D Biology and teplizumab Mechanism of Action

 

T1D is an autoimmune disease which occurs in genetically-predisposed individuals. Specialized white blood cells of our immune system, known as self-reactive T cells (also called auto-reactive), are triggered, presumably by CVB viral infection of the beta cells in at least 50% of cases, to attack and destroy beta cells of the pancreas, thus causing a decline in the natural production of insulin. Simultaneously, another type of T cell, Tregs, which normally suppress the activity of self-reactive T cells, fail to do so effectively.

 

11

 

 

The clinical progression of T1D is relatively well understood and predictable, as it is a continuum marked by clinically-relevant biomarkers which identify stages of the disease. In an individual with genetic risk (primarily driven by human leukocyte antigen (“HLA”) haplotypes), the natural evolution of T1D has been described in stages (see figure below).

 

● Stage 1: emergence of T1D-related autoantibodies which reflect the initiation of the autoimmune process; this stage is associated with normoglycemia.

 

● Stage 2: persistence T1D-related autoantibodies, but with further loss of beta cell function and development of dysglycemia.

 

● Stage 3: symptomatic or clinical T1D, when remaining beta cell capacity is insufficient to maintain glucose metabolism.

 

Stages of Type 1 Diabetes

 

 

 

It is important to note that once subjects develop two or more T1D-related autoantibodies (Stage 1), the progression to clinical T1D (Stage 3) is not a matter of “if” but “when” as greater than 95 percent of the Stage 1 subjects and virtually all of the Stage 2 subjects will progress to Stage 3 necessitating insulin dependence. The progression of Stage 1 to Stage 3 is 44% in five years, and of Stage 2 to Stage 3 is 75% in four to five years.

 

Current Clinical Development Program

 

At-Risk Individuals (Stage 2)

 

Phase 2 Clinical Trial of teplizumab in At Risk Relatives who develop T1D (At-Risk TN-10 Study)

 

In June 2020, we announced that new data from the “At-Risk” TN-10 Study, presented by TrialNet at the 2020 American Diabetes Association Scientific Sessions on June 15, 2020, which demonstrated that a single 14-day course of our lead drug candidate, teplizumab, delayed the median onset of clinical T1D, as compared to placebo, by approximately three years in at-risk individuals. These new data from the “At-Risk” TN-10 Study added approximately one year to the two-year median delay that was previously observed.

 

The “At-Risk” TN-10 Study, a pivotal Phase 2 clinical trial, conducted at TrialNet sites and sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (“NIDDK”), part of the National Institute of Health (“NIH”), evaluated teplizumab for the delay of clinical T1D in at-risk individuals. At-risk was defined by the presence of two or more T1D-related autoantibodies and dysglycemia (abnormal glucose metabolism). Seventy-six subjects were enrolled, ages eight to 49, with 72 percent under the age of 18, and randomized to receive a single course of either teplizumab or placebo. Subjects were followed in a blinded fashion until a minimum 40 subjects developed clinical T1D which triggered the analysis of the primary endpoint, and then indefinitely in other TrialNet studies after this time. Those who developed clinical T1D after the primary analysis was completed are eligible to enroll in a Provention trial which we initiated in March 2020, described below.

 

12

 

 

The trial results showed the median time to clinical diagnosis of T1D after one course of teplizumab was approximately five years (59.6 months) (an improvement of 12 months from previously published data) compared to approximately two years (27.1 months) for the placebo group (24.9 months in previously published data). Nearly half of those treated with teplizumab are estimated to be free of clinical T1D at five years. The hazard ratio was 0.457 or a 54 percent reduction in risk of developing clinical T1D (p=0.01).

 

In addition, teplizumab treatment was associated with a greater on-study C-peptide (p=0.009), a measure of a persons’ own insulin production, compared to placebo. For both groups, C-peptide area under the curve (“AUC”) mean slopes preceding study entry were similar and declining. In the placebo group, this decline continued over the six months after study entry. By contrast, the teplizumab-treated group showed an increased C-peptide AUC over this period (p=0.02 relative to study entry).

 

Mechanistically, the association between the induction of partially exhausted CD8 T cells and the delay of clinical T1D conferred by teplizumab, previously described in newly diagnosed T1D patients, was also confirmed in subjects at-risk. C-peptide levels at three, six and 18 months post-teplizumab administration correlated with the levels of exhausted CD8+ T cells in the peripheral blood (p=0.01 vs placebo). Subjects with the highest increase (top quartile) in exhausted CD8 T cells had no progression to clinical T1D in the period of observation of the study (p=0.005 vs placebo). Finally, inflammatory cytokines IFN-gamma and TNF-alpha were lower in the exhausted CD8 T cells in teplizumab vs placebo-treated subjects (p<0.0001).

 

In summary, while no additional safety signals have been noted, the results showed that teplizumab’s effect on delaying the onset of clinical T1D was not only consistent from previous analyses, but was durable and now extended to a median of approximately three years (32.5 months). See below for further analysis.

 

Breakthrough Therapy Designation (United States)

 

In August 2019, the FDA granted breakthrough therapy designation to teplizumab for the delay or prevention of clinical T1D in individuals at-risk of developing the disease. Breakthrough therapy designation is an FDA program designed to expedite the development and review of therapeutic candidates intended to treat serious or life-threatening diseases.

 

PRIME Eligibility (European Union)

 

In October 2019, the EMA granted PRIority MEdicines (“PRIME”) eligibility to teplizumab for the prevention or delay of clinical T1D in individuals at-risk of developing the disease. The PRIME initiative is designed to expedite the development and review of promising therapies that target an unmet need and show potential clinical benefit so the medicine can reach patients earlier. The designation offers the opportunity for enhanced interaction and dialogue with the EMA to optimize development, as well as the potential for accelerated assessment at the time of application for a marketing authorization.

 

Phase 2 Clinical Trial of teplizumab in At Risk Relatives who develop T1D (TN-10 Extension)

 

We initiated an open-label Phase 2 study in March 2020 to evaluate the safety of teplizumab in participants who were in the TN-10 trial and have subsequently developed clinical T1D after the conclusion of that trial. Eligible subjects will receive teplizumab treatment within one year of their clinical T1D diagnosis. Participants will have a follow-up period of up to 78 weeks (18 months) from the first dose of treatment. The study may enroll up to 30 participants and is currently enrolling.

 

13

 

 

Newly-Diagnosed Patients (Stage 3)

 

Phase 3 Clinical Trial of teplizumab in Pediatric Patients Newly-Diagnosed T1D (PROTECT Study)

 

The PROTECT study (PROvention T1D trial Evaluating C-peptide with Teplizumab) is a randomized, double-blind, placebo-controlled, multicenter Phase 3 clinical trial in pediatric and adolescent patients (aged eight to 17 years) that are newly-diagnosed with clinical T1D. Patients with minimum beta-cell cell function (C-peptide >0.2 pmol/mL) and within six weeks of T1D diagnosis will receive two courses of teplizumab, six months apart. Each course will consist of 12 days of teplizumab administered intravenously. The primary endpoint is the change in C-peptide at 18 months. Secondary endpoints including insulin use, HbA1C levels, hypoglycemic events and safety will also be evaluated. The study is expected to enroll approximately 300 patients with 2:1 randomization (200 active: 100 placebo) and enrollment commenced in the second quarter of 2019. We expect to complete enrollment in the second half of 2021 and report top line results for the Phase 3 PROTECT study in mid-2023, subject to change for any potential COVID-19 related or other interruptions.

 

In March 2020, we announced a temporary pause in the randomization of patients with newly diagnosed T1D into our global Phase 3 PROTECT study of teplizumab. This pause was taken to protect patients, caregivers, clinical site staff, company employees and contractors as part of the collective global efforts to combat the COVID-19 pandemic. Patients that were undergoing study therapy were allowed to complete their course, as recommended by the PROTECT study’s Data Safety Monitoring Board, which was expanded to include infectious disease expertise. In June 2020, we resumed enrollment on a country by country, site by site basis based upon review of local COVID-19 infection rates and the site’s ability to maintain the safety of participants.

 

We are also conducting an extension study of the PROTECT trial, PROTECT Extension. The purpose of this study is to evaluate the long-term safety profile of PROTECT study patients who received a 12-day course of teplizumab treatment upon T1D diagnosis and a second 12-day course of teplizumab treatment approximately six months later. The extension study will provide a total of 5-year safety data from the initiation of treatment for the participants in the PROTECT Study.

 

We believe that combination therapy may enhance the potential therapeutic benefit of teplizumab by increasing efficacy, enhancing the durability of response, or restoring insulin production by beta cells. Combination therapies may include beta-cell transplant and beta cell antigens, tolerogenic cytokines, other immune modulators which could enhance the removal of self-reactive lymphocytes or increase the function of Tregs, or metabolic agents that could further improve or preserve beta cell function or mass. We are collaborating with Precigen (formerly Intrexon) and its subsidiary, ActoBio Therapeutics, to explore the combination of teplizumab and the oral administration of a Lactococcus lactis strain genetically engineered to secrete human proinsulin and human interleukin-10, an anti-inflammatory cytokine. We plan to explore other combination therapies as the Phase 3 program progresses.

 

Prior Clinical Evaluation of teplizumab

 

To date, clinical development of teplizumab has included both academic and biopharmaceutical sponsors. Approximately 1,100 subjects have been enrolled in teplizumab clinical trials, with over 800 subjects receiving teplizumab. These studies represent various doses, formulations, and indications and includes earlier smaller investigator-sponsored studies. The majority of patients were enrolled in T1D studies (>1,000), and the rest in renal or renal-pancreatic allograft rejection, pancreatic islet transplant, psoriatic arthritis or plaque psoriasis trials.

 

In T1D patients, ten studies have been conducted, of which nine involved intravenous dosing (two Phase 1, three Phase 2, two Phase 3 and a Phase 3 extension study) and one subcutaneous dosing (Phase 1).

 

14

 

 

Among the T1D studies of teplizumab:

 

  ● In Stage 2, the At-Risk study enrolled Stage 2 individuals who were characterized as having at least two T1D autoantibodies and evidence of hyperglycemia
  ● In Stage 3, five studies (Study 1, Study 2, Study 3, Study 4 “AbATE”, and Study 5 “Delay”) were completed under the direction of Dr. Kevan Herold (currently at Yale University) and collaborators. Studies 2, 3 and 4 were sponsored by the Immune Tolerance Network. Four additional studies were conducted by MacroGenics: three with intravenous administration (“Protégé”, “Protégé Extension”, and “Protégé Encore”) and one with subcutaneous administration (SUBCUE) of teplizumab. Among these studies, “Protégé” and “Protégé Encore” were Phase 3 studies. Protégé was the largest completed study for treatment of T1D, which enrolled 516 patients (aged eight to 35 years and T1D diagnosis within 12 weeks of study entry) and randomized into three teplizumab dosing regimens compared to placebo. Teplizumab showed promising immunological and clinical activities in these studies and was well tolerated. In particular, teplizumab treatment showed promising data on the preservation of C-peptide levels and the reduction of exogenous insulin use.

 

Stage 2 Program

 

Stage 2: At-Risk TN-10 Study

 

The At-Risk TN-10 study was developed and conducted by Type 1 Diabetes TrialNet, funded by the National Institutes of Health, the American Diabetes Association, or the ADA, and the Juvenile Diabetes Research Foundation. The objective of the study was to determine whether treatment of at-risk subjects with teplizumab results in a delay or prevention of clinical T1D in patients at-risk, i.e., with pre-symptomatic Stage 2 T1D. The primary endpoint was completed in 2018. The study was conducted in 18 sites in the United States, Canada and Germany.

 

Participants over eight years of age with Stage 2 T1D (presence of at least two T1D autoantibodies and dysglycemia, who were non-diabetic relatives of T1D individuals) were randomized 1:1 to receive teplizumab or placebo. Dysglycemia was defined on oral glucose tolerance test (“OGTT”) as: (a) Fasting plasma glucose ≥ 110mg/dL, and <126mgdL, or (b) 2-hour plasma glucose ≥140mg/dL, and <200mg/dL, or (c) 30, 60, or 90-minute value on OGTT ≥200mg/dL.

 

The primary endpoint was the time from randomization to the clinical diagnosis of diabetes, using ADA criteria. Criteria for clinical T1D diagnosis are based on glucose testing, or the presence of unequivocal hyperglycemia with acute metabolic decompensation (diabetic ketoacidosis). One of the following criteria must be met on two occasions as soon as possible but no less than one day apart for diabetes to be defined:

 

  ● Symptoms of diabetes plus casual plasma glucose concentration > 200 mg/dL (11.1 mmol/l). Casual is defined as any time of day without regard to time since last meal. The classic symptoms of diabetes include polyuria, polydipsia, and unexplained weight loss.
  ● Fasting plasma glucose ≥ 126 mg/dL (7 mmol/l). Fasting is defined as no caloric intake for at least eight hours.
  ● 2-hour plasma glucose ≥ 200 mg/dL (11.1 mmol/l). The test should be performed using a glucose load containing the equivalent of 1.75g/kg body weight to a maximum of 75 g anhydrous glucose dissolved in water.

 

Teplizumab was administered over a 14-day course: 51 μg/m2, 103 μg/m2, 207 μg/m2, and 413 μg/m2 on study days 0–3, respectively, and 826 μg/m2 on each of study days four through 13. A total of 112 participants were screened and 76 were randomized, 44 to teplizumab and 32 to placebo. The baseline characteristics were balanced for age (median ~13-14 years of age), relationship to the relative with T1D, type of T1D autoantibodies and HbA1c.

 

At-Risk TN-10 Study– Primary Data Readout in June 2019

 

Treatment with a single course of teplizumab delayed the time to T1D (see figure below): 19 of the 44 (43%) teplizumab-treated and 23 of the 32 (72%) placebo-treated participants were diagnosed with T1D. The annualized rates of T1D development were 14.9% and 35.9% per year, for the teplizumab and placebo groups, respectively. The median time to T1D was 24.4 months in the placebo and 48.4 months in the teplizumab groups (hazard ratio = 0.412 (95% CI: 0.216, 0.783) p=0.006 (2-sided)).

 

15

 

 

Time to T1D

 

 

In pre-specified analyses, the effects of teplizumab on the primary outcome based on baseline characteristics were evaluated. Although subgroup analyses had small sample sizes and need to be taken with caution, participants without anti-ZnT8 antibodies showed a greater effect size compared to those who did not have the antibody. The presence of HLA-DR4 and absence of HLA-DR3 were also associated with greater effect size, as was a below median C-peptide response to the OGTT at baseline (1.75 nmol/L). These larger effect sizes are attributed to more rapid progression of the disease in these subgroups, rather than clinically-actionable baseline characteristics able to predict response to teplizumab. We believe all patients with Stage 2 T1D can benefit from teplizumab as long as they have beta cells to be protected.

 

Teplizumab treatment was associated with few adverse events, described in the table below. Similar to previous studies with teplizumab in newly-diagnosed T1D patients, the lymphocyte count declined to a nadir on day five by 72.3% (IQR 82.1, 68.4%) (p<0.0001). The transient lymphopenia is believed to be the mechanistic consequence of margination (adhesion to the blood vessel wall) rather than depletion. Fifteen (34.1%) of the grade 3 events in the teplizumab group involved lymphopenia during the first 30 days after study drug administration. The lymphocyte counts recovered quickly: Lymphopenia resolved in all participants by day 45 except in one, whose counts returned on day 105. A spontaneously resolving rash, as previously noted, occurred in 36% of drug treated participants. The rates of infection were similar in the two treatment arms. The adverse events below were determined to be possibly, probably or definitely related to the study drug.

 

Adverse Events

 

Adverse Effect Category   Teplizumab   Placebo
    No. of Events   No. of Subjects (%)   No. of Events   No. of Subjects (%)
Blood/Bone Marrow***   45   33 (75)   2   2 (6.2)
Dermatology/Skin***   17   16 (36.4)   1   1 (3.1)
Pain   11   5 (11.4)   5   3 (9.4)
Infection   8   5 (11.4)   5   3 (9.4)
Gastrointestinal   5   4 (9.1)   3   3 (9.4)
Metabolic/Laboratory   7   4 (9.1)   2   2 (6.2)
Pulmonary/Upper Respiratory   6   4 (9.1   0   0 (0)
Constitutional Symptoms   3   2 (4.5)   0   0 (0)
Allergy/Immunology   2   2 (4.5)   0   0 (0)
Cardiac General   1   1 (2.3)   1   1 (3.1)
Endocrine   0   0 (0)   2   2 (6.2)
Vascular   1   1 (2.3)   1   1 (3.1)
Neurology   1   1 (2.3)   0   0 (0)
Ocular/Visual   1   1 (2.3)   0   0 (0)
Musculoskeletal/Soft Tissue   2   1 (2.3)   0   0 (0)
Hepatobiliary/Pancreas   0   0 (0)   1   1 (3.1)
Syndromes   1   1 (2.3)   0   0 (0)
Hemorrhage/Bleeding   1   1 (2.3)   0   0 (0)
Total Events and Subjects   112   44 (100)   23   32 (100)

 

*** p < 0.001 Teplizumab vs placebo

 

16

 

 

Other anti-CD3 mAb experimental treatments, such as otelixizumab, have been associated with Epstein Barr virus (“EBV”), clinical reactivation in patients with latent infection. At entry, 30 participants (39%) (16 teplizumab and 14 placebo) had antibodies against EBV in TN-10. At weeks 3-6 after study drug treatment, there was quantifiable EBV DNA in whole blood in eight of the seropositive participants – all in the teplizumab group, one of whom had symptoms of pharyngitis, rhinorrhea, and cough on day 38. In these participants, the EBV DNA levels were below the level of quantification between day 43 and 134 (average 77 days). At entry, 17 participants (ten teplizumab and seven placebo) had antibodies against cytomegalovirus (“CMV”). One teplizumab participant, who was CMV seropositive, had detectable levels of CMV DNA at day 20 that was undetectable by day 42. These results show that, while viral reactivation may be observed during the first weeks post-teplizumab administration, these are typically asymptomatic and that immune competence is maintained that results in the resolution of viremia.

 

The TN-10 trial results demonstrate that a single course of teplizumab significantly delayed the progression to clinical T1D in high-risk Stage 2 relatives who had at least two autoantibodies and dysglycemia. The median delay in the diagnosis of diabetes was approximately two years, and at the conclusion of the trial, the frequency of diabetes-free subjects was double in the drug (57%) vs placebo-treated subjects (28%). The relatively rapid rate of progression to clinical diabetes in the placebo group, consistent with the previously reported natural history, reflects the very high risk of these individuals and reflects the inevitability of progression from Stage 2 to Stage 3 disease, consistent with observations of high rates of beta cell killing in these subjects. The rapid development of clinical T1D may also reflect the enrichment of pediatric participants (72.4%) in whom the rate of progression is rapid. The safety profile was consistent with previous experience and teplizumab was well-tolerated.

 

At-Risk TN-10 Study – June 2020 Data Update

 

After the primary readout in the TN-10 study, patients were followed indefinitely in other TrialNet observational studies. On June 15, 2020, we announced that new data from the TN-10 study was presented on that date by TrialNet at the 2020 American Diabetes Association Annual meeting. These follow-up data demonstrated that the single 14-day course of teplizumab had delayed the onset of clinical T1D, as compared to placebo, by a median of approximately three years in at-risk individuals. In other words, the follow-up data from the TN-10 added approximately one year to the two-year median delay that was previously observed and reported in the primary analysis. The median time to clinical diagnosis of T1D after one course of teplizumab was approximately five years compared to approximately two years for the placebo group (unchanged from previously published data). Nearly half of those treated with teplizumab are estimated to be free of clinical T1D at five years. The hazard ratio was 0.457 or a 54 percent reduction in risk of developing clinical T1D (p=0.01).

 

17

 

 

 

 

In addition, teplizumab treatment was associated with a greater on-study C-peptide (p=0.009), a measure of a persons’ own insulin production, compared to placebo. For both groups, C-peptide AUC mean slopes preceding study entry were similar and declining. In the placebo group, this decline continued over the six months after study entry. By contrast, the teplizumab-treated group showed an increased C-peptide AUC over this period (p=0.02 relative to study entry).

 

 

 

Note: Adapted from presentation 277-OR at ADA 2020 (Sims et al, June 15, 2020).

 

18

 

 

Mechanistically, the association between the expansion of partially exhausted CD8 T cells and the delay of clinical T1D conferred by teplizumab, previously described in newly diagnosed T1D patients, was also confirmed in subjects at-risk. C-peptide levels at three, six and 18 months post-teplizumab administration correlated with the levels of exhausted CD8+ T cells in the circulation (p=0.01 vs placebo). Subjects with the highest increase (top quartile) in exhausted CD8 T cells at 3 months post-teplizumab had no progression to clinical T1D in the period of observation of the study (p=0.005 vs placebo). Finally, inflammatory cytokines IFN-gamma and TNF-alpha were lower in the exhausted CD8 T cells in teplizumab vs placebo-treated subjects (p<0.0001).

 

In summary, the follow-up results showed that teplizumab’s effect on delaying the onset of clinical T1D was not only consistent from previous analyses, but was durable and now extended the median delay to approximately three years, without any additional safety signals noted.

 

Stage 3 Program

 

Protégé Study

 

Protégé was a randomized, controlled Phase 3 clinical trial conducted in 83 centers in North America (U.S., Canada, Mexico), India, Israel, and Europe (Czech Republic, Estonia, Germany, Latvia, Poland, Romania, Spain, Sweden, Ukraine) completed between 2007 and 2011. Patients aged eight to 35 years with recently diagnosed T1D (≤12 weeks) were followed for 12 months (Protégé) and continued to 24 months (Protégé Extension). Three dose regimens of teplizumab were administered to 417 patients as intravenous infusions for six to 14 days; 99 patients received placebo. At 12 months, the primary efficacy endpoint, the proportion of patients with insulin use <0.5 U/kg per day and HbA1c <6.5%, ranged from 13.7% to 20.8% patients in the teplizumab groups, depending on dosing regimen, and 20.4% in the placebo group. The difference between teplizumab-treated patients and placebo-treated patients was not significant. The change in HbA1c from baseline also did not show a significant difference between teplizumab and placebo. However, subgroup analyses indicated the following findings:

 

19

 

 

  ● We believe that the primary endpoint could have been achieved if cut-offs were changed to insulin use of <0.25 U/kg per day and HbA1c <7.0%, not only at 12 months but also at 24 months (figure below).

 

 

 

20

 

 

  ●

C-peptide levels significantly improved in the teplizumab group compared with placebo group in all patients, and further analyses indicated that this difference was more pronounced in younger patients (aged eight to 11 years) and patients enrolled in United States sites. These findings are consistent with other clinical trials, showing a stronger effect in T1D patients who are younger (<17 years), more recently diagnosed (<10 weeks), and with higher C-peptide levels at baseline.

 

 

 

Protégé Encore Study

 

Protégé Encore was a randomized, controlled Phase 3 clinical trial conducted in 125 centers in 16 countries completed between 2009 and 2012. Patients aged eight to 35 years with recently diagnosed T1D were to be followed for 24 months. Three dose regimens of teplizumab, given as intravenous infusions for six to 14 days, were compared with placebo. The primary endpoint, the proportion of patients with insulin use <0.5 U/kg per day and HbA1c <6.5% at 12 months, was not met. Study enrollment was stopped at 254 patients (400 planned) when the Protégé study showed that the primary endpoint was not met. Efficacy analyses were not conducted in this study.

 

21

 

 

A summary of the C-peptide data in the completed Phase 2 clinical trials and Phase 3 Protégé study are shown in the table below. All these studies have shown consistent and significant C-peptide benefit. Furthermore, subgroup analysis of the Protégé data indicated that younger patients (aged eight to 17 years) with minimum baseline beta cell function (C-peptide >0.2 pmol/mL) along with even more robust data in newly-diagnosed T1D (diagnosis under six weeks, Study 1), informed the inclusion criteria that will be applied in our planned Phase 3 study, PROTECT.

 

 

 

* Full 9.0 mg/m2/course 14-Day regimen was explored in 205 treated patients and 98 placebos;
** Delay study based on 12-month time-point. All other studies based on 24-month time-points

 

SUBCUE Study

 

SUBCUE was a randomized, controlled Phase 1 clinical trial to evaluate the safety and tolerability, pharmacokinetic (“PK”), and pharmacodynamics (“PD”) of subcutaneously injected teplizumab conducted between 2010 and 2011. Patients aged 18 to 35 years who were diagnosed with T1D within 12 months were to be given three dosing regimens of teplizumab or placebo. Patients were to be followed for 91 days. However, the study was stopped after one subject was enrolled, upon the Protégé study results.

 

Safety Data

 

Teplizumab safety data in T1D subjects have been analyzed from five clinical studies with similar study characteristics including a randomized controlled design and testing the proposed cumulative dose of 9034 µg/m2 (~9.0 mg/m2) per treatment course. Four of these studies enrolled subjects with newly diagnosed Stage 3 clinical T1D (two Phase 2 studies, AbATE and Delay, and two Phase 3 studies, Protégé and Encore). One of these trials enrolled Stage 2 subjects in the At-risk (TN-10) study. The safety summary provided below pools data from the four Stage 3 clinical studies and a separate summary for the Stage 2, At-risk study (TN-10).

 

In Stage 3 teplizumab and placebo subjects, there were no major differences in the overall adverse events (“AEs”) (99.6% and 99.1%), and serious adverse events (“SAEs”) (12.2% (91 of 729 subjects), and 8.9% (19 out of 213 subjects), although there were more severe AEs in teplizumab subjects (59% and 25%). In At-risk Stage 2 subjects, there was a higher incidence of AEs, SAEs, and severe AEs in the teplizumab subjects compared with placebo (AEs: 97.7% and 68.8%, SAEs: 15.9% (7 of 44 subjects) and 3.1% (1 of 32 subjects), and severe AEs: 59.1% and 9.4%).

 

The most common AEs were related to decreases in white blood cells (lymphopenia, leukopenia and neutropenia) as well as rash. Lymphopenia was expected based on the mechanism of action of teplizumab and was observed in approximately 80% of Stage 3 and 73% of Stage 2 T1D subjects who received teplizumab compared with approximately 18% of Stage 3 and 6% of Stage 2 subjects who received placebo. Lymphopenia was commonly mild to moderate and resolved within 14 days. In Stage 3 T1D subjects, approximately 36% and 12% of teplizumab - and placebo-treated subjects, respectively, reported rash. In Stage 2 TID subjects, approximately 14% and 0% of teplizumab- and placebo-treated subjects, respectively, reported rash. In teplizumab-treated patients, the rash was predominantly mild to moderate and usually resolved within one to two weeks. Laboratory abnormalities were also reported as AEs. The main differences in incidence in teplizumab and placebo subjects were related to liver function tests. For example, increased alanine aminotransferase occurred in 27.8% and 12.7% of Stage 3 teplizumab and placebo subjects and 4.5% and 3.1% of Stage 2 teplizumab and placebo subjects. These transaminase elevations were likely due to cytokine effects on the liver, usually resolved within 14 days of dose completion, and did not cause significant or lasting clinical concern. Cytokine release syndrome, which may include symptoms of rash, headache, nausea, vomiting, and chills/fever, occurred in 6% and 1.4% of teplizumab- and placebo-treated Stage 3 subjects and 2.3% and 0% of teplizumab- and placebo-treated Stage 2 subjects. Cytokine release syndrome was predominantly mild to moderate in severity, and in the majority of subjects (~80%), the treatment course was completed.

 

22

 

 

In both Stage 3 and Stage 2 subjects, a total of 118 subjects (98 teplizumab (12.4%), 20 control (8.2%)) experienced 1 or more SAEs for a total of 167 SAEs. The majority, 76.7%, (128 out of 167) of SAEs were not considered treatment-related, while 23.4% (39 out of 167) were deemed related.

 

  ●

In Stage 3 subjects, 110 of 729 total participants (91 teplizumab (12.2%), 19 control (8.8%)) reported at total of 158 SAEs. The most common SAEs were related to diabetes control including diabetic ketoacidosis, hypoglycemic seizures/unconsciousness, hyperglycemia, hypoglycemia (consistent with the underlying disorder) and were reported in 4.9% and 2.3% of Stage 3 teplizumab and placebo subjects, respectively. These events did not occur in any Stage 2 subjects.

     
  ●

In Stage 2 subjects, 8 of 76 total participants (7 of 44 teplizumab (15.9%), 1 of 32 controls (3.1%)) reported a total of 9 SAEs during the study. Of the 8 SAEs reported in teplizumab subjects, 4 were infections (pneumonia, cellulitis, wound infection, and gastroenteritis). Two of the 8 SAEs reported in teplizumab subjects were considered by the investigators to be related to study treatment and included serum sickness and pneumonia.

 

Three deaths were observed in Stage 3 subjects and categorized by the principal investigator (in accordance with International Conference on Harmonisation/Good Clinical Practice guidelines) and included in the Investigator Brochure for teplizumab filed with the FDA. The relationship between each death and teplizumab is listed in the Investigator Brochure as follows: one death, “none”; one death “not related”; and one death “unlikely.” The specific causes of deaths were (1) unknown for subject with gastrointestinal symptoms which the relationship was listed as “none” in the Investigator Brochure, (2) anterior myocardial infarction with ventricular tachycardia and cardio-respiratory arrest for which the relationship was listed as “not related” in the Investigator Brochure and (3) diabetic ketoacidosis for which the relationship was listed as “unlikely” in the Investigator Brochure. No deaths were reported in Stage 2 subjects.

 

The most common severe AE occurring in at least 10% of Stage 3 subjects was lymphopenia observed in 43.6% (326 out of 729 subjects) and 5.2% (11 out of 213 subjects) of teplizumab and placebo subjects, respectively. In Stage 2 subjects, lymphopenia was also the most frequently observed severe AE, occurring in 47.5% (21of 44 subjects) teplizumab-treated subjects but none of the placebo subjects. This AE is consistent with the mechanism of action of teplizumab.

 

Overall, in both Stage 3 and Stage 2 subjects, infections were reported in comparable rates between teplizumab and controls (53.0% vs 52.7%) with the most common infections reported involving upper respiratory infections (19.0% vs 17.6%), nasopharyngitis (11.1% vs 9.4%) and pharyngitis (5.1% vs 4.5%). The rate of primary EBV infections does not appear to be increased with teplizumab (1.9% vs 3.6%). While there were more cases of EBV reactivation with teplizumab (3.9% vs 1.2%), they were asymptomatic in the majority of subjects and were associated with transient viremia.

 

The safety profile of teplizumab in the at-risk population (Stage 2 T1D), appeared to be comparable with those of newly diagnosed patients (Stage 3 T1D). No new safety signals were identified. The majority of the adverse events were mild to moderate and were transient and manageable.

 

Phase 2 Clinical Trial of teplizumab in combination with AG019 in newly diagnosed T1D patients

 

This is a Phase 1b/2a clinical trial being conducted in collaboration with Precigen exploring the combination of teplizumab with Precigen’s AG019 in participants with recent-onset T1D. AG019 is a capsule consisting of engineered Lactococcus lactis specifically modified to deliver human proinsulin and the tolerance-enhancing cytokine human interleukin-10 to the mucosal lining of the gastro-intestinal tissues. The primary objective of the study is to assess the safety and tolerability of different doses of AG019 alone as well as AG019 in association with teplizumab. The secondary objectives of this study are: to obtain PD data of AG019 alone as well as AG019 in association with teplizumab; and PK data to determine the potential presence of AG019 in systemic circulation (safety - systemic exposure) and the presence of L. lactis bacteria in fecal excretion (local exposure). The study will enroll 48 participants and will be conducted in two phases:

 

  ● Phase 1b: open-label part of the study which will investigate the safety and tolerability of two different doses of AG019 in two age groups (18 to 40 years of age and 12 to 17 years of age).

 

23

 

 

  ● Phase 2a: randomized, double-blind part of the study which will investigate the safety and tolerability of AG019, in association with teplizumab, in two age groups (18 to 40 years of age and 12 to 17 years of age).

 

The study commenced in October 2018 and is currently enrolling the Phase 2a. In January 2021, Precigen presented the following positive interim data from the Phase 1b (monotherapy) and Phase 2a (combination) arms of the study:

 

  ● AG019 monotherapy as well as the combination of AG019 and teplizumab were well-tolerated and safe.
  ● 58% (7/12) and 70% (7/10) adult showed insulin C-peptide stabilization at 6-months in monotherapy and combination arms, respectively.
  ● Increase in pre-proinsulin (PPI) - specific Type 1 regulatory (Tr1) cells in both monotherapy and combination arms.
  ● Significant decrease in PPI-specific CD8+ T cells in both monotherapy and combination arms.

 

PRV-101 (CVB Vaccine) for Acute Infection and T1D

 

PRV-101 is a polyvalent (more than one strain) prophylactic CVB vaccine intended to prevent acute CVB infection and the development of CVB-induced T1D and celiac autoimmunity. Based on epidemiological and pre-clinical study data to date, we believe that, if successful, PRV-101 may prevent up to 50% of T1D cases and up to 20% of celiac cases. Preclinical studies completed to date by Vactech and replicated independently by us demonstrate that CVB triggers diabetes in animal models of T1D and that vaccination against CVB protects mice from acute infection as well as prevents the onset of diabetes triggered by CVB infection.

 

Current Clinical Development Program

 

First in Human Phase 1 Clinical Trial of PRV-101 (PROVENT Study)

 

In December 2020, we announced the initiation of the PROVENT (PROtocol for coxsackievirus VaccinE in healthy voluNTeers) study, a first-in-human study of PRV-101 for the prevention of acute CVB infection and the potential delay or prevention of T1D and celiac disease.

 

PROVENT is a placebo-controlled, double-blind, randomized first-in-human study being conducted at the Clinical Research Services Turku - CRST Oy, a clinical trial unit in Turku, Finland. The study’s primary endpoint is the safety of two dose levels of PRV-101 in healthy adult volunteers provided three administrations with 4-week intervals. Tolerability and immunogenicity will also be evaluated. The primary objective of this first-in-human (“FIH”) clinical trial is to evaluate the safety and tolerability of multiple doses of PRV-101 administered at two different dose levels. A secondary objective is to evaluate the immunogenicity of PRV-101 (ability to elicit antibodies, including neutralizing antibodies, against CVB). Results of PROVENT are expected in the fourth quarter of 2021.

 

CVB Infection Market

 

Enteroviruses are responsible for an estimated ten to 15 million symptomatic infections in the United States annually. CVB contributes to a major part of the healthcare costs of enteroviruses as they cause the most serious complications and are among the most frequently reported enteroviral infections according to the CDC. Acute CVB infection is usually asymptomatic or causes common cold-type symptoms. It often also leads to a febrile illness associated by rash, hand-foot-mouth disease and/or mild GI distress. However, CVB infections also cause more severe manifestations including pericarditis, myocarditis, meningitis and pancreatitis.

 

  - Myocarditis: CVB is the most common etiologic agents for myocarditis in the Western world, responsible for up to 33% of cases of myocarditis. Myocarditis is an important cause of sudden unexpected death: the prevalence of myocarditis in children and adolescents leading to sudden unexpected death has been reported to be as high as 8% to 42%. In certain individuals, acute myocarditis progresses to chronic myocarditis and dilated cardiomyopathy, which is a severe life-threatening condition.

 

24

 

 

  - Otitis media: otitis media (middle ear inflammation) may develop in patients with upper respiratory disease caused by enterovirus. Otitis media constitutes 18% of physician visits in the United States (largest single reason in children). The costs of otitis media treatment in the United States were estimated to be approximately $3 billion in 2014.
  - Meningitis: CVB is a common cause of enteroviral meningitis. Meningitis beyond the neonatal period is characterized by the sudden onset of fever of 38-40°C. Headache and photophobia are almost universally reported in these patients. Reports on the incidence of viral meningitis vary from approximately 50,000 hospitalized cases to over 2 million cases of aseptic meningitis per year. Based on 300,000 annual cases of aseptic meningitis in the United States (of which enteroviruses, and coxsackie viruses in particular, are the most common cause), the economic impact is estimated to be $1.5 billion in direct costs alone.

 

Overview of CVB Infection of the Pancreas, T1D and PRV-101’s Mechanism of Action

 

Longitudinal studies of more than 200,000 children studied for up to two decades in Finland by our technology licensor, Vactech, and its collaborators (“DIPP Study”), identified CVB infection as a likely environmental trigger in the onset of T1D autoimmunity and T1D-associated celiac disease (“CD”) autoimmunity. Subsequent full-virome analysis of the TEDDY Study (400,000 children international study) confirmed that CVB is the only virus whose persistent infection is associated with the development of T1D and celiac disease autoimmunity (T1D-associated and also independent of T1D).

 

CVB infection is very common and is responsible for various symptoms and complications ranging from mild respiratory disease, gastrointestinal disturbances and hand-foot-mouth disease to life-threatening cardiomyopathy and meningitis. However, in patients with a certain genetic background, CVB appears responsible for the development of autoimmunity. The T1D association with CVB infection has been observed in independent cohorts in 15 countries, including in North America, Europe and Australasia. These epidemiological observations have been substantiated by biological experimentation. Insulin-producing beta cells in the pancreas express specialized receptors associated with the transport, storage and release of insulin. These receptors appear to be used by CVB to preferentially infect these cells and polymorphism in these receptors are associated with development of T1D autoimmunity. Infection by enteroviruses can be detected in the pancreatic beta cells of approximately 60% of T1D patients and in the gut of most patients with T1D-associated CD. Importantly, if mothers have anti-CVB immunity at the time of the pregnancy, a 50% reduction in the onset of T1D autoimmunity (T1D-associated auto-antibodies) has been observed in their offspring, presumably due to protection by maternal antibodies passed on to the fetus. This observation strongly suggests the potential efficacy of CVB vaccination for children and/or mothers, resulting in the development of protective antibodies potentially capable of preventing or delaying the onset of T1D.

 

An analysis of stool samples collected from these individuals identified enterovirus infections prior to the first detection of T1D auto-antibodies. Enterovirus RNA was also detected in stool samples. Examination of antibodies present in DIPP children who developed at least two islet cell auto-antibodies (sign of incipient T1D) and/or progressed to T1D confirmed that among all enteroviruses, only CVB was significantly associated with initiation of beta cell autoimmunity.

 

25

 

 

Enterovirus RNA in Blood is Linked to the Development of T1D

 

OR: odd ratio; CI: confidence interval; EV: enterovirus

 

 

 

Preclinical Evaluation PRV-101

 

Preclinical Data for PRV-101

 

The mechanism of action and efficacy of PRV-101 is supported by the results of several in vivo studies. Inactivated CVB-based viral vaccines efficiently protect mice from CVB infections and from viral spread to the pancreas, as seen for CVB1 and CVB3 vaccines. Similar experiments conducted with a vaccine covering all six CVB serotypes demonstrated that it can induce a strong neutralizing anti-CVB response in mice and protect the animals against multiple CVB infections from the corresponding live viruses. Independent experiments confirm that CVB infection can accelerate T1D onset in T1D susceptible NOD (Non-obese diabetic) or SOCS-1-Tg (suppressor of cytokine signaling 1 transgenic) mice, suggesting that protection from CVB infection would therefore protect against T1D development. This hypothesis has been confirmed in experiments conducted by the Karolinska Institute (Sweden) and the University of Tampere (Finland), demonstrating that CVB1 and CVB3 vaccines produced by Provention indeed protected SOCS-1-Tg mice against T1D induced by CVB1 and CVB3, respectively. These mice develop T1D after CVB infection as a consequence of a direct infection of insulin-producing beta cells in the pancreas and the subsequent immune response against the beta cells, mimicking human T1D. A three-injection vaccination course induced robust neutralizing antibody responses against CVB1/CVB3 and protected mice from both CVB1/CVB3 infection and CVB1/CVB3-driven T1D. CVB1/CVB3 infection led to a loss of insulin-producing cells in unvaccinated mice, which also was prevented by the vaccine. These data strongly supported the development of PRV-101 for the prevention of T1D in humans.

 

Formalin-Inactivated CVB1 Vaccine is effective against CVB1-Induced T1D in a Mouse Model.

 

As seen in the left panel below, CVB1 infection led to loss of insulin-producing cells, and this pathology was completely prevented by the CVB1 vaccine (right panel). In this experiment, while 50% of unvaccinated mice develop T1D as a consequence of CVB1 infection, all vaccinated mice were protected (not shown).

 

26

 

 

 

 

Important from a safety point of view, the formalin-inactivated CVB1 vaccines did not cause any undesirable effects in the pancreas. There was no vaccine-induced pancreatic pathological change, islet autoimmunity or diabetes in the vaccinated mice. Similar results were obtained for Provention-manufactured CVB1 and CVB3 vaccines (not shown).

 

Finally, maternal CVB infection during gestation in mice protects the offspring from CVB infection and subsequent T1D development, presumably through transfer of specific antibodies from the mother to the fetus, corroborating previous findings in humans in the DIPP study and further supporting the use of a prophylactic vaccine to protect against CVB-associated-T1D.

 

CTA-Enabling Program to Support FIH Study

 

The CVB vaccine toxicology program to date has consisted of Good Laboratory Practices (“GLP”) and non-GLP safety and immunogenicity studies conducted in mice. These studies were designed to identify and characterize potential toxicities associated with PRV-101 treatment, including those arising from the immune responses induced by the product. They mirrored the administration regimen that is now used in the PROVENT FIH study, and by the same route of administration.

 

Pharmacology studies have also been conducted to determine the desired composition of the vaccine, leading to successful GMP manufacturing of the final polyvalent vaccine for clinical trials.

 

PRV-3279 (Humanized CD32B x CD79B Dual Affinity Biologic for SLE and Other Autoimmune Diseases)

 

PRV-3279 is a humanized CD32B x CD79B dual affinity biologic in a new class of bispecific scaffold antibody-like molecules called DARTs. It is designed to simultaneously bind to CD32B and CD79B on B cells. The simultaneous binding of both CD32B and CD79B triggers CD32B-coupled immunoreceptor tyrosine-based inhibitory motif signaling, which leads to the suppression of B cells activated to produce auto-antibodies, while not causing broad B cell depletion.

 

We believe PRV-3279 may intercept the pathophysiology of SLE by preventing the production of auto-antibodies by abnormally active B cells.

 

Current Clinical/Preclinical Development Program

 

Phase 1b/2a clinical trial of PRV-3279 in Healthy Volunteers and Patients with Lupus

 

We are conducting a two-part study in SLE, the PREVAIL (PRV-3279 EVAluation In Lupus) study. PREVAIL is a randomized, double-blind, placebo-controlled Phase 1b/2a clinical trial to evaluate the safety, tolerability, PK, PD, and immunogenicity of multiple ascending doses of PRV-3279 in 16 healthy adult volunteers (Part 1) and the efficacy of PRV-3279 in patients with lupus (Part 2).

 

27

 

 

On March 12, 2020, we announced positive top-line results from the Phase 1b portion of the PREVAIL study. PRV-3279 was well-tolerated, with no serious adverse events, and as expected, did not deplete B cells and demonstrated profound and sustained binding to circulating B lymphocytes, with reduction of circulating immunoglobulin M levels in a dose-proportional manner. While anti-drug antibody production was observed at both dose levels tested, immunogenicity was found not to affect exposure, safety or pharmacodynamic parameters. Data from PREVAIL-1 was presented at the American College of Rheumatology (ACR) conference in November 2020.

 

Based on these results, we plan to commence the Phase 2a portion of the PREVAIL study in lupus patients in the second half of 2021.

 

Our ultimate goal is to determine if PRV-3279 can intercept the pathophysiology of SLE by preventing the production of auto-antibodies by abnormally active B cells. Part 2 will have a planned treatment duration of six months and endpoints will include lupus clinical assessments and biomarker measurements. Clinical endpoints will include the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), the British Isles Lupus Assessment Group score, urine protein to creatinine ratio, and daily glucocorticoid use. Additional biomarkers will include urinary/renal markers (e.g., serum creatinine, estimated glomerular filtration rate) and blood/circulating markers (e.g., auto-antibodies, complement (C3 and C4), B cell function/phenotype, including CD32B expression/response relationship).

 

In support of the clinical evaluation of PRV-3279 in lupus in PREVAIL-2, we and our partner, MacroGenics, studied the effect of PRV-3279 on B cells from lupus patients ex vivo. PRV-3279 was able to reduce the activation of these B cells similarly to its effects on healthy volunteer B cells, regardless of the activity level of the lupus patients. These data were presented at the ACR conference in November 2020.

 

Current Preclinical Development Program

 

Preclinical Studies for the Prevention of the Immunogenicity of Biotherapeutics Including Gene Therapy

 

We believe that PRV-3279 has the potential to prevent or reduce the immunogenicity of biotherapeutics, including but not limited to gene therapy vectors and transgenes (new proteins expressed as a result of the gene therapy).

 

As the field of gene therapy advances, patients’ immune responses to the viral vectors and the transgene products remain a key challenge negatively impacting the safety, efficacy and ability to deliver additional courses systemically. One of the current mitigation strategies to overcome these immune responses is pharmacological modulation of the patients’ antibody immune responses with the B cell depleting agent rituximab in combination with the immune-suppressive agent sirolimus. Prolonged use of rituximab has been associated with certain adverse events. The use of PRV-3279, as a non-depleting B cell inhibitor, is a potential strategy to address this unmet need in serious genetic diseases.

 

PRV-3279 has been shown to reduce B cell responses to viral antigens using an experimental vaccine challenge in Phase 1. In January 2021, we announced positive pre-clinical data in a mouse model of gene therapy for Pompe disease. A PRV-3279 mouse surrogate was tested in mice transgenic for human CD32B, which received gene therapy with an AAV vector AAV9 encoding for the enzyme GAA gene. Errors in the GAA gene cause the serious human glycogen storage disease type II (Pompe disease).

 

In the study, the PRV-3279 surrogate reduced anti-AAV9 vector antibody levels in a dose-dependent fashion. Anti-AAV9 antibodies have been linked to reduced efficacy, safety concerns and the inability to re-dose patients, and thus, based on these and other study data, we believe PRV-3279 co-administration with gene therapy products has the potential to improve the safety and efficacy of this therapeutic modality. The PRV-3279 surrogate in combination with sirolimus increased skeletal muscle levels of GAA enzyme expression. Consistent with prior results from clinical trials in healthy human subjects, the PRV-3279 surrogate decreased IgM production and was well tolerated.

 

Based on these data, we plan to look for opportunities to work with academic and industry experts to combine PRV-3279 with gene therapy and other biotherapeutic products to further our mission of preventing and intercepting devastating immune-mediated conditions.

 

28

 

 

SLE Market and Other Opportunities for PRV-3279

 

Sales of therapies to treat SLE are expected to climb to nearly $3 billion by 2025-2027, approximately 7-8% annual growth from 2019. This growth is driven primarily by treatments that target B cells belimumab, with a new indication in lupus nephritis in 2020, and off-label use of rituximab - and the approval of new mechanisms (voclosporin for lupus nephritis, approved in January 2021, and the expected approval of novel mechanisms such as Type I interferon inhibitors for SLE). The uptake of belimumab has been driven largely by safety rather than substantial efficacy, supporting the unmet need and potential for novel and safe non-depleting B cell therapies with greater efficacy.

 

In addition to SLE, PRV-3279 has the potential to treat other B cell- and auto-antibody-driven autoimmune diseases. Such diseases include multiple sclerosis and RA, where B cell therapies rituximab and recently approved ocrelizumab (Ocrevus) have sales in excess of $1 billion. Several niche/orphan indications may also be explored, including T1D (potentially in combination with teplizumab), Sjogren’s syndrome, vasculitis (e.g., polymyalgia rheumatica, giant cell arteritis, Behçets disease), myasthenia gravis, pemphigus, neuromyelitis optica, anti-NMDA receptor encephalitis, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, Grave’s ophthalmopathy, IgG4-related disease, and idiopathic thrombocytopenic purpura.

 

SLE Background Information

 

SLE is a chronic autoimmune disorder that can affect nearly every major organ system, causing inflammation, tissue injury, organ damage, and in some patients, organ failure. The prognosis of SLE is highly variable in individual patients, often waxing and waning throughout their lifetime. The natural history of SLE ranges from relatively benign disease to rapidly progressive and even fatal disease. Comorbidities, such as infections, malignancies, hypertension, lipid disorders and diabetes increase the risk of disability and death in patients with SLE. Organ systems commonly affected by SLE include the central nervous system, kidneys, gastrointestinal system, mucous membranes, heart, skin, hematologic system, musculoskeletal system and lungs, with specific organ involvement defining subsets of the disease (e.g., lupus nephritis). According to the Lupus Foundation of America, at least 1.5 million Americans are afflicted by SLE and more than 16,000 new cases of lupus are reported annually. It is estimated that five million people throughout the world suffer from some form of lupus. Lupus affects primarily women of childbearing age (15 to 44 years). However, men, children, and teenagers can also develop lupus.

 

The pathogenesis of SLE is characterized by an abnormal overactivation of B cells and subsequent pathologic production of auto-antibodies (antibodies that attack one’s own cells and tissues). Uncontrolled activation of B cells is normally terminated when the activating stimulus is exhausted and when a negative feedback loop is triggered by the engagement of an inhibitory Fc receptor (“FcR”), known as FcgammaRIIb (“CD32B”). Mutations in the CD32B gene in humans are associated with an increased likelihood of SLE, and reduced expression of CD32B is apparent in B cells from SLE patients. It is thought that activation of this inhibitory pathway could ameliorate the overactive B cell-driven pathology of SLE and other autoimmune diseases. In addition, the excess auto-antibodies produced bind to target antigens and form immune complexes.

 

When the B cell receptor (“BCR”) (which is the “Y” shaped molecule, resembling an antibody in the figure below) is bound and activated by an antigen, it initiates a cascade of biochemical changes necessary for the activation of the CD32B inhibitory pathway, thus triggering the negative feedback loop. CD79B is a subunit of the BCR that plays a key role in this process when it is close to CD32B. Therefore, if a pharmacologic treatment is to activate the CD32B inhibitory pathway, it also has to simultaneously bind to CD79B. PRV-3279 (formerly MGD010), is a humanized CD32B x CD79B DART protein developed originally by MacroGenics as a bi-specific therapy with these properties, and thus a potential treatment for SLE and other similar diseases. It is designed to simultaneously bind to CD32B and CD79B on B cells.

 

29

 

 

 

 

PRV-3279 and related molecules have shown inhibitory effects on BCR-induced B cell proliferation and antibody secretion (including B cells obtained from SLE patients) as well as beneficial effects in mouse models of autoimmunity. PRV-3279 is expected to boost the negative feedback loop on B cells by robustly engaging the available CD32B and CD79B.

 

PRV-3279 has been studied in humans and was shown to be well tolerated. Proof of mechanism and PRV-3279’s inhibitory effect on antibody immune responses were demonstrated in a Phase 1a single ascending dose study in healthy volunteers, including a cohort demonstrating inhibition of the immunogenicity of the hepatitis A vaccine. Immunogenicity of PRV-3279 was also observed, but had no impact on mechanistic effects, safety or pharmacokinetics, and decreased with increasing doses of PRV-3279, possibly a reflection of its mechanism of action.

 

Our ultimate goal is to determine if PRV-3279 can intercept the pathophysiology of SLE by preventing the production of auto-antibodies by abnormally active B cells.

 

Current Treatment Options for SLE and Their Limitations

 

The treatment and management of SLE depends on disease severity and disease manifestations. Hydroxychloroquine plays a central role in the long-term treatment of SLE and is the cornerstone of SLE therapy. Corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive agents (e.g., azathioprine, cyclophosphamide, cyclosporine, methotrexate, and mycophenolate mofetil) have also been used in the treatment and management of SLE. These treatments are only modestly effective and present safety and/or immune suppression concerns with prolonged use. The B cell-depleting antibody rituximab (Rituxan), while not approved for treatment of SLE, appears to be beneficial in certain subsets of patients.

 

In 2011, the FDA approved belimumab (Benlysta), an antibody that targets B lymphocyte stimulator, for the treatment of mild to moderate SLE in combination with standard therapy, providing additional clinical validation of the therapeutic benefit of B cell-targeted therapy for autoimmune diseases. However, the modest therapeutic benefit of belimumab and delayed onset of disease intervention indicate the need for additional therapeutic strategies to inhibit overactive B cells. We believe PRV-3279 can fulfill that requirement and is uniquely differentiated to allow for rapid inhibition of activated B cells (potentially more effective than belimumab), while sparing non-activated B cells from depletion or inactivation (potentially safer than rituximab).

 

30

 

 

In December 2020 and January 2021, the FDA approved belimumab and voclosporin, respectively, for the treatment of lupus nephritis. We will focus development of PRV-3279 in SLE.

 

Overview of CD32B Biology and Relevance in Lupus

 

CD32B is expressed widely on the surface of human B cells. In addition to its expression on B cells, CD32B is also expressed on other immune cells such as dendritic cells, macrophages, neutrophils, and mast cells. It is a single-chain protein with a portion that sits outside of the cell membrane, which can be bound by chemical signals.

 

CD32B is the only known inhibitory FcR in the immune system. It plays an important role not only for innate and adaptive immune responses, but also in the maintenance of immune tolerance and controlling autoimmunity. Mice deficient in CD32B have increased antibody responses due in part to chronic B cell activation, and as a result, develop autoimmune disease similar to human SLE. In contrast, B cell-specific overexpression of CD32B and cross-linking of CD32B with antibodies ameliorate the incidence and severity of lupus in mouse lupus models. In humans, mutations and decreased expression of the CD32B gene are associated with an increased likelihood of SLE. These results underscore the important role of CD32B in regulating the antibody immune response and suggest that drug-mediated engagement of CD32B could provide therapeutic benefit in autoimmune diseases by dampening the effects of chronically activated B cells and reducing the production of auto-antibodies. In particular, preventing the production of auto-antibodies could intercept the disease course in lupus nephritis, a subtype of lupus driven by accumulation of auto-antibodies and immune complexes (a mass of antibodies and other molecules) in the kidneys.

 

Consistently, a monoclonal antibody anti-CD19 which binds CD32B with high affinity, XmAb5871 (Xencor), was shown in 2018 to be efficacious -albeit missing the primary endpoint- in a Phase 2 lupus trial, particularly in patients with B cell biomarker signatures, providing indirect validation for the potential of PRV-3279 in lupus. XmAb5871, which has shown thrombocytopenia (unlike PRV-3279, XmAb5871 binds to CD32A, which is expressed on platelets), has not moved forward in development to date.

 

Mechanism of Action of PRV-3279

 

PRV-3279 is in a new class of bispecific scaffold antibody-like molecules called DARTs. It is designed to simultaneously bind to CD32B and CD79B on B cells. The simultaneous binding of both CD32B and CD79B triggers CD32B-coupled immunoreceptor tyrosine-based inhibitory motif signaling, which leads to the suppression of B cells activated to produce auto-antibodies, while not causing broad B cell depletion.

 

To prolong its half-life in the body, PRV-3279 contains a human IgG1 Fc region (a specific antibody fragment) that is manipulated to eliminate its effector function. As a molecule designed to inhibit immune responses, PRV-3279 does not activate any part of the immune system either in the body or in laboratory tests. PRV-3279 also does not bind to platelets, a unique feature compared to competing molecules targeting CD32B that are associated with toxicity due to binding to platelets (e.g., XmAb5871, an anti-CD19 mAb which binds to CD32 via the Fc fragment).

 

Prior Preclinical Evaluation of PRV-3279

 

The only nonhuman species that PRV-3279 binds to is chimpanzees. An initial non-GLP study with PRV-3279 in chimpanzees demonstrated it to be well tolerated at all doses, with an assigned no observed-adverse-effect level (“NOAEL”), of 10 mg/kg.

 

Due to the lack of target binding, chronic four-week and three-month repeat-dose GLP toxicology studies were performed using a surrogate DART molecule similar to PRV-3279 that was designed to target human CD32B and mouse CD79B in a transgenic mouse line that expresses human CD32B. A NOAEL at the highest dose of 50 mg/kg was assigned in the three-month study. We believe these studies, and our regulatory interactions, support the advancement of PRV-3279 in long-term efficacy studies in humans, such as PREVAIL-2.

 

31

 

 

Prior Clinical Evaluation and Proof of Mechanism for PRV-3279

 

To date, there have been two clinical trials completed with PRV-3279. The first study was conducted at a single site in the U.S., from February 2015 to February 2017 and was a FIH, double-blind, placebo-controlled Phase 1a clinical trial to evaluate the safety, tolerability, PK, PD, and immunogenicity of PRV-3279 in healthy adult volunteers.

 

A total of 49 subjects were randomized; 12 received placebo and 37 received PRV-3279 intravenously at escalating doses from 0.1 mg/kg to 10 mg/kg in six cohorts. PRV-3279 was well tolerated over the range of doses, with only mild adverse events that resolved quickly, including headache, somnolence (sleepiness), upper respiratory tract infection, folliculitis and night sweats. Target binding and proof of mechanism were demonstrated by measuring functional B cell inhibition at doses of 1 mg/kg or higher, without broader B cell activation or depletion observed.

 

Subsequently, proof of mechanism was further confirmed in a dose escalation extension of the study in which single doses of PRV-3279 at 3 mg/kg and 10 mg/kg (16 subjects) were compared with placebo (eight subjects) for the ability to affect B cell responses to a hepatitis A vaccine, which was administered to participants who had no previous hepatitis A immunity, on day two of the study. At both doses, PRV-3279 reduced the proportion of volunteers who generated an immune response against the vaccine, as well as the amount of antibody they produced, in both cases as compared to placebo.

 

PRV-3279 exhibited an approximate half-life of seven days after a single dose. A majority (~86%) of study participants developed antibodies against PRV-3279 (i.e., immunogenicity) after receiving the 3 mg/kg dose, but no detrimental effect was observed on the pharmacokinetics of PRV-3279. The proportion of participants developing antibodies against PRV-3279 decreased with increasing dose (29% in the 10 mg/kg dose) and such antibodies did not occur in the multiple dose chimpanzee study, suggesting that PRV-3279 may limit its own immunogenicity at therapeutic doses, which is consistent with its mechanism of action.

 

The second study was the Phase 1b portion of the PREVAIL study, which was a double-blind, placebo-controlled, multiple ascending dose study in 16 health volunteers described above.

 

PRV-015 (human anti-interleukin 15 mAb) for Non-Responsive Celiac Disease (NCRD)

 

PRV-015 is a fully human immunoglobulin (“IgG1) mAb that binds to and inhibits pro-inflammatory cytokine interleukin (IL-15), which has been identified as a major mediator in the pathophysiology of celiac disease. PRV-015 has emerged as a leading candidate for the treatment of nonresponsive celiac disease, in which patients continue to have disease activity despite ongoing gluten free diet (“GFD”).

 

PRV-015 has undergone clinical testing in approximately 250 subjects who have received PRV-015 across two Phase 1 (healthy volunteers and psoriasis, rheumatoid arthritis (“RA”) and three Phase 2 clinical trials (celiac disease, RCD-II, RA). No serious adverse events deemed related to PRV-015 were observed that would preclude further clinical development. Proof of mechanism and/or proof of concept was demonstrated in RA, celiac disease and refractory celiac disease Type II. The effect of PRV-015 in celiac disease was evidenced by reduction in inflammation and symptoms after a controlled gluten challenge in a Phase 2a clinical trials with 63 celiac patients.

 

Celiac Disease Market

 

There is no approved drug for CD. The annual healthcare utilization by NRCD patients in 2013 was $18,206, for $4,796 in matched controls due to the extra costs of uncontrolled CD investigations and treatment of complications. Given the large prevalence (15 to 20 million patients world-wide, 1% of the population in the Western world and 0.5% in Asia), and the unmet need (50% of patients on GFD continue to suffer from disease activity due to contaminating gluten in the diet), NRCD is considered a substantial opportunity for pharmaceutical development of an effective and well-tolerated adjunctive treatment to the GFD.

 

32

 

 

Current Clinical Development Program

 

Phase 2b Clinical Trial of PRV-015 in Celiac Disease (PROACTIVE Study)

 

We and our partner Amgen conducted chronic toxicology studies in 2019 and early 2020. In August 2020, we initiated the PROACTIVE study (PROvention Amgen Celiac ProtecTIVE Study), a randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 2 clinical trial in adult patients with NRCD. PRV-015 will be administered every two weeks via subcutaneous route for six months. The hypothesis of this study is that PRV-015 will be superior to the GFD at intercepting the effects of contaminating gluten exposure in celiac patients following a GFD, as measured by symptoms and objective signs of intestinal inflammation after 24 weeks of treatment. Approximately 220 subjects are planned to be enrolled. We expect to report top line results for the Phase 2b PROACTIVE study in 2022.

 

Celiac Disease Background Information

 

Celiac disease is a systemic autoimmune disease triggered by gluten consumption in genetically susceptible individuals. Approximately 1% of the western population is affected by celiac disease. This prevalence has been reported to be doubling every 20 years. Gluten is ubiquitous in food and elicits autoimmune responses in celiac patients, with damage to the mucosal lining of the small intestine. Celiac disease causes debilitating symptoms and serious medical complications, as the small bowel damage can lead to nutrient malabsorption and results in a range of subsequent intestinal and extra-intestinal clinical manifestations. The stimulation of intestinal lymphocytes for decades can lead to the development of lymphoma, with increased mortality.

 

Gluten is the main protein present in some of the most common cereals (wheat, barley, rye). Modern diets are increasingly enriched with gluten and it is also used as an additive in processed foods, cosmetics and oral medications. Gluten is also present in trace amounts in foods labeled as “gluten-free”, as a tableting excipient, and in products such as toothpaste and lipstick. As little as 50mg/day of gluten triggers the disease. A normal diet contains >10 g/day, 200 times the amount that causes damage and intestinal histological abnormalities. As such, celiac patients face enormous challenges to follow a strict GFD.

 

The pathophysiology of celiac disease is characterized by an abnormal immune response to gluten. Humans lack enzymes to fully digest gluten, which against the right genetic background triggers inflammation and autoimmunity in the intestine and in other organs. An adaptive immune response is triggered when gluten peptides are deamidated in the extracellular space, by the enzyme tissue transglutaminase, normally an intracellular enzyme that is released by damaged cells. This deamidation renders gluten peptides high-avidity binders to HLA-DQ2 and HLA-DQ8, which present these peptides to intestinal CD4+ T cells, thereby activating these T cells and initiating the inflammatory cascade. The innate immune system’s intraepithelial lymphocytes (“IELs”), primarily CD8+, are able to directly lyse and destroy intestinal epithelial cells, damaging the mucosal lining of the small intestine, in response to IL-15 release stimulated by gluten peptides. In healthy individuals, the activated T cells are controlled by Tregs, but this does not happen in celiac disease as IL-15 confers the effector CD4+ T cells resistance to suppression by Tregs.

 

Celiac disease causes debilitating symptoms and serious medical complications. In many patients, gastrointestinal symptoms derived from intestinal mucosal damage dominate the patient reported symptoms at diagnosis. The normal villi (absorptive finger-like prolongations) present in the gut of healthy individuals are lost in active celiac disease as a result of mucosal atrophy and crypt enlargement. Small bowel damage often leads to nutrient malabsorption that can result in a range of further clinical manifestations (anemia, osteopenia, failure to thrive in children). In addition, extra-intestinal symptoms and systemic manifestations are often present, such as dermatitis, infertility, or neurological and skeletal disorders. Mortality is increased in subjects with persistent intestinal mucosal damage.

 

The most serious complication of celiac disease is the development of an in situ small bowel T cell lymphoma after many years of exposure, voluntary or inadvertent, to gluten. This malignant complication of celiac disease, which appears to be independent of gluten and unresponsive to a strict GFD, is termed RCD-II when the percentage of aberrant IELs is >20% and Type I refractory celiac disease when the percentage is <20%. In RCD-II, aberrant IELs proliferate in what represents a slow-growing non-Hodgkin lymphoma localized (in situ) in the small bowel, primarily in the epithelial compartment. RCD-II affects approximately 0.5% of celiac patients and can lead to overt and systemic enteropathy-associated T cell lymphoma, with very poor prognosis and >80% mortality in five years.

 

33

 

 

Current Treatment Options and Their Limitations

 

Celiac disease is the only common autoimmune disorder with no approved medication. The only current available strategy for the management of celiac disease is a lifelong total avoidance of gluten. While simple in theory, the ubiquity of gluten in foodstuffs, medications, household substances, cosmetics, and gluten-free items makes total avoidance of gluten difficult, if not impossible.

 

The main challenge to the successful maintenance of a GFD is that cereal flours are widely used in the food industry and are present in numerous food products either naturally or as additives. Although gluten-free products can be purchased, commercially manufactured gluten-free products may be difficult to find, tend to be less flavorful and are more expensive than regular gluten containing foods. In addition, labeling of food products is deficient in many countries. Even in countries with superior labeling guidelines foods labeled “gluten-free” may nevertheless contain gluten. For example, in northern European countries amounts of up to 100 parts per million are permitted in gluten-free products designated apt for celiac sufferers.

 

For these reasons, celiac sufferers are regularly exposed to gluten contamination in the food and beverages they consume. This exposure to gluten contamination and the associated physiological and psychological consequences results in a self-limitation of social activities and/or a reduction in the variety of foods consumed. Thus, the only currently available management option of a GFD presents both a considerable challenge and substantial burden for patients. A study by Shah and collaborators (2014) found the burden of celiac disease and GFD on patient quality of life to be very high, second only to end-stage renal disease – a condition that requires multiple, weekly dialysis treatments.

 

As a result of the difficulty in maintaining total avoidance of gluten while on a GFD, gluten contamination causes 50% or more of all diagnosed celiac patients on a GFD to continue to experience disease activity. Patients who continue to have symptoms despite attempting to maintain a GFD are deemed to have NRCD. NRCD has been defined as “persistent symptoms, signs or laboratory abnormalities typical of celiac disease despite 6–12 months of dietary gluten avoidance”. As requested by patient support groups and experts, alternative treatment options that can be administered independently or in combination with a GFD, as well as treatments for refractory celiac disease, are required in order to improve the quality of life for celiac patients.

 

Overview of IL-15 Biology and PRV-015 Mechanism of Action

 

IL-15 is a pro-inflammatory cytokine that serves as a potent growth, survival, and activation factor for T cells, particularly IELs, and for natural killer (“NK”), cells. Increased expression of IL-15 has been demonstrated in a variety of inflammatory conditions, including celiac disease, RA, and psoriasis. IL-15 is considered a central regulator of celiac disease immunopathology and a non-redundant driver of lymphomagenesis in RCD-II.

 

Substantial evidence suggests a pathophysiological role for IL-15 in celiac disease:

 

Innate immunity:

 

  ● IL-15 is an essential, non-redundant growth and activation factor for the IELs which destroy the intestinal mucosa;
  ● The expression of IL-15 in the intestinal epithelium is necessary for villous atrophy; and
  ● In some patients, IL-15 drives progression towards lymphomagenesis and potentially fatal RCD-II.

 

Adaptive immunity:

 

  ● IL-15 enhances the presentation of deamidated gluten peptides by APCs;
  ● IL-15 renders the activated CD4+ T cells resistant to inhibition by Tregs; and
  ●

IL-15 has been proven to be a key factor in the loss of tolerance to food antigens.

 

 

By activating the IELs, IL-15 is believed to be the main mediator in the mucosal damage that ensues in response to gluten exposure in celiac disease. The expression of IL-15 in the intestinal epithelium is necessary for villous atrophy in animal models of celiac disease and circumstantial evidence suggests this to be the case in humans, as well. In addition, IL-15 renders effector T cells resistant to inhibition by Tregs, promoting loss of tolerance to food antigens.

 

One of the studied mouse models of celiac disease is an IL-15-transgenic mouse, in which IL-15 overexpression by gut epithelial cells leads to celiac-like disease, including T and B cell-mediated pathology. IEL apoptosis has been observed in this animal model after treatment with anti-IL-15 or anti-IL-15-receptor monoclonal antibodies.

 

34

 

 

Figure 1. Multiple actions of IL-15 in the pathophysiology of celiac and refractory celiac disease

 

 

 

PRV-015 (formerly AMG 714 and HuMax-IL15), is a fully human immunoglobulin (IgG) mAb which binds to and inhibits the function of IL-15 in all its forms (cis, trans, soluble IL-15 bound to IL-15R). PRV-015 inhibits IL-15-induced T cell proliferation and shows a dose-dependent inhibition of IL-15-induced TNF- production. PRV-015 underwent preclinical testing and was subsequently evaluated in a Phase 1 and Phase 2 study in subjects with RA, in a Phase 1 study in healthy volunteers and in patients with psoriasis, and in two Phase 2a studies in celiac disease and refractory celiac disease Type-II.

 

Pre-clinical Evaluation of PRV-015

 

The nonclinical development of PRV-015 consisted of a series of in vitro studies demonstrating the binding properties of PRV-015 against human IL-15; in vitro and in vivo studies providing proof-of-concept for the benefit of blocking the IL-15 pathway in celiac disease; and a series of GLP studies evaluating the nonclinical safety profile of Hu714MuXHu, the PRV-015 surrogate molecule which is active in macaques.

 

Pharmacology

 

PRV-015 was found to be efficacious in a mouse model of celiac disease triggered by the transgenic expression of human IL-15 in the gut epithelium. In this model, PRV-015 prevented IEL activation and proliferation, as well as histological abnormalities. In addition, PRV-015 was able to induce apoptosis of human IELs in ex vivo culture of small intestinal explants from active celiac disease and RCD-II patients. In this culture experiment, PRV-015 resulted in a suppression of IL-15-driven anti-apoptotic signaling via JAK3 and STAT5.

 

Toxicology

 

In vitro studies demonstrated that PRV-015 had high binding affinity for human IL-15, but lower affinity for macaque IL-15. Additionally, PRV-015 neutralized human IL-15 but did not efficiently neutralize macaque IL-15. To enable preclinical and toxicology studies in macaques, a surrogate antibody, Hu714MuXHu, was developed by Amgen by fusing the F(ab) portion of a mouse anti-human IL-15 mAb known to neutralize macaque IL-15, M111, with human IgG1 Fc. Hu714MuXHu was shown to neutralize macaque IL-15 with approximately the same potency as PRV-015 neutralizes human IL-15.

 

35

 

 

There was a decrease in NK cell counts and NK cell activity following administration of Hu714MuXHu to monkeys, reflecting a PD response to IL-15 blockade in this species, given the known role of IL-15 in NK cell biology in animal models (rodents and non-human primates). Of note, no changes in absolute or relative numbers of NK cells were observed in any of the human studies. This difference between observations in preclinical studies and clinical trials appears related to a differential sensitivity of human versus cynomolgus monkey NK cells to IL-15 deprivation. Human NK cells are not dependent on IL-15 for their survival, possibly due to the redundant role of IL-2 on human NK cells.

 

Pharmacokinetics of PRV-015

 

The PK of PRV-015 was consistent with a typical human immunoglobulin G1 antibody with no apparent target-mediated disposition within the investigated dosing range. The mean half-life in human studies has been 20 to 22 days, potentially enabling monthly dosing.

 

There was no development of anti-drug antibodies to PRV-015 in healthy volunteers, patients with psoriasis or patients with refractory celiac disease. Only one RA patient in the phase 2b study was positive for anti-drug antibodies. Approximately 14% of patients with celiac disease developed anti-drug antibodies in the Phase 2a clinical trial, with an additional 10% presenting pre-existing anti-drug antibodies, a reflection of the abnormal antibody responses which characterize celiac disease. The anti-drug antibodies were not associated with injection reactions or adverse events, and they were non-neutralizing, with no impact on PK.

 

Proof of Mechanism for PRV-015 and Prior Clinical Evaluation

 

PRV-015 was initially developed for RA in two small Phase 1 and 2 studies with approximately 200 patients with moderate-to-severe disease. Although PRV-015 missed the primary endpoint in the Phase 2 study at week 14, the results were significant at weeks 12 and 16, establishing proof-of-concept. Approximately 60% of patients with active RA in both Phase 1 and Phase 2 studies versus approximately 30% of patients in the placebo groups demonstrated a response to treatment as measured by the American College of Rheumatology 20% improvement score (ACR 20) at 8 and 12 weeks, respectively. PRV-015 also led to decreases in RA inflammatory biomarkers such as C-reactive protein and erythrocyte sedimentation rate. PRV-015 was not effective in psoriasis in a small Phase 1 study, suggesting PRV-015’s action is selective, unlike that of broad systemic immune suppressants.

 

Upon gluten challenge in a Phase 2 clinical trial in celiac disease (CELIM-NRCD-001), PRV-015 did not prevent gluten-induced architectural mucosal injury, and thus missed the primary endpoint, yet the high dose of PRV-015, 300 mg, showed statistically significant attenuation of gluten’s effects on the change from baseline in intestinal inflammation, in patient-reported symptom questionnaires (the Celiac Disease Patient Reported Endpoint, CeD PRO, a registrational endpoint in NRCD) and in diarrhea, compared with placebo. The totality of the results from the patients who had gluten challenge indicate that 300 mg PRV-015 (formerly AMG 714) given every two weeks can ameliorate the inflammation and symptoms caused by substantial gluten exposure, the first demonstration of such dual benefit in intestinal inflammation and symptoms for any experimental medication for celiac disease. The results suggest that PRV-015 can be a potential adjunctive treatment for NRCD to the GFD to ameliorate or resolve persistent inflammation seen in the majority of celiac patients already on GFD.

 

In the Phase 2a clinical trial in RCD-II (CELIM-RCD-002), the primary endpoint (reduction in intestinal IELs) was not achieved, yet PRV-015 showed statistically significant benefit over placebo in reducing T cell receptor clonality (no increase in clonality with PRV-015) and symptoms (diarrhea). Other endpoints, such as histology, did not reach statistically significant differences between groups, but the results consistently favored PRV-015 numerically. PRV-015 was generally well tolerated, with no observed immunogenicity.

 

36

 

 

Summary data of the Phase 2a clinical trial as presented at Digestive Disease Week in June 2018 is shown below:

 

 

 

The CELIM-NRCD-001 study included 62 randomized celiac patients on a gluten-free diet, of which 49 patients underwent a substantial gluten challenge of 2.5 grams per day for 10 weeks in order to assess the ability of PRV-015 to ameliorate the effects of gluten. Upon gluten challenge, PRV-015 did not prevent gluten-induced architectural mucosal changes, the primary endpoint in the study. However, in secondary efficacy assessments, the PRV-015 300 mg dose consistently attenuated the effects of gluten in intestinal inflammation (intraepithelial lymphocyte density, p=0.03), and in gastrointestinal symptoms as measured by three independent endpoints: the Celiac Disease Patient Reported Endpoint (CeD-PRO, p=0.02), the Celiac Disease Gastrointestinal Symptom Rating Scale (CeD-GSRS, p=0.07) and the Bristol Stool Form Scale (BSFS/diarrhea, p=0.0002). The CeD-PRO is a validated endpoint acceptable for registrational trials. In addition, patients in the PRV-015 300 mg arm had a significantly improved Physician Global Assessment of disease (PGA, p=0.03). The totality of the results demonstrated proof-of-concept for PRV-015 300 mg given subcutaneously every two weeks in the amelioration of inflammation and symptoms caused by the consumption of gluten by celiac patients. Importantly, PRV-015 was well tolerated, and only 14% of patients developed anti-drug antibodies, which were non-neutralizing and not correlated with impact of efficacy or safety. The PK profile was consistent with a monoclonal antibody, and potentially enables future monthly dosing.

 

37

 

 

Summary of clinical trials

 

Study Number (Phase; Sponsor)   Key Design Features   Dose Route, Duration   Study Population

Hx-IL15-001

(Phase 1;

Genmab)

   Double-blind, placebo-controlled, single SC infusion, dose escalation, study with open-label, repeat-dose (4 weekly doses) follow-up  

Initial single dose: 0 or 0.15 to 8 mg/kg SC infusion

Repeated dose: 0.5 to 4 mg/kg SC infusion once weekly for four weeks. five doses over eight weeks

   30 subjects with RA
             

20030210

(Phase 2;

Genmab/ Amgen)

   Double-blind, placebo-controlled, multiple SC infusion, parallel-group, multicenter study   0 or 40 to 280 mg SC infusion dose every two weeks for 12 weeks with initial 200% loading dose   180 subjects with RA
             

20050193

(Phase 1;

Amgen)

   Double-blind, placebo-controlled, single SC or IV doses, dose-escalation study   SC doses: 0, 30, 100, 300 or 700 mg (cohorts 1 to 4) IV dose: 0 or 100 mg (cohort 5)  

40 healthy subjects

 

             

20060349

(Phase 1b/2a; Amgen)

   Double-blind, placebo-controlled, multiple SC doses, dose-escalating study  

0 or 150 mg SC (cohort 1)

0 or 300 mg SC (cohort 2)

Every two weeks for 12 weeks

   22 subjects with moderate to severe psoriasis
             
CELIM-NRCD-001 (Phase 2a; Celimmune)   Double-blind, placebo- controlled, SC, parallel group, multicenter study   0, 150 mg or 300 mg PRV-015 once every two weeks for six consecutive doses over ten weeks   63 subjects with NRCD
             
CELIM-RCD-002 (Phase 2a; Celimmune)   Double-blind, placebo controlled IV infusion, parallel group, multicenter study   0 or 8 mg/kg IV, a total of seven times over ten weeks   24 subjects with Type II refractory celiac disease

 

Safety of PRV-015

 

Approximately 250 subjects have been exposed to PRV-015 to date, including approximately 200 subjects for 12 weeks of biweekly dosing. In all studies to date, PRV-015 was generally well tolerated by healthy volunteers, patients with active RA, and patients with celiac disease or RCD-II. While PRV-015 has the potential, to increase susceptibility to infections as is the case with immune modulators, PRV-015 has not demonstrated this effect in the six clinical trials completed to date. No deaths or clinically significant changes in laboratory parameters were observed, including no NK cell depletion.

 

The only adverse events clearly increased in PRV-015-treated patients have been injection site reactions, which were more commonly reported in subjects exposed to PRV-015, in a dose-dependent fashion (up to ~52% on PRV-015 vs ~26% in placebo in the celiac Phase 2a clinical trial), and nasopharyngitis (most cases with suspected allergic origin at a single site in RCD-II). In the population which will be studied in Phase 2b, celiac disease, there were no SAEs in the Phase 2a clinical trial, while there were six SAEs (five on PRV-015 and one on placebo) in the RCD-II, a much sicker patient population with immune suppression at baseline. Of the five SAE on PRV-015 in RCD-II patients, two were infections (both resolved while on PRV-015). There was one mild balance disorder (considered unlikely to be related to PRV-015 and resolved while on the drug). Another patient had mild cerebellar syndrome which lead to discontinuation from the study.

 

PRV-6527 (Small Molecule CSF-1R Inhibitor) for Crohn’s Disease

 

PRV-6527 (previously known as JNJ-40346527) is a highly potent and selective small-molecule oral inhibitor of CSF-1R, which we acquired the rights to for irritable bowel diseases (“IBDs”), including Crohn’s disease, in April 2017. It was developed by Janssen and has undergone clinical testing in 178 subjects to date, across Phase 1 (healthy volunteers; 94 received single dose up to 600 mg or two doses of 450 mg) and two Phase 2 clinical trials (RA 63 patients received 200 mg/day for 12 weeks; and 21 Hodgkin’s lymphoma (“HL”), patients received 150 mg/day to 650 mg/day for at least three weeks). No serious adverse events deemed related to PRV-6527 were observed that would preclude further clinical development and proof of mechanism was demonstrated based on inhibition of CSF-1R signaling and myeloid cell counts in blood. While clinical data in the RA study was inconclusive and did not demonstrate efficacy in this disease, PRV-6527 ameliorates Crohn’s-like disease in mouse models, and CSF-1R and its pathway are upregulated in CD.

 

38

 

 

We conducted a Phase 2a proof of concept clinical trial, referred to as the PRINCE study, in approximately 80 patients with CD to assess a clinical and histologic/tissue (gut mucosa) anti-inflammatory effects after 12 weeks of treatment with PRV-6527. This study evaluated doses and dosing duration that were previously tested by Janssen. The primary efficacy endpoint of the study was the change in the Crohn’s Disease Activity Index (CDAI) score at week 12. While PRV-6527 demonstrated a substantial improvement in this symptom driven score at week 12, it did not differentiate from placebo. This high placebo response was deemed to be possibly related to the standard of care and/or background medication used (~85%) in the study’s predominantly biologic-naïve population. PRV-6527 was associated with improvements in several key secondary objective endpoints in the steroid-free population (75% of study subjects), including mucosal endoscopy (as assessed by the Simple Endoscopic Score for Crohn’s Disease, SES-CD) and tissue histology (as measured by the Global Histological Activity Score, GHAS). Analysis of exploratory serum and tissue biomarkers showed that patients treated with PRV-6527 had significant reductions in circulatory inflammatory monocytes, as well as macrophages, dendritic cells and the CSF1 gene signature in colonic tissue, providing proof of mechanism in the interception of inflammatory myeloid cells. PRV-6527 was found to be generally well tolerated, with no drug-related serious adverse events. In December 2019, Janssen declined to exercise its right to buy back PRV-6527 from us for a one-time payment of $50.0 million and single-digit royalties on future net sales in inflammatory bowel disease indications. We retain the rights and are free to sublicense the program on a worldwide basis to another partner in the field of inflammatory bowel disease.

 

Significant Contracts and Agreements Related to Research and Development Activities

 

License and Acquisition Agreements

 

MacroGenics Asset Purchase Agreement

 

In May 2018, we entered into the MacroGenics Asset Purchase Agreement with MacroGenics pursuant to which we acquired MacroGenics’ interest in teplizumab (renamed PRV-031), a humanized mAb for the treatment of T1D. As partial consideration for the MacroGenics Asset Purchase Agreement, we granted MacroGenics a warrant to purchase 2,162,389 shares of our common stock at an exercise price of $2.50 per share. In July 2019, these warrants were exercised by MacroGenics on a cashless basis. We are obligated to pay MacroGenics contingent milestone payments totaling $170.0 million upon the achievement of certain regulatory approval milestones, including $60.0 million payable within 90 days of an approval of a BLA for a first indication in the United States. In addition, we are obligated to make contingent milestone payments to MacroGenics totaling $225.0 million upon the achievement of certain sales milestones. We have also agreed to pay MacroGenics a single-digit royalty on net sales of the product. We have also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to MacroGenics, aggregate milestone payments of up to approximately $0.7 million and other consideration, for certain third-party intellectual property under agreements we assumed pursuant to the Asset Purchase Agreement. Further, we are required to pay MacroGenics a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to teplizumab by us to a third party. We are obligated to use reasonable commercial efforts to develop and seek regulatory approval for teplizumab.

 

Vactech License

 

In April 2017, we entered into a License Agreement with Vactech, pursuant to which Vactech granted us exclusive global rights for the purpose of developing and commercializing the CVB vaccine platform technology. In consideration of the licenses and other rights granted by Vactech, we issued two million shares of our common stock to Vactech. We paid Vactech a total of approximately $0.5 million for transition and advisory services during the first 18 months of the term of the agreement. Vactech is obligated to transition its intellectual property, provide reference samples, assist with the technology transfer to a third-party contract manufacturer, and participate on our scientific advisory board. In addition, we may be obligated to make a series of contingent milestone payments to Vactech totaling up to an additional $24.5 million upon the achievement of certain clinical development and regulatory filing milestones, of which, $0.5 million became payable to Vactech in January 2021 upon the dosing of the first patient in the Phase 1 PROVENT study. In addition, we have agreed to pay Vactech tiered single-digit royalties on net sales of any approved product based on the CVB platform technology and three additional payments totaling $19.0 million upon the achievement of certain annual net sales levels. The Vactech Agreement may be terminated by us on a country by country basis without cause (in which case the exclusive global rights to the technology will transfer back to Vactech) and by either party upon a material breach or insolvency of the other party. If we terminate the agreement with respect to two or more specified European countries, the agreement will be deemed terminated with respect to all of the European Union, and if we terminate the agreement with respect to the United States, the agreement will be deemed terminated with respect to all of North America and expires upon the expiration of our last obligation to make royalty payments to Vactech.

 

39

 

 

MacroGenics License Agreement

 

In May 2018, we entered into a License Agreement with MacroGenics, pursuant to which MacroGenics granted us exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a humanized protein and a potential treatment for SLE and other similar diseases. As partial consideration for the MacroGenics License Agreement, we granted MacroGenics a warrant to purchase 270,299 shares of our common stock at an exercise price of $2.50 per share. In July 2019, these warrants were exercised by MacroGenics on a cashless basis. We are obligated to make contingent milestone payments to MacroGenics totaling $42.5 million upon the achievement of certain developmental and approval milestones for the first indication, and an additional $22.5 million upon the achievement of certain regulatory approvals for a second indication. In addition, we are obligated to make contingent milestone payments to MacroGenics totaling $225.0 million upon the achievement of certain sales milestones. We have also agreed to pay MacroGenics a single-digit royalty on net sales of the product. Further, we are required to pay MacroGenics a low double-digit percentage of certain consideration to the extent received in connection with a future grant of rights to PRV-3279 by us to a third party. We are obligated to use commercially reasonable efforts to develop and seek regulatory approval for PRV-3279. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by us without cause upon prior notice to MacroGenics, and by MacroGenics in the event that we challenge the validity of any licensed patent under the agreement, but only with respect to the challenged patent.

 

Amgen License and Collaboration Agreement

 

In November 2018, we entered into a License and Collaboration Agreement (the “Amgen Agreement”) with Amgen, Inc. (“Amgen”) for PRV-015 (formerly AMG 714), a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet NRCD. Under the terms of the agreement, we will conduct and fund a Phase 2b trial in NRCD and lead the development and regulatory activities for the program. Amgen agreed to make an equity investment of up to $20.0 million in us, which was completed in September 2019 through the purchase of 2,500,000 shares of our common stock. Amgen is also responsible for the manufacturing of PRV-015. Upon completion of the Phase 2b trial, a $150.0 million milestone payment is due from Amgen to us, plus an additional regulatory milestone payment, and single digit royalties on future sales; provided, however, that Amgen has the right to elect not to pay the $150.0 million milestone, in which case we will have an option to negotiate for the transfer to us of rights to AMG 714 pursuant to a termination license agreement between Amgen and us. The material terms of the termination license agreement have been negotiated and agreed and form part of the Amgen Agreement. Under the terms of the termination license agreement, we would be obligated to make certain contingent milestone payments to Amgen and other third parties totaling up to $70.0 million upon the achievement of certain clinical and regulatory milestones and a low double-digit royalty on net sales of any approved product based on the IL-15 technology. The agreement may be terminated by either party upon a material breach or upon an insolvency event and by Amgen if we are not able to fund our clinical development obligations (among other termination triggers). The agreement expires upon the expiration of Amgen’s last obligation to make royalty payments to us.

 

Intravacc Development Services Agreement

 

In March 2018, we entered into a Development Services Agreement with The Institute of Translational Vaccinology (“Intravacc”), pursuant to which Intravacc will provide services related to process development, Good Manufacturing Practice (“GMP”), and non-GMP manufacturing of our polyvalent CVB vaccine, including providing proprietary technology for manufacturing purposes. We will pay Intravacc approximately 10.0 million euros for their services over the development and manufacturing period. Each party retains its existing intellectual property and will share newly developed intellectual property via a fully-paid non-exclusive license between the parties for all development work through phase 1 clinical trials. Any future use, including commercial use, of Intravacc’s technology will be subject to a separate nonexclusive license agreement. The Intravacc Development Services Agreement may be terminated by us with ninety days’ notice without cause and by either party upon a material breach or insolvency of the other party.

 

AGC Biologics Agreement

 

In February 2019, we entered into services agreement with AGC Biologics (“AGC”), to manufacture and supply teplizumab for our anticipated clinical and commercial supply needs. We may terminate the agreement or any stage of services thereunder with 90 days’ prior written notice. If we provide less than 12 months’ notice of termination for the termination of a scheduled batch, we may incur a cancellation fee. The amount of the cancellation fee would depend on the timing of such notice. Each party also has the right to terminate the agreement for other customary reasons such as material breach and bankruptcy. The agreement contains provisions relating to compliance by AGC with current GMP, cooperation by AGC in connection with potential marketing applications for teplizumab, indemnification, confidentiality, dispute resolution and other customary matters for an agreement of this kind.

 

40

 

 

Parexel Services Agreement

 

In February 2019, we entered into a services agreement with Parexel (the “Parexel Services Agreement”), pursuant to which we retained Parexel to perform implementation and management services in connection with the PROTECT study of teplizumab. We may terminate the services agreement or any work order for any reason and without cause with 90 days’ written notice. Either party may terminate the agreement in the event of a material breach or, bankruptcy petition by the other party or, if any approval from a regulatory authority is revoked, suspended or expires without renewal.

 

Intellectual Property

 

We believe that our current patent applications and any future patents and other proprietary rights that we own, or control through licensing, are and will be essential to our business. We believe that these intellectual property rights will affect our ability to compete effectively with others. We also rely and will rely on trade secrets, know-how, continuing technological innovations and licensing opportunities to develop, maintain and strengthen our competitive position. We seek to protect these, in part, through confidentiality agreements with certain employees, consultants, advisors and other parties. Our success will depend in part on our ability, and the ability of our licensor, to obtain, maintain (including making periodic filings and payments) and enforce patent protection for our/their intellectual property, including those patent applications to which we have secured exclusive rights.

 

We plan to spend considerable resources and focus in the future on obtaining United States and foreign patents. We have and will continue to actively protect our intellectual property. No assurances can be given that any of our patent applications will result in the issuance of a patent or that the examination process will not require us to narrow our claims. In addition, any issued patents may be contested, circumvented, found unenforceable or invalid, and we may not be able to successfully enforce our patent rights against third parties. No assurance can be given that others will not independently develop a similar or competing technology or design around any patents that may be issued to us. We intend to expand our international operations in the future and our patent portfolio, copyright, trademark and trade secret protections may not be available or may be limited in foreign countries.

 

PRV-031 (teplizumab anti-CD3 antibody)

 

Through our agreement with MacroGenics, we have acquired a patent portfolio that includes seven issued patents, including two United States patents and five ex-United States patents in Australia, Israel, Mexico and Singapore. The issued patents are set to expire no earlier than dates ranging from 2026 and 2028, subject to any disclaimers, patent term adjustments or extensions available under the law. These issued patents cover use of certain humanized antibodies that bind to CD3 in the treatment of autoimmune disorders, including T1D and RA.

 

We have additionally filed one PCT international patent application, one United States non-provisional patent application, one United States provisional patent application, and one Taiwanese patent application directed to various new uses of anti-CD3 antibodies, including teplizumab for the prevention or delay of clinical T1D. If issued, patents claiming priority to these applications will expire no earlier than 2040, subject to any disclaimers, patent term adjustments or extensions available under the law.

 

PRV-101 (CVB/T1D)

 

Through our agreement with Vactech, we have a licensed patent portfolio that includes three issued United States patents, one pending United States patent application, and 14 patents in various European countries (i.e., one granted European patent validated in 14 European Patent Convention member states). The issued United States patents, pending United States patent application and the European country patents disclose use of a CVB vaccine composition in the prevention or treatment of T1D.

 

The patents issued in the United States and various European countries generally have terms of 20 years from their respective priority filing dates, subject to available extensions, and are thus set to expire no earlier than 2032, subject to any disclaimers, patent term adjustments or extensions available under the law.

 

41

 

 

PRV-3279 (CD32B/CD79B diabody)

 

Through our agreement with MacroGenics, we have licensed a patent portfolio that includes: i) 187 issued patents, including 12 United States patents, 110 patents in European countries, and 65 patents in other ex-United States jurisdictions; and ii) 38 pending patent applications, including seven pending United States patent applications, four pending European patent applications, and 27 pending patent applications in other ex-United States jurisdictions.

 

The patents and patent applications disclose a platform technology for making diabodies, specific anti-CD32B antibodies, specific anti-CD79B antibodies, specific diabodies that co-ligate both CD32B and CD79B, as well as use of these antibodies and diabodies in treating various disorders, including cancer, autoimmune disorder, inflammatory disorder, and IgE-mediated allergic disorder.

 

The issued patents in the United States and various ex-United States countries generally have terms of 20 years from their respective priority filing dates, subject to available extensions, and are thus set to expire no earlier than dates ranging from 2032 and 2034, subject to any disclaimers, patent term adjustments or extensions available under the law. In the event that the pending patent applications issue as patents, although there can be no assurance that the patent applications will issue, the patents would be set to expire no earlier than dates ranging from 2032 and 2037, subject to any disclaimers, patent term adjustments or extensions available under the law.

 

We have additionally filed one PCT international patent application, two United States non-provisional patent applications, and one United States provisional patent application directed to new use of B cell inhibitors and the prevention of immunogenicity associated with gene therapy, including PRV-3279. If issued, patents claiming priority to these applications will expire no earlier than 2040, subject to any disclaimers, patent term adjustments or extensions available under the law.

 

PRV-015 (IL-15)

 

Through our agreement with Amgen, we have licensed a patent portfolio that includes: i) 79 issued patents, including eight United States patents, 42 patents in European countries, and 29 patents in other ex-United States jurisdictions; and ii) 19 pending patent applications, including two pending United States patent applications, one pending European patent application, and 16 pending patent applications in other ex-United States jurisdictions.

 

The patents and patent applications disclose anti-IL-15 antibodies, methods of using the same, manufacturing conditions and dosages of the same.

 

The issued patents are set to expire no earlier than dates ranging from 2022 and 2027, subject to any disclaimers or extensions under the law. In the event that the pending patent applications issue as patents, although there can be no assurance that the patent applications will issue, the patents would be set to expire no earlier than dates ranging from 2026 and 2037, subject to any disclaimers, patent term adjustments of extensions available under the law.

 

PRV-6527 (CSF-1R)

 

Through our agreement with Janssen Pharmaceutica NV, we have licensed a patent portfolio that includes: i) 73 issued patents, including one United States patent, one patent in European countries, and 71 patents in other ex-United States jurisdictions; and ii) three pending patent applications, including one pending United States patent application, one pending European patent application, and one pending patent applications in other ex-United States jurisdictions. The issued patents are set to expire no earlier than dates ranging from 2027 and 2030, subject to any disclaimers, patent term adjustments or extensions under the law. In the event that the pending patent applications issue as patents, although there can be no assurance that the patent applications will issue, the patents would be set to expire no earlier than dates ranging from 2027 and 2030, subject to any disclaimers, patent term adjustments or extensions under the law.

 

42

 

 

Sales and Marketing

 

We are a clinical stage company without a history of revenue or marketing experience. We intend to commercialize teplizumab ourselves in the U.S., however, because commercialization is expensive and time consuming, we intend to explore multiple commercialization strategies outside the U.S., including:

 

  ● exploring strategic partners for commercialization in markets outside the United States;
  ● developing drug candidates through the earlier stages of clinical development with the objectives of rapid, cost effective risk reduction and value creation and then establishing strategic partnership for late stage clinical development and subsequent commercialization;
  ● developing a robust pipeline of promising drug candidates at various stages of the development process to establish optionality and regular value inflection opportunities and revenue(s);
  ● strategically entering into co-development partnership(s) to retain potential for commercialization rights on selected drug candidate(s) and market opportunities; and
  ● partnering with industry participants to incorporate our technology into new and existing drugs.

 

We expect that partnering with pharmaceutical or biotherapeutic companies may accelerate product acceptance into target market areas outside the United States and gain the sales and marketing advantages of the partner’s distribution infrastructure. We intend to continue to strengthen our market position and solidify our leadership position in immunotherapy by continuing to improve our technology, broadening our clinical and therapeutic applications, identifying new clinical and therapeutic applications and forming strategic relationships with our licensors.

 

Manufacturing

 

We do not currently own or operate manufacturing facilities for the production of clinical or commercial quantities of any of our product candidates. Although we rely and intend to continue to rely upon third–party contract manufacturers to produce our products and product candidates, we have recruited personnel and consultants with experience to manage these third–party contract manufacturers. In certain cases, our collaboration partners for each respective program are responsible for providing clinical drug supply or drug product for those program’s clinical trials. In other cases, we have engaged third-party manufacturers to provide services related to process development, non-GMP and GMP manufacturing and other related services.

 

The table below lists the third-party responsible for manufacturing drug supply for each of our programs:

 

Product Candidate   Supplier   Party Responsible for Costs
PRV-031 (teplizumab)   AGC Biologics   Provention
PRV-101   Intravacc   Provention
PRV-3279  

Existing drug supply – MacroGenics

Future drug supply – vendors being evaluated

  

MacroGenics

Provention

PRV-015   Amgen   Amgen

 

We have historically relied upon an existing supply of teplizumab produced by MacroGenics for use in our clinical trials of teplizumab. This existing supply is insufficient to fully supply the ongoing PROTECT study to completion or our potential commercialization need. In February 2019, we entered into an agreement with AGC Biologics to manufacture teplizumab for our anticipated clinical trial needs as well as for potential commercialization of teplizumab.

 

Supplies of teplizumab sufficient to supply the PROTECT study have been manufactured by our CMO’s and are in the process of being released by Provention for clinical use.

 

In order to obtain regulatory approval for teplizumab, third-party manufacturers have been required to consistently produce teplizumab in commercial quantities and of specified quality on a repeated basis and document their ability to do so. The required number of batches of teplizumab have been manufactured at our CMO’s by the processes we intend to use for commercialization. The quality and consistency of these lots, along with their comparability to teplizumab manufactured for clinical studies, is now under review by the FDA.

 

If the FDA finds that the teplizumab manufactured by the current third-parties is not of sufficient quality, or is not comparable to drug product used in the TN-10 study, delays in FDA acceptance of our BLA submission may occur. Such delays would, in turn, delay the potential marketing and commercialization of teplizumab, which would materially and adversely affect our business.

 

43

 

 

Competition

 

We face substantial competition from well-established large pharmaceutical companies, as well as innovative new entrants. Nevertheless, we believe our strategic intent is sufficiently differentiated in that we are focusing on intercepting or potentially preventing the onset and progression of immune-mediated and inflammatory diseases by selecting and developing product candidates that are aimed at relevant and predominantly upstream pathophysiological targets.

 

The symptomatic treatment of T1D is a highly competitive market with large incumbents such as Sanofi, Novo Nordisk and Eli Lilly providing insulin and Medtronic, Abbott, and Dexcom providing blood glucose monitoring products and many working on new ways to manage the disease. Our goal is to delay or prevent the onset of T1D and spare patients the need to live with blood glucose monitoring and daily insulin injections and this therapy’s many complications and clinically relevant shortfalls. We believe our enteroviral vaccine approach is unique in that it aims to prevent the onset of T1D prior to the rise of immune cells and auto-antibodies programmed to attack insulin producing beta cells. We are aware of competitive vaccine technologies in development that are attempting to alter the autoimmune cycle once these auto-antibodies have been detected. However, we believe our vaccine approach may intercept the process prior to this cycle being initiated (primary prevention).

 

We believe our secondary prevention (i.e., interception) approach with teplizumab is more advanced and differentiated from other immunomodulation therapies which have shown preservation of beta cell function in early phase studies of newly diagnosed onset T1D including anti-thymocyte globulin (ATG), CTLA4-Ig (costimulatory blocker), anti-CD20 (Rituxan) and LFA3-Ig (alefacept). All of these Phase 2 studies were conducted by the academic community or by T1D networks and do not appear to be in active Phase 3 development by industry sponsors. The most recent data were reported with Thymoglobulin which is an approved anti-thymocyte globulin obtained by immunization of rabbits with human thymocytes and is indicated for the treatment of renal transplant acute rejection in conjunction with concomitant immunosuppression and for induction in adult renal transplant recipients. Low dose ATG was administered intravenously for 2 days in early onset T1D (within 100 days of diagnosis). While C-peptide preservation was observed, due to the risk of serum sickness, ATG was administered during a 2-3 day hospitalization and required pre-medication, including intravenous corticosteroids. In January 2020, a Phase 3 trial in newly diagnosed T1D patients with ladarixin (Dompe) an interleukin-8 inhibitor, was announced on the basis of post-hoc results in a subset of patients after the drug failed to improve C-peptide in Phase 2a. Importantly, teplizumab is the only experimental drug with positive data in Stage 2, in the prevention/delay of clinical T1D, and no other pivotal studies are on-going in this indication.

 

PRV-015 has the potential to be the first drug ever approved for CD since it is the only medication which has shown simultaneous improvement in gluten-induced symptoms and gut inflammation to date, and since most clinical-stage products are early in development and have not established proof-of-concept. Competition includes experimental medications in development by 9 Meters (larazotide acetate, Phase 2b study completed in 2014; Phase 3 started in 2019 as a symptomatic relief, not disease-modifying agent), ImmunogenX (IMGX-003/latiglutenase, Phase 2b study completed in 2016 missed primary endpoint, new phase 2a started in 2019), Zedira/Dr. Falk (ZED1227, phase 2a on-going), Cour (NP-GLI, Phase 1/2 completed in 2019) and PvP Biologics (KumaMax, Phase 1 completed in 2019).

 

The market for lupus is currently led by large pharmaceutical companies commercializing older, off-patent products such as steroids, immunosuppressive agents including azathioprine, cyclosphosphamide, cyclosporine and mycophenolate. In addition, Glaxo SmithKline (GSK) and Roche offer recently approved B cell-targeted agents. GSK received approval for belimumab (Benlysta) in 2011, the first drug approval in lupus in 50 years. Despite modest efficacy and slow onset of effect, belimumab’s annual sales are currently approximately $800 million and are expected to grow with the December 2020 approval in lupus nephritis. Roche’s rituximab (Rituxan), a blockbuster drug, is used off-label in lupus despite not having been approved in SLE. The lupus field is competitive and new experimental drugs are being tested in late-stage trials by large pharmaceutical companies and early to mid-stage biotech companies and include the anti-interferon alpha receptor anifrolumab (Astra Zeneca), which posted a positive Phase 3 trial in late 2019. The calcineurin inhibitor voclosporin (Aurinia Pharmaceuticals) was approved for lupus nephritis in January 2021. We expect that PRV-3279 will be differentiated from the competition because of greater and faster-onset efficacy, better safety (PRV-3279 does not deplete B cells and is not expected to be immune-suppressive), and less side effects (since PRV-3279 is a highly specific mAb with likely minimal off-target side effects). There are no drugs approved for the prevention of the immunogenicity of biotherapeutics, and rituximab is occasionally used off-label.

 

44

 

 

Government Regulation

 

Our business activities, including the manufacturing, research, development and marketing of our product candidates, are subject to extensive regulation by numerous governmental authorities in the United States and other countries. Before marketing in the United States, any new drug developed by us or our collaborators must undergo rigorous preclinical testing, clinical trials and an extensive regulatory clearance process implemented by the FDA. The process for obtaining regulatory approval and compliance with applicable federal, state and local laws and regulations requires the expenditure of substantial time and financial resources. Moreover, government coverage and reimbursement policies will both directly and indirectly impact our ability to successfully commercialize any future approved products, and such coverage and reimbursement policies will be impacted by enacted and any applicable future healthcare reform and drug pricing measures. In addition, we are subject to state and federal laws, including, among others, anti-kickback laws, false claims laws, data privacy and security laws, and transparency laws that restrict certain business practices in the pharmaceutical industry.

 

US Regulation of Drugs and Biologics

 

In the United States, the FDA regulates human drugs under the Federal Food, Drug, and Cosmetic Act (“FDCA”) and in the case of biologics, also under the Public Health Service Act (“PHSA”) and their implementing regulations. The FDA regulates, among other things, the development, testing, manufacture, safety, efficacy, record keeping, packaging, labeling, storage, approval, advertising, promotion, import, export, sale and distribution of biopharmaceutical products.

 

The process required by the FDA before a drug or biologic may be marketed in the United States generally involves the following:

 

  ● completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices (“GLP”) regulations or other applicable regulations;
  ● submission to the FDA of an Investigational New Drug Application (“IND”), which must become effective before human clinical trials may begin;
  ● approval by an independent institutional review board (“IRB”) or ethics committee at each clinical trial site before each clinical trial may be initiated;
  ● performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practices (“GCPs”), and other clinical-trial related regulations to evaluate the safety and efficacy of the investigational product for each proposed indication;
  ● preparation and submission to the FDA of a New Drug Application (“NDA”) or BLA requesting marketing approval for one or more proposed indications, including payment of application user fees;
  ● review of the NDA or BLA by an FDA advisory committee, where applicable;
  ● satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the drug or biologic is produced to assess compliance with GMP requirements to assure that the facilities, methods and controls are adequate to preserve the product’s identity, strength, quality and purity;
  ● satisfactory completion of any FDA audits of the non-clinical and clinical trial sites to assure compliance with GCPs and the integrity of the clinical data submitted in support of the NDA or BLA; and
  ● FDA review and approval of the NDA or BLA, which may be subject to additional post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (“REMS”), and any post-approval studies required by the FDA.

 

Preclinical and Clinical Development

 

Before testing any drug product candidates in humans, the product candidate intended for human use must undergo rigorous laboratory and animal testing until adequate proof of safety is established. This preclinical testing generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as in vitro and animal studies, to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety and toxicology studies. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND, An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.

 

45

 

 

The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, in accordance with GCP requirements, which include the requirement that all patients provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing the objectives of the study, inclusion and exclusion criteria, the parameters to be used in monitoring the safety and effectiveness criteria to be evaluated. Each protocol, as well as any subsequent amendments, must be submitted to the FDA as part of the IND. Additionally, each clinical trial and its related documentation, including the trial protocol and informed consent form, must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. Some clinical trials are also overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group may recommend continuation of the study as planned, changes in study conduct, or cessation of the study at designated checkpoints based on access to certain data from the study.

 

Clinical trials for new product candidates are then typically conducted in humans in three sequential phases that may overlap. Phase 1 trials involve the initial introduction of the product candidate into a small number of healthy human volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The emphasis of Phase 1 trials is on testing for safety or adverse events, dosage, tolerance, metabolism, distribution, excretion and clinical pharmacology. Phase 2 involves studies in a limited patient population to determine the initial efficacy of the compound for specific targeted indications, to determine dosage tolerance and optimal dosage, and to identify possible adverse side effects and safety risks. Once a compound shows evidence of effectiveness and is found to have an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to more fully evaluate clinical outcomes. Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product labeling. Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA or BLA. Failure to exhibit due diligence with regard to conducting mandatory Phase 4 clinical trials could result in withdrawal of approval for products.

 

During the development of a new drug or biological product, sponsors have the opportunity to meet with the FDA at certain points, including prior to submission of an IND, at the end of phase 2, and before submission of an NDA or BLA. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Regulatory authorities, IRBs and Data Monitoring Committees may require additional data before allowing clinical trials to commence, continue or proceed from one phase to another, and could demand that studies be discontinued or suspended at any time if there are significant safety issues. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the clinical protocol, GCP, or other IRB requirements or if the drug has been associated with unexpected serious harm to patients.

 

Information about certain clinical trials, including details of the protocol and eventually study results, also must be submitted within specific time frames to the National Institutes of Health for public dissemination on the Clinicaltrials.gov data registry.

 

Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the physical characteristics of the drug or biologic and finalize a process for manufacturing the product in commercial quantities in accordance with GMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, potency and purity of the final drug or biological product. For biological products in particular, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined in order to help reduce the risk of the introduction of adventitious agents. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.

 

46

 

 

Generating the required data and information for regulatory approval takes many years and requires the expenditure of substantial resources. Following completion of the required testing, the results of the preclinical studies and clinical trials, along with information relating to the product’s chemistry, manufacturing, and controls and proposed labeling, are submitted to the FDA as part of an NDA or BLA requesting approval to market the product for one or more indications. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product in the proposed patient population to the satisfaction of the FDA. Under the PDUFA, each NDA or BLA must be accompanied by a user fee, which for federal fiscal year 2021 is $2,875,842 for an application requiring clinical data. The sponsor of an approved NDA or BLA is also subject to an annual program fee, which for fiscal year 2021 is $336,432. The FDA adjusts the PDUFA user fees on an annual basis, but fee waivers or reductions are available in certain circumstances.

 

Under applicable laws and FDA regulations, each NDA or BLA submitted for FDA approval is given an internal administrative review within 60 days following submission of the NDA or BLA. If deemed sufficiently complete to permit a substantive review, the FDA will accept the NDA or BLA for filing. The FDA can refuse to file any NDA and BLA that it deems incomplete or not properly reviewable. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA or BLA. The FDA has established internal goals of eight months from submission for priority review of NDAs or BLAs that cover product candidates that offer major advances in treatment or provide a treatment where no adequate therapy exists, and 12 months from submission for the standard review of NDAs and BLAs. However, the FDA is not legally required to complete its review within these periods, these performance goals may change over time and the review is often extended by FDA requests for additional information or clarification.

 

Before approving an NDA or BLA, the FDA will typically conduct pre-approval inspections of the facilities at which the product is manufactured to determine whether the manufacturing processes and facilities are in compliance with GMP requirements and adequate to assure consistent production of the product within required specifications. The FDA may also audit the clinical trial sponsor and one or more sites at which clinical trials have been conducted to determine compliance with GCPs and data integrity. Additionally, the FDA may refer any NDA or BLA, including applications for novel product candidates which present difficult questions of safety or efficacy, to an advisory committee. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it considers such recommendations when making final decisions on approval. The FDA likely will re-analyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process.

 

Before receiving FDA approval to market a potential product, we or our collaborators must demonstrate through adequate and well-controlled clinical trials that the potential product is safe and effective in the patient population that will be treated. In addition, under the Pediatric Research Equity Act (“PREA”), an NDA or BLA or supplement thereto must contain data to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers of the requirement to provide data from pediatric studies.

 

After the FDA evaluates an NDA or BLA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug or biologic with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the NDA or BLA identified by the FDA. The Complete Response Letter may require additional clinical data and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA or BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. In addition, delays or rejections may be encountered based upon changes in regulatory policy, regulations or statutes governing product approval during the period of product development and regulatory agency review.

 

47

 

 

If regulatory approval of a potential product is granted, this approval will be limited to those disease states and conditions for which the product is approved. Marketing or promoting a drug for an unapproved indication is generally prohibited. Furthermore, FDA approval may require that contraindications, warnings or precautions be included in the product labeling and entail ongoing requirements for risk management, including post-marketing, or Phase 4, studies, testing and surveillance programs, and distribution restrictions. Following approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval and may require the development of additional data or preclinical studies and clinical trials.

 

Any drug is likely to produce some toxicities or undesirable side effects in animals and in humans when administered at sufficiently high doses and/or for sufficiently long periods of time. Unacceptable toxicities or side effects may occur at any dose level at any time in the course of studies in animals designed to identify unacceptable effects of a product candidate, known as toxicological studies, or during clinical trials of our potential products. The appearance of any unacceptable toxicity or side effect could cause us or regulatory authorities to interrupt, limit, delay or abort the development of any of our product candidates. Further, such unacceptable toxicity or side effects could ultimately prevent a potential product’s approval by the FDA or foreign regulatory authorities for any or all targeted indications or limit any labeling claims and market acceptance, even if the product is approved.

 

In addition, as a condition of approval, the FDA may require an applicant to develop a REMS. A REMS uses risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events, and whether the product is a new molecular entity. REMS can include medication guides, physician communication plans for healthcare professionals, and elements to assure safe use (“ETASU”). ETASU may include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The FDA may require a REMS before approval or post-approval if it becomes aware of a serious risk associated with use of the product. The requirement for a REMS can materially affect the potential market and profitability of a product.

 

Any trade name that we intend to use for a potential product must be approved by the FDA irrespective of whether we have secured a formal trademark registration from the United States Patent and Trademark Office. The FDA conducts a rigorous review of proposed product names and may reject a product name if it believes that the name inappropriately implies medical claims or if it poses the potential for confusion with other product names. The FDA will not approve a trade name until the NDA or BLA for a product is approved. If the FDA determines that the trade names of other products that are approved prior to the approval of our potential products may present a risk of confusion with our proposed trade name, the FDA may elect to not approve our proposed trade name. If our trade name is rejected, we will lose the benefit of any brand equity that may already have been developed for this trade name, as well as the benefit of our existing trademark applications for this trade name.

 

We and our collaborators and contract manufacturers also are required to comply with the applicable FDA GMP regulations. GMP regulations include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation. Manufacturing facilities are subject to inspection by the FDA. These facilities must be approved before we can use them in commercial manufacturing of our potential products and must maintain ongoing compliance for commercial product manufacture. Manufacturers and other entities involved in the manufacture and distribution of approved drugs or biologics are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with GMPs and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain GMP compliance. Future inspections by the FDA and other regulatory agencies may identify compliance issues at the facilities of our contract manufacturers that may disrupt production or distribution or require substantial resources to correct. In addition, the discovery of conditions that violate these rules, including failure to conform to GMPs, could result in enforcement actions, and the discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved NDA or BLA, including voluntary recall and regulatory sanctions.

 

48

 

 

If a product is approved, we must also comply with post-marketing requirements, including, but not limited to, compliance with advertising and promotion requirements, which include restrictions on promoting products for unapproved uses or patient populations (known as ‘‘off-label use’’), monitoring and record-keeping activities, reporting of adverse events, product sampling and distribution restrictions, and limitations on industry sponsored scientific and educational activities. Although physicians may prescribe legally available products for off-label uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. If there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, we may be required to submit and obtain FDA approval of a new NDA or BLA or an NDA or BLA supplement, which may require us to develop additional data or conduct additional pre-clinical studies and clinical trials.

 

FDA may withdraw approval of an NDA or BLA if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: restrictions on the marketing or manufacturing of the product; complete withdrawal of the product from the market or product recalls; fines, warning letters or other enforcement-related letters or clinical holds on post-approval clinical trials; refusal of the FDA to approve pending NDAs or BLAs or supplements to approved NDAs or BLAs, or suspension or revocation of product approvals; product seizure or detention, or refusal to permit the import or export of products; injunctions or the imposition of civil or criminal penalties; and consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs; or mandated modification of promotional materials and labeling and the issuance of corrective information.

 

In addition to FDA requirements, we must also comply with federal and state anti-fraud and abuse laws, including anti-kickback and false claims laws, healthcare information privacy and security laws, post-marketing safety surveillance, and disclosure of payments or other transfers of value to healthcare professionals and entities. In addition, we are subject to other federal and state regulation including, for example, the implementation of corporate compliance programs.

 

If we elect to distribute our products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain.

 

Outside of the United States, our ability to market a product is contingent upon receiving a marketing authorization from the appropriate regulatory authorities, including the EMA. The requirements governing the conduct of clinical trials, marketing authorization, pricing and reimbursement vary widely from country to country. At present, foreign marketing authorizations are applied for at a national level, although within the European Community, centralized registration procedures are available to companies wishing to market a product in more than one European Community member state. If the regulatory authority is satisfied that adequate evidence of safety, quality and efficacy has been presented, marketing authorization will be granted. This foreign regulatory development and approval process involves all of the risks associated with achieving FDA marketing approval in the United States as discussed above. In addition, foreign regulations may include applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals and entities.

 

Expedited development and review programs

 

The FDA is authorized to designate certain products for expedited development or review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs include fast track designation, breakthrough therapy designation, priority review designation, and accelerated approval pathway.

 

49

 

 

The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new drugs and biologics that meet certain criteria. Specifically, new drugs and biologics are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. Fast track designation provides opportunities for more frequent interactions with the FDA review team to expedite development and review of the product. The sponsor of a drug or biologic can request the FDA to designate the product for fast track status any time before receiving NDA or BLA approval. Fast track designation may be withdrawn by the sponsor or rescinded by the FDA if the designation is no longer supported by data emerging from the clinical trial process.

 

Additionally, a drug or biologic may be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing currently approved therapies on one or more clinically significant endpoints. The benefits of breakthrough therapy designation include the same benefits as fast track designation, plus intensive guidance from the FDA to ensure an efficient drug development program. Drugs or biologics designated as breakthrough therapies are also eligible for accelerated approval of their respective marketing applications.

 

A product may also be eligible for accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (“IMM”) that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a drug or biologic shown to be effective can be safely used only if distribution or use is restricted, it will require such post-marketing restrictions as it deems necessary to assure safe use of the product. If the FDA determines that the conditions of approval are not being met, such as the required post-marketing confirmatory trial does not demonstrate a clinical benefit, the FDA can withdraw its accelerated approval for such drug or biologic. In addition, unless otherwise informed by the FDA, the FDA currently requires, as a condition for accelerated approval, that all advertising and promotional materials that are intended for dissemination or publication be submitted to the agency in advance for review.

 

Finally, the FDA may designate a product for priority review if it is a drug or biologic that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines at the time that the marketing application is submitted, on a case-by-case basis, whether the proposed drug represents a significant improvement in treatment, prevention or diagnosis of disease when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting drug reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA’s goal for taking action on a marketing application from ten months to six months for an original BLA or NDA from the date of filing.

 

Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, fast track designation, priority review, accelerated approval and breakthrough therapy designation, do not change the standards for approval and may not ultimately expedite the development or approval process.

 

Orphan drug designation and exclusivity

 

Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for the treatment of rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available for the disease or condition will be recovered from sales of the product in the United States.

 

Orphan drug designation qualifies a company for certain tax credits. In addition, if a drug candidate that has orphan drug designation subsequently receives the first FDA approval for that drug for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years following product approval unless the subsequent product candidate is demonstrated to be clinically superior. Absent a showing of clinical superiority, FDA cannot approve the same product made by another manufacturer for the same indication during the market exclusivity period unless it has the consent of the sponsor or the sponsor is unable to provide sufficient quantities.

 

50

 

 

A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first drug. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation. To qualify for orphan exclusivity, however, the drug must be clinically superior to the previously approved product that is the same drug for the same condition. If a product designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity.

 

Regulation of companion diagnostic tests

 

Although we do not believe that a companion diagnostic test will be required for the safe and effective use of our product candidates, FDA may disagree and require use of a companion diagnostic to identify appropriate patient populations for our products. Under the FDCA, in vitro diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and in vitro companion diagnostics. According to the guidance, for novel drugs, a companion diagnostic device and its corresponding therapeutic should be approved or cleared contemporaneously by FDA for the use indicated in the therapeutic product’s labeling. Approval or clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population.

 

Reimbursement

 

Potential sales of any of our product candidates, if approved, will depend, at least in part, on the extent to which such products will be covered by third-party payors, such as government health care programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly managing access and using restrictive measures to contain costs. If a third-party payor decides to provide coverage for an approved drug product, patient access and reimbursement is not certain. Further, one payor’s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. Decreases in third-party reimbursement or a decision by a third-party payor to not cover a product candidate, if approved, could reduce utilization of our products, and have a material adverse effect on our sales, results of operations and financial condition. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.

 

In addition, the United States government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our future revenues and results of operations.

 

Healthcare Laws and Regulations

 

Sales of our product candidates, if approved, or any other future product candidate will be subject to healthcare regulation and enforcement by the federal government and the states and foreign governments in which we might conduct our business. The healthcare laws and regulations that may affect our ability to operate include the following:

 

  ● The federal anti-kickback statute makes it illegal for any person or entity to knowingly and willfully, directly or indirectly, solicit, receive, offer, or pay any remuneration that is in exchange for or to induce the referral of business, including the purchase, order, lease of any good, facility, item or service for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. The term “remuneration” has been broadly interpreted to include anything of value.

 

51

 

 

  ● Federal false claims and false statement laws, including the federal civil False Claims Act, prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, for payment to, or approval by, federal programs, including Medicare and Medicaid, claims for items or services, including drugs, that are false or fraudulent.
     
  ● The United States federal Health Insurance Portability and Accountability Act of 1996, as amended (“HIPAA”), which prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters and which also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain types of entities, which include many healthcare providers and health plans with which we interact.
     
  ● The Federal Food, Drug, and Cosmetic Act, which among other things, strictly regulates drug product and medical device marketing, prohibits manufacturers from marketing such products prior to approval or for unapproved indications and regulates the distribution of samples.
     
  ● Federal laws, including the Medicaid Drug Rebate Program, that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs.
     
  ● The so-called “federal sunshine” law, which requires pharmaceutical and medical device companies to monitor and report certain financial interactions with physicians and teaching hospitals (and additional categories of healthcare practitioners beginning with reports submitted in 2022) to the federal government for re-disclosure to the public.

 

Also, many states have similar laws and regulations, such as anti-kickback and false claims laws that may be broader in scope and may apply to claims reimbursed by private payors as well as government programs or regardless of reimbursement. Additionally, we may be subject to state laws that require pharmaceutical companies to comply with the federal government’s and/or pharmaceutical industry’s voluntary compliance guidelines, impose specific restrictions on interactions between pharmaceutical companies and healthcare providers or require pharmaceutical companies to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, as well as state laws governing the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA. Many of these laws and regulations also contain ambiguous requirements or require administrative guidance for implementation.

 

Additionally, to the extent that our product is sold in a foreign country, we may be subject to similar foreign laws.

 

Segments and Geographic Information

 

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. We view our operations and manage our business in one operating and reporting segment.

 

Employees

 

As of February 22, 2020, we had 59 full-time employees which are located throughout the United States. While we lease office space for our principal executive offices in Red Bank, NJ, our employees work remotely. None of our employees are represented by a labor union or covered by a collective bargaining agreement, and we believe our relationship with our employees is good. Additionally, we utilize independent contractors and other third parties to assist with various aspects of our drug and product development.

 

We provide salaries and benefits that are competitive based on compensation information from independent compensation consultant. A portion of the compensation for almost all of our employees is performance-based. Performance-based compensation takes into account both individual and Company-wide performance. In addition, a portion of performance-based compensation consists of equity incentives. The split between base salary and performance-based compensation is tailored to each employee’s job function and level. In addition, we provide nationally competitive benefits, including healthcare, a 401(k) program and a technology allowance.

 

52

 

 

We are committed to the well-being of our employees and recognize that a remote workforce especially values the ability to balance work with other aspects of their lives. As a virtual company, we embrace variable work schedules for our employees. We also allow part-time arrangements and flexible work schedules.

 

In addition, we seek to provide a collaborative and inclusive workplace where all employees feel empowered to do their best work and contribute to our mission. We are an equal opportunity employer and strictly prohibit and do not tolerate discrimination against employees, including based on race, creed, color, religion, national origin, citizenship status, age, gender, military and veteran status and sexual orientation. We also prohibit any form of harassment or abuse in the workplace.

 

We strive to hire qualified candidates from diverse backgrounds, cultures, and ethnicities. At December 31, 2020, 33% of our C-suite team was female.

 

We also provide professional development and advancement opportunities for our employees that includes internal training, skills building and opportunities for internal advancement.

 

Our Corporate Information

 

We are a Delaware corporation formed on October 4, 2016. Our principal executive offices are located at 55 Broad Street, 2nd Floor, Red Bank, New Jersey 07701. Our phone number is (908) 336-0360 and our web address is http://www.proventionbio.com. Information contained in or accessible through our web site is not, and should not be deemed to be, incorporated by reference in, or considered part of, this prospectus supplement.

 

Available Information

 

We make available free of charge through our website our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act. We make these reports available through our website as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the SEC. You can review our electronically filed reports and other information that we file with the SEC on the SEC’s web site at http://www.sec.gov. We also make available, free of charge on our website, the reports filed with the SEC by our executive officers, directors and 10% stockholders pursuant to Section 16 under the Exchange Act as soon as reasonably practicable after copies of those filings are provided to us by those persons. The information contained on, or that can be accessed through, our website is not a part of or incorporated by reference in this Annual Report on Form 10-K.

 

ITEM 1A. RISK FACTORS

 

Certain factors may have a material adverse effect on our business, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the following discussion of risk factors in its entirety, in addition to other information contained in this Annual Report on Form 10-K, as well as our other public filings with the SEC. The risks and uncertainties described below are those we currently believe to be material, but they are not the only ones we face. If any of the following risks, or any other risks and uncertainties that we have not yet identified or that we currently consider not to be material, actually occur or become material risks, our business and financial condition could be materially and adversely affected.

 

53

 

 

Risks Related to Our Business

 

We are a clinical stage biopharmaceutical company with a limited operating history.

 

We are a clinical-stage biopharmaceutical company formed in October 2016 and have a limited operating history. We do not lease or own any laboratory space and we have historically had a remote work environment for our employees. We outsource our manufacturing, clinical trial, payroll, legal and certain other functions.

 

We have acquired or in-licensed four clinical stage assets and a late stage preclinical enteroviral vaccine platform. Marketing approval of our product candidates will require extensive clinical testing data to support safety and efficacy requirements, as well as pharmaceutical development, manufacturing and preclinical data, all of which are needed for regulatory approval. The likelihood of success of our business plan must be considered in light of the challenges, substantial expenses, difficulties, complications and delays frequently encountered in connection with developing and expanding early-stage businesses and the regulatory and competitive environment in which we operate. Biopharmaceutical product development is a highly speculative undertaking, involves a substantial degree of risk, and is a capital-intensive business.

 

Accordingly, you should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in the early stages of development, especially clinical-stage biopharmaceutical companies such as ours. Potential investors should carefully consider the risks and uncertainties that a company with a limited operating history will face. In particular, we may not be able to:

 

  ● successfully implement or execute our current business plan;
  ● successfully start and complete clinical trials and obtain regulatory approval for the marketing of our product candidates;
  ● successfully contract for the manufacture of our clinical drug products and establish a commercial drug supply;
  ● secure market exclusivity and/or adequate intellectual property protection for our product candidates;
  ● attract and retain an experienced management and advisory team;
  ● raise sufficient funds in the capital markets to effectuate our business plan, including clinical development, regulatory approval and commercialization for our product candidates;
  ● successfully recruit and retain a fully functional launch ready commercial organization;
  ● successfully launch teplizumab in the U.S.;
  ● successfully execute our teplizumab launch plan for the At-Risk indication, including raising awareness and expanding screening to identify patients At-Risk of developing clinical T1D; and
  ● successfully establish strategic partnerships to launch teplizumab outside the U.S.

 

If we cannot successfully execute any one of the foregoing, our business may not succeed, and your investment will be adversely affected.

 

We expect to incur substantial expenses and may never become profitable or be able to sustain profitability.

 

We expect to incur substantial expenses without corresponding revenues unless and until we are able to obtain regulatory approval and successfully commercialize our product candidates. We expect to incur significant expense to complete our clinical programs for our product candidates in the United States and elsewhere. We may never be able to obtain regulatory approval for the marketing of our product candidates in any indication in the United States or internationally. Even if we are able to commercialize our product candidates, we may not be able to generate significant revenues or ever achieve profitability.

 

We expect to incur significant research and development expenses as we advance clinical trials for our product candidates as well as significant costs to build out our commercial infrastructure and conduct pre-commercial activities for teplizumab as we prepare for potential commercialization in 2021. As a result, we expect to incur substantial losses for the foreseeable future, and these losses will be increasing. We are uncertain when or if we will be able to achieve or sustain profitability. If we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Failure to become and remain profitable may impair our ability to sustain operations and adversely affect our business and our ability to raise capital.

 

54

 

 

We need to raise additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate certain or all of our product development programs or commercialization efforts.

 

We expect our operating costs to be substantial as we incur costs to support our commercialization efforts for teplizumab, including costs related to the buildout of an internal commercial infrastructure, and our ongoing and planned clinical trials for teplizumab and our other product candidates. We will operate at a loss for the foreseeable future or until such time as we obtain regulatory approval for and execute a successful commercial launch of teplizumab, if ever. For the years ended December 31, 2020 and 2019, we had a net loss of $98.6 million and $43.3 million, respectively, and as of December 31, 2020, we had an accumulated deficit of $177.6 million and $121.8 million in cash, cash equivalents and marketable securities. We believe our current cash, cash equivalents and marketable securities, coupled with the net proceeds from our follow-on offering in January 2021 and partial exercise by the underwriters of their option to purchase additional shares in February 2021, will be sufficient to fund projected operating requirements for at least the next 12 months from the issuance of these financial statements. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. If we obtain regulatory approval for teplizumab, we have substantial milestone payments that will become payable to our partners. We will need substantial additional capital to fund these milestone payments, as well as to fund the clinical development programs for all of our product candidates.

 

We do not have any prospective financing arrangements or credit facilities as a source of future funds, and there can be no assurance that we will be able to raise sufficient additional capital on acceptable terms, or at all. We may seek additional capital through a combination of private equity offerings, public equity offerings, debt financings and strategic collaborations. If we raise additional funds through the issuance of equity or convertible debt securities, the percentage ownership of our stockholders could be significantly diluted, and these newly issued securities may have rights, preferences or privileges senior to those of existing stockholders. Debt financing, if obtained, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, could increase our expenses and could require that our assets secure such debt. Moreover, any debt we incur must be repaid regardless of our operating results. If we choose to pursue additional indications and/or geographies for our product candidates, in-license or acquire additional development assets, or otherwise expand more rapidly than we presently anticipate, we may also need to raise additional capital sooner than expected.

 

If we are unable to raise additional capital when required or on acceptable terms, we may need to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates or cease operations altogether, or relinquish or license on unfavorable terms, our rights to technologies or any future product candidates that we otherwise would seek to develop or commercialize.

 

Our forecast of the period of time through which our financial resources will adequately support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this Risk Factors section. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.

 

We may not be able to correctly estimate or control our future operating expenses, which could lead to cash shortfalls.

 

Our operating expenses may fluctuate significantly in the future as a result of a variety of factors, many of which are outside of our control. These factors include:

 

  ● the success of our development strategy;
  ● the time, resources, and expense required to develop and conduct clinical trials and seek regulatory approvals for our product candidates;
  ● the cost of preparing, filing, prosecuting, defending, and enforcing patent claims and other patent related costs, including litigation costs and the results of such litigation;
  ● the cost of manufacturing and maintaining sufficient inventories of our products to meet anticipated demand;
  ● any product liability or other lawsuits related to our product candidates and the costs associated with defending them or the results of such lawsuits;
  ● the cost of growing our ongoing development operations and establishing commercialization operations;
  ● the cost to attract and retain personnel with the skills required for effective operations;
  ● the costs associated with being a public company; and
  ● the costs associated with commercialization.

 

Any material increases in our operating expenses will have a material impact on our financial condition and business operations. In addition, if we are unable to correctly estimate or control our future operating expenses, we may need to raise additional capital, delay or cease development of one or more of our product candidates, which could have a material adverse effect on our business, operating results and prospects.

 

55

 

 

Risks Related to Product Development, Regulatory Approval, Manufacturing and Commercialization

 

The results of our PK/PD bridging study for teplizumab may be unacceptable to the regulatory authorities. This may require further CMC development activities, additional study and information requests by the FDA and could affect the timing of the review of and decision by the FDA of our BLA submission.

 

The FDA has confirmed that it will require the BLA for teplizumab to include analytical data demonstrating the comparability between the study drug previously manufactured by MacroGenics and Eli Lilly and the to-be-commercialized drug product derived from the drug substance manufactured by our contract manufacturing partner, AGC Biologics. In addition to conducting analytical tests to evaluate comparability, we have also conducted a double-blind, single low-dose, PK/ PD bridging study in healthy subjects to support the switch to teplizumab study drug derived from drug substance manufactured by AGC Biologics in our Phase 3 PROTECT study. This single low-dose study was the first time the teplizumab drug product derived from the drug substance manufactured by AGC Biologics has been used in humans. We believe, based on the data and our analysis, that the results of the PK/PD study suggest that the drug substances manufactured by AGC Biologics and Eli Lilly are comparable. Comparison of drug plasma concentration versus time after dosing shows a lower AUC, for the teplizumab drug product derived from the drug substance manufactured by AGC Biologics. Based on our PK/PD modeling, we do not believe this lower AUC is significant enough to clinically impact the efficacy or safety of the to-be-commercialized teplizumab drug product when used as proposed in our BLA filing. At our February 2021 mid-cycle review meeting with FDA, among other matters, we addressed various questions and preliminary concerns raised by FDA relating to the PK/PD study results and our conclusions, including that we believe study results support PD comparability and that our modeling supports that the lower PK AUC, which potentially indicates that the drug substance manufactured by AGC Biologics may have cleared faster from the blood stream than the drug substance manufactured by Eli Lilly, should not impact safety or efficacy in a clinically meaningful way. At the meeting, FDA indicated that they will be providing us with various additional information requests which we plan to address promptly after receipt. The FDA stated it could not comment on a resolution to its concerns relating to the PK/PD study results at the meeting. Ultimately, there is no guarantee that the FDA will agree with our analysis and interpretation of the PK/PD bridging study, including with respect to the observed lower AUC and, as a result, the agency could require additional analyses and modeling, or additional information from ongoing or new studies to support the commercial use of the teplizumab drug product derived from the drug substance manufactured by AGC Biologics. If we are unable to satisfy the FDA’s comparability requirements, the timing of the FDA’s review and decision on the teplizumab BLA could be delayed, or its approvability negatively impacted, including the potential issuance of a complete response letter, which would have a material adverse impact on our business.

 

The results of the teplizumab CMC comparability plan may be unacceptable to the regulatory authorities. This may require further CMC development activities and could affect the timing of BLA submission.

 

In November 2019, we completed a Type B multidisciplinary meeting with the FDA to discuss the proposed contents of a BLA for teplizumab (PRV-031) for the prevention or delay of T1D in individuals at-risk of developing T1D. Based on official FDA meeting minutes, we do not anticipate the need to conduct any additional clinical trials in the at-risk population prior to BLA submission. However, for the CMC module, the FDA confirmed that it would require the demonstration of comparability between the study drug previously manufactured by MacroGenics and Eli Lilly and the to-be-commercialized drug substance and drug product scheduled for production by Provention and its contract manufacturing partners.

 

If we are unable to demonstrate the ability to manufacture drug substance and drug product that is comparable to the study drug previously manufactured by MacroGenics and Eli Lilly, the timing of the FDA’s review and decision on the teplizumab BLA could be delayed, which could have a material impact on our business.

 

We may not be successful in our efforts to develop and obtain regulatory approval for our product candidates. If we are unable to obtain approval for or generate revenues from our product candidates, our ability to create stockholder value will be limited.

 

Our product candidates are in various stages of clinical development and late stages of preclinical development. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates, which may never occur. For example, our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products impractical to manufacture, unmarketable, or unlikely to receive marketing approval. We currently generate no revenue from sales of any product, and we may never be able to develop or commercialize a marketable product.

 

We will be required to submit our clinical trial protocols and receive approvals from the regulatory authorities before we can commence any clinical trials with PRV-101 and PRV-015, and any additional studies with PRV-3279. Nonclinical study results for our product candidates, including toxicology studies, may not support the filing of an IND or foreign equivalent for the product candidate.

 

56

 

 

Moreover, we may not be successful in obtaining acceptance from the regulatory authorities to start our clinical trials. Prior to commencing any clinical trials, we will also have to obtain approval from the Institutional Review Board (“IRB”), or ethics committee for each of the institutions at which we plan to conduct our clinical trials. If we do not obtain such acceptance, the time in which we expect to commence clinical programs for any product candidate will be extended and such extension will increase our expenses and increase our need for additional capital.

 

Further, there is no guarantee that our clinical trials will be successful or that we will continue clinical development in support of an approval from the regulatory authorities for any indication. For example, our clinical trial results may show our product candidates to be less effective than expected or have unacceptable side effects or toxicities. For example, our Phase 2a PRINCE trial did not achieve its primary endpoint of a change in Crohn’s Disease Activity Index Score at week 12 as compared to placebo. We note that most drug candidates never reach the clinical development stage and even those that do commence clinical development have only a small chance of successfully completing clinical development and gaining regulatory approval.

 

Our business currently depends entirely on the successful development, regulatory approval and commercialization of our product candidates. Our product candidates will require additional preclinical and clinical development, regulatory and marketing approval in multiple jurisdictions, obtaining sufficient manufacturing capacity and expertise for both clinical development and commercial production and substantial investment and significant commercialization efforts before we generate any revenue from product sales.

 

The success of our current and future product candidates will depend on several factors, including the following:

 

  ● successful completion of preclinical and clinical studies with positive results;
  ● sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;
  ● entry into collaborations to further the development of our product candidates;
  ● Investigational new drug or clinical trial applications, being cleared such that our product candidates can commence clinical trials;
  ● successful initiation of, enrollment in and completion of clinical trials;
  ● successful data from our clinical programs that support a finding of safety and effectiveness and an acceptable risk-benefit profile of our product candidates in the intended populations;
  ● receipt of regulatory and marketing approvals from applicable regulatory authorities;
  ● establishment of arrangements with third-party manufacturers for clinical supply and commercial manufacturing and, where applicable, commercial manufacturing capabilities;
  ● successful development of our internal manufacturing processes and transfer, where applicable, from our reliance on CMOs, to our own manufacturing facility, or from our own manufacturing facility to CMOs or the facilities of collaboration partners;
  ● establishment and maintenance of patent and trade secret protection or regulatory exclusivity for our product candidates;
  ● commercial launch of our product candidates, if and when approved, whether alone or in collaboration with others;
  ● acceptance of our product candidates and their therapeutic uses, if and when approved, by patients, the medical community and third-party payors;
  ● effective competition with other therapies and treatment options;
  ● establishment and maintenance of healthcare coverage and adequate reimbursement from third-party payors for any approved products;
  ● enforcement and defense of intellectual property rights and claims;
  ● maintenance of a continued acceptable safety profile of the product candidates following approval; and
  ● achieving desirable medicinal properties for the intended indications.

 

If we do not succeed in one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates. We cannot assure you that our product candidates will be successfully developed or commercialized. If we are unable to develop, or obtain regulatory approval for, or, if approved, to successfully commercialize our product candidates, it could have a material adverse effect on our business, operating results and prospects.

 

57

 

 

The outbreak of the novel coronavirus 2019 (COVID-19) has caused delays to our clinical trials. Moreover, the longer the pandemic persists, the more impact it will have on our clinical trial and other business plans and timelines. In addition, this pandemic has caused substantial disruption in the financial markets and may adversely impact economies worldwide, both of which could result in adverse effects on our business, operations and ability to raise capital.

 

The COVID-19 pandemic continues to drive global uncertainty and has caused, and may continue to cause, delays to the development of certain of our product candidates. Delays in completing our clinical trials are expected to increase our costs, slow our development and approval process and could negatively impact our ability to commence product sales and generate revenues. Out of an abundance of caution to protect patients, caregivers, clinical site staff, company employees as well as due to facility closures, quarantine, travel restrictions and other governmental restrictions in March 2020 we temporarily paused the enrollment and randomization of new patients with newly diagnosed T1D into our global Phase 3 PROTECT study of teplizumab. During the second quarter of 2020, we began enrolling patients in the PROTECT study on a country by country and site by site basis and as of September 30, 2020, all sites have been activated, with a majority of the sites actively enrolling patients. As a result of the delay, we now expect to report top line results from the Phase 3 PROTECT study in mid-2023, subject to change for any further COVID-19-related or other interruptions. In addition, we, with our development partner Amgen, collectively decided that, to protect the integrity and quality of the PRV-015 Phase 2b trial in gluten free diet non-responsive celiac disease, we would stagger study startup throughout the third quarter of 2020 rather than initiating screening in the second quarter of 2020, as had originally been scheduled. We initiated the Phase 2b trial in August 2020. Additionally, our plans to initiate the Phase 2a portion of the PREVAIL study in lupus patients has been delayed from the first half to the second half of 2021 predominantly due to COVID-19 related impacts on our plans.

 

Timely enrollment in our clinical trials is dependent upon global clinical trial sites which may be adversely affected by global health matters, such as pandemics. We are currently conducting clinical trials for our product candidates in many countries, including the United States, European Union, and Canada and may expand to other geographies. Many of these regions in which we operate are currently being or may in the future be affected by COVID-19. Some factors from the COVID-19 outbreak that may delay or otherwise adversely affect enrollment in the clinical trials of our product candidates, as well as adversely impact our business generally, include:

 

  ● delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff, and delays enrolling patients in our clinical trials or increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19, being forced to quarantine, or not accepting home health visits, particularly for older patients with a higher risk of contracting COVID-19;
  ● limitations on travel that could interrupt key trial activities, such as clinical trial site initiations and monitoring, domestic and international travel by employees, contractors or patients to clinical trial sites, including any government-imposed travel restrictions or quarantines that may impact the ability or willingness of patients, employees or contractors to travel to our clinical trial sites or secure visas or entry permissions, any of which could delay or adversely impact the conduct or progress of our clinical trials;
  ● interruption or delays in the operations of the United States Food and Drug Administration and foreign regulatory authorities, which may impact review and approval timelines;
  ● interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; and
  ● business disruptions caused by potential workplace, laboratory and office closures and an increased reliance on employees working from home, disruptions to or delays in ongoing laboratory experiments and operations or travel, and staffing shortages.

 

The pandemic has already caused significant disruptions in the financial markets, and may continue to cause such disruptions, which could adversely impact our ability to raise additional funds through public offerings or private placements and may also impact the volatility of our stock price and trading in our stock. Moreover, it is possible the pandemic will significantly impact economies worldwide, which could result in adverse effects on our business and operations. The rapid development and fluidity of the pandemic precludes any prediction as to the ultimate impact of COVID-19. Additionally, the pandemic could negatively impact our ability to execute a successful launch of teplizumab if we receive marketing approval, which could impact our revenue making potential and have other negative material adverse impacts on our business. The full extent of the impact and effects of COVID-19 on our business, operations, liquidity, financial condition and results of operations remain uncertain at this time.

 

58

 

 

Clinical drug development involves a risky, lengthy and expensive process, with an uncertain outcome. We may encounter substantial delays in completing our clinical trials which in turn will require additional costs, or we may fail to demonstrate adequate safety and efficacy to the satisfaction of applicable regulatory authorities.

 

It is impossible to predict if or when any of our product candidates will prove safe or effective in humans or will receive regulatory approval, and the risk of failure through the development process is high. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include:

 

  ● delays in reaching, or failing to reach, a consensus with regulatory agencies on study design;
  ● delays in reaching, or failing to reach, agreement on acceptable terms with a sufficient number of prospective clinical research organizations (“CROs”), and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
  ● delays in obtaining required Institutional Review Board (“IRB”), or Ethics Committee (“EC”), approval at each clinical trial site;
  ● delays in recruiting a sufficient number of suitable patients to participate in our clinical trials;
  ● delays as a result of the impact of the COVID-19 pandemic on clinical trial recruitment or other clinical trial activities;
  ● imposition of a clinical hold by regulatory agencies, IRBs, or ECs;
  ● failure by our CROs, other third parties or us to adhere to clinical trial, regulatory or legal requirements;
  ● failure to perform in accordance with the FDA’s GCP or applicable regulatory guidelines in other countries;
  ● delays in the testing, validation, manufacturing and delivery of sufficient quantities of our product candidates to the clinical sites;
  ● delays in having patients’ complete participation in a study or return for post-treatment follow-up;
  ● subjects choosing an alternative treatment for the indications for which we are developing our product candidates, or participating in competing clinical trials;
  ● clinical study sites or patients dropping out of a study;
  ● delay or failure to address any patient safety concerns that arise during the course of a trial;
  ● unanticipated costs or increases in costs of clinical trials of our product candidates;
  ● occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits; or
  ● changes in regulatory requirements and guidance that require amending or submitting new clinical protocols.

 

We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs or ECs of the institutions in which such trials are being conducted, by an independent Safety Review Board for such trial or by the FDA, EMA, MHRA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA, MHRA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.

 

Product development costs for any of our product candidates will increase if we have delays in testing or approval or if we need to perform more or larger clinical trials than planned. Additionally, changes in regulatory requirements and policies may occur and we may need to amend study protocols to reflect these changes. Amendments may require us to resubmit our study protocols to the FDA, comparable foreign regulatory authorities, and IRBs for reexamination, which may impact the costs, timing or successful completion of that study. If we experience delays in completion of, or if we, the FDA or other regulatory authorities, the IRB, or other reviewing entities, or any of our clinical trial sites suspend or terminate any of our clinical trials of any of our product candidates, its commercial prospects may be materially harmed and our ability to generate product revenues will be delayed. Any delays in completing our clinical trials will increase our costs, slow down our development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. In addition, if one or more clinical trials are delayed, our competitors may be able to bring products to market before we do, and the commercial viability of any of our product candidates could be significantly reduced. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.

 

59

 

 

The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Further, product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through pre-clinical studies and initial clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies, and we cannot be certain that we will not face similar setbacks. Additionally, data submitted to regulators are subject to varying interpretations that could delay, limit or prevent agency approval. We cannot assure you that the FDA, EMA, MHRA or comparable foreign regulatory authorities will view the results as we do, that the views of different regulatory authorities on our study results and data will be consistent with each other or that any future trials of any of our product candidates will achieve positive results. For example, we have initiated the process of seeking scientific advice from the EMA’s Committee for Medicinal Products for Human Use (“CHMP”), with respect to the regulatory pathway for teplizumab for the delay or prevention of T1D in at-risk individuals. While the guidance provided in scientific advice procedures do not seek to pre-evaluate the results of studies, the initial scientific advice letter that we received from CHMP in December 2020 suggested that an additional confirmatory study would be necessary to support a marketing authorization application (“MAA”), for the use of PRV-031 in at-risk individuals. We plan to engage with CHMP to further elucidate the disease-modifying effect of PRV-031 supported by study data in the context of clinical management of T1D, specifically in at-risk individuals. If, however, the EMA determines that our current PRV-031 data package is insufficient to support an MAA for at-risk individuals and requires additional studies or data, such determination would delay or prevent approval of PRV-031 in Europe for this indication. We also plan to engage with MHRA in the United Kingdom to discuss a potential regulatory path for PRV-031 in the United Kingdom. Specifically, in the first half of 2021, we plan to file an application for the Innovation Passport. The Innovation Passport is the mandated entry point to the ILAP in the United Kingdom to facilitate approval of and market access to an innovative medicine. Additionally, we plan to engage the MHRA in a scientific advice procedure to discuss, among other topics, ILAP. The initial discussions with and feedback from the MHRA will help us evaluate the possible regulatory paths forward in the UK and the EU for teplizumab. We also plan additional engagements with MHRA, EMA and other European stakeholders in 2021, however, these stakeholders may not agree with our views on our teplizumab data package or our view of the relevant medical need in at-risk populations and our efforts may not lead to favorable positions or decisions relating to or an approval of teplizumab by MHRA or EMA. Even if PRV-031 is approved in United Kingdom and/or in Europe, the MHRA or EMA, may limit the indication for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of an approval, amongst other requirements which the Company may or may not be able to comply with.

 

We have conducted and are conducting clinical trials outside the United States and anticipate conducting additional clinical trials outside the United States, and the FDA may not accept data from such trials.

 

We are currently conducting clinical trials for our product candidates in countries outside of the United States and we anticipate that we will conduct additional clinical trials in countries outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of such study data by the FDA is subject to certain conditions. For example, the clinical trial must be conducted in accordance with GCP requirements and the FDA must be able to validate the data from the clinical trial through an onsite inspection if it deems such inspection necessary. Where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data alone unless those data are considered applicable to the United States patient population and United States medical practice, the clinical trials were performed by clinical investigators of recognized competence, and the data is considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, such clinical trials would be subject to the applicable local laws of the foreign jurisdictions where the clinical trials are conducted. A description of any studies related to overdosage is also required, including information on dialysis, antidotes, or other treatments, if known. There can be no assurance the FDA will accept data from clinical trials conducted outside of the United States. If the FDA does not accept any such data, it would likely result in the need for additional clinical trials, which would be costly and time-consuming and delay aspects of our development plan.

 

60

 

 

Risks inherent in conducting international clinical trials include, but are not limited to:

 

  ● foreign regulatory requirements that could burden or limit our ability to conduct our clinical trials;
  ● administrative burdens of conducting clinical trials under multiple foreign regulatory schema;
  ● foreign currency fluctuations which could negatively impact our financial condition since certain payments are paid in local currencies;
  ● manufacturing, customs, shipment and storage requirements;
  ● cultural differences in medical practice and clinical research; and
  ● diminished protection of intellectual property in some countries.

 

Biologics carry unique risks and uncertainties, which could have a negative impact on future results of operations.

 

The successful discovery, development, manufacturing and sale of biologics is a long, expensive and uncertain process. There are unique risks and uncertainties with biologics. For example, access to and supply of necessary biological materials, such as cell lines, may be limited and governmental regulations restrict access to and regulate the transport and use of such materials. In addition, the development, manufacturing and sale of biologics is subject to regulations that are often more complex and extensive than the regulations applicable to other pharmaceutical products. Manufacturing biologics, especially in large quantities, is often complex and may require the use of innovative technologies. Such manufacturing also requires facilities specifically designed and validated for this purpose and sophisticated quality assurance and quality control procedures. Biologics are also frequently costly to manufacture because production inputs are derived from living animal or plant material, and some biologics cannot be made synthetically. Failure to successfully discover, develop, manufacture and sell biologics could adversely impact our business and results of operations.

 

If we are not able to obtain any required regulatory approvals for our product candidates, we will not be able to commercialize our product candidates and our ability to generate revenue will be limited.

 

The research, testing, manufacturing, labeling, packaging, storage, approval, sale, marketing, advertising and promotion, pricing, export, import and distribution of drug products are subject to extensive regulation by the FDA, EMA, MHRA and other regulatory authorities in the United States, European Union, United Kingdom and other countries, where regulations differ from country to country. We are not permitted to market our product candidates as prescription pharmaceutical products in the United States until we receive approval of a New Drug Application. or NDA, or BLA from the FDA, or in any foreign countries until we receive the requisite approval from such countries. In the United States, the FDA generally requires the completion of clinical trials of each drug to establish its safety and efficacy and extensive pharmaceutical development to ensure its quality before an NDA or a BLA is approved. Regulatory authorities in other jurisdictions impose similar requirements. Of the large number of drugs in development, only a small percentage result in the submission of an NDA or a BLA to the FDA or other regulatory authorities and even fewer are eventually approved for commercialization. Changes in regulatory approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for a submitted product application may cause delays in the approval or rejection of an application. We have only limited experience in filing the applications necessary to gain regulatory approvals and expect to rely on consultants and third party CROs with expertise in this area to assist us in this process. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate’s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. If our development efforts for our product candidates, including regulatory approval, are not successful for their planned indications, our business will be materially adversely affected. Our success depends on the receipt of regulatory approval and the issuance of such regulatory approvals is uncertain and subject to a number of risks, including the following:

 

  ● the results of our clinical trials may not be satisfactory or may not meet the level of statistical or clinical significance required by the FDA, EMA, MHRA or other regulatory agencies for marketing approval;
  ● the dosing of our product candidates in a particular clinical trial may not be at an optimal level;
  ● we may be required to provide additional analysis or data for already completed clinical studies, or conduct additional studies;

 

61

 

 

  ● the FDA, EMA, MHRA or comparable foreign regulatory authorities may require us to obtain clearance or approval of companion diagnostic tests;
  ● the FDA, EMA, MHRA or comparable foreign regulatory authorities may disagree on the design or implementation of our clinical trials, including the methodology used in our studies, our chosen endpoints, our statistical analysis, or our proposed product indication;
  ● our failure to demonstrate to the satisfaction of the FDA, EMA, MHRA or comparable regulatory authorities that a product candidate is safe and effective for its proposed indication;
  ● we may fail to demonstrate that a product candidate’s clinical benefits outweigh its safety risks;
  ● immunogenicity might affect a product candidate efficacy and/or safety;
  ● the FDA, EMA, MHRA or comparable foreign regulatory authorities may disagree with our interpretation of data from nonclinical studies or clinical trials;
  ● the FDA, EMA, MHRA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with whom we contract for clinical and commercial supplies; or
  ● there may be changes in the approval policies or regulations that render our nonclinical and clinical data insufficient for approval.

 

Additionally, even if we obtain regulatory approval for one indication, there is no guarantee we will be able to gain regulatory approval for additional indications. For example, we intend to initially seek regulatory approval for our CVB vaccine product candidate for the prevention of acute CVB infection. The results of longitudinal studies demonstrating the connection between CVB and T1D or celiac disease will be necessary to expand the indicated use of this vaccine to T1D. These studies must be completed and submitted to the FDA or EMA prior to receiving approval in the United States or European Union to market the CVB vaccine for additional indications such as prevention of T1D. Such studies will be costly and time consuming and may not demonstrate to the FDA or EMA’s satisfaction the connection between the CVB virus and the onset of T1D or celiac disease. Failure or delay in obtaining regulatory approval for our product candidates for the foregoing, or any other reasons, will prevent or delay us from commercializing our product candidates, and our ability to generate revenue will be materially impaired. We cannot guarantee that regulators will agree with our assessment of the results of the clinical trials we have conducted or intend to conduct in the future or that such future trials will be successful. The FDA, EMA and other regulators have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional clinical trials, or pre-clinical or other studies. In addition, varying interpretations of the data obtained from pre-clinical and clinical testing could delay, limit or prevent regulatory approval of our product candidates.

 

The FDA, EMA, or comparable foreign regulatory authorities could require the clearance or approval of a companion diagnostic device for teplizumab as a post-marketing commitment or otherwise, which may require substantial financial resources and could delay or prevent regulatory approval of teplizumab.

 

The FDA has communicated to the Company that it (i) acknowledges that the diagnosis stage 2 T1D may be well understood to future prescribers of teplizumab, and therefore, specification of autoantibody testing in the labeling may not be required for the safe and effective use of teplizumab and (ii) is continuing to discuss internally the requirement for a companion diagnostic(s) for teplizumab, and given these uncertainties, the Company should consider seeking additional advice from the agency on the process of companion diagnostic development, as it remains possible it will be required as a post-marketing commitment. The Company’s position is that a companion diagnostic should not be required for the use of teplizumab in at-risk individuals based upon, among other reasons, (i) relevant FDA precedent and guidance, (ii) the fact that the presence of autoantibodies is supportive, but not sufficient, for a diagnoses of stage 2 T1D and (iii) the commercial availability of FDA-cleared tests or Clinical Laboratory Improvement Amendments (“CLIA”), licensed laboratory-developed tests to identify T1D, which the teplizumab final label can direct physicians to use.

 

Should the FDA, EMA, or comparable foreign regulatory authorities disagree with us and require the use of a companion diagnostic, we may face delays or obstacles in obtaining approval of our BLA for teplizumab, as the FDA may take the position that a companion diagnostic device is required prior to granting approval of the BLA. In addition, if a companion diagnostic is required, we may be dependent on the cooperation and efforts of third-party collaborators to develop one or more companion diagnostics, which generally require FDA clearance or approval. We and our potential future collaborators may encounter difficulties in developing, validating or obtaining clearance/approval for such companion diagnostics. Any delay or failure by us or our potential future collaborators to develop or obtain regulatory clearance or approval of such companion diagnostics, if necessary, may delay or prevent approval of teplizumab, PRV-101 or our other product candidates. 

 

62

 

 

Even if we obtain marketing approval for any of our product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates could be subject to labeling and other restrictions and withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates.

 

Even if we obtain regulatory approval for any of our product candidates for an indication, the FDA, EMA, or foreign equivalent may still impose significant restrictions on their indicated uses or marketing or the conditions of approval or impose ongoing requirements for potentially costly and time-consuming post-approval studies, including Phase 4 clinical trials, post-market surveillance to monitor safety and efficacy and a Risk Evaluation and Mitigation Strategy (“REMS”). If the FDA concludes a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS; the FDA will not approve the NDA or BLA without an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA may also require a REMS for an approved product when new safety information emerges. Any such post-marketing requirements may negatively impact our commercialization plans or require us to raise additional capital to support the execution of such requirements. Additionally, if we face challenges or are unable to comply with post-marketing requirements, we may not be able to maintain marketing approval, or we may decide to abandon the program.

 

Our product candidates will also be subject to ongoing regulatory requirements governing the manufacturing, labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, recordkeeping and reporting of adverse events and other post-market information. These requirements include registration with the FDA, as well as continued compliance with current GCP regulations for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current GMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents.

 

With respect to sales and marketing activities by us or any future licensor, advertising and promotional materials must comply with FDA rules in addition to other applicable federal, state and local laws in the United States and similar legal requirements in other countries. We may also be subject, directly or indirectly through our customers and licensors, to various fraud and abuse laws, including, without limitation, the United States Anti-Kickback Statute, United States False Claims Act, and similar state laws, which impact, among other things, our proposed sales, marketing, and scientific/educational grant programs. If we participate in the United States Medicaid Drug Rebate Program, the Federal Supply Schedule of the United States Department of Veterans Affairs, or other government drug programs, we will be subject to complex laws and regulations regarding reporting and payment obligations. All of these activities are also potentially subject to United States federal and state consumer protection and unfair competition laws. Similar requirements exist in many of these areas in other countries.

 

In addition, if any of our product candidates are approved for a particular indication, our product labeling, advertising and promotion would be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product’s approved labeling. If we receive marketing approval for our product candidates, physicians may nevertheless legally prescribe our products to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability and government fines. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees of permanent injunctions under which specified promotional conduct is changed or curtailed.

 

63

 

 

If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, problems with the facility where the product is manufactured, or we or our manufacturers fail to comply with applicable regulatory requirements, we may be subject to the following administrative or judicial sanctions:

 

  ● restrictions on the marketing or manufacturing of the product;
  ● withdrawal of the product from the market;
  ● voluntary or mandatory product recalls;
  ● restrictions of the labeling of a product;
  ● restrictions on product distribution or use
  ● requirements to conduct post-marketing studies or clinical trials;
  ● issuance of warning letters or untitled letters;
  ● injunctions or the imposition of civil or criminal penalties or monetary fines, restitution, or disgorgement of profit or revenues;
  ● suspension, withdrawal, or revocation of regulatory approval;
  ● suspension or termination of any ongoing clinical trials;
  ● refusal to approve pending applications or supplements to approved applications filed by us;
  ● suspension or imposition of restrictions on operations, including costly new manufacturing requirements; or
  ● product seizure or detention or refusal to permit the import or export of product.

 

The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue. Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Adverse regulatory action, whether pre- or post-approval, can also potentially lead to product liability claims and increase our product liability exposure.

 

Even though we may obtain or apply for orphan drug designation for a product candidate, we may not be able to obtain orphan drug marketing exclusivity.

 

We have obtained orphan drug designation from the FDA for teplizumab for the treatment of newly diagnosed T1D. Separately, some of the subsets of lupus erythematosus, which we may target with PRV-3279, are orphan indications (e.g., lupus nephritis). Although we obtained orphan drug designation for PRV-031 for the treatment of newly diagnosed T1D, the FDA has denied our request for orphan drug designation for PRV-031 for the use in at-risk individuals. We are evaluating next steps with respect to this denial. There is no guarantee that the FDA, EMA or comparable foreign regulatory authorities will grant any future application for orphan drug designation for any of our other product candidates which would make us ineligible for the additional exclusivity and other benefits of orphan drug designation, including the potential to receive a transferable priority review voucher for obtaining approval of a designated rare pediatric disease product. Additionally, orphan drug designation does not convey any advantage in or shorten the duration of, the regulatory review and approval process.

 

64

 

 

Even if we obtain approval for a product that has been designated as an orphan drug, such as teplizumab for the treatment of newly-diagnosed T1D, orphan exclusivity does not prevent FDA from approving other drugs that have a different active ingredient for use in treating the same indication. Furthermore, the FDA can waive orphan drug exclusivity if we are unable to manufacture sufficient supply of teplizumab or if the FDA finds that a subsequent applicant for newly-diagnosed T1D demonstrates clinical superiority to teplizumab. Accordingly, orphan drug exclusivity for a product may not effectively protect the product from competition.

 

Although we may pursue expedited regulatory approval pathways for a product candidate, it may not qualify for expedited development or, if it does qualify for expedited development, it may not actually lead to a faster development or regulatory review or approval process.

 

Although we believe there may be an opportunity to accelerate the development of certain of our product candidates through one or more of the FDA’s expedited programs, such as fast track, breakthrough therapy, accelerated approval or priority review, we cannot be assured that any of our other product candidates will qualify for such programs.

 

For example, a drug may be eligible for designation as a breakthrough therapy if the drug is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Although breakthrough designation or access to any other expedited program may expedite the development or approval process, it does not change the standards for approval. If we apply for breakthrough therapy designation or any other expedited program for our product candidates, the FDA may determine that our proposed target indication or other aspects of our clinical development plans do not qualify for such expedited program. Even if we are successful in obtaining a breakthrough therapy designation or access to any other expedited program, we may not experience faster development timelines or achieve faster review or approval compared to conventional FDA procedures. For example, the time required to identify and resolve issues relating to chemistry, manufacturing and controls, the acquisition of a sufficient supply of our product for clinical trial purposes or the need to conduct additional preclinical or clinical studies may delay approval by the FDA, even if the product candidate qualifies for a breakthrough therapy designation or access to any other expedited program. Access to an expedited program may also be withdrawn by the FDA if it believes that the designation is no longer supported by data from our clinical development program. Additionally, qualification for any expedited review procedure does not ensure that we will ultimately obtain regulatory approval for such product candidate.

 

Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.

 

Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.

 

Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/ or to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.

 

Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates.

 

In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval for our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell our product candidates.

 

65

 

 

Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We do not know whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the United States Congress (“Congress”) of the FDA’s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.

 

The FDA’s and other regulatory authorities’ policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We also cannot predict the likelihood, nature, or extent of adverse government regulation that may arise from pending or future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.

 

Healthcare reform and other governmental and private payor initiatives may have an adverse effect upon, and could prevent, our product candidates’ commercial success, if approved.

 

The United States government and individual states have been aggressively pursuing healthcare reform designed to impact delivery of, and/or payment for, healthcare, which include initiatives intended to reduce the cost of healthcare. For example, in March 2010, the United States Congress enacted the Patient Protection and Affordable Care Act, as modified by the Health Care and Education Reconciliation Act(the “ACA”), which, among other things, expanded healthcare coverage through Medicaid expansion and the implementation of the individual health insurance mandate, included changes to the coverage and reimbursement of drug products under government healthcare programs, imposed an annual fee on manufacturers of branded drugs and expanded government enforcement authority. We face uncertainties because there have been, and may be additional, federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA. For example, tax reform legislation was enacted at the end of 2017 that eliminated the tax penalty for individuals who do not maintain sufficient health insurance coverage beginning in 2019. The ACA has also been subject to judicial challenge. The case Texas v. Azar, which challenges the constitutionality of the ACA, including provisions that are unrelated to healthcare reform but were enacted as part of the ACA, was argued before the Supreme Court in November 2020. Pending resolution of the litigation, all of the ACA but the individual mandate to buy health insurance remains in effect.

 

Beyond ACA, in 2020 and early 2021, the United States Department of Health and Human Services has issued various rules that affect pricing or payment for drug products. For example, effective January 2022, revisions to the federal anti-kickback statute would remove protection for traditional Medicare Part D discounts offered by pharmaceutical manufacturers to PBMs and health plans. Additional healthcare reform efforts have sought to address certain issues related to the COVID-19 pandemic, including an expansion of telehealth coverage under Medicare and accelerated or advanced Medicare payments to healthcare providers. Some of these changes have been and may continue to be subject to legal challenge. For example, courts have temporarily enjoined a new “most favored nation” payment model for select drugs covered under Medicare Part B that was to take effect on January 1, 2021 and would limit payment based on international drug price. The nature and scope of health care reform in the wake of the transition from the Trump administration to the Biden administration remains uncertain, although President Biden supported reforms to lower drug prices during his campaign for the presidency. Adoption of new healthcare reform legislation at the federal or state level could affect demand for, or pricing of, our products or product candidates if approved for sale. We cannot predict, however, the ultimate content, timing or effect of any healthcare reform legislation or action, or its impact on us, and healthcare reform could increase compliance costs and may adversely affect our future business and financial results.

 

In addition, other legislative changes have been adopted that could have an adverse effect upon, and could prevent, our products’ or product candidates’ commercial success. More broadly, the Budget Control Act of 2011, as amended, or the Budget Control Act, includes provisions intended to reduce the federal deficit, including reductions in Medicare payments to providers through 2030 (except May 1, 2020 to March 31, 2021). Any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs, or any significant taxes or fees imposed as part of any broader deficit reduction effort or legislative replacement to the Budget Control Act, or otherwise, could have an adverse impact on our anticipated product revenues.

 

66

 

 

In addition to governmental efforts in the U.S., foreign jurisdictions as well as private health insurers and managed care plans are likely to continue challenging manufacturers’ ability to obtain reimbursement, as well as the level of reimbursement, for pharmaceuticals and other healthcare-related products and services. These cost-control initiatives could significantly decrease the available coverage and the price we might establish for our products, which would have an adverse effect on our financial results.

 

If we fail to successfully commercialize any of our product candidates, we may need to acquire additional product candidates and our business will be adversely affected.

 

We have never developed and obtained approval for any product candidates or commercialized any product candidates. We have limited product candidates and do not have any other compounds in pre-clinical testing, lead optimization or lead identification stages beyond our product candidates. We cannot be certain that any of our product candidates will prove to be sufficiently effective and safe to meet applicable regulatory standards for any indication. If we fail to successfully obtain regulatory approval or commercialize any of our product candidates for their targeted indications, whether as stand-alone therapies or in combination with other therapeutic agents, and if we are unable to acquire additional product candidates in the future, our business will be adversely affected.

 

Even if we receive regulatory approval for any of our product candidates, we may not be able to successfully commercialize the product and the revenue that we generate from its sales, if any, may be limited.

 

If approved for marketing, the commercial success of our product candidates will depend upon each product’s acceptance by the medical community, including physicians, patients and health care payors. The degree of market acceptance for any of our product candidates will depend on a number of factors, including:

 

  ● demonstration of clinical safety and efficacy;
  ● relative convenience, dosing burden and ease of administration;
  ● the prevalence and severity of any adverse events and the overall safety profile;
  ● the clinical indications for which our products are approved;
  ● the acceptance of physicians to include T1D screening in routine patient medical care;
  ● the willingness of physicians to prescribe our product candidates, and the target patient population to try new therapies;
  ● the willingness of physicians and patients to accept 14 consecutive days of IV therapy
  ● efficacy of our product candidates compared to future competing products or therapies;
  ● the introduction of any new products that may in the future become available targeting indications for which our product candidates may be approved;
  ● new procedures or therapies that may reduce the incidences of any of the indications in which our product candidates may show utility;
  ● pricing and cost-effectiveness;
  ● the inclusion or omission of our product candidates in applicable therapeutic and vaccine guidelines;
  ● the effectiveness of our own or any future collaborators’ sales and marketing strategies;
  ● limitations or warnings contained in approved labeling from regulatory authorities, including any interactions of our products with other medicines patients are taking;
  ● our ability to obtain and maintain sufficient third-party coverage or reimbursement from government health care programs, including Medicare and Medicaid, private health insurers and other third-party payors or to receive the necessary pricing approvals from government bodies regulating the pricing and usage of therapeutics; and
  ● the willingness of patients to pay out-of-pocket in the absence of third-party coverage or reimbursement or government pricing approvals.

 

If any of our product candidates are approved, but do not achieve an adequate level of acceptance by physicians, health care payors, and patients, we may not generate sufficient revenue and we may not be able to achieve or sustain profitability. Our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful.

 

67

 

 

In addition, even if we obtain regulatory approvals, the timing or scope of any approvals may prohibit or reduce our ability to commercialize our product candidates successfully. For example, if the approval process takes too long, we may miss market opportunities and give other companies the ability to develop competing products or establish market dominance. Any regulatory approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render our product candidates not commercially viable. For example, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve any of our product candidates with a label that does not include the labeling claims necessary or desirable for the successful commercialization for that indication. Further, the FDA or comparable foreign regulatory authorities may place conditions on approvals or require risk management plans or a REMS, to assure the safe use of the drug. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of our product candidates. Moreover, product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following the initial marketing of the product. Any of the foregoing scenarios could materially harm the commercial success of our product candidates.

 

We currently have a limited commercial organization. If we are unable to establish satisfactory sales and commercial support and marketing capabilities, we may not successfully commercialize any of our product candidates.

 

We have just recently begun to build out our commercial infrastructure and at present, we have only limited sales personnel. In order to commercialize products that are approved for commercial sales, we must develop our own sales infrastructure. If we are not successful recruiting sales personnel or in building our sales and marketing infrastructure in the U.S., we will have difficulty successfully commercializing our product candidates, which would adversely affect our business, operating results and financial condition.

 

If we are unable to establish a satisfactory sales infrastructure, we may not realize a positive return on this investment. In addition, we will have to compete with established and well-funded pharmaceutical and biotechnology companies to recruit, hire, train and retain sales personnel. Factors that may inhibit our efforts to commercialize our product candidates without strategic partners or licensees include:

 

  ● our inability to recruit and retain adequate numbers of effective sales, market access, patient services, medical affairs and other key commercial personnel;
  ● the inability of sales personnel to obtain access to or persuade adequate numbers of physicians to prescribe any of our product candidates;
  ● the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and
  ● unforeseen costs and expenses associated with creating an independent commercial organization.

 

We may enter into collaborations with third parties for the research, development, and commercialization of certain of the product candidates we may develop. If any such collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates.

 

We may seek additional third-party collaborators for the research, development, and commercialization of certain of the product candidates we may develop. If we enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of any product candidates we may seek to develop with them. Our ability to generate revenues from these arrangements will depend on our collaborators’ abilities to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any collaboration that we enter into.

 

Collaborations pose numerous risks to us, including the following:

 

  ● collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;
  ● collaborators may not pursue development and commercialization of any product candidates we may develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator’s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;
  ● collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;
  ● collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our medicines or product candidates we may develop if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;

 

68

 

 

  ● collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;
  ● collaborators may not properly obtain, maintain, enforce, or defend our intellectual property or proprietary rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation;
  ● disputes may arise between the collaborators and us that result in the delay or termination of the research, development, or commercialization of our products or product candidates or that result in costly litigation or arbitration that diverts management attention and resources;
  ● we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control;
  ● collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates we may develop; and
  ● collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished, or terminated.

 

If our collaborations do not result in the successful development and commercialization of product candidates, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of product candidates could be delayed, and we may need additional resources to develop product candidates. In addition, if one of our collaborators terminates its agreement with us, we may find it more difficult to find a suitable replacement collaborator or attract new collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, regulatory approval, and commercialization described in this Annual Report on Form 10-K apply to the activities of our collaborators.

 

These relationships, or those like them, may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. In addition, we could face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex. Our ability to reach a definitive collaboration agreement will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator’s evaluation of several factors. If we license rights to any product candidates, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture.

 

Amgen has the right to assume control over the activities of our anti-IL-15 mAb product candidate.

 

Pursuant to the Amgen Agreement, Amgen reserves the right, at any time until 120 days after the delivery of the final data package relating to the Phase 2b PROACTIVE study which we initiated in August 2020, to assume control over all activities with respect to our anti-IL-15 monoclonal antibody (“mAb”), product candidate, including pricing and marketing decisions, after the payment of a $150.0 million milestone. There can be no assurance that Amgen’s strategic direction will be in line with ours should it assume control of activities, or that their decisions will have a positive impact on our results of operations. Moreover, we may not realize the full economic benefit of this agreement.

 

We face competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.

 

The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We have existing competitors and will have potential new competitors in a number of jurisdictions, many of which have or will have substantially greater name recognition, commercial infrastructures and financial, technical and personnel resources than we have. Established competitors may invest heavily to quickly discover and develop novel compounds that could make any of our product candidates obsolete or uneconomical. Any new product that competes with an approved product may need to demonstrate compelling advantages in efficacy, cost, convenience, tolerability and safety to be commercially successful. Other competitive factors, including generic competition, could force us to lower prices or could result in reduced sales. In addition, new products developed by others could emerge as competitors to our product candidates. If we are not able to compete effectively against our current and future competitors, our business will not grow, and our financial condition and operations will suffer.

 

69

 

 

Our potential competitors both in the United States and throughout the world include companies developing and/or marketing drugs and therapeutic solutions for immune-mediated diseases, including oncological, autoimmune and inflammatory diseases, as well as companies working in our specific fields, including T1D, enteroviral and emerging viral diseases, lupus, and inflammatory bowel diseases, such as CD.

 

There can be no assurance that our product candidates will be more effective or achieve greater market acceptance than competitive products, or that our competitors will not succeed in developing products and technologies that are more effective than those being developed by us or that would render our products and technologies less competitive or obsolete. Additionally, there can be no assurance that the development by others of new or improved products will not make our product candidates superfluous or obsolete.

 

Our product candidates may face competition sooner than expected.

 

We intend to seek data exclusivity or market exclusivity for our monoclonal antibodies teplizumab and PRV-015, our DART molecule PRV-3279 and our PRV-101 CVB vaccine product candidates provided under the Federal Food, Drug and Cosmetic Act (“FDCA”), and similar laws in other countries. We believe that these product candidates will qualify for 12 years of data exclusivity under the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”), which was enacted as part of the Health Care Reform Law. Under the BPCIA, an application for a biosimilar product or BLA cannot be submitted to the FDA until four years, or if approved by the FDA, until 12 years, after the original brand product identified as the reference product is approved under a BLA. The BPCIA provides an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as “interchangeable” based on its similarity to an existing brand product. The law is complex and the processes the FDA establishes to implement the law could have a material adverse effect on the future commercial prospects for our biological product candidates. There is also a risk that Congress could repeal or amend the BPCIA to shorten this exclusivity period, potentially creating the opportunity for biosimilar competition sooner than anticipated after the expiration of our patent protection. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference product in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.

 

Our product candidates that are not, or are not considered, biologics that would qualify for exclusivity under the BPCIA may be eligible for market exclusivity as drugs under the FDCA. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application (“ANDA”), or a 505(b)(2) NDA, submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages, or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent.

 

Even if, as we expect, our product candidates are considered to be reference products eligible for 12 years of exclusivity under the BPCIA or five years of exclusivity under the FDCA, another company could market competing products if the FDA approves a full BLA or full NDA for such product containing the sponsor’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the products. Moreover, an amendment or repeal of the BPCIA could result in a shorter exclusivity period for our product candidates, which would have a material adverse effect on our business.

 

70

 

 

Our future growth depends, in part, on our ability to penetrate international markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.

 

Our future profitability will depend, in part, on our ability to commercialize our product candidates in international markets for which we intend to rely on collaborations with third parties. If we commercialize any of our product candidates in international markets, we would be subject to additional risks and uncertainties, including:

 

  ● our customers’ ability to obtain reimbursement for our product candidates in international markets;
  ● our inability to directly control commercial activities because we are relying on third parties;
  ● the burden of complying with complex and changing international regulatory, tax, accounting and legal requirements;
  ● different medical practices and customs in foreign countries affecting acceptance in the marketplace;
  ● import or export licensing requirements;
  ● longer accounts receivable collection times;
  ● longer lead times for shipping;
  ● language barriers for technical training;
  ● reduced protection of intellectual property rights in some foreign countries;
  ● foreign currency exchange rate fluctuations; and
  ● the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute.

 

International sales of our product candidates could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs, any of which may adversely affect our results of operations.

 

If we market any of our product candidates or, if approved, commercial products, in a manner that violates healthcare laws, or if we violate government price reporting laws, we may be subject to civil or criminal penalties.

 

The marketing and sale of pharmaceutical products are subject to comprehensive governmental regulation within the United States Numerous federal, state and local authorities have jurisdiction over, or enforce laws related to, such activities, including the United States FDA, United States Drug Enforcement Agency, Centers for Medicare & Medicaid Services, the United States Department of Health and Human Services Office of Inspector General, the United States Department of Justice, state Attorneys General, state departments of health and state pharmacy boards. See “Business—Government Regulation.”

 

The FDA enforces laws and regulations which require that the promotion of pharmaceutical products be consistent with the approved prescribing information. While physicians may prescribe an approved product for a so-called “off label” use, it is unlawful for a pharmaceutical company to promote its products in a manner that is inconsistent with its approved label and any company which engages in such conduct can subject that company to significant liability. The federal government has levied large civil and criminal fines and/or other penalties against companies for alleged improper promotion and has investigated and/or prosecuted several companies in relation to off-label promotion. The FDA has also requested that certain companies enter consent decrees or permanent injunctions under which specified promotional conduct is changed, curtailed or prohibited. Similarly, industry codes in the European Union and other foreign jurisdictions prohibit companies from engaging in off-label promotion and regulatory agencies in various countries enforce violations of the code with civil penalties. While we intend to ensure that our promotional materials are consistent with our label, regulatory agencies may disagree with our assessment and may issue untitled letters, warning letters or may institute other civil or criminal enforcement proceedings.

 

We are also subject to various federal and state laws pertaining to health care “fraud and abuse,” including anti-kickback laws and false claims laws, for activities related to sales of any of our products or product candidates that may in the future receive marketing approval. Anti-kickback laws generally prohibit persons from soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid. Although the specific provisions of these laws vary, their scope is generally broad and there may not be regulations, guidance or court decisions that apply the laws to particular industry practices. False claims laws prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, information or claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent.

 

71

 

 

If any of our product candidates are approved, we anticipate that we will need to participate in the Medicaid Drug Rebate Program and a number of other federal and state government pricing programs in the United States in order to obtain coverage for the product by certain government healthcare programs. These programs would generally require us to pay rebates or provide discounts to certain private purchasers or government payers in connection with our products when dispensed to beneficiaries of these programs. In some cases, such as with the Medicaid Drug Rebate Program, the rebates are based on pricing and rebate calculations that we report on a monthly and quarterly basis to the government agencies that administer the programs. We may have reimbursement obligations or be subject to penalties if we fail to provide timely and accurate information to the government, pay the correct rebates or offer the correct discounted pricing.

 

Over the past few years, numerous pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of alleged promotional and marketing activities, such as: allegedly providing free trips, free goods, sham consulting fees and grants and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion that caused claims to be submitted to Medicare or Medicaid for non-covered, off-label uses; and submitting inflated best price information to the Medicaid Drug Rebate Program to reduce liability for Medicaid rebates. Most states also have statutes or regulations similar to the federal anti-kickback statute and False Claims Act, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Efforts to ensure that our activities comply with applicable healthcare laws and regulations will involve substantial costs. Given the breadth of the laws and regulations, limited guidance for certain laws and regulations and evolving government interpretations of the laws and regulations, governmental authorities may possibly conclude that our business practices may not comply with healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to sanctions, including substantial civil monetary penalties, exclusion of our products from reimbursement under government programs, substantial criminal fines and imprisonment, any of which could adversely affect our business, financial condition, results of operations, prospects and reputation.

 

We are dependent on third parties to manufacture our product candidates, and our commercialization of our product candidates could be halted, delayed or made less profitable if those third parties fail to obtain manufacturing approval from the FDA or comparable foreign regulatory authorities, fail to provide us with sufficient quantities of our product candidates or fail to do so at acceptable quality levels or prices.

 

We do not currently have, nor do we plan to acquire, the capability or infrastructure to manufacture drug substance or the active pharmaceutical ingredient (“API”), in our product candidates for use in our clinical trials or for commercial products, if any. As a result, we are obligated to rely on contract manufacturers for clinical supplies of our product candidates and will be obligated, if and when any of our product candidates are approved for commercialization, to rely on contract manufacturers for commercial supply. We may not be able to engage a contract manufacturer for commercial supply of any of our product candidates on acceptable terms to us, or at all.

 

The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA, EMA, MHRA or other regulatory authorities pursuant to inspections that will be conducted after we submit an NDA or BLA to the FDA or equivalent applications to other relevant regulatory authorities. We will be completely dependent on our contract manufacturers for compliance with GMPs for manufacture of both active drug substances and finished drug products. These GMP regulations cover all aspects of the manufacturing, testing, quality control and record keeping relating to our product candidates. If our contract manufacturers do not successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA, MHRA or other regulatory authorities, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. If the FDA, EMA, MHRA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.

 

Our contract manufacturers are subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for compliance with GMPs and similar regulatory requirements. Although we are responsible for oversight of manufacturing of our product candidates, we do not have control over our contract manufacturers’ compliance with these regulations and standards. Failure by any of our contract manufacturers to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure to grant approval to market any of our product candidates, delays, suspensions or withdrawals of approvals, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our business. In addition, although we have audit and certain other oversight rights under our contracts with our contract manufacturers, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. Failure by our contract manufacturers to comply with or maintain any of these standards could adversely affect our ability to develop, obtain regulatory approval for or market any of our product candidates.

 

72

 

 

If, for any reason, these third parties are unable or unwilling to perform, we may not be able to terminate our agreements with them, to the extent applicable, and we may not be able to locate alternative manufacturers or formulators or enter into favorable agreements with them and we cannot be certain that any such third parties will have the manufacturing capacity to meet future requirements. If these manufacturers or any alternate manufacturer of finished drug product experiences any significant difficulties in its respective manufacturing processes for our API or finished drug products or should cease doing business with us, we could experience significant interruptions in the supply of any of our product candidates or may not be able to create a supply of our product candidates at all. Were we to encounter manufacturing issues, our ability to produce a sufficient supply of any of our product candidates might be negatively affected. Our inability to coordinate the efforts of our third-party manufacturers, or the lack of capacity available at our third-party manufacturers, could impair our ability to supply any of our product candidates at required levels. Because of the significant regulatory requirements that we would need to satisfy in order to qualify a new active drug substances or finished drug products manufacturer, if we face these or other difficulties with our current manufacturers, we could experience significant interruptions in the supply of any of our product candidates if we decided to transfer the manufacture of any of our product candidates to one or more alternative manufacturers in an effort to deal with the manufacturing issues.

 

Any manufacturing problem or the loss of a contract manufacturer could be disruptive to our operations and result in lost sales. Additionally, we rely on third parties to supply the raw materials needed to manufacture our potential products. Any reliance on suppliers may involve several risks, including a potential inability to obtain critical materials and reduced control over production costs, delivery schedules, reliability and quality. Any unanticipated disruption to a contract manufacturer caused by problems at suppliers could delay shipment of any of our product candidates, increase our cost of goods sold and result in lost sales.

 

We cannot guarantee that our future manufacturers and suppliers will be able to reduce the costs of commercial scale manufacturing of any of our product candidates over time. If the commercial-scale manufacturing costs of any of our product candidates are higher than expected, these costs may significantly impact our operating results. In order to reduce costs, we may need to develop and implement process improvements. However, in order to do so, we will need, from time to time, to notify or make submissions with regulatory authorities, and the improvements may be subject to approval by such regulatory authorities. We cannot be sure that we will receive these necessary approvals or that these approvals will be granted in a timely fashion. We also cannot guarantee that we will be able to enhance and optimize output in our commercial manufacturing process. If we cannot enhance and optimize output, we may not be able to reduce our costs over time.

 

Our experience manufacturing teplizumab is limited. As a result, if we encounter manufacturing issues, we may experience delays in commercialization, if approved, or in our ongoing and planned clinical trials, including the PROTECT study.

 

We have limited experience manufacturing teplizumab. We currently rely on a single third-party manufacturer to supply us with teplizumab drug substance. We have historically relied upon an existing supply of teplizumab produced by MacroGenics for use in our clinical trials of teplizumab. This existing supply is insufficient to fully supply the ongoing PROTECT study to completion or our potential commercial needs. In February 2019, we entered into an agreement with AGC Biologics to manufacture teplizumab for our anticipated clinical trial needs as well as for our potential commercialization of teplizumab.

 

Supplies of teplizumab sufficient to supply the PROTECT study have been manufactured by our CMO’s and are in the process of being made available for clinical use.

 

In order to obtain regulatory approval for teplizumab, third-party manufacturers have been required to consistently produce teplizumab in commercial quantities and of specified quality on a repeated basis and document their ability to do so. The required number of batches of teplizumab have been manufactured at our CMO’s by the processes we intend to use for commercialization. The quality and consistency of these lots, along with their comparability to teplizumab manufactured previously for clinical studies, is now under review by the FDA. See “The results of our PK/PD bridging study for PRV-031 may be unacceptable to the regulatory authorities. This may require further CMC development activities, additional study and information requests by the FDA and could affect the timing of the review of and decision by the FDA of our BLA submission.”

 

73

 

 

If the FDA finds that the teplizumab manufactured by the current third-parties is not of sufficient quality, or is not comparable to drug product used in the TN-10 study, delays in FDA acceptance of our BLA submission may occur. Such delays would, in turn, delay the potential marketing and commercialization of teplizumab, which would materially and adversely affect our business.

 

Changes in product candidate manufacturing or formulation may result in additional costs or delay.

 

As product candidates are developed through preclinical studies to late-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered in an effort to optimize processes. During the course of a development program, sponsors may also change the contract manufacturers used to produce the product candidates. Also, if we, through third-parties, engage in the scale-up of manufacturing, we may encounter unexpected issues relating to the manufacturing process or the quality, purity and stability of the product, and we may be required to refine or alter our manufacturing processes to address these issues. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of clinical trials. Such changes may also require additional testing, notification or approval by the FDA, EMA or other regulatory authorities. This could delay completion of clinical trials; require the conduct of bridging clinical trials or studies, or the repetition of one or more clinical trials; increase clinical trial costs; delay approval of our product candidates and jeopardize our ability to commence product sales and generate revenue.

 

We expect to rely on third parties to conduct clinical trials for our product candidates. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize any of our product candidates and our business would be substantially harmed.

 

We rely on third-party CROs and vendors to conduct and manage our clinical programs including contracting with clinical sites to perform our clinical trials. We plan to rely heavily on these parties for execution of clinical trials for our product candidates and will control only certain aspects of their activities. Nevertheless, we will be responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on CROs and clinical sites will not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCPs, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities for any products in clinical development. The FDA and its foreign equivalents enforce these GCP regulations through periodic inspections of trial sponsors, principal investigators and trial sites. If we or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, the FDA or other regulatory authorities will determine that any of our clinical trials comply with GCPs. In addition, our clinical trials must be conducted with products produced under GMP regulations and will require a large number of test subjects. Our failure or the failure of our CROs or clinical sites to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement action up to and including civil and criminal penalties.

 

Although we design the clinical trials for our product candidates in consultation with CROs, we expect that the CROs will manage all of the clinical trials conducted at contracted clinical sites. As a result, many important aspects of our drug development programs would be outside of our direct control. In addition, the CROs and clinical sites may not perform all of their obligations under arrangements with us or in compliance with regulatory requirements. If the CROs or clinical sites do not perform clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development and commercialization of any of our product candidates for the subject indication may be delayed or our development program materially and irreversibly harmed. We cannot control the amount and timing of resources these CROs and clinical sites will devote to our program or any of our product candidates. If we are unable to rely on clinical data collected by our CROs, we could be required to repeat, extend the duration of, or increase the size of our clinical trials, which could significantly delay commercialization and require significantly greater expenditures.

 

If any of our relationships with these third-party CROs or clinical sites terminate, we may not be able to enter into arrangements with alternative CROs or clinical sites. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, any such clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for any of our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.

 

74

 

 

The outcome of pre-clinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA or comparable foreign regulatory authorities.

 

We currently have no products approved for sale and we cannot guarantee that we will ever have marketable products. Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any future collaborators may decide, or regulators may require us, to conduct additional clinical trials or pre-clinical studies. We will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe and effective for use in a diverse population before we can seek marketing approvals for their commercial sale. Success in pre-clinical studies and early-stage clinical trials does not mean that future larger registration clinical trials will be successful. This is because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and comparable foreign regulatory authorities despite having progressed through pre-clinical studies and early-stage clinical trials.

 

From time to time, we may publish or report interim or preliminary data from our clinical trials. Interim or preliminary data from clinical trials that we may conduct may not be indicative of the final results of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Interim or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the interim or preliminary data. As a result, interim or preliminary data should be viewed with caution until the final data are available.

 

In some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences in and adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain marketing approval to market our product candidates.

 

Third-party coverage and reimbursement and health care cost containment initiatives and treatment guidelines may constrain our future revenues.

 

Our ability to successfully market our product candidates will depend in part on the level of reimbursement that government health administration authorities, private health coverage insurers and other organizations provide for the cost of our products and related treatments. Countries in which any of our product candidates are sold through reimbursement schemes under national health insurance programs frequently require that manufacturers and sellers of pharmaceutical products obtain governmental approval of initial prices and any subsequent price changes. In certain countries, including the United States, government-funded and private medical care plans can exert significant indirect pressure on prices. We may not be able to sell our product candidates profitably if adequate prices are not approved or coverage and reimbursement is unavailable or limited in scope. Increasingly, third-party payors attempt to contain health care costs in ways that are likely to impact our development of products including:

 

  ● failing to approve or challenging the prices charged for health care products;
  ● introducing reimportation schemes from lower priced jurisdictions;
  ● limiting both coverage and the amount of reimbursement for new therapeutic products;
  ● denying or limiting coverage for products that are approved by the regulatory agencies but are considered to be experimental or investigational by third-party payors; and
  ● refusing to provide coverage when an approved product is used in a way that has not received regulatory marketing approval.

 

75

 

 

Moreover, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products. There have been several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. While any proposed measures will require authorization through additional legislation to become effective, Congress has indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.

 

Risks Relating to Our Intellectual Property Rights

 

We depend on rights to certain pharmaceutical compounds that are licensed to us. We do not control these pharmaceutical compounds and any loss of our rights to them could prevent us from selling our products.

 

We are dependent on licenses from third parties for all but one of our pharmaceutical compounds. We do not own the patents that underlie these licenses. Our rights to use the pharmaceutical compounds we license are subject to the continuation of and compliance with the terms of those licenses. Thus, the patents and patent applications applicable to our product candidates were not written by us or our attorneys, and we did not have control over the drafting and prosecution. The former patent owners and our licensors might not have given the same attention to the drafting and prosecution of these patents and applications as we would have if we had been the owners of the patents and applications and had control over the drafting. Moreover, under certain of our licenses, patent prosecution activities remain under the control of the licensor. We cannot be certain that drafting of the licensed patents and patent applications, or patent prosecution, by the licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights.

 

Our rights to develop and commercialize the product candidates we license are subject to the validity of the owner’s intellectual property rights. Enforcement of our licensed patents or defense or any claims asserting the invalidity of these patents is often subject to the control or cooperation of our licensors. Legal action could be initiated against the owners of the intellectual property that we license and an adverse outcome in such legal action could harm our business because it might prevent such companies or institutions from continuing to license intellectual property that we may need to operate our business. In addition, such licensors may resolve such litigation in a way that benefits them but adversely affects our ability to develop and commercialize our product candidates.

 

In addition, our rights to practice the inventions claimed in the licensed patents and patent applications are subject to our licensors abiding by the terms of those licenses and not terminating them. Our licenses may be terminated by the licensor if we are in material breach of certain terms or conditions of the license agreement or in certain other circumstances. Certain of our licenses contained in our agreements with Janssen and Vactech contain provisions that allow the licensor to terminate the license if (i) we breach any payment obligation or other material provision under the agreement and fail to cure the breach within a fixed time following written notice of termination, (ii) we or any of our affiliates, licensees or sublicensees directly or indirectly challenge the validity, enforceability, or extension of any of the licensed patents, (iii) we declare bankruptcy or dissolve, (iv) we fail to maintain a licensed product in active development or fail to use commercially reasonable efforts to develop or commercialize a licensed product. Our rights under the licenses are subject to our continued compliance with the terms of the license, including the payment of royalties due under the license. Termination of these licenses could prevent us from marketing some or all of our products. Because of the complexity of our products and the patents we have licensed, determining the scope of the license and related royalty obligations can be difficult and can lead to disputes between us and the licensor. An unfavorable resolution of such a dispute could lead to an increase in the royalties payable pursuant to the license. If a licensor believed we were not paying the royalties due under the license or were otherwise not in compliance with the terms of the license, the licensor might attempt to revoke the license. If such an attempt were successful, we might be barred from producing and selling some or all of our products.

 

It is difficult and costly to protect our intellectual property rights, and we cannot ensure the protection of these rights.

 

Our commercial success will depend, in part, on obtaining and maintaining patent protection for our technologies, products and processes, successfully defending these patents against third-party challenges and successfully enforcing these patents against third party competitors. The patent positions of pharmaceutical companies can be highly uncertain and involve complex legal, scientific and factual questions for which important legal principles remain unresolved. Changes in either the patent laws or in interpretations of patent laws may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowable or enforceable in our patents. We currently own 7 issued patents and 8 pending patent applications, and license 356 issued patents and 61 pending patent applications related to our product candidates, in which the pending applications may never be approved by United States or foreign patent offices. The existing patents and patent applications relating to our product candidates and related technologies may be challenged, invalidated or circumvented by third parties and might not protect us against competitors with similar products or technologies.

 

76

 

 

The degree of future protection for our proprietary rights is uncertain, because legal means afford only limited protection and may not adequately protect our rights, permit us to gain or keep our competitive advantage, or provide us with any competitive advantage at all. For example, others have filed, and in the future are likely to file, patent applications covering products and technologies that are similar, identical or competitive to any of our product candidates, or important to our business. We cannot be certain that any patent application owned by a third party will not have priority over patent applications filed by us, or that we will not be involved in interference, opposition or invalidity proceedings before United States or foreign patent offices. Additionally, the composition of matter patents for teplizumab have expired, and although we have filed method of use patents for teplizumab, these may not provide adequate protection from competitors.

 

In the future we may rely on know-how and trade secrets to protect technology, especially in cases when we believe patent protection is not appropriate or obtainable. However, know-how and trade secrets are difficult to protect. While we intend to require employees, academic collaborators, consultants and other contractors to enter into confidentiality agreements, we may not be able to adequately protect our trade secrets or other proprietary or licensed information. Typically, research collaborators and scientific advisors have rights to publish data and information in which we may have rights. If we cannot maintain the confidentiality of our proprietary technology and other confidential information, our ability to receive patent protection and our ability to protect valuable information owned by us may be imperiled. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts are sometimes less willing to protect trade secrets than patents. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how.

 

If we fail to obtain or maintain patent protection or trade secret protection for our product candidates or our technologies, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and attain profitability.

 

We may also rely on the trademarks we may develop to distinguish our products from the products of our competitors. We cannot guarantee that any trademark applications filed by us or our licensors will be approved. Third parties may also oppose such trademark applications, or otherwise challenge our use of the trademarks. In the event that the trademarks we use are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition, and could require us to devote resources to advertising and marketing new brands. Further, we cannot provide assurance that competitors will not infringe the trademarks we use, or that we will have adequate resources to enforce these trademarks.

 

Our product candidates may infringe the intellectual property rights of others, which could increase our costs and delay or prevent our development and commercialization efforts.

 

Our success depends in part on avoiding infringement of the proprietary technologies of others. The pharmaceutical industry has been characterized by frequent litigation regarding patent and other intellectual property rights. Identification of third-party patent rights that may be relevant to our proprietary technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. Additionally, because patent applications are maintained in secrecy until the application is published, we may be unaware of third-party patents that may be infringed by commercialization of any of our product candidates or any future product candidate. There may be certain issued patents and patent applications claiming subject matter that we may be required to license in order to research, develop or commercialize any of our product candidates, and we do not know if such patents and patent applications would be available to license on commercially reasonable terms, or at all. Any claims of patent infringement asserted by third parties would be time-consuming and may:

 

  ● result in costly litigation;
  ● divert the time and attention of our technical personnel and management;

 

77

 

 

  ● prevent us from commercializing a product until the asserted patent expires or is held finally invalid or not infringed in a court of law;
  ● require us to cease or modify our use of the technology and/or develop non-infringing technology; or
  ● require us to enter into royalty or licensing agreements.

 

Third parties may hold proprietary rights that could prevent any of our product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to any of our product candidates or our processes could subject us to potential liability for damages and require us to obtain a license to continue to manufacture or market any of our product candidates or any future product candidates. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. In addition, we cannot be sure that we could redesign our product candidates or any future product candidates or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing any of our product candidates or a future product candidate, which could harm our business, financial condition and operating results.

 

A number of companies, including several major pharmaceutical companies, have conducted, or are conducting, research in immune-mediated diseases within the therapeutic fields in which we intend to operate, which has resulted, or may result, in the filing of many patent applications related to this research. If we were to challenge the validity of these or any issued United States patent in court, we would need to overcome a statutory presumption of validity that attaches to every issued United States patent. This means that, in order to prevail, we would have to present clear and convincing evidence as to the invalidity of the patent’s claims. If we were to challenge the validity of these or any issued United States patent in an administrative trial before the Patent Trial and Appeal Board in the United States Patent and Trademark Office, we would have to prove that the claims are unpatentable by a preponderance of the evidence. There is no assurance that a jury and/or court would find in our favor on questions of infringement, validity or enforceability.

 

We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.

 

As is commonplace in our industry, we will employ individuals who were previously employed at other pharmaceutical companies, including our competitors or potential competitors. We may be subject in the future to claims that our employees or prospective employees are subject to a continuing obligation to their former employers (such as non-competition or non-solicitation obligations) and that such obligations has been breached or claims that our employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.

 

Risks Related to Ownership of our Common Stock

 

The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for stockholders.

 

The market price of our common stock has been volatile and can be subject to wide fluctuations in response to various factors, some of which are beyond our control, including, the reporting of results of our clinical trials or partner-sponsored clinical trials involving our programs. These factors include those discussed in this “Risk Factors” section of this Annual Report on Form 10-K and others such as:

 

  ● our commercialization, marketing and manufacturing prospects;
  ● our intentions and our ability to establish collaborations and/or partnerships;
  ● the timing or likelihood of regulatory filings and approvals;
  ● our development, commercialization, marketing and manufacturing capabilities;
  ● our expectations regarding the potential market size and the size of the patient populations for our product candidates;
  ● the implementation of our business model and strategic plans for our business and technology;
  ● the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates, along with any product modifications and improvements;

 

78

 

 

  ● estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our ability to obtain additional capital;
  ● our financial performance; and
  ● developments and projections relating to our competitors and our industry, including competing therapies and procedures.

 

In addition, the stock markets in general, and the markets for biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that may have been unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the market price or liquidity of our common stock. In the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of our stockholders were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our management would be diverted from the operation of our business.

 

An active, liquid and orderly market for our common stock may not develop, which could result in substantial losses for stockholders.

 

Prior to our IPO, there was no public market for shares of our common stock. Although our common stock is listed on The Nasdaq Global Select Market (“Nasdaq”), the market for our shares has demonstrated varying levels of trading activity and an active public market for our shares may not be sustained. The lack of an active market may impair the ability to sell shares at the time a shareholder wish to sell them or at a price that a shareholder may consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses, applications, or technologies using our shares as consideration.

 

We have incurred increased costs as a result of operating as a public company, and our management is now required to devote substantial time to additional compliance initiatives and corporate governance practices.

 

As a public company, and particularly commencing January 1, 2021 when we will no longer be an “emerging growth company” or a “smaller reporting company,” we do and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased our legal and financial compliance costs and will make some activities more time-consuming and costly.

 

Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (“Section 404”), commencing January 1, 2021, because we will no longer be an emerging growth company, we will be required to include with our annual report an attestation report on internal control over financial reporting issued by our independent registered public accounting firm, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, engage outside consultants and potentially increase our efforts to assess and document the adequacy of our systems of internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude, within the prescribed timeframe or at all, that our internal controls over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. We could also become subject to stockholder or other third-party litigation as well as investigations by the stock exchange on which our securities are listed, the SEC or other regulatory authorities, which could require additional financial and management resources and could result in fines, trading suspensions or other remedies.

 

79

 

 

Future capital raises may dilute our existing stockholders’ ownership and/or have other adverse effects on our operations.

 

If we raise additional capital by issuing equity securities, our existing stockholders’ percentage ownership will be reduced, and these stockholders may experience substantial dilution. We may also issue equity securities that provide for rights, preferences and privileges senior to those of our common stock. If we raise additional funds by issuing debt securities, these debt securities would have rights senior to those of our common stock and the terms of the debt securities issued could impose significant restrictions on our operations, including liens on our assets. If we raise additional funds through collaborations and licensing arrangements, we may be required to relinquish some rights to our technologies or product candidates, or to grant licenses on terms that are not favorable to us.

 

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

 

Our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 23.8% of our voting stock as of December 31, 2020. Therefore, these stockholders may have the ability to influence us through this ownership position. For example, if these stockholders were to choose to act together, they may be able to significantly influence all matters submitted to our stockholders for approval, including elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.

 

Sales of a substantial number of shares of our common stock in the public market could cause our stock price to decline.

 

Sales of a substantial number of shares of our common stock in the public market could cause the market price of our common stock to decline. If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline.

 

In accordance with the guidelines specified under Rule 10b5-1 of the Exchange Act and our policies regarding stock transactions, a number of our employees, including executive officers, have adopted and may continue to adopt stock trading plans pursuant to which they have arranged to sell shares of our common stock from time to time in the future. Generally, sales under such plans by our executive officers and directors require public filings. Sales by such persons could be viewed negatively by holders and potential purchasers of our common stock, resulting in a decline in the market price of our common stock.

 

In addition, as of December 31, 2020, approximately 11.3 million shares of common stock were subject to outstanding options, reserved for future issuance under our equity incentive plans or subject to outstanding warrants. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.

 

If we are unable to maintain effective internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our securities may decrease.

 

Section 404 of the Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on our internal control over financial reporting and, for the year ended December 31, 2020, requires attestation by our independent registered public accounting firm.

 

If we are unable to comply with the requirements of Section 404 in a timely manner, if we are unable to assert that our internal control over financial reporting is effective or if we are unable to provide an attestation report from our independent registered public accounting firm, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could decrease.

 

Provisions in our organizational documents and provisions under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.

 

Our amended and restated certificate of incorporation and bylaws contains provisions that could delay or prevent changes in control or changes in our management without the consent of our board of directors. These provisions include the following:

 

  ● no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;

 

80

 

 

  ● the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;
  ● the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;
  ● the ability of our board of directors to amend our bylaws without obtaining stockholder approval;
  ● the required approval of at least 66 2/3% of the shares entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;
  ● the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer, the president or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and
  ● advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders’ meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of us.

 

In addition, these provisions would apply even if we were to receive an offer that some stockholders may consider beneficial.

 

We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction.

 

Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.

 

Our amended and restated certificate of incorporation and bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law.

 

In addition, as permitted by Section 145 of the Delaware General Corporation Law, our bylaws became effective immediately prior to the completion of the IPO and our indemnification agreements that we have entered into with our directors and officers provide that:

 

  ● we will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful;
  ● we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law;
  ● we are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification;
  ● we will not be obligated pursuant to our bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification;
  ● the rights conferred in our bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and
  ● we may not retroactively amend our bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.

 

81

 

 

Our certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

 

Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our bylaws, any action to interpret, apply, enforce, or determine the validity of our certificate of incorporation or bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. In addition, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Securities Act or any other claim for which the federal and state courts have concurrent jurisdiction.

 

The choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.

 

We do not intend to pay dividends on our common stock, and, consequently, the ability to achieve a return on investment will depend on appreciation in the price of our common stock.

 

We do not intend to pay any cash dividends on our common stock for the foreseeable future. We intend to invest our future earnings, if any, to fund our growth. Therefore, shareholders are not likely to receive any dividends on their common stock for the foreseeable future. Since we do not intend to pay dividends, the ability to receive a return on investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it.

 

General Risk Factors

 

We will need to grow the size of our organization, and we may experience difficulties in managing this growth.

 

As our development and commercialization plans and strategies continue to develop, we intend to expand the size of our employee and consultant/contractor base. Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate and integrate additional employees. In addition, our management may have to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. Our future financial performance and our ability to develop and commercialize our product candidates and any other future product candidates and our ability to compete effectively will depend, in part, on our ability to effectively manage our future growth.

 

If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. In addition, the loss of the services of our co-founders would adversely impact our business prospects.

 

Our management team has expertise in many different aspects of drug development and commercialization. However, our ability to compete in the highly competitive pharmaceuticals industry depends in large part upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We will need to hire additional personnel as we further develop our product candidates. Competition for skilled personnel in our market is intense and competition for experienced scientists may limit our ability to hire and retain highly qualified personnel on acceptable terms. Despite our efforts to retain valuable employees, members of our management, scientific and medical teams may terminate their employment with us on short notice. We have entered into employment agreements with certain of our executive officers. However, these employment arrangements will provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. Moreover, there can be no assurance that anyone we expect to employ in a key management position will be available to join our team when we expect them to, if at all. The loss of the services of any of our executive officers or other key employees, or our inability to hire targeted executives, could potentially harm our business, operating results or financial condition. In particular, we believe that the loss of the services of our co-founders would have a material adverse effect on our business. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level, and senior managers as well as junior, mid-level, and senior scientific and medical personnel.

 

82

 

 

Other pharmaceutical companies with which we compete for qualified personnel have greater financial and other resources, different risk profiles, and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can develop and commercialize product candidates would be limited.

 

If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.

 

We face a potential risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any of our product candidates or any other future product. For example, we may be sued if any product we develop, including any of our product candidates, or any materials that we use in our products allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. In the US, claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:

 

  ● decreased demand for any of our product candidates or any future products that we may develop;
  ● injury to our reputation;
  ● withdrawal of clinical trial participants;
  ● costs to defend the related litigation;
  ● a diversion of management’s time and our resources;
  ● substantial monetary awards to trial participants or patients;
  ● product recalls, withdrawals or labeling, marketing or promotional restrictions;
  ● the inability to commercialize some or all of our product candidates; and
  ● a decline in the value of our stock.

 

Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop. We maintain product liability insurance covering our clinical trials. Although we will maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.

 

We may acquire businesses or products, or form strategic alliances, in the future, and we may not realize the benefits of such acquisitions.

 

We may acquire additional businesses or products, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction.

 

83

 

 

We are generally a virtual company and may be unable to adequately protect our information technology systems from cyber-attacks, which could result in the disclosure of confidential information, damage our reputation, and subject us to significant financial and legal exposure.

 

We are a virtual company and may be unable to adequately protect our information technology systems from cyber-attacks, which could result in the disclosure of confidential information, damage our reputation, and subject us to significant financial and legal exposure.

 

Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include wrongful conduct by hostile foreign governments, industrial espionage, deployment of harmful malware, denial-of-service, and other means to threaten data confidentiality, integrity and availability. A successful cyber-attack could cause serious negative consequences for our company, including the disruption of operations, the misappropriation of confidential business information and trade secrets, and the disclosure of corporate strategic plans. To date, we have not experienced threats to our data and information technology systems. However, although we devote resources to protect our information technology systems, we realize that cyber-attacks are a threat, and there can be no assurance that our efforts will prevent information security breaches that would result in business, legal or reputational harm to us, or would have a material adverse effect on our operating results and financial condition.

 

We rely on the proper function, availability and security of our information technology systems to operate our business and a cyber-attack or other breach or disruption of these systems could have a material adverse effect on our business and results of operations.

 

We rely on information technology systems to process, transmit and store electronic information in our day-to-day operations. The form and function of such systems may change over time as our business needs change. The nature of our business involves the receipt and storage of personal and financial information regarding our customers. We use our information technology systems to manage or support a variety of business processes and activities, including sales, procurement and supply chain, manufacturing and accounts payable. In addition, we use enterprise information technology systems to record, process, and summarize transactions and other financial information and results of operations for internal reporting purposes and to comply with regulatory financial reporting, legal, and tax requirements. Our information technology systems may be susceptible to damage, disruptions or shutdowns due to computer viruses, attacks by computer hackers, failures during the process of upgrading or replacing software, databases or components thereof, power outages, hardware failures, telecommunication failures, user errors or catastrophic events. Any failure by us to maintain or protect our information technology systems and data integrity, including from cyber-attacks, intrusions, disruptions or shutdowns, could result in the unauthorized access to personally identifiable information, theft of intellectual property or other misappropriation of assets or the loss of key data and information, or otherwise compromise our confidential or proprietary information and disrupt our operations. If our information technology systems are breached or suffer severe damage, disruption or shutdown and we are unable to effectively resolve the issues in a timely manner, our business and operating results may be materially and adversely affected.

 

If our efforts to maintain the privacy and security of our patient, employee, supplier or Company information are not successful, we could incur substantial additional costs and become subject to litigation, enforcement actions and reputational damage.

 

Our business, like that of most biopharmaceutical companies, involves the receipt, storage and transmission of patient information, as well as confidential information about our employees, our suppliers and our Company. Our information systems are vulnerable to an increasing threat of continually evolving cybersecurity risks. Unauthorized parties may attempt to gain access to our systems or information through fraud or other means of deceiving our employees or third-party service providers. Hardware, software or applications we develop or obtain from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise information and device security. The methods used to obtain unauthorized access, disable or degrade service or sabotage systems are also constantly changing and evolving, and may be difficult to anticipate or detect for long periods of time. The ever-evolving threats mean we must continually evaluate and adapt our systems and processes, and our efforts may not be adequate to safeguard against all data security breaches, misuse of data or sabotage of our systems. Any future significant compromise or breach of our data security, whether external or internal, or misuse of patient, employee, supplier or Company data, could result in additional significant costs, lost sales, fines, lawsuits and damage to our reputation. In addition, as the regulatory environment related to information security, data collection and use, and privacy becomes increasingly rigorous, with new and constantly changing requirements applicable to our business, compliance with those requirements could also result in additional costs.

 

84

 

 

We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies and contractual obligations could adversely affect our business.

 

We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information, including comprehensive regulatory systems in the United States and EU. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in enforcement action against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.

 

There are numerous United States federal and state laws and regulations related to the privacy and security of personal information. For example, the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), as amended, and its implementing regulations establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. While we have determined that we are neither a “covered entity” nor a “business associate” directly subject to HIPAA, many of the United States health care providers, including United States clinical trial sites, with which we interact are subject to HIPAA, and we have assumed contractual obligations related to protecting the privacy of personal information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. If we are unable to properly protect the privacy and security of protected health information, we could be found to have breached our contracts and we could face civil and criminal penalties. In addition, our operations have been affected by the California Consumer Privacy Act (“CCPA”), which took effect on January 1, 2020. The CCPA gives California consumers (defined to include all California residents) certain rights, including the right to ask covered companies to disclose the types of personal information collected, the categories of sources from which such information was collected, the business purpose for collecting or selling the consumer’s personal information, the categories of third parties with whom a covered company shares personal information, and specific pieces of information collected by a covered company. The CCPA imposes several obligations on covered companies to provide notice to California consumers regarding their data processing activities. The CCPA also gives California consumers the right to ask covered companies to delete a consumer’s personal information and it places limitations on a covered company’s ability to sell personal information, including providing consumers a right to opt out of sales of their personal information.

 

In addition, we may be subject to privacy and security laws in the various jurisdictions in which we operate, obtain or store personally identifiable information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. For example, the processing of personal data in the European Economic Area (the “EEA”), is subject to the General Data Protection Regulation (the “GDPR”), which took effect in May 2018. The GDPR increases obligations with respect to clinical trials conducted in the EEA, such as in relation to the provision of fair processing notices, responding to data subjects who exercise their rights and reporting certain data breaches to regulators and affected individuals. The GDPR also requires us to enter certain contractual arrangements with third parties that process GDPR-covered personal data on our behalf. The GDPR also increases the scrutiny applied to transfers of personal data from the EEA (including from clinical trial sites in the EEA) to countries that are considered by the European Commission to lack an adequate level of data protection, such as the United States. The July 2020 invalidation by the Court of Justice of the European Union of the EU-United States Privacy Shield framework, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the U.S., has led to increased scrutiny on data transfers from the EEA to the United States generally and may increase our costs of compliance with data privacy legislation. If our or our partners’ or service providers’ privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to 20 million Euros or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.

 

85

 

 

Data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect and continued legal challenges, and our ongoing efforts to comply with evolving laws and regulations may be costly and require ongoing modifications to our policies, procedures and systems. Our efforts to comply may also be unsuccessful. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. Failure to comply with laws regarding data protection would expose us to risk of enforcement actions taken by data protection authorities in the EU and elsewhere and carries with it the potential for significant penalties if we are found to be non-compliant. Similarly, failure to comply with federal and state laws in the United States regarding privacy and security of personal information could expose us to penalties under such laws. Any such failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices, claims for damages by data subjects, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects.

 

If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.

 

The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. We only recently obtained research coverage by securities and industry analysts. If there are insufficient securities or industry analysts covering us, the market price for our stock would be negatively impacted. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

 

ITEM 1B. Unresolved Staff Comments

 

None.

 

ITEM 2. Properties

 

We currently lease a 7,000 square foot office located at 55 Board Street, 2nd Floor, Red Bank, NJ 07701. The initial term of this lease will expire in 2026.

 

ITEM 3. Legal Proceedings

 

We are not a party to any pending legal proceedings.

 

ITEM 4. Mine Safety Disclosures

 

Not applicable.

 

86

 

 

PART II

 

ITEM 5. Market for the Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities

 

Market Information

 

Our common stock was publicly traded under the symbol “PRVB” on The Nasdaq Capital Market from July 24, 2018 until December 22, 2019, at which time our common stock was transitioned to and began trading on The Nasdaq Global Select Market. Prior to July 24, 2018, there was no public market for our common stock.

 

The following performance graph shall not be deemed “soliciting material” or to be “filed” with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933 or Securities Exchange Act of 1934, each as amended, except to the extent that we specifically incorporate it by reference into such filing.

 

The following graph and chart compares the cumulative annual stockholder return on our Common Stock over the period commencing July 24, 2018 and ending on December 31, 2020, to that of the total return for the Nasdaq Biotechnology Index and the Russell 2000 Index, assuming an investment of $100 on July 24, 2018. In calculating cumulative total annual stockholder return, reinvestment of dividends, if any, is assumed. The indices are included for comparative purposes only. They do not necessarily reflect management’s opinion that such indices are an appropriate measure of the relative performance of our common stock and are not intended to forecast or be indicative of future performance of our common stock.

 

 

   7/24/2018   12/31/2018   12/31/2019   12/31/2020 
Provention Bio, Inc.  $100.00   $36.80   $309.77   $352.18 
Nasdaq Biotechnology Index   100.00    82.21    102.86    130.04 
Russell 2000 Index   100.00    80.79    101.42    121.66 

 

87

 

 

Holders of Record

 

As of February 22, 2021, there were approximately 17 holders of record of our common stock. This number does not include beneficial owners whose shares are held by nominees in street name. The actual number of holders of our Common Stock is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees.

 

Dividends

 

We have never declared or paid cash dividends on our common stock, and we do not expect to pay any cash dividends on our common stock in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects, then applicable contractual restrictions and any other factors deemed relevant by our board of directors.

 

Equity Compensation Plans

 

The information required by this item will be set forth in our Proxy Statement for the 2021 Annual Meeting of Stockholders and is incorporated in this Annual Report on Form 10-K by reference.

 

Recent Sales of Unregistered Securities

 

During the year ended December 31, 2020, there were no sales of our securities that were not reported in a Current Report on Form 8-K or our Quarterly Report on Form 10-Q.

 

Issuer Purchases of Equity Securities

 

There were no repurchases of equity securities during the fourth quarter of 2020.

 

ITEM 6. Selected Financial Data

 

Omitted.

 

ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Overview

 

We are a clinical stage biopharmaceutical company, focused on the development and commercialization of novel therapeutics and innovative approaches aimed at intercepting and preventing immune-mediated diseases. Since our inception, we have devoted substantially all of our efforts to business planning, research and development, pre-commercial activities, recruiting management and technical staff, acquiring operating assets, partnering and raising capital. We have not yet commenced any revenue-generating operations, do not have any positive cash flows from operations and we will need to raise additional capital to finance our operations.

 

We have not generated any revenue to date and, through December 31, 2020, we had an accumulated deficit of $177.6 million. We have financed our operations primarily through equity offerings.

 

In April 2017, we completed a private placement of 11,381,999 shares of Series A Convertible Redeemable Preferred Stock at $2.50 per share. We received net proceeds of $26.7 million. In connection with the Series A Convertible Redeemable Preferred stock sale, we issued warrants to purchase 558,740 shares of Series A Convertible Redeemable Preferred Stock with an exercise price of $2.50 per share with a seven-year term.

 

In July 2018, we issued and sold an aggregate of 15,969,563 shares of common stock in our IPO at a public offering price of $4.00 per share. In connection with the IPO, we issued to MDB, the underwriter in the IPO, and its designees warrants to purchase 1,596,956 shares of common stock at an exercise price of $5.00 per share. We received net proceeds from the IPO of $59.3 million, after deducting underwriting discounts and commissions of approximately $3.7 million and other offering expenses of approximately $0.8 million. Upon the closing of the IPO, all of our shares of Series A Convertible Redeemable Preferred Stock outstanding at the time of the IPO were automatically converted into 11,381,999 shares of common stock. In addition, the warrants issued in connection with the Series A Convertible Redeemable Preferred Stock also converted to warrants for the purchase of 558,740 shares of our common stock.

 

88

 

 

In September 2019, we completed an underwritten public offering in which we sold 5,750,000 shares of common stock at a public offering price of $8.00 per share. The 5,750,000 shares sold included the full exercise of the underwriters’ option to purchase 750,000 shares at a price of $8.00 per share. Concurrent with the underwritten public offering, we sold 2,500,000 shares of common stock to Amgen. at the public offering price of $8.00 per share in a private placement pursuant to the terms of our License and Collaboration Agreement with Amgen. Aggregate net proceeds from the underwritten public offering and the concurrent private placement were $62.7 million, net of approximately $2.8 million in underwriting discounts and commissions and other offering expenses of $0.5 million.

 

In August 2019, we established an ATM program through which we may sell, from time to time at our sole discretion, up to $50.0 million of shares of our common stock. We have sold 725,495 shares of our common stock for aggregate net proceeds of approximately $9.9 million, net of $0.3 million in sales commissions, under the ATM program as of December 31, 2020, all of which occurred during the quarter ended June 30, 2020.

 

In June 2020, we completed an underwritten public offering in which we sold 7,590,000 shares of common stock at a public offering price of $14.50 per share. The 7,590,000 shares sold included the full exercise of the underwriters’ option to purchase 990,000 shares at a price of $14.50 per share. We received net proceeds from the underwritten public offering of $103.3 million, after deducting underwriting discounts and commissions of approximately $6.6 million and other offering expenses of $0.2 million.

 

In January 2021, we completed an underwritten public offering in which we sold 6,250,000 shares of common stock at a public offering price of $16.00 per share. In February 2021, the underwriters partially exercised their option to purchase an additional 587,500 shares at a price of $16.00 per share. In the aggregate, total net proceeds from this underwritten public offering was $102.3 million, after deducting underwriting discounts and commissions of approximately $6.6 million and other offering expenses of $0.5 million.

 

We expect that over the next several years we will continue to incur losses from operations as we increase our expenditures in research and development in connection with our regulatory submissions, clinical trials and other development activities, as well as costs to support our commercialization efforts to launch teplizumab, if we receive regulatory approval in the United States. If adequate funds are not available to us on a timely basis, or at all, we may be required to terminate or delay certain development activities.

 

Financial operations overview

 

Research and Development Expenses

 

Research and development expenses consist primarily of clinical studies, the cost of manufacturing our drug candidates for clinical study, regulatory costs, other internal operating expenses, and the cost of conducting preclinical activities. Expenses also include the cost of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in our research and development functions. In addition, our research and development expenses include payments to third parties, as well as the fair value of equity issuances to third parties for the license rights to products in development (prior to marketing approval). Our expenses related to clinical trials are primarily related to activities at contract research organizations (“CROs”) and other consultants that design, obtain regulatory approval, and conduct clinical trials on our behalf. Our expenses related to the production of drug substance or drug product for our clinical trials and development programs are primarily related to activities performed by licensors, strategic partners or contract manufacturing organizations (“CMOs”) and other consultants on our behalf. Our development efforts from inception through December 31, 2020 were principally related to the acquisition and development of our clinical programs.

 

All research and development expenses are charged to operations as incurred in accordance with ASC 730, Research and Development. We account for non-refundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received, rather than when the payment is made.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for our personnel serving in our executive, business development, pre-commercial and finance and accounting functions. General and administrative expenses also include professional fees for marketing and other pre-commercial activities, legal, including patent-related expenses, consulting, insurance, board of director fees, tax and accounting services. We expect that our general and administrative expenses will increase significantly in the future as a result of the build out of our commercial organization and pre-commercial activities for teplizumab.

 

89

 

 

Interest Income

 

Interest income consists of interest income earned on our cash, cash equivalents and marketable securities.

 

Change in Fair Value of Warrant Liability

 

Change in fair value of warrant liability represents the re-measurement of liability classified warrants using the Black-Scholes option-pricing model at each financial reporting period. The fair value was affected by changes in inputs to the model including the fair value of our Series A Convertible Redeemable Preferred Stock, expected stock price volatility, the estimated term until exercise, and the risk-free interest rate.

 

Upon the completion of the IPO in July 2018, the warrants issued in connection with the Series A Convertible Redeemable Preferred Stock converted to warrants for the purchase of 558,740 shares of our common stock. The liability associated with these warrants was revalued just prior to the completion of the IPO, with the change in the fair value of the warrant liability charged to earnings. The warrant liability was then reclassified to additional paid-in capital upon the completion of the IPO in July 2018, as the warrants no longer contain redemption provisions outside our control.

 

RESULTS OF OPERATIONS

 

Comparison of years ended December 31, 2020 and 2019

 

   For the Years Ended December 31,     
   2020   2019   Increase (Decrease) 
   (in thousands, except per share data)     
Statement of Comprehensive Loss Data:            
Operating expenses:               
Research and development  $66,360   $36,359   $30,001 
General and administrative   33,327    8,013    25,314 
Total operating expenses   99,687    44,372    55,315 
Loss from operations   (99,687)   (44,372)   55,315 
Interest income   583    1,087    (504)
Change in fair value of warrant liability   —    —    — 
Loss before income tax benefit   (99,104)   (43,285)   55,819 
Income tax benefit   523    —    523 
Net loss   (98,581)   (43,285)   55,296 
Accretion on Series A Convertible Redeemable Preferred Stock   —    —    — 
Net loss attributable to common stockholders  $(98,581)  $(43,285)  $55,296 
                
Net loss per common share, basic and diluted  $(1.88)  $(1.06)     
Weighted average common shares outstanding, basic and diluted   52,457    40,747      

 

Research and Development Expenses

 

Research and development expenses were $66.4 million for the year ended December 31, 2020, an increase of $30.0 million, compared to $36.4 million for the year ended December 31, 2019. The increase related primarily to increased costs for our teplizumab program, including manufacturing activities, the PROTECT study, and BLA submission activities. Specifically, during the year ended December 31, 2020, we incurred $21.3 million in manufacturing costs for teplizumab, including production costs for GMP and process performance qualification (“PPQ”) batches of drug supply and drug product. Also contributing to the increase were costs for the PROACTIVE study (PRV-015), which was initiated in August 2020. These costs were offset by a decrease in clinical development expenses for the PRINCE study (PRV-6527) and the PREVAIL study (PRV-3279), each of which were substantially completed in 2019. Research and development expenses for the years ended December 31, 2020 and 2019 also included $11.7 million and $5.1 million in personnel costs, including stock-based compensation of $5.6 million and $1.3 million in each respective year. The increase in stock-based compensation relates to the increase in headcount as well as the vesting of certain performance-based metrics related primarily to the completion of CMC activities and submission of the BLA for teplizumab.

 

90

 

 

General and Administrative Expenses

 

General and administrative expenses were $33.3 million for the year ended December 31, 2020, an increase of $25.3 million, compared to $8.0 million for the year ended December 31, 2019. General and administrative expenses for the years ended December 31, 2020 and 2019 were comprised of the following:

 

   For the Years Ended December 31,     
   2020   2019   Increase (Decrease) 
   (in thousands)     
Pre-commercial expenses  $16,298   $—   $16,298 
Other general and administrative expenses   17,029    8,013    9,016 
Total general and administrative expenses  $33,327   $8,013   $25,314 

 

Pre-commercial expenses were $16.3 million for the year ended December 31, 2020 and primarily consisted of $11.7 million in external costs for our pre-commercial activities such as marketing and market access, and $4.6 million in personnel costs, including stock-based compensation of $1.7 million. There were no pre-commercial expenses during the year ended December 31, 2019.

 

Other general and administrative expenses were $17.0 million for the year ended December 31, 2020 and primarily consisted of $9.0 million in personnel costs, including stock-based compensation of $5.9 million, $5.0 million in professional fees and legal expenses, and approximately $2.0 million in insurance and other public company costs. Other general and administrative expenses were $8.0 million for the year ended December 31, 2019 and were primarily comprised of $3.5 million in personnel costs, including stock-based compensation of $1.5 million, $2.7 million in professional fees and legal expenses, and approximately $1.3 million in insurance and other public company costs.

 

The increase in general and administrative stock-based compensation in 2020 relates to the increase in headcount as well as the vesting of certain performance-based metrics related primarily to the completion of CMC activities and submission of the BLA for teplizumab.

 

Interest Income

 

Interest income was $0.6 million for the year ended December 31, 2020, compared to $1.1 million for the year ended December 31, 2019. The decrease in interest income during the year ended December 31, 2020 primarily related to an overall reduction in interest rates in 2020, which is largely a result of changes in the economic environment related to the COVID-19 pandemic.

 

Income Tax Benefit

 

We recorded an income tax benefit of $0.5 million during the year ended December 31, 2020, which related to proceeds from the sale of certain of our prior year New Jersey net operating losses. We did not record any income tax benefit or provision during the year ended December 31, 2019.

 

91

 

 

Comparison of years ended December 31, 2019 and 2018

 

   For the Years Ended December 31,     
   2019   2018   Increase (Decrease) 
   (in thousands, except per share data)     
Statement of Comprehensive Loss Data:            
Operating expenses:               
Research and development  $36,359   $22,649   $13,710 
General and administrative   8,013    4,165    3,848 
Total operating expenses   44,372    26,814    17,558 
Loss from operations   (44,372)   (26,814)   17,558 
Interest income   1,087    669    418 
Change in fair value of warrant liability   —    (520)   (520)
Loss before income tax benefit   (43,285)   (26,665)   16,620 
Income tax benefit   —    187    (187)
Net loss   (43,285)   (26,478)   16,807 
Accretion on Series A Convertible Redeemable Preferred Stock   —    (276)   (276)
Net loss attributable to common stockholders  $(43,285)  $(26,754)  $16,531 
                
Net loss per common share, basic and diluted  $(1.06)  $(1.19)     
Weighted average common shares outstanding, basic and diluted   40,747    22,441      

 

Research and Development Expenses

 

Research and development expenses were $36.4 million for the year ended December 31, 2019, an increase of $13.8 million, compared to $22.6 million for the year ended December 31, 2018. Research and development expenses for the year ended December 31, 2019 primarily included external clinical development expenses of $22.6 million for teplizumab, PRV-6527, PRV-300, and PRV-3279, development costs of $6.4 million for PRV-101 and internal personnel costs of $5.1 million, including stock-based compensation of $1.3 million.

 

Research and development expenses for the year ended December 31, 2018 included external clinical development expenses of $10.7 million for PRV-6527, PRV-300 and teplizumab, development costs of $4.1 million for PRV-101, non-cash product acquisition costs of $4.0 million, which represented the fair value of warrants issued in connection with the acquisition of teplizumab and PRV-3279 in May 2018, and internal personnel costs of $2.9 million, including stock-based compensation of $0.6 million. 

 

General and Administrative Expenses

 

General and administrative expenses were $8.0 million for the year ended December 31, 2019, an increase of $3.8 million, compared to $4.2 million for the year ended December 31, 2018. General and administrative expenses for the year ended December 31, 2019 primarily included $3.5 million in personnel costs, including stock-based compensation of $1.5 million, $2.7 million in professional fees and legal expenses, and $1.3 million in insurance and other public company costs. General and administrative expenses were $4.2 million for the year ended December 31, 2018 and were primarily comprised of $1.7 million in personnel costs, including stock-based compensation of $0.5 million, $1.5 million in professional fees and legal expenses, and $0.6 million in insurance and other costs associated with being a public company.

 

Change in fair value of warrant liability

 

Change in fair value of warrant liability was a loss of approximately $0.5 million during the year ended December 31, 2018. This loss represents the change in fair value of our warrant liability using a Black-Scholes option-pricing model with updated assumptions as of July 18, 2018, the date just prior to the completion of our IPO, and was primarily impacted by a change in the fair value of our Series A Convertible Redeemable Preferred Stock.

 

Upon the completion of the IPO in July 2018, the warrants issued in connection with the Series A Convertible Redeemable Preferred Stock converted to warrants for the purchase of 558,740 shares of our common stock. The warrant liability was then reclassified to additional paid-in capital upon the completion of the IPO in July 2018, as the warrants no longer contain redemption provisions outside our control. As such, we did not record any gain or loss related to the warrant liability during the year ended December 31, 2019.

 

92

 

 

Interest Income

 

Interest income was $1.1 million during the year ended December 31, 2019 compared to $0.7 million during the year ended December 31, 2018. The increase in interest income in 2019 related primarily to an increase in average cash, cash equivalents and marketable securities balances that resulted from the net proceeds from our IPO in July 2018 and our underwritten public offering and concurrent private placement in September 2019.

 

Income Tax Benefit

 

We did not record any income tax benefit or provision during the year ended December 31, 2019. We recorded an income tax benefit of $0.2 million during the year ended December 31, 2018, which related to the proceeds from the sale of certain of our prior year New Jersey net operating losses.

 

LIQUIDITY AND CAPITAL RESOURCES

 

Overview

 

There is considerable time and cost associated with developing a potential drug or pharmaceutical product to the point of regulatory approval and commercialization. We have funded our operations to date through offerings of equity securities. We expect to continue to incur losses, as we plan to continue to fund development activities.

 

As of December 31, 2020, we had cash, cash equivalents and marketable securities of $121.8 million. We currently have invested our cash, cash equivalents and marketable securities primarily in money market funds and corporate debt securities.

 

In January 2021, we completed an underwritten public offering in which we sold 6,250,000 shares of common stock at a public offering price of $16.00 per share. In February 2021, the underwriters partially exercised their option to purchase an additional 587,500 shares at a price of $16.00 per share. In the aggregate, total net proceeds from this underwritten public offering was $102.3 million, after deducting underwriting discounts and commissions of approximately $6.6 million and other offering expenses of $0.5 million.

 

We will need to raise additional capital to fund our operations, to develop and commercialize teplizumab, PRV-015, PRV-3279 and PRV-101 and to develop, acquire, or in-license other products. We currently plan to raise additional capital through equity offerings, debt, or potential out-licensing transactions. Such additional funding will be necessary to continue to develop our product candidates, to pursue the license or purchase of other technologies, to commercialize our product candidates or to purchase other products. We may seek to sell common or preferred equity or convertible debt securities, enter into a credit facility or another form of third-party funding, or seek other debt financing. In addition, we may consider raising additional capital to fund operating activities, to expand our business, to pursue strategic investments, to take advantage of financing opportunities, or for other reasons. The sale of equity and convertible debt securities may result in dilution to our stockholders and those securities may have rights senior to those of our common stock. If we raise additional funds through the issuance of preferred stock, convertible debt securities or other debt financing, these securities or other debt could contain covenants that would restrict our operations. Any other third-party funding arrangement could require us to relinquish valuable rights. We may require additional capital beyond our currently anticipated amounts. Additional capital may not be available on reasonable terms, or at all. If we are unable to obtain sufficient additional funds when required, we may be forced to delay, restrict or eliminate all or a portion of our development programs, dispose of assets or technology or cease operations.

 

Our cash requirements for 2021 will be impacted by a number of factors, the most significant of which are expenses related to teplizumab, including costs to build out our commercial infrastructure and other pre-commercial activities for teplizumab, the PROTECT clinical trial, manufacturing activities for teplizumab and any potential milestone payments that may become due upon a potential regulatory approval of teplizumab by the FDA. Other factors include costs related to our Phase 2b clinical study of PRV-015, our first-in-human safety study of PRV-101 and the timing of our planned Phase 2a study of PRV-3279.

 

Based on our current business plans, management believes that our cash, cash equivalents and marketable securities on hand at December 31, 2020, coupled with the funds raised in our January 2021 common stock offering, are sufficient to meet our obligations for at least the next 12 months from the issuance of these financial statements.

 

93

 

 

Cash Flows

 

The following table shows a summary of our cash flows for the years ended December 31, 2020, 2019 and 2018:

 

   For the Years Ended December 31, 
   2020   2019   2018 
   (in thousands) 
Net cash (used in) provided by:               
Operating activities  $(76,336)  $(36,065)  $(22,642)
Investing activities   25,174    (46,250)   — 
Financing activities   114,291    62,941    59,347 
Net change in cash and cash equivalents  $63,129   $(19,374)  $36,705 

 

Cash Flows from Operating Activities

 

Net cash used in operating activities was $76.3 million for the year ended December 31, 2020 and primarily related to cash used to fund clinical development, manufacturing, and pre-commercial activities for teplizumab, clinical development activities for PRV-015, development activities for PRV-101, and increased personnel costs to support our clinical programs and the build out of our corporate and commercial infrastructure. Our working capital was $109.8 million as of December 31, 2020.

 

Net cash used in operating activities was $36.1 million for the year ended December 31, 2019 and primarily related to cash used to fund clinical development activities for teplizumab, PRV-6527, PRV-3279 and PRV-300, development activities for PRV-101, and increased personnel costs to support our clinical programs and our public company infrastructure.

 

Net cash used in operating activities was $22.6 million for the year ended December 31, 2018 and primarily related to cash used to fund clinical development activities for PRV-6527, PRV-300 and teplizumab, development activities for PRV-101, and increased personnel costs to support our recently acquired programs and our new public company infrastructure.

 

Cash Flows from Investing Activities

 

Net cash provided by investing activities was $25.2 million for the year ended December 31, 2020 and primarily related to the proceeds received from the maturity of marketable securities totaling $55.0 million offset by purchases of marketable securities totaling $28.7 million and net capital expenditures associated with the build out of our new corporate headquarters and information systems infrastructure of $1.1 million.

 

Net cash used in investing activities for the year ended December 31, 2019 was $46.2 million and relates to the purchase of marketable securities during the period.

 

There was no cash used in or provided by investing activities for the year ended December 31, 2018.

 

Cash Flows from Financing Activities

 

Net cash provided by financing activities was $114.3 million for the year ended December 31, 2020 and primarily related to net proceeds received from our underwritten public offering in June 2020 of $103.3 million, net proceeds received from the sale of our common stock under our ATM program of $9.9 million, as well as $1.1 million received from stock option exercises during the period.

 

Net cash provided by financing activities was $62.9 million for the year ended December 31, 2019 and primarily related to the net proceeds we received from the completion of our underwritten public offering and concurrent private placement in September 2019.

 

Net cash provided by financing activities was $59.3 million for the year ended December 31, 2018 and primarily related to the net proceeds we received from the completion of our IPO in July 2018.

 

94

 

 

Commitments and Contractual Obligations

 

The table below presents a summary of our contractual obligations as of December 31, 2020:

 

   Payments Due By Period 
       Within           More than 
   Total   1 year   1-3 Years   3-5 Years   5 years 
   (In thousands) 
Purchase obligations (1)  $1,350   $1,350   $—   $—   $— 
Operating lease obligations (2)   1,144    185    448    470    41 
Total (3)  $2,494   $1,535   $448   $470   $41 

 

(1) Purchase obligations represent our commitments under binding forecasts, and purchase orders (inclusive of cancellation fees), including those provided under our agreement(s) with AGC. The actual amounts incurred will be determined based on the amount of goods purchased and the pricing then in effect under the applicable arrangement.
   
(2) Operating lease obligations represent the gross minimum cash rent payments under our lease in Red Bank, NJ.
   
(3) This table does not include (a) any milestone payments which may become payable to third parties under license and collaboration agreements as the timing and likelihood of such payments are not known with certainty, (b) any royalty payments to third parties as the amounts, timing and likelihood of such payments are not known, and (c) contracts that are entered into in the ordinary course of business that are not material in the aggregate in any period presented above.

 

We have entered into a number of license, collaboration, acquisition and other agreements with third parties. For further details regarding our significant contracts, and the commitments and contractual obligations contained within each contract, please refer to the section titled Significant Contracts and Agreements Related to Research and Development Activities within Item 1. above.

 

In July 2020, we entered into an agreement to lease approximately 7,000 square feet of office space in Red Bank, NJ, for which the initial lease term expires approximately 64 months from the lease commencement date, which occurred in October 2020, with base annual lease payments of approximately $0.2 million.

 

In addition, in the course of normal business operations, we have agreements with contract service providers to assist in the performance of our research and development and manufacturing activities. Expenditures to CROs, CMOs and other clinical development related vendors represent significant costs in clinical development. Subject to required notice periods and our obligations under binding purchase orders, we can elect to discontinue the work under these agreements at any time. We could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require upfront payments and even long-term commitments of cash.

 

We also have employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control or termination without cause, occur.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. We do not have any interest in special purpose entities, structured finance entities or other variable interest entities.

 

95

 

 

Critical Accounting Policies and Estimates

 

Preparation of financial statements in accordance with generally accepted accounting principles in the United States requires us to make estimates and assumptions affecting the reported amounts of assets, liabilities, and expenses and the disclosures of contingent assets and liabilities. We use our historical experience and other relevant factors when developing our estimates and assumptions and we continually evaluate these estimates and assumptions. The amounts of assets and liabilities reported in our balance sheets and the amounts of expenses reported in our statements of comprehensive loss are affected by estimates and assumptions, which are used for, but not limited to, the accounting for research and development, stock-based compensation and accrued expenses. The accounting policies discussed below are considered critical to an understanding of our financial statements because their application places the most significant demands on our judgment. Actual results could differ from our estimates. For additional accounting policies, see Note 3 to our Financial Statements— Summary of Significant Accounting Policies, which outlines our application of significant accounting policies.

 

Research and Development

 

Research and development expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel serving our development functions, and other internal operating expenses, the cost of clinical studies, and the cost of our drug candidates for clinical study. In addition, research and development expenses include payments to third parties for the development and manufacturing of our product candidates and the estimated fair value for the issuance of equity for the license rights to products in development (prior to marketing approval). Our expenses related to clinical trials are primarily related to activities at CROs that design, gain approval for and conduct clinical trials on our behalf. Such amounts are then recognized as an expense as the related goods are delivered or the services are performed.

 

Accrued Research and Development Expenses

 

As part of the process of preparing our financial statements, we are required to estimate our accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.

 

We base our expenses related to CROs and CMOs on our estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.

 

Stock-Based Compensation

 

We recognize stock-based compensation expense for awards of equity instruments based on the grant-date fair value of those awards. The grant-date fair value of the award is recognized as compensation expense ratably over the requisite service period, which generally equals the vesting period of the award. We also grant performance-based stock options. The grant-date fair value of the performance-based stock options is recognized as compensation expense once it is probable that the performance condition will be achieved. We record actual forfeitures in the period the forfeiture occurs.

 

96

 

 

In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, which supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payments arrangements related to the acquisition of goods and services from both employees and nonemployees. During the third quarter of 2018, we early adopted ASU 2018-07. After the adoption of ASU 2018-07, the measurement date for non-employee awards is the date of grant. Compensation expense for non-employees is recognized, without changes to the fair value of the award, over the requisite service period, which is the vesting period of the respective award. The adoption of ASU 2018-07 did not have a material impact our financial statements or footnote disclosures.

 

Prior to the third quarter of 2018, we accounted for awards of equity instruments issued to non-employees in accordance with ASC Topic 505-50 “Equity-Based Payment to Non-Employees” and accordingly the value of the stock compensation to non-employees was based upon the measurement date as determined at either a) the date at which a performance commitment was reached, or b) at the date at which the necessary performance to earn the equity instruments was complete, which was normally the end of the vesting period. At the end of each financial reporting period prior to completion of the service, the fair value of these awards was remeasured using updated assumption inputs in the Black-Scholes option-pricing model.

 

We used the Black-Scholes option-pricing model to estimate the fair value of option awards with the following weighted-average assumptions for the period indicated:

 

   Years Ended December 31, 
   2020   2019   2018 
             
Exercise price  $12.87   $10.34   $3.93 
Expected volatility   74%   72%   61%
Expected dividends   —    —    — 
Expected term (in years)   6.2    6.3    6.2 
Risk-free interest rate   0.59%   1.90%   2.78%

 

The weighted-average valuation assumptions were determined as follows:

 

  ● Risk-free interest rate: we base the risk-free interest rate on the interest rate payable on United States Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected option term.
  ● Expected annual dividends: the estimate for annual dividends is 0%, because we have not historically paid, and do not expect for the foreseeable future to pay, a dividend.
  ● Expected stock price volatility: the expected volatility used is based on historical volatilities of similar entities within our industry which were commensurate with our expected term assumption.
  ● Expected term of options: the expected term of options represents the period of time options are expected to be outstanding. The expected term of the options granted to employees is derived from the “simplified” method as described in Staff Accounting Bulletin 107 relating to stock-based compensation, whereby the expected term is an average between the vesting period and contractual period due to our limited operating history.

 

Stock-based compensation expense is included in both research and development expenses and general and administrative expenses in the Statements of Comprehensive Loss.

 

Determination of Fair Value of Common Stock

 

Prior to our IPO, there was no public market for our common stock. The estimated fair value of our common stock had been determined by our board of directors as of the date of each option grant and quarter end, with input from management, considering our most recently available third-party valuations of common stock. These factors included, but were not limited to: our most recently available valuations of our common stock by an unrelated third party; the price at which we sold shares of our convertible redeemable preferred stock to outside investors in arms-length transactions; the rights, preferences and privileges of our convertible preferred stock relative to those of our common stock; our results of operations, financial position and capital resources; current business conditions and projections; the lack of marketability of our common stock; the hiring of key personnel and the experience of management; the risk inherent in the development of our products; our stage of development and material risks related to our business; the fact that the option grants involved illiquid securities in a private company; and the likelihood of achieving a liquidity event, such as our IPO or sale, in light of prevailing market conditions.

 

97

 

 

We determined the estimated fair value of our common stock at various dates prior to our IPO using contemporaneous valuations performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants’ Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. We determined that the probability-weighted expected return method (“PWERM”), was the most appropriate method available under this guidance for allocating our enterprise value to determine the estimated fair value of our common stock. A PWERM is a scenario-based analysis that estimates value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class.

 

Our common stock valuations as of April 25, 2017, June 30, 2017, September 11, 2017, September 30, 2017, December 1, 2017, December 31, 2017, March 1, 2018, March 31, 2018, May 7, 2018, June 30, 2018 and July 18, 2018 were prepared using the PWERM.

 

Our board of directors and management developed best estimates based on application of these approaches and the assumptions underlying these valuations, giving careful consideration to the advice from our third-party valuation expert. Such estimates involved inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our equity-based compensation could be materially different.

 

Subsequent to the completion of our IPO, our board of directors determines the fair market value of our common stock based on its closing price as reported on the date of grant on the primary stock exchange on which our common stock is traded.

 

Recent Accounting Pronouncements

 

See Note 3, “Significant Accounting Policies”, in the accompanying notes to financial statements, which is incorporated herein by reference.

 

ITEM 7A. Quantitative and Qualitative Disclosures about Market Risk

 

We are exposed to market risk related to changes in interest rates. We had cash, cash equivalents and marketable securities of $121.8 million as of December 31, 2020, consisting of cash and investments in money market funds and certain short-term investment-grade corporate debt securities. Our investments in money market funds and investment-grade corporate debt securities are not insured by the federal government. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of United States interest rates, particularly because a significant portion of our investments are in short-term securities. Due to the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our portfolio.

 

The majority of our business is conducted in US dollars. However, we do contract with certain CROs to perform clinical trial activities abroad which are denominated in other currencies, including Euros. Historically, fluctuations in foreign currency exchange rates have not materially affected our results of operations. During the years ended December 31, 2020, 2019 and 2018, our results of operations were not materially affected by fluctuations in foreign currency exchange rates. As of December 31, 2020, substantially all of our total liabilities were denominated in the United States dollar.

 

ITEM 8. Financial Statements and Supplementary Data

 

The financial information required by Item 8 is contained in Part IV, Item 15 of this Annual Report on Form 10-K.

 

ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

None.

 

98

 

 

ITEM 9A. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

As of the end of the period covered by this report, management performed, with the participation of our principal executive and principal financial officers, an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosures. Based on the evaluation, our principal executive and principal financial officers concluded that, as of December 31, 2020, our disclosure controls and procedures were effective.

 

Management’s Annual Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act, as a process designed by, or under the supervision of, our principal executive and principal financial and accounting officers and effected by our board of directors and management to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with Generally Accepted Accounting Principles (“GAAP”), and that receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate. Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2020. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in the original Internal Control—Integrated Framework updated in 2013. Based on that assessment, our management concluded that, as of December 31, 2020, our internal control over financial reporting was effective.

 

Changes in Internal Control over Financial Reporting

 

There were no significant changes in our internal control over financial reporting for the quarterly period ended December 31, 2020 identified in connection with the evaluation required by Rules 13a-15(e) and 15d-15(e) of the Exchange Act that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Attestation Report on Internal Control over Financial Reporting

 

EisnerAmper LLP, our independent registered public accounting firm, issued an attestation report on our internal control over financial reporting. The report of EisnerAmper LLP is contained in Item 15 of Part IV of this Annual Report on Form 10-K.

 

ITEM 9B. Other Information

 

None.

 

99

 

 

PART III

 

ITEM 10. Directors, Executive Officers and Corporate Governance

 

Information required under this item relating to our Board of Directors, executive officers and corporate governance will be included in our definitive proxy statement for the 2021 Annual Meeting of Stockholders, to be filed with the SEC within 120 days after the end of the year ended December 31, 2020 (the “2021 Proxy Statement”), and such required information is incorporated herein by reference.

 

ITEM 11. Executive Compensation

 

Information required under this item relating to executive compensation is incorporated herein by reference from information included in the 2021 Proxy Statement.

 

ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters

 

Information required under this item relating to securities authorized for issuance under equity compensation plans and to security ownership of certain beneficial owners and management is incorporated herein by reference from information included in the 2021 Proxy Statement.

 

ITEM 13. Certain Relationships and Related Transactions and Director Independence

 

Information required under this item relating to certain relationships and transactions with related parties and about director independence is incorporated herein by reference from information included in the 2021 Proxy Statement.

 

ITEM 14. Principal Accounting Fees and Services

 

Information required under this item relating to the fees for professional services rendered by our independent accountants in 2020 and 2019 is incorporated herein by reference from information included in the 2021 Proxy Statement.

 

100

 

 

PART IV

 

ITEM 15. Exhibits, Financial Statements Schedules

 

(a) Financial Statements

 

See accompanying index to Financial Statements on page F-1.

 

(b) Financial Statement Schedules

 

All schedules have been omitted because the required information is included in the financial statements or the notes thereto, or is not applicable.

 

(c) Index to Exhibits

 

The following exhibits are filed or incorporated by reference as part of this Annual Report on Form 10-K:

 

Exhibit
Number		   Exhibit Title
     
3.1   Second Amended and Restated Certificate of Incorporation of Provention Bio, Inc., effective as of July 19, 2018 (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed on July 19, 2018).
     
3.2   Amended and Restated By-Laws of Provention Bio, Inc., as adopted on May 19, 2020 (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed on May 20, 2020).
     
4.1   Specimen Certificate representing shares of common stock of Provention (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-1/A (File No. 333-224801) filed on June 20, 2018).
     
4.2   Form of Underwriter’s Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Registration Statement on Form S-1/A (File No. 333-224801) filed on June 12, 2018).
     
4.3   Form of Warrant dated April 25, 2017, issued to MDB Capital Group, LLC (incorporated by reference to Exhibit 4.3 to the Company’s Registration Statement on Form S-1 (File No. 333-224801) filed on May 9, 2018).
     
4.4  

Description of Registrant’s Securities.

     
10.1   Form of Indemnification Agreement entered into by Provention with its Officers and Directors (incorporated by reference to Exhibit 10.2 to the Company’s Registration Statement on Form S-1 (File No. 333-224801) filed on May 9, 2018).
     
10.2   Amended and Restated 2017 Provention Bio, Inc. Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company’s Registration Statement on Form S-8 (File No. 333-237113) filed on March 12, 2020). +
     
10.3   Form of Stock Option Award under 2017 Provention Bio, Inc. Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to the Company’s Registration Statement on Form S-1 (File No. 333-224801) filed on May 9, 2018). +
     
10.4   License Agreement by and between Provention and Vactech Ltd., dated April 25, 2017 ((incorporated by reference to Exhibit 10.6 to the Company’s Registration Statement on Form S-1 (File No. 333-224801) filed on May 9, 2018). †

 

101

 

 

10.5   License, Development and Commercialization Agreement by and between Provention and Janssen Pharmaceutica NV (CSF-1R), dated April 25, 2017 ((incorporated by reference to Exhibit 10.7 to the Company’s Registration Statement on Form S-1 (File No. 333-224801) filed on May 9, 2018). †
     
10.6   Form of Registration Rights Agreement between Provention and investors for an offering completed on April 25, 2017 (incorporated by reference to Exhibit 10.10 to the Company’s Registration Statement on Form S-1 (File No. 333-224801) filed on May 9, 2018).
     
10.7   Employment Agreement, dated April 25, 2017, between Provention and Ashleigh Palmer (incorporated by reference to Exhibit 10.13 to the Company’s Registration Statement on Form S-1 (File No. 333-224801) filed on May 9, 2018). +
     
10.8   Employment Agreement, dated April 25, 2017, between Provention and Francisco Leon (incorporated by reference to Exhibit 10.14 to the Company’s Registration Statement on Form S-1 (File No. 333-224801) filed on May 9, 2018). +
     
10.9   Employment Agreement, dated June 20, 2017, between Provention and Eleanor Ramos (incorporated by reference to Exhibit 10.15 to the Company’s Registration Statement on Form S-1 (File No. 333-224801) filed on May 9, 2018). +
     
10.10   Employment Agreement, dated September 21, 2017, between Provention and Andrew Drechsler (incorporated by reference to Exhibit 10.16 to the Company’s Registration Statement on Form S-1 (File No. 333-224801) filed on May 9, 2018). +
     
10.11   Development Services Agreement by and between Provention and Intravacc dated March 6, 2018 (incorporated by reference to Exhibit 10.18 to the Company’s Registration Statement on Form S-1/A (File No. 333-224801) filed on May 16, 2018). †
     
10.12   License Agreement by and between Provention and MacroGenics, Inc. dated May 7, 2018 (incorporated by reference to Exhibit 10.19 to the Company’s Registration Statement on Form S-1/A (File No. 333-224801) filed on May 16, 2018). †
     
10.13   Asset Purchase Agreement by and between Provention and MacroGenics, Inc. dated May 7, 2018 (incorporated by reference to Exhibit 10.20 to the Company’s Registration Statement on Form S-1/A (File No. 333-224801) filed on May 16, 2018). †

 

10.14   License and Collaboration Agreement by and between Provention and Amgen, Inc. dated November 5, 2018 (incorporated by reference to Exhibit 10.23 to the Company’s Annual Report on Form 10-K (File No. 001-38552) filed on March 19, 2019). †
     
10.15   Employment Agreement, dated January 7, 2020, between Provention and Jason Hoitt (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-38552) filed on January 8, 2020). +
     
10.16   Employment Agreement, dated August 3, 2020, between Provention and Heidy Abreu King-Jones (incorporated by reference to Exhibit 10.1 to the Company’s Form 10-Q (File No. 001-38552) filed on August 6, 2020). +
     
10.17   Provention Bio, Inc. 2020 Inducement Plan (incorporated by reference to Exhibit 99.1 to the Company’s Form 8-K filed on October 30, 2020). +

 

102

 

 

10.18   First Amended Employment Agreement, effective May 19, 2020, between Provention and Ashleigh Palmer (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed on May 20, 2020). +
     
10.19   First Amended Employment Agreement, effective June 10, 2020, between Provention and Francisco Leon (incorporated by reference to Exhibit 10.3 to the Company’s Form 10-K filed on June 11, 2020). +
     
10.20   First Amended Employment Agreement, effective June 9, 2020, between Provention and Eleanor Ramos (incorporated by reference to Exhibit 10.4 to the Company’s Form 8-K filed on June 11, 2020). +
     
10.21   First Amended Employment Agreement, effective June 9, 2020, between Provention and Andrew Drechsler (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed on June 11, 2020). +
     
10.22   First Amended Employment Agreement, effective June 9, 2020, between Provention and Jason Hoitt (incorporated by reference to Exhibit 10.2 to the Company’s Form 8-K filed on June 11, 2020). +
     
23.1   Consent of EisnerAmper LLP
     
31.1   Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15(d)-14(a) (filed herewith, Exhibit 31.1).
     
31.2   Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15(d)-14(a) (filed herewith, Exhibit 31.2).
     
32.1   Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350 (filed herewith, Exhibit 32.1).
     
32.2   Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350 (filed herewith, Exhibit 32.2).
     
101   The following materials from Provention Bio, Inc.’s Annual Report on Form 10-K for the years ended December 31, 2020 and 2019, formatted in Inline Extensible Business Reporting Language (“iXBRL”): (i) Balance Sheets at December 31, 2020 and 2019, (ii) Statements of Comprehensive Loss for the years ended December 31, 2020, 2019 and 2018, (iii) Statements of Stockholders’ Equity at December 31, 2020, 2019 and 2018, (iv) Statements of Cash Flows for the years ended December 31, 2020, 2019 and 2018, and (v) Notes to Financial Statements.
     
104   The cover page from this Annual Report on Form 10-K for the year ended December 31, 2020, formatted in iXBRL (Contained in Exhibit 101).

 

 

+ Compensation Related Contract.
† Confidential treatment received for certain portions of this exhibit.

 

ITEM 16. Form 10-K Summary

 

Not applicable.

 

103

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Registrant:
     
  Provention Bio, Inc.
     
Date: February 25, 2021 By: /s/ Andrew Drechsler
    Andrew Drechsler
   

Chief Financial Officer

(Authorized Officer and Principal Financial Officer)

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

 

Signature    Title    Date
         
/s/ Ashleigh Palmer   Chief Executive Officer (Principal Executive Officer), Director   February 25, 2021
Ashleigh Palmer      
         
/s/ Andrew Drechsler   Chief Financial Officer (Principal Financial Officer, Principal Accounting Officer)   February 25, 2021
Andrew Drechsler      
         
/s/ Jeffrey Bluestone   Director   February 25, 2021
Jeffrey Bluestone        
         
/s/ Avery Catlin   Director   February 25, 2021
Avery Catlin        
         
/s/ Sean Doherty   Director   February 25, 2021
Sean Doherty        
         
/s/  John Jenkins   Director   February 25, 2021
 John Jenkins        
         
/s/ Wayne Pisano   Director   February 25, 2021
Wayne Pisano        
         
/s/ Nancy Wysenski   Director   February 25, 2021
Nancy Wysenski        

 

104

 

 

PROVENTION BIO, INC.

 

INDEX TO FINANCIAL STATEMENTS

 

Reports of Independent Registered Public Accounting Firm F-2
   
Audited Financial Statements:  
Balance Sheets as of December 31, 2020 and 2019 F-4
Statements of Comprehensive Loss for the Years Ended December 31, 2020, 2019, and 2018 F-5
Statements of Stockholders’ Equity for the Years Ended December 31, 2020, 2019, and 2018 F-6
Statements of Cash Flows for the Years Ended December 31, 2020, 2019, and 2018 F-7
Notes to Financial Statements F-8

 

F-1

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Stockholders of Provention Bio, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying balance sheets of Provention Bio, Inc. (the “Company”) as of December 31, 2020 and 2019, and the related statements of comprehensive loss, stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2020, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.

 

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the Company’s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”), and our report dated February 25, 2021 expressed an unqualified opinion.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the financial statements and (ii) involved especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

Accruals for research and development expenses

 

As disclosed in the Note 3 to the financial statements, the Company is required to estimate its accrued expenses related to research and development activities. Liabilities related to research and development were included in accrued expenses and totaled approximately $5,165,000 as of December 31, 2020.

 

We considered the auditing of accruals related to research and development activities a critical audit matter due to the complexity of estimation of those accruals related to third party clinical research organizations (CROs) and contract manufacturing organizations (CMOs). The complexity of the Company’s estimates for these accruals was primarily due to determination of progress and direct and indirect costs incurred under these arrangements, where invoicing under milestones may not match the timing of services provided to date. As a result, auditor judgement was required to perform procedures and evaluate audit evidence related to the accruals for research and development expenses.

 

Our approach to addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. We obtained an understanding and tested the design and effectiveness of controls over the Company’s process for estimating research and development accruals, including controls over inputs used by management to make the estimates and the completeness and accuracy of the data used in the estimates. Our audit procedures also included inspection of a sample of contracts, related invoices and payments, comparing the Company’s estimate of progress under arrangements to information received from vendors, including confirmation of progress with third parties, and recalculation of progress and resulting accruals.

 

/s/ EisnerAmper LLP  

We have served as the Company’s auditor since 2016.

EISNERAMPER LLP

Iselin, New Jersey

February 25, 2021

 

F-2

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Stockholders of Provention Bio, Inc.

 

Opinion on Internal Control over Financial Reporting

 

We have audited Provention Bio, Inc.’s (the “Company”) internal control over financial reporting as of December 31, 2020, based on criteria established in the Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in the Internal Control - Integrated Framework (2013) issued by COSO.

 

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the balance sheets of Provention Bio, Inc. as of December 31, 2020 and 2019, and the related statements of comprehensive loss, stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2020, and the related notes and our report dated February 25, 2021 expressed an unqualified opinion.

 

Basis for Opinion

 

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

 

Definition and Limitations of Internal Control over Financial Reporting

 

An entity’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. An entity’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the entity; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the entity are being made only in accordance with authorizations of management and directors of the entity; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the entity’s assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

/s/ EisnerAmper LLP  

EISNERAMPER LLP

Iselin, New Jersey

February 25, 2021

 

F-3

 

 

PROVENTION BIO, INC.

BALANCE SHEETS

(in thousands of U.S. dollars, except share and per share data)

 

   2020   2019 
   As of December 31, 
   2020   2019 
         
ASSETS          
Current assets:          
Cash and cash equivalents  $102,294   $39,165 
Marketable securities   19,530    46,208 
Prepaid expenses and other current assets   4,730    623 
Total current assets   126,554    85,996 
           
Fixed assets, net   1,437    — 
Operating lease right-of-use assets   408    — 
Other assets   120    — 
Total assets  $128,519   $85,996 
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable  $7,568   $1,775 
Accrued expenses and other current liabilities   9,162    2,065 
Total current liabilities   16,730    3,840 
           
Operating lease liabilities, long-term   715    — 
Total liabilities   17,445    3,840 
           
Commitments and Contingencies (Note 6)   -      
           
Stockholders’ equity:          
Preferred stock, $0.0001 par value; 25,000,000 shares authorized; no shares issued or outstanding at December 31, 2020 and December 31, 2019   —    — 
Common stock, $0.0001 par value; 100,000,000 shares authorized; 56,517,891 shares issued and outstanding at December 31, 2020; 47,658,361 shares issued and outstanding at December 31, 2019   6    5 
Additional paid-in capital   288,725    161,212 
Accumulated other comprehensive loss   (15)   — 
Accumulated deficit   (177,642)   (79,061)
Total stockholders’ equity   111,074    82,156 
Total liabilities and stockholders’ equity  $128,519   $85,996 

 

The accompanying notes are an integral part of the financial statements.

 

F-4

 

 

PROVENTION BIO, INC.

STATEMENTS OF COMPREHENSIVE LOSS

(in thousands of U.S. dollars, except per share data)

 

   2020   2019   2018 
   For the Years Ended December 31, 
   2020   2019   2018 
Operating expenses:               
Research and development  $66,360   $36,359   $22,649 
General and administrative   33,327    8,013    4,165 
Total operating expenses   99,687    44,372    26,814 
                
Loss from operations   (99,687)   (44,372)   (26,814)
Interest income   583    1,087    669 
Change in fair value of warrant liability   —    —    (520)
Loss before income tax benefit   (99,104)   (43,285)   (26,665)
Income tax benefit   523    —    187 
Net loss   (98,581)   (43,285)   (26,478)
Accretion on Series A Convertible Redeemable Preferred Stock   —    —    (276)
Net loss attributable to common stockholders  $(98,581)  $(43,285)  $(26,754)
                
Net loss per common share, basic and diluted  $(1.88)  $(1.06)  $(1.19)
Weighted average common shares outstanding, basic and diluted   52,457    40,747    22,441 
                
Net loss  $(98,581)  $(43,285)  $(26,478)
Other comprehensive income (loss):               
Unrealized gain (loss) on marketable securities   (15)   —    — 
Total comprehensive loss  $(98,596)  $(43,285)  $(26,478)

 

The accompanying notes are an integral part of the financial statements.

 

F-5

 

 

PROVENTION BIO, INC.

STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands of U.S. dollars)

 

         1         2    3    4    5    6 
   Convertible Redeemable
Preferred Stock		   Common Stock  

Additional

Paid-In

  

Accumulated Other Comprehensive

Income

   Accumulated  

Total

Stockholders’

 
   Shares   Amount   Shares   Amount   Capital   (Loss)   Deficit   Equity 
                                 
Balance at December 31, 2017   11,382   $26,185    10,000   $1   $3,264   $—   $(9,298)  $(6,033)
Issuance of common stock upon conversion of Series A Convertible Redeemable Preferred Stock   (11,382)   (26,461)   11,382    1    26,460    —    —    26,461 
Accretion of Series A Convertible Redeemable Preferred Stock to redemption value   —    276    —    —    (276)   —    —    (276)
Reclassification of Series A warrants liability   —    —    —    —    1,518    —    —    1,518 
Issuance of common stock in connection with initial public offering, net of issuance costs   —    —    15,970    2    56,281    —    —    56,283 
Issuance of common stock in connection with stock option exercises   —    —    10    —    25    —    —    25 
Fair value of warrants issued in connection with initial public offering of common stock   —    —    —    —    3,039    —    —    3,039 
Fair value of warrants issued in connection with the acquisition of product rights   —    —    —    —    3,978    —    —    3,978 
Stock-based compensation   —    —    —    —    1,141    —    —    1,141 
Net loss   —    —    —    —    —    —    (26,478)   (26,478)
Balance at December 31, 2018   —   $—    37,362   $4   $95,430   $—   $(35,776)  $59,658 
Issuance of common stock in connection with public follow on offering, net of issuance costs   —    —    5,750    1    42,650    —    —    42,651 
Issuance of common stock in connection with private placement with Amgen   —    —    2,500    —    20,000    —    —    20,000 
Issuance of common stock in connection with stock option exercises   —    —    79    —    290    —    —    290 
Issuance of common stock in connection with warrant exercises   —    —    1,967    —    —    —    —    — 
Stock-based compensation   —    —    —    —    2,842    —    —    2,842 
Net loss   —    —    —    —    —    —    (43,285)   (43,285)
Balance at December 31, 2019   —   $—    47,658   $5   $161,212   $—   $(79,061)  $82,156 
Issuance of common stock in connection with underwritten public offering, net of issuance costs   —    —    7,590    1    103,269    —    —    103,270 
Issuance of common stock in connection with at-the-market stock sales, net of issuance costs   —    —    725    —    9,869    —    —    9,869 
Issuance of common stock in connection with stock option exercises   —    —    219    —    1,152    —    —    1,152 
Issuance of common stock in connection with warrant exercises   —    —    326    —    —    —    —    — 
Unrealized gain (loss) on marketable securities, net of tax   —    —    —    —    —    (15)   —    (15)
Stock-based compensation   —    —    —    —    13,223    —    —    13,223 
Net loss   —    —    —    —    —    —    (98,581)   (98,581)
Balance at December 31, 2020   —   $—    56,518   $6   $288,725   $(15)  $(177,642)  $111,074 

 

The accompanying notes are an integral part of the financial statements.

 

F-6

 

 

PROVENTION BIO, INC.

STATEMENTS OF CASH FLOWS

(in thousands of U.S. dollars)

 

    1    2    3 
   For the Years Ended December 31, 
   2020   2019   2018 
Operating activities               
Net loss  $(98,581)  $(43,285)  $(26,478)
Adjustments to reconcile net loss to net cash used in operating activities:               
Stock-based compensation expense   13,223    2,842    1,141 
Stock-based consideration in connection with acquisition of product rights (Note 6)   —    —    3,978 
Change in fair value of warrant liability   —    —    520 
Amortization of premium and discounts on marketable securities   247    (16)   — 
Non-cash operating lease expense   25    —    — 
Depreciation   33    —    — 
                
Changes in operating assets and liabilities:               
Prepaid expenses and other current assets   (4,112)   2,367    (2,396)
Accounts payable   5,793    1,207    109 
Accrued interest receivable   131    58    — 
Accrued expenses   7,025    762    484 
Other assets   (120)   —    — 
Net cash used in operating activities   (76,336)   (36,065)   (22,642)
                
Investing activities               
Purchase of marketable securities   (28,715)   (46,250)   — 
Maturities of marketable securities   55,000    —    — 
Purchase of fixed assets   (1,111)   —    — 
Net cash provided by (used in) investing activities   25,174    (46,250)   — 
                
Financing activities               
Proceeds from underwritten public offering, net   103,270    42,651    — 
Proceeds from private placement with Amgen   —    20,000    — 
Proceeds from initial public offering, net   —    —    59,322 
Proceeds from at-the-market stock sales, net   9,869    —    — 
Proceeds from stock option exercises   1,152    290    25 
Net cash provided by financing activities   114,291    62,941    59,347 
                
Net increase (decrease) in cash and cash equivalents   63,129    (19,374)   36,705 
Cash and cash equivalents at beginning of period   39,165    58,539    21,834 
Cash and cash equivalents at end of period  $102,294   $39,165   $58,539 
                
Supplemental disclosure of cash flow information:               
Right-of-use assets obtained in exchange for new operating lease liabilities  $413   $—   $— 
                
Supplemental disclosure of non-cash financing transactions:               
Conversion of Series A Preferred Stock to common stock upon completion of IPO  $—   $—   $26,461 
Reclassification of Series A Preferred Stock warrant liability to stockholders’ equity  $—   $—   $1,518 
Accretion of Series A Convertible Redeemable Preferred Stock  $—   $—   $276 

 

The accompanying notes are an integral part of the financial statements.

 

F-7

 

 

PROVENTION BIO, INC.

NOTES TO FINANCIAL STATEMENTS

(tabular dollars and shares in thousands, except per share data)

 

1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

 

Business

 

Provention Bio, Inc. (the “Company”) was incorporated on October 4, 2016 under the laws of the State of Delaware. The Company is a clinical stage biopharmaceutical company, focused on the development and commercialization of novel therapeutics and innovative approaches to intercept and prevent immune-mediated diseases. Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. The Company’s business is subject to significant risks and uncertainties and will be dependent on raising substantial additional capital before it becomes profitable and it may never achieve profitability.

 

Basis of presentation

 

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented.

 

2. LIQUIDITY

 

The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has incurred recurring losses since inception and as of December 31, 2020, the Company had an accumulated deficit of $177.6 million. To date, the Company has not generated any revenues and has financed its operations primarily through equity offerings.

 

In April 2017, the Company completed its private placement of 11,381,999 shares of Series A Convertible Redeemable Preferred Stock at $2.50 per share (the “Series A Offering”). The Company received net proceeds of $26.7 million. In connection with the sale of Series A Convertible Redeemable Preferred Stock, the Company issued warrants to purchase 558,740 shares of Series A Convertible Redeemable Preferred Stock with an exercise price of $2.50 per share with a seven-year term.

 

In July 2018, the Company issued and sold an aggregate of 15,969,563 shares of common stock in its initial public offering (“IPO”) at a public offering price of $4.00 per share. In connection with the IPO, the Company issued to MDB Capital Group, LLC (“MDB”), the underwriter in the IPO, and its designees warrants to purchase 1,596,956 shares of common stock at an exercise price of $5.00 per share. The Company received net proceeds from the IPO of $59.3 million, after deducting underwriting discounts and commissions of approximately $3.7 million and other offering expenses of approximately $0.8 million. Upon the closing of the IPO, all of the Company’s shares of redeemable convertible preferred stock outstanding at the time of the offering were automatically converted into 11,381,999 shares of common stock. In addition, the warrants issued in connection with the Series A Convertible Redeemable Preferred Stock also converted to warrants for the purchase of 558,740 shares of the Company’s common stock.

 

In September 2019, the Company completed an underwritten public offering in which it sold 5,750,000 shares of common stock at a public offering price of $8.00 per share. The 5,750,000 shares sold included the full exercise of the underwriters’ option to purchase 750,000 shares at a price of $8.00 per share. Concurrent with the underwritten public offering, the Company sold 2,500,000 shares of common stock to Amgen, Inc. at the public offering price of $8.00 per share in a private placement, pursuant to the terms of the Company’s License and Collaboration Agreement with Amgen Inc, dated as of November 5, 2018. Aggregate net proceeds from the underwritten public offering and the concurrent private placement were $62.7 million, net of approximately $2.8 million in underwriting discounts and commissions and other offering expenses of $0.5 million.

 

F-8

 

 

In August 2019, the Company established an at-the-market (“ATM”) program through which the Company may sell, from time to time at its sole discretion, up to $50.0 million of shares of its common stock. The Company has sold 725,495 shares of common stock for aggregate net proceeds of approximately $9.9 million, net of $0.3 million in sales commissions, under the ATM program, all of which occurred during the quarter ended June 30, 2020.

 

In June 2020, the Company completed an underwritten public offering in which it sold 7,590,000 shares of common stock at a public offering price of $14.50 per share. The 7,590,000 shares sold included the full exercise of the underwriters’ option to purchase 990,000 shares at a price of $14.50 per share. The Company received net proceeds from the underwritten public offering of $103.3 million, after deducting underwriting discounts and commissions of approximately $6.6 million and other offering expenses of $0.2 million.

 

In January 2021, the Company completed an underwritten public offering in which it sold 6,250,000 shares of common stock at a public offering price of $16.00 per share. In February 2021, the underwriters partially exercised their option to purchase an additional 587,500 shares at a price of $16.00 per share. In the aggregate, total net proceeds from the underwritten public offering was $102.3 million, after deducting underwriting discounts and commissions of approximately $6.6 million and other offering expenses of $0.5 million.

 

The Company has devoted substantially all of its financial resources and efforts to research and development and expects to continue to incur significant expenses and increasing operating losses over the next several years due to, among other things, costs related to research funding, development of its product candidates and its preclinical programs, strategic alliances, the development of its administrative and commercial organization and pre-commercial activities for teplizumab. The Company’s net losses may fluctuate significantly from quarter to quarter and year to year.

 

The Company will require substantial additional financing to fund its operations and to continue to execute its strategy. The Company may raise capital through public or private equity or debt financings. The sale of equity or other securities may result in dilution to the Company’s stockholders and certain of those securities may have rights senior to those of the Company’s existing shares. If the Company raises additional funds through the issuance of preferred stock, convertible debt securities or other debt financing, these securities or other debt could contain covenants that would restrict the Company’s operations. Any other third-party funding arrangement could require the Company to relinquish valuable rights. The source, timing and availability of any future financing will depend principally upon market conditions, and, more specifically, on the progress of the Company’s clinical development programs. Funding may not be available when needed, at all, or on terms acceptable to the Company. Lack of necessary funds may require the Company, among other things, to delay, scale back or eliminate some or all of the Company’s planned operations.

 

The Company’s cash requirements for 2021 will be impacted by a number of factors, the most significant of which are expenses related to teplizumab, including costs to build out the Company’s commercial infrastructure and pre-commercial activities for teplizumab, the PROTECT clinical trial, manufacturing activities for teplizumab and any potential milestone payments that may become due upon a potential regulatory approval of teplizumab by the FDA. Other factors include costs related to the Company’s Phase 2b clinical study of PRV-015 and first-in-human safety study of PRV-101.

 

Based on the Company’s current business plans, management believes that its cash, cash equivalents and marketable securities on hand at December 31, 2020, coupled with net proceeds from the Company’s follow on offering in January 2021 and partial exercise by the underwriters to purchase additional shares in February 2021, are sufficient to meet the Company’s obligations for at least the next 12 months from the issuance of these financial statements.

 

3. SIGNIFICANT ACCOUNTING POLICIES

 

A summary of the significant accounting policies followed by the Company in the preparation of the financial statements is as follows:

 

Use of estimates

 

The process of preparing financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates and changes in estimates may occur.

 

F-9

 

 

Segment and geographic information

 

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating and reporting segment.

 

Cash, cash equivalents and concentration of credit risk

 

The Company considers only those investments which are highly liquid, readily convertible to cash, or that mature within 90 days from the date of purchase to be cash equivalents. Marketable securities are those investments with original maturities in excess of 90 days. The carrying amounts reported in the balance sheets for cash and cash equivalents are valued at cost, which approximates their fair value.

 

The Company has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements. The Company holds cash and cash equivalents in banks in excess of FDIC insurance limits. However, the Company believes risk of loss is minimal as the cash and cash equivalents are held by large, highly-rated financial institutions.

 

Marketable securities

 

The Company considers securities with original maturities of greater than 90 days to be available for sale securities. Available for sale securities are classified as either current or non-current assets based on the nature of the securities and their availability for use in current operations. Available for sale securities are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity.

 

On a quarterly basis, the Company reviews the status of each security in an unrealized loss position, to evaluate the existence of potential credit losses. The Company first considers whether it intends to sell, or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through income. For securities that do not meet this criteria, the Company considers a number of factors to determine if the decline in fair value has resulted from credit losses or other factors, including but not limited to: (1) the extent of the decline; (2) changes to the rating of the security by a rating agency; (3) any adverse conditions specific to the security; and (4) other market conditions that may affect the fair value of the security. If this assessment indicates that a credit loss exists and the present value of cash flows expected to be collected is less than the amortized cost basis, an allowance for credit losses is required for the credit loss. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. As of December 31, 2020, the Company has not recognized any impairment or credit losses on its available for sale securities.

 

Financial instruments

 

Cash, cash equivalents and marketable securities are reflected in the accompanying financial statements at fair value. The carrying amount of accounts payable and accrued expenses, including accrued research and development expenses, approximates fair value due to the short-term nature of those instruments.

 

Net loss per common share

 

Net loss per share information is determined using the two-class method, which includes the weighted-average number of shares of common stock outstanding during the period and other securities that participate in dividends (a participating security). The Company considered the Series A Preferred Stock, all of which were automatically converted to common stock upon the Company’s IPO, to be participating securities because they included rights to participate in dividends, if any, with the common stock.

 

F-10

 

 

Under the two-class method, basic net loss per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. The net loss attributable to common stockholders is calculated by adjusting the net loss of the Company for the accretion on the Preferred Stock. Net losses are not allocated to preferred stockholders as they do not have an obligation to share in the Company’s net losses. In periods with net income attributable to common stockholders, the Company would allocate net income first to preferred stockholders based on dividend rights under the Company’s certificate of incorporation and then to preferred and common stockholders based on ownership interests. Diluted net loss per share attributable to common stockholders is computed using the more dilutive of (1) the two-class method or (2) the if-converted method.

 

Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders for all periods presented since the effect of potentially dilutive securities are anti-dilutive given the net loss of the Company.

 

Fixed assets, net

 

Fixed assets, which consists primarily of leasehold improvements, furniture and fixtures, software, office equipment and certain clinical equipment, are carried at cost less accumulated depreciation. Depreciation is computed over the estimated useful lives of the respective assets, generally three to seven years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset.

 

Leases

 

The Company determines if an arrangement is a lease at contract inception. A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company classifies its leases as operating or financing by considering factors such as the length of the lease term, the present value of the lease payments, the specialized nature of the asset being leased and the potential for ownership of the asset to transfer during the lease term.

 

Leases with terms greater than one-year are recognized on the Company’s balance sheets as right-of-use (“ROU”) assets and lease liabilities and are measured at the present value of the fixed payments due over the lease term minus the present value of any incentives, rebates or abatements expected to be received from the lessor. Options to extend a lease are typically excluded from the expected lease term as the exercise of the option is typically not reasonably certain. Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee’s incremental borrowing rate. As the implicit rate is not typically readily determinable, the Company uses an incremental borrowing rate, which is established based upon the information available at the lease commencement date, to determine the present value of lease payments due under an arrangement. The incremental borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments.

 

ROU assets are amortized on a straight-line basis over the term of the lease. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are recognized in the statements of comprehensive loss in the same line item as expenses arising from fixed lease payments at the time when the event giving rise to the payment occurs.

 

Foreign currency translation

 

The Company considers the U.S. dollar to be its functional currency. Expenses denominated in foreign currencies are translated at the exchange rate on the date the expense is incurred. The effect of exchange rate fluctuations on translating foreign currency assets and liabilities into U.S. dollars is included in the Statements of Comprehensive Loss. Foreign exchange transaction gains and losses are included in the results of operations and are not material in the Company’s financial statements.

 

F-11

 

 

Research and development expenses

 

Research and development expenses primarily consist of costs associated with the preclinical and clinical development of the Company’s product candidate portfolio, including the following:

 

  ● external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”) and other vendors and contract manufacturing organizations (“CMOs”) for the production of drug substance and drug product; and

 

  ● employee-related expenses, including salaries, benefits and share-based compensation expense.

 

Research and development expenses also include costs of acquired product licenses and related technology rights where there is no alternative future use, costs of prototypes used in research and development, consultant fees and amounts paid to certain of our collaborative partners.

 

All research and development expenses are charged to operations as incurred in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic (“ASC”) 730, Research and Development. The Company accounts for non-refundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received, rather than when the payment is made.

 

Accrued research and development expenses

 

As part of the process of preparing our financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company’s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and make adjustments if necessary. The significant estimates in the Company’s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.

 

The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on the Company’s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company’s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company’s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.

 

Stock-based compensation expense

 

The Company follows the provisions of ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and non-employees, including stock options. Stock-based compensation expense is based on the grant date fair value estimated in accordance with the provisions of ASC 718 and is generally recognized as an expense over the requisite service period. For grants containing performance-based vesting provisions, the grant-date fair value of the performance-based stock options is recognized as compensation expense once it is probable that the performance condition will be achieved. The Company accounts for actual forfeitures in the period the forfeiture occurs.

 

F-12

 

 

Stock Options

 

The Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. Due to the lack of trading history, the Company’s computation of stock-price volatility is based on the volatility rates of comparable publicly held companies over a period equal to the expected term of the options granted by the Company. The Company’s computation of expected term is determined using the “simplified” method, which is the midpoint between the vesting date and the end of the contractual term. The Company believes that it does not have sufficient reliable exercise data in order to justify the use of a method other than the “simplified” method of estimating the expected exercise term of employee stock option grants. The Company utilizes a dividend yield of zero based on the fact that the Company has never paid cash dividends to stockholders and has no current intentions to pay cash dividends. The risk-free interest rate is based on the zero-coupon United States Treasury yield at the date of grant for a term equivalent to the expected term of the option.

 

In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, (“ASU 2018-07”) which supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payments arrangements related to the acquisition of goods and services from both employees and nonemployees. During the third quarter of 2018, the Company early adopted ASU 2018-07. After the adoption of ASU 2018-07, the measurement date for non-employee awards is the date of grant. Compensation expense for non-employees is recognized, without changes to the fair value of the award, over the requisite service period, which is the vesting period of the respective award. The adoption of ASU 2018-07 did not have a material impact the Company’s financial statements or footnote disclosures.

 

Prior to the third quarter of 2018, the Company accounted for awards of equity instruments issued to non-employees in accordance with ASC Topic 505-50, Equity-Based Payment to Non-Employees, (“ASC 505-50”) and accordingly the value of the stock compensation to non-employees was based upon the measurement date as determined at either a) the date at which a performance commitment was reached, or b) at the date at which the necessary performance to earn the equity instruments was completed, which was normally the end of the vesting period. At the end of each financial reporting period prior to completion of the service, the fair value of these awards was remeasured using updated assumption inputs in the Black-Scholes option-pricing model.

 

Stock-based compensation expense is included in both research and development expenses and general and administrative expenses in the Statements of Comprehensive Loss.

 

Warrant liability

 

In April 2017, the Company issued warrants to purchase shares of Series A Convertible Redeemable Preferred Stock in connection with the issuance of the Series A Preferred Stock. The Company accounted for these warrants as a liability in the financial statements because the underlying instrument into which the warrants were exercisable contained redemption provisions that were outside the Company’s control.

 

Upon the completion of the IPO in July 2018, the warrants issued in connection with the Series A Convertible Redeemable Preferred Stock converted to warrants for the purchase of 558,740 shares of our common stock and the warrants no longer contain redemption provisions that are outside the Company’s control. The liability associated with these warrants was revalued just prior to the completion of the IPO, with the change in the fair value of the warrant liability charged to earnings. The warrant liability was then reclassified to additional paid-in capital upon the completion of the IPO in July 2018.

 

The fair value of the warrants was determined using the Black-Scholes option-pricing model and were re-measured to fair value at each financial reporting period date with any changes in fair value recognized in the statements of operations. See Note 11 to our financial statements for further information.

 

F-13

 

 

Income taxes

 

The Company utilizes the liability method of accounting for deferred income taxes, as set forth in ASC 740, Income Taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. A valuation allowance is established against deferred tax assets when, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense.

 

Recent accounting pronouncements

 

The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”). ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s financial statements.

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. Effective January 1, 2019, the Company adopted ASU 2016-02. The adoption had no impact on the Company’s financial statements and related disclosures as the Company did not have any lease agreements at the time of adoption. In July 2020, the Company entered into an agreement to lease its new corporate headquarters in Red Bank, NJ. Upon commencement of the lease, which occurred in October 2020, the lease was accounted for as an operating lease. Refer to Note 13 - Leases for details about the Company’s lease portfolio, including Topic 842 required disclosures.

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Effective January 1, 2020, the Company adopted ASU 2016-13 using the modified retrospective method for all financial assets measured at amortized cost. Results for reporting periods beginning after January 1, 2020 are presented under ASC 326 (Financial Instruments - Credit Losses), while prior period amounts continue to be reported in accordance with previously applicable GAAP. The adoption of this ASU had no impact on the Company’s financial statements and related disclosures.

 

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820), which modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, including, among other changes, the consideration of costs and benefits when evaluating disclosure requirements. Effective January 1, 2020, the Company adopted ASU 2018-13. The adoption had no impact on the Company’s financial statements and related disclosures.

 

In August 2018, the FASB issued ASU No. 2018-15, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Effective January 1, 2020, the Company adopted ASU 2018-15. The adoption had no impact on the Company’s financial statements and related disclosures.

 

F-14

 

 

In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808), which clarifies the interaction between the guidance for collaborative arrangements (Topic 808) and the new revenue recognition standard (Topic 606). Effective January 1, 2020, the Company adopted ASU 2018-18. The adoption had no impact on the Company’s financial statements and related disclosures.

 

4. CAPITALIZATION

 

As of December 31, 2020 and 2019, the Company had authorized 100,000,000 shares of common stock, $0.0001 par value per share, of which 56,517,891 and 47,658,361 shares, respectively, were issued and outstanding. In addition, as of December 31, 2020 and 2019, the Company had authorized 25,000,000 shares of preferred stock, $0.0001 par value per share, of which, none were issued and outstanding.

 

5. CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES

 

The Company considers all highly liquid investments purchased with original maturities of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents as of December 31, 2020 and 2019 were $102.3 million and $39.2 million, respectively, and included cash, investments in money market funds, and United States Treasury securities with original maturities of 90 days or less.

 

The Company considers securities with original maturities of greater than 90 days at the date of purchase to be available for sale securities. The Company held available for sale securities with a fair value totaling $19.5 million and $46.2 million at December 31, 2020 and 2019, respectively. These available for sale securities consisted solely of investment-grade corporate debt securities and United States Treasury securities and had expected maturities of less than one year. The Company may sell certain of its marketable securities prior to their stated maturities for reasons including, but not limited to, managing liquidity, credit risk, duration and asset allocation.

 

The Company evaluates securities with unrealized losses, if any, to determine whether the decline in fair value has resulted from credit loss or other factors. As of December 31, 2020, the Company has not recognized any impairment or credit losses on the Company’s available for sale securities. While the Company classifies these securities as available for sale, the Company does not currently intend to sell its investments and the Company currently believes it has the ability to hold these investments until maturity.

 

The following table summarizes the amortized cost, fair value and allowance for credit losses of the Company’s available for sale securities:

 

   December 31, 2020 
   Amortized Cost   Gross Unrealized Gains   Gross Unrealized Losses   Fair Value 
                 
Corporate debt securities  $19,545   $—   $(15)  $19,530 
Total  $19,545   $—   $(15)  $19,530 

 

   December 31, 2019 
   Amortized Cost   Gross Unrealized Gains   Gross Unrealized Losses   Fair Value 
                 
U.S. Treasury securities  $46,208   $—   $—   $46,208 
Total  $46,208   $—   $—   $46,208 

 

F-15

 

 

The Company’s available for sale securities are reported at fair value on the Company’s balance sheets. Unrealized gains (losses) are reported within accumulated other comprehensive income (loss) in the Statements of Comprehensive Loss. The cost of securities sold and any realized gains/losses from the sale of available for sale securities are based on the specific identification method. The changes in accumulated other comprehensive income (loss) associated with the unrealized gain (loss) on available for sale securities for the years ended December 31, 2020, 2019 and 2018, were as follows:

 

   For the Years Ended December 31, 
   2020   2019   2018 
             
Beginning balance  $—   $—   $— 
Current period changes in fair value before reclassifications, net of tax   (15)   —    — 
Amounts reclassified from accumulated other comprehensive income (loss), net of tax   —    —    — 
Other comprehensive income (loss)   (15)   —    — 
Ending balance  $(15)  $—   $— 

 

6. LICENSE AND OTHER AGREEMENTS

 

In May 2018, the Company entered into an Asset Purchase Agreement with MacroGenics (the “MacroGenics Asset Purchase Agreement”) pursuant to which the Company acquired MacroGenics’ interest in teplizumab (renamed PRV-031), a humanized mAb for the treatment of Type 1 Diabetes (“T1D”). As partial consideration for the MacroGenics Asset Purchase Agreement, the Company granted MacroGenics a warrant to purchase 2,162,389 shares of the Company’s common stock at an exercise price of $2.50 per share. The Company is obligated to pay MacroGenics contingent milestone payments totaling $170.0 million upon the achievement of certain regulatory approval milestones, including $60.0 million payable within 90 days of an approval of a Biologics License Application (“BLA”) in the United States. In addition, the Company is obligated to make contingent milestone payments to MacroGenics totaling $225.0 million upon the achievement of certain sales milestones. The Company has also agreed to pay MacroGenics a single-digit royalty on net sales of the product. The Company has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to MacroGenics, aggregate milestone payments of up to approximately $0.7 million and other consideration, for certain third-party intellectual property under agreements the Company assumed pursuant to the MacroGenics Asset Purchase Agreement. Further, the Company is required to pay MacroGenics a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to teplizumab by the Company to a third party. The Company is obligated to use reasonable commercial efforts to develop and seek regulatory approval for teplizumab.

 

In May 2018, the Company entered into a License Agreement with MacroGenics, Inc. (the “MacroGenics License Agreement”), pursuant to which MacroGenics, Inc. (“MacroGenics”) granted the Company exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a humanized protein and a potential treatment for systemic lupus erythematosus (“SLE”) and other similar diseases. As partial consideration for the MacroGenics License Agreement, the Company granted MacroGenics a warrant to purchase 270,299 shares of the Company’s common stock at an exercise price of $2.50 per share. The Company is obligated to make contingent milestone payments to MacroGenics totaling $42.5 million upon the achievement of certain developmental and approval milestones for the first indication, and an additional $22.5 million upon the achievement of certain regulatory approvals for a second indication. In addition, the Company is obligated to make contingent milestone payments to MacroGenics totaling $225.0 million upon the achievement of certain sales milestones. The Company has also agreed to pay MacroGenics a single-digit royalty on net sales of the product. Further, the Company is required to pay MacroGenics a low double-digit percentage of certain consideration to the extent received in connection with a future grant of rights to PRV-3279 by the Company to a third party. The Company is obligated to use commercially reasonable efforts to develop and seek regulatory approval for PRV-3279. The license agreement may also be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to MacroGenics, and by MacroGenics in the event that the Company challenges the validity of any licensed patent under the agreement.

 

As of December 31, 2020, the Company has not achieved any milestones that would trigger payments to MacroGenics.

 

The Company recorded the warrants issued under the MacroGenics Asset Purchase Agreement and the MacroGenics License Agreement at an estimated fair value of $1.64 per share, approximately $4.0 million in the aggregate, as license fee expense included as part of Research & development expense during the second quarter of 2018.

 

In July 2019, MacroGenics elected to exercise its warrants for an aggregate of 2,432,688 shares on a cashless basis, resulting in the Company’s net issuance of 1,948,474 shares. Following the MacroGenics’ July 2019 warrant exercises, there were no additional warrants outstanding in connection with the MacroGenics License Agreement and the MacroGenics Asset Purchase Agreement.

 

F-16

 

 

In November 2018, the Company entered into a License and Collaboration Agreement (the “Amgen Agreement”) with Amgen, Inc. (“Amgen”) for PRV-015 (formerly AMG 714), a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease (“NRCD”). Under the terms of the agreement, the Company will conduct and fund a Phase 2b trial in NRCD and lead the development and regulatory activities for the program. Amgen agreed to make an equity investment of up to $20.0 million in the Company, subject to certain terms and conditions set forth in the agreement. Amgen is also responsible for the manufacturing of PRV-015. Upon completion of the Phase 2b trial, a $150.0 million milestone payment is due from Amgen to the Company, plus an additional regulatory milestone payment, and single digit royalties on future sales; provided, however, that Amgen has the right to elect not to pay the $150.0 million milestone, in which case we will have an option to negotiate for the transfer to the Company of rights to AMG 714 pursuant to a termination license agreement between Amgen and the Company. The material terms of the termination license agreement have been negotiated and agreed and form part of the Amgen Agreement. Under the terms of the termination license agreement, the Company would be obligated to make certain contingent milestone payments to Amgen and other third parties totaling up to $70.0 million upon the achievement of certain clinical and regulatory milestones and a low double-digit royalty on net sales of any approved product based on the IL-15 technology. The agreement may be terminated by either party upon a material breach or upon an insolvency event and by Amgen if we are not able to fund our clinical development obligations (among other termination triggers). The agreement expires upon the expiration of Amgen’s last obligation to make royalty payments to Provention. In September 2019, in a private placement completed concurrently with the Company’s underwritten public offering, Amgen purchased 2,500,000 shares of the Company’s common stock at the underwritten public offering price of $8.00 per share, for a total investment of $20.0 million.

 

In April 2017, the Company entered into a License Agreement with Vactech Ltd. (the “Vactech License Agreement”), pursuant to which Vactech Ltd. (“Vactech”) granted the Company exclusive global rights for the purpose of developing and commercializing the group B coxsackie virus vaccine (“CVB”) platform technology. In consideration of the licenses and other rights granted by Vactech, the Company issued two million shares of its common stock to Vactech. The Company recorded the issuance of the shares at their estimated fair value of approximately $1.70 per share for a total of $3.4 million as a license fee expense included as part of Research & development expense for the year ended December 31, 2017. Provention paid Vactech a total of approximately $0.5 million for transition and advisory services during the first 18 months of the term of the agreement. In addition, Provention may be obligated to make a series of contingent milestone payments to Vactech totaling up to an additional $24.5 million upon the achievement of certain clinical development and regulatory filing milestones, of which, $0.5 million became payable to Vactech in January 2021 upon the dosing of the first patient in the Phase 1 PROVENT study. In addition, the Company has agreed to pay Vactech tiered single-digit royalties on net sales of any approved product based on the CVB platform technology and three additional payments totaling $19.0 million upon the achievement of certain annual net sales levels. The Vactech License Agreement may be terminated by the Company on a country by country basis without cause (in which case the exclusive global rights to the technology will transfer back to Vactech) and by either party upon a material breach or insolvency of the other party. If the Company terminates the agreement with respect to two or more specified European countries, the agreement will be deemed terminated with respect to all of the EU, and if the Company terminates the agreement with respect to the United States, the agreement will be deemed terminated with respect to all of North America. The agreement expires upon the expiration of the Company’s last obligation to make royalty payments to Vactech. As of December 31, 2020, the Company has not achieved any milestones that would trigger payments to Vactech.

 

In March 2018, the Company entered into a Development Services Agreement with The Institute of Translational Vaccinology (the “Intravacc Development Services Agreement”), pursuant to which The Institute of Translational Vaccinology (“Intravacc”) will provide services related to process development, non-GMP and GMP manufacturing of the Company’s polyvalent CVB vaccine, including providing proprietary technology for manufacturing purposes. The Company will pay Intravacc approximately 10 million euros for their services over the development and manufacturing period. Each party retains its existing intellectual property and will share newly developed intellectual property via a fully-paid non-exclusive license between the parties for all development work through phase 1 clinical trials. Any future use, including commercial use, of Intravacc’s technology will be subject to a separate nonexclusive license agreement. The Intravacc Development Services Agreement may be terminated by us with ninety days’ notice without cause and by either party upon a material breach or insolvency of the other party. As of December 31, 2020, the Company had paid Intravacc a total of approximately 9.0 million euros, or approximately $10.5 million, for services provided by Intravacc under the Intravacc Development Services Agreement.

 

F-17

 

 

In April 2017, the Company entered into the Janssen CSF-1R License Agreement, pursuant to which Janssen Pharmaceutica NV (“Janssen”) granted the Company exclusive global rights to technology owned or controlled by Janssen Pharmaceutica NV for the purpose of developing and commercializing a colony stimulating factor 1 receptor (“CSF-1R”) inhibitor named JNJ-40346527 (renamed PRV-6527) for inflammatory bowel diseases including Crohn’s disease and UC. The Company evaluated PRV-6527 for Crohn’s disease in a recently completed Phase 2a clinical trial (the PRINCE study). In December 2019, Janssen declined its option to buy back the rights to PRV-6527 and as such, all rights will remain with the Company. The Company will be obligated to make contingent milestone payments to Janssen totaling $35.0 million upon the achievement of certain clinical and regulatory milestones for the first indication and an additional $20.0 million upon the achievement of certain clinical and regulatory milestones for a second indication. In addition, the Company has agreed to pay Janssen tiered single-digit royalties on net sales of any approved product based on the CSF-1R technology and three additional payments totaling $100.0 million upon the achievement of certain annual net sales levels. As of December 31, 2020, no milestones have been achieved that would trigger payments to Janssen under the CSF-1R License Agreement. The Company is not actively developing PRV-6527.

 

7. NET LOSS PER SHARE OF COMMON STOCK

 

The following table sets forth the computation of basic and diluted loss per share for the years ended December 31, 2020, 2019, and 2018:

 

   For the Years Ended December 31, 
   2020   2019   2018 
             
Net loss, basic  $(98,581)  $(43,285)  $(26,478)
Accretion of Series A Convertible Redeemable Preferred Stock   —    —    (276)
Net loss attributable to common stockholders  $(98,581)  $(43,285)  $(26,754)
                
Weighted average shares of common stock outstanding - basic and diluted   52,457    40,747    22,441 
Net loss per share of common stock, basic and diluted  $(1.88)  $(1.06)  $(1.19)

 

 

The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as they would be antidilutive:

 

   For the Years Ended December 31, 
   2020   2019   2018 
             
Stock options   9,503    5,894    3,476 
Warrants   1,705    2,125    4,588 

 

F-18

 

 

8. ACCRUED EXPENSES

 

Accrued expenses consisted of the following:

 

   As of December 31, 
   2020   2019 
         
Accrued research and development costs  $5,165   $1,700 
Accrued compensation   1,443    54 
Accrued professional fees   1,197    221 
Accrued pre-commercial costs   1,191    — 
Other accrued liabilities   166    90 
Total accrued expenses  $9,162   $2,065 

 

9. FAIR VALUE OF ASSETS AND LIABILITIES

 

The carrying amounts reported in the balance sheet for cash and cash equivalents, accounts payable and accrued expenses approximate fair value based on the short-term nature of these items.

 

In accordance with accounting principles generally accepted in the United States, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level hierarchy prioritizes the inputs used to measure fair value as follows:

 

Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.

 

Level 2 – Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 – Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

 

F-19

 

 

The following is a summary of assets and their related classifications under the fair value hierarchy:

 

   December 31, 2020 
   Financial Instruments Carried at Fair Value 
  

Quoted prices
in active markets for

identical items

  

Significant
other observable
inputs

  

Significant

unobservable
inputs

     
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                    
Cash and cash equivalents1  $102,294   $—   $—   $102,294 
Investments in Corporate debt securities2   —    19,530    —    19,530 

 

   December 31, 2019 
   Financial Instruments Carried at Fair Value 
  

Quoted prices
in active markets for

identical items

  

Significant

other observable

inputs

  

Significant

unobservable
inputs

     
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                    
Cash and cash equivalents 1  $39,165   $—   $—   $39,165 
Investments in U.S. Treasury securities2   46,208    —    —    46,208 

 

 

1 Cash and cash equivalents primarily include investments in money market funds and United States Treasury securities with maturity dates within 90 days from the purchase date
2 Investments in United States Treasury and investment-grade corporate debt securities are classified as available for sale securities

 

 

10. STOCK OPTIONS

 

In 2017, the Company adopted the Provention Bio, Inc. 2017 Equity Incentive Plan (the “2017 Plan”). Pursuant to the 2017 Plan, the Company’s Board of Directors may grant incentive stock options, nonqualified stock options, and restricted stock to employees, officers, directors, consultants and advisors. As of December 31, 2020, there were options to purchase an aggregate of 9,503,228 shares of common stock outstanding under the 2017 Plan. Options issued under the 2017 Plan are exercisable for up to 10 years from the date of issuance.

 

In 2018, the Company amended and restated its 2017 Plan to, among other things, include an evergreen provision, which would automatically increase the number of shares available for issuance under the 2017 Plan in an amount equal to (1) the difference between (x) 18% of the total shares of the Company’s common stock outstanding, on a fully diluted basis, on December 31st of the preceding calendar year, and (y) the total number of shares of the Company’s common stock reserved under the 2017 Plan on December 31st of such preceding calendar year or (2) an amount less than this calculated increase as determined by the board of directors.

 

In connection with the evergreen provisions of the 2017 Plan, the number of shares available for issuance under the 2017 Plan was increased by 2,270,353 shares, as determined by the board of directors under the provisions described above, effective as of January 1, 2021. As of December 31, 2020, there were 109,499 shares available for future grants.

 

In October 2020, the Company adopted the Provention Bio, Inc. 2020 Inducement Plan (the “2020 Inducement Plan”). Pursuant to the terms of the 2020 Inducement Plan, the Company may grant nonstatutory stock options, stock appreciation rights, restricted stock unit awards and restricted stock for up to a total of 2,000,000 shares of common stock to individuals that were not previously an employee or director of the Company or individuals returning to employment after a bona fide period of non-employment with the Company. As of December 31, 2020, there were no options to purchase shares of common stock outstanding under the 2020 Inducement Plan. Options issued under the 2020 Inducement Plan are exercisable for up to 10 years from the date of issuance.

 

F-20

 

 

Stock-based compensation

 

Total stock-based compensation expense recognized for both employees and non-employees was as follows:

 

   Years Ended December 31, 
   2020   2019   2018 
             
General and administrative  $7,611   $1,546   $512 
Research and development   5,612    1,296    629 
Total stock-based compensation expense  $13,223   $2,842   $1,141 

 

Option activity

 

The Company grants options with service-based vesting requirements as well as options with performance-based vesting requirements. Generally, the service-based requirements vest over a four-year period in multiple tranches. Each tranche of the performance-based component vests upon the achievement of a specific milestone. These milestones are related to the Company’s clinical trials, manufacturing activities, regulatory activities, commercial activities and certain other performance metrics.

 

A summary of option activity for the years ended December 31, 2020 and 2019 are presented below:

 

           Weighted-    
       Weighted-   Average    
       Average   Remaining    
   Underlying   Exercise   Contractual  Intrinsic 
Stock Option Awards  Shares   Price   Term  Value 
                
Outstanding at December 31, 2018   3,476   $2.85         
Granted   2,797   $10.34         
Exercised   (79)  $3.66         
Forfeited or expired   (300)  $4.19         
Outstanding at December 31, 2019   5,894   $6.33   8.5 years  $— 
Outstanding at January 1, 2020   5,894    6.33       
Granted   4,126   $12.87         
Exercised   (219)  $5.28         
Forfeited or expired   (298)  $9.39         
Outstanding at December 31, 2020   9,503   $9.10   8.3 years  $74,536 
Exercisable at December 31, 2020   3,730   $5.88   7.4 years  $41,263 

 

The weighted average grant-date fair value of options granted during the year ended December 31, 2020 was $8.32 per share. As of December 31, 2020, there were approximately 1,869,000 unvested options subject to performance-based vesting criteria with approximately $13.2 million of unrecognized compensation expense. This expense will be recognized when each milestone becomes probable of occurring. In addition, as of December 31, 2020, there were approximately 3,904,000 unvested options outstanding subject to time-based vesting with approximately $25.1 million of unrecognized compensation expense which will be recognized over a period of 3.2 years.

 

F-21

 

 

Cash proceeds from, and the aggregate intrinsic value of, stock options exercised during the periods presented below were as follows:

 

   Years Ended December 31, 
   2020   2019   2018 
             
Cash proceeds from options exercised  $1,152   $290   $25 
Aggregate intrinsic value of options exercised  $1,615   $551   $5 

 

The Company uses the Black-Scholes option-pricing model to estimate the fair value of option awards with the following weighted-average assumptions for the period indicated:

 

   Years Ended December 31, 
   2020   2019   2018 
             
Exercise price  $12.87   $10.34   $3.93 
Expected volatility   74%   72%   61%
Expected dividends   —    —    — 
Expected term (in years)   6.2    6.3    6.2 
Risk-free interest rate   0.59%   1.90%   2.78%

 

The weighted-average valuation assumptions were determined as follows:

 

  ● Risk-free interest rate: The Company bases the risk-free interest rate on the interest rate payable on United States Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected option term.
     
  ● Expected annual dividends: The estimate for annual dividends is 0%, because the Company has not historically paid, and does not expect for the foreseeable future to pay, a dividend.
     
  ● Expected stock price volatility: The expected volatility used is based on historical volatilities of similar entities within the Company’s industry which were commensurate with the Company’s expected term assumption.
     
  ● Expected term of options: The expected term of options represents the period of time options are expected to be outstanding. The expected term of the options granted to employees is derived from the “simplified” method as described in Staff Accounting Bulletin 107 relating to stock-based compensation, whereby the expected term is an average between the vesting period and contractual period due to the limited operating history.

 

11. WARRANTS

 

In connection with the April 2017 sale of Series A Convertible Redeemable Preferred Stock, the Company issued warrants to MDB, the Placement Agent, and its designees to purchase 558,740 shares of Series A Convertible Redeemable Preferred Stock with an exercise price of $2.50 per share with a seven-year term. Upon completion of the IPO in July 2018, the warrants automatically became warrants for the purchase of 558,740 shares of the Company’s common stock. During the year ended December 31, 2020, certain warrant holders from the Series A offering elected to exercise warrants for an aggregate of 312,689 shares, on a cashless basis, resulting in the Company’s net issuance of 259,542 shares. As of December 31, 2020, a total of 316,754 warrants have been exercised on a cashless basis and there were 241,986 warrants outstanding related to the Series A Offering.

 

In May 2018, in connection with the MacroGenics License Agreement and the MacroGenics Asset Purchase Agreement, the Company issued warrants to MacroGenics to purchase 2,432,688 shares of the Company’s common stock at an exercise price of $2.50 per share. These warrants had a seven-year term. The Company recorded the warrants issued under MacroGenics License Agreement and the MacroGenics Asset Purchase Agreement at an estimated fair value of $1.64 per share, approximately $4.0 million in the aggregate, as license fee expense included as part of Research & development expense during the year ended December 31, 2018.

 

F-22

 

 

The Company used valuation methods and assumptions that consider, among other factors, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants issued to MacroGenics. The fair values of these instruments were determined using models based on inputs that require management judgment and estimates.

 

The fair value of the warrants issued to MacroGenics was measured at issuance on May 7, 2018 using the Black-Scholes option pricing model based on the following assumptions:

 

Equity value upon issuance on May 7, 2018  $2.58 
Exercise price  $2.50 
Expected volatility   62.0%
Expected dividends   — 
Contractual term (in years)   7.0 
Risk-free interest rate   2.86%

 

The MacroGenics warrants were evaluated under ASC 480, Distinguishing Liabilities from Equity, (“ASC 480”) and ASC 815, Derivatives and Hedging, (“ASC 815”) and the Company determined that equity classification was appropriate.

 

In July 2019, MacroGenics elected to exercise its warrants for an aggregate of 2,432,688 shares on a cashless basis, resulting in the Company’s net issuance of 1,948,474 shares. Following the MacroGenics’ July 2019 warrant exercises, there were no additional warrants outstanding in connection with the MacroGenics License Agreement and the MacroGenics Asset Purchase Agreement.

 

In connection with the Company’s completion of its IPO, in July 2018, the Company issued to MDB, the underwriter in the IPO, and its designees warrants to purchase 1,596,956 shares of the Company’s common stock at an exercise price of $5.00 per share. These warrants have a five-year term.

 

The Company used valuation methods and assumptions that consider, among other factors, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants. The fair values of these instruments were determined using models based on inputs that require management judgment and estimates.

 

The fair value of the warrants issued to MDB were measured at issuance on July 19, 2018 using the Black-Scholes option-pricing model based on the following assumptions:

 

Equity value upon issuance on July 19, 2018  $4.00 
Exercise price  $5.00 
Expected volatility   60.0%
Expected dividends   — 
Contractual term (in years)   5.0 
Risk-free interest rate   2.74%

 

The Company estimated the fair value of the warrants issued to MDB to be $1.90 per share, approximately $3.0 million in the aggregate, which was recorded as a cost of the IPO. The MDB warrants were evaluated under ASC 480 and ASC 815 and the Company determined that equity classification was appropriate.

 

During the year ended December 31, 2020, certain warrant holders from the IPO elected to exercise warrants for an aggregate of 107,051 shares, on a cashless basis, resulting in the Company’s net issuance of 66,316 shares. As of December 31, 2020, a total of 134,114 warrants have been exercised on a cashless basis and there were 1,462,842 warrants outstanding related to the IPO.

 

F-23

 

 

12. FIXED ASSETS

 

Fixed assets consisted of the following:

 

   As of December 31, 
   2020   2019 
         
Leasehold improvements  $828   $— 
Furniture and fixtures   149    — 
Office equipment   35    — 
Clinical equipment   27    — 
Construction in progress   431    — 
    1,470    — 
Less accumulated depreciation   (33)   — 
Fixed assets, net  $1,437   $— 

 

Depreciation expense was $33 thousand for the year ended December 31, 2020. The Company had no depreciation expense for the year ended December 31, 2019.

 

13. LEASES

 

The Company’s lease portfolio consists of one office lease located in Red Bank, NJ. This lease is classified as an operating lease and has an initial term of 64 months from the lease commencement date, which began in October 2020. The Company has the option to renew or terminate the current term of a lease agreement at the end of the lease term. In its initial assessment of the lease term of the Red Bank, NJ office lease, the Company concluded that it is not reasonably certain to exercise the option to renew or terminate and therefore, this option was not considered in its lease assessment. The Company does not separate lease and non-lease components for all classes of underlying assets. The Company’s leases do not contain residual value guarantees and the Company does not sublease any of its leased assets. The Company does not record leases with an initial lease term of one-year or less on its balance sheets. As of December 31, 2020, the Company has not entered into any short-term leases.

 

The components of lease costs from continuing operations were as follows:

 

   Year Ended
December 31, 2020		 
     
Operating lease costs  $25 
Variable lease costs   3 
Total lease costs  $28 

 

During the year ended December 31, 2020, the Company did not have any operating cash outflows that were used in connection to its operating leases.

 

F-24

 

 

Supplemental balance sheet information related to leases are as follows:

 

   Classification  As of December 31, 2020 
        
Operating leases        
Lease right-of-use assets        
Non-current  Operating lease right-of-use assets  $408 
Lease liabilities        
Current  Accrued expenses  $72 
Non-current  Operating lease liabilities, long-term  $715 
         
Weighted average remaining lease term        
Operating leases      5.2 years 
         
Weighted average discount rate        
Operating leases      15.0%

 

As of December 31, 2020, maturities of lease liabilities on an annual basis for the remaining years of the Company’s commenced lease agreements were as follows:

 

   Operating Leases 
     
Year ending December 31,     
2021  $185 
2022   221 
2023   227 
2024   232 
2025   238 
Thereafter   41 
Total lease payments   1,144 
Less: present value discount   357 
Present value of lease liabilities  $787 

 

14. INCOME TAXES

 

The Company recorded no provision or benefit for federal income taxes, as the Company has incurred a net loss for all periods presented, and the Company has provided a full valuation allowance against its deferred tax assets. The Company recorded a benefit from state income taxes of approximately $0.5 million for the year ended December 31, 2020. The benefit from state income taxes solely reflects the reversal of valuation allowances previously recorded against the Company’s New Jersey State net operating losses (‘NOLs”) that resulted from the Company’s sale of approximately $6.8 million of its New Jersey state NOLs under the State of New Jersey’s Technology Business Tax Certificate Transfer Program (the “Program”) for cash proceeds of $0.5 million. The Program allows qualified technology and biotechnology businesses in New Jersey to sell unused amounts of NOLs and defined research and development tax credits. For the year ended December 31, 2019, the Company recorded no provision or benefit for state income taxes.

 

At December 31, 2020, the Company had Federal net operating loss carryforwards of approximately $139.1 million, of which approximately $5.4 million will expire in varying amounts beginning in 2036. The balance of the Federal net operating loss carryforwards generated in 2018 and prospectively can be carried forward indefinitely. The Company has state NOLs in various jurisdictions of approximately $129.8 million, certain of which begin to expire beginning in 2036. Utilization of net operating losses may be subject to substantial annual limitations due to the “change in ownership” provisions of the Internal Revenue Code, and similar state provisions. The Company has not yet completed a study to determine if an ownership change has occurred to date or determined the Company’s ability to utilize the aforementioned carryforwards. The Company had research and development tax credit carryforwards, including orphan drug tax credits, of approximately $16.3 million at December 31, 2020.

 

F-25

 

 

Income tax benefits computed using the federal statutory income tax rate differs from the Company’s effective tax rate primarily due to the following:

 

   For the Years Ended December 31, 
   2020   2019   2018 
             
Tax Provision at statutory tax rate   21.0%   21.0%   21.0%
Change in valuation allowance   (34.6)   (36.5)   (26.9)
Orphan drug credits   10.4    10.4    — 
State income taxes, net of federal benefit   5.2    6.5    6.2 
Sale of NJ net operating losses   0.4    —    0.7 
Permanent items   (2.2)   (2.1)   (0.5)
Other   0.3    0.7    0.2 
Effective Tax Rate   0.5%   —%   0.7%

 

The components of income tax benefit are as follows:

 

   For the Years Ended December 31, 
   2020   2019   2018 
             
Current:            
Federal  $—   $—   $— 
State   (523)   —    (187)
Deferred:               
Federal   —    —    — 
State   —    —    — 
Income tax benefit  $(523)  $—   $(187)

 

The income tax benefit recognized for the years ended December 31, 2020 and 2018 represent sales by the Company of its 2017 and 2018 New Jersey state net operating losses, from which the Company realized $0.5 million $0.2 million, respectively.

 

Significant components of the Company’s net deferred tax assets are as follows:

 

       
   As of December 31, 
   2020   2019 
         
Deferred tax assets:          
NOL Carryforward  $37,773   $17,520 
Federal research and development credits   15,819    5,045 
Equity compensation   4,245    1,018 
Product License   1,598    1,768 
Other   390    213 
Total deferred tax assets   59,825    25,564 
Less valuation allowance   (59,825)   (25,564)
Net deferred tax assets  $—   $— 

 

The Company’s gross deferred tax assets of $59.8 million and $25.6 million at December 31, 2020 and 2019, respectively, primarily consist of net operating loss carryforwards for income tax purposes. A valuation allowance is required to be recorded when it is not more likely than not that some portion or all of the net deferred tax assets will be realized. Since the Company cannot be assured of generating taxable income and thereby realizing the net deferred tax assets, a full valuation allowance has been recorded. The Company has no uncertain tax positions at December 31, 2020. Since the Company is in a loss carryforward position, the Company is generally subject to US federal and state income tax examinations by tax authorities for all years for which a loss carryforward is available. The Company has never been, nor is currently under audit. The Company’s policy is to recognize interest accrued related to unrecognized tax benefits and penalties in income tax expense, however the Company has recorded no such expense to date.

 

F-26

 

 

In March 2020, the US government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) which includes numerous modifications to income tax provisions, including a limitation on business interest expense and net operating loss provisions and the acceleration of alternative minimum tax credits. Given the Company’s history of losses, the CARES Act did not have a material impact on its income tax positions.

 

15. RELATED PARTY TRANSACTIONS

 

In connection with the MacroGenics Asset Purchase Agreement, the Company made payments of approximately $0.1 million and $0.3 million to Tolerance Therapeutics, Inc. during the years ended December 31, 2020 and 2018, respectively. The Company did not make any payments to Tolerance Therapeutics Inc. during the year ended December 31, 2019. Dr. Jeffrey Bluestone, who was appointed to the Company’s board of directors in March 2019, is a majority stockholder in Tolerance Therapeutics, Inc.

 

In July 2018, MDB served as the underwriter for the Company’s IPO and the Company paid MDB cash underwriters’ fees and expenses of $3.6 million. Further, the Company issued to MDB underwriter warrants to purchase 1,596,956 shares of the Company’s common stock. The warrants are exercisable, beginning July 3, 2019 for five years at $5.00 per share. At the time of the IPO, MDB and affiliated parties beneficially owned greater than 5% of the Company’s common stock and two employees of MDB were members of the Board of Directors of the Company. See Notes 3 and 11 for further information. These MDB employees are no longer members of the Board of Directors of the Company.

 

16. RETIREMENT SAVINGS PLAN

 

The Company has an employee savings and retirement plan which is qualified under Section 401(k) of the Internal Revenue Code. The Company matches 100% of eligible employee contributions on the first 4% of employee salary (up to the IRS maximum). Employer contributions for the years ended December 31, 2020, 2019 and 2018 were $0.2 million, $0.1 million, and $0.1 million, respectively.

 

17. SUBSEQUENT EVENTS

 

In January 2021, the Company completed an underwritten public offering in which it sold 6,250,000 shares of common stock at a public offering price of $16.00 per share. In February 2021, the underwriters partially exercised their option to purchase an additional 587,500 shares at a price of $16.00 per share. In the aggregate, total net proceeds from the underwritten public offering was $102.3 million, after deducting underwriting discounts and commissions of approximately $6.6 million and other offering expenses of $0.5 million.

 

On February 17, 2021, the Company entered into a License Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”), a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (the “Huadong License Agreement”), pursuant to which the Company granted Huadong exclusive rights for the purpose of developing and commercializing PRV-3279, a DART® (bispecific antibody-based molecule) targeting the B cell surface proteins CD32B and CD79B, in Greater China (mainland China, Hong Kong, Macau and Taiwan). Provention Bio will retain exclusive worldwide rights to develop PRV-3279 for combination uses to reduce the immunogenicity of biotherapeutics, but Huadong will have the exclusive right to distribute PRV-3279 in that field in Greater China. In consideration of the license and other rights granted as part of the Huadong License Agreement, the Company will receive and upfront payment of $6.0 million and up to $11.5 million in research, development and manufacturing funding over the next three years. If Huadong successfully develops, obtains regulatory approval for, and commercializes PRV-3279 in Greater China, the Company is eligible to receive up to $37.0 million in regulatory milestones and up to $135.0 million in commercial milestones based on aggregate net sales in a calendar year in Greater China. If commercialized, the Company would also be eligible to receive low double-digit royalties on net sales of PRV-3279 by Huadong in Greater China. The License Agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Huadong without cause upon at least 12 months prior notice to the Company and by the Company in the event Huadong challenges a licensed patent or in the event that the Company’s upstream license terminates. The Company may also terminate the License Agreement if Huadong ceases commercialization of PRV-3279 for a consecutive period of six months after first commercial sale. The Company is generally responsible for the manufacturing of PRV-3279 at least through regulatory approval in Greater China and Huadong will exclusively purchase all clinical and commercial supply requirements of PRV-3279 from the Company until Huadong exercises its option to assume manufacturing responsibilities, which may be triggered after regulatory approval in China. The Company will retain all rights to PRV-3279 in the rest of the world. The Company plans to begin a Phase 2a trial of PRV-3279 in systemic lupus erythematosus in the second half of 2021 and expects a portion of such trial to be conducted in Hong Kong.

 

F-27

 

 EX-4.4 2 ex4-4.htm

 

Exhibit 4.4

 

DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT
TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

 

As of February 25, 2021, Provention Bio, Inc. (the “Company”) had one class of common stock registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 

The following description of the Company’s common stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the Company’s Second Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) and the Company’s Amended and Restated Bylaws (the “Bylaws”), each of which is incorporated herein by reference as an exhibit to the Annual Report on Form 10-K filed with the Securities and Exchange Commission, of which this Exhibit 4.4 is a part. The Company encourages you to read its Certificate of Incorporation, its Bylaws and the applicable provisions of the General Corporation Law of the State of Delaware (the “DGCL”) for additional information.

 

Authorized Capital Stock

 

The Company’s authorized capital stock consists of 100,000,000 shares of common stock, par value $0.0001 per share and 25,000,000 shares of preferred stock, par value $0.0001 per share.

 

Common Stock

 

Holders of the Company’s common stock are entitled to such dividends as may be declared by its board of directors, or any authorized committee thereof, out of funds legally available for such purpose, subject to the preferences applicable to any series of preferred stock outstanding at any time. The shares of common stock are neither redeemable nor convertible. Holders of common stock have no preemptive or subscription rights to purchase any of the Company’s securities.

 

Each holder of common stock is entitled to one vote for each such share outstanding in the holder’s name. No holder of common stock is entitled to cumulate votes in voting for directors.

 

Subject to any preferential rights of outstanding shares of preferred stock, if any, holders of common stock will share ratably in all assets legally available for distribution to the Company’s stockholders in the event of the Company’s liquidation, dissolution or winding up, after payments of all debts and other liabilities. All of the outstanding shares of common stock are fully paid and non-assessable.

 

Listing

 

The Company’s common stock is listed on the Nasdaq Global Select Market under the symbol “PRVB.”

 

Transfer Agent and Registrar

 

The transfer agent and registrar for the Company’s common stock is Broadridge Corporate Issuers Solutions, Inc. Its address is 51 Mercedes Way, Edgewood, New York 11717.

 

Anti-Takeover Effects of Delaware Law and Certificate of Incorporation and Bylaws

 

Certain provisions of Delaware law, the Certificate of Incorporation and Bylaws could have the effect of delaying, deferring or discouraging another party from acquiring control of the Company. These provisions, which are summarized below, encourage persons seeking to acquire control of the Company to first negotiate with the Company’s board of directors and the holders of the Company’s capital stock.

 

 
 

 

Undesignated Preferred Stock

 

The ability to authorize undesignated preferred stock makes it possible for the Company’s board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to acquire the Company. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of the Company.

 

Stockholder Action; Special Meeting of Stockholders

 

The Certificate of Incorporation and Bylaws provide that stockholders may act by written consent. However, stockholders pursuing an action by written consent will be required to comply with certain notice and record date requirements that are set forth in the Bylaws and the DGCL. A special meeting of stockholders may be called by the chairperson of the board of directors, the chief executive officer, the president (in the absence of the chief executive officer) or the board of directors at any time and for any purpose or purposes as shall be stated in the notice of the meeting. A special meeting of stockholders may also be called at the request of the holders of record of at least 20% of the Company’s outstanding shares of common stock. This provision may prevent stockholders from calling a special meeting because, unless certain significant stockholders were to join with them, they might not obtain the percentage necessary to request the meeting. Therefore, stockholders holding less than 20% of the Company’s outstanding shares of common stock, without the assistance of management, may be unable to propose a vote on any transaction, which may delay, defer or prevent a change of control.

 

Requirements for Advance Notification of Stockholder Nominations and Proposals

 

The Bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. In addition, the Bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed. These provisions may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of the Company.

 

Super-Majority Voting

 

The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation’s certificate of incorporation or bylaws, unless a corporation’s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. The Bylaws may be amended or repealed by a majority vote of the board of directors or the affirmative vote of the holders of at least 66 2/3% of the total voting power of outstanding voting securities. In addition, the affirmative vote of the holders of at least 66 2/3% of the voting power of the outstanding shares of the capital stock entitled to vote thereon is required to amend, repeal or to adopt any provisions of the Certificate of Incorporation that are inconsistent with, among others, the provisions relating to the general powers of the board of directors, the number and election of directors, the filling of vacancies on the board of directors, the ability of the board of directors to adopt, amend or repeal the Bylaws, the ability to call special stockholder meetings, director liability and director and officer indemnification.

 

Board of Directors

 

The Certificate of Incorporation authorizes the board of directors to, by a resolution of the majority of the board of directors, fix the number of directors from time to time and to appoint new directors to fill any vacancies. The limitations on the ability of the Company’s stockholders to remove directors, change the authorized number of directors and fill vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of the Company.

 

 
 

 

Exclusive Forum

 

The Certificate of Incorporation requires, unless the Company’s consents in writing to the selection of an alternative forum, that the Court of Chancery in the State of Delaware will be the sole and exclusive forum for any stockholder to bring (i) any derivative action or proceeding brought on the Company’s behalf, (ii) any action asserting a claim of breach of fiduciary duty owed by any of the Company’s directors, officers or other employees to the Company or the Company’s stockholders, (iii) any action asserting a claim against the Company, its directors, officers or employees arising pursuant to any provision of the DGCL or the Certificate of Incorporation or Bylaws or (iv) any action asserting a claim against the Company, its directors, officers or employees governed by the internal affairs doctrine, except for, as to each of (i) through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery, which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery or for which the Court of Chancery does not have subject matter jurisdiction. Although the Company believes this provision benefits the Company by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against the Company’s directors and officers.

 

Delaware Law

 

The Company is subject to Section 203 of the DGCL. This statute regulating corporate takeovers prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for three years following the date that the stockholder became an interested stockholder, unless:

 

  ● prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
     
  ● upon completion of the transaction that resulted in the interested stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a) shares owned by persons who are directors and also officers, and (b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
     
  ● on or subsequent to the date of the transaction, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.

 

Generally, a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An interested stockholder is any person who, together with such person’s affiliates and associates (i) owns 15% or more of a corporation’s voting securities or (ii) is an affiliate or associate of a corporation and was the owner of 15% or more of the corporation’s voting securities at any time within the three-year period immediately preceding a business combination of the corporation governed by Section 203. The Company expects the existence of this provision to have an anti-takeover effect with respect to transactions the Company’s board of directors does not approve in advance. The Company also anticipates that Section 203 may discourage takeover attempts that might result in a premium over the market price for the shares of common stock held by the Company’s stockholders.

 

 

 

 

 EX-23.1 3 ex23-1.htm

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the Registration Statements of Provention Bio, Inc. on Form S-3 (No(s). 333-252045 and 333-232995) and Form S-8 (No(s). 333-249869, 333-237113, 333-230400 and 333-226814) of our reports dated February 25, 2021, on our audits of the financial statements as of December 31, 2020 and 2019 and for each of the years in the three-year period ended December 31, 2020 and the effectiveness of Provention Bio, Inc.’s internal control over financial reporting as of December 31, 2020, which reports are included in this Annual Report on Form 10-K to be filed on or about February 25, 2021.

 

/s/ EisnerAmper LLP  
   
EISNERAMPER LLP  
Iselin, New Jersey  
February 25, 2021  

 

 

 

 

 EX-31.1 4 ex31-1.htm

 

Exhibit 31.1

 

SECTION 302 CERTIFICATION

 

I, Ashleigh Palmer, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of Provention Bio, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 25, 2021  
  /s/ Ashleigh Palmer
  Ashleigh Palmer
  Chief Executive Officer
  (Principal Executive Officer)

 

 

 

 EX-31.2 5 ex31-2.htm

 

Exhibit 31.2

 

SECTION 302 CERTIFICATION

 

I, Andrew Drechsler, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of Provention Bio, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 25, 2021  
  /s/ Andrew Drechsler
  Andrew Drechsler
  Chief Financial Officer
  (Principal Financial Officer)

 

 

 

 EX-32.1 6 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Provention Bio, Inc. (“Provention Bio”) on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission (the “SEC”) on the date hereof (the “Report”), I, Ashleigh Palmer, Chief Executive Officer of Provention Bio, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Provention Bio.

 

Date: February 25, 2021  
  /s/ Ashleigh Palmer
  Ashleigh Palmer
  Chief Executive Officer

 

 

 

 EX-32.2 7 ex32-2.htm

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Provention Bio, Inc. (“Provention Bio”) on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission (the “SEC”) on the date hereof (the “Report”), I, Andrew Drechsler, Chief Financial Officer of Provention Bio, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Provention Bio.

 

Date: February 25, 2021  
  /s/ Andrew Drechsler
  Andrew Drechsler
  Chief Financial Officer

 

 

 

 GRAPHIC 8 form10-k_001.jpg begin 644 form10-k_001.jpg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
  • V",KA5[C=[>M98\):6DIDCT>>YG M<6HDTU9V!M!(#O8G[QQCOT[TPN:/5&5'X]NDNKI[/3(P+CRA,I^!K>^5]0 M\PE8MN56,@<H7)-=R+':1&+=(S1HT0)8!.!BA3BMAJ M<5LCRNBNYOO#6F0^$KB[MK.8S0QF3[1,[(2/,*@C@HPQ_#PU<-6D9)FD9)[! M1115%",JNI5@"#V-9EU9^2"Z-\GH3R*N7%VD Q]Y_P"Z/ZUERS/,VYSGT'85 M$FC.;0RBBBH,@K?T?Q'!I @G32PU];*RK/'.T:R!L\3(!A\9]1D<&L"O5_!< M>HW'A2PL[6*2T25IV%Y'"EQ:S=4QT'/2ID]!2V.,LO%45HL6=.E;MAXOTJ]U/^UM718I;:[EN;:%&D+C>@!4$+M< M$J.I7'O5ZP\+^&;BRT?4&MU==6GM[-+=)FQ'*&83L#G)!"C'UH'A[PU.WE&W#%7 /4G'(/%2VB;HY.\\77%[H*Z=)'.K"!+,;L \XXSBJ]AKUO86#)%IJ_;#;R6_VA9V".KY!9X^C, 2 G/%377A#2;W7+II-!E(NM3G@ MN)(IFC73XE7*RXZ8;[W/&#@4NC'Q5N&NKV233"L<\ZW$2071C:-P@0@MMY4[0<<&ICHGANTTF6231 MC=2VND6VH&;[6Z"=G.>>:Y7QOH%EH\++:Z'=6<<5SY$5Z]QO2\39G=@\YSSE1MQ[T:/ M0-&9&@^(WTC5;^^N[)KW[=;RPSH9#'D2'+'=@^_YUI+X]989K6'1[<6'V>*V MM[4N76-(Y-YW9&7+'KTK0O/$^MGX8Z?,VHRL\U_-;2DA?GB"#"'CI6SI%P;[ MQ)X NFM[:)YK6X9DMX1&F06 PHX["A]V@9GP_$2VU/4(K2XLX[&Q<7"SFXN' M=2LJX*#:N4&0,$ X%5/$GC#3E#:7I$*W%DL-E&)=[8!MV+87(RP.<9./I5?Q MBMXWAO1IM>CV>('FF#[T"RM;@_(9 /?IGFN)IJ*W&DCNG^)!ENS?2:-&U]#+ M/)8R^><0>=]X,N/GQU'2HXOB++:VFGI;:8@GLY(W5YIC(JA1@K&"-R!@3D;C M[5Q-%/E0^5')=JGZ<>U?0'A7Q1:>+=(&H6D- MQ" =KI,A&&]CT8>XK@O"'P<@MMEYXE9;B;JMG&?W:_[Q_B^G3ZUZG;QQPJT4 M2A(TPJHJA548' QVK";B]C&;3V)J***S("H7N[:*)99+B)(V8*KLX )/8'UI MUQ!%=6\D$Z"2*1=KHW1AZ&O-WTB:W\.:3'<://-#%:WUN+=+?>8I';]V=O88 M! /09[9H ]'-S +@VYGC\X+O,>\;MOKCKCWJ*?;?Z"6XO-AVFV-IY;+YO^]QMSGC..]:V@1WVCZU):R6,ZV,B MLZRR-D1J,G)VC9DGJ!S\PXP* +__ C]U_STA_,_X4?\(_=?\](?S/\ A6O_ M &M8?\_*_D:#J]@.MRGY&M.:9IS3,C_A'[K_ )Z0_F?\*/\ A'[K_GI#^9_P MK5.MZ:.MW'^M-.O:6.M[%^M'-,.:9F?\(_=?\](?S/\ A1_PC]U_STA_,_X5 MHGQ#I(ZW\/YTA\1Z..NH0_G3YI]AWGV,_P#X1^Z_YZ0_F?\ "C_A'[K_ )Z0 M_F?\*O\ _"2Z*.NHP?G2?\)/HG_03M_^^J+S[!>?8H_\(_=?\](?S/\ A45Q MH&H&)E@D@$I'RLQ.!^E:7_"4Z'_T$[?_ +ZJ,^*="\X-_:=K]TC._GJ*+S[! M>?8Y(_#_ %8G)N;0D]]S?X4G_"O]5_Y^+3_OIO\ "NO_ .$MT ?\Q2W_ #-' M_"7>'_\ H*V_YFJ]I5[?@5SU.WX'(?\ "O\ 5?\ GXM/^^F_PH_X5_JO_/Q: M?]]-_A78CQ5H+=-5M?Q?%6(]=TF;_5ZG:-_VV7_&CVM3^D+VE3^D<./A_JP. M1VX/M(_P#A7H<_%+_P@FM%UUD><'P'K)ZWEN>_,C_X M4H\!ZR 0+VW )SCS'Z^O2O1J*/;3#VLCS@^ M8*;#>6Q3KM,CX_+%*? >LEE M8WMN67[I,CY'TXXKT:BCVTP]K(\X;P%K#9W7ELV>N9'.?TIW_""ZUO5_MT&] M>%;S'R/H<5Z+11[:8>UD>;GX?ZL22;FT)/4EF_PI/^%?ZK_S\6G_ 'TW^%>D MT4_;S#VTCRJ^^'/B&X7RX+NPCC/4EWR?_':S/^%1Z]_S^:?_ -]O_P#$U[11 M2]M,/;3/%O\ A4FO9 ^UZ?SWWO\ _$TO_"H]>_Y_-/\ ^^W_ /B:]D8?OXS@ M=#SGGM4E'MIC]O,\7_X5'KW_ #^:?_WV_P#\31_PJ/7O^?S3_P#OM_\ XFO: M**/;3#V\SQ?_ (5'KW_/YI__ 'V__P 33A\)O$*C"W]BH]!+(!_Z#7LU%'MI MB]O,\:/PI\2,NTZE:%?[IFD(_+%-_P"%3>(25/V^QROW3YC\?3Y>*]GHH]M, M/;3/&O\ A57B39L_M*TV9)V^=)C)Z\8I1\*_$RD$:G: A=@(FDX7TZ=/:O9* M*/;2#VTSQI?A1XC2/RUU&S5,YVB60#/TQ2'X3^(CG.H61RVF>-GX5>)6;$?\ "DO$G_/]IG_?;_\ Q-'_ I+Q)_S_:9_WV__ ,37O=%'M)!S ML\$_X4EXD_Y_M,_[[?\ ^)IZ?!CQ3'&\<>J6"(_WU6:0!OJ-O->\44>TD'.S MQ6]^%GBZ^LK"S-YHT%O8J1"EOYB?,?O.3MY8X&35 _!7Q01C^T[#OTFDXSU_ MA[U[S11[1ASL\4U?X6>,=;N4FO-2TOY(TC5$>0( JA0<;>N!UJH?@WXL;S,Z MO9'S !)F>7YP.@/R\_C7NU%'M&'.SP;_ (4MXGQC^TM/QC;CS9.GI]WI[4]? M@WXL7=MU:R7<06Q/*-V.F?EYKW:BCVD@YV>#_P#"F/%7EB/^U+#RQG">=)CG MKQM[TC_!?Q1(J+)J>GNJ#"!I9"%'H,KQ7O-%'M)!SL\%_P"%*>)BH7^T-.V@ MY"^9)@'Z;:4?!;Q0I4C4M/!7[I$L@V_3Y>*]YHH]I(.=G@K_ 4\32,6?4=. M=CU9I9"?S*TG_"DO$G_/]IG_ 'V__P 37O=%'M)!SL\$_P"%)>)/^?[3/^^W M_P#B:/\ A27B3_G^TS_OM_\ XFO>Z*/:2#G9X)_PI+Q)_P _VF?]]O\ _$T? M\*2\2?\ /]IG_?;_ /Q->]T4>TD'.SPRR^!^L/=H+_4[*.VS\[0;F?'L" *] M:\/>%M(\+V?V?3+58R1^\F;F20^K-W_E6S12_3H.E/IB M##R<8RWKG/ _*I)'T444 %%%>?:7<^+9-8TX7DTR%9S%-"S0^7*HW&5^.=HS M&J8YX.X@U#>?\>4__7-OY5-4-Y_QY3_]PIQI*0"QRR0MNBD>-AW1B/Y5M6'C/7M.(V7S3(/X+CYQ^? M7]:PC332:3W):3W/6-!^(ECJ,B6^H(+*X8X#$YC8_7M^/YUVFI1ZQ.>I1ZQ/5:*0$,H92"",@CO2US', M%%%% !1110 4444 %%%% !1110!&V//C^[G!Z]>W2I*C8_OHQGJ#QCKT[U)0 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'/CR'SMQM/ MWNGXU)3)CB%SG''7&2\@_,.@Z<"@"2BBB@ M KR+0X=(7Q#ID*7ESY&EO&IC E*J)2.E>GZQ<:A:Z3<3 MZ78I?7J*#%;/,(A(J5#>?\>4__7-OY5-4-Y_QY3_]K1:*[U U3O4#511$U0M]\=>GX5,U0- M]\?0T (:2E-)3&--)2FDI ----.--- A#333C330!W?@?QH;!H]*U.3_ $4G M$,S'_5'^Z?\ 9_E7J@((R.17S>>E=_X(\;_9#'I.JR_N#\L$['[GHK'T]#VK MGJTK^]$YZM*_O1/4:* !TI] !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !3)<^2^-V3DG#=QTX%/IB9WR?>Z M]^G0=* 'T444 4=8M]0NM)N(-+ODL;UU BN7A$HC.1D[21GC-%BN$02*MZ-Y?\>4__7-OY4UN-;G&=JBEJ7M44M=)TE.6JDE6Y*J2=ZM%HJR5 M6>K,E57JT6BN]0O4[U U440M4+??'3H:F:H6^^.G>@!#24II*8QII*4TE(!I MIIIQIIH$(:::<::: $IIIU-- '>>"_'1L/+TS5I"UK]V*=N3%[-_L^_:O559 M74,I#*1D$'((KYM-=?X1\WY5SU:5]8G/5I7UB>R M45#:W5O>VT=S:S)+#(,JZ'((J:N4Y0HHHH **** "BBB@"-A^_C.!T/)//:I M*C;'GQ_=S@]>O;I4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !42&ZE2'R!>%XK6<*QCV(5!9!ND R?ESG'IW%Y9VVH6]5) M*MRU4DJT6BK)59ZLO59ZM%HKO4+5,]0-5%$35"WWQSZU,U0M]X=>] "&DI32 M4QC324II*0#3333C63KNMPZ+:"1@'G?B*+U]S["DVDKLF325V7;J[M[*$S74 MR11CNQZ_3UKF[KQQ8Q$BWMYIL?Q-A!_C7&WE]=:EGHH] .PIB0/ M(1L1F[# SFN2>(?V3DGB7]DZD>/')YTU<>TO_P!:K]IXSTVX8).LELQ[M\R_ MF*XQ[2YBA+R6\J1EL;BAQGZU 8MH)/7MQ4+$3[D1Q$^]SUB.2.:(21.KHW1E M.0:4UYEIFJWNCR"6 YB)P\;?=;_ ^]>B:?J$&IV:7-NX]#[U[)H/B33O$5KYMG+^\4?O( M7X=#[CT]Z\ J6UN[BQN4N;29X9T.5=#@BBI24M>H5*2EKU/I&BO/?#7Q+@NM MEKK86WFZ"Y4?NV^H_A/Z?2O0$=)$5T961AD,IR"*Y)1<79G)*#B[,=1114DA M1110!&Q_?1C/4'C'7IWJ2F-GSD^]C!Z=/QI] !1110 4444 %%(S*BEF(50, MDDX %?-/Q4^,EUK5S/HGANY>#2T)2:ZC.'N3W"GLG\_IQ0!ZYXH^+WA'PM*] MO-?&]O$ZV]D!(5/H6SM'TSFO/;S]I4"3%EX9+)ZS7>"?P"FO <44P/H73_VD M[-W"ZEX=GB7/+V]P),?@0/YUZ=X6^(7AGQ@NW2=11KC&3;2C9*/^ GK]1FOB MRGPSRVTZ3P2O%-&VY)(V*LI]01TI ??%%>+?"+XOOKTL7AWQ%*O]HD8M;L\? M:,?PM_M^_?Z]?:: "BBB@ HHHH **** "F3'$+G...N,X_"GTR;/DOC=G'\/ M7\* 'T444 %%%% !116;K^NZ?X:T6YU;4YA%:VZY8]V/95'1K?3$;]Q9(WRJ.Q;^\WOV[5QHH ]XD_:5F\W]UX73R_P#:O.?_ M $"MO2?VC=!N95CU32;VQ!_Y:1L)E'UZ']#7S910!]SZ)XATCQ'8B\T?4(+R M#N8FR5/HPZ@^QK3KX8T'Q!JOAG5(]1TB\DMKA.NT_*X_NL.C#V-?6/PW^(EG MX^T4W,#K7E'AFWM1XK@BBU.T-N;B-Q/';3)---&)?DE9E"K M*PD.X$Y(7ISP >P5#>?\>4__ %S;^535#>?\>4__ %S;^5-;C6YQG:H9:F[5 M#+72=)3EZU4DJW)522K1:*LE5GJS)59ZM%HKO4#5.]0M5%$+5"WWA^-3-4+? M?7IWH&(:2E-)3 ::2E-)2 8[*BL[G"J"2?0"O)=7U-]5U.6[<_*3B-?[JCH* M]$\47#6WAN]=3AF41@_[Q KRW&!QT]*Y,1+:)R8F6T3L-$\/64NFB\ODN"), M"-4'0^I]N]= L]I+F>2( G-NH+%<\8!X_/BHTBOH+6*&1Q(5CC5 KY^5@, M]>3C-.-K(+=C+($V.=Z!R2H_V?>O(YG+5L\;&8B7-:*Y5IKNW;>SMHGV7SU+ M[2^5:M:^8OEB3DR-O!_.L/7/#EKJ, FTF,17 !+0CA91ZK[_ ,ZTHSM:-XF# M,"?G9>GL?>A9)XM3#DQ'9@$Y.,$=<=C4I.+O'S=C_ $_&M7QU:11WT%U;QJBS1X<@_>8'J?3. M:Y524D7G'?/I7=2J:*:/9H5N:*J(]6/6DIEO+YUM#+_?16_,4^O6/7$-;>@^ M+=6\.N%M9O,ML_-;R\I^']W\*Q#332:3T8FDU9GN&@>/M'UO;%))]CNSQY4Q MP"?]ENA_G755\R8S6_HWC77-#"I#=&>W7_ECKCYX_S'(_*NSL=4L-3B$EC=PW"^L;@X^OI6$H2CNC M"4)1W188?OD.#T/.>!TI]1L/W\9P.AY)Y[5)4DA1110 4444 >2?'KQA)H7A M>+1+*4I=ZKN61E/*P#[W_?1('TS7R_7I7QUU%[[XH7OXWU]+;G,ZCX?GL;EXXY8[B)5W"53@- MTXQZ^U9%=PEJM]9S17$ZJAERK0+C>OK]1_2L;7-%CMK9+VS*FV/!P3D"; M'5),?:@##<@=I5X)_'@_C7Q?7OG[->I/G7M+8_(/*N$'H>5;_P!EK4H]_HHH MH **** "BBB@ IDPS"XP3QT!P:?4'K>7_0=,QY@!X>G%(>M2V]O-=3"&"-GD;HHH2OL!%BEVD &M=?# MUT IWH6(Y Z#CH3VK,GMY;:4QS(4<M.491T:*<)**ET9'@FM[P9XGN? M!_BFRUFW8[8GVSQ@_P"LB/WE_+GZ@5A>IH^M20?>=M<17=K%!^5 #Z*** ,OQ!I8UC1Y+/[8UFQDCD2 M=55BC(ZNIPW!Y45SMEX/NH]1CFN?%,MW']N%^\'V:)/,E"A1RHR!@#@>E=9? MZ=9:I:FUO[6&Z@)!,4R!E)'3@UY;HUM<6WBG2I#HNF6QFF5E@AT4I)$O[P28 ME)X*%5R<K1:*[U U3O4#511$U0M]]>G>I MFJ%OO+SZ]J!B&DI324P&FDI324@,'Q?&9/#-SC^$HQ^@85YD2>@QUKV.\MEO M;*>U?A94*9],BO'Y89+:>2&5=LD;%6![$5QXE:IG'B5[R9WVB:S%<:; CNXN M8HA$%7@8'<>^,9S5HWDLC .NY9&X9^> .?QKA=/O9; B6+:.>3W(]*ZNRUN3 M4YIO,\N-!"/N1<[_ .?M7F3IJ+NEH>7B,&ZOOPU?;;ST_-_\$O<,))&21&!W MA/0@=<]CG\ZMVS8EFD2!5R,J6[MZ'VJC;M.UDHE4EC\Q&AX] M^M<"CA2'VAL=CWKN=>N43PK(K%]\K[!NP!D$?K7'Z39M?ZG#;X)!;+^RCDFM ML.FTUYGIX.'[M).]ST2R0QV%LAZK$H_2IJ4^U)7MI65CW4K(0TTTXTTTQB4E M+24@&FG12R02"2&1XI!T9&*G\Q332&@#I=/^('B+3G0?;5ND&?EN4WG_ +ZZ M_K766'Q>C.%U+2W4]WMWW#\CC^=>6'[PHJ'3B^AFZ<7T/>K'X@^&K_ &HK Y M_AN%*'\SQ^M=#;W5O=)OMYXIE]8W##]*^8Z=%++;OO@EDB8?Q1L5/Z5FZ"Z, MS>'71GU!17SU9^-O$EA@1:O.ZCHLV)!_X]6_:?%K6X<"ZM+.Y'<@%#^F1^E9 MNA+H9NA+H>4_&BV>V^*^LEO^6OE2+[@QK_A7!H%:10QVJ3@GT'K7I'Q>U>+Q M/J-CK<5B]M*L7V><;]P."2IZ>Y'Y5YJ.O-9N+6C,VG%V9WK6T+6YAM?+> 2( MB>6OS$\9 .?H?6J5T9I98]0MI"L.X12I,,J,=3Q]:PK34S:VS-ZLJE6O>D[*3NUVM?17 M>O\ P=MR.IZXKG;V^FOI 9,*JDE47.U<]<#M4*#E+FEZG,J M3H5/=ETUTZ[66_3?[BKVKW']FRW=M:UZYP=B6\4>?GT444@"BBB@ HHHH *CGQY#YV@;3][I^ M-24R8XA<9Q^% #Z*** "BBB@"&[B,]E/"O62-E'XC%?!SQ&*5XGX=&* MD8[@U][U\>?%CPT_AGXA:C$$*VMVYN[=NQ5SD@?1MPH XD\G-:OAY@-4VY 9 MXV5,],]?Z5E#D]<"G([1.KHQ5P>5Y9N&4?WE&&P>V:@6:W\U=T+!P6-I&9;FXD6*)%')9C@5BCD:/JGX&6[P?"VP9P1YTTTBY]"Y']*]'K+\. M:/'X?\-Z=I$7*VEND6?4@DW,XMHO,,*.&\B%N(AD21KNR>_'J?:B\\1Z8/+-O%-))'DALE>:YT:1JG0:?=?\ M?LU>M/"6K7&!*BVR=VE;G\A6"PUWHFM=IX>T;^R[4R3 ?:Y1\_^P/[O^-3:3X?L])&] 9;C&#,XY_ =JTS7 M=1H*&K.^A05,2DI:2NDZ1#333C330 E)2TE(!II#2FD- #3]X=:*#]X44 )2 M4M)0 E(:6D- $-U;17EK);S#,<@P?;WKSS4=.FTR[,$PXZH_9QZUZ0:@N[2" M^@,-Q&'0_F#Z@]JSJ4^;U,JE/G7F>949SUKHKWPE<1L6LY%E3LCG:P_H:R9- M'U*(X:QG_!<_RKE<)+='*X26Z*9.0.N:2K\6B:G,0%LY1[N-H_6MFQ\*!6#W MTH;_ *91G^9IJ$GT&H2?0I^&--CNM3@N;VW,VGPR!I8]VWS0I&D4:QQH$11@*HP!0:V5&-M3=48VU/=(/B MWX9EQYGVR$_[<&?Y$UIP?$7PG/C&L1(?2167^8KYWI*'1B)T8GTY;^)M"N@/ M(UBQ?/83KG^=:,5Q!.,Q31R#_88&OE#:#U I4=XCF-V0^JL1_*I=%=R?8+N? M65%?+EOX@UJT_P"/?5[Z/_=N&_QK2@^(/BNV(VZU._M*JO\ S%3[%]R71?<^ MD:9-GR7QNSC^'K^%>"0?%KQ5#C?+:3#_ &X,?R(K1C^-&K;"MQI-G(",'RY& M0G^=3[*0G2D>VT5Y/!\;H.!<:',OJ8YP?Y@5IP?&;P[)CSK;4(3_ -SEV)]G+L>BT5QMO\4_",^,ZDT)_Z:PN/Z5J6_C;PQ=8\G7+$D]FE"_SQ4\K M[$\K[&]7"_%'P!'X[\.^7!LCU6TS):2-P">Z$^C8'T(!KL(=3L+G_47UM+G^ MY*K?R-6@01D'-(1\&WUC=:9?365[;R6]U Q26*0892.U5\^M?9/C?X;:#XYA M#7T1@OT7$=[ )%'H>S#V/X8KP;Q!\!_%^DR,UA'#JUN.C0.$?'NC=_H30!Y MCFCH?K71/X \80R>6WAC5MWM:L1^8&*VM)^#GCG5I O]CFRC/62\<1@?ARWZ M4A'#!6?A<[ASZ5T/@7X+Z M7X8:.\U69=3U!3N4%<0QGU"G[Q]S^5>H4*Y6E@HHHIB"BBB@ HHHH **** " MBBB@ IB'YY.2?F[CIP.E/IB9WR?>Z]^G0=* 'T444 0W=LEY:2VTC2JDBE2T M4A1@/9@00?I7F?AV/2;>+PW(/-N6>Z,4=M+JTLTD!4-L=HB=NX8.X8 7/'2O M4J\W\-)W\.OPZG,Y%R?[,BCMSR>"X3=LX');/3- 'I%0WG_'E/_P!< MV_E4U0WG_'E/_P!G>I6J)_OKT[T#$-)2FDI@--)2FDI ----. M)'/-(:!#3333C330 A---.--- "4TTZFF@!*2EI* $---.--- "4E+24@&FD M-*:0T -/WA^-%!^\.G>B@!*2EI* $I#2TAH 0T&AB!U('UI.U "&DI33?:D( M#332FD- A#332DTAI )24M)0 E)2TE A#333C332$%-;[IIU-;[IZ?C2 #33 M3C330 4F >HI:2@!H '(&#[59@U*_MB#!?741']R9A_6JYX'-)WQ2$;D'C7Q M/; "+7K_ .S2[OYYK4@^*7B^ 8_M))1_P!-8$/\@*XZBERKL)Q78]$M_C1X MCBQYUKI\_P!49?Y&M2W^.-R,?:M"C;_KE<$?S%>39Q0:7)'L3R1['MMO\;]) M?_CXTF^B_P!QD?\ J*U8/C#X3F(#RW<&?^>EN?Z9KY\I*ETXDNE$^F+?XC^$ M+G&S7+92>TFY/YBM:W\1Z)=X^SZO8R9[+<+G^=?*'44FU3V'Y4O9(3I(^P(Y M8Y1F.17'JIS3Z^0(YIH3F*:6,C^XY7^5:5OXI\06F/L^N:A'CL+AC_,U/LO, M7LO,^K:*^:+;XF>,+7&W67D [31(_P#2MBU^,_B>''GPV%P/]J(J?T-+V4B? M9,]_HKQJT^.D@P+W00?4P7']"/ZUOV7QH\,W&!']:(73]6M9G/2/?M?\ [Y.#6U46L1:P4Q!AY.,9;KG.>!^5 M/J./'F2_=^\.G7H.M $E%%% %>]O;?3[?S[J3RXMZ1[L$_,S!5''J2!7!Z;X M9>XU^VNK;2])L187I:>:VO9)GR%.8RI4#)# G)XKL]E7[W(\3:E.DLYGGAECAVRL0!SA 1P!T(Z4 =/ M4-Y_QY3_ /7-OY5-4-Y_QY3_ /7-OY4UN-;G&=JKRU8[57EKI1THJ254DJU) M522K1:*TG>JSU8DJN]6BRN]0M4SU"U441-4+_>7GUJ9JA;[R]:!B&DI324P& MFDI324@.PL(;&>'1T:.)+J*RDFR0,3+^\!4_[0X(_&J<6@Z>6@$B3"+=&%F\ MX8N@R%FV\?+@CW]^:YDTTBHY7W,^5]SH/L6D#3OM)M)RPLOMFT777]YMV?=] M._6I;G0+&%9PGFM&HF8W7FC;;E>51ACDGCZYXKF332*?*^X^5]SKVT>RL4FG M6UE"KY\2O)*&6=!"6#KQQD],56?0M/CE*0QSWLAB%S%!'+M9XG8!.<=0N2?J M*PKK4;J[CCCF=2D9W*JQJH)X&3@X)EE"E@V0A\W9Y;$#;G;WSU[8JN^F:2\2&*">*21+ MEE8W&X(83QQCG<9K1OM+TRX2\NY"( M[BRAC:\BB<*K2/& H' /F?>QQS7(&IA=3+9/9JP$#N)&4*,L1TR>N!Z=*EQ MUN0XN]SJKSPUI\$H,5M=2GR)'CMC-MDN&4H!VXX8GY<@XX/6K-QX=T^7R='7 M-M(UQ-Y+2."RD)$Y5SCGY2^/>N*M;J6SF\V'9NP5Q)&KJ0>V&!%2?VI>_:KB MZ,^;BX4K)(5!;!X../EXXXQQQ4\K[BY7W.@30M*N1:O%'^3G&*GNO#^BV99Y+>[/[R"(PF4Q[=\C*6!91[?2L TE%GW!)WW$I*6DIE"4E+24"$---.---(04UONFG M4UONGK^%( ---.--- !24M)0!J^%UC?Q3IJS*&B,OSA@",;3V/%;NG:3I&KZ M%I]A:23B:YNIT@FN0B,)1&A4-M)RN ?Q-<94]G>W%A,TULX21D*;]H) (P<9 MZ''<'-$TI M+N3RKJ4002,J&5D$A$B(KABO(PQ) XX&RW,LT-O#(^Z.W0I$N/NJ26(_, MFH<#%%GW%9]ST*W\/:?I[RW"64VR/SH8YYI@Z7:?9G?S%&,#D#&,X^M47\-: M1&1]F2XU"62V^VV]K%.%>2%V547./O*-Y..>!7,7>K7M];16T\JF&)MRHD:H M"V,;FV@;C@8R:AO;R>_N3<7+AI,!1M4*% & !P !V%*S%9G81^%-';3?/9[ MHNTS(2&W>01*$$;E04S@]<]Q@5 ^BZ'-F.WMKB&5_MH1VN]X0V_0XV\[O3\J MXW Q119]QV?<[S4?"UD]OKEX?.9X#.\X:_L0<&WN&R0/\ 9;J/ MU%<=12:3W$TGN?6/A_7K'Q)I$.I:?)NBDX*G[R,.JL.Q%:"'+R<@X;L.G KP M3X.:[)I_BMM*9S]GU!#A>PD49!_$9'Y5[VA^>3D_>[CIP.EXR%=/;JT_\ WV/\*C/A#36ZMY_[^#_"F'P+I)ZO=?]_!_A7344_:2[C]I+NTGW.3/P[T4_\M+S_ +^C_"F'X<:( M2#YEYQ_TU'^%=?5>YLUNBI::XCV_\\I2F?KBCVD^X>TGW.8_X5QH?_/2\_[^ MC_"C_A6^A_\ /2\_[^C_ K?_LF/_G[OO_ E_P#&C^R8_P#G[OO_ )?_&G[ M27E[_W]'^%'_"M="_YZ7O_ ']'^%=!_9,?_/W??^!+ M_P"-']DQ_P#/W??^!+_XT>TEW#VL^YSW_"M-"_YZ7O\ W]'^%'_"M-"_YZ7O M_?T?X5T/]DQ_\_=]_P"!+_XT?V3'_P _=]_X$O\ XT>TEW#VD^YSO_"L]"_Y MZ7O_ '^'^%)_PK+0?^>E[_W^'^%='_9,?_/W??\ @2_^-']DQ_\ /W??^!+_ M .-'M)=P]I/NE[_P!_A_A2?\*PT'_GI??]_A_A72?V3'_S]WW_ M ($O_C1_9,?_ #]WW_@2_P#C1[27TEW#VD^YS7_"K MM _YZ7W_ '^'^%)_PJWP_P#\]+[_ +_#_"NF_LF/_G[OO_ E_P#&C^R8_P#G M[OO_ )?_&CVDNX>TGW.9_X59X?_ .>E]_W^'_Q-)_PJSP__ ,]+[_O\/_B: MZ?\ LF/_ )^[[_P)?_&C^R8_^?N^_P# E_\ &E[27'O^>E_P#]_A_\373_ -DQ_P#/W??^!+_XT?V3'_S]WW_@ M2_\ C1[27E_P#]_A_\374? MV3'_ ,_=]_X$O_C1_9,?_/W??^!+_P"-'M)=P]I/NM__ -_A_P#$T?\ "I_#O_/6_P#^_P /_B:ZK^R8 M_P#G[OO_ )?_&C^R8_^?N^_\"7_ ,:/:2[A[2?TGW.4_X5+X<_P">NH?]_P ?_$T?\*E\.?\ /74/^_X_^)KJ_P"R8_\ MG[OO_ E_\:='IB1RJXNKQBISAKAB#]1GFCVDNX>TGW//M;\#>!?#D$<^L:I= M6<4K;$>6< $XSC[M5M*\*?#O7)HH=,UFYNGE+A!'-G)4 MSMQP"/SKOO%]K+ M>^#-%IIY;"=(HU&69C&P ]2:X'6M*\0+I7AZ*PM+Y3#X:NX9DAR-LY@ M0(I _BW @>]'M)=P]I/N;G_"H_#?_/74/^_X_P#B:3_A47AO_GKJ'_?\?_$U MR$WA77+6*_FM8]>\Z"#3+BT'VN9LW!<"X."V&.T<@\#FM/PMIOBF/XCRW.J2 M:C'BYN3,3%(UO/ ?]4-Y?8 /EP%4$8.:/:2[A[2?FH_]_P ?_$UUW]F1 M_P#/W?\ _@4U']F1_P#/W?\ _@4U/GEW#VD^YR'_ J+PU_STU'_ +_C_P") MH_X5%X9_YZ:C_P!_Q_\ $UV TE3_ ,O5_P#^!34[^R(_^?R^_P# E_\ &CGE MW#VD^YQG_"H?#/\ STU'_O\ C_XFE_X4]X:/_+34?^_X_P#B:[$Z5$.MY?#_ M +>F_P :8=/A'2[OS_V\O_C1SR[B]I+ND_L]?^?N^_\ IJ.:7%QUFU#_P('_Q-=7_ &^H_]_Q_\376C3%/ M2ZOS_P!O+T\:3G_EYO\ \;IO\:.9]Q>TGW.._P"%/^%?^>VI?]_Q_P#$T?\ M"GO"G_/;4O\ O^/_ (FNS&CKWN[W_P "GI?[&C_Y_+__ ,"6_P :.=]Q^TGW M.+_X4[X4_P">^H_]_P ?_$T?\*<\*G_EOJ/_ ($#_P")KM?[&C_Y_+__ ,"6 M_P :/['C_P"?N_\ _ I_\:7.^X<\^YQ?_"F?"Q_Y;ZC_ .! _P#B:7_A2_A? M_GKJ7_@0/_B:[/\ L>+_ )^[[_P)?_&C^R(_^?N__P# I_\ &CG?%O^>N MI?\ @0/_ (FC_A2WA;_GKJ7_ ($#_P")KM?[)C_Y^[[_ ,"7_P :/[)C_P"? MN^_\"7_QHYWW#GEW.*_X4MX6_P">NI?^! _^)H_X4KX6_P">VI?^! _^)KM? M[)C_ .?N^_\ E_\:/[)C_Y^[[_P)?\ QHYWW#GEW.*_X4KX6_YZZE_X$#_X MFD_X4KX6_P">NI?^! _^)KMO[)C_ .?N^_\ E_\:/[)C_Y^[[_P)?\ QHYW MW#GEW.)_X4KX6_YZZE_X$#_XFC_A2OA;_GKJ7_@0/_B:[;^R8_\ G[OO_ E_ M\:/[)C_Y^[[_ ,"7_P :.=]PYY=SF-%^%OA[0-8MM4M);XSVY)3S9@5R01R, M>]=L%PS').XYY[5AZOX8BU;2+FP:_OHQ.FPOY[-M_ FM'2M.72=-ALDN+FX6 M(8$ES(9'/U)I-WW);;W+E%%%( HHHH *KWUY'864EU*K,D8R0O7KBK%4-;MI MKS1KF"!0TKK\JDXR00<9JH).23V(J-J#<=[%^BLO^T=2_P"@)/\ ]_XO_BJ/ M[1U+_H"3_P#?^+_XJJ]E+R^]?YD^VCY_<_\ (U**R_[1U+_H"3_]_P"+_P"* MH_M'4O\ H"3_ /?^+_XJCV4O+[U_F'MH^?W/_(U**R_[1U+_ * D_P#W_B_^ M*H_M'4O^@)/_ -_XO_BJ/92\OO7^8>VCY_<_\C4HK+_M'4O^@)/_ -_XO_BJ M/[1U+_H"3_\ ?^+_ .*H]E+R^]?YA[:/G]S_ ,C4JO->1P7=M;,K%[@L%(Z# M:,G-4_[1U+_H"3_]_P"+_P"*JGVCY_<_\C4HK+_M'4O\ H"3_ /?^+_XJC^T=2_Z D_\ W_B_^*H] ME+R^]?YA[:/G]S_R-2BLO^T=2_Z D_\ W_B_^*H_M'4O^@)/_P!_XO\ XJCV M4O+[U_F'MH^?W/\ R-2BLO\ M'4?^@)/_P!_XO\ XJC^T=1_Z D__?\ B_\ MBJ/92\OO7^8>VCY_<_\ (U**R_[1U+_H"3_]_P"+_P"*H_M'4O\ H"3_ /?^ M+_XJCV4O+[U_F'MH^?W/_(U**R_[1U'_ * D_P#W_B_^*H_M'4?^@)/_ -_X MO_BJ/92\OO7^8>VCY_<_\C4HK+_M'4?^@)/_ -_XO_BJ/[1U'_H"3_\ ?^+_ M .*H]E+R^]?YA[:/G]S_ ,C4HK+_ +1U'_H"3_\ ?^+_ .*H_M'4?^@)/_W_ M (O_ (JCV4O+[U_F'MH^?W/_ "-2BLO^T=1_Z D__?\ B_\ BJ/[1U'_ * D M_P#W_B_^*H]E+R^]?YA[:/G]S_R-2BLO^T=1_P"@)/\ ]_XO_BJ/[1U'_H"3 M_P#?^+_XJCV4O+[U_F'MH^?W/_(N/=HE]#:$-YDJ/(#V 4@'_P!"%6*P)9=3 M?5;>[&C3;8HI(R//CR2Q4C^+_9-6_P"T=1_Z D__ '_B_P#BJJ5)Z6M]Z_S) MC65W>_W/_(U**R_[1U'_ * D_P#W_B_^*H_M'4?^@)/_ -_XO_BJGV4O+[U_ MF5[:/G]S_P C4HK+_M'4?^@)/_W_ (O_ (JC^T=1_P"@)/\ ]_XO_BJ/92\O MO7^8>VCY_<_\C4HK+_M'4?\ H"3_ /?^+_XJC^T=1_Z D_\ W_B_^*H]E+R^ M]?YA[:/G]S_R-2BLO^T=1_Z D_\ W_B_^*H_M'4?^@)/_P!_XO\ XJCVW%9K:AJ!/.BS_]_P"+_P"*I/M^H?\ 0$G_ ._\ M7_Q5'LI?TU_F+VT?/[G_ )&D23UI*SA?:@?^8)UCY_<_\C1"$]>*>% K,_M'4?^@)/_W_ (O_ (JHVU34 M",#1IQ])XO\ XJE[.3_X=?YA[:"[_<_\C5:15ZGGTJ)IF/3BLO[=??\ 0&N/ M^_\ %_C1]OOO^@+UO5?YA M*JN5VO?T?^1K1QJZ*^3A@"!4HC4=%%9<=]J21(G]B3_*H'^OB_\ BJ=_:.H_ M] 2?_O\ Q?\ Q52ZVCY_<_\ (TZ*S/[1U'_H"3_]_P"+ M_P"*H_M'4?\ H"3_ /?^+_XJCVVCY_<_\C3HK,_M'4?^@)/_ -_X MO_BJ/[1U'_H"3_\ ?^+_ .*H]G+R^]?YA[:/G]S_ ,C3HK,_M'4?^@)/_P!_ MXO\ XJC^T=1_Z D__?\ B_\ BJ/9R\OO7^8>VCY_<_\ (TZ*S/[1U'_H"3_] M_P"+_P"*H_M'4?\ H"3_ /?^+_XJCVVCY_<_\C3HK+_M'4?^@)/_ M -_XO_BJ7^T=1_Z D_\ W_B_^*H]E+R^]?YA[:/G]S_R-.BLS^T=1_Z D_\ MW_B_^*H_M'4?^@)/_P!_XO\ XJCVX1 P,$ MOE-GN< \?F*I_P!H:C_T!)_^_P#%_P#%4ND0W"?;);F P-/<&18RP8@;5')' M'8T_/I5)].T[^TTUEU07"Q>6)B_&T_IWZUM1G&-^97[ M>O0PQ$)S2Y)6[^G7Y]C%/C:&*:Z2:T(2*.21#'*'+;6"X.. 22.YJR_B'4(F MAMGT5UOYG*Q1&==C*%W%M^.W3&.M.'AK0K:7:XQYRO&D4DYV[7Y954GUYXIW M_",:28_L^9O.#>:)?M#><.-OWLYQCCTK9RPW1/\ '_/[_P!#G4<9UDOP_P N MVW;KAVUQ%YBB-U$;H#*1@1?=/7H,\Y]:9_PC>A7X=XF+@O(7 M:"X/S;^64D'H?2GS8?1N+)<,6KJ,U?Y?Y&5/XFU&2XO@(_)MHY+7RFC8;P)" M.#D'.0?PJW+XS$,;SMI[BU;SA;R^:/WC1YR",?+G!P>:OR>'-(-RJN'$DD<8 M"><1O$1&TXSR1QS2MX5TEI9Y&@"I8 MQ7M)?U\OP]!=&UV35+J>VFLC;21Q1S >8'#(X)'0<'BMFJ5MI=I97+W,*%9& MB2)B6)^5!\M6HI8YXEEB=7C<95E.017+4<7*\%9'=14U&U1W8^BCI169J%%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45"] MY;1S"%[F%93T0N Q_"@7EL9S +B$RCK'O&X?A3Y7V)YH]R;I7$67BR[N+S4] MDD,R/%)+8Q[@"OED@AN_(^;FNPF,%Q:E'E'E3KL#*^-V1V-9IT+0X#90>3#$ M\((A ;:S#;M(/=L@]ZWHRIQ34U=LYL1&K-Q=.5DO/>^G_!]2MIWB!I]'M#>? MN[^YMC*@1&93P2#G&!TZ$US5EXFU1]/ED-_-<;;!IYR8%C:!N-NPXPV>>QKM M["SL;*S.E6\NY(U(,;2[F53V]0.:JGPWI$]O'"L9*0P-:?+*<[#U4G/-;0JT M8N5XZ-_U_7_#&$Z&(FHVGJEWZ_K]WW;F?+XED^VO8"U96\KB9Y0K,=F[:X59(VYC>X(4/MQ MNVDXW;2*N:7I6F6C+O6E.5'V=E%W'3CB/:IRDFM= M+]/^!]_FR?:+@+,3+Y5M)"!!,H!*^7*/XN,D'WJS9>+KD:8);RS5 MIETXWQ*/@.-V ,8XSUK43PUI%K.;KRV"1EG6-I6\J,D'5[@53J8>2UC^'_!(5'%0?NR[[O_ (']6,W4/$M] M=RVHL;=HH!?1P/)Y@_>,5W%,8Z<@9J_H_B!=9N/+BMB@2 23$OGRW+$;.G)X M)S5MO"VF?:UNECD$B.LBJ)6";U& Q7.,X'6H]$T>33([II1&;FZG::7R@0@S MT SV']:4IT'3M%:HJG3Q4:MYO1[_ "7X7-*IDA[M^5.CC"#)ZTTW=N+>2X\Y M##'NWN#D+CK^6*X]7L>AHMR4 8 Q2TBL&4,I!4C(([TM24%%%% !2$@#)Z4 MM13YV#ZT(&2*P89!S2U4#%3D'%2K/_>'Y4VA)DU%5UOK1IO)%S#YW3R]XW?E MUH6^M'+A+J!B@)8"0':!Z^E'*^PN>/U:XU-4CNIKEOMKQ26YM@(TA! M(W>8!U''>H-*\4:HQ24W;WA$$\UQ!) $6-4SM*L ,\@#OUKM[*SL].B,%OA% MFD:3:7R68\G&:IQ:-H\$EG;(%$MJ'\I#+\VU\[@1GD'/>N_V]%W]S\/Z_KJ> M9]5Q"L_:?C_7];+J8]M>:QYNEQSZGO&KP,P*0J#;L%# KZC!QS5-M0UJ#0M9 MOSJ\DCV=PUM&I@0 X=1NZ=<$\5T6F:+HUC>/-9L'EB!0!IR_D@]54$_**>VD M:5-I]W:!2]O>2F679(3N8D$D'MR!2]M34OATTZ+O_E9>8_JU9Q^+77[3[)+\ M;ORO8Q$OM5:2QL4OKQ)+V=U,UW:I&\:HFX[5Q@Y]32ZO-K=CHS7/]LH98)Q" M?)C0AP7 !;(^5@#T'%6VT[0GA:WDNW)23I#5; M#P\RVER;J^# "1T4,03SA> 6QT'>L-/$.J0BUC@F6\,E\L#BXB\F:/*YV.N, M9/)##TKJ]4M+*\T^2/4 OV<8=F9MNPCD,#V(]:SX_#>DO T:&21Q<"9IO/+2 M>8HXRV<\ XQ[U%*I34??5]>QI7HUG/\ =2MIW_K[WM 81-EE0MD[<\'\1S^-6I)0O ZU!' MM@MXX(1LCC4*H] !4!NK<6ZW!F3R&QB3/RG)P.?K7(TG)N*T.^,G&*4GK;4F M/)R:FA8G*GM4-3PK@%CWI/8I;DM%%!.!S4%@3CK2!@>AJ-FR:0=:=A7)J*** M0PHJK?W\=A'&622625Q'%%& 6=CS@9XZ G)]*ABUFU,#R7+?8S')Y3K<$*0V M,XSG!X.>*M0DU=(AU8)\K>IGZ[#--K>D"&*"1@)^)U)3[J]<5D7&EW=E=^1! M;VMU(MA*[+)&=@W29VH/;. *[ WMJ"0;F+(*@_./XON_GV]:8NHV+^=MO(#Y M/^MQ(/D^OI6\*TXI)1T1RU,/3G)R*(R[>1 ML #LWH3'Q]16GK]LT_A^_6XLH0L$9^S;6W]L XP,'\ZU3JE@MLMRU[;B!CM$ MAD&TGTS4<6JP/=7,#%4\IT169AB0LNX;?PH]I-M2Y=O\_P"D+V--1<>;=6Z= MOGUU.?U]8O/ODFB+3S6<26>4))<,V0OH;> M.IJ_%JEHZ6QDGBBDN%#1QM*I)^F#S^%$^I6T5N)DECDW#<@$BC<,@$@DXXR* M3J3MRV\OZ^X:I4^;GYENG^OZ_<<]KRM)_P )"&7I4@=>F< M>U2G4K$&(&\@!F_U8\P?/SCCUYJE5DDHJ/\ 5O\ @7$Z$)-R61DXY&Z,\3.5B8+\JD \DCU'2GQZI:1:;87$,;"UN#''' MM7 0-PN1V&<#\:KVCLGR?UK_ %\O,CV24FN?;UWT_).V[W5]C#:_N4UZ.V6X MN&"S^0Z2M]Y/+/S;0O0GG=GK5&RN]1BCT^!)OLZK!;^0KL5$F?OY4*=Q[8R, M=:ZTZO:)/=1RR+$ELRH\LC!5+,,[0?7&/SJ9]0LHS"'NX%,W^JS(/G^GK2]J MTK'H$MDU&**(1QK?2!5"X &%Z5LT5$ZW-'E]/P+IX=0ES7 M[].ZL)9)S*Q6FIK;VLJVD(A5H,$HCR%CG(" MG=V^7CK72PVL5O),\2E3,V]QGC=ZX[5-5_6$G>UUK^-B'A6XVO9Z+3RO^=SC M&OIY9ID6]GEF::YCFMR,HD0#X/3C!"X.>^*B^VO;:9(K3S0OMMH[?8=@#&$9 MW''W1R3]*[2"WBMD98D"JSLY'JS')/YFI*KZQ';ET_KR(^J2>KEK_7G_ $SC MGU.:V66W749IF;[+]GD(R91N D(X^N?2I;=;VYN+7?J-ZJW-S<1R*I "JI;; MCCCH.:ZRBI>(5M(_E_D6L*[ZRT^?^?R.&FUB^6"TW N+9A\BQ9<[NG'.WG/.:["F31+/ \+[MCJ5.T MX.#[TWB(M6Y;?UZ$K"34N;GO;^N_E_P#-\-ECH%MGD#<$_W Q"_IBM6FQQI# M$D4:A40!54= !VIU<\YP()/O@5WN!Z48%=/UJ5K6_JQQ?48W3O\ \'6_]?GT.0TI M;V:ZES?U_G9)'(:7;V=UK1CAAC:S-J4,:PE#$-P.V7/WF M/]#ZUI>'XC#X; C3:ZF;8N,8^=L<5NTA=1U85,Z[FK>GX7*IX90=[]^G>W^1 MRKVUO)X 3R<>G-/,['H *OVVKTOOOYD?5M%K9Z;>2M_ MP3B'O9[K2952]N+HR6H]ZLWM\R++ U_/:S27LB1R*VU40 M!26;CG';U)KIH(DMH$@A79$@PJ@]*DR?6K=>-](_U]QFL)*VLM?G_G%DWK)_C_FO%1:/(&T^*U%Q--;FPE^UQ2CY82/NXXX[_ )9KMEB/\3?@*2XM(;JW:"92 MT38W+G&[!Z'VH^LQM;E%]4G?FYK_ ->OWE72$D?2;*2XYD,"%L^NT=:T::6 MX'Z4PL37+)\S;.Z*Y8I#RP%,))ZTE%(84JC)I0A/6I ,"BX6"BBBD,SM4LYY MVM+FUV-/:R^8J. M71[RW\B>&.!YH;V:U1$MQ*L:I))YA*\.6PRD$ M..>.A!KKJ*%B9H;P=-]S!UO29K[4K:X%I%=0I#)&T;S&/EBN#D#V-64TJ1_# M*Z9<2AY1"$WKT##[I'T('Y5JT5'MI?_L&FF<]E'YU M/28'H*+H+,@,[>U(97/\56-H]!1M'H/RIW0K,JEB>I-)BK>!Z"EHY@Y2H%8] M ?RIPB<_PU9HHY@Y2 0-W(%.$ [DFI:*5V.R&A$7H!2E@.]+@'M28'H*0QI? LT%-))ZFI,#T%&!Z"F(BHZU+@>@I:+A8C"'OQ3PH%+12&%%%% !1110!__]D! end GRAPHIC 9 form10-k_002.jpg begin 644 form10-k_002.jpg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end GRAPHIC 10 form10-k_003.jpg begin 644 form10-k_003.jpg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end GRAPHIC 11 form10-k_004.jpg begin 644 form10-k_004.jpg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end GRAPHIC 14 form10-k_007.jpg begin 644 form10-k_007.jpg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end GRAPHIC 15 form10-k_008.jpg begin 644 form10-k_008.jpg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end GRAPHIC 16 form10-k_009.jpg begin 644 form10-k_009.jpg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end GRAPHIC 17 form10-k_010.jpg begin 644 form10-k_010.jpg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end GRAPHIC 18 form10-k_011.jpg begin 644 form10-k_011.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@!JR(_W'5OH&X-0T+4%DNM(OG66V\ MK,**VUO/E;GGCA@?QK6UG3-4O_L4MU'%));:G#)"MJ[@"+>,LX/!8#/]* [G M3B6,R&,2*7'5<\_E3ZX_3--N;;QO=74=E,(IFE:XGN(X^^WR_*L>I745A;&^@TY9/[12'/VB-@H*".,CY\Y/(.!BK=C MXHM[VXM+=K'4;:6Z>98UGMB !'U9B,A0<\9ZUSMYXF6'-05VM=:LI51HT+"4 ;I"0@R>Y(( ]JVZ "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,]7FN+KQ3-%/< M">613'I=[ICJ;FS21PDF4S@JI7ESR,XQ7IAZ5BMX4T8V5Q:)80QQSQR1/Y:! M"5ZM;E(Y2%)_=F5U_P!6O!*# MN*7Q!87FH^*5N]-TVYM;^W/V1=2$J!#$\9.\IUD5&Q\AQRIP/6K@ /(QS0!YS9V>JW\]J+2%FL[BX2262^LXT%L8" 0 ML6,GS#N8-GY>U>CT@4*, #VI: "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@!#T-9OAW_D6=*_Z](O\ T 5I'H:S?#O_ M "+.E?\ 7I%_Z * -.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH *@O9FM[&XF3&Z.)G&?4#-3U5U/\ Y!-Y_P!<'_\ M030!@Z;9>(+[2K.[?Q*ZM/ DI4646 64'^M6O[(U[_H9Y/\ P"B_PJ[X?_Y% MK2O^O.'_ - %:- &#_9&O?\ 0SR?^ 47^%,;1_$6?D\4D#_:L(S_ (5T-% ' M._V/XE_Z&H?^"Z/_ !H_L?Q+_P!#4/\ P71_XUT5% '._P!C^)?^AJ'_ (+H M_P#&C^Q_$O\ T-0_\%T?^-=%10!SO]C^)?\ H:A_X+H_\:/['\2_]#4/_!=' M_C7144 <[_8_B7MXJ'XZ='_C1_9/B?\ Z&B+_P %J_\ Q5=%10!SO]D^)_\ MH:(O_!:O_P 5573[7Q/>V[RGQ+"FV>6+ TU?X)&3/WN^W-=967H/_'A/_P!? MMU_Z/>@"C_9/B?\ Z&B+_P %J_\ Q5']D^)_^AHB_P#!:O\ \57144 <[_9/ MB?\ Z&B+_P %J_\ Q5']D^)_^AHB_P#!:O\ \57144 8":9XD5<'Q';L?4Z: M/Z/3O[.\1_\ 0PVW_@N'_P (;1KUFQ'\+Z=P?RDS6[10!B M?9?$_P#T%=+_ / !_P#X[1]E\3_]!72__ !__CM;=% &)]E\3_\ 05TO_P M'_\ CM5+5_$]Q>WUO_:6E+]E=4W?87^;*!O^>OOBNFK)TS_D-:W_ -=XO_1* M4 1?9?$__05TO_P ?_X[1]E\3_\ 05TO_P '_\ CM;=% &)]E\3_P#05TO_ M , '_P#CM1M;^+=QVZGHQ7MFPDS_ .C:WZ* .?\ L_B__H):+_X R_\ QVC[ M/XO_ .@EHO\ X R__':Z"B@#G_L_B_\ Z"6B_P#@#+_\=H^S^+_^@EHO_@#+ M_P#':Z"B@#G_ +/XO_Z"6B_^ ,O_ ,=H^S^+_P#H):+_ . ,O_QVN@HH Y_R M/& Z:CHC>QLI1_[5I/)\8_\ /[H7_@)-_P#'*Z&B@#GO)\8_\_NA?^ DW_QR MCR?&/_/[H7_@)-_\\GQC_P _NA?^ DW_ ,\GQC_S^Z%_X"3?_'*/)\8_\_NA?^ DW_QRNAHH P0GBW S<:(3 M[02C_P!GJ]H=U/?:#875R5,\L"/(4& 6(YP/2M"LKPS_ ,BQIG_7LG\J -6B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JKJ?_()O M/^N#_P#H)JU574_^03>?]<'_ /030!!X?_Y%K2O^O.'_ - %:-9WA_\ Y%K2 MO^O.'_T 5HT %%%% !1110 4444 %%%% !1110 5EZ#_ ,>$_P#U^W7_ */> MM2LO0?\ CPG_ .OVZ_\ 1[T :E%%% !1110 4444 %%%% !1110 4444 %%% M% !63IG_ "&M;_Z[Q?\ HE*UJR=,_P"0UK?_ %WB_P#1*4 :U%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %97AG_D6-,_Z]D_E6K65X9_Y M%C3/^O9/Y4 :M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444A( M'4XH 6BDW+_>'YT;U_O#\Z5T%A:QO%%M1FTN".XNXX&98'S^] 'S*,= M"1G'OBMC'YT;E_O#\Z+H+&#X)DU&;P;I'YT706%HH!!Z'-%, H MHHH **** "BBB@""\DGALIY;6 3SHA:.(MMWL!PN>V>F:Y?X=Z_)XDT*YOQI MTUG;->3^3YY&]\R,S$@=,$[>O5377TV.-(DV1HJ+DG"C R3D_K0 ZBBB@ HH MHH **** "BBB@ HHHH **** "BBB@ KBO#7B&ZOO'/B+29-(FMVM9$>>=G!C MP458]G&3N +=L 5VM-$:*[.J*'?&Y@.3CIF@!U%%% !1110 4444 %%%% !1 M110 44565G8%C*1R> H]:F4N4:5RS14'S_\ /8_]\BCY_P#GL?\ OD5/M/+\ MA\I/14'S_P#/8_\ ?(H^?_GL?^^11[3R_(.4GHJ#Y_\ GL?^^11\_P#SV/\ MWR*/:>7Y!R^9!K$M_!I%U-I<4G MW&J6BVDKQ@QVXSN2,<+NS_$<9Z#KBN@^?_GL?^^11\__ #V/_?(H]IY?D'*3 MT5!\_P#SV/\ WR*/G_Y[-_WR*/:>7Y!RD]%0?/\ \]C_ -\BCY_^>Q_[Y%'M M/+\@Y2>BH/G_ .>Y_P"^11\__/<_]\BCVGE^0_V>V,@CCR1N;'3D&KJ:EIT@B*3 MVI\V/S8_F7+)C.X#TQWKE]0M=3;6GO\ 3I[)/-LQ:L+A7)7YBVX8Z]>AK O? M K3!H8+X>0;>.(&1FRA2,H/E'!!Z]>YX-<"Q=-K5K^OD='L97/19=6TN&S>[ M>YM/LZ9!D#J1D=L^OM4'_"0:3]GAG\V'9+%YW091-F__/-;&G:+/8^(FU 3P"%E;*I6W'[& M1WEJ5+RE0 ,C@#VJS5#2W\Q)6_V@/TJ_7=AY MZ/J%E$RB2>"6)2QP 2"!G\ZYM-"NKG2DL;NW4JDUM(?M&H/=*PC8%@ Z_+D9 MZ=>E>/#$T[:V.V5*5]#N;#4=/U.U6YLRLD+$A6VE=V#@D9ZCWZ5,]S9Q211N M8U>5BD:D\LP&2![X!->8V'@^_LKFS*7,<:Q*F'A<+Y.W=N"C9D@DYX(!R(M'351IC&3[8>D?V:3D9QG=MQC)'.<5R-EX>D_M>UNY[6TM[.&9I5L8W M+I$WEJH9> "2PSTXX[UO/%*WB2'40Z^2EF]N1GYMQ=6'X8!J7BJ:?0?LIM'2 M9ASC8N?2JEWJFF6#PI=2QQM,<1@Y.XY [>[#\ZXS5=%O;V_U&2'[.LETI\F^ M:1A+;CR]FQ0!TSD],XK/M_"U^BVQ#Q1K'<>;Y32@A!F+[NU%7G83@#T[ MYIQQ-+JT'LI'IV8:UQ'AO3+K2-0OY)!"L$_*@/O=FW,<[L X MP>C9/OBND^T^]1+%TT]+%*C)FW:D&'CIN;'YU-573SNLT/J3_,U:KU:+O3B_ M(XYZ2854N"OV@!P"-G /UJW65JDGEW$?NA_G66*FH4^9]T71CS2L+'>6,MS/ M;H4,MOM\U?[NX97\Q3H[FSEEEB0QM)"P610>5)&0#^!%<+J7AY]2\12WDXMY M;-^?*D).3Y+("1C'#$']:HIX5N_MZW$D=D[+#GS'9CNF\A8P6& 3AE)SG//K M7$L32MNC=TIW/2]\&,[4QZYI));>)&=T4!5+'N<#KQ7E:^$]4^RNI:%8C,LI MM%D3:Q\HH2?W>T8.#]TGWSS4D&@ZC)>WD6Q%DB:)1J,DK>8X%L$*#CE2QY/U MXS3^L4^Z!4Y=F>C1:OI4\T4,:[,IRI/(;H"!ZYK:_L^\M]+T+R##)>:5@F-G*I)^[*, V.#SD'%+ZS2TU M0_92U-IO%WAU%1C<@[T9\+#(Q0*<,7 7*8/!W8JVVN:.MY!:&XB,TX5HPH)4 MAL[?F' W8.,GG'%TZ^5U$5M'.C@GDEPN,?]\FL3 M5=$O;Z]U%X?LZR70/DW[2,);=?+V>6H Z9R>N/F/&:E8JF^Q7L9':7FJ:98! M3=2QQ!D9QG)RJXR>/3(_.K>890^%[];-XP\4>Y90L32 A-PC QM1 M0,["3@=_7-:WAK3+K1[V^>40K!-@J%?>[-N8DEL D8/\66]\4WB:26Z%[*6A MV^8?^>:U-:$%'QP-YP*QOM/O6KIC;[4MZN:O#5XU*J2\R:M-QC=ERBBBO3.4 M*SEDQD>C-_,UHUAO)B60?[;?SKCQ=3DY7ZF]&/-;[T>=[UR#>,[:"[O+> MZ@GW6\TBDPQEP(DV R,>PRXI\7C"W:8PRV=XDGGSQJJ1;\K$0&?CH.17+[61 MKR(ZSS?>CS?>N//CO2$MS(S3*XD,9B*KO!"AB>N,8(/7VZT/XWTYK26>W,NP M!_*FEB812E<;@I')P#GI_*G[2?8.6)T^I:@]CIES=11/-+%&S)$BDEVQP ![ MXKSM8=8T>>PL+Z2]MHENA>F\M0USM+1.LH)VD#,F" 0<;^*UX_'*?VI-;3Z= M=101;PTP3=MVR^7N..BU+<>.=/7SX[-_-GB<* QPKCS%C /6NC\+23IH8CN9KB69)YE=KA<-_K&P.@R,8P:S9_& MFFP7#0[+R4HP5FB@+*"7,8Y]W!4?X4L?C+3I90GEW:XVB5VA(6$LY0!SV.Y2 M._Y4G7DUL'LTGN=7YOO2>=[UQNF^-K:[L(I;BUN8;F15*0",DREF*CR_[W(/ M7'Y583QCI\HE:**]D6$'SV2W)\A@"2C^C<'CZ>HJ75DA\B.J\WWH\WWKE)_& M%C#?K#MD:V6*26:[ _=QA$5_QX<5'#XZTBXGB@C-PT\C;3&$!*=.3@_[0Z9/ MMP:/:R[!RQ.MEES$_/8UI#I6 \N5(S6^.E=.$J<[E\C.M'E2"BBBNTYPHHHH M **** "BD)"@DD #N:IRZBBG$:[CZ]!0!=J"YM(KM567=A3D8.*H-?3L>&"_ M05@>)-7U2T6W:UN6C4L0Q"@Y].U14C&46I*Z-*2;FE%V9TO]C6GI)_WV:/[& MM/23_OLUS^B>(KN^!AN' F49# ;Q]/6MC[9_A_(5T0C&$ M5&*LC&3;=WN;%%8_VRX_YZ'\A1]LN/\ GH?R%4(NG3+,DDP\DY/S&D_LNR_Y MX_\ CQ_QJG]LN/\ GH?R%'VRX_YZ'\A6/U:C_(ON1?M9]V7/[*LO^>/_ (\? M\:/[+LO^>/\ X\?\:I_;+C_GH?R%'VRX_P">A_(4OJU'^1?<@]K/^9ES^R[+ M_GC_ ./'_&C^R[+_ )X_^/'_ !JG]LN/^>A_(4?;+C_GH?R%'U:C_(ON0>UG MW9<_LNR_YX_^/'_&C^R[+_GC_P"/'_&J?VRX_P">A_(4?;+C_GH?R%'U:C_( MON0>UGW9<_LNR_YX_P#CQ_QH_LJR_P">/_CQ_P :I_;+C_GH?R%'VRX_YZ'\ MA1]6H_R+[D'M9]V:L420QB.,84=!3ZQ_MEQ_ST/Y"C[9/_ (\?\:I_;+C_ )Z'\A1]LN/^>A_(5E]6H_R+[D5[ M6?=ES^R[+_GC_P"/'_&C^R[/_GC_ ./'_&J?VRX_YZ'\A1]LN/\ GH?R%'U: MC_(ON0>UG_,RY_9=E_SQ_P#'C_C1_9=E_P \?_'C_C5/[9/\ C1_9=E_SQ_\ 'C_C5/[9/^-4_MEQ_P ]#^0H^V7'_/0_D*/JU'^1?UGW9<_LNR_YX_P#C MQ_QJQ#!';Q^7$NUGW12/X>L) M&G+K<,)A,K#S#A1+C>!Z9V@^W-=7]LN/^>A_(4?;+C_GH?R%$;1(;B*ZDN M)XY)96BCWD+$KD?='K@ $_7UKN/MEQ_ST/Y"C[9,].,9Q[9JQ=Z/&]@(;9 )8[-K.+SBQ41M@'(')/RBNJ^ MV7'_ #T/Y"C[9A_(4_[.J?\_/P_P""+ZS&UN7\3D_^$=L!# B+<(;=%2&19#NCVL6! M!]A_(4?;+C_GH? MR%/^SJE[^U_#_@B^LQ_E,SS&)'!Y/I75CI6/]LN/^>A_(4Y;Z=3RP8>A%=.$ MPCP][ROXKL,!:*** "FR.L:%V M. *=67?3^9+Y8/RKU]S0!%<7+W#<\*.BU#110 56O[-;ZU:%N">0?0U9K+&M MQ"Y>)X74*Q&X'/Z4FTMRH1DW[ICQVTUA=J&&V1#D'L1740S+/$'4_4>E03PP M:A""K@L.58=15>VBFAD9'8;U_B48!%2ER[;&LI>TTENB_P":N\QY.X"LAK=Y M" F-[G )[5J+"6.X]33C;8P0,8Z4/4<5RWL-M+9;6'8#D]68]S4J2(XRKJ1[ M&JTQD*%=W!K*GB SQ0Y6%&CS;LOWNM6MHK!299!_"O3\37$:U?7&JS!YL *, M(B]!_P#7KHUT2ZN%#,8XP>QY-36GAI(;E9IY!)M.0H'&:F492T-J52C2U6K- M>P4II]LK##"-01^%6*,8HK4XGJ%%%% !1110 444A(49)XH 6C('>JSSLW X M%1'GKS5J#'8NY![BEJC3UE9>^1Z&AP"Q;HIJ.'&13J@04444 %%%% !1110 M4444 %%,DECA7=(X4>]4GU5 <)&Q]R<5482ELB7)+6Q^5NGL:U* &2OY<3/Z"L,G)R>IK6OCB MU;\*R: "H+R5X+*:6-0TB(2H/KBIZ1E#*5/0C% (R?#^J2:E9L9RIGC.&P,9 M!Z&KEQIMK/#_ -Y>#7+1/<:%JDN$^0DC#=&%=!;ZY!,!OC=#^8J(RTM( MZ*M*[YJ>S(VL+BT;="1+&.S'##\:MK<1P6;W=UF&.-2SE^J@5)]JMYD*[B0? M:JESIJ7FE7=@';RYU(!)R1_DT.W04'*]IG'ZIXYOBIG@+6MIYBHBQJ#(=S!0 M6)Z1PWDTL-LC*S MHL89)-K!@0W\/3FF2Z+ITDL%P+_9/%+-(67'[P2;OE(S_"6.#]?6N>_\VYZ? M*O\ EVE;Y&QI/Q FFG&XO>V817ED90#&6&0H(ZL 0L4P\O:CL.DG^]USCK7IEGIVRTMK!9'584 +@^E: M1NWIL<]9QA%-[];$]IJ$-O%YQK)GT.4@F*Y+'^ M[(.*P;RQO+=R#%(#_>2M&Y+HO8N+PN<-^[+]=M;%4G M=&,H\K:O<****9(4444 %5IGW/M'059JB#GGUJX;C1'//%:V\D\\BQQ1J6=V M. !7!:AXVO;^A[M:W,AQ',2GVI2[B8^BBB MH$%%%% !1110 5!=7 MHMW5CPH]ZGK%U"7S+HCLG K2G'FE9D5)21Y7 M+.Q9C7,>(?%O]@7K0M9^>JI"YVOAB'=E.!WP%S[UMZA?+I]FT[+N;HB_WF/0 M5YE;+HDMP\\NH/))"WF%I)681!"3M!/102>*Z9RY;)&$8WU9TEQ\1M,MAYSC M?:_:I(1)'EBRK&&5@,=6)QCM6]9:PUUH@OA#'+<>7YGV:VEWD ]!GN<=>/I7 M&Z=I_AW,9LKB-MMT75 YXED4C&".A .!4]C;6MI:K_9<[-%"[*CJ^=I!Y4'T M!XJ>:5@E%/1:'2>;K^K18U34H]$T['(5OWC#T+?_ %_PK*TJ6+3O$ET/#-@= M9C:-5CEF0_NG[MN(Z=?2LX:AH9O2?$.HSSW8.Y8&!V!>QX_^M7<6?COPI!:) M%;W4,,:C[B>6@'X;A7DSHWDI-V?F[O\ R7W'/3PM6HU*6ENN[_R7W$,OACQ# MJ[Q7NJ:U'#=POOMXHH@R1'O]3P/6NLDM?M.GFUNG\PO'LD=1MR<.-(F1$LM4T^*1SS-=7402->YP'RQ]!Q[FGZ1J>I:CJH^S:C::AIR#,TR1!5 M!/149JBZ<)\JNV_5_>>A3PR@G)?.[W--]+N9)XYVU2;ST#*&$2 MX"D '"]CQUJ$^&K)IHFBBJ+2MH%%%% !1110 4444 %%%!..M !14;3 ?=&:9YS>@K&6 M(IKJ;+#U'T)Z*A$_JOY5(KJPR#50JPGLR9TIPW0ZBF[U_O#\Z4$'HI^HK)K6O_\ CU/U%9- !1110!'-;PW"[98U<>XK-ET*'):WD:(^G45K446N M--K8RH])F'W[L@?["@5.-+C/WI[AF]?,(Q^57J*5D#DWNS.:ZA6-8IK:2XV# M#OMSCW/K45Q9V,,RN+&-XL99E'*G/7Z5J,!L88Z@U5LOG#D],!:+%*3MHK56-$7:J@+Z 5SNH VLS(P(3JIQQBID MFM4:TI*3M(Z)'$B*Z]&&13B >HKDX=G&:>A-2C*"N]B_C'2BBBJ,0HHHH **** "L_[LLD9ZJM<3JWPVLY+R6\T_,4D@8,A)*?,,$@9X)'I6 MC5]4,Q4^(<[Z7*_V>-)8;$SS1.3\D@8#'^Z0<@U3;Q =6BN+@*L< P]*OMX O7=PT,67A%NS L,QCH/TK8TWP):VEXU]J4GF328W1CHY'3Y M>YHU%J6? .FRV>GSWTH(>\8;%/IV_P :]!1=B*OH,51L;4J%D=0@48CC_NC_ M !J_42=P84445(@HHHH *CGGAM8'GN)HX84&6DD8*JCW)X%4=9UF'1K5':)[ MBYG?R[:UC/SSOZ#T ZD] .:SK3P])?S)J'B&1+RZ!W1VX'^CV_LBGJ?]H\GV MZ4 7['Q#I>J77V>QN&N&P3O2%_+XZ_.1MS^-5+H$74N?[U;B1(GW5 K-U2'8 MPG ^4C#8[5K1DHRU,ZD;QT.1\4EA#:]=GF'/Y5P]GH>HMIE[9;#F=90CF])C M^9LC]WCCZUM:SKESK/AI9(5@B>:: PI;S!YE5Y"N&5AA6X^G;M61:WNJ:5J% MC:ZK(81(\V1-M!9 !LW$<9Z]*UG9RN9QNHV-6X\*7%S))')<=L\$?WC5FSM;BPTM;*Y\H_9R8XGC_CC'W21V;'!^F:QY/%] M+F5M!J+;L;6G6UF=0DFN[19U\O:,)N8WNS"\GW_+&<8]:Z"/P[>Q7#7":W.LS*$9Q$,D#H.M<4^9I:?@CU(PP\ M6TW;YR_R,3R='^U6D&F:8#)(Y5DOHE\MEQTR03GIR/US6OI.FZG8:KF&QL[' M3Y%_?Q1R[@2,X** K'/)QR!3Y-$U%K^RGFOS?1PR;F64;"ON,=:Z&LXTDY\ M[T:_KT(KR@HJ-/9[]>OGJ5!QQC\ZMM#&X8,@(8[C[GUIHMX50J(UVMC(]<4.%7I+^ON,E*'5$M%%%=!D% M%%% !1110 4444 %5W1NZC M;M$WK*\6^A,J1.BYP-XZ_2K--1%C140851@"L_5-62P CC DN&Z+GA1ZFLDN M9VB:-\JO(TJ.1[5R9NK^ZY>X< _PI\H'Y4">_MN8[F3Z,=P_6M/9>9G[7R.Q M24CAOSJ:N?TO6%O'\B<".X[8Z/\ 3WK;A;/RFNFA4DII^HK) MH **** "BBB@ K/UO43I6C7-XB"29%"PQG^.5B%1?Q8BM"L._P#^)CXHT^P' M,-BIOY_]_E(1^>]O^ B@#942"%1*5,H4!RO0MCG'MFJ.DS*ZRQY^96K1KGX] M,O8=5$J$"(/NW ]O2I=^AI#E::;.@K/:^SKYTN6%-CVGVB)R>6(?:ZX]LJ?Q MK0K%US_1M3T34>@CNC:R'_8F7;_Z&$JC,N2:/8ROO:W7/MQ5N**.&,1QJ%4= M *?10 4444 %%%% !1110 4444 0SVL-RN)4#>A[BJITF0<0W4Z#T/S?SK0J MD^D:=)"87L8&C:0RE2O!<]6^M #!IDYYDO)BO^R *L0V$-L=RQG>?XGY)_&J M<.G6QURZNGBMVD18?)(P7BPI!SZ9XQ]*N6MA:6._[+;1P[SE]BXW'WHN!8HH MHH **** "HKBXAM+66YN)!'!"ADD=NBJ!DFI:YWQ#_Q--3T[P^.8IF^UWG_7 M&,C"G_>?:/HIH 30+2;4;E_$6HQLMQAZ;]J:%IF+A$B1@"YZG&?0 G\*1_$&FI(T8EDD*QQR'RX68;7&4Y QDCG M% &G2,H=2K#(/45AW7BW2H+%KJ*1[A%17_=QL1\V,#.,!L'..M2/XGTU68"1 MVPI(01MYA8%@5V8R"-AS0!!/H$5L[O:6D#([^8Z"-02PZ'..3]:S;^PL;X!- M0L4DV]/.B#8^F16M!XMTF2QCNI9FA#0B5@48A25#%,@8+ $' YJ4>(=-=G^< M[4&"#&WF;]^S9LQG.:UC4E'0S=-/4Y4>'='">4D"^7G/EHGRY^@%68O#"Q S M:58I;3K\V_8%,GL?7\:Z:XUC3;.RBO96*02 LK"%L@#J2,9&.^:BF\2Z9"V/ M/&P.4:1E8)P#N(;&&QCD"IG-R5K%TU[.2DC MK^'2F34(&VK(WE7EFYPZO\ MWE%=G#-'<0)-"X>-QE6'<5RDK1ZI=7.KZ;:,9[&;RI8IXR//&Q6)VD9!PU-L M=2%E?+#I"_:K>Z7S!:%MK0-W&37,FX.TCT9TXUX*5/=?U9^BV;W6FZ.EN=2M M[2?R9=P?R6E&!P0.H^M11ZQ:RQLZ!V"#Y\#.TYP%^I/05'J2Z?*S1WID5I(0 M#M!.Q<_>R!QSWJ-K?2X4G02NOD@"79URS;E/ Y()X(J[NYSQA#E5T[EM]26- M&:2WG78P,J2?;9E ME>8D@A5+.H[KMZ@>W>K-C!:R2>?#/+*J.S*C\!&;DD# /(/&>QIIL4HP2V?X MFC1115& 4444 %%%% !534=4L=(MQ/?W4<$;':N[DN?15'+'V I-5U*'1]+N M-0N S1PKG8OWG8\*H]R2 /K67HVARF;^V-9*SZO,O/=;9?\ GE'Z =SU8\F@ M"U:ZM'JD;O%:WL"1N!NN8#%O![J#SCZ@5;[U8>)7B9,8!&.*I1R'>89.)5Z_ M[0]17%BX/22.S"S6L6<:5,6I7".,,)6Z_6NDTR)_ED*$)@\GO4\NF6T]^MVZ MDNHQCLV.A/TJY6$ZBDM#HA3Y7J%8<^@R2WE1M;1/]Y,_4TN?6X^330XNY)@F65#AT;<#]*[F%]SQM_>&?TK.N-#L;@$XRG$PG!QA(MT445Z!P!1110 4444 %:UA_QZ+]3 M636M8?\ 'HOU- !?_P#'J?J*R:UK_P#X]3]1630 4444 %%%% !D 98@ & M]0@B_P!=Y)DB_P"NB?.OZJ*K:/=7MQJUTIOA>V<:E7D$2HBS;ON1XY("\$G/ M/?K6\#@@T 5[*\34+"VO8_N7$22C_@0!_K4]8GA;]QIMQIO?3KN6V ]$SO3_ M ,<=:VZ "BBB@ HHHH **** "BBB@ HHHH I6QB.KZB$C<2A8?,8GAOE;;@= MLZC2X@6%&@B."5?8W.!R#G&,_A7+C3K:QLK%;[3_\ M1&TR,Q))%*\2W1_UAD5,L'(VX/L>] 'H.#Z4@!/05PEEI-_JNI64MW8P(L>F MPAX[Z.24J?,?A6W##8QG.3R,U7\9WNKF:Q23_09EMY[B.WMIWD:9T>+:%90/ MG(+ 9! R>M 'H=% .X!MNW(SM]/:B@ KG]!'VW6]M MZ1Q%&TAZ("QS[5B>#(RGA#3G88>:,SO_ +SL7/\ Z%0!H7VDV.I36\E[;I<" M#<4BE4-'EA@DJ>"<=#VR:H?\(IIJV)M$:X2+?&XQ(#MV9"C!!! !Q@@]O2MR MB@#"A\):=!;BVBEO%ML+NA$WRNRXPS<9)P /3CI4DWAFQENY+M9+F&Y=V?S8 MI,,I8L6QD$<[F%;-%%P,%?"&F+"L&ZZ-NO*PF7Y0^T+OZ9W$ #TZ\58E\.V, MMQ/G:;'IHF MV3W$\D\GF223N&9CM"]@ !A12:?I5KIJMY"9=F8F1@-V"C*5W8R7$[2)<"-7A,+C9N)4G/!SP:JG0(]FT7,N7&),\AAN#<#/'2M>BE MRHI59I63*DFG0/''&B^6BN7(');((.2?K2V5HUJK[Y?,=MHR%VC"C XJU119 M$\\FK-A1113)"BBE498 ]S0 E%>>VGBS5+,PW=]]HEMYVN$591$(W=7*H(RO MS*/4N,8![XK?B\03PZ[)::A'@+"JF.R5K@"0R,,DJN0, ?> Q0 _Q44":/YY MQ;?VI 92>@Z[,^V_;708QQ7%ZGK8UI;C2);:)(H]0AL;O,@82!V(.WVP!\W4 M-D=15R'4M1\.@6VK)-?Z>G$6HPKOD1>PF0[MTGCW$E77E M77J*2QU"RU2W$]A=PW47]Z%PV/KZ?C275W;12):R7,*7,REHH6E9MB5^4>I KH*=23V%3BMQKN ML:%W8*JC)). *QYO$,8M5"FK78IU'>R.P'B&44W$WB6>.WFAMY9IH+F3RW>$IF(P DD;0&()( (QGBK M$C/#XNLKRQ2]$H4F9Y$=05* AL_=VYXVX!R35^QB]B/:R6IZ_$Y/RGJ*EK/L M[D7%M!<+P)%!Q]:T*Z,/)RAKNCFKQ49Z;,****W,0HHHH *UK#_CT7ZFLFM: MP_X]%^IH +__ (]3]1636M?_ /'J?J*R: "BBB@ HQGI17*_$=[N'P%J-U8R MO%<6IBN%9&*DA9%)''J* +UO_P 3'Q?-)61I$5V1MR%AG:W3(]#R:YS1-8O;[Q%>V4\B&&(3 M; % (VS;!S]*-4UB>X5/[(O'2?>T4=JUH0\\H(Z[P,1@9RP_/M0!LVFDZ;I\ MK2V=A;6\CC#-%$%)&<]O>KE8-O?WR>)TM9KI)K2YCF:,HB[%="/D4@[B0"=V M[OTK>H Q(/\ 1/&E[%T2_LX[A?\ ?C/EM_XZT?Y5MUSGB?4+/2=0T74+FZ@A M,-T89%>0!O*E4JQQUP&"$_2KMOX@M[VXCBLK34+A&;!N!;,D2CU+/C/X9H U MJ*** "BBB@ HHHH **** "BBB@"E;"'^V-1*,YFVP>8"!M'RMMQ^N:O D=": MJPB;^T+LO&HA(C\IP!EC@[LGJ<''6K- !41MX6NX[LQJ;B-&C23NJL02/H2H M_*I:* "BBB@"GJV[^Q;_ &_>^S28^NTUB6%[=II'AS3; PI/=6*R&:9"ZHJ1 MIG"@C))8=_6NDE02PO&>C*5_.N:\-V-MJW@S2$NQ(9;1#$)(Y&C='0F-L,I! M'3'O0!:;Q$UG&]M>0K)J2!0([9LI*3NY4D\ ;#N!^[[U37QD'TC[6;"6-C%M M\PE3$MQY7F"/@YZ=\8[5HP^'+.#4K:Y2.-8;6WD@@B"G(\PY=F8G+$_U)SS1 M'X5T>)0JVSE NW8TSE?N[-V"<;MOR[NN* ZD#^++6"W8R6]P]Q&I:6*)02 $ M5MW7[IWK@^_M57_A-[40SW)@D:)/* 563"EM_)DW;,?)UR.P[UIKX>M3?WMU M/A_M$$=LH0%#'$G(&X');/.>.@]*1/"VD1I,(X)4>9@\LJ3N)';GDMG))W-G MUS0!JPRK/!',H(610P!QG!&>U/J.WMXK6VBMX(UCAB0)&B]%4# %24 %%%% M!1110 4444 %%%% !1110 4444 48]$TJ&262+3+-'F#+(RPJ"X;J#QSGO4U MK8VEB +2UA@ 7:/+0+QG../GKS]: MG@M;>UMUM[>".*%/NQHN%'T%344 8E[X5TF]N#^#-_-/UC2S?QI)$0L\?W<]&'I6S/;I<1[7SD'((Z@U2875N!V4ZT7'DF-HW0AB&'7%=@CK*BR(06\BVZY$!_P!6P0A5_P!D_P!*PG&4OLLVA*,? MM(XKQ9K$^D^+A"UM&(9UC9)9G*"0D[2%;&W(QT)&T.A! /)4CCZUFZIK]Y;7-I;W-M;H9E#RRB1_+3+850=O4^^*T3X M6AD2\B@TN6".\A$$Z0CRU91G!QT!Y/-:?_"(VLTT5YJTLA6+;BW24^6^TY7> M/XB".U4N2+)?/)'0Z;"UO86=NPP^!D>GB_4T %__ ,>I^HK) MK6O_ /CU/U%9- !56_U&UTVW,]W,L:]AW;V [TZ^O(["SDN9?NH.GJ>PKR'6 M]6N-5OWEE@K.I4Y$=6%PSK/78ZB_^(K!F2PLEQV>4Y/Y"LT_$#6# MPT=JR]U,7!_6N3>1(UW.P4>]5S?Q=@Y_"N?GFSU/J^'AHTCTS3OB)'*X34+3 M9GK)$<_H:[.VNH+R!9[:598VZ,IKP%+V%S@DJ?\ :%=/X9UV;2;U<,6A?[Z9 MX8?XU<*K3M(YZV"IRCS4=STR?0M(N91+/IMK)("6#M&,@DY)S[GFI+W2-.U* M:.6^L;>YDC7:CRH&*CK@'TJS#*D\*2QMN1P&4^U/KI/)*L.FV-O=R7<-I#'< M2C#RJ@#-^/X599P@R3BAF"*6-4V8LV3UK*K5Y%YB;L5[33M,T^0R66FVT,A. M3*(P7)]V//ZU<-Q(>I!JI;N O\ M,US<]26MR;LZ1;C^\OY5,K!AD'(KF8/$UA(X642VY/>1?E_,5M12C =&#*1D M$'((JXUI1=IC3[EVBD5@R@CI2UUE!1110 444V1PBY[]J3=E=@#NJ#)/X5"; M@]@!]:B)+')Y-5KR_M;",/*;;/[NUN''J<#^M36_B33YG"2%[=CT\U<#\QQ24ZJU"[.D!!&0\/G[%K&MZ2W&V<7L(]8Y>OY.K?G70USG MB(_V5J-AXA7B*V)@O/\ KW[,6J>&P57$L\AFD'0MT'T%7**<:4(?"B959RW M84445H0%%%% !1110 5K6'_'HOU-9-:UA_QZ+]30 7__ !ZGZBLFM:__ ./4 M_45DT !:5"Z\S+:1KF7>W3^$>@J=(YXF7W!K M-UJ-IM&NXT^\T9 KDK:U-3G>YQDES+J]\UU-W.$3LB]A6M!I^Y>E8^F.NU37 M56PKAHWFU&[:YN6W2N?P ]![ M5U7B9&?0+C;VPQ^@(KF--=1BN:FO=N2C4AT_*9Q56\L@H/%;UK/&L>#Z5GZA M(ISBA-W B\,ZE)'2"5%>.12K*PR"#P0:DHH M YO0+F32KO\ X1J^=BT:EM/F<_Z^$?P9_OIT/JN#ZUTE9VLZ/;ZS:>3*7CD1 MA)%-&=KQ..C*>Q'_ -;I69:>()M-E6Q\2;(9,[8M04;8)_3=_P \W]CP>Q[4 M =)161HWB?1O$$US#IMZDL]JY2:%@5=<=]IY*^XXK4?SF.R!0TA&[YON@>]) MM)78#BP4$L0 .I)Z4B.DB[D=7'3*G-/CLI9T47051SN5#D-[?3_"H+7018R3 MFUF\M)3DJ5R ?6L77BG8KD8HNH#.8/.3S1U0G!JOJ.HC38UE>"22+.'9,?+^ M%:;Z7:R.CNF77H_?/K4LME!+;"W==T8_O')_.H>)TT17(8.JZL+'3X;N#9*L MDB@ _P 2GTK3'(!K"\76<5KI<21#:BMP.PK9MV#VT3*<@HI'Y5K3J<^I+5B2 MBBBM20HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH *UK#_ (]%^IK)K6L/^/1?J: "_P#^/4_45DUK7_\ QZGZ MBLF@"EJM@NHV$D!ZD97ZUY#J^FRV-W)'(A'/->UUG:IHMKJL>V9!N[-WK.I3 MYD=6&Q+HO75,\ N+9X'+(,H?3M35GP.M>DW_ ("NT8FV977TK*_X0747?!MD M^M8\LUHT=WM*#UC.QQ)D9^%!)]JZ;PGX>GO;U79#D]_05U&E_#V19 ]T551U M KNM/TVWTZ$1P(!ZGUJXP;W,*N)A'X'=]^B)K6W2TM8X$&%08J:BBMSSB&YB M,L7R_?7E?K5-769&!&".&4]16E5:YLUF;S$8QRCHX_KZUE5IX.R)6D<]E&:VM#TE[1_M5RH:Z<8CC'85M06,@X@LTMQ M_??!(_"M*VM%M\L27D/5VZFKC3;WT0[#X(O)B"DY;JQ]34M%%=!04444 %5[ MN)F021C,B<@>H[BK%%)JZLP,TB.Z@93RC @@_P C7$WVDW&DW!:)&>V/*E>2 MOM7>W%EOD-8_O),->S#I_<%=7%&(HU0= *9;VT=NIV\L?O,>IJ:MX0Y?4:04445 M8PHHHH *BG@BGB9)8U=2,%6&0?:I:* /+]!^%LL/B@>(-2NHX)XY-T5OIRF" M-1G@$CD^XKU>SW>?)E1MVC!SWY[5!5FS!!D)Z'&.*QK_ ,J.Y:HJ.XG2V@> M9\E4&2%')K/B>6YD+O(P!Z(IX%<<8N3T-34HJH]BJ1':-H.>AQUJO;W4D5Q' M Y+HWR@D\K_C53I.*N).YE>-3C3D_P!ZM"UXLX !C]VO&,=JRO'#8M(0.[BM MA,^6F>NT?RK?#[,B8ZBBBND@**** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "M:P_X]%^IK)K6L/^/1?J: "_\ M^/4_45DUK7__ !ZGZBLF@#*O]0O1J::;IL%N]R8#<.]R[*BINV@#:"22<^PQ M5&XUS5DGO%CTZU L;2.YN(I)SO.X,65" 5X"G!/7VK4O])AOYHY_/N;:XC4Q MB:VDV,4/53P.U6=4U*\MO#SZI:6\0>. W#PW99 M3M"YQ\N?FI]OX>TBSU-=1M;"""Y6-H@T2!>"03P._'6G"2#7+34[*:-UB662 MSEPW+#:,D'MPU#\@6^HG]I26>EP7.HHAGF952*S#/O9ONJH."3_A6;J'C;2[ M**5?WHN4BW^5*FS:Y4E4;/()QZ'MSS6S>:=!>VD5N[2((65XI(VP\;+T8'UK M+E\':3,S-)]I;S$VRYER93@CSL8+%)5@# 2RF5MS9^8X!_D*L8/I0P"LOQ#JS:+I#7J+$2)8X\ MRE@J[V"Y.T$\9SQ6K@^E5-0M[6XMD%X^R*.:.4-OVX=6!7GZX^M &5%XGMXK M2.6[99F9&E9[&)V2.(':7;< 0,^W:GCQ9IK_ "PI=SR"9;POI%B21F(D+'.>,8&TC! M#$$GI6K87AOK7SC;36_SLNR9<-P2,_0XK//A[3+2.-VEN([6VVR-$TY\IBA+ M!W![@DG/&3UJ]9:OIVINZV-_;73(,N(9 Q7ZXH N44N#Z&H5N;=YV@2>-ID^ M]&&&X=.H_$?G0!+1110 44N#Z&DP?2@# \0>()-'O[&U1K2,7,K;>>W8^E:+06YU:WN2Y%Y% M"ZQJ'Q\C%=QQWY"\UGOX:TY[B0-)83_=)Z'TYZ4UO$%U;ZE?6ESIX9H+H_P#A#K47X9)IX].6V\C[&CD*1YA?:?\ 8]%[=.E6VM-, MT2X_M*[OGC4;DB-U/\D(<[F"9Z9([D]/2C0#6C??&K[67< =K#!'L:=4%I>V MNH0">SN(KB(G >)@PS]14YX!)[=: "BHH+F"Z0O;S1RH#@M&P(SC/\B*EH * M*** "BBB@ J2WD2&9B[[?,PHR>,\U'01D8J9QYHV&G9FA-$D\+12+N1A@BJ$ M<$]M(1L+H",.O?\ #M3TNWBW&9E,0Q\V#E1WSZU;$\1 (D4@]#FN%J5-ZFJ: M97-VTL65CE/!XV$']:CALI&N$GE.T+R$ZDG'>K;7,*]9%'XUG7>M1Q@QVR-/ M-V5!FASE/0-$8?C1_-EM+:/YI'D 'UK? P /3BL?3].FFO#J6I+_I&?W4>< M^6/4^];%==&#C'4SD[L****U)"BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ K6L/^/1?J:R:UK#_CT7ZF@ O_ M /CU/U%9-:U__P >I^HK)H **** *>JWS:9I%Y?I;2736T32^1%]Y\ X-87ASPEI7A:347 MTV+8;^X,\F?X1V1?]D9./K0!NT444 %HXZ5VE% 'GRZ'X@G$CSV\_^ MMMYU1KC.V57;PV?F0_;4:]):5PK^8ZD-D* M24X!&?08KMJ* .<\*"[ECNI[FY:>&)_LEJ^\L)8XR?WGN23C/^S5S2;&ZM+' M4HR%BFFO+B6%N",.B@#@[C2->DL;=+>&^A5?^/I6N_->:79C>HWC M"[N?O#L=O%:>@Z/J=GXAGO;X!Q)!M,VY27?$620/=6KJ:*=P"BBBD!PNI:%K MSM+-!-=$RW=PS(DY8[21Y! +J% YXSQG)!JK/_:<^L2:?%2R#W9/DN)2R*^#\QVX7G/!QS6];6U[<^$9TNE)O[VWED>- MFSL>120@ST"Y"_A6W10]58.MS$O+*]_X1BTM($?S8T@6>**38SHNWS$5LC!( M!&^OK;3;1KJ M[D,<*E5)"ECDD 9))) I+.^@OHC+#Y@4-M_>Q-$<_1@#5+Q+IL^K:)):6V MWS3+%( TICR%=6(W $J<#J*YJ^T+4KJ_M[=M,1PUI<(LMQ?R7 @9BF'#LN=P MP2![<$4(#KIM8T^W.)KE8VW[ K @D[@G ]-S 9Z M>"[RZDC\W[+B\\&WTEU&8)D2V223R8TD""W#2 M[PRY0D''&%P1@A[XJYI?AK4;3P?> MZ5-<1?:YR"'5V*D!4&"< X.TCZ&@;W.L!!VX(.[ISU^E5;74K.]D:.VG61E7 M>0 >!N*Y_-6'X5R5WX2O[J\AGBBMK*$<);6\V%MCO#;P2AY(_N;>@]ZVM"T6 MYTR[EEG>)E>'RQL)SGSI']/1Q^.:!&[1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:UA_QZ+]3636M8 M?\>B_4T +>C=:2>PS616\RAE*GH1@UA,ICD:-OO(R7<1EM4@=IHQ_&@4Y'XBAC6YR]OX@U:X&J3 MEW6.T$VQ18$Q'9'N&9=W7)Z8]JFTWQ>9)[>+53!9O%9--?#!(1\IM9>^Q@^1 M_P#6-;&D_P!G:AIUW':VFRVDFDBFC8??; #'KW&*KS7.G:=KL,CZ7+%*$6Q6 M_" * 1O$8YW,..H! -/J3T)]*\2:?K-W+;6?V@R1*7?S(2@"[L \_P![J/4< MUK5C:!)#?2:CJ\#2;+V<*%EB\MT\H>7@]SD@GGGFMFD,**** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "M>R7;:1^XS60J&21(UZL8YFMR$D[J?NM]:S7D,#;+A#$WJWW3]#0!C67AZ:VCN;26_$VG MW$CR-"(C'("V.DBODT?_?0HL!1_L.S_P"FO_?PT?V'9_\ 37_OX:O?:(/^>T?_ 'T* M/M$'_/:/_OH46 H_V'9_]-?^_AH_L.S_ .FO_?PU>^T0?\]H_P#OH4?:(/\ MGM'_ -]"BP%'^P[/_IK_ -_#1_8=G_TU_P"_AJ]]H@_Y[1_]]"C[1!_SVC_[ MZ%%@*/\ 8=G_ --?^_AH_L.S_P"FO_?PUH)(DF=CJV.N#FG4 9O]AV?_ $U_ M[^&C^P[/_IK_ -_#5XW$(.#-&"/]H4?:(/\ GM'_ -]"BP%'^P[/_IK_ -_# M1_8=G_TU_P"_AJ]]H@_Y[1_]]"C[1!_SVC_[Z%%@*/\ 8=G_ --?^_AH_L.S M_P"FO_?PU>^T0?\ /:/_ +Z%'VB#_GM'_P!]"BP%'^P[/_IK_P!_#1_8=G_T MU_[^&KWVB#_GM'_WT*/M$'_/:/\ [Z%%@*/]AV?_ $U_[^&C^P[/_IK_ -_# M5[[1!_SVC_[Z%'VB#_GM'_WT*+ 4/[#M/^FO_?PT?V':?]-?^_AJ_P#:(/\ MGM'_ -]"C[1!_P ]H_\ OH46 H_V'9_]-?\ OX:/[#L_^FO_ '\-:"21R9V. MK8ZX.:1IHD.'D13Z%@* *']AV?\ TU_[^&C^P[/_ *:_]_#5[[1!_P ]H_\ MOH4?:(/^>T?_ 'T*+ 4?[#L_^FO_ '\-']AV?_37_OX:O?:(/^>T?_?0H^T0 M?\]H_P#OH46 H_V'9_\ 37_OX:/[#L_^FO\ W\-7OM$'_/:/_OH4?:(/^>T? M_?0HL!1_L.S_ .FO_?PT?V'9_P#37_OX:O?:(/\ GM'_ -]"C[1!_P ]H_\ MOH46 H_V'9_]-?\ OX:/[#L_^FO_ '\-7OM$'_/:/_OH4?:(/^>T?_?0HL!0 M_L.T_P"FO_?PT?V':?\ 37_OX:O_ &B#_GM'_P!]"C[1!_SVC_[Z%%@*/]AV M?_37_OX:/[#L_P#IK_W\-7OM$'_/:/\ [Z%'VB#_ )[1_P#?0HL!1_L.S_Z: M_P#?PT?V'9_]-?\ OX:O?:(/^>T?_?0H^T0?\]H_^^A18"C_ &'9_P#37_OX M:/[#L_\ IK_W\-7UECT?_?0H^T0?\]H M_P#OH46 H_V'9_\ 37_OX:/[#L_^FO\ W\-7OM$'_/:/_OH4?:(/^>T?_?0H ML!1_L.T_Z:_]_#1_8=G_ --?^_AJ]]H@_P">T?\ WT*/M$'_ #VC_P"^A18" MC_8=G_TU_P"_AH_L.S_Z:_\ ?PU>^T0?\]H_^^A1]H@_Y[1_]]"BP%'^P[/_ M *:_]_#1_8=G_P!-?^_AJ]]H@_Y[1_\ ?0H^T0?\]H_^^A18"C_8=G_TU_[^ M&C^P[/\ Z:_]_#5[[1!_SVC_ .^A1]H@_P">T?\ WT*+ 4/[#M/^FO\ W\-' M]AVG_37_ +^&K_VB#_GM'_WT*/M$'_/:/_OH46 H_P!AV?\ TU_[^&I$T>R0 MY\GR_Y]+?_ +]+_A1]GLO^?2W_ ._2_P"%5?/]Z//]Z.5A="V=QI-_ M+=QV]O"SVDYMY@8 -K@ XZ<\$@--XH_P!S MNQ(<'/F'=UY'&,&E9CNCT%6TEI5A5;%I67>J (69?4#J1[TK_P!EQ2I%)'9) M(X)5'" L!U(!ZUPNE^#[S3=;L-0;4;=C BBOX5RA\,D>!X?#Z3P+)$R/O M$7[J1EDWX9>ZG8T\'-%>0WBKMSSU)/2BS" MZ.N-_H?VNUMD6TEDNF=(O*17!*+N8$C@8%7?L]E_SZ6__?I?\*\_T#P;=:1K M<&I3WUL^P[GCAC8 GR?+)'89ZXQ[5VWG^]'*PNBU]GLO^?2W_P"_2_X4?9[+ M_GTM_P#OTO\ A57S_>CS_>CE8718LXX8]6F$,21@VZ$A% S\S^E:=9.G/OU2 M<_\ 3!/_ $)ZUJB>Y4=C$TV"T;3H"UM S%223&"2-I9&$()"J,GC'-4[";%A"/0'^9J+6(#JFB7^GK((VNK=X0[#(4LI&2/QJY) MZV)BUI*TCMV17$DB*@P1D9)Z=:7.E>>L&RQ\YEW+'A-Q7U ZD> M]J.I:OX?TO3VO9Q:/")5@'DHDA,C' 4 =ZY[PYX:GT;2]2L);U/*NXQ'&+< M',(V%**XM(E<3*P$! 8/=).H M/J JE?QXXH46/0] 271I 2AT]P%WG:8SA>F?IGO3I&TF%6:5;&-5."7" XS M@Y]JX&Y\!++]L$%Q:P"X-]]R#&!.5* XZA=O3WXJTGA2:XO%NM1GLIBUZ]W) M$L)*'=;B$*-WH1G)I6871VH&EM,(5CLC*5WB,*A8KZXZX]ZD^SV7_/I;_P#? MI?\ "O/O#W@F;1-5M+J6^BN5@"MNPXD#"(1;1SC9@9P?R[UV_G^]/E9-T36\ M<,>M+Y,4<>;8YV*!GYAZ4U8K>34K\S012-O3!= 3C8/6FV,F_6A[6Q_]"%1O M)LU2^'^TG_H HMK;R'?0FNVTRQLI[RXMH%@@C:61A"#A5&2<8YX%+$VES0PR MI#:A)HQ*FZ-02N,YP?8CZ5GZK"VIZ/?6".$:YMY(0Y&0I92,X_&N/UK1=>O- M,TO3Y3;-M/HJ9W-IRX7<OTY M'YT\'2C,L(2Q\UONQX3<>,\#KTYKB9_!%O+J;W0^R>6;QKA4:#)$?V;R0GX' M#>G'K6;I7@V^@U?$[6RP6LE@PNO*/FR^1$ ?+;/RJ2,'/;/7-/E8]+'?:?J6 M@ZG8?;K;[&8-NYBZHI09(RP/W>AZTXWVB+J$=D4M?-DMSX+G=TZD M5PW_ @,D<-CY-U9B2VB4.K0'R[EUG,H\P=UP2/7/-'_ @4WVC3[L:C")K+ MS)4B$9\CS&G$NW9WC R .H.#VH46%T=Y'=:/(#F.TB/F-$%E1$+,#C@'KSTJ M=5TUYGA6*S:9 "\85"R@],CJ*X"Y\#&Y_M!GNK9GN8YUB9HB3$TD_FAOPZ<5 MH:1X9?3/$]SJKW,61MK87J0#WIEOK/A^ZN4@CCA#OY^"\ 51Y+!9,DC P2/K7('P M+,C:VT>H1$ZMYWF>:A81[I=Z;/0#D,.A.#VI=0\#SWUMY7]HQIA[IP0AP3+, MDH!]ODP?7-*S&W$[P/I!$1 L2)?]7C9\_P#N^OX4N[21,\)6Q\U%W/'A-RKZ MD=0/>N0TCPJFGZK97\[6LC6T,ZB-48A))) ^Y"W3&,=NO&*SM;\#WFLZO::)YHDC5&,B)]X MKCKBI/M&DFQ^UB"W\LIN \M=W3=MQ_>QVZUR1\,7,ES!=,VE12B"[@D2WM2B M*)@,%.^01R3UR:@B\$&-I?\ 38S"=.,"0^6=J7+1"%Y_Q4 8^OK2LQW1V-EJ M&@Z@TR6OV)WA;9*FQ0R-@,01[ C-7%AL'4,MM;,I&01&I!'Y5YCJ'@^^M[?[ M/8^6T]S>(1"."%0D42A$4=%4# 'Y4^5B MNBP(H(]5LC##%&2L@)1 ,\#TK6K$ADWZM9C_ &9?Y+6W4S*B%8UC!:M:[GMH M68RR99HP2?G;VK9KGK6;;"RYZ2R_^AM1!73%+I'6LK7[-M9\/:AIB2K$]W T0D89"D M]R*YUO!'F/(PO(XI99;QI)H8\2%9X]@&?]DC-.S"Z.V$VC-$)0=/,9;:'!CP M3Z9]:4R:.LQ^M<;;>$W:?3)+X:4%LIGD,5I:[%;,/E MJW/5@1NR>G [51L? ]W8::]M'?6CONA7>\;'S8XV8_/G.'.[[RC(]>>'9BNC MT%6TEY4B5;%I77>J#869?4#N/>D\S1S"TW^@>4K;&D^3:K>A/0'VKSS2O -U MIL]HRZG"BQ0F*9XD;?(-C*,!LA2 PPPP1C'-26/@:>RL[9/M-E)/;7$,@22- MVAF6.-D_>*3][#$\=P.M%F%T=S97NBW^EIJ<,=L+-P2)9(U0 E3G/3D58'] ME%XD"61>8;HEPF7'JOJ/I7'KX8FC\(:7HRW5L\VGSI./,B/D2E79MK+UV_-^ M! JLG@^8:U9:A)._M7+^&O#TN@M<&6 M[CG$MM'!A4(QM:0Y^AW_ *5E6'@R^TZU,<-_: QW=O"Q^?!!Z M9.,=>:+,&T=X9='5E0_V>&8X53Y>2?;UIKSZ3'=+;M!;!BK,6\M=JX(!!/8\ MCBN'L/ <4,&H+?3VT\US:B&.5(<-"XDDDWKGIRZ_]\U:@\'*T$,=[=)<%K*Y MAO)-F#--,ZNT@],%>![#TI68[H[)WTF.58G%BDC-L5&V EO3'K[5'8SZ5J4, MDUM;0LD AY)_-5]X(YQM M4+M)P, UUVC6C:5:W$+RK(9;N>X!48P)'+ ?AG%/E8KHTM1@LQIET5M8 1"V M"(UXX/M6T.@KG+^;.G7(S_RR;^5=$.@J9*R'%ZBT445!84444 %%%% &!KK[ M-3M/^N,G_H251\_WK1UW3;R\NK::U6-@B.K!WV]2I'8^E9O]BZO_ ,\(/^__ M /\ 8UTP<>579SR4N9V0OG^]'G^])_8NK_\ /"#_ +__ /V-']BZO_SP@_[_ M /\ ]C57AW%:78@OY96TVZ6W=DG,+B-E'(;:<8]\UQ6EZ]X@0:7"'N9"([15 MCELS_I ;B=G,'_?\_\ MQ-'NWOM:QP&C:MXAMKVQL=DD=J9"0)H6;S@TTF_+;25VKMQR!TZ@TEUXA M\46VAV5QYEP]]/&\YC%B @VN (S@$YVY/;///&*] _L;6/\ GC!_W_/_ ,31 M_8^L?\\8/^_Y_P#B:2Y>XVY=CD)-:\2QWD\D*&=#->10VS6^T (FZ)MW7D\< M\&L^?Q)XB6.V^R7%Q-&X):XFTXQYFPF(MH4G;DMS@=,9XKO_ .QM7_YX0?\ M?\__ !-']CZQ_P \8/\ O^?_ (FCW>X>]V%$YVC. <<@>M'G^])_8NK_ //" M#_O_ /\ V-']BZO_ ,\(/^__ /\ 8T[P[DVEV%\_WH\_WI/[%U?_ )X0?]__ M /[&C^Q=7_YX0?\ ?_\ ^QHO#N.TNQH:(^_4;D_],4_]">MZL30].O+.XN); MI(U#HJJ$?=T+$]AZUMUSU+F?YFIO/\ >F+H6K1@J(8& M 8X/G$9&2?[M._L75_\ GA!_W_\ _L:Z;P[F%I=A?/\ >L?4KS4CKVE6MG,8 M;219GN7$(?.W:57)X7.2*U_[%U?_ )X0?]__ /[&C^QM7_YX0?\ ?_\ ^QI7 MAW'[W8\_MO$WB9Q']L+6\;W"),'_ '_/_P 30N7N%Y=CB_[9\17$2QV]Q*(B M]UY=VUD \R)&&C)0C"Y;RW.EV<]PGESRP(\B8QM8J"1CMS5C^Q MM8_YXP?]_P __$T?V-J__/"#_O\ _P#V--./<3YNPOG^]'G^])_8NK_\\(/^ M_P#_ /8T?V+J_P#SP@_[_P#_ -C1>'<+2[%S1GWZRWM;'_T(5#?2;-9O1[I_ MZ *LZ+IE]::A)/=)$J&+8H23<2?$KE(!(7,L.1&K,=OF+NX7YB,9SCM7--KEWI4<%GI5R(5D M@N9L6^G2G?*NS8NV7+ '.">G/:O1AHVKCI!!_P!__P#[&F'0-3:X2X:UMC,B ME%D,WS!3C(!V]#@?E5>[>]Q)R['%7-YK!U".63[1:)_:<8G6"(L&5K89!ZY7 M?\N>@_"J-MJ_B?2]*T^U5IW@:UMWEG>VR]MG>&7H=QX3J"1FO1O[&U?_ )XP M?]_S_P#$T?V/K'_/&#_O^?\ XFCW>X7EV.&-WK#7+74]O(\T@TTNJ1/LSN?> M54XP<8SZ=ZAM-9US5)X5NENF@2_LYHV:W,;*"7\Q6P ,# R.<>IKO_[&U?\ MYXP?]_S_ /$T?V/K'_/&#_O^?_B:/=ON%Y=C(\2:G>V=I;-:/)%&]PJ7-Q%# MYS0QX/S!,'/(4=#C-8L>N^()-=MKX>]V.-\&/J-O8WS317!F%G; M>4D^X;G$1R.??&:Q5USQ&EY]M62[;SK:W2ZF>R*BW;]X754VD'#;5S@\'\:] M,_L;5S_RP@_[_P#_ -C1_8^L?\\8/^_Y_P#B:'R]PO+L<:FN>(VUNRMIMWE7 M%N@=8+<@1N8R2Y++TW8Z-QT(-9^FZOXF30I'2YNG:RTV*0++9Y>68LP<$D9. MT#H.OXUZ%_8VKXQY,'_?\_\ Q-']C:Q_SQ@_[_G_ .)H]WN%Y=CC+KQ)J[EY M(WN;:P-Y,BW*6!DD""-3&-A&2&8MSCMCBJL^H:[#JMX\*W-Y.MYYL$,T!5%7 M[*2N". "XP1G@^YKO?['UC.?)@_[_G_XFC^QM7QCR8/^_P"?_B:/=[A>78XN MTUKQ!="***YG:&2[MXOMDEAY;J&1C*-A&,*P7#$=\#3+>_TH22H)/LLL,MNR,TCKB(C> M RM) M9(&WQ,\N2C>H^7@U-_8VL?\ /&#_ +_G_P")I>[W&FUT.&MO$NMWFKRV^]W MN/)DMEM<*D1MP[-YG9@Y QGOC%16&J>(M.T2"W+SN@M+-VF:TW/;*S%9<#^, MJ #@Y/.:[J/0-2A:5HK2U0ROOD*S8WMC&3\O)P!^52?V-K'_ #Q@_P"_Y_\ MB:/=[A[W8X(:]XLE61D>1(XO*\IC8\W"-<%-[ _=/EX; QCKP*6Z\2>)+=+> M-1(5O+B&#,MUY=ZRVAM@%5HV CV/\ Q_*U6$ MUGQ)<6< BN67<+IA<"SRS!$!C!#* "6R.!R/>NL@\*7-M=274&F6,5Q+G?*C MX9L\G)VU:_L;6/\ GC!_W_/_ ,32]VWQ!>5]CA;/Q'XIN9KGS8Q;N+=W2%K5 MV"?NU*.,+R2Q.5S[8XIBZYK]S86EP(Y?M4;72B>2V++Q&"K *H)&21RH/'0X MY[W^QM8_YXP?]_S_ /$T?V/K'_/&#_O^?_B:?N]P3EV,?POJM[?Z.9;]91.L MKIND4+O4=", 9'O@=.E;/G^](=&U<]8(/^__ /\ 8T?V+J__ #P@_P"__P#] MC3O#N*TNQ%>39LIQG_EFW\J[,=*XZ70M7EB>/R;<;AC/GGC_ ,=KL:RJM:6- M*=];A1116)J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 80 4444 %%%% !1110 4444 %%%% '__9 end GRAPHIC 19 form10-k_012.jpg begin 644 form10-k_012.jpg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end GRAPHIC 20 image_001.jpg begin 644 image_001.jpg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�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image_002.jpg begin 644 image_002.jpg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end GRAPHIC 22 image_003.jpg begin 644 image_003.jpg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end GRAPHIC 23 image_004.jpg begin 644 image_004.jpg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end GRAPHIC 24 image_005.jpg begin 644 image_005.jpg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end EX-101.SCH 25 prvb-20201231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statement of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - LIQUIDITY link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - CAPITALIZATION link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - LICENSE AND OTHER AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - FAIR VALUE OF ASSETS AND LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - STOCK OPTIONS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - WARRANTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - FIXED ASSETS link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - RETIREMENT SAVINGS PLAN link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - FAIR VALUE OF ASSETS AND LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - STOCK OPTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - FIXED ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - LIQUIDITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - CAPITALIZATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - SCHEDULE OF AVAILABLE FOR SALE SECURITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - LICENSE AND OTHER AGREEMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - SCHEDULE OF COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - SUMMARY OF STOCK OPTION ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - SCHEDULE OF AGGREGATED INTRINSIC VALUE OF STOCK OPTION EXERCISED (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION VALUATION OF ASSUMPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - STOCK OPTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANTS ISSUED (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - WARRANTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - SCHEDULE OF FIXED ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - FIXED ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - SCHEDULE OF LEASE COSTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - LEASES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - SCHEDULE OF EFFECTIVE TAX RATE (Details) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - SCHEDULE OF COMPONENTS OF INCOME TAX BENEFITS (Details) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - RETIREMENT SAVINGS PLAN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 26 prvb-20201231_cal.xml XBRL CALCULATION FILE EX-101.DEF 27 prvb-20201231_def.xml XBRL DEFINITION FILE EX-101.LAB 28 prvb-20201231_lab.xml XBRL LABEL FILE Equity Components [Axis] Convertible Redeemable Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Class of Stock [Axis] Series A Convertible Redeemable Preferred Stock [Member] Sale of Stock [Axis] IPO [Member] Legal Entity [Axis] MDB Capital Group, LLC [Member] Option Indexed to Issuer's Equity, Type [Axis] Options Held [Member] Amgen Inc [Member] Private Placement [Member] Award Type [Axis] At The Market [Member] Statistical Measurement [Axis] Maximum [Member] Underwritten Public Offering [Member] Underwriter's Option [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Minimum [Member] Cash and Cash Equivalents [Axis] Corporate Debt Securities [Member] US Treasury Securities [Member] Macro Genics Inc [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Asset Purchase Agreement [Member] Biologics License Application [Member] License Agreement [Member] First Indication [Member] Second Indication [Member] Macro Genics Asset Purchase Agreement and Macro Genics License Agreement [Member] License and Collaboration Agreement [Member] Vactech [Member] Income Statement Location [Axis] Research and Development Expense [Member] First Eighteen Months [Member] Dosing Of First Patient In Phase 1 PROVENT Study [Member] Intravacc Development Services Agreement [Member] Euro [Member] License Developmentand Commercialization Agreement [Member] Janssen Pharmaceutica NV [Member] Antidilutive Securities [Axis] Stock Options [Member] Warrants [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Cash and Cash Equivalents [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Investments In Corporate Debt Securities [Member] Investments In US Treasury Securities [Member] Plan Name [Axis] Two Thousand Seventeen Plan [Member] Two Thousand and Twenty Inducement Plan [Member] General and Administrative Expense [Member] Share-based Payment Arrangement, Option [Member] Stock Option One [Member] Stock Option Two [Member] Title of Individual [Axis] Placement Agent [Member] Warrant [Member] Series A Offering [Member] MacroGenics License Agreement & MacroGenics Asset Purchase Agreement [Member] Measurement Input Type [Axis] Measurement Input, Option Volatility [Member] Measurement Input, Expected Dividend Rate [Member] Measurement Input, Expected Term [Member] Measurement Input, Risk Free Interest Rate [Member] Cashless Basis [Member] Long-Lived Tangible Asset [Axis] Leasehold Improvements [Member] Furniture and Fixtures [Member] Office Equipment [Member] Clinical Equipment [Member] Construction in Progress [Member] Balance Sheet Location [Axis] Accrued Expenses [Member] Income Tax Authority [Axis] State and Local Jurisdiction [Member] NEW JERSEY New Jersey's Technology Business Tax Certificate Transfer Program [Member] Domestic Tax Authority [Member] Geographical [Axis] Tolerance Therapeutics, Inc. [Member] Related Party [Axis] Directors [Member] Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd [Member] Research Development and Manufacturing Funding [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Marketable securities Prepaid expenses and other current assets Total current assets Fixed assets, net Operating lease right-of-use assets Other assets Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable Accrued expenses and other current liabilities Total current liabilities Operating lease liabilities, long-term Total liabilities Commitments and Contingencies (Note 6) Stockholders’ equity: Preferred stock, $0.0001 par value; 25,000,000 shares authorized; no shares issued or outstanding at December 31, 2020 and December 31, 2019 Common stock, $0.0001 par value; 100,000,000 shares authorized; 56,517,891 shares issued and outstanding at December 31, 2020; 47,658,361 shares issued and outstanding at December 31, 2019 Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Income Statement [Abstract] Operating expenses: Research and development General and administrative Total operating expenses Loss from operations Interest income Change in fair value of warrant liability Loss before income tax benefit Income tax benefit Net loss Accretion on Series A Convertible Redeemable Preferred Stock Net loss attributable to common stockholders Net loss per common share, basic and diluted Weighted average common shares outstanding, basic and diluted Net loss Other comprehensive income (loss): Unrealized gain (loss) on marketable securities Total comprehensive loss Statement [Table] Statement [Line Items] Beginning balance, value Balance, shares Issuance of common stock upon conversion of Series A Convertible Redeemable Preferred Stock Issuance of common stock upon conversion of Series A Convertible Redeemable Preferred Stock, shares Accretion of Series A Convertible Redeemable Preferred Stock to redemption value Reclassification of Series A warrants liability Issuance of common stock in connection with initial public offering, net of issuance costs Issuance of common stock in connection with initial public offering, net of issuance costs, shares Issuance of common stock in connection with public follow on offering, net of issuance costs Issuance of common stock in connection with public follow on offering, net of issuance costs, shares Issuance of common stock in connection with underwritten public offering, net of issuance costs Issuance of common stock in connection with underwritten public offering, net of issuance costs, shares Issuance of common stock in connection with private placement with Amgen Issuance of common stock in connection with private placement with Amgen, shares Issuance of common stock in connection with stock option exercises Issuance of common stock in connection with stock option exercises, shares Issuance of common stock in connection with at-the-market stock sales, net of issuance costs Issuance of common stock in connection with at-the-market stock sales, net of issuance costs, shares Issuance of common stock in connection with warrant exercises Issuance of common stock in connection with warrant exercises, shares Fair value of warrants issued in connection with initial public offering of common stock Fair value of warrants issued in connection with the acquisition of product rights Unrealized gain (loss) on marketable securities, net of tax Stock-based compensation Ending balance, value Shares, Outstanding, Ending Balance Statement of Cash Flows [Abstract] Operating activities Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation expense Stock-based consideration in connection with acquisition of product rights (Note 6) Change in fair value of warrant liability Amortization of premium and discounts on marketable securities Non-cash operating lease expense Depreciation Changes in operating assets and liabilities: Prepaid expenses and other current assets Accounts payable Accrued interest receivable Accrued expenses Other assets Net cash used in operating activities Investing activities Purchase of marketable securities Maturities of marketable securities Purchase of fixed assets Net cash provided by (used in) investing activities Financing activities Proceeds from underwritten public offering, net Proceeds from private placement with Amgen Proceeds from initial public offering, net Proceeds from at-the-market stock sales, net Proceeds from stock option exercises Net cash provided by financing activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure of cash flow information: Right-of-use assets obtained in exchange for new operating lease liabilities Supplemental disclosure of non-cash financing transactions: Conversion of Series A Preferred Stock to common stock upon completion of IPO Reclassification of Series A Preferred Stock warrant liability to stockholders’ equity Accretion of Series A Convertible Redeemable Preferred Stock Accounting Policies [Abstract] DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Liquidity LIQUIDITY SIGNIFICANT ACCOUNTING POLICIES Capitalization CAPITALIZATION Cash and Cash Equivalents [Abstract] CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES License And Other Agreements LICENSE AND OTHER AGREEMENTS Earnings Per Share [Abstract] NET LOSS PER SHARE OF COMMON STOCK Payables and Accruals [Abstract] ACCRUED EXPENSES Fair Value Disclosures [Abstract] FAIR VALUE OF ASSETS AND LIABILITIES Share-based Payment Arrangement [Abstract] STOCK OPTIONS Warrants and Rights Note Disclosure [Abstract] WARRANTS Property, Plant and Equipment [Abstract] FIXED ASSETS Lessee Disclosure [Abstract] LEASES Income Tax Disclosure [Abstract] INCOME TAXES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Payment for Pension and Other Postretirement Benefits [Abstract] RETIREMENT SAVINGS PLAN Subsequent Events [Abstract] SUBSEQUENT EVENTS Use of estimates Segment and geographic information Cash, cash equivalents and concentration of credit risk Marketable securities Financial instruments Net loss per common share Fixed assets, net Leases Foreign currency translation Research and development expenses Accrued research and development expenses Stock-based compensation expense Warrant liability Income taxes Recent accounting pronouncements SCHEDULE OF AVAILABLE FOR SALE SECURITIES SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) SCHEDULE OF COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE SCHEDULE OF ACCRUED EXPENSES SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE SUMMARY OF STOCK OPTION ACTIVITY SCHEDULE OF AGGREGATED INTRINSIC VALUE OF STOCK OPTION EXERCISED SCHEDULE OF SHARE-BASED COMPENSATION VALUATION OF ASSUMPTIONS Entity Listings [Line Items] SCHEDULE OF FAIR VALUE OF WARRANTS ISSUED SCHEDULE OF FIXED ASSETS SCHEDULE OF LEASE COSTS SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION SCHEDULE OF MATURITIES OF LEASE LIABILITIES SCHEDULE OF EFFECTIVE TAX RATE SCHEDULE OF COMPONENTS OF INCOME TAX BENEFITS SCHEDULE OF DEFERRED TAX ASSETS Schedule of Capitalization, Equity [Line Items] Retained Earnings (Accumulated Deficit) Stock Issued During Period, Shares, New Issues Shares Issued, Price Per Share Proceeds from Issuance of Redeemable Convertible Preferred Stock Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Class of Warrant or Right, Exercise Price of Warrants or Rights Sale of Stock, Number of Shares Issued in Transaction Sale of Stock, Price Per Share Proceeds from Issuance Initial Public Offering Underwriting discounts and commissions Other offering expenses Conversion of Stock, Shares Converted Aggregate net proceeds from underwritten public offering and Amgen private placement Sale of Stock, Consideration Received on Transaction Sales Commissions and Fees Proceeds from Issuance or Sale of Equity Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Number of operating segments Fixed assets estimated useful life years Warrants to purchase Schedule of Cash and Cash Equivalents [Table] Cash and Cash Equivalents [Line Items] Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Beginning balance Current period changes in fair value before reclassifications, net of tax Amounts reclassified from accumulated other comprehensive income (loss), net of tax Other comprehensive income (loss) Ending balance Cash and Cash Equivalents, at Carrying Value Available-for-sale Securities and Held-to-maturity Securities Amount payable by the entity on achievement of various milestones Fair Value per share of each warrant Warrants issued during period, fair value Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of warrants issuance shares Potential proceeds from investment by collaborator Amount payable by the entity on achievement of various milestones Proceeds from Issuance of Private Placement Payments made for develpoment and manufacturing services Payments made on tiered single-digit royalties Net loss, basic Net loss attributable to common stockholders Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share Accrued research and development costs Accrued compensation Accrued professional fees Accrued pre-commercial costs Other accrued liabilities Total accrued expenses Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value of assets Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Total stock-based compensation expense Stock Options Underlying Shares, Outstanding beginning Weighted-Average Exercise Price, Outstanding beginning balance Stock Options Underlying Shares, Granted Weighted-Average Exercise Price, Granted Stock Options Underlying Shares, Exercised Weighted-Average Exercise Price, Exercised Stock Options Underlying Shares, Forfeited or expired Weighted-Average Exercise Price, Forfeited or expired Stock Options Underlying Shares, Outstanding ending balance Weighted-Average Exercise Price, Outstanding ending balance Weighted-Average Remaining Contractual Term, Outstanding Ending Intrinsic Value, Outstanding Beginning Stock Options Underlying Shares, Exercisable Weighted-Average Exercise Price, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Intrinsic Value, Exercisable Cash proceeds from options exercised Aggregate intrinsic value of options exercised Exercise price Expected volatility Expected dividends Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Risk-free interest rate Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of options outstanding Option exercisable expiration period Number of shares, description Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Number of options authorized Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Equity value upon issuance Exercise price Fair value assumptions measurement input percentage Fair value assumptions measurement input term Warrants term Warrants outstanding, shares Fair value per share of each warrant Fair value of warrant issued Fair value of warrants for MDB Number of warrants exercised Fixed assets, net Less accumulated depreciation Depreciation expense Operating lease costs Variable lease costs Total lease costs Lessee, Lease, Description [Line Items] Lease right-of-use assets Non-current Lease liabilities Current Lease liabilities Non-Current Weighted average remaining lease term Operating leases Weighted average discount rate Operating leases 2021 2022 2023 2024 2025 Thereafter Total lease payments Less: present value discount Present value of lease liabilities Description on lease Tax Provision at statutory tax rate Change in valuation allowance Orphan drug credits State income taxes, net of federal benefit Sale of NJ net operating losses Permanent items Other Effective Tax Rate Current: Federal Current: State Deferred: Federal Deferred: State Income tax benefit NOL Carryforward Federal research and development credits Equity compensation Product License Other Total deferred tax assets Less valuation allowance Net deferred tax assets Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Income tax benefit from state income taxes Net operating loss Proceeds from NJ NOL sale Deferred Tax Assets, Operating Loss Carryforwards, Domestic [custom:OperatingLossCarryforwardsExpireAmount-0] [custom:OperatingLossCarryforwardsExpireDescription] Deferred Tax Assets, Operating Loss Carryforwards, State and Local Tax Credit Carryforward, Amount Deferred tax assets, gross Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Related party transaction, amounts of transaction Underwriter's fee Number of warrants to purchase common stock Warrant term Warrant exercise price Ownership percentage Employee contribution description Retirement plan contributions Subsequent Event [Table] Subsequent Event [Line Items] Upfront payment receivable Future research and development funding receivable Future development and regulatory milestones receivable Future commercial milestones receivable Convertible Redeemable Preferred Stock [Member]. Accretion of series A convertible redeemable preferred stock to redemption value. Issuance of common stock in connection with initial public offering, net of issuance costs. Issuance of common stock in connection with private placement with Amgen. Value of stock issued as a result of the exercise of stock warrants. Redeemable Stock [Member]. Issuance of common stock in connection with initial public offering, net of issuance costs, shares. Issuance of common stock in connection with private placement with Amgen, shares. Number of share warrants (or share units) exercised during the current period. Issuance of common stock in connection with public follow on offering, net of issuance costs. Reclassification of Series A Preferred Stock warrant liability to stockholders&#8217; equity. MDB Capital Group, LLC [Member]. Aggregate net proceeds from underwritten public offering and Amgen private placement. Other offering expenses. Underwritten Public Offering [Member] Underwriter's Option [Member] Proceeds From Issuance Or Sale Of Equity Offering. Macro Genics Inc [Member]. Amount payable by the entity on achievement of various milestones. Biologics License Application [Member]. License Agreement [Member] First Indication [Member] Second Indication [Member] Fair Value per share of each warrant. Macro Genics Asset Purchase Agreement and Macro Genics License Agreement [Member] Warrants issued during period, fair value. Number of elected warrants exercise on a cashless basis. Potential proceeds from investment by collaborator. License and Collaboration Agreement [Member]. Amount payable by the entity on achievement of various milestones. Vactech [Member]. Payments made for develpoment and manufacturing services. First Eighteen Months [Member]. Payments made on tiered single-digit royalties. Intravacc Development Services Agreement [Member]. Euro [Member]. License Developmentand Commercialization Agreement [Member]. Janssen Pharmaceutica NV [Member]. Accrued research and development costs, current. Accrued pre-commercial costs. Investments In US Treasury Securities [Member]. Two Thousand Seventeen Plan [Member]. Number of shares, description. Two Thousand and Twenty Inducement Plan [Member]. Stock Option One [Member]. Stock Option Two [Member]. Number of share options (or share units) exercised during the current period. Placement Agent [Member]. Warrant term, description. MacroGenics License Agreement & MacroGenics Asset Purchase Agreement [Member]. Fair value of warrants for MDB. Cashless Basis [Member]. Warrants [Text Block] Schedule of fair value of warrants issued [Table Text Block] Equity value upon issuance. Clinical Equipment [Member]. Schedule of Supplemental Balance Sheet Information [Table Text Block] Proceeds from New Jersey NOL sale. New Jersey's Technology Business Tax Certificate Transfer Program [Member]. Operating loss carryforwards expire amount. Operating loss carryforwards expire description. Accrued Expenses [Member]. Deferred tax assets, Product License. Tolerance Therapeutics, Inc [Member]. underwriters' fees and expenses. Directors [Member] Retirement savings plan [Text Block] Underwriting discounts and commissions. Upfront payment. Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd [Member]. Research Development and Manufacturing Funding [Member]. Development and regulatory milestones. Commercial milestones. Proceeds from underwritten public offering, net. Warrants issued in connection with acquisition of product rights. Amount payable by the entity on achievement of various milestones. Payments made on tiered single-digit royalties. Number of warrants exercised. Effective income tax rate reconciliation permanent differences amount. Future development and regulatory milestones receivable. Upfront payment receivable. Future research and development funding receivable. Expected dividends Future commercial milestones receivable. Proceeds from underwritten public offering, net. Dosing Of First Patient In Phase 1 PROVENT Study [Member] Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Accretion (Amortization) of Discounts and Premiums, Investments Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Interest Receivable, Net Increase (Decrease) in Other Noncurrent Assets Net Cash Provided by (Used in) Operating Activities Payments to Acquire Marketable Securities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Marketable Securities, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Share-based Payment Arrangement [Policy Text Block] Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Amount payable by the entity on achievement of various milestones [Default Label] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Lease, Cost Lessee, Operating Lease, Liability, to be Paid Deferred Tax Assets, Other Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance EX-101.PRE 29 prvb-20201231_pre.xml XBRL PRESENTATION FILE XML 30 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001695357 2020-01-01 2020-12-31 0001695357 2020-06-30 0001695357 2021-02-22 0001695357 2020-12-31 0001695357 2019-12-31 0001695357 2019-01-01 2019-12-31 0001695357 2018-01-01 2018-12-31 0001695357 PRVB:ConvertibleRedeemablePreferredStockMember 2017-12-31 0001695357 us-gaap:CommonStockMember 2017-12-31 0001695357 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001695357 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001695357 us-gaap:RetainedEarningsMember 2017-12-31 0001695357 2017-12-31 0001695357 PRVB:ConvertibleRedeemablePreferredStockMember 2018-01-01 2018-12-31 0001695357 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001695357 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001695357 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001695357 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001695357 PRVB:ConvertibleRedeemablePreferredStockMember 2018-12-31 0001695357 us-gaap:CommonStockMember 2018-12-31 0001695357 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001695357 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001695357 us-gaap:RetainedEarningsMember 2018-12-31 0001695357 2018-12-31 0001695357 PRVB:ConvertibleRedeemablePreferredStockMember 2019-01-01 2019-12-31 0001695357 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001695357 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001695357 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001695357 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001695357 PRVB:ConvertibleRedeemablePreferredStockMember 2019-12-31 0001695357 us-gaap:CommonStockMember 2019-12-31 0001695357 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001695357 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001695357 us-gaap:RetainedEarningsMember 2019-12-31 0001695357 PRVB:ConvertibleRedeemablePreferredStockMember 2020-01-01 2020-12-31 0001695357 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001695357 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001695357 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001695357 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001695357 PRVB:ConvertibleRedeemablePreferredStockMember 2020-12-31 0001695357 us-gaap:CommonStockMember 2020-12-31 0001695357 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001695357 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001695357 us-gaap:RetainedEarningsMember 2020-12-31 0001695357 PRVB:SeriesAConvertibleRedeemablePreferredStockMember 2017-04-01 2017-04-30 0001695357 PRVB:SeriesAConvertibleRedeemablePreferredStockMember 2017-04-30 0001695357 us-gaap:IPOMember 2018-07-01 2018-07-31 0001695357 us-gaap:IPOMember 2018-07-31 0001695357 us-gaap:IPOMember PRVB:MDBCapitalGroupLLCMember 2018-07-31 0001695357 PRVB:SeriesAConvertibleRedeemablePreferredStockMember us-gaap:IPOMember 2018-07-31 0001695357 2019-09-01 2019-09-30 0001695357 2019-09-30 0001695357 us-gaap:OptionMember 2019-09-01 2019-09-30 0001695357 us-gaap:OptionMember 2019-09-30 0001695357 us-gaap:PrivatePlacementMember PRVB:AmgenIncMember 2019-09-01 2019-09-30 0001695357 us-gaap:PrivatePlacementMember PRVB:AmgenIncMember 2019-09-30 0001695357 srt:MaximumMember PRVB:AtTheMarketMember 2019-08-01 2019-08-31 0001695357 PRVB:AtTheMarketMember 2020-04-01 2020-06-30 0001695357 PRVB:UnderwrittenPublicOfferingMember 2020-06-29 2020-06-30 0001695357 PRVB:UnderwrittenPublicOfferingMember 2020-06-30 0001695357 PRVB:UnderwritersOptionMember 2020-06-29 2020-06-30 0001695357 PRVB:UnderwritersOptionMember 2020-06-30 0001695357 2020-06-01 2020-06-30 0001695357 us-gaap:SubsequentEventMember PRVB:UnderwritersOptionMember 2021-01-01 2021-01-31 0001695357 us-gaap:SubsequentEventMember PRVB:UnderwritersOptionMember 2021-01-31 0001695357 us-gaap:SubsequentEventMember PRVB:UnderwritersOptionMember 2021-02-01 2021-02-28 0001695357 us-gaap:SubsequentEventMember PRVB:UnderwritersOptionMember 2021-02-28 0001695357 us-gaap:SubsequentEventMember 2021-02-01 2021-02-28 0001695357 srt:MinimumMember 2020-01-01 2020-12-31 0001695357 srt:MaximumMember 2020-01-01 2020-12-31 0001695357 us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001695357 us-gaap:USTreasurySecuritiesMember 2019-12-31 0001695357 PRVB:AssetPurchaseAgreementMember PRVB:MacroGenicsIncMember 2018-05-31 0001695357 PRVB:AssetPurchaseAgreementMember PRVB:MacroGenicsIncMember 2018-05-01 2018-05-31 0001695357 PRVB:BiologicsLicenseApplicationMember PRVB:AssetPurchaseAgreementMember PRVB:MacroGenicsIncMember 2018-05-01 2018-05-31 0001695357 PRVB:LicenseAgreementMember PRVB:MacroGenicsIncMember 2018-05-01 2018-05-31 0001695357 srt:MaximumMember PRVB:AssetPurchaseAgreementMember PRVB:MacroGenicsIncMember 2018-05-01 2018-05-31 0001695357 PRVB:LicenseAgreementMember PRVB:MacroGenicsIncMember 2018-05-31 0001695357 PRVB:FirstIndicationMember PRVB:LicenseAgreementMember PRVB:MacroGenicsIncMember 2018-05-01 2018-05-31 0001695357 PRVB:SecondIndicationMember PRVB:LicenseAgreementMember PRVB:MacroGenicsIncMember 2018-05-01 2018-05-31 0001695357 PRVB:MacroGenicsIncMember 2018-05-01 2018-05-31 0001695357 PRVB:MacroGenicsAssetPurchaseAgreementAndMacroGenicsLicenseAgreementMember 2018-05-31 0001695357 PRVB:MacroGenicsAssetPurchaseAgreementAndMacroGenicsLicenseAgreementMember 2018-05-01 2018-05-31 0001695357 PRVB:MacroGenicsIncMember 2019-07-31 0001695357 PRVB:MacroGenicsIncMember 2019-07-01 2019-07-31 0001695357 PRVB:LicenseAndCollaborationAgreementMember PRVB:AmgenIncMember 2018-11-30 0001695357 PRVB:LicenseAndCollaborationAgreementMember PRVB:AmgenIncMember 2018-11-01 2018-11-30 0001695357 PRVB:AmgenIncMember 2018-11-01 2018-11-30 0001695357 PRVB:LicenseAgreementMember PRVB:VactechMember 2017-04-30 0001695357 us-gaap:ResearchAndDevelopmentExpenseMember PRVB:LicenseAgreementMember PRVB:VactechMember 2017-04-01 2017-04-30 0001695357 PRVB:FirstEighteenMonthsMember PRVB:LicenseAgreementMember PRVB:VactechMember 2017-04-01 2017-04-30 0001695357 PRVB:LicenseAgreementMember PRVB:VactechMember 2017-04-01 2017-04-30 0001695357 PRVB:DosingOfFirstPatientInPhaseOnePROVENTStudyMember us-gaap:SubsequentEventMember PRVB:LicenseAgreementMember PRVB:VactechMember 2021-01-01 2021-01-31 0001695357 PRVB:EuroMember PRVB:IntravaccDevelopmentServicesAgreementMember 2020-01-01 2020-12-31 0001695357 PRVB:IntravaccDevelopmentServicesAgreementMember 2020-01-01 2020-12-31 0001695357 PRVB:FirstIndicationMember PRVB:LicenseDevelopmentandCommercializationAgreementMember PRVB:JanssenPharmaceuticaNVMember 2017-04-01 2017-04-30 0001695357 PRVB:SecondIndicationMember PRVB:LicenseDevelopmentandCommercializationAgreementMember PRVB:JanssenPharmaceuticaNVMember 2017-04-01 2017-04-30 0001695357 PRVB:LicenseDevelopmentandCommercializationAgreementMember PRVB:JanssenPharmaceuticaNVMember 2017-04-01 2017-04-30 0001695357 PRVB:StockOptionsMember 2020-01-01 2020-12-31 0001695357 PRVB:StockOptionsMember 2019-01-01 2019-12-31 0001695357 PRVB:StockOptionsMember 2018-01-01 2018-12-31 0001695357 PRVB:WarrantsMember 2020-01-01 2020-12-31 0001695357 PRVB:WarrantsMember 2019-01-01 2019-12-31 0001695357 PRVB:WarrantsMember 2018-01-01 2018-12-31 0001695357 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001695357 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001695357 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001695357 us-gaap:CashAndCashEquivalentsMember 2020-12-31 0001695357 PRVB:InvestmentsInCorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001695357 PRVB:InvestmentsInCorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001695357 PRVB:InvestmentsInCorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001695357 PRVB:InvestmentsInCorporateDebtSecuritiesMember 2020-12-31 0001695357 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001695357 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001695357 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001695357 us-gaap:CashAndCashEquivalentsMember 2019-12-31 0001695357 PRVB:InvestmentsInUSTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001695357 PRVB:InvestmentsInUSTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001695357 PRVB:InvestmentsInUSTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001695357 PRVB:InvestmentsInUSTreasurySecuritiesMember 2019-12-31 0001695357 PRVB:TwoThousandSeventeenPlanMember 2020-12-31 0001695357 PRVB:TwoThousandSeventeenPlanMember 2020-01-01 2020-12-31 0001695357 srt:MaximumMember PRVB:TwoThousandSeventeenPlanMember us-gaap:SubsequentEventMember 2021-01-02 0001695357 PRVB:TwoThousandAndTwentyInducementPlanMember 2020-10-31 0001695357 PRVB:TwoThousandAndTwentyInducementPlanMember 2020-10-01 2020-10-31 0001695357 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001695357 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001695357 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0001695357 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001695357 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001695357 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0001695357 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001695357 PRVB:StockOptionOneMember 2020-12-31 0001695357 PRVB:StockOptionTwoMember 2020-12-31 0001695357 PRVB:StockOptionTwoMember 2020-01-01 2020-12-31 0001695357 PRVB:PlacementAgentMember PRVB:SeriesAConvertibleRedeemablePreferredStockMember 2017-04-30 0001695357 us-gaap:WarrantMember us-gaap:IPOMember 2018-07-31 0001695357 PRVB:SeriesAOfferingMember 2020-12-31 0001695357 PRVB:SeriesAOfferingMember 2020-01-01 2020-12-31 0001695357 PRVB:MacroGenicsLicenseAgreementAndMacroGenicsAssetPurchaseAgreementMember 2018-05-31 0001695357 us-gaap:ResearchAndDevelopmentExpenseMember PRVB:MacroGenicsLicenseAgreementAndMacroGenicsAssetPurchaseAgreementMember PRVB:MacroGenicsIncMember 2018-12-31 0001695357 us-gaap:ResearchAndDevelopmentExpenseMember PRVB:MacroGenicsLicenseAgreementAndMacroGenicsAssetPurchaseAgreementMember PRVB:MacroGenicsIncMember 2018-01-01 2018-12-31 0001695357 PRVB:MacroGenicsIncMember 2020-01-01 2020-12-31 0001695357 PRVB:MacroGenicsIncMember 2018-05-07 0001695357 us-gaap:MeasurementInputOptionVolatilityMember PRVB:MacroGenicsIncMember 2018-05-07 0001695357 us-gaap:MeasurementInputExpectedDividendRateMember PRVB:MacroGenicsIncMember 2018-05-07 0001695357 us-gaap:MeasurementInputExpectedTermMember PRVB:MacroGenicsIncMember 2018-05-07 0001695357 us-gaap:MeasurementInputRiskFreeInterestRateMember PRVB:MacroGenicsIncMember 2018-05-07 0001695357 PRVB:MDBCapitalGroupLLCMember 2020-01-01 2020-12-31 0001695357 PRVB:MDBCapitalGroupLLCMember 2018-07-19 0001695357 us-gaap:MeasurementInputOptionVolatilityMember PRVB:MDBCapitalGroupLLCMember 2018-07-19 0001695357 us-gaap:MeasurementInputExpectedDividendRateMember PRVB:MDBCapitalGroupLLCMember 2018-07-19 0001695357 us-gaap:MeasurementInputExpectedTermMember PRVB:MDBCapitalGroupLLCMember 2018-07-19 0001695357 us-gaap:MeasurementInputRiskFreeInterestRateMember PRVB:MDBCapitalGroupLLCMember 2018-07-19 0001695357 us-gaap:IPOMember PRVB:MDBCapitalGroupLLCMember 2020-12-31 0001695357 us-gaap:IPOMember PRVB:MDBCapitalGroupLLCMember 2020-12-01 2020-12-31 0001695357 PRVB:CashlessBasisMember us-gaap:WarrantMember us-gaap:IPOMember 2020-12-31 0001695357 PRVB:CashlessBasisMember us-gaap:WarrantMember us-gaap:IPOMember 2020-01-01 2020-12-31 0001695357 us-gaap:WarrantMember us-gaap:IPOMember 2020-12-31 0001695357 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001695357 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001695357 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001695357 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001695357 us-gaap:OfficeEquipmentMember 2020-12-31 0001695357 us-gaap:OfficeEquipmentMember 2019-12-31 0001695357 PRVB:ClinicalEquipmentMember 2020-12-31 0001695357 PRVB:ClinicalEquipmentMember 2019-12-31 0001695357 us-gaap:ConstructionInProgressMember 2020-12-31 0001695357 us-gaap:ConstructionInProgressMember 2019-12-31 0001695357 PRVB:AccruedExpensesMember 2020-12-31 0001695357 us-gaap:StateAndLocalJurisdictionMember 2020-01-01 2020-12-31 0001695357 stpr:NJ 2020-12-31 0001695357 PRVB:NewJerseysTechnologyBusinessTaxCertificateTransferProgramMember 2020-01-01 2020-12-31 0001695357 us-gaap:DomesticCountryMember 2020-12-31 0001695357 us-gaap:DomesticCountryMember 2020-01-01 2020-12-31 0001695357 us-gaap:StateAndLocalJurisdictionMember 2020-12-31 0001695357 us-gaap:ResearchAndDevelopmentExpenseMember 2020-12-31 0001695357 stpr:NJ us-gaap:StateAndLocalJurisdictionMember 2020-01-01 2020-12-31 0001695357 stpr:NJ us-gaap:StateAndLocalJurisdictionMember 2018-01-01 2018-12-31 0001695357 PRVB:AssetPurchaseAgreementMember PRVB:ToleranceTherapeuticsIncMember 2020-01-01 2020-12-31 0001695357 PRVB:AssetPurchaseAgreementMember PRVB:ToleranceTherapeuticsIncMember 2018-01-01 2018-12-31 0001695357 us-gaap:IPOMember PRVB:MDBCapitalGroupLLCMember 2018-07-02 2018-07-31 0001695357 PRVB:DirectorsMember us-gaap:CommonStockMember PRVB:MDBCapitalGroupLLCMember 2018-07-31 0001695357 us-gaap:SubsequentEventMember PRVB:UnderwritersOptionMember 2021-01-01 2021-02-28 0001695357 PRVB:ResearchDevelopmentAndManufacturingFundingMember us-gaap:SubsequentEventMember PRVB:LicenseAgreementMember PRVB:HangzhouZhongmeiHuadongPharmaceuticalCoLtdMember 2021-02-01 2021-02-25 0001695357 srt:MaximumMember PRVB:ResearchDevelopmentAndManufacturingFundingMember us-gaap:SubsequentEventMember PRVB:LicenseAgreementMember PRVB:HangzhouZhongmeiHuadongPharmaceuticalCoLtdMember 2021-02-01 2021-02-25 0001695357 srt:MaximumMember us-gaap:SubsequentEventMember PRVB:LicenseAgreementMember PRVB:HangzhouZhongmeiHuadongPharmaceuticalCoLtdMember 2021-02-25 iso4217:USD shares iso4217:USD shares PRVB:Segment pure iso4217:EUR 0001695357 false Large Accelerated Filer 2020 FY --12-31 P7Y P7Y P5Y P5Y 10-K true 2020-12-31 false 001-38552 PROVENTION BIO, INC. DE 81-5245912 55 Broad Street 2nd floor Red Bank NJ 07701 908 336-0360 Common Stock, $0.0001 par value PRVB NASDAQ Yes No Yes Yes false false true false 718700000 63374738 102294000 39165000 19530000 46208000 4730000 623000 126554000 85996000 1437000 408000 120000 128519000 85996000 7568000 1775000 9162000 2065000 16730000 3840000 715000 17445000 3840000 0.0001 0.0001 25000000 25000000 0 0 0 0 0.0001 0.0001 100000000 100000000 56517891 56517891 47658361 47658361 6000 5000 288725000 161212000 -15000 -177642000 -79061000 111074000 82156000 128519000 85996000 66360000 36359000 22649000 33327000 8013000 4165000 99687000 44372000 26814000 -99687000 -44372000 -26814000 583000 1087000 669000 520000 -99104000 -43285000 -26665000 -523000 -187000 -98581000 -43285000 -26478000 276000 -98581000 -43285000 -26754000 -1.88 -1.06 -1.19 52457000 40747000 22441000 -98581000 -43285000 -26478000 -15000 -98596000 -43285000 -26478000 11382 26185000 10000 1000 3264000 -9298000 -6033000 -11382 -26461000 11382 1000 26460000 26461000 -276000 276000 276000 1518000 1518000 15970 2000 56281000 56283000 10 25000 25000 3039000 3039000 3978000 3978000 1141000 1141000 -26478000 -26478000 37362 4000 95430000 -35776000 59658000 37362 4000 95430000 -35776000 59658000 5750 1000 42650000 42651000 2500 20000000 20000000 79 290000 290000 1967 2842000 2842000 -43285000 -43285000 47658 5000 161212000 -79061000 82156000 47658 5000 161212000 -79061000 82156000 7590 1000 103269000 103270000 725 9869000 9869000 219 1152000 1152000 326 -15000 -15000 13223000 13223000 -98581000 -98581000 56518 6000 288725000 -15000 -177642000 111074000 -98581000 -43285000 -26478000 13223000 2842000 1141000 3978000 520000 -247000 16000 25000 33000 4112000 -2367000 2396000 5793000 1207000 109000 -131000 -58000 7025000 762000 484000 120000 -76336000 -36065000 -22642000 28715000 46250000 55000000 1111000 25174000 -46250000 103270000 42651000 20000000 59322000 9869000 1152000 290000 25000 114291000 62941000 59347000 63129000 -19374000 36705000 39165000 58539000 21834000 102294000 39165000 58539000 413000 26461000 1518000 276000 <p id="xdx_801_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z5QdPtrTSPjg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>1. <span id="xdx_82B_zVMpWK96iXrc">DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Business</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Provention Bio, Inc. (the “Company”) was incorporated on October 4, 2016 under the laws of the State of Delaware. The Company is a clinical stage biopharmaceutical company, focused on the development and commercialization of novel therapeutics and innovative approaches to intercept and prevent immune-mediated diseases. Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. The Company’s business is subject to significant risks and uncertainties and will be dependent on raising substantial additional capital before it becomes profitable and it may never achieve profitability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Basis of presentation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_80F_ecustom--LiquidityTextBlock_zQGpq2vjJMq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>2. <span id="xdx_826_zGE0GKsUv5Te">LIQUIDITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has incurred recurring losses since inception and as of December 31, 2020, the Company had an accumulated deficit of $<span id="xdx_900_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20201231_zKK2a3Qp3eYa" title="Retained Earnings (Accumulated Deficit)">177.6</span> million<i>. </i>To date, the Company has not generated any revenues and has financed its operations primarily through equity offerings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">In April 2017, the Company completed its private placement of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20170401__20170430__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertibleRedeemablePreferredStockMember_pii" title="Stock Issued During Period, Shares, New Issues">11,381,999</span> shares of Series A Convertible Redeemable Preferred Stock at $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_c20170430__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertibleRedeemablePreferredStockMember_pii" title="Shares Issued, Price Per Share">2.50</span> per share (the “Series A Offering”). The Company received net proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_c20170401__20170430__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertibleRedeemablePreferredStockMember_pn5n6" title="Proceeds from Issuance of Redeemable Convertible Preferred Stock">26.7</span> million. </span><span style="font: 10pt Times New Roman, Times, Serif">In connection with the sale of Series A Convertible Redeemable Preferred Stock, the Company issued warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20170430__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertibleRedeemablePreferredStockMember_pii" title="Class of Warrant or Right, Number of Securities Called by Each Warrant or Right">558,740</span> shares of Series A Convertible Redeemable Preferred Stock with an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20170430__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertibleRedeemablePreferredStockMember_pii" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">2.50</span> per share with a seven-year term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">In July 2018, the Company issued and sold an aggregate of <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20180701__20180731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pii" title="Sale of Stock, Number of Shares Issued in Transaction">15,969,563</span> shares of common stock in its initial public offering (“IPO”) at a public offering price of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_c20180731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pii" title="Sale of Stock, Price Per Share">4.00</span> per share. In connection with the IPO, the Company issued to MDB Capital Group, LLC (“MDB”), the underwriter in the IPO, and its designees warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20180731__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pii" title="Class of Warrant or Right, Number of Securities Called by Each Warrant or Right">1,596,956</span> shares of common stock at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20180731__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pii" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">5.00</span> per share. The Company received net proceeds from the IPO of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20180701__20180731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pn5n6" title="Proceeds from Issuance Initial Public Offering">59.3</span> million, after deducting underwriting discounts and commissions of approximately $<span id="xdx_908_eus-gaap--PaymentsOfStockIssuanceCosts_c20180701__20180731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pn5n6" title="Underwriting discounts and commissions">3.7</span> million and other offering expenses of approximately $<span id="xdx_901_ecustom--OtherOfferingExpenses_c20180701__20180731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pn5n6">0.8</span> million. Upon the closing of the IPO, all of the Company’s shares of redeemable convertible preferred stock outstanding at the time of the offering were automatically converted into <span id="xdx_90A_eus-gaap--ConversionOfStockSharesConverted1_c20180701__20180731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pii" title="Conversion of Stock, Shares Converted">11,381,999</span> shares of common stock. In addition, the warrants issued in connection with the Series A Convertible Redeemable Preferred Stock also converted to warrants for the purchase of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20180731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertibleRedeemablePreferredStockMember_pii" title="Class of Warrant or Right, Number of Securities Called by Each Warrant or Right">558,740</span> shares of the Company’s common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">In September 2019, the Company completed an underwritten public offering in which it sold <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pii_c20190901__20190930_zs48OF9rolR4" title="Sale of Stock, Number of Shares Issued in Transaction">5,750,000</span> shares of common stock at a public offering price of $<span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_pii_c20190930_zVpL1FXSOO3d" title="Sale of Stock, Price Per Share">8.00</span> per share. The <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pii_c20190901__20190930_zfSw1uVg9DUh" title="Sale of Stock, Number of Shares Issued in Transaction">5,750,000</span> shares sold included the full exercise of the underwriters’ option to purchase <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20190901__20190930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--OptionMember_pii" title="Sale of Stock, Number of Shares Issued in Transaction">750,000</span> shares at a price of $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_c20190930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--OptionMember_pii" title="Sale of Stock, Price Per Share">8.00</span> per share. Concurrent with the underwritten public offering, the Company sold <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20190901__20190930__dei--LegalEntityAxis__custom--AmgenIncMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pii" title="Sale of Stock, Number of Shares Issued in Transaction">2,500,000</span> shares of common stock to Amgen, Inc. at the public offering price of $<span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_c20190930__dei--LegalEntityAxis__custom--AmgenIncMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pii" title="Sale of Stock, Price Per Share">8.00</span> per share in a private placement, pursuant to the terms of the Company’s License and Collaboration Agreement with Amgen Inc, dated as of November 5, 2018. Aggregate net proceeds from the underwritten public offering and the concurrent private placement were $<span id="xdx_907_ecustom--NetProceedsFromNewSharesIssuedTransactionPlusAmgenPrivatePlacement_c20190901__20190930_pn5n6">62.7</span> million, net of approximately $<span id="xdx_905_eus-gaap--PaymentsOfStockIssuanceCosts_c20190901__20190930_pn5n6" title="Underwriting discounts and commissions">2.8</span> million in underwriting discounts and commissions and other offering expenses of $<span id="xdx_909_ecustom--OtherOfferingExpenses_c20190901__20190930_pn5n6">0.5</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In August 2019, the Company established an at-the-market (“ATM”) program through which the Company may sell, from time to time at its sole discretion, up to $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn6n6_c20190801__20190831__us-gaap--AwardTypeAxis__custom--AtTheMarketMember__srt--RangeAxis__srt--MaximumMember_z0sK0ORmmSd2" title="Sale of Stock, Consideration Received on Transaction">50.0</span> </span><span style="font: 10pt Times New Roman, Times, Serif">million of shares of its common stock. The Company has sold <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pii_c20200401__20200630__us-gaap--AwardTypeAxis__custom--AtTheMarketMember_zFss5bQr1fpg">725,495 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock for aggregate net proceeds of approximately $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20200401__20200630__us-gaap--AwardTypeAxis__custom--AtTheMarketMember_zh9BnYwa9DE6">9.9 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million, net of $<span id="xdx_90A_eus-gaap--SalesCommissionsAndFees_pn5n6_c20200401__20200630__us-gaap--AwardTypeAxis__custom--AtTheMarketMember_zv5YEv55Eabi">0.3 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million in sales commissions, under the ATM program, all of which occurred during the quarter ended June 30, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In June 2020, the Company completed an underwritten public offering in which it sold <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pii_c20200629__20200630__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zBLwJsmLB5N2">7,590,000</span> shares of common stock at a public offering price of $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_pii_c20200630__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_z5if4UYiYnbk">14.50</span> per share. The <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20200629__20200630__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_pii" title="Sale of Stock, Number of Shares Issued in Transaction">7,590,000</span> shares sold included the full exercise of the underwriters’ option to purchase <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20200629__20200630__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersOptionMember_z6E9MSQ0LJ7i">990,000</span> shares at a price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pii_c20200630__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersOptionMember_zCRN4iu8R5Z7">14.50</span> per share. The Company received net proceeds from the underwritten public offering of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20200601__20200630_zPP77XrKNBNg">103.3</span> million, after deducting underwriting discounts and commissions of approximately $<span id="xdx_905_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20200601__20200630_zR1sjTDfNk87">6.6</span> million and other offering expenses of $<span id="xdx_90C_ecustom--OtherOfferingExpenses_pn5n6_c20200601__20200630_z6KdgzBDZLzb">0.2</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In January 2021, the Company completed an underwritten public offering in which it sold <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pii_c20210101__20210131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersOptionMember_zdzN99WgutFe">6,250,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock at a public offering price of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_c20210131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersOptionMember_pii">16.00 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share. In February 2021, the underwriters partially exercised their option to purchase an additional <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20210201__20210228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersOptionMember_zA1Q2l4uu7Ah">587,500 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares at a price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_c20210228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersOptionMember_pii">16.00 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share. In the aggregate, total net proceeds from the underwritten public offering was $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn3n6_c20210201__20210228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersOptionMember_zvTOyn45Ik4f">102.3 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million, after deducting underwriting discounts and commissions of approximately $<span id="xdx_903_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20210201__20210228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zaa7Y67AWg8e">6.6 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million and other offering expenses of $<span id="xdx_90F_ecustom--OtherOfferingExpenses_pn5n6_c20210201__20210228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersOptionMember_zjkpITE8q8V2">0.5 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The Company has devoted substantially all of its financial resources and efforts to research and development and expects to continue to incur significant expenses and increasing operating losses over the next several years due to, among other things, costs related to research funding, development of its product candidates and its preclinical programs, strategic alliances, the development of its administrative and commercial organization and pre-commercial activities for teplizumab<i>. </i>The Company’s net losses may fluctuate significantly from quarter to quarter and year to year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company will require substantial additional financing to fund its operations and to continue to execute its strategy. The Company may raise capital through public or private equity or debt financings. The sale of equity or other securities may result in dilution to the Company’s stockholders and certain of those securities may have rights senior to those of the Company’s existing shares. If the Company raises additional funds through the issuance of preferred stock, convertible debt securities or other debt financing, these securities or other debt could contain covenants that would restrict the Company’s operations. Any other third-party funding arrangement could require the Company to relinquish valuable rights. The source, timing and availability of any future financing will depend principally upon market conditions, and, more specifically, on the progress of the Company’s clinical development programs. Funding may not be available when needed, at all, or on terms acceptable to the Company. Lack of necessary funds may require the Company, among other things, to delay, scale back or eliminate some or all of the Company’s planned operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s cash requirements for 2021 will be impacted by a number of factors, the most significant of which are expenses related to teplizumab, including costs to build out the Company’s commercial infrastructure and pre-commercial activities for teplizumab, the PROTECT clinical trial, manufacturing activities for teplizumab and any potential milestone payments that may become due upon a potential regulatory approval of teplizumab by the FDA. Other factors include costs related to the Company’s Phase 2b clinical study of PRV-015 and first-in-human safety study of PRV-101.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Based on the Company’s current business plans, management believes that its cash, cash equivalents and marketable securities on hand at December 31, 2020, coupled with net proceeds from the Company’s follow on offering in January 2021 and partial exercise by the underwriters to purchase additional shares in February 2021, are sufficient to meet the Company’s obligations for at least the next 12 months from the issuance of these financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> -177600000 11381999 2.50 26700000 558740 2.50 15969563 4.00 1596956 5.00 59300000 3700000 800000 11381999 558740 5750000 8.00 5750000 750000 8.00 2500000 8.00 62700000 2800000 500000 50000000.0 725495 9900000 300000 7590000 14.50 7590000 990000 14.50 103300000 6600000 200000 6250000 16.00 587500 16.00 102300000 6600000 500000 <p id="xdx_803_eus-gaap--SignificantAccountingPoliciesTextBlock_zFlXIMTqYebi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>3. <span id="xdx_82C_znOthy7NWxx1">SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A summary of the significant accounting policies followed by the Company in the preparation of the financial statements is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_847_eus-gaap--UseOfEstimates_zCVDRkKo7Ymj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_867_z36ChYOMJUT7">Use of estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The process of preparing financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates and changes in estimates may occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_843_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zwaBVKrjFZn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86A_zJAI5awwXPQf">Segment and geographic information</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in <span id="xdx_902_eus-gaap--NumberOfOperatingSegments_pii_dc_uSegment_c20200101__20201231_zVfHpDnmaHJ" title="Number of operating segments">one</span> operating and reporting segment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_znbC5VlaS6G9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_869_zXGDk8IctAsk">Cash, cash equivalents and concentration of credit risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company considers only those investments which are highly liquid, readily convertible to cash, or that mature within 90 days from the date of purchase to be cash equivalents. Marketable securities are those investments with original maturities in excess of 90 days. The carrying amounts reported in the balance sheets for cash and cash equivalents are valued at cost, which approximates their fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements. The Company holds cash and cash equivalents in banks in excess of FDIC insurance limits. However, the Company believes risk of loss is minimal as the cash and cash equivalents are held by large, highly-rated financial institutions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84B_eus-gaap--MarketableSecuritiesPolicy_zf2mtooWAS66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_863_zPJ9pr6F4WC8">Marketable securities</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company considers securities with original maturities of greater than 90 days to be available for sale securities. Available for sale securities are classified as either current or non-current assets based on the nature of the securities and their availability for use in current operations. Available for sale securities are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On a quarterly basis, the Company reviews the status of each security in an unrealized loss position, to evaluate the existence of potential credit losses. The Company first considers whether it intends to sell, or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through income. For securities that do not meet this criteria, the Company considers a number of factors to determine if the decline in fair value has resulted from credit losses or other factors, including but not limited to: (1) the extent of the decline; (2) changes to the rating of the security by a rating agency; (3) any adverse conditions specific to the security; and (4) other market conditions that may affect the fair value of the security. If this assessment indicates that a credit loss exists and the present value of cash flows expected to be collected is less than the amortized cost basis, an allowance for credit losses is required for the credit loss. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. As of December 31, 2020, the Company has not recognized any impairment or credit losses on its available for sale securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zDun4XshcXU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86F_zQsDp8yVLm45">Financial instruments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Cash, cash equivalents and marketable securities are reflected in the accompanying financial statements at fair value. The carrying amount of accounts payable and accrued expenses, including accrued research and development expenses, approximates fair value due to the short-term nature of those instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zL6mBToNRpSj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86C_zberJYtmW8Mk">Net loss per common share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Net loss per share information is determined using the two-class method, which includes the weighted-average number of shares of common stock outstanding during the period and other securities that participate in dividends (a participating security). The Company considered the Series A Preferred Stock, all of which were automatically converted to common stock upon the Company’s IPO, to be participating securities because they included rights to participate in dividends, if any, with the common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Under the two-class method, basic net loss per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. The net loss attributable to common stockholders is calculated by adjusting the net loss of the Company for the accretion on the Preferred Stock. Net losses are not allocated to preferred stockholders as they do not have an obligation to share in the Company’s net losses. In periods with net income attributable to common stockholders, the Company would allocate net income first to preferred stockholders based on dividend rights under the Company’s certificate of incorporation and then to preferred and common stockholders based on ownership interests. Diluted net loss per share attributable to common stockholders is computed using the more dilutive of (1) the two-class method or (2) the if-converted method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders for all periods presented since the effect of potentially dilutive securities are anti-dilutive given the net loss of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zQD6atRvzHga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_869_z2tPqXFTrNc8">Fixed assets, net</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Fixed assets, which consists primarily of leasehold improvements, furniture and fixtures, software, office equipment and certain clinical equipment, are carried at cost less accumulated depreciation. Depreciation is computed over the estimated useful lives of the respective assets, generally <span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_dtY_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_zqWyB3dLAnGi" title="Fixed assets estimated useful life years">three</span> to <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_dtY_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_zyM14HCIh3D1">seven</span> years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_842_eus-gaap--LesseeLeasesPolicyTextBlock_zfAoZouQGnk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86C_zWeQjPooB6Xb">Leases</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company determines if an arrangement is a lease at contract inception. A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company classifies its leases as operating or financing by considering factors such as the length of the lease term, the present value of the lease payments, the specialized nature of the asset being leased and the potential for ownership of the asset to transfer during the lease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Leases with terms greater than one-year are recognized on the Company’s balance sheets as right-of-use (“ROU”) assets and lease liabilities and are measured at the present value of the fixed payments due over the lease term minus the present value of any incentives, rebates or abatements expected to be received from the lessor. Options to extend a lease are typically excluded from the expected lease term as the exercise of the option is typically not reasonably certain. Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee’s incremental borrowing rate. As the implicit rate is not typically readily determinable, the Company uses an incremental borrowing rate, which is established based upon the information available at the lease commencement date, to determine the present value of lease payments due under an arrangement. The incremental borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">ROU assets are amortized on a straight-line basis over the term of the lease. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are recognized in the statements of comprehensive loss in the same line item as expenses arising from fixed lease payments at the time when the event giving rise to the payment occurs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ziZGsONZtzs3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86B_zLVVhNcPLvu8">Foreign currency translation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company considers the U.S. dollar to be its functional currency. Expenses denominated in foreign currencies are translated at the exchange rate on the date the expense is incurred. The effect of exchange rate fluctuations on translating foreign currency assets and liabilities into U.S. dollars is included in the Statements of Comprehensive Loss. Foreign exchange transaction gains and losses are included in the results of operations and are not material in the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_zu72xiFe4ikc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_867_zX3PEqeR3jlj">Research and development expenses</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Research and development expenses primarily consist of costs associated with the preclinical and clinical development of the Company’s product candidate portfolio, including the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="text-align: justify; width: 0.25in">●</td> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”) and other vendors and contract manufacturing organizations (“CMOs”) for the production of drug substance and drug product; and</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="text-align: justify; width: 0.25in">●</td> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">employee-related expenses, including salaries, benefits and share-based compensation expense.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Research and development expenses also include costs of acquired product licenses and related technology rights where there is no alternative future use, costs of prototypes used in research and development, consultant fees and amounts paid to certain of our collaborative partners.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">All research and development expenses are charged to operations as incurred in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic (“ASC”) 730, <i>Research and Development</i>. The Company accounts for non-refundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received, rather than when the payment is made.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p id="xdx_841_ecustom--AccruedResearchAndDevelopmentExpensesPolicyTextBlock_z8KzeBkF2tM" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_864_zjKXXHSg2Sg2">Accrued research and development expenses</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As part of the process of preparing our financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company’s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and make adjustments if necessary. The significant estimates in the Company’s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on the Company’s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company’s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company’s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_844_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zNUJ1AaeFQs8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86B_z6PhR0ocw5W5">Stock-based compensation expense</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font: 10pt Times New Roman, Times, Serif">The Company follows the provisions of ASC 718, <i>Compensation—Stock Compensation</i>, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and non-employees, including stock options. Stock-based compensation expense is based on the grant date fair value estimated in accordance with the provisions of ASC 718 and is generally recognized as an expense over the requisite service period. For grants containing performance-based vesting provisions, the grant-date fair value of the performance-based stock options is recognized as compensation expense once it is probable that the performance condition will be achieved. The Company accounts for actual forfeitures in the period the forfeiture occurs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>Stock Options</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. Due to the lack of trading history, the Company’s computation of stock-price volatility is based on the volatility rates of comparable publicly held companies over a period equal to the expected term of the options granted by the Company. The Company’s computation of expected term is determined using the “simplified” method, which is the midpoint between the vesting date and the end of the contractual term. The Company believes that it does not have sufficient reliable exercise data in order to justify the use of a method other than the “simplified” method of estimating the expected exercise term of employee stock option grants. The Company utilizes a dividend yield of zero based on the fact that the Company has never paid cash dividends to stockholders and has no current intentions to pay cash dividends. The risk-free interest rate is based on the zero-coupon United States Treasury yield at the date of grant for a term equivalent to the expected term of the option.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In June 2018, the FASB issued ASU No. 2018-07, <i>Improvements to Nonemployee Share-Based Payment Accounting, </i>(“ASU 2018-07”) which supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payments arrangements related to the acquisition of goods and services from both employees and nonemployees. During the third quarter of 2018, the Company early adopted ASU 2018-07. After the adoption of ASU 2018-07, the measurement date for non-employee awards is the date of grant. Compensation expense for non-employees is recognized, without changes to the fair value of the award, over the requisite service period, which is the vesting period of the respective award. The adoption of ASU 2018-07 did not have a material impact the Company’s financial statements or footnote disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Prior to the third quarter of 2018, the Company accounted for awards of equity instruments issued to non-employees in accordance with ASC Topic 505-50, <i>Equity-Based Payment to Non-Employees,</i> (“ASC 505-50”) and accordingly the value of the stock compensation to non-employees was based upon the measurement date as determined at either a) the date at which a performance commitment was reached, or b) at the date at which the necessary performance to earn the equity instruments was completed, which was normally the end of the vesting period. At the end of each financial reporting period prior to completion of the service, the fair value of these awards was remeasured using updated assumption inputs in the Black-Scholes option-pricing model.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Stock-based compensation expense is included in both research and development expenses and general and administrative expenses in the Statements of Comprehensive Loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84D_ecustom--WarrantLiabilityPolicyTextBlock_zrsB0QTiiec5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_860_zyFPWQbVMaHf">Warrant liability</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In April 2017, the Company issued warrants to purchase shares of Series A Convertible Redeemable Preferred Stock in connection with the issuance of the Series A Preferred Stock. The Company accounted for these warrants as a liability in the financial statements because the underlying instrument into which the warrants were exercisable contained redemption provisions that were outside the Company’s control.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Upon the completion of the IPO in July 2018, the warrants issued in connection with the Series A Convertible Redeemable Preferred Stock converted to warrants for the purchase of <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pii_c20180731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertibleRedeemablePreferredStockMember_zLmjCZ0xxA7j" title="Warrants to purchase">558,740</span> shares of our common stock and the warrants no longer contain redemption provisions that are outside the Company’s control. The liability associated with these warrants was revalued just prior to the completion of the IPO, with the change in the fair value of the warrant liability charged to earnings. The warrant liability was then reclassified to additional paid-in capital upon the completion of the IPO in July 2018.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The fair value of the warrants was determined using the Black-Scholes option-pricing model and were re-measured to fair value at each financial reporting period date with any changes in fair value recognized in the statements of operations. See Note 11 to our financial statements for further information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zdw56bKTudH7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_869_zA9CxIuN3HW8">Income taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company utilizes the liability method of accounting for deferred income taxes, as set forth in ASC 740, <i>Income Taxes.</i> Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. A valuation allowance is established against deferred tax assets when, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zlkD10EXeYjg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86B_zJULrvgvKKkl">Recent accounting pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”). ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In February 2016, the FASB issued ASU No. 2016-02, <i>Leases (Topic 842)</i> (“ASU 2016-02”)<i>,</i> which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. Effective January 1, 2019, the Company adopted ASU 2016-02. <span style="background-color: white">The adoption had no impact on the Company’s financial statements and related disclosures as the Company did not have any lease agreements at the time of adoption. In July 2020, the Company entered into an agreement to lease its new corporate headquarters in Red Bank, NJ. Upon commencement of the lease, which occurred in October 2020, the lease was accounted for as an operating lease.</span> Refer to Note 13 - Leases for details about the Company’s lease portfolio, including Topic 842 required disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In June 2016, the FASB issued ASU No. 2016-13, <i>Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, which replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Effective January 1, 2020, the Company adopted ASU 2016-13 using the modified retrospective method for all financial assets measured at amortized cost. Results for reporting periods beginning after January 1, 2020 are presented under ASC 326 (Financial Instruments - Credit Losses), while prior period amounts continue to be reported in accordance with previously applicable GAAP. The adoption of this ASU had no impact on the Company’s financial statements and related disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In August 2018, the FASB issued ASU No. 2018-13, <i>Fair Value Measurement (Topic 820)</i>, which modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, including, among other changes, the consideration of costs and benefits when evaluating disclosure requirements. Effective January 1, 2020, the Company adopted ASU 2018-13. The adoption had no impact on the Company’s financial statements and related disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In August 2018, the FASB issued ASU No. 2018-15, <i>Intangibles - Goodwill and Other - Internal-Use Software</i> (Subtopic 350-40): <i>Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</i> (a consensus of the FASB Emerging Issues Task Force). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Effective January 1, 2020, the Company adopted ASU 2018-15. The adoption had no impact on the Company’s financial statements and related disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In November 2018, the FASB issued ASU No. 2018-18, <i>Collaborative Arrangements (Topic 808)</i>, which clarifies the interaction between the guidance for collaborative arrangements (Topic 808) and the new revenue recognition standard (Topic 606). Effective January 1, 2020, the Company adopted ASU 2018-18. The adoption had no impact on the Company’s financial statements and related disclosures.</span></p> <p id="xdx_85F_zFMiLdrzVKB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_847_eus-gaap--UseOfEstimates_zCVDRkKo7Ymj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_867_z36ChYOMJUT7">Use of estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The process of preparing financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates and changes in estimates may occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_843_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zwaBVKrjFZn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86A_zJAI5awwXPQf">Segment and geographic information</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in <span id="xdx_902_eus-gaap--NumberOfOperatingSegments_pii_dc_uSegment_c20200101__20201231_zVfHpDnmaHJ" title="Number of operating segments">one</span> operating and reporting segment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 1 <p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_znbC5VlaS6G9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_869_zXGDk8IctAsk">Cash, cash equivalents and concentration of credit risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company considers only those investments which are highly liquid, readily convertible to cash, or that mature within 90 days from the date of purchase to be cash equivalents. Marketable securities are those investments with original maturities in excess of 90 days. The carrying amounts reported in the balance sheets for cash and cash equivalents are valued at cost, which approximates their fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements. The Company holds cash and cash equivalents in banks in excess of FDIC insurance limits. However, the Company believes risk of loss is minimal as the cash and cash equivalents are held by large, highly-rated financial institutions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84B_eus-gaap--MarketableSecuritiesPolicy_zf2mtooWAS66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_863_zPJ9pr6F4WC8">Marketable securities</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company considers securities with original maturities of greater than 90 days to be available for sale securities. Available for sale securities are classified as either current or non-current assets based on the nature of the securities and their availability for use in current operations. Available for sale securities are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On a quarterly basis, the Company reviews the status of each security in an unrealized loss position, to evaluate the existence of potential credit losses. The Company first considers whether it intends to sell, or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through income. For securities that do not meet this criteria, the Company considers a number of factors to determine if the decline in fair value has resulted from credit losses or other factors, including but not limited to: (1) the extent of the decline; (2) changes to the rating of the security by a rating agency; (3) any adverse conditions specific to the security; and (4) other market conditions that may affect the fair value of the security. If this assessment indicates that a credit loss exists and the present value of cash flows expected to be collected is less than the amortized cost basis, an allowance for credit losses is required for the credit loss. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. As of December 31, 2020, the Company has not recognized any impairment or credit losses on its available for sale securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zDun4XshcXU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86F_zQsDp8yVLm45">Financial instruments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Cash, cash equivalents and marketable securities are reflected in the accompanying financial statements at fair value. The carrying amount of accounts payable and accrued expenses, including accrued research and development expenses, approximates fair value due to the short-term nature of those instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zL6mBToNRpSj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86C_zberJYtmW8Mk">Net loss per common share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Net loss per share information is determined using the two-class method, which includes the weighted-average number of shares of common stock outstanding during the period and other securities that participate in dividends (a participating security). The Company considered the Series A Preferred Stock, all of which were automatically converted to common stock upon the Company’s IPO, to be participating securities because they included rights to participate in dividends, if any, with the common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Under the two-class method, basic net loss per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. The net loss attributable to common stockholders is calculated by adjusting the net loss of the Company for the accretion on the Preferred Stock. Net losses are not allocated to preferred stockholders as they do not have an obligation to share in the Company’s net losses. In periods with net income attributable to common stockholders, the Company would allocate net income first to preferred stockholders based on dividend rights under the Company’s certificate of incorporation and then to preferred and common stockholders based on ownership interests. Diluted net loss per share attributable to common stockholders is computed using the more dilutive of (1) the two-class method or (2) the if-converted method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders for all periods presented since the effect of potentially dilutive securities are anti-dilutive given the net loss of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zQD6atRvzHga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_869_z2tPqXFTrNc8">Fixed assets, net</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Fixed assets, which consists primarily of leasehold improvements, furniture and fixtures, software, office equipment and certain clinical equipment, are carried at cost less accumulated depreciation. Depreciation is computed over the estimated useful lives of the respective assets, generally <span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_dtY_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_zqWyB3dLAnGi" title="Fixed assets estimated useful life years">three</span> to <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_dtY_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_zyM14HCIh3D1">seven</span> years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> three seven <p id="xdx_842_eus-gaap--LesseeLeasesPolicyTextBlock_zfAoZouQGnk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86C_zWeQjPooB6Xb">Leases</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company determines if an arrangement is a lease at contract inception. A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company classifies its leases as operating or financing by considering factors such as the length of the lease term, the present value of the lease payments, the specialized nature of the asset being leased and the potential for ownership of the asset to transfer during the lease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Leases with terms greater than one-year are recognized on the Company’s balance sheets as right-of-use (“ROU”) assets and lease liabilities and are measured at the present value of the fixed payments due over the lease term minus the present value of any incentives, rebates or abatements expected to be received from the lessor. Options to extend a lease are typically excluded from the expected lease term as the exercise of the option is typically not reasonably certain. Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee’s incremental borrowing rate. As the implicit rate is not typically readily determinable, the Company uses an incremental borrowing rate, which is established based upon the information available at the lease commencement date, to determine the present value of lease payments due under an arrangement. The incremental borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">ROU assets are amortized on a straight-line basis over the term of the lease. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are recognized in the statements of comprehensive loss in the same line item as expenses arising from fixed lease payments at the time when the event giving rise to the payment occurs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ziZGsONZtzs3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86B_zLVVhNcPLvu8">Foreign currency translation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company considers the U.S. dollar to be its functional currency. Expenses denominated in foreign currencies are translated at the exchange rate on the date the expense is incurred. The effect of exchange rate fluctuations on translating foreign currency assets and liabilities into U.S. dollars is included in the Statements of Comprehensive Loss. Foreign exchange transaction gains and losses are included in the results of operations and are not material in the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_zu72xiFe4ikc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_867_zX3PEqeR3jlj">Research and development expenses</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Research and development expenses primarily consist of costs associated with the preclinical and clinical development of the Company’s product candidate portfolio, including the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="text-align: justify; width: 0.25in">●</td> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”) and other vendors and contract manufacturing organizations (“CMOs”) for the production of drug substance and drug product; and</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="text-align: justify; width: 0.25in">●</td> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">employee-related expenses, including salaries, benefits and share-based compensation expense.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Research and development expenses also include costs of acquired product licenses and related technology rights where there is no alternative future use, costs of prototypes used in research and development, consultant fees and amounts paid to certain of our collaborative partners.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">All research and development expenses are charged to operations as incurred in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic (“ASC”) 730, <i>Research and Development</i>. The Company accounts for non-refundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received, rather than when the payment is made.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p id="xdx_841_ecustom--AccruedResearchAndDevelopmentExpensesPolicyTextBlock_z8KzeBkF2tM" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_864_zjKXXHSg2Sg2">Accrued research and development expenses</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As part of the process of preparing our financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company’s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and make adjustments if necessary. The significant estimates in the Company’s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on the Company’s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company’s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company’s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_844_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zNUJ1AaeFQs8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86B_z6PhR0ocw5W5">Stock-based compensation expense</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font: 10pt Times New Roman, Times, Serif">The Company follows the provisions of ASC 718, <i>Compensation—Stock Compensation</i>, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and non-employees, including stock options. Stock-based compensation expense is based on the grant date fair value estimated in accordance with the provisions of ASC 718 and is generally recognized as an expense over the requisite service period. For grants containing performance-based vesting provisions, the grant-date fair value of the performance-based stock options is recognized as compensation expense once it is probable that the performance condition will be achieved. The Company accounts for actual forfeitures in the period the forfeiture occurs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>Stock Options</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. Due to the lack of trading history, the Company’s computation of stock-price volatility is based on the volatility rates of comparable publicly held companies over a period equal to the expected term of the options granted by the Company. The Company’s computation of expected term is determined using the “simplified” method, which is the midpoint between the vesting date and the end of the contractual term. The Company believes that it does not have sufficient reliable exercise data in order to justify the use of a method other than the “simplified” method of estimating the expected exercise term of employee stock option grants. The Company utilizes a dividend yield of zero based on the fact that the Company has never paid cash dividends to stockholders and has no current intentions to pay cash dividends. The risk-free interest rate is based on the zero-coupon United States Treasury yield at the date of grant for a term equivalent to the expected term of the option.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In June 2018, the FASB issued ASU No. 2018-07, <i>Improvements to Nonemployee Share-Based Payment Accounting, </i>(“ASU 2018-07”) which supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payments arrangements related to the acquisition of goods and services from both employees and nonemployees. During the third quarter of 2018, the Company early adopted ASU 2018-07. After the adoption of ASU 2018-07, the measurement date for non-employee awards is the date of grant. Compensation expense for non-employees is recognized, without changes to the fair value of the award, over the requisite service period, which is the vesting period of the respective award. The adoption of ASU 2018-07 did not have a material impact the Company’s financial statements or footnote disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Prior to the third quarter of 2018, the Company accounted for awards of equity instruments issued to non-employees in accordance with ASC Topic 505-50, <i>Equity-Based Payment to Non-Employees,</i> (“ASC 505-50”) and accordingly the value of the stock compensation to non-employees was based upon the measurement date as determined at either a) the date at which a performance commitment was reached, or b) at the date at which the necessary performance to earn the equity instruments was completed, which was normally the end of the vesting period. At the end of each financial reporting period prior to completion of the service, the fair value of these awards was remeasured using updated assumption inputs in the Black-Scholes option-pricing model.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Stock-based compensation expense is included in both research and development expenses and general and administrative expenses in the Statements of Comprehensive Loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84D_ecustom--WarrantLiabilityPolicyTextBlock_zrsB0QTiiec5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_860_zyFPWQbVMaHf">Warrant liability</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In April 2017, the Company issued warrants to purchase shares of Series A Convertible Redeemable Preferred Stock in connection with the issuance of the Series A Preferred Stock. The Company accounted for these warrants as a liability in the financial statements because the underlying instrument into which the warrants were exercisable contained redemption provisions that were outside the Company’s control.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Upon the completion of the IPO in July 2018, the warrants issued in connection with the Series A Convertible Redeemable Preferred Stock converted to warrants for the purchase of <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pii_c20180731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertibleRedeemablePreferredStockMember_zLmjCZ0xxA7j" title="Warrants to purchase">558,740</span> shares of our common stock and the warrants no longer contain redemption provisions that are outside the Company’s control. The liability associated with these warrants was revalued just prior to the completion of the IPO, with the change in the fair value of the warrant liability charged to earnings. The warrant liability was then reclassified to additional paid-in capital upon the completion of the IPO in July 2018.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The fair value of the warrants was determined using the Black-Scholes option-pricing model and were re-measured to fair value at each financial reporting period date with any changes in fair value recognized in the statements of operations. See Note 11 to our financial statements for further information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 558740 <p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zdw56bKTudH7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_869_zA9CxIuN3HW8">Income taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company utilizes the liability method of accounting for deferred income taxes, as set forth in ASC 740, <i>Income Taxes.</i> Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. A valuation allowance is established against deferred tax assets when, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zlkD10EXeYjg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86B_zJULrvgvKKkl">Recent accounting pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”). ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In February 2016, the FASB issued ASU No. 2016-02, <i>Leases (Topic 842)</i> (“ASU 2016-02”)<i>,</i> which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. Effective January 1, 2019, the Company adopted ASU 2016-02. <span style="background-color: white">The adoption had no impact on the Company’s financial statements and related disclosures as the Company did not have any lease agreements at the time of adoption. In July 2020, the Company entered into an agreement to lease its new corporate headquarters in Red Bank, NJ. Upon commencement of the lease, which occurred in October 2020, the lease was accounted for as an operating lease.</span> Refer to Note 13 - Leases for details about the Company’s lease portfolio, including Topic 842 required disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In June 2016, the FASB issued ASU No. 2016-13, <i>Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, which replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Effective January 1, 2020, the Company adopted ASU 2016-13 using the modified retrospective method for all financial assets measured at amortized cost. Results for reporting periods beginning after January 1, 2020 are presented under ASC 326 (Financial Instruments - Credit Losses), while prior period amounts continue to be reported in accordance with previously applicable GAAP. The adoption of this ASU had no impact on the Company’s financial statements and related disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In August 2018, the FASB issued ASU No. 2018-13, <i>Fair Value Measurement (Topic 820)</i>, which modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, including, among other changes, the consideration of costs and benefits when evaluating disclosure requirements. Effective January 1, 2020, the Company adopted ASU 2018-13. The adoption had no impact on the Company’s financial statements and related disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In August 2018, the FASB issued ASU No. 2018-15, <i>Intangibles - Goodwill and Other - Internal-Use Software</i> (Subtopic 350-40): <i>Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</i> (a consensus of the FASB Emerging Issues Task Force). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Effective January 1, 2020, the Company adopted ASU 2018-15. The adoption had no impact on the Company’s financial statements and related disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In November 2018, the FASB issued ASU No. 2018-18, <i>Collaborative Arrangements (Topic 808)</i>, which clarifies the interaction between the guidance for collaborative arrangements (Topic 808) and the new revenue recognition standard (Topic 606). Effective January 1, 2020, the Company adopted ASU 2018-18. The adoption had no impact on the Company’s financial statements and related disclosures.</span></p> <p id="xdx_80D_ecustom--CapitalizationTextBlock_zbWLAeI2a6rb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>4. <span id="xdx_824_zvAoVE7TujRe">CAPITALIZATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">As of December 31, 2020 and 2019, the Company had authorized <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_c20201231_pii" title="Common Stock, Shares Authorized"><span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_c20191231_pii" title="Common Stock, Shares Authorized">100,000,000</span></span> shares of common stock, $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_c20201231_pii" title="Common Stock, Par or Stated Value Per Share"><span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_c20191231_pii" title="Common Stock, Par or Stated Value Per Share">0.0001</span></span> par value per share, of which <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_c20201231_pii" title="Common Stock, Shares, Issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_c20201231_pii" title="Common Stock, Shares, Outstanding">56,517,891</span></span> and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_c20191231_pii" title="Common Stock, Shares, Issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_c20191231_pii" title="Common Stock, Shares, Outstanding">47,658,361</span></span> shares, respectively, were issued and outstanding. In addition, as of December 31, 2020 and 2019, the Company had authorized <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_c20201231_pii" title="Preferred Stock, Shares Authorized"><span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_c20191231_pii" title="Preferred Stock, Shares Authorized">25,000,000</span></span> shares of preferred stock, $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_c20201231_pii" title="Preferred Stock, Par or Stated Value Per Share"><span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_c20191231_pii" title="Preferred Stock, Par or Stated Value Per Share">0.0001</span></span> par value per share, of which, <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_pii_dn_c20201231_zaT7rc9vtGG4" title="Preferred Stock, Shares Issued"><span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_pii_dn_c20191231_zWkuTYpQh3g5" title="Preferred Stock, Shares Issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pii_dn_c20201231_zfy0uhyBAglb" title="Preferred Stock, Shares Outstanding"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_pii_dn_c20191231_zwU5CLhIRTlb" title="Preferred Stock, Shares Outstanding">none</span></span></span></span> were issued and outstanding.</span></p> 100000000 100000000 0.0001 0.0001 56517891 56517891 47658361 47658361 25000000 25000000 0.0001 0.0001 0 0 0 0 <p id="xdx_801_eus-gaap--CashCashEquivalentsAndMarketableSecuritiesTextBlock_zyLwghcEvywb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>5. <span id="xdx_82F_zDEZrC2lUGH7">CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The Company considers all highly liquid investments purchased with original maturities of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents as of December 31, 2020 and 2019 were $<span><span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20201231_z9hG3zjgF68a" title="Cash and Cash Equivalents, at Carrying Value">102.3</span></span> million and $<span id="xdx_904_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20191231_zrGOptuP9Owa" title="Cash and Cash Equivalents, at Carrying Value">39.2</span> million, respectively, and included cash, investments in money market funds, and United States Treasury securities with original maturities of 90 days or less.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The Company considers securities with original maturities of greater than 90 days at the date of purchase to be available for sale securities. The Company held available for sale securities with a fair value totaling $<span id="xdx_90B_eus-gaap--AvailableForSaleSecuritiesAndHeldToMaturitySecurities_iI_pn5n6_c20201231_zlurjBdW6Y2j" title="Available-for-sale Securities and Held-to-maturity Securities">19.5</span> million and $<span id="xdx_909_eus-gaap--AvailableForSaleSecuritiesAndHeldToMaturitySecurities_iI_pn5n6_c20191231_zdCdJdFQ5uoa" title="Available-for-sale Securities and Held-to-maturity Securities">46.2</span> million at December 31, 2020 and 2019, respectively. These available for sale securities consisted solely of investment-grade corporate debt securities and United States Treasury securities and had expected maturities of less than one year. The Company may sell certain of its marketable securities prior to their stated maturities for reasons including, but not limited to, managing liquidity, credit risk, duration and asset allocation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The Company evaluates securities with unrealized losses, if any, to determine whether the decline in fair value has resulted from credit loss or other factors. As of December 31, 2020, the Company has not recognized any impairment or credit losses on the Company’s available for sale securities. While the Company classifies these securities as available for sale, the Company does not currently intend to sell its investments and the Company currently believes it has the ability to hold these investments until maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The following table summarizes the amortized cost, fair value and allowance for credit losses of the Company’s available for sale securities:</span></p> <p id="xdx_89A_eus-gaap--ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_zG52N8IaFUSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"/><span id="xdx_8BA_zvMuie5VG6D7" style="display: none">SCHEDULE OF AVAILABLE FOR SALE SECURITIES</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortized Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Unrealized Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Unrealized Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1.5pt">Corporate debt securities</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AvailableForSaleSecuritiesAmortizedCost_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CorporateDebtSecuritiesMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Amortized Cost">19,545</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CorporateDebtSecuritiesMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Gross Unrealized Gains"><span style="-sec-ix-hidden: xdx2ixbrl0824">—</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CorporateDebtSecuritiesMember_zoHRHELAKS1i" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Gross Unrealized Losses">(15</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AvailableForSaleSecurities_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CorporateDebtSecuritiesMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair Value">19,530</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesAmortizedCost_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost">19,545</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Gains"><span style="-sec-ix-hidden: xdx2ixbrl0832">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20201231_z92qOn5nrpI9" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Losses">(15</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleSecurities_iI_pn3n3_c20201231_zOgpCLUTbNLe" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">19,530</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortized Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Unrealized Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Unrealized Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1.5pt">U.S. Treasury securities</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesAmortizedCost_c20191231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Amortized Cost">46,208</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20191231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Gross Unrealized Gains"><span style="-sec-ix-hidden: xdx2ixbrl0840">—</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20191231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember_z4hhwaEnMZA" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Gross Unrealized Losses"><span style="-sec-ix-hidden: xdx2ixbrl0842">—</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AvailableForSaleSecurities_c20191231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair Value">46,208</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesAmortizedCost_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost">46,208</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Gains"><span style="-sec-ix-hidden: xdx2ixbrl0848">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20191231_zw5QF4cRDHLb" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Losses"><span style="-sec-ix-hidden: xdx2ixbrl0850">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AvailableForSaleSecurities_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">46,208</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zzeqnQy3GeVg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The Company’s available for sale securities are reported at fair value on the Company’s balance sheets. Unrealized gains (losses) are reported within accumulated other comprehensive income (loss) in the Statements of Comprehensive Loss. The cost of securities sold and any realized gains/losses from the sale of available for sale securities are based on the specific identification method. The changes in accumulated other comprehensive income (loss) associated with the unrealized gain (loss) on available for sale securities for the years ended December 31, 2020, 2019 and 2018, were as follows:</span></p> <p id="xdx_896_eus-gaap--ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_z9qULbYim7Z4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B9_zbI7yQrzMqWf" style="display: none">SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Beginning balance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iS_pn3n3_c20200101__20201231_z1y4IEKnBvFj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl0856">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iS_pn3n3_c20190101__20191231_zZhosGp8kMHh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl0858">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iS_pn3n3_c20180101__20181231_zzp0qCvmNWyg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl0860">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 46%; text-align: left">Current period changes in fair value before reclassifications, net of tax</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_c20200101__20201231_pn3n3" style="width: 14%; text-align: right" title="Current period changes in fair value before reclassifications, net of tax">(15</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_c20190101__20191231_pn3n3" style="width: 14%; text-align: right" title="Current period changes in fair value before reclassifications, net of tax"><span style="-sec-ix-hidden: xdx2ixbrl0864">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_c20180101__20181231_pn3n3" style="width: 14%; text-align: right" title="Current period changes in fair value before reclassifications, net of tax"><span style="-sec-ix-hidden: xdx2ixbrl0866">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Amounts reclassified from accumulated other comprehensive income (loss), net of tax</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodAfterTax_pn3n3_c20200101__20201231_zpdePKTGx67j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amounts reclassified from accumulated other comprehensive income (loss), net of tax"><span style="-sec-ix-hidden: xdx2ixbrl0868">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodAfterTax_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amounts reclassified from accumulated other comprehensive income (loss), net of tax"><span style="-sec-ix-hidden: xdx2ixbrl0870">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodAfterTax_c20180101__20181231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amounts reclassified from accumulated other comprehensive income (loss), net of tax"><span style="-sec-ix-hidden: xdx2ixbrl0872">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other comprehensive income (loss)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other comprehensive income (loss)">(15</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other comprehensive income (loss)"><span style="-sec-ix-hidden: xdx2ixbrl0876">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_c20180101__20181231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other comprehensive income (loss)"><span style="-sec-ix-hidden: xdx2ixbrl0878">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iE_pn3n3_c20200101__20201231_zXJasLvo5nMl" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">(15</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iE_pn3n3_c20190101__20191231_zkHwlTEJXhah" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl0882">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iE_pn3n3_c20180101__20181231_zDjyFthRBBUa" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl0884">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_z7taOqbwaPzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 102300000 39200000 19500000 46200000 <p id="xdx_89A_eus-gaap--ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_zG52N8IaFUSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"/><span id="xdx_8BA_zvMuie5VG6D7" style="display: none">SCHEDULE OF AVAILABLE FOR SALE SECURITIES</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortized Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Unrealized Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Unrealized Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1.5pt">Corporate debt securities</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AvailableForSaleSecuritiesAmortizedCost_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CorporateDebtSecuritiesMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Amortized Cost">19,545</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CorporateDebtSecuritiesMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Gross Unrealized Gains"><span style="-sec-ix-hidden: xdx2ixbrl0824">—</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CorporateDebtSecuritiesMember_zoHRHELAKS1i" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Gross Unrealized Losses">(15</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AvailableForSaleSecurities_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CorporateDebtSecuritiesMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair Value">19,530</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesAmortizedCost_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost">19,545</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Gains"><span style="-sec-ix-hidden: xdx2ixbrl0832">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20201231_z92qOn5nrpI9" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Losses">(15</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleSecurities_iI_pn3n3_c20201231_zOgpCLUTbNLe" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">19,530</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortized Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Unrealized Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Unrealized Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1.5pt">U.S. Treasury securities</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesAmortizedCost_c20191231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Amortized Cost">46,208</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20191231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Gross Unrealized Gains"><span style="-sec-ix-hidden: xdx2ixbrl0840">—</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20191231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember_z4hhwaEnMZA" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Gross Unrealized Losses"><span style="-sec-ix-hidden: xdx2ixbrl0842">—</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AvailableForSaleSecurities_c20191231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair Value">46,208</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesAmortizedCost_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost">46,208</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Gains"><span style="-sec-ix-hidden: xdx2ixbrl0848">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_c20191231_zw5QF4cRDHLb" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Losses"><span style="-sec-ix-hidden: xdx2ixbrl0850">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AvailableForSaleSecurities_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">46,208</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 19545000 15000 19530000 19545000 15000 19530000 46208000 46208000 46208000 46208000 <p id="xdx_896_eus-gaap--ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_z9qULbYim7Z4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B9_zbI7yQrzMqWf" style="display: none">SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Beginning balance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iS_pn3n3_c20200101__20201231_z1y4IEKnBvFj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl0856">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iS_pn3n3_c20190101__20191231_zZhosGp8kMHh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl0858">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iS_pn3n3_c20180101__20181231_zzp0qCvmNWyg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl0860">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 46%; text-align: left">Current period changes in fair value before reclassifications, net of tax</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_c20200101__20201231_pn3n3" style="width: 14%; text-align: right" title="Current period changes in fair value before reclassifications, net of tax">(15</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_c20190101__20191231_pn3n3" style="width: 14%; text-align: right" title="Current period changes in fair value before reclassifications, net of tax"><span style="-sec-ix-hidden: xdx2ixbrl0864">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_c20180101__20181231_pn3n3" style="width: 14%; text-align: right" title="Current period changes in fair value before reclassifications, net of tax"><span style="-sec-ix-hidden: xdx2ixbrl0866">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Amounts reclassified from accumulated other comprehensive income (loss), net of tax</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodAfterTax_pn3n3_c20200101__20201231_zpdePKTGx67j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amounts reclassified from accumulated other comprehensive income (loss), net of tax"><span style="-sec-ix-hidden: xdx2ixbrl0868">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodAfterTax_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amounts reclassified from accumulated other comprehensive income (loss), net of tax"><span style="-sec-ix-hidden: xdx2ixbrl0870">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodAfterTax_c20180101__20181231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amounts reclassified from accumulated other comprehensive income (loss), net of tax"><span style="-sec-ix-hidden: xdx2ixbrl0872">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other comprehensive income (loss)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other comprehensive income (loss)">(15</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other comprehensive income (loss)"><span style="-sec-ix-hidden: xdx2ixbrl0876">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_c20180101__20181231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other comprehensive income (loss)"><span style="-sec-ix-hidden: xdx2ixbrl0878">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iE_pn3n3_c20200101__20201231_zXJasLvo5nMl" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">(15</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iE_pn3n3_c20190101__20191231_zkHwlTEJXhah" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl0882">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iE_pn3n3_c20180101__20181231_zDjyFthRBBUa" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl0884">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> -15000 -15000 -15000 <p id="xdx_806_ecustom--LicenseAndOtherAgreementsTextBlock_z74IH3QxfXnk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>6. <span id="xdx_820_zaRMlrQD3MK6">LICENSE AND OTHER AGREEMENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In May 2018, the Company entered into an Asset Purchase Agreement with MacroGenics (the “MacroGenics Asset Purchase Agreement”) pursuant to which the Company acquired MacroGenics’ interest in teplizumab (renamed PRV-031), a humanized mAb for the treatment of Type 1 Diabetes (“T1D”). As partial consideration for the MacroGenics Asset Purchase Agreement, the Company granted MacroGenics a warrant to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20180531__dei--LegalEntityAxis__custom--MacroGenicsIncMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_pii">2,162,389 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of the Company’s common stock at an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20180531__dei--LegalEntityAxis__custom--MacroGenicsIncMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_pii">2.50 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share. The Company is obligated to pay MacroGenics contingent milestone payments totaling $<span id="xdx_901_ecustom--AmountPayableByEntityOnAchievementOfVariousMilestones_pn5n6_c20180501__20180531__dei--LegalEntityAxis__custom--MacroGenicsIncMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zH85CqNnWbr9">170.0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million upon the achievement of certain regulatory approval milestones, including $<span id="xdx_903_ecustom--AmountPayableByEntityOnAchievementOfVariousMilestones_pn5n6_c20180501__20180531__dei--LegalEntityAxis__custom--MacroGenicsIncMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--BiologicsLicenseApplicationMember_z7SqsRULeEz1">60.0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million payable within 90 days of an approval of a Biologics License Application (“BLA”) in the United States. In addition, the Company is obligated to make contingent milestone payments to MacroGenics totaling $<span id="xdx_90E_ecustom--AmountPayableByEntityOnAchievementOfVariousMilestones_pn5n6_c20180501__20180531__dei--LegalEntityAxis__custom--MacroGenicsIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zLc3NMXKL7Vf">225.0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million upon the achievement of certain sales milestones. The Company has also agreed to pay MacroGenics a single-digit royalty on net sales of the product. The Company has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to MacroGenics, aggregate milestone payments of up to approximately $<span id="xdx_909_ecustom--AmountPayableByEntityOnAchievementOfVariousMilestones_pn5n6_c20180501__20180531__dei--LegalEntityAxis__custom--MacroGenicsIncMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zAwsZYVym0jk">0.7 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million and other consideration, for certain third-party intellectual property under agreements the Company assumed pursuant to the MacroGenics Asset Purchase Agreement. Further, the Company is required to pay MacroGenics a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to teplizumab by the Company to a third party. The Company is obligated to use reasonable commercial efforts to develop and seek regulatory approval for teplizumab.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In May 2018, the Company entered into a License Agreement with MacroGenics, Inc. (the “MacroGenics License Agreement”), pursuant to which MacroGenics, Inc. (“MacroGenics”) granted the Company exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a humanized protein and a potential treatment for systemic lupus erythematosus (“SLE”) and other similar diseases. As partial consideration for the MacroGenics License Agreement, the Company granted MacroGenics a warrant to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20180531__dei--LegalEntityAxis__custom--MacroGenicsIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_pii" title="Class of Warrant or Right, Number of Securities Called by Each Warrant or Right">270,299</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20180531__dei--LegalEntityAxis__custom--MacroGenicsIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_pii" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">2.50</span> per share. The Company is obligated to make contingent milestone payments to MacroGenics totaling $<span id="xdx_90D_ecustom--AmountPayableByEntityOnAchievementOfVariousMilestones_pn5n6_c20180501__20180531__dei--LegalEntityAxis__custom--MacroGenicsIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--AwardTypeAxis__custom--FirstIndicationMember_z2nSSICyqXEa" title="Amount payable by the entity on achievement of various milestones">42.5</span> million upon the achievement of certain developmental and approval milestones for the first indication, and an additional $<span id="xdx_907_ecustom--AmountPayableByEntityOnAchievementOfVariousMilestones_pn5n6_c20180501__20180531__dei--LegalEntityAxis__custom--MacroGenicsIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--AwardTypeAxis__custom--SecondIndicationMember_zrTFmWyjVJVa" title="Amount payable by the entity on achievement of various milestones">22.5</span> million upon the achievement of certain regulatory approvals for a second indication. In addition, the Company is obligated to make contingent milestone payments to MacroGenics totaling $<span id="xdx_901_ecustom--AmountPayableByEntityOnAchievementOfVariousMilestones_pn5n6_c20180501__20180531__dei--LegalEntityAxis__custom--MacroGenicsIncMember_zlx83BwCQk85" title="Amount payable by the entity on achievement of various milestones">225.0</span> million upon the achievement of certain sales milestones. The Company has also agreed to pay MacroGenics a single-digit royalty on net sales of the product. Further, the Company is required to pay MacroGenics a low double-digit percentage of certain consideration to the extent received in connection with a future grant of rights to PRV-3279 by the Company to a third party. The Company is obligated to use commercially reasonable efforts to develop and seek regulatory approval for PRV-3279. The license agreement may also be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to MacroGenics, and by MacroGenics in the event that the Company challenges the validity of any licensed patent under the agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">As of December 31, 2020, the Company has not achieved any milestones that would trigger payments to MacroGenics.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company recorded the warrants issued under the MacroGenics Asset Purchase Agreement and the MacroGenics License Agreement at an estimated fair value of $<span id="xdx_90B_ecustom--FairValuePerShareOfEachWarrant_c20180531__us-gaap--TypeOfArrangementAxis__custom--MacroGenicsAssetPurchaseAgreementAndMacroGenicsLicenseAgreementMember_pii" title="Fair Value per share of each warrant">1.64</span> per share, approximately $<span id="xdx_908_ecustom--WarrantsIssuedDuringPeriodFairValue_pn5n6_c20180501__20180531__us-gaap--TypeOfArrangementAxis__custom--MacroGenicsAssetPurchaseAgreementAndMacroGenicsLicenseAgreementMember_zKyJ3s5l3lIi" title="Warrants issued during period, fair value">4.0</span> million in the aggregate, as license fee expense included as part of Research &amp; development expense during the second quarter of 2018.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In July 2019, MacroGenics elected to exercise its warrants for an aggregate of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20190731__dei--LegalEntityAxis__custom--MacroGenicsIncMember_zMqCsGMbm9Y1" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights">2,432,688</span> shares on a cashless basis, resulting in the Company’s net issuance of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesOther_pii_c20190701__20190731__dei--LegalEntityAxis__custom--MacroGenicsIncMember_zGxJS5FZnTQc" title="Number of warrants issuance shares">1,948,474</span> shares. Following the MacroGenics’ July 2019 warrant exercises, there were no additional warrants outstanding in connection with the MacroGenics License Agreement and the MacroGenics Asset Purchase Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In November 2018, the Company entered into a License and Collaboration Agreement (the “Amgen Agreement”) with Amgen, Inc. (“Amgen”) for PRV-015 (formerly AMG 714), a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease (“NRCD”). Under the terms of the agreement, the Company will conduct and fund a Phase 2b trial in NRCD and lead the development and regulatory activities for the program. Amgen agreed to make an equity investment of up to $<span id="xdx_905_ecustom--PotentialProceedsFromInvestmentByCollaborator_iI_pn5n6_c20181130__dei--LegalEntityAxis__custom--AmgenIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndCollaborationAgreementMember_z8WKJhfoeIYd" title="Potential proceeds from investment by collaborator">20.0</span> million in the Company, subject to certain terms and conditions set forth in the agreement. Amgen is also responsible for the manufacturing of PRV-015. Upon completion of the Phase 2b trial, a $<span id="xdx_90B_ecustom--AmountReceivablebytheentityonachievementofvariousmilestones_pn5n6_c20181101__20181130__dei--LegalEntityAxis__custom--AmgenIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndCollaborationAgreementMember_zl0aJEHrCpk1" title="Amount payable by the entity on achievement of various milestones">150.0</span> million milestone payment is due from Amgen to the Company, plus an additional regulatory milestone payment, and single digit royalties on future sales; provided, however, that Amgen has the right to elect not to pay the $150.0 million milestone, in which case we will have an option to negotiate for the transfer to the Company of rights to AMG 714 pursuant to a termination license agreement between Amgen and the Company. The material terms of the termination license agreement have been negotiated and agreed and form part of the Amgen Agreement. Under the terms of the termination license agreement, the Company would be obligated to make certain contingent milestone payments to Amgen and other third parties totaling up to $<span id="xdx_901_ecustom--AmountPayableByEntityOnAchievementOfVariousMilestones_pn5n6_c20181101__20181130__dei--LegalEntityAxis__custom--AmgenIncMember_zEom7IVOgmQ1" title="Amount payable by the entity on achievement of various milestones">70.0</span> million upon the achievement of certain clinical and regulatory milestones and a low double-digit royalty on net sales of any approved product based on the IL-15 technology. The agreement may be terminated by either party upon a material breach or upon an insolvency event and by Amgen if we are not able to fund our clinical development obligations (among other termination triggers). The agreement expires upon the expiration of Amgen’s last obligation to make royalty payments to Provention. In September 2019, in a private placement completed concurrently with the Company’s underwritten public offering, Amgen purchased <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pii_c20190901__20190930__dei--LegalEntityAxis__custom--AmgenIncMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zFGAvaCyAczh" title="Sale of Stock, Number of Shares Issued in Transaction">2,500,000</span> shares of the Company’s common stock at the underwritten public offering price of $<span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_pii_c20190930__dei--LegalEntityAxis__custom--AmgenIncMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zScDsiPXdm63" title="Sale of Stock, Price Per Share">8.00</span> per share, for a total investment of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20190901__20190930__dei--LegalEntityAxis__custom--AmgenIncMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zfeypefooZXe" title="Proceeds from Issuance of Private Placement">20.0</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In April 2017, the Company entered into a License Agreement with Vactech Ltd. (the “Vactech License Agreement”), pursuant to which Vactech Ltd. (“Vactech”) granted the Company exclusive global rights for the purpose of developing and commercializing the group B coxsackie virus vaccine (“CVB”) platform technology. In consideration of the licenses and other rights granted by Vactech, the Company issued two million shares of its common stock to Vactech. The Company recorded the issuance of the shares at their estimated fair value of approximately $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_c20170430__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--VactechMember_pii">1.70 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share for a total of $<span id="xdx_907_ecustom--WarrantsIssuedDuringPeriodFairValue_pn5n6_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--VactechMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zP546qGui3re">3.4 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million as a license fee expense included as part of Research &amp; development expense for the year ended December 31, 2017. Provention paid Vactech a total of approximately $<span id="xdx_908_ecustom--PaymentsMadeForDevelpomentAndManufacturingServices_pn5n6_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--VactechMember__us-gaap--AwardTypeAxis__custom--FirstEighteenMonthsMember_zSkBGSU9yWDd">0.5 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million for transition and advisory services during the first 18 months of the term of the agreement. In addition, Provention may be obligated to make a series of contingent milestone payments to Vactech totaling up to an additional $<span id="xdx_904_ecustom--AmountPayableByEntityOnAchievementOfVariousMilestones_pn5n6_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--VactechMember_zbv7ykryAtO">24.5 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million upon the achievement of certain clinical development and regulatory filing milestones, of which, $<span id="xdx_905_ecustom--AmountPayableByEntityOnAchievementOfVariousMilestones_c20210101__20210131__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--VactechMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--DosingOfFirstPatientInPhaseOnePROVENTStudyMember_pn5n6" title="Amount payable by the entity on achievement of various milestones">0.5</span> million became payable to Vactech in January 2021 upon the dosing of the first patient in the Phase 1 PROVENT study. In addition, the Company has agreed to pay Vactech tiered single-digit royalties on net sales of any approved product based on the CVB platform technology and three additional payments totaling $<span id="xdx_900_ecustom--AmountPayableByEntityOnAchievementOfVariousSalesMilestones_pn5n6_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--VactechMember_z0NCSniWqggk">19.0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million upon the achievement of certain annual net sales levels. The Vactech License Agreement may be terminated by the Company on a country by country basis without cause (in which case the exclusive global rights to the technology will transfer back to Vactech) and by either party upon a material breach or insolvency of the other party. If the Company terminates the agreement with respect to two or more specified European countries, the agreement will be deemed terminated with respect to all of the EU, and if the Company terminates the agreement with respect to the United States, the agreement will be deemed terminated with respect to all of North America. The agreement expires upon the expiration of the Company’s last obligation to make royalty payments to Vactech. As of December 31, 2020, the Company has not achieved any milestones that would trigger payments to Vactech.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In March 2018, the Company entered into a Development Services Agreement with The Institute of Translational Vaccinology (the “Intravacc Development Services Agreement”), pursuant to which The Institute of Translational Vaccinology (“Intravacc”) will provide services related to process development, non-GMP and GMP manufacturing of the Company’s polyvalent CVB vaccine, including providing proprietary technology for manufacturing purposes. The Company will pay Intravacc approximately 10 million euros for their services over the development and manufacturing period. Each party retains its existing intellectual property and will share newly developed intellectual property via a fully-paid non-exclusive license between the parties for all development work through phase 1 clinical trials. Any future use, including commercial use, of Intravacc’s technology will be subject to a separate nonexclusive license agreement. The Intravacc Development Services Agreement may be terminated by us with ninety days’ notice without cause and by either party upon a material breach or insolvency of the other party. As of December 31, 2020, the Company had paid Intravacc a total of approximately <span id="xdx_904_ecustom--PaymentsMadeForDevelpomentAndManufacturingServices_pn5n6_uEUR_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--IntravaccDevelopmentServicesAgreementMember__us-gaap--AwardTypeAxis__custom--EuroMember_zIyFUxj2BZLd" title="Payments made for develpoment and manufacturing services">9.0</span> million euros, or approximately $<span id="xdx_90E_ecustom--PaymentsMadeForDevelpomentAndManufacturingServices_pn5n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--IntravaccDevelopmentServicesAgreementMember_z0EKDrlXTN3k" title="Payments made for develpoment and manufacturing services">10.5</span> million, for services provided by Intravacc under the Intravacc Development Services Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">In April 2017, the Company entered into the Janssen CSF-1R License Agreement, pursuant to which Janssen Pharmaceutica NV (“Janssen”) granted the Company exclusive global rights to technology owned or controlled by Janssen Pharmaceutica NV for the purpose of developing and commercializing a colony stimulating factor 1 receptor (“CSF-1R”) inhibitor named JNJ-40346527 (renamed PRV-6527) for inflammatory bowel diseases including Crohn’s disease and UC. The Company evaluated PRV-6527 for Crohn’s disease in a recently completed Phase 2a clinical trial (the PRINCE study). In December 2019, Janssen declined its option to buy back the rights to PRV-6527 and as such, all rights will remain with the Company. The Company will be obligated to make contingent milestone payments to Janssen totaling $<span id="xdx_90D_ecustom--AmountPayableByEntityOnAchievementOfVariousMilestones_pn5n6_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--LicenseDevelopmentandCommercializationAgreementMember__dei--LegalEntityAxis__custom--JanssenPharmaceuticaNVMember__us-gaap--AwardTypeAxis__custom--FirstIndicationMember_zAMzTfSWAdG1" title="Amount payable by the entity on achievement of various milestones">35.0</span> million upon the achievement of certain clinical and regulatory milestones for the first indication and an additional $<span id="xdx_907_ecustom--AmountPayableByEntityOnAchievementOfVariousMilestones_pn5n6_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--LicenseDevelopmentandCommercializationAgreementMember__dei--LegalEntityAxis__custom--JanssenPharmaceuticaNVMember__us-gaap--AwardTypeAxis__custom--SecondIndicationMember_zPMARlv6tdn5" title="Amount payable by the entity on achievement of various milestones">20.0</span> million upon the achievement of certain clinical and regulatory milestones for a second indication. In addition, the Company has agreed to pay Janssen tiered single-digit royalties on net sales of any approved product based on the CSF-1R technology and three additional payments totaling $<span id="xdx_90C_ecustom--AmountPayableByEntityOnAchievementOfVariousSalesMilestones_pn5n6_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--LicenseDevelopmentandCommercializationAgreementMember__dei--LegalEntityAxis__custom--JanssenPharmaceuticaNVMember_zOxC7YNlAkw8" title="Payments made on tiered single-digit royalties">100.0</span> million upon the achievement of certain annual net sales levels. As of December 31, 2020, no milestones have been achieved that would trigger payments to Janssen under the CSF-1R License Agreement. The Company is not actively developing PRV-6527.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 2162389 2.50 170000000.0 60000000.0 225000000.0 700000 270299 2.50 42500000 22500000 225000000.0 1.64 4000000.0 2432688 1948474 20000000.0 150000000.0 70000000.0 2500000 8.00 20000000.0 1.70 3400000 500000 24500000 500000 19000000.0 9000000.0 10500000 35000000.0 20000000.0 100000000.0 <p id="xdx_80D_eus-gaap--EarningsPerShareTextBlock_zN4gC2etPvqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>7. <span id="xdx_82A_z6pWF5w3l4u7">NET LOSS PER SHARE OF COMMON STOCK</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following table sets forth the computation of basic and diluted loss per share for the years ended December 31, 2020, 2019, and 2018:</span></p> <p id="xdx_893_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zStMlM73SPd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span><span id="xdx_8BF_zlcMogamhPTc" style="display: none">SCHEDULE OF COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Net loss, basic</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--NetIncomeLoss_c20200101__20201231_pn3n3" style="width: 12%; text-align: right" title="Net loss, basic">(98,581</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--NetIncomeLoss_c20190101__20191231_pn3n3" style="width: 12%; text-align: right" title="Net loss, basic">(43,285</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--NetIncomeLoss_c20180101__20181231_pn3n3" style="width: 12%; text-align: right" title="Net loss, basic">(26,478</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accretion of Series A Convertible Redeemable Preferred Stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--TemporaryEquityAccretionToRedemptionValueAdjustment_iN_pn3n3_di_c20200101__20201231_zCDR57LmPO03" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accretion of Series A Convertible Redeemable Preferred Stock"><span style="-sec-ix-hidden: xdx2ixbrl0951">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--TemporaryEquityAccretionToRedemptionValueAdjustment_iN_pn3n3_di_c20190101__20191231_zh2UASmkqdHk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accretion of Series A Convertible Redeemable Preferred Stock"><span style="-sec-ix-hidden: xdx2ixbrl0953">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--TemporaryEquityAccretionToRedemptionValueAdjustment_iN_pn3n3_di_c20180101__20181231_zvGbwYf1Bhyd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accretion of Series A Convertible Redeemable Preferred Stock">(276</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss attributable to common stockholders">(98,581</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss attributable to common stockholders">(43,285</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20180101__20181231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss attributable to common stockholders">(26,754</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted average shares of common stock outstanding - basic and diluted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_pn3n3_c20200101__20201231_z55BRhBerWZ7" style="text-align: right" title="Weighted average common shares outstanding, basic and diluted">52,457</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_pn3n3_c20190101__20191231_zls2kEQHw7V3" style="text-align: right" title="Weighted average common shares outstanding, basic and diluted">40,747</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_pn3n3_c20180101__20181231_zRa4rLS1mXg4" style="text-align: right" title="Weighted average common shares outstanding, basic and diluted">22,441</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net loss per share of common stock, basic and diluted</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--EarningsPerShareBasicAndDiluted_pii_c20200101__20201231_zEt8vrz7CHj3" style="text-align: right" title="Net loss per common share, basic and diluted">(1.88</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--EarningsPerShareBasicAndDiluted_pii_c20190101__20191231_zzdrNcPkaFc8" style="text-align: right" title="Net loss per common share, basic and diluted">(1.06</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--EarningsPerShareBasicAndDiluted_pii_c20180101__20181231_z8NWcJzdSpLf" style="text-align: right" title="Net loss per common share, basic and diluted">(1.19</td><td style="text-align: left">)</td></tr> </table> <p id="xdx_8A5_zBnvUPH7QjR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as they would be antidilutive:</span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zUNc0Q66o8i7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BE_zPOEXkzS7Xq3" style="display: none">SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zkPfJoOGDJM9" style="width: 14%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share">9,503</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zf4uHGxsbYw7" style="width: 14%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share">5,894</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20180101__20181231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zZ5Q3405uPvk" style="width: 14%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share">3,476</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zWF79FftEjp2" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share">1,705</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zJQkHfRg9qk1" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share">2,125</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20180101__20181231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zvkibsuJc40h" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share">4,588</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A0_zlnJeuOzsPjc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_893_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zStMlM73SPd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span><span id="xdx_8BF_zlcMogamhPTc" style="display: none">SCHEDULE OF COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Net loss, basic</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--NetIncomeLoss_c20200101__20201231_pn3n3" style="width: 12%; text-align: right" title="Net loss, basic">(98,581</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--NetIncomeLoss_c20190101__20191231_pn3n3" style="width: 12%; text-align: right" title="Net loss, basic">(43,285</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--NetIncomeLoss_c20180101__20181231_pn3n3" style="width: 12%; text-align: right" title="Net loss, basic">(26,478</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accretion of Series A Convertible Redeemable Preferred Stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--TemporaryEquityAccretionToRedemptionValueAdjustment_iN_pn3n3_di_c20200101__20201231_zCDR57LmPO03" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accretion of Series A Convertible Redeemable Preferred Stock"><span style="-sec-ix-hidden: xdx2ixbrl0951">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--TemporaryEquityAccretionToRedemptionValueAdjustment_iN_pn3n3_di_c20190101__20191231_zh2UASmkqdHk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accretion of Series A Convertible Redeemable Preferred Stock"><span style="-sec-ix-hidden: xdx2ixbrl0953">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--TemporaryEquityAccretionToRedemptionValueAdjustment_iN_pn3n3_di_c20180101__20181231_zvGbwYf1Bhyd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accretion of Series A Convertible Redeemable Preferred Stock">(276</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss attributable to common stockholders">(98,581</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss attributable to common stockholders">(43,285</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20180101__20181231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss attributable to common stockholders">(26,754</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted average shares of common stock outstanding - basic and diluted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_pn3n3_c20200101__20201231_z55BRhBerWZ7" style="text-align: right" title="Weighted average common shares outstanding, basic and diluted">52,457</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_pn3n3_c20190101__20191231_zls2kEQHw7V3" style="text-align: right" title="Weighted average common shares outstanding, basic and diluted">40,747</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_pn3n3_c20180101__20181231_zRa4rLS1mXg4" style="text-align: right" title="Weighted average common shares outstanding, basic and diluted">22,441</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net loss per share of common stock, basic and diluted</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--EarningsPerShareBasicAndDiluted_pii_c20200101__20201231_zEt8vrz7CHj3" style="text-align: right" title="Net loss per common share, basic and diluted">(1.88</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--EarningsPerShareBasicAndDiluted_pii_c20190101__20191231_zzdrNcPkaFc8" style="text-align: right" title="Net loss per common share, basic and diluted">(1.06</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--EarningsPerShareBasicAndDiluted_pii_c20180101__20181231_z8NWcJzdSpLf" style="text-align: right" title="Net loss per common share, basic and diluted">(1.19</td><td style="text-align: left">)</td></tr> </table> -98581000 -43285000 -26478000 276000 -98581000 -43285000 -26754000 52457000 40747000 22441000 -1.88 -1.06 -1.19 <p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zUNc0Q66o8i7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BE_zPOEXkzS7Xq3" style="display: none">SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zkPfJoOGDJM9" style="width: 14%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share">9,503</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zf4uHGxsbYw7" style="width: 14%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share">5,894</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20180101__20181231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zZ5Q3405uPvk" style="width: 14%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share">3,476</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zWF79FftEjp2" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share">1,705</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zJQkHfRg9qk1" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share">2,125</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20180101__20181231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zvkibsuJc40h" style="text-align: right" title="Antidilutive securities excluded from computation of earnings per share">4,588</td><td style="text-align: left"> </td></tr> </table> 9503000 5894000 3476000 1705000 2125000 4588000 <p id="xdx_807_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zsW7aMGDAcpl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>8. <span id="xdx_822_zjT8UaBsCY8k">ACCRUED EXPENSES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Accrued expenses consisted of the following:</span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zoXKglhdhzSj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B3_zHbJWpSkSyki" style="display: none">SCHEDULE OF ACCRUED EXPENSES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 64%; text-align: left">Accrued research and development costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--AccruedResearchAndDevelopmentCostsCurrent_c20201231_pn3n3" style="width: 14%; text-align: right" title="Accrued research and development costs">5,165</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--AccruedResearchAndDevelopmentCostsCurrent_c20191231_pn3n3" style="width: 14%; text-align: right" title="Accrued research and development costs">1,700</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Accrued compensation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AccruedBonusesCurrent_c20201231_pn3n3" style="text-align: right" title="Accrued compensation">1,443</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AccruedBonusesCurrent_c20191231_pn3n3" style="text-align: right" title="Accrued compensation">54</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Accrued professional fees</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AccruedProfessionalFeesCurrent_c20201231_pn3n3" style="text-align: right" title="Accrued professional fees">1,197</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AccruedProfessionalFeesCurrent_c20191231_pn3n3" style="text-align: right" title="Accrued professional fees">221</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Accrued pre-commercial costs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--AccruedPrecommercialCosts_c20201231_pn3n3" style="text-align: right" title="Accrued pre-commercial costs">1,191</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--AccruedPrecommercialCosts_c20191231_pn3n3" style="text-align: right" title="Accrued pre-commercial costs"><span style="-sec-ix-hidden: xdx2ixbrl1007">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other accrued liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--OtherAccruedLiabilitiesCurrent_c20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other accrued liabilities">166</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--OtherAccruedLiabilitiesCurrent_c20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other accrued liabilities">90</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AccruedLiabilitiesCurrent_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total accrued expenses">9,162</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AccruedLiabilitiesCurrent_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total accrued expenses">2,065</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zbVWj8o4MiN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zoXKglhdhzSj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B3_zHbJWpSkSyki" style="display: none">SCHEDULE OF ACCRUED EXPENSES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 64%; text-align: left">Accrued research and development costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--AccruedResearchAndDevelopmentCostsCurrent_c20201231_pn3n3" style="width: 14%; text-align: right" title="Accrued research and development costs">5,165</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--AccruedResearchAndDevelopmentCostsCurrent_c20191231_pn3n3" style="width: 14%; text-align: right" title="Accrued research and development costs">1,700</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Accrued compensation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AccruedBonusesCurrent_c20201231_pn3n3" style="text-align: right" title="Accrued compensation">1,443</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AccruedBonusesCurrent_c20191231_pn3n3" style="text-align: right" title="Accrued compensation">54</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Accrued professional fees</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AccruedProfessionalFeesCurrent_c20201231_pn3n3" style="text-align: right" title="Accrued professional fees">1,197</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AccruedProfessionalFeesCurrent_c20191231_pn3n3" style="text-align: right" title="Accrued professional fees">221</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Accrued pre-commercial costs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--AccruedPrecommercialCosts_c20201231_pn3n3" style="text-align: right" title="Accrued pre-commercial costs">1,191</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--AccruedPrecommercialCosts_c20191231_pn3n3" style="text-align: right" title="Accrued pre-commercial costs"><span style="-sec-ix-hidden: xdx2ixbrl1007">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other accrued liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--OtherAccruedLiabilitiesCurrent_c20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other accrued liabilities">166</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--OtherAccruedLiabilitiesCurrent_c20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other accrued liabilities">90</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AccruedLiabilitiesCurrent_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total accrued expenses">9,162</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AccruedLiabilitiesCurrent_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total accrued expenses">2,065</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5165000 1700000 1443000 54000 1197000 221000 1191000 166000 90000 9162000 2065000 <p id="xdx_801_eus-gaap--FairValueDisclosuresTextBlock_zpVtRa53IIJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>9. <span id="xdx_821_zUNRcSBl4UO5">FAIR VALUE OF ASSETS AND LIABILITIES</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The carrying amounts reported in the balance sheet for cash and cash equivalents, accounts payable and accrued expenses approximate fair value based on the short-term nature of these items.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In accordance with accounting principles generally accepted in the United States, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level hierarchy prioritizes the inputs used to measure fair value as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Level 2 – Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Level 3 – Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"><span style="font: 10pt Times New Roman, Times, Serif">The following is a summary of assets and their related classifications under the fair value hierarchy:</span></p> <p id="xdx_892_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zvWziF2LFLx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"><span id="xdx_8BD_zuv6KuGm1RWl" style="display: none">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Financial Instruments Carried at Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Quoted prices<br/> in active markets for </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>identical items</b></span></p></td><td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Significant<br/> other observable<br/> inputs</b></span></p></td><td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Significant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>unobservable<br/> inputs</b></span></p></td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left"><span id="xdx_F49_zXVWEmw6jqA9" style="font: 10pt Times New Roman, Times, Serif">Cash and cash equivalents<sup>1</sup></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashAndCashEquivalentsMember_fMQ_____zgftj4ZMEmi" style="width: 12%; text-align: right" title="Fair value of assets">102,294</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashAndCashEquivalentsMember_fMQ_____zQdxYpU3QM6l" style="width: 12%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl1023">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashAndCashEquivalentsMember_fMQ_____ziruwxuk0T7k" style="width: 12%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl1025">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashAndCashEquivalentsMember_fMQ_____zQMooXLlVbRf" style="width: 12%; text-align: right" title="Fair value of assets">102,294</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span id="xdx_F42_zzRkC2Jst09l" style="font: 10pt Times New Roman, Times, Serif">Investments in Corporate debt securities<sup>2</sup></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__custom--InvestmentsInCorporateDebtSecuritiesMember_fMg_____zfsgC2M04Q8i" style="text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl1029">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__custom--InvestmentsInCorporateDebtSecuritiesMember_fMg_____zYVhudgsqgme" style="text-align: right" title="Fair value of assets">19,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__custom--InvestmentsInCorporateDebtSecuritiesMember_fMg_____ziA7ZbV3bOoj" style="text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl1033">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20201231__us-gaap--CashAndCashEquivalentsAxis__custom--InvestmentsInCorporateDebtSecuritiesMember_fMg_____zUpVV7viRsB9" style="text-align: right" title="Fair value of assets">19,530</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2019</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Financial Instruments Carried at Fair Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Quoted prices<br/> in active markets for </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>identical items</b></p></td><td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Significant</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>other observable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>inputs</b></p></td><td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Significant </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>unobservable<br/> inputs</b></p></td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_F46_zziyF89BH3v5" style="width: 36%; text-align: left">Cash and cash equivalents <sup>1</sup></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashAndCashEquivalentsMember_fMQ_____zamdVAEk95Kk" style="width: 12%; text-align: right" title="Fair value of assets">39,165</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashAndCashEquivalentsMember_fMQ_____zLH5EPq9wuS9" style="width: 12%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl1039">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashAndCashEquivalentsMember_fMQ_____zjBRZZ2VlEY1" style="width: 12%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl1041">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20191231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashAndCashEquivalentsMember_fMQ_____zsE13AVxU7y2" style="width: 12%; text-align: right" title="Fair value of assets">39,165</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td id="xdx_F43_z8aKz952yyQa" style="text-align: left">Investments in U.S. Treasury securities<sup>2</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__custom--InvestmentsInUSTreasurySecuritiesMember_fMg_____zmp79aXXZQV8" style="text-align: right" title="Fair value of assets">46,208</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__custom--InvestmentsInUSTreasurySecuritiesMember_fMg_____z9awhtBztgeb" style="text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl1047">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__custom--InvestmentsInUSTreasurySecuritiesMember_fMg_____zx160qDCAip1" style="text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl1049">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20191231__us-gaap--CashAndCashEquivalentsAxis__custom--InvestmentsInUSTreasurySecuritiesMember_fMg_____z0twxO1ngUb2" style="text-align: right" title="Fair value of assets">46,208</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"/> <div style="margin-top: 0; margin-bottom: 0; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 0.1in"><sup id="xdx_F0E_zfYEmrwgjPoj">1</sup></td> <td id="xdx_F10_zc9cgUOUUmP3">Cash and cash equivalents primarily include investments in money market funds and United States Treasury securities with maturity dates within 90 days from the purchase date</td> </tr> <tr style="vertical-align: top; text-align: left"> <td><sup id="xdx_F0B_zqqBI4SM4MM2">2</sup></td> <td id="xdx_F1F_zXNIfAste9E8">Investments in United States Treasury and investment-grade corporate debt securities are classified as available for sale securities</td> </tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><sup> </sup></span></p> <p id="xdx_8A6_zOiRR6iAXGo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zvWziF2LFLx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"><span id="xdx_8BD_zuv6KuGm1RWl" style="display: none">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Financial Instruments Carried at Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Quoted prices<br/> in active markets for </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>identical items</b></span></p></td><td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Significant<br/> other observable<br/> inputs</b></span></p></td><td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Significant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>unobservable<br/> inputs</b></span></p></td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left"><span id="xdx_F49_zXVWEmw6jqA9" style="font: 10pt Times New Roman, Times, Serif">Cash and cash equivalents<sup>1</sup></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashAndCashEquivalentsMember_fMQ_____zgftj4ZMEmi" style="width: 12%; text-align: right" title="Fair value of assets">102,294</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashAndCashEquivalentsMember_fMQ_____zQdxYpU3QM6l" style="width: 12%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl1023">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashAndCashEquivalentsMember_fMQ_____ziruwxuk0T7k" style="width: 12%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl1025">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashAndCashEquivalentsMember_fMQ_____zQMooXLlVbRf" style="width: 12%; text-align: right" title="Fair value of assets">102,294</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span id="xdx_F42_zzRkC2Jst09l" style="font: 10pt Times New Roman, Times, Serif">Investments in Corporate debt securities<sup>2</sup></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__custom--InvestmentsInCorporateDebtSecuritiesMember_fMg_____zfsgC2M04Q8i" style="text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl1029">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__custom--InvestmentsInCorporateDebtSecuritiesMember_fMg_____zYVhudgsqgme" style="text-align: right" title="Fair value of assets">19,530</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__custom--InvestmentsInCorporateDebtSecuritiesMember_fMg_____ziA7ZbV3bOoj" style="text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl1033">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20201231__us-gaap--CashAndCashEquivalentsAxis__custom--InvestmentsInCorporateDebtSecuritiesMember_fMg_____zUpVV7viRsB9" style="text-align: right" title="Fair value of assets">19,530</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2019</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Financial Instruments Carried at Fair Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Quoted prices<br/> in active markets for </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>identical items</b></p></td><td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Significant</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>other observable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>inputs</b></p></td><td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Significant </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>unobservable<br/> inputs</b></p></td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_F46_zziyF89BH3v5" style="width: 36%; text-align: left">Cash and cash equivalents <sup>1</sup></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashAndCashEquivalentsMember_fMQ_____zamdVAEk95Kk" style="width: 12%; text-align: right" title="Fair value of assets">39,165</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashAndCashEquivalentsMember_fMQ_____zLH5EPq9wuS9" style="width: 12%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl1039">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashAndCashEquivalentsMember_fMQ_____zjBRZZ2VlEY1" style="width: 12%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl1041">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20191231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashAndCashEquivalentsMember_fMQ_____zsE13AVxU7y2" style="width: 12%; text-align: right" title="Fair value of assets">39,165</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td id="xdx_F43_z8aKz952yyQa" style="text-align: left">Investments in U.S. Treasury securities<sup>2</sup></td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__custom--InvestmentsInUSTreasurySecuritiesMember_fMg_____zmp79aXXZQV8" style="text-align: right" title="Fair value of assets">46,208</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__custom--InvestmentsInUSTreasurySecuritiesMember_fMg_____z9awhtBztgeb" style="text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl1047">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__custom--InvestmentsInUSTreasurySecuritiesMember_fMg_____zx160qDCAip1" style="text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl1049">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20191231__us-gaap--CashAndCashEquivalentsAxis__custom--InvestmentsInUSTreasurySecuritiesMember_fMg_____z0twxO1ngUb2" style="text-align: right" title="Fair value of assets">46,208</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"/> <div style="margin-top: 0; margin-bottom: 0; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 0.1in"><sup id="xdx_F0E_zfYEmrwgjPoj">1</sup></td> <td id="xdx_F10_zc9cgUOUUmP3">Cash and cash equivalents primarily include investments in money market funds and United States Treasury securities with maturity dates within 90 days from the purchase date</td> </tr> <tr style="vertical-align: top; text-align: left"> <td><sup id="xdx_F0B_zqqBI4SM4MM2">2</sup></td> <td id="xdx_F1F_zXNIfAste9E8">Investments in United States Treasury and investment-grade corporate debt securities are classified as available for sale securities</td> </tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><sup> </sup></span></p> 102294000 102294000 19530000 19530000 39165000 39165000 46208000 46208000 <p id="xdx_805_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zPwVVc3eJ3q6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>10. <span id="xdx_827_zbGmO2ioeGl8">STOCK OPTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In 2017, the Company adopted the Provention Bio, Inc. 2017 Equity Incentive Plan (the “2017 Plan”). Pursuant to the 2017 Plan, the Company’s Board of Directors may grant incentive stock options, nonqualified stock options, and restricted stock to employees, officers, directors, consultants and advisors. As of December 31, 2020, there were options to purchase an aggregate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zJ2R8lGBYTBh" title="Number of options outstanding">9,503,228</span> shares of common stock outstanding under the 2017 Plan. Options issued under the 2017 Plan are exercisable for up to <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20200101__20201231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zuf1cpWEZQni" title="Option exercisable expiration period">10</span> years from the date of issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In 2018, the Company amended and restated its 2017 Plan to, among other things, include an evergreen provision, which would automatically increase <span id="xdx_908_ecustom--NumberOfSharesDescription_c20200101__20201231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember" title="Number of shares, description">the number of shares available for issuance under the 2017 Plan in an amount equal to (1) the difference between (x) 18% of the total shares of the Company’s common stock outstanding, on a fully diluted basis, on December 31st of the preceding calendar year, and (y) the total number of shares of the Company’s common stock reserved under the 2017 Plan on December 31st of such preceding calendar year or (2) an amount less than this calculated increase as determined by the board of directors.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In connection with the evergreen provisions of the 2017 Plan, the number of shares available for issuance under the 2017 Plan was increased by <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20210102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember__srt--RangeAxis__srt--MaximumMember_pii" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant">2,270,353</span> shares, as determined by the board of directors under the provisions described above, effective as of January 1, 2021. As of December 31, 2020, there were <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20201231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_pii" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant">109,499</span> shares available for future grants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">In October 2020, the Company adopted the Provention Bio, Inc. 2020 Inducement Plan (the “2020 Inducement Plan”). Pursuant to the terms of the 2020 Inducement Plan, the Company may grant nonstatutory stock options, stock appreciation rights, restricted stock unit awards and restricted stock for up to a total of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_c20201031__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyInducementPlanMember_zuoHqvBSvBsg" title="Number of options authorized">2,000,000</span> shares of common stock to individuals that were not previously an employee or director of the Company or individuals returning to employment after a bona fide period of non-employment with the Company. As of December 31, 2020, there were no options to purchase shares of common stock outstanding under the 2020 Inducement Plan. </span><span style="font: 10pt Times New Roman, Times, Serif">Options issued under the 2020 Inducement Plan are exercisable for up to <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20201001__20201031__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyInducementPlanMember_zKyI3tmvaozj" title="Option exercisable expiration period">10</span> years from the date of issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Stock-based compensation </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Total stock-based compensation expense recognized for both employees and non-employees was as follows:</span></p> <p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zkCyIPpAa4j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BD_z0gusL8EODXd" style="display: none">SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">General and administrative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="width: 14%; text-align: right" title="Total stock-based compensation expense">7,611</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="width: 14%; text-align: right" title="Total stock-based compensation expense">1,546</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_c20180101__20181231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="width: 14%; text-align: right" title="Total stock-based compensation expense">512</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensation_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">5,612</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">1,296</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_c20180101__20181231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">629</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">13,223</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">2,842</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_c20180101__20181231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">1,141</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zY5npEynZlLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Option activity</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company grants options with service-based vesting requirements as well as options with performance-based vesting requirements. Generally, the service-based requirements vest over a four-year period in multiple tranches. Each tranche of the performance-based component vests upon the achievement of a specific milestone. These milestones are related to the Company’s clinical trials, manufacturing activities, regulatory activities, commercial activities and certain other performance metrics.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A summary of option activity for the years ended December 31, 2020 and 2019 are presented below:</span></p> <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zbRm7bjTvBJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BC_zDxXW0Bm5vWh" style="display: none">SUMMARY OF STOCK OPTION ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Weighted-</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Average</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Remaining</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Underlying</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Stock Option Awards</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Term</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 42%">Outstanding at December 31, 2018</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20190101__20191231_zi9NUfU4rfkh" style="width: 11%; text-align: right" title="Stock Options Underlying Shares, Outstanding beginning">3,476</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20181231_zrL0jddUzWL9" style="width: 11%; text-align: right" title="Weighted-Average Exercise Price, Outstanding beginning balance">2.85</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 11%; text-align: right"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190101__20191231_pii" style="text-align: right" title="Stock Options Underlying Shares, Granted">2,797</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190101__20191231_pii" style="text-align: right" title="Weighted-Average Exercise Price, Granted">10.34</td><td style="text-align: left"> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20190101__20191231_z45QLC0eXYfi" style="text-align: right" title="Stock Options Underlying Shares, Exercised">(79</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20190101__20191231_pii" style="text-align: right" title="Weighted-Average Exercise Price, Exercised">3.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Forfeited or expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pii_di_c20190101__20191231_zOOOqrx9t7Yc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock Options Underlying Shares, Forfeited or expired">(300</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20190101__20191231_pii" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-Average Exercise Price, Forfeited or expired">4.19</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at December 31, 2019</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20190101__20191231_zKbsTt5WVnVj" style="text-align: right" title="Stock Options Underlying Shares, Outstanding beginning">5,894</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20190101__20191231_zwEiK6fwEuAc" style="text-align: right" title="Weighted-Average Exercise Price, Outstanding ending balance">6.33</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231_zBmuNe4FRRQb" title="Weighted-Average Remaining Contractual Term, Outstanding Ending">8.5 </span>years</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c20191231_pn3n3" style="text-align: right" title="Intrinsic Value, Outstanding Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1115">—</span></td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at January 1, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20201231_zSuuCghvHSCk" style="text-align: right" title="Stock Options Underlying Shares, Outstanding beginning">5,894</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231_z83sRikmKpXb" style="text-align: right" title="Weighted-Average Exercise Price, Outstanding beginning balance">6.33</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"/><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Intrinsic Value, Outstanding Beginning"/><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_pii" style="text-align: right" title="Stock Options Underlying Shares, Granted">4,126</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_pii" style="text-align: right" title="Weighted-Average Exercise Price, Granted">12.87</td><td style="text-align: left"> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20200101__20201231_zOM8MKGvVkp1" style="text-align: right" title="Stock Options Underlying Shares, Exercised">(219</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231_pii" style="text-align: right" title="Weighted-Average Exercise Price, Exercised">5.28</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Forfeited or expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pii_di_c20200101__20201231_zYbeHjpmX6o8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock Options Underlying Shares, Forfeited or expired">(298</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200101__20201231_pii" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-Average Exercise Price, Forfeited or expired">9.39</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200101__20201231_zQ3Fw2uujCR1" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock Options Underlying Shares, Outstanding ending balance">9,503</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20201231_zPD2OzKZOTf1" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Exercise Price, Outstanding ending balance">9.10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zHFfjw2AZh1d" title="Weighted-Average Remaining Contractual Term, Outstanding Ending">8.3</span> years</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c20201231_pn3n3" style="padding-bottom: 2.5pt; text-align: right" title="Intrinsic Value, Outstanding Beginning">74,536</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable at December 31, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20200101__20201231_zC3vCarTIwY2" style="text-align: right" title="Stock Options Underlying Shares, Exercisable">3,730</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20201231_zQB9eUybvnGi" style="text-align: right" title="Weighted-Average Exercise Price, Exercisable">5.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231_zu2upPvkmTPf" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term">7.4</span> years</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20201231_pn3n3" style="text-align: right" title="Intrinsic Value, Exercisable">41,263</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AA_zm7edaSPWjA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The weighted average grant-date fair value of options granted during the year ended December 31, 2020 was $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_pii" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value">8.32</span> per share. As of December 31, 2020, there were approximately <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_c20201231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__custom--StockOptionOneMember_pii" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares">1,869,000</span> unvested options subject to performance-based vesting criteria with approximately $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20201231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__custom--StockOptionOneMember_zZ8f4MM3jc4c" title="Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount">13.2</span> million of unrecognized compensation expense. This expense will be recognized when each milestone becomes probable of occurring. In addition, as of December 31, 2020, there were approximately <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_c20201231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__custom--StockOptionTwoMember_pii" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares">3,904,000</span> unvested options outstanding subject to time-based vesting with approximately $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20201231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__custom--StockOptionTwoMember_zD210529maK4" title="Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount">25.1</span> million of unrecognized compensation expense which will be recognized over a period of <span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20201231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__custom--StockOptionTwoMember_z1hBGruSbzVe" title="Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition">3.2</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Cash proceeds from, and the aggregate intrinsic value of, stock options exercised during the periods presented below were as follows:</span></p> <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_z9M6f32K7Da9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B9_zNGIfuIXoTW4" style="display: none">SCHEDULE OF AGGREGATED INTRINSIC VALUE OF STOCK OPTION EXERCISED</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Cash proceeds from options exercised</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ProceedsFromStockOptionsExercised_c20200101__20201231_pn3n3" style="width: 14%; text-align: right" title="Cash proceeds from options exercised">1,152</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ProceedsFromStockOptionsExercised_c20190101__20191231_pn3n3" style="width: 14%; text-align: right" title="Cash proceeds from options exercised">290</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ProceedsFromStockOptionsExercised_c20180101__20181231_pn3n3" style="width: 14%; text-align: right" title="Cash proceeds from options exercised">25</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Aggregate intrinsic value of options exercised</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20200101__20201231_pn3n3" style="text-align: right" title="Aggregate intrinsic value of options exercised">1,615</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20190101__20191231_pn3n3" style="text-align: right" title="Aggregate intrinsic value of options exercised">551</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20180101__20181231_pn3n3" style="text-align: right" title="Aggregate intrinsic value of options exercised">5</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A9_zRripRKiCbC" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company uses the Black-Scholes option-pricing model to estimate the fair value of option awards with the following weighted-average assumptions for the period indicated:</span></p> <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zZY0GWvVhkI5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BA_zq6xlhBgJdml" style="display: none">SCHEDULE OF SHARE-BASED COMPENSATION VALUATION OF ASSUMPTIONS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Exercise price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_zrQcAzGrzOnk" style="width: 14%; text-align: right" title="Exercise price">12.87</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231_z3vXxjie3aB7" style="width: 14%; text-align: right" title="Exercise price">10.34</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20180101__20181231_zlpRAksJUqx4" style="width: 14%; text-align: right" title="Exercise price">3.93</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231_zNqQHVzpDLsa" style="text-align: right" title="Expected volatility">74</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231_zIvQmSaz57xh" style="text-align: right" title="Expected volatility">72</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20180101__20181231_zXagNfVZseWf" style="text-align: right" title="Expected volatility">61</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp0_uPercentage_c20200101__20201231_zZMl5HMHVW59" style="text-align: right" title="Expected dividends">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp0_uPercentage_c20190101__20191231_zbaQgKgxLuUk" style="text-align: right" title="Expected dividends">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp0_uPercentage_c20180101__20181231_zRvv4lJh9tuf" style="text-align: right" title="Expected dividends">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_zpmfbN2KyrXf" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term">6.2</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231_zcENMkk1InAh" style="text-align: right" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term">6.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231_zQbgFQ4atFX8" style="text-align: right" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term">6.2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231_z2qNRJz5vxwa" style="text-align: right" title="Risk-free interest rate">0.59</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231_zJth0Ho7ake" style="text-align: right" title="Risk-free interest rate">1.90</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20180101__20181231_z00tPS0UaHwi" style="text-align: right" title="Risk-free interest rate">2.78</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AC_zyHAHC4HbZXk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The weighted-average valuation assumptions were determined as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate: The Company bases the risk-free interest rate on the interest rate payable on United States Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected option term.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Expected annual dividends: The estimate for annual dividends is <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20200101__20201231_zTua09mP9Q8c" title="Expected dividends">0%</span>, because the Company has not historically paid, and does not expect for the foreseeable future to pay, a dividend.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Expected stock price volatility: The expected volatility used is based on historical volatilities of similar entities within the Company’s industry which were commensurate with the Company’s expected term assumption.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Expected term of options: The expected term of options represents the period of time options are expected to be outstanding. The expected term of the options granted to employees is derived from the “simplified” method as described in Staff Accounting Bulletin 107 relating to stock-based compensation, whereby the expected term is an average between the vesting period and contractual period due to the limited operating history.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> 9503228 P10Y the number of shares available for issuance under the 2017 Plan in an amount equal to (1) the difference between (x) 18% of the total shares of the Company’s common stock outstanding, on a fully diluted basis, on December 31st of the preceding calendar year, and (y) the total number of shares of the Company’s common stock reserved under the 2017 Plan on December 31st of such preceding calendar year or (2) an amount less than this calculated increase as determined by the board of directors. 2270353 109499 2000000 P10Y <p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zkCyIPpAa4j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BD_z0gusL8EODXd" style="display: none">SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">General and administrative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="width: 14%; text-align: right" title="Total stock-based compensation expense">7,611</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="width: 14%; text-align: right" title="Total stock-based compensation expense">1,546</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_c20180101__20181231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="width: 14%; text-align: right" title="Total stock-based compensation expense">512</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensation_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">5,612</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">1,296</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_c20180101__20181231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">629</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">13,223</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">2,842</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_c20180101__20181231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">1,141</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 7611000 1546000 512000 5612000 1296000 629000 13223000 2842000 1141000 <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zbRm7bjTvBJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BC_zDxXW0Bm5vWh" style="display: none">SUMMARY OF STOCK OPTION ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Weighted-</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Average</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Remaining</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Underlying</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Stock Option Awards</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Term</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 42%">Outstanding at December 31, 2018</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20190101__20191231_zi9NUfU4rfkh" style="width: 11%; text-align: right" title="Stock Options Underlying Shares, Outstanding beginning">3,476</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20181231_zrL0jddUzWL9" style="width: 11%; text-align: right" title="Weighted-Average Exercise Price, Outstanding beginning balance">2.85</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 11%; text-align: right"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190101__20191231_pii" style="text-align: right" title="Stock Options Underlying Shares, Granted">2,797</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190101__20191231_pii" style="text-align: right" title="Weighted-Average Exercise Price, Granted">10.34</td><td style="text-align: left"> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20190101__20191231_z45QLC0eXYfi" style="text-align: right" title="Stock Options Underlying Shares, Exercised">(79</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20190101__20191231_pii" style="text-align: right" title="Weighted-Average Exercise Price, Exercised">3.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Forfeited or expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pii_di_c20190101__20191231_zOOOqrx9t7Yc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock Options Underlying Shares, Forfeited or expired">(300</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20190101__20191231_pii" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-Average Exercise Price, Forfeited or expired">4.19</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at December 31, 2019</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20190101__20191231_zKbsTt5WVnVj" style="text-align: right" title="Stock Options Underlying Shares, Outstanding beginning">5,894</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20190101__20191231_zwEiK6fwEuAc" style="text-align: right" title="Weighted-Average Exercise Price, Outstanding ending balance">6.33</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231_zBmuNe4FRRQb" title="Weighted-Average Remaining Contractual Term, Outstanding Ending">8.5 </span>years</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c20191231_pn3n3" style="text-align: right" title="Intrinsic Value, Outstanding Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1115">—</span></td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at January 1, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20201231_zSuuCghvHSCk" style="text-align: right" title="Stock Options Underlying Shares, Outstanding beginning">5,894</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231_z83sRikmKpXb" style="text-align: right" title="Weighted-Average Exercise Price, Outstanding beginning balance">6.33</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"/><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Intrinsic Value, Outstanding Beginning"/><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_pii" style="text-align: right" title="Stock Options Underlying Shares, Granted">4,126</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_pii" style="text-align: right" title="Weighted-Average Exercise Price, Granted">12.87</td><td style="text-align: left"> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20200101__20201231_zOM8MKGvVkp1" style="text-align: right" title="Stock Options Underlying Shares, Exercised">(219</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231_pii" style="text-align: right" title="Weighted-Average Exercise Price, Exercised">5.28</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Forfeited or expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pii_di_c20200101__20201231_zYbeHjpmX6o8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock Options Underlying Shares, Forfeited or expired">(298</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200101__20201231_pii" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-Average Exercise Price, Forfeited or expired">9.39</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200101__20201231_zQ3Fw2uujCR1" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock Options Underlying Shares, Outstanding ending balance">9,503</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20201231_zPD2OzKZOTf1" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Exercise Price, Outstanding ending balance">9.10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zHFfjw2AZh1d" title="Weighted-Average Remaining Contractual Term, Outstanding Ending">8.3</span> years</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c20201231_pn3n3" style="padding-bottom: 2.5pt; text-align: right" title="Intrinsic Value, Outstanding Beginning">74,536</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable at December 31, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20200101__20201231_zC3vCarTIwY2" style="text-align: right" title="Stock Options Underlying Shares, Exercisable">3,730</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20201231_zQB9eUybvnGi" style="text-align: right" title="Weighted-Average Exercise Price, Exercisable">5.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231_zu2upPvkmTPf" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term">7.4</span> years</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20201231_pn3n3" style="text-align: right" title="Intrinsic Value, Exercisable">41,263</td><td style="text-align: left"> </td></tr> </table> 3476 2.85 2797 10.34 79 3.66 300 4.19 5894 6.33 P8Y6M 5894 6.33 4126 12.87 219 5.28 298 9.39 9503 9.10 P8Y3M18D 74536000 3730 5.88 P7Y4M24D 41263000 8.32 1869000 13200000 3904000 25100000 P3Y2M12D <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_z9M6f32K7Da9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B9_zNGIfuIXoTW4" style="display: none">SCHEDULE OF AGGREGATED INTRINSIC VALUE OF STOCK OPTION EXERCISED</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Cash proceeds from options exercised</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ProceedsFromStockOptionsExercised_c20200101__20201231_pn3n3" style="width: 14%; text-align: right" title="Cash proceeds from options exercised">1,152</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ProceedsFromStockOptionsExercised_c20190101__20191231_pn3n3" style="width: 14%; text-align: right" title="Cash proceeds from options exercised">290</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ProceedsFromStockOptionsExercised_c20180101__20181231_pn3n3" style="width: 14%; text-align: right" title="Cash proceeds from options exercised">25</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Aggregate intrinsic value of options exercised</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20200101__20201231_pn3n3" style="text-align: right" title="Aggregate intrinsic value of options exercised">1,615</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20190101__20191231_pn3n3" style="text-align: right" title="Aggregate intrinsic value of options exercised">551</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20180101__20181231_pn3n3" style="text-align: right" title="Aggregate intrinsic value of options exercised">5</td><td style="text-align: left"> </td></tr> </table> 1152000 290000 25000 1615000 551000 5000 <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zZY0GWvVhkI5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BA_zq6xlhBgJdml" style="display: none">SCHEDULE OF SHARE-BASED COMPENSATION VALUATION OF ASSUMPTIONS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Exercise price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_zrQcAzGrzOnk" style="width: 14%; text-align: right" title="Exercise price">12.87</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231_z3vXxjie3aB7" style="width: 14%; text-align: right" title="Exercise price">10.34</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20180101__20181231_zlpRAksJUqx4" style="width: 14%; text-align: right" title="Exercise price">3.93</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231_zNqQHVzpDLsa" style="text-align: right" title="Expected volatility">74</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231_zIvQmSaz57xh" style="text-align: right" title="Expected volatility">72</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20180101__20181231_zXagNfVZseWf" style="text-align: right" title="Expected volatility">61</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp0_uPercentage_c20200101__20201231_zZMl5HMHVW59" style="text-align: right" title="Expected dividends">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp0_uPercentage_c20190101__20191231_zbaQgKgxLuUk" style="text-align: right" title="Expected dividends">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp0_uPercentage_c20180101__20181231_zRvv4lJh9tuf" style="text-align: right" title="Expected dividends">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_zpmfbN2KyrXf" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term">6.2</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231_zcENMkk1InAh" style="text-align: right" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term">6.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231_zQbgFQ4atFX8" style="text-align: right" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term">6.2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231_z2qNRJz5vxwa" style="text-align: right" title="Risk-free interest rate">0.59</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231_zJth0Ho7ake" style="text-align: right" title="Risk-free interest rate">1.90</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20180101__20181231_z00tPS0UaHwi" style="text-align: right" title="Risk-free interest rate">2.78</td><td style="text-align: left">%</td></tr> </table> 12.87 10.34 3.93 0.74 0.72 0.61 0 0 0 P6Y2M12D P6Y3M18D P6Y2M12D 0.0059 0.0190 0.0278 0 <p id="xdx_80F_ecustom--WarrantsTextBlock_zFNtgzXtXp8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>11. <span id="xdx_825_z8rNbHtnwMo9">WARRANTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">In connection with the April 2017 sale of Series A Convertible Redeemable Preferred Stock, the Company issued warrants to MDB, the Placement Agent, and its designees to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20170430__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertibleRedeemablePreferredStockMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_zAaXGdxFchua" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights">558,740</span> shares of Series A Convertible Redeemable Preferred Stock with an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20170430__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertibleRedeemablePreferredStockMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_zoNmK5o0Gni6" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">2.50</span> per share with a <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20170430__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertibleRedeemablePreferredStockMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_zZHbYZrVmt9b" title="Warrants term::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl1215">seven</span></span>-year term. Upon completion of the IPO in July 2018, the warrants automatically became warrants for the purchase of <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20180731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pii" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights">558,740</span> shares of the Company’s common stock. During the year ended December 31, 2020, certain warrant holders from the Series A offering elected to exercise warrants for an aggregate of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20201231__us-gaap--TypeOfArrangementAxis__custom--SeriesAOfferingMember_zLW0rRXWkOZ7" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights">312,689</span> shares, on a cashless basis, resulting in the Company’s net issuance of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesOther_pii_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--SeriesAOfferingMember_zFkdmj5pcX8b" title="Number of warrants issuance shares">259,542</span> shares. As of December 31, 2020, a total of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20201231_zuuZzTJaIFd5" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights">316,754</span> warrants have been exercised on a cashless basis and there were <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pii_c20201231__us-gaap--TypeOfArrangementAxis__custom--SeriesAOfferingMember_zKuozOJEdcJc" title="Warrants outstanding, shares">241,986</span> warrants outstanding related to the Series A Offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In May 2018, in connection with the MacroGenics License Agreement and the MacroGenics Asset Purchase Agreement, the Company issued warrants to MacroGenics to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20180531__us-gaap--TypeOfArrangementAxis__custom--MacroGenicsLicenseAgreementAndMacroGenicsAssetPurchaseAgreementMember_pii" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights">2,432,688</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20180531__us-gaap--TypeOfArrangementAxis__custom--MacroGenicsLicenseAgreementAndMacroGenicsAssetPurchaseAgreementMember_pii" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">2.50</span> per share. These warrants had a <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20180531__us-gaap--TypeOfArrangementAxis__custom--MacroGenicsLicenseAgreementAndMacroGenicsAssetPurchaseAgreementMember_zhMnzV5flOYf" title="Warrants term::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl1231">seven</span></span>-year term. The Company recorded the warrants issued under MacroGenics License Agreement and the MacroGenics Asset Purchase Agreement at an estimated fair value of $<span id="xdx_900_ecustom--FairValuePerShareOfEachWarrant_c20181231__us-gaap--TypeOfArrangementAxis__custom--MacroGenicsLicenseAgreementAndMacroGenicsAssetPurchaseAgreementMember__dei--LegalEntityAxis__custom--MacroGenicsIncMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pii" title="Fair value per share of each warrant">1.64</span> per share, approximately $<span id="xdx_903_ecustom--WarrantsIssuedDuringPeriodFairValue_pn5n6_c20180101__20181231__us-gaap--TypeOfArrangementAxis__custom--MacroGenicsLicenseAgreementAndMacroGenicsAssetPurchaseAgreementMember__dei--LegalEntityAxis__custom--MacroGenicsIncMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zWODwm0R6EL6" title="Warrants issued during period, fair value">4.0</span> million in the aggregate, as license fee expense included as part of Research &amp; development expense during the year ended December 31, 2018.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company used valuation methods and assumptions that consider, among other factors, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants issued to MacroGenics. The fair values of these instruments were determined using models based on inputs that require management judgment and estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The fair value of the warrants issued to MacroGenics was measured at issuance on May 7, 2018 using the Black-Scholes option pricing model based on the following assumptions:</span></p> <p id="xdx_893_ecustom--ScheduleOfFairValueOfWarrantsIssuedTableTextBlock_hdei--LegalEntityAxis__custom--MacroGenicsIncMember_zEmC8mcsaYQ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> <span><span id="xdx_8BA_zKmZ0Rg4rLI9" style="display: none">SCHEDULE OF FAIR VALUE OF WARRANTS ISSUED</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Equity value upon issuance on May 7, 2018</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--FairValueOfWarrantsIssuedPerShare_iI_pii_c20180507__dei--LegalEntityAxis__custom--MacroGenicsIncMember_zet2p4nxKav5" style="width: 16%; text-align: right" title="Equity value upon issuance">2.58</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20180507__dei--LegalEntityAxis__custom--MacroGenicsIncMember_zcaGzWvor2Na" style="text-align: right" title="Exercise price">2.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pii_uPercentage_c20180507__dei--LegalEntityAxis__custom--MacroGenicsIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zandMl3SW7ah" style="text-align: right" title="Fair value assumptions measurement input percentage">62.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pii_c20180507__dei--LegalEntityAxis__custom--MacroGenicsIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zM4gFvmkKwL9" style="text-align: right" title="Fair value assumptions measurement input percentage"><span style="-sec-ix-hidden: xdx2ixbrl1245">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contractual term (in years)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20180507__dei--LegalEntityAxis__custom--MacroGenicsIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zFWSZ10bj5Qj" style="text-align: right" title="Fair value assumptions measurement input term">7.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pii_uPercentage_c20180507__dei--LegalEntityAxis__custom--MacroGenicsIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zMYUF4h5tKh4" style="text-align: right" title="Fair value assumptions measurement input percentage">2.86</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A3_zQ8CBmaNIbRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The MacroGenics warrants were evaluated <span style="background-color: white">under ASC 480, <i>Distinguishing Liabilities from Equity, </i>(“ASC 480”) and ASC 815, <i>Derivatives and Hedging</i>, (“ASC 815”) and the Company determined that equity classification was appropriate</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In July 2019, MacroGenics elected to exercise its warrants for an aggregate of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20190731__dei--LegalEntityAxis__custom--MacroGenicsIncMember_zbZO4DIoBQpi" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights">2,432,688</span> shares on a cashless basis, resulting in the Company’s net issuance of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesOther_pii_c20190701__20190731__dei--LegalEntityAxis__custom--MacroGenicsIncMember_zeV4Ivw3cpS4" title="Number of warrants issuance shares">1,948,474</span> shares. Following the MacroGenics’ July 2019 warrant exercises, there were no additional warrants outstanding in connection with the MacroGenics License Agreement and the MacroGenics Asset Purchase Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">In connection with the Company’s completion of its IPO, in July 2018, the Company issued to MDB, the underwriter in the IPO, and its designees warrants to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20180731__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pii" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights">1,596,956</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20180731__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zHhaZSIQyZ9" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">5.00</span> per share. These warrants have a <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20201231_zXX5xuXpFkUa" title="Warrants term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1259">five</span></span>-year term. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company used valuation methods and assumptions that consider, among other factors, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants. The fair values of these instruments were determined using models based on inputs that require management judgment and estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The fair value of the warrants issued to MDB were measured at issuance on July 19, 2018 using the Black-Scholes option-pricing model based on the following assumptions:</span></p> <p id="xdx_893_ecustom--ScheduleOfFairValueOfWarrantsIssuedTableTextBlock_hdei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember_zRJj5nza7Qo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B5_zuMDpss5wV22" style="display: none">SCHEDULE OF FAIR VALUE OF WARRANTS ISSUED</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Equity value upon issuance on July 19, 2018</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--FairValueOfWarrantsIssuedPerShare_iI_pii_c20180719__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember_zzBEc3vaHM42" style="width: 16%; text-align: right" title="Equity value upon issuance">4.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20180719__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember_zQ0dHKMIMJ8l" style="text-align: right" title="Exercise price">5.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pii_uPercentage_c20180719__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zPJlTXNHRTj1" style="text-align: right" title="Fair value assumptions measurement input percentage">60.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_c20180719__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_pii" style="text-align: right" title="Fair value assumptions measurement input percentage"><span style="-sec-ix-hidden: xdx2ixbrl1269">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contractual term (in years)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20180719__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgIractTqgK7" style="text-align: right" title="Fair value assumptions measurement input term">5.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pii_uPercentage_c20180719__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zuPytzI2w7l7" style="text-align: right" title="Fair value assumptions measurement input percentage">2.74</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A9_zLszO81x7OBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"><span style="font: 10pt Times New Roman, Times, Serif">The Company estimated the fair value of the warrants issued to MDB to be $<span id="xdx_901_ecustom--FairValueOfWarrantsIssuedPerShare_iI_pii_c20201231__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zzc3XiSjZbgc" title="Fair value of warrants for MDB">1.90</span> per share, approximately $<span id="xdx_903_ecustom--WarrantsIssuedDuringPeriodFairValue_pn5n6_c20201201__20201231__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zgtMI3zHPbm8" title="Fair value of warrant issued">3.0</span> million in the aggregate, which was recorded as a cost of the IPO. The MDB warrants were evaluated <span style="background-color: white">under ASC 480 and ASC 815 and the Company determined that equity classification was appropriate.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">During the year ended December 31, 2020, certain warrant holders from the IPO elected to exercise warrants for an aggregate of <span id="xdx_907_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrants_iI_pii_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--CashlessBasisMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zEjUq9vU5MBc" title="Number of warrants exercised">107,051</span> shares, on a cashless basis, resulting in the Company’s net issuance of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesOther_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--CashlessBasisMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zFlK1gI4KETd" title="Number of warrants issuance shares">66,316</span> shares. As of December 31, 2020, a total of <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--CashlessBasisMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zrKedm1tBau1" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights">134,114</span> warrants have been exercised on a cashless basis and there were <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pii_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zOBuqwT0P1ka" title="Warrants outstanding, shares">1,462,842</span> warrants outstanding related to the IPO.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> 558740 2.50 558740 312689 259542 316754 241986 2432688 2.50 1.64 4000000.0 <p id="xdx_893_ecustom--ScheduleOfFairValueOfWarrantsIssuedTableTextBlock_hdei--LegalEntityAxis__custom--MacroGenicsIncMember_zEmC8mcsaYQ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> <span><span id="xdx_8BA_zKmZ0Rg4rLI9" style="display: none">SCHEDULE OF FAIR VALUE OF WARRANTS ISSUED</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Equity value upon issuance on May 7, 2018</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--FairValueOfWarrantsIssuedPerShare_iI_pii_c20180507__dei--LegalEntityAxis__custom--MacroGenicsIncMember_zet2p4nxKav5" style="width: 16%; text-align: right" title="Equity value upon issuance">2.58</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20180507__dei--LegalEntityAxis__custom--MacroGenicsIncMember_zcaGzWvor2Na" style="text-align: right" title="Exercise price">2.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pii_uPercentage_c20180507__dei--LegalEntityAxis__custom--MacroGenicsIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zandMl3SW7ah" style="text-align: right" title="Fair value assumptions measurement input percentage">62.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pii_c20180507__dei--LegalEntityAxis__custom--MacroGenicsIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zM4gFvmkKwL9" style="text-align: right" title="Fair value assumptions measurement input percentage"><span style="-sec-ix-hidden: xdx2ixbrl1245">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contractual term (in years)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20180507__dei--LegalEntityAxis__custom--MacroGenicsIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zFWSZ10bj5Qj" style="text-align: right" title="Fair value assumptions measurement input term">7.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pii_uPercentage_c20180507__dei--LegalEntityAxis__custom--MacroGenicsIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zMYUF4h5tKh4" style="text-align: right" title="Fair value assumptions measurement input percentage">2.86</td><td style="text-align: left">%</td></tr> </table> 2.58 2.50 62.0 P7Y 2.86 2432688 1948474 1596956 5.00 <p id="xdx_893_ecustom--ScheduleOfFairValueOfWarrantsIssuedTableTextBlock_hdei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember_zRJj5nza7Qo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B5_zuMDpss5wV22" style="display: none">SCHEDULE OF FAIR VALUE OF WARRANTS ISSUED</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Equity value upon issuance on July 19, 2018</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--FairValueOfWarrantsIssuedPerShare_iI_pii_c20180719__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember_zzBEc3vaHM42" style="width: 16%; text-align: right" title="Equity value upon issuance">4.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20180719__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember_zQ0dHKMIMJ8l" style="text-align: right" title="Exercise price">5.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pii_uPercentage_c20180719__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zPJlTXNHRTj1" style="text-align: right" title="Fair value assumptions measurement input percentage">60.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_c20180719__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_pii" style="text-align: right" title="Fair value assumptions measurement input percentage"><span style="-sec-ix-hidden: xdx2ixbrl1269">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contractual term (in years)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20180719__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgIractTqgK7" style="text-align: right" title="Fair value assumptions measurement input term">5.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pii_uPercentage_c20180719__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zuPytzI2w7l7" style="text-align: right" title="Fair value assumptions measurement input percentage">2.74</td><td style="text-align: left">%</td></tr> </table> 4.00 5.00 60.0 P5Y 2.74 1.90 3000000.0 107051 66316 134114 1462842 <p id="xdx_802_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zCnp4oZlTGyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>12. <span id="xdx_82E_zvVKilRJb5Xb">FIXED ASSETS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Fixed assets consisted of the following:</span></p> <p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_zNNRXWIM5eH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BB_zhmCP3b3yeu8" style="display: none">SCHEDULE OF FIXED ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Leasehold improvements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVEy1GGBgvfk" style="width: 14%; text-align: right" title="Fixed assets, net">828</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zNjToBRwxuek" style="width: 14%; text-align: right" title="Fixed assets, net"><span style="-sec-ix-hidden: xdx2ixbrl1293">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Furniture and fixtures</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zjVMSxSTWdTi" style="text-align: right" title="Fixed assets, net">149</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z5GApRzeDmNh" style="text-align: right" title="Fixed assets, net"><span style="-sec-ix-hidden: xdx2ixbrl1297">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zF30zqHD8iAg" style="text-align: right" title="Fixed assets, net">35</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zQIy6INo507j" style="text-align: right" title="Fixed assets, net"><span style="-sec-ix-hidden: xdx2ixbrl1301">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Clinical equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalEquipmentMember_zjiHwtqDump2" style="text-align: right" title="Fixed assets, net">27</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalEquipmentMember_zT4zKxr89VCl" style="text-align: right" title="Fixed assets, net"><span style="-sec-ix-hidden: xdx2ixbrl1305">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Construction in progress</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zCFbmqXRZPCa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fixed assets, net">431</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zCpfpvnEiaoh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fixed assets, net"><span style="-sec-ix-hidden: xdx2ixbrl1309">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231_zBG87d45sck9" style="text-align: right" title="Fixed assets, net">1,470</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231_zt8GddcI7Kdh" style="text-align: right" title="Fixed assets, net"><span style="-sec-ix-hidden: xdx2ixbrl1313">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20201231_zBg9OWBOcEM6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated depreciation">(33</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20191231_z8nTmKEZlnfa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated depreciation"><span style="-sec-ix-hidden: xdx2ixbrl1317">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Fixed assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231_z6RF92iOGoWe" style="border-bottom: Black 2.5pt double; text-align: right" title="Fixed assets, net">1,437</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231_zFOqjSFKOJfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Fixed assets, net"><span style="-sec-ix-hidden: xdx2ixbrl1321">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zm2YXuFaSKTh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Depreciation expense was $<span id="xdx_90E_eus-gaap--Depreciation_pn3n3_c20200101__20201231_zlD39lYQC1M9" title="Depreciation expense">33</span> thousand for the year ended December 31, 2020. The Company had <span title="Depreciation expense">no</span> depreciation expense for the year ended December 31, 2019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_zNNRXWIM5eH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BB_zhmCP3b3yeu8" style="display: none">SCHEDULE OF FIXED ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Leasehold improvements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVEy1GGBgvfk" style="width: 14%; text-align: right" title="Fixed assets, net">828</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zNjToBRwxuek" style="width: 14%; text-align: right" title="Fixed assets, net"><span style="-sec-ix-hidden: xdx2ixbrl1293">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Furniture and fixtures</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zjVMSxSTWdTi" style="text-align: right" title="Fixed assets, net">149</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z5GApRzeDmNh" style="text-align: right" title="Fixed assets, net"><span style="-sec-ix-hidden: xdx2ixbrl1297">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zF30zqHD8iAg" style="text-align: right" title="Fixed assets, net">35</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zQIy6INo507j" style="text-align: right" title="Fixed assets, net"><span style="-sec-ix-hidden: xdx2ixbrl1301">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Clinical equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalEquipmentMember_zjiHwtqDump2" style="text-align: right" title="Fixed assets, net">27</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ClinicalEquipmentMember_zT4zKxr89VCl" style="text-align: right" title="Fixed assets, net"><span style="-sec-ix-hidden: xdx2ixbrl1305">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Construction in progress</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zCFbmqXRZPCa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fixed assets, net">431</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zCpfpvnEiaoh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fixed assets, net"><span style="-sec-ix-hidden: xdx2ixbrl1309">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231_zBG87d45sck9" style="text-align: right" title="Fixed assets, net">1,470</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231_zt8GddcI7Kdh" style="text-align: right" title="Fixed assets, net"><span style="-sec-ix-hidden: xdx2ixbrl1313">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20201231_zBg9OWBOcEM6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated depreciation">(33</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20191231_z8nTmKEZlnfa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated depreciation"><span style="-sec-ix-hidden: xdx2ixbrl1317">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Fixed assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231_z6RF92iOGoWe" style="border-bottom: Black 2.5pt double; text-align: right" title="Fixed assets, net">1,437</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231_zFOqjSFKOJfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Fixed assets, net"><span style="-sec-ix-hidden: xdx2ixbrl1321">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 828000 149000 35000 27000 431000 1470000 33000 1437000 33000 <p id="xdx_804_eus-gaap--LesseeOperatingLeasesTextBlock_zlFmKZi2Xd4i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>13. <span id="xdx_823_z4lUnCSqNPR6">LEASES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--LesseeOperatingLeaseDescription_c20200101__20201231_zwWsmwNTpNmd" title="Description on lease">The Company’s lease portfolio consists of one office lease located in Red Bank, NJ. This lease is classified as an operating lease and has an initial term of 64 months from the lease commencement date, which began in October 2020.</span> The Company has the option to renew or terminate the current term of a lease agreement at the end of the lease term. In its initial assessment of the lease term of the Red Bank, NJ office lease, the Company concluded that it is not reasonably certain to exercise the option to renew or terminate and therefore, this option was not considered in its lease assessment. The Company does not separate lease and non-lease components for all classes of underlying assets. The Company’s leases do not contain residual value guarantees and the Company does not sublease any of its leased assets. The Company does not record leases with an initial lease term of one-year or less on its balance sheets. As of December 31, 2020, the Company has not entered into any short-term leases.</span></p> <p id="xdx_89A_eus-gaap--LeaseCostTableTextBlock_zSQW0Oxm5Ggb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B7_zOL9wG5xyxnf" style="display: none">SCHEDULE OF LEASE COSTS</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The components of lease costs from continuing operations were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20200101__20201231_zDq3wdwgY0gh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended<br/> December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseCost_pn3n3_maLCzJFC_zgQE5BGWfotg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 80%; text-align: left">Operating lease costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">25</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--VariableLeaseCost_pn3n3_maLCzJFC_z0W3nIqdcnjd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Variable lease costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LeaseCost_iT_pn3n3_mtLCzJFC_zNrFFeHjlCg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease costs</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">28</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zlWwDjx4GVxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">During the year ended December 31, 2020, the Company did not have any operating cash outflows that were used in connection to its operating leases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span><span><span/></span></span></span></p> <p id="xdx_895_ecustom--ScheduleOfSupplementalBalanceSheetInformationTableTextBlock_z9YcOyv1LtUg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Supplemental balance sheet information related to leases are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BC_z7td86IQQwea" style="display: none">SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Classification</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Operating leases</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lease right-of-use assets</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 44%">Non-current</td><td style="width: 2%"> </td> <td style="width: 30%; text-align: left">Operating lease right-of-use assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231_zTIUUiyaZpy" style="width: 20%; text-align: right" title="Lease right-of-use assets Non-current">408</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lease liabilities</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Current</td><td> </td> <td style="text-align: left">Accrued expenses</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20201231__us-gaap--BalanceSheetLocationAxis__custom--AccruedExpensesMember_zBusKCq1qhQb" style="text-align: right" title="Lease liabilities Current">72</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Non-current</td><td> </td> <td style="text-align: left">Operating lease liabilities, long-term</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_ztprJzE2YMnc" style="text-align: right" title="Lease liabilities Non-Current">715</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Weighted average remaining lease term</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating leases</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zk8mR9DMn2Fh" title="Weighted average remaining lease term Operating leases">5.2</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Weighted average discount rate</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating leases</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_c20201231_zgsCAx0s9Zh3" style="text-align: right" title="Weighted average discount rate Operating leases">15.0</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A9_zWBcPAM93uQa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zsmRRp9bbvOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">As of December 31, 2020, maturities of lease liabilities on an annual basis for the remaining years of the Company’s commenced lease agreements were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span><span id="xdx_8B8_zOnBMWMALSbh" style="display: none">SCHEDULE OF MATURITIES OF LEASE LIABILITIES</span></span></span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20201231_zxL7l4FsmKSd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Year ending December 31,</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzhYw_zWHvwJ2EFKd" style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left">2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">185</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzhYw_zj1vwVtShNSg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">221</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzhYw_zSSD9zY5vn1l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">227</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzhYw_zLlLhjAmFvdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">232</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPzhYw_zb9bYpiUUdvl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">238</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPzhYw_zQZPvNHm7SWh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">41</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzhYw_zSAVNQAFstMk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,144</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_zQQCI4iqC5u7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Less: present value discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">357</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zecOEvSM8mA1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">787</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zRFzPAX1FStl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> The Company’s lease portfolio consists of one office lease located in Red Bank, NJ. This lease is classified as an operating lease and has an initial term of 64 months from the lease commencement date, which began in October 2020. <p id="xdx_89A_eus-gaap--LeaseCostTableTextBlock_zSQW0Oxm5Ggb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B7_zOL9wG5xyxnf" style="display: none">SCHEDULE OF LEASE COSTS</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The components of lease costs from continuing operations were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20200101__20201231_zDq3wdwgY0gh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended<br/> December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseCost_pn3n3_maLCzJFC_zgQE5BGWfotg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 80%; text-align: left">Operating lease costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">25</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--VariableLeaseCost_pn3n3_maLCzJFC_z0W3nIqdcnjd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Variable lease costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LeaseCost_iT_pn3n3_mtLCzJFC_zNrFFeHjlCg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease costs</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">28</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 25000 3000 28000 <p id="xdx_895_ecustom--ScheduleOfSupplementalBalanceSheetInformationTableTextBlock_z9YcOyv1LtUg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Supplemental balance sheet information related to leases are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BC_z7td86IQQwea" style="display: none">SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Classification</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Operating leases</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lease right-of-use assets</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 44%">Non-current</td><td style="width: 2%"> </td> <td style="width: 30%; text-align: left">Operating lease right-of-use assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231_zTIUUiyaZpy" style="width: 20%; text-align: right" title="Lease right-of-use assets Non-current">408</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lease liabilities</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Current</td><td> </td> <td style="text-align: left">Accrued expenses</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20201231__us-gaap--BalanceSheetLocationAxis__custom--AccruedExpensesMember_zBusKCq1qhQb" style="text-align: right" title="Lease liabilities Current">72</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Non-current</td><td> </td> <td style="text-align: left">Operating lease liabilities, long-term</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_ztprJzE2YMnc" style="text-align: right" title="Lease liabilities Non-Current">715</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Weighted average remaining lease term</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating leases</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zk8mR9DMn2Fh" title="Weighted average remaining lease term Operating leases">5.2</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Weighted average discount rate</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating leases</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_c20201231_zgsCAx0s9Zh3" style="text-align: right" title="Weighted average discount rate Operating leases">15.0</td><td style="text-align: left">%</td></tr> </table> 408000 72000 715000 P5Y2M12D 0.150 <p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zsmRRp9bbvOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">As of December 31, 2020, maturities of lease liabilities on an annual basis for the remaining years of the Company’s commenced lease agreements were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span><span id="xdx_8B8_zOnBMWMALSbh" style="display: none">SCHEDULE OF MATURITIES OF LEASE LIABILITIES</span></span></span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20201231_zxL7l4FsmKSd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Year ending December 31,</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzhYw_zWHvwJ2EFKd" style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left">2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">185</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzhYw_zj1vwVtShNSg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">221</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzhYw_zSSD9zY5vn1l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">227</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzhYw_zLlLhjAmFvdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">232</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPzhYw_zb9bYpiUUdvl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">238</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPzhYw_zQZPvNHm7SWh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">41</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzhYw_zSAVNQAFstMk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,144</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_zQQCI4iqC5u7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Less: present value discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">357</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zecOEvSM8mA1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">787</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 185000 221000 227000 232000 238000 41000 1144000 357000 787000 <p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_zS474g3vC454" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>14. <span id="xdx_829_zBkodiVxfdp2">INCOME TAXES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recorded no provision or benefit for federal income taxes, as the Company has incurred a net loss for all periods presented, and the Company has provided a full valuation allowance against its deferred tax assets. The Company recorded a benefit from state income taxes of approximately $<span id="xdx_907_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn5n6_c20200101__20201231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zQwWeVC5BXZi" title="Income tax benefit from state income taxes">0.5</span> million for the year ended December 31, 2020. The benefit from state income taxes solely reflects the reversal of valuation allowances previously recorded against the Company’s New Jersey State net operating losses (‘NOLs”) that resulted from the Company’s sale of approximately $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20201231__us-gaap--IncomeTaxAuthorityAxis__stpr--NJ_zIDxpGC6oRLl" title="Net operating loss">6.8</span> million of its New Jersey state NOLs under the State of New Jersey’s Technology Business Tax Certificate Transfer Program (the “Program”) for cash proceeds of $<span id="xdx_90E_ecustom--ProceedsFromNetOperatingLossSale_pn5n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--NewJerseysTechnologyBusinessTaxCertificateTransferProgramMember_zZ45fZEnIzU6" title="Proceeds from NJ NOL sale">0.5</span> million. The Program allows qualified technology and biotechnology businesses in New Jersey to sell unused amounts of NOLs and defined research and development tax credits. For the year ended December 31, 2019, the Company recorded no provision or benefit for state income taxes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">At December 31, 2020, the Company had Federal net operating loss carryforwards of approximately $<span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20201231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zJQ8EQhiEOZ5">139.1 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million, of which approximately $<span id="xdx_90D_ecustom--OperatingLossCarryforwardsExpireAmount_iI_pn5n6_c20201231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zmBmrzs9dPGj">5.4 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million will expire in varying amounts <span id="xdx_902_ecustom--OperatingLossCarryforwardsExpireDescription_c20200101__20201231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zWGzNgCQe3ee">beginning in 2036</span></span><span style="font: 10pt Times New Roman, Times, Serif">. The balance of the Federal net operating loss carryforwards generated in 2018 and prospectively can be carried forward indefinitely. The Company has state NOLs in various jurisdictions of approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20201231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zFnFyuCvjCA2">129.8 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million, certain of which <span id="xdx_908_ecustom--OperatingLossCarryforwardsExpireDescription_c20200101__20201231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z55GMrTFzoaf">begin to expire beginning in 2036</span></span><span style="font: 10pt Times New Roman, Times, Serif">. Utilization of net operating losses may be subject to substantial annual limitations due to the “change in ownership” provisions of the Internal Revenue Code, and similar state provisions. The Company has not yet completed a study to determine if an ownership change has occurred to date or determined the Company’s ability to utilize the aforementioned carryforwards. The Company had research and development tax credit carryforwards, including orphan drug tax credits, of approximately $<span id="xdx_906_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zk9XFrgTT9mh">16.3 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million at December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zUGQ48R3jbWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Income tax benefits computed using the federal statutory income tax rate differs from the Company’s effective tax rate primarily due to the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B1_zZYkMNZObNO2" style="display: none">SCHEDULE OF EFFECTIVE TAX RATE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left; padding-bottom: 1.5pt">Tax Provision at statutory tax rate</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_c20200101__20201231_zxibWml5rq1f" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Tax Provision at statutory tax rate">21.0</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">%</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_c20190101__20191231_zi80EDyy5CPh" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Tax Provision at statutory tax rate">21.0</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">%</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_c20180101__20181231_zotOtGLVx4Ma" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Tax Provision at statutory tax rate">21.0</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Change in valuation allowance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_c20200101__20201231_zEoq9TscGtPb" style="text-align: right" title="Change in valuation allowance">(34.6</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_c20190101__20191231_zpBRen7Q8kdd" style="text-align: right" title="Change in valuation allowance">(36.5</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_c20180101__20181231_zIAtgQhm2ON1" style="text-align: right" title="Change in valuation allowance">(26.9</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Orphan drug credits</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_pii_dp_uPercentage_c20200101__20201231_zxJpiqj4kLpa" style="text-align: right" title="Orphan drug credits">10.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_pii_dp_uPercentage_c20190101__20191231_zih6uPp317j7" style="text-align: right" title="Orphan drug credits">10.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_pii_dp_uPercentage_c20180101__20181231_zc9inS2I4aRj" style="text-align: right" title="Orphan drug credits"><span style="-sec-ix-hidden: xdx2ixbrl1401">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">State income taxes, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_c20200101__20201231_zbsBxNiLKU1g" style="text-align: right" title="State income taxes, net of federal benefit">5.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_c20190101__20191231_zVNprW5Mp5mi" style="text-align: right" title="State income taxes, net of federal benefit">6.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_c20180101__20181231_zuegGToi3Twa" style="text-align: right" title="State income taxes, net of federal benefit">6.2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Sale of NJ net operating losses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pii_dp_c20200101__20201231_z8Gt7PN5qFx6" style="text-align: right" title="Sale of NJ net operating losses">0.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pii_dp_c20190101__20191231_zGTFIrMUxYSi" style="text-align: right" title="Sale of NJ net operating losses"><span style="-sec-ix-hidden: xdx2ixbrl1411">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pii_dp_c20180101__20181231_zOaoxtPdANIh" style="text-align: right" title="Sale of NJ net operating losses">0.7</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Permanent items</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount_pii_dp_uPercentage_c20200101__20201231_zSpIPJVF9Ugg" style="text-align: right" title="Permanent items">(2.2</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount_pii_dp_uPercentage_c20190101__20191231_ziqMb7b8OaP1" style="text-align: right" title="Permanent items">(2.1</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount_pii_dp_uPercentage_c20180101__20181231_ziL6XbQNyTY3" style="text-align: right" title="Permanent items">(0.5</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pii_dp_c20200101__20201231_zOdNQmjSI0ae" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other">0.3</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pii_dp_c20190101__20191231_zi2r2xcBn1Rl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other">0.7</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pii_dp_c20180101__20181231_z1zbx5nbowlk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other">0.2</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Effective Tax Rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pii_dp_c20200101__20201231_zyh92dirJuT1" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective Tax Rate">0.5</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pii_dp_c20190101__20191231_zeLR5plSPQU2" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective Tax Rate"><span style="-sec-ix-hidden: xdx2ixbrl1429">—</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pii_dp_c20180101__20181231_z7GP2QhoANz3" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective Tax Rate">0.7</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> <p id="xdx_8A6_zNRAfHjI3Mib" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zkGR15cinzag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The components of income tax benefit are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BA_ze9QDSW329u2" style="display: none">SCHEDULE OF COMPONENTS OF INCOME TAX BENEFITS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20200101__20201231_zGo4uv42fwKl" style="text-align: right" title="Current: Federal"><span style="-sec-ix-hidden: xdx2ixbrl1435">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--CurrentFederalTaxExpenseBenefit_c20190101__20191231_pn3n3" style="text-align: right" title="Current: Federal"><span style="-sec-ix-hidden: xdx2ixbrl1437">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--CurrentFederalTaxExpenseBenefit_c20180101__20181231_pn3n3" style="text-align: right" title="Current: Federal"><span style="-sec-ix-hidden: xdx2ixbrl1439">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 46%">State</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20200101__20201231_pn3n3" style="width: 14%; text-align: right" title="Current: State">(523</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20190101__20191231_pn3n3" style="width: 14%; text-align: right" title="Current: State"><span style="-sec-ix-hidden: xdx2ixbrl1443">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20180101__20181231_pn3n3" style="width: 14%; text-align: right" title="Current: State">(187</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="text-align: right" title="Deferred: Federal"><span style="-sec-ix-hidden: xdx2ixbrl1447">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="text-align: right" title="Deferred: Federal"><span style="-sec-ix-hidden: xdx2ixbrl1449">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_c20180101__20181231_zPL12cDCU9v5" style="text-align: right" title="Deferred: Federal"><span style="-sec-ix-hidden: xdx2ixbrl1451">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deferred: State"><span style="-sec-ix-hidden: xdx2ixbrl1453">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deferred: State"><span style="-sec-ix-hidden: xdx2ixbrl1455">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20180101__20181231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deferred: State"><span style="-sec-ix-hidden: xdx2ixbrl1457">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Income tax benefit</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax benefit">(523</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--IncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax benefit"><span style="-sec-ix-hidden: xdx2ixbrl1461">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--IncomeTaxExpenseBenefit_c20180101__20181231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax benefit">(187</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A2_zHDR1zd7D5Z4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The income tax benefit recognized for the years ended December 31, 2020 and 2018 represent sales by the Company of its 2017 and 2018 New Jersey state net operating losses, from which the Company realized $<span id="xdx_90F_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn5n6_c20200101__20201231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__srt--StatementGeographicalAxis__stpr--NJ_zW581Ja97wV1" title="Income tax benefit from state income taxes">0.5</span> million $<span id="xdx_906_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn5n6_c20180101__20181231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__srt--StatementGeographicalAxis__stpr--NJ_zVDFSqyQcm3e">0.2</span> million, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zEM6sSEjZpka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Significant components of the Company’s net deferred tax assets are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BE_znUFY1KpIPW5" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20201231_zwCHQQ3j6LKj" style="display: none; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20191231_zsySm0ucDee6" style="display: none; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzqw4_zGgIP3sP0av9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: left">NOL Carryforward</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">37,773</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">17,520</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGzqw4_zudsnal0VQnf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Federal research and development credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,819</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,045</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzqw4_zHpi8bXLkPZk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Equity compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,245</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,018</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--DeferredTaxAssetsProductLicense_iI_pn3n3_maDTAGzqw4_zZlT9MyElmGl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Product License</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,598</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,768</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzqw4_zhP3wQmn77Dj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">390</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">213</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzqw4_maDTANzrHs_zv91Ly4ni43g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59,825</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,564</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzrHs_zJn7nDeZPqj3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(59,825</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,564</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzrHs_zkdLSYQtRM6e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1491">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1492">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zK6AHthE8qqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s gross deferred tax assets of $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsGross_iI_pn5n6_c20201231_zHRnnR3TRQC4" title="Deferred tax assets, gross">59.8</span> million and $<span id="xdx_904_eus-gaap--DeferredTaxAssetsGross_iI_pn5n6_c20191231_zAQgakgiuu6" title="Deferred tax assets, gross">25.6</span> million at December 31, 2020 and 2019, respectively, primarily consist of net operating loss carryforwards for income tax purposes. A valuation allowance is required to be recorded when it is not more likely than not that some portion or all of the net deferred tax assets will be realized. Since the Company cannot be assured of generating taxable income and thereby realizing the net deferred tax assets, a full valuation allowance has been recorded. The Company has no uncertain tax positions at December 31, 2020. Since the Company is in a loss carryforward position, the Company is generally subject to US federal and state income tax examinations by tax authorities for all years for which a loss carryforward is available. The Company has never been, nor is currently under audit. The Company’s policy is to recognize interest accrued related to unrecognized tax benefits and penalties in income tax expense, however the Company has recorded no such expense to date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In March 2020, the US government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) which includes numerous modifications to income tax provisions, including a limitation on business interest expense and net operating loss provisions and the acceleration of alternative minimum tax credits. Given the Company’s history of losses, the CARES Act did not have a material impact on its income tax positions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 500000 6800000 500000 139100000 5400000 beginning in 2036 129800000 begin to expire beginning in 2036 16300000 <p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zUGQ48R3jbWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Income tax benefits computed using the federal statutory income tax rate differs from the Company’s effective tax rate primarily due to the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B1_zZYkMNZObNO2" style="display: none">SCHEDULE OF EFFECTIVE TAX RATE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left; padding-bottom: 1.5pt">Tax Provision at statutory tax rate</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_c20200101__20201231_zxibWml5rq1f" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Tax Provision at statutory tax rate">21.0</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">%</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_c20190101__20191231_zi80EDyy5CPh" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Tax Provision at statutory tax rate">21.0</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">%</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_c20180101__20181231_zotOtGLVx4Ma" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Tax Provision at statutory tax rate">21.0</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Change in valuation allowance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_c20200101__20201231_zEoq9TscGtPb" style="text-align: right" title="Change in valuation allowance">(34.6</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_c20190101__20191231_zpBRen7Q8kdd" style="text-align: right" title="Change in valuation allowance">(36.5</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_c20180101__20181231_zIAtgQhm2ON1" style="text-align: right" title="Change in valuation allowance">(26.9</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Orphan drug credits</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_pii_dp_uPercentage_c20200101__20201231_zxJpiqj4kLpa" style="text-align: right" title="Orphan drug credits">10.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_pii_dp_uPercentage_c20190101__20191231_zih6uPp317j7" style="text-align: right" title="Orphan drug credits">10.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_pii_dp_uPercentage_c20180101__20181231_zc9inS2I4aRj" style="text-align: right" title="Orphan drug credits"><span style="-sec-ix-hidden: xdx2ixbrl1401">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">State income taxes, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_c20200101__20201231_zbsBxNiLKU1g" style="text-align: right" title="State income taxes, net of federal benefit">5.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_c20190101__20191231_zVNprW5Mp5mi" style="text-align: right" title="State income taxes, net of federal benefit">6.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_c20180101__20181231_zuegGToi3Twa" style="text-align: right" title="State income taxes, net of federal benefit">6.2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Sale of NJ net operating losses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pii_dp_c20200101__20201231_z8Gt7PN5qFx6" style="text-align: right" title="Sale of NJ net operating losses">0.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pii_dp_c20190101__20191231_zGTFIrMUxYSi" style="text-align: right" title="Sale of NJ net operating losses"><span style="-sec-ix-hidden: xdx2ixbrl1411">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pii_dp_c20180101__20181231_zOaoxtPdANIh" style="text-align: right" title="Sale of NJ net operating losses">0.7</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Permanent items</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount_pii_dp_uPercentage_c20200101__20201231_zSpIPJVF9Ugg" style="text-align: right" title="Permanent items">(2.2</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount_pii_dp_uPercentage_c20190101__20191231_ziqMb7b8OaP1" style="text-align: right" title="Permanent items">(2.1</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount_pii_dp_uPercentage_c20180101__20181231_ziL6XbQNyTY3" style="text-align: right" title="Permanent items">(0.5</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pii_dp_c20200101__20201231_zOdNQmjSI0ae" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other">0.3</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pii_dp_c20190101__20191231_zi2r2xcBn1Rl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other">0.7</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pii_dp_c20180101__20181231_z1zbx5nbowlk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other">0.2</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Effective Tax Rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pii_dp_c20200101__20201231_zyh92dirJuT1" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective Tax Rate">0.5</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pii_dp_c20190101__20191231_zeLR5plSPQU2" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective Tax Rate"><span style="-sec-ix-hidden: xdx2ixbrl1429">—</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pii_dp_c20180101__20181231_z7GP2QhoANz3" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective Tax Rate">0.7</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> 0.210 0.210 0.210 -0.346 -0.365 -0.269 0.104 0.104 0.052 0.065 0.062 0.004 0.007 -0.022 -0.021 -0.005 0.003 0.007 0.002 0.005 0.007 <p id="xdx_898_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zkGR15cinzag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The components of income tax benefit are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BA_ze9QDSW329u2" style="display: none">SCHEDULE OF COMPONENTS OF INCOME TAX BENEFITS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20200101__20201231_zGo4uv42fwKl" style="text-align: right" title="Current: Federal"><span style="-sec-ix-hidden: xdx2ixbrl1435">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--CurrentFederalTaxExpenseBenefit_c20190101__20191231_pn3n3" style="text-align: right" title="Current: Federal"><span style="-sec-ix-hidden: xdx2ixbrl1437">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--CurrentFederalTaxExpenseBenefit_c20180101__20181231_pn3n3" style="text-align: right" title="Current: Federal"><span style="-sec-ix-hidden: xdx2ixbrl1439">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 46%">State</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20200101__20201231_pn3n3" style="width: 14%; text-align: right" title="Current: State">(523</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20190101__20191231_pn3n3" style="width: 14%; text-align: right" title="Current: State"><span style="-sec-ix-hidden: xdx2ixbrl1443">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20180101__20181231_pn3n3" style="width: 14%; text-align: right" title="Current: State">(187</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="text-align: right" title="Deferred: Federal"><span style="-sec-ix-hidden: xdx2ixbrl1447">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="text-align: right" title="Deferred: Federal"><span style="-sec-ix-hidden: xdx2ixbrl1449">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_c20180101__20181231_zPL12cDCU9v5" style="text-align: right" title="Deferred: Federal"><span style="-sec-ix-hidden: xdx2ixbrl1451">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deferred: State"><span style="-sec-ix-hidden: xdx2ixbrl1453">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deferred: State"><span style="-sec-ix-hidden: xdx2ixbrl1455">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20180101__20181231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deferred: State"><span style="-sec-ix-hidden: xdx2ixbrl1457">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Income tax benefit</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax benefit">(523</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--IncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax benefit"><span style="-sec-ix-hidden: xdx2ixbrl1461">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--IncomeTaxExpenseBenefit_c20180101__20181231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax benefit">(187</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> -523000 -187000 -523000 -187000 500000 200000 <p id="xdx_89A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zEM6sSEjZpka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Significant components of the Company’s net deferred tax assets are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BE_znUFY1KpIPW5" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20201231_zwCHQQ3j6LKj" style="display: none; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20191231_zsySm0ucDee6" style="display: none; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzqw4_zGgIP3sP0av9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: left">NOL Carryforward</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">37,773</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">17,520</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGzqw4_zudsnal0VQnf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Federal research and development credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,819</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,045</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzqw4_zHpi8bXLkPZk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Equity compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,245</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,018</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--DeferredTaxAssetsProductLicense_iI_pn3n3_maDTAGzqw4_zZlT9MyElmGl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Product License</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,598</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,768</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzqw4_zhP3wQmn77Dj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">390</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">213</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzqw4_maDTANzrHs_zv91Ly4ni43g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59,825</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,564</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzrHs_zJn7nDeZPqj3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(59,825</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,564</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzrHs_zkdLSYQtRM6e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1491">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1492">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 37773000 17520000 15819000 5045000 4245000 1018000 1598000 1768000 390000 213000 59825000 25564000 59825000 25564000 59800000 25600000 <p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_znMBXmz77JW7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>15. <span id="xdx_82C_zcRw3kGrtV08">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In connection with the MacroGenics Asset Purchase Agreement, the Company made payments of approximately $<span id="xdx_903_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn5n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__dei--LegalEntityAxis__custom--ToleranceTherapeuticsIncMember_z2oXMAJ6bzWk" title="Related party transaction, amounts of transaction">0.1 million</span></span> <span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90B_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn5n6_c20180101__20181231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__dei--LegalEntityAxis__custom--ToleranceTherapeuticsIncMember_z9q0EwgXrpg8" title="Related party transaction, amounts of transaction">0.3 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million to Tolerance Therapeutics, Inc. during the years ended December 31, 2020 and 2018, respectively. The Company did not make any payments to Tolerance Therapeutics Inc. during the year ended December 31, 2019. Dr. Jeffrey Bluestone, who was appointed to the Company’s board of directors in March 2019, is a majority stockholder in Tolerance Therapeutics, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In July 2018, MDB served as the underwriter for the Company’s IPO and the Company paid MDB cash underwriters’ fees and expenses of $<span id="xdx_908_ecustom--UnderwritersFees_pn5n6_c20180702__20180731__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zj85FOTLetvf" title="Underwriter's fee">3.6 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million. Further, the Company issued to MDB underwriter warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pii_c20180731__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zbl9MaWFoQGg" title="Number of warrants to purchase common stock">1,596,956 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of the Company’s common stock. The warrants are exercisable, beginning July 3, 2019 for <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20180731__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z9CoLb9I6Vx2" title="Warrant term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1508">five years</span></span></span> at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20180731__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_ztGaf7cJn64a" title="Warrant exercise price">5.00 </span>per share. At the time of the IPO, MDB and affiliated parties beneficially owned greater than <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_c20180731__dei--LegalEntityAxis__custom--MDBCapitalGroupLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKvzuTHClXA9" title="Ownership percentage">5% </span>of the Company’s common stock and two employees of MDB were members of the Board of Directors of the Company. See Notes 3 and 11 for further information. These MDB employees are no longer members of the Board of Directors of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 100000 300000 3600000 1596956 5.00 0.05 <p id="xdx_806_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zyEWfliiDMg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>16. <span id="xdx_82E_zpuTfY0RowE4">RETIREMENT SAVINGS PLAN</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company has an employee savings and retirement plan which is qualified under Section 401(k) of the Internal Revenue Code. <span style="background-color: white"><span id="xdx_906_eus-gaap--DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_c20200101__20201231_zlV20TOaiiAe" title="Employee contribution description">The Company matches 100% of eligible employee contributions on the first 4% of employee salary (up to the IRS maximum).</span> Employer contributions for the</span> years ended December 31, 2020, 2019 and 2018 were $<span id="xdx_90D_eus-gaap--DefinedContributionPlanCostRecognized_pn5n6_c20200101__20201231_zowAvkgLeph5" title="Retirement plan contributions">0.2</span> million, $<span id="xdx_909_eus-gaap--DefinedContributionPlanCostRecognized_pn5n6_c20190101__20191231_zJh3yCw2u3w1" title="Retirement plan contributions">0.1</span> million, and $<span id="xdx_905_eus-gaap--DefinedContributionPlanCostRecognized_pn5n6_c20180101__20181231_zPKxokssl1r6" title="Retirement plan contributions">0.1</span> million, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> The Company matches 100% of eligible employee contributions on the first 4% of employee salary (up to the IRS maximum). 200000 100000 100000 <p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_zBnzqoMpYt43" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>17. <span id="xdx_823_zBJ0esTKVZje">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In January 2021, the Company completed an underwritten public offering in which it sold <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pii_c20210101__20210131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersOptionMember_zo1LIJ5SiL25">6,250,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock at a public offering price of $<span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_pii_c20210131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersOptionMember_zmXfn9l9ljd1">16.00 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share. In February 2021, the underwriters partially exercised their option to purchase an additional <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20210201__20210228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersOptionMember_zHXNnlym2OHl">587,500 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares at a price of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pii_c20210228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersOptionMember_zXCFbswVi0M2">16.00 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share. In the aggregate, total net proceeds from the underwritten public offering was $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20210101__20210228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersOptionMember_zuuwLpo3sUR7" title="Proceeds from Issuance or Sale of Equity">102.3 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million, after deducting underwriting discounts and commissions of approximately $<span id="xdx_90E_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20210101__20210228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersOptionMember_z1t2xTjJTii" title="Underwriting discounts and commissions">6.6 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million and other offering expenses of $<span id="xdx_900_ecustom--OtherOfferingExpenses_pn5n6_c20210101__20210228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersOptionMember_zsMyoPlqKTeg">0.5 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On February 17, 2021, the Company entered into a License Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”), a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (the “Huadong License Agreement”), pursuant to which the Company granted Huadong exclusive rights for the purpose of developing and commercializing PRV-3279, a DART® (bispecific antibody-based molecule) targeting the B cell surface proteins CD32B and CD79B, in Greater China (mainland China, Hong Kong, Macau and Taiwan). Provention Bio will retain exclusive worldwide rights to develop PRV-3279 for combination uses to reduce the immunogenicity of biotherapeutics, but Huadong will have the exclusive right to distribute PRV-3279 in that field in Greater China. In consideration of the license and other rights granted as part of the Huadong License Agreement, the Company will receive and upfront payment of $<span id="xdx_904_ecustom--UpfrontPaymentReceivable_pn5n6_c20210201__20210225__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--HangzhouZhongmeiHuadongPharmaceuticalCoLtdMember__us-gaap--IncomeStatementLocationAxis__custom--ResearchDevelopmentAndManufacturingFundingMember_zX9dJICufeN8">6.0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million and up to $<span id="xdx_902_ecustom--FutureResearchAndDevelopmentFundingReceivable_pn5n6_c20210201__20210225__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--HangzhouZhongmeiHuadongPharmaceuticalCoLtdMember__us-gaap--IncomeStatementLocationAxis__custom--ResearchDevelopmentAndManufacturingFundingMember__srt--RangeAxis__srt--MaximumMember_zj4YtjVrXnAg">11.5 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million in research, development and manufacturing funding over the next three years. If Huadong successfully develops, obtains regulatory approval for, and commercializes PRV-3279 in Greater China, the Company is eligible to receive up to $<span id="xdx_906_ecustom--FutureDevelopmentAndRegulatoryMilestonesReceivable_iI_pn5n6_c20210225__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--HangzhouZhongmeiHuadongPharmaceuticalCoLtdMember__srt--RangeAxis__srt--MaximumMember_zaG0Qe5lXmsi">37.0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million in regulatory milestones and up to $<span id="xdx_900_ecustom--FutureCommercialMilestonesReceivable_iI_pn5n6_c20210225__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--HangzhouZhongmeiHuadongPharmaceuticalCoLtdMember__srt--RangeAxis__srt--MaximumMember_z2gjhwZWBtPi">135.0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million in commercial milestones based on aggregate net sales in a calendar year in Greater China. If commercialized, the Company would also be eligible to receive low double-digit royalties on net sales of PRV-3279 by Huadong in Greater China. The License Agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Huadong without cause upon at least 12 months prior notice to the Company and by the Company in the event Huadong challenges a licensed patent or in the event that the Company’s upstream license terminates. The Company may also terminate the License Agreement if Huadong ceases commercialization of PRV-3279 for a consecutive period of six months after first commercial sale. The Company is generally responsible for the manufacturing of PRV-3279 at least through regulatory approval in Greater China and Huadong will exclusively purchase all clinical and commercial supply requirements of PRV-3279 from the Company until Huadong exercises its option to assume manufacturing responsibilities, which may be triggered after regulatory approval in China. The Company will retain all rights to PRV-3279 in the rest of the world. The Company plans to begin a Phase 2a trial of PRV-3279 in systemic lupus erythematosus in the second half of 2021 and expects a portion of such trial to be conducted in Hong Kong.</span></p> 6250000 16.00 587500 16.00 102300000 6600000 500000 6000000.0 11500000 37000000.0 135000000.0 Cash and cash equivalents primarily include investments in money market funds and United States Treasury securities with maturity dates within 90 days from the purchase date Investments in United States Treasury and investment-grade corporate debt securities are classified as available for sale securities XML 31 R1.htm IDEA: XBRL DOCUMENT v3.20.4
    Cover - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2020
    Feb. 22, 2021
    Jun. 30, 2020
    Cover [Abstract]      
    Document Type 10-K    
    Amendment Flag false    
    Document Annual Report true    
    Document Transition Report false    
    Document Period End Date Dec. 31, 2020    
    Document Fiscal Period Focus FY    
    Document Fiscal Year Focus 2020    
    Current Fiscal Year End Date --12-31    
    Entity File Number 001-38552    
    Entity Registrant Name PROVENTION BIO, INC.    
    Entity Central Index Key 0001695357    
    Entity Tax Identification Number 81-5245912    
    Entity Incorporation, State or Country Code DE    
    Entity Address, Address Line One 55 Broad Street    
    Entity Address, Address Line Two 2nd floor    
    Entity Address, City or Town Red Bank    
    Entity Address, State or Province NJ    
    Entity Address, Postal Zip Code 07701    
    City Area Code 908    
    Local Phone Number 336-0360    
    Title of 12(b) Security Common Stock, $0.0001 par value    
    Trading Symbol PRVB    
    Security Exchange Name NASDAQ    
    Entity Well-known Seasoned Issuer Yes    
    Entity Voluntary Filers No    
    Entity Current Reporting Status Yes    
    Entity Interactive Data Current Yes    
    Entity Filer Category Large Accelerated Filer    
    Entity Small Business false    
    Entity Emerging Growth Company false    
    Entity Shell Company false    
    Entity Public Float     $ 718.7
    Entity Common Stock, Shares Outstanding   63,374,738  
    ICFR Auditor Attestation Flag true    

    XML 32 R2.htm IDEA: XBRL DOCUMENT v3.20.4
    Balance Sheets - USD ($)
    $ in Thousands
    Dec. 31, 2020
    Dec. 31, 2019
    Current assets:    
    Cash and cash equivalents $ 102,294 $ 39,165
    Marketable securities 19,530 46,208
    Prepaid expenses and other current assets 4,730 623
    Total current assets 126,554 85,996
    Fixed assets, net 1,437
    Operating lease right-of-use assets 408
    Other assets 120
    Total assets 128,519 85,996
    Current liabilities:    
    Accounts payable 7,568 1,775
    Accrued expenses and other current liabilities 9,162 2,065
    Total current liabilities 16,730 3,840
    Operating lease liabilities, long-term 715
    Total liabilities 17,445 3,840
    Commitments and Contingencies (Note 6)  
    Stockholders’ equity:    
    Preferred stock, $0.0001 par value; 25,000,000 shares authorized; no shares issued or outstanding at December 31, 2020 and December 31, 2019
    Common stock, $0.0001 par value; 100,000,000 shares authorized; 56,517,891 shares issued and outstanding at December 31, 2020; 47,658,361 shares issued and outstanding at December 31, 2019 6 5
    Additional paid-in capital 288,725 161,212
    Accumulated other comprehensive loss (15)
    Accumulated deficit (177,642) (79,061)
    Total stockholders’ equity 111,074 82,156
    Total liabilities and stockholders’ equity $ 128,519 $ 85,996
    XML 33 R3.htm IDEA: XBRL DOCUMENT v3.20.4
    Balance Sheets (Parenthetical) - $ / shares
    Dec. 31, 2020
    Dec. 31, 2019
    Statement of Financial Position [Abstract]    
    Preferred Stock, Par or Stated Value Per Share $ 0.0001 $ 0.0001
    Preferred Stock, Shares Authorized 25,000,000 25,000,000
    Preferred Stock, Shares Issued 0 0
    Preferred Stock, Shares Outstanding 0 0
    Common Stock, Par or Stated Value Per Share $ 0.0001 $ 0.0001
    Common Stock, Shares Authorized 100,000,000 100,000,000
    Common Stock, Shares, Issued 56,517,891 47,658,361
    Common Stock, Shares, Outstanding 56,517,891 47,658,361
    XML 34 R4.htm IDEA: XBRL DOCUMENT v3.20.4
    Statements of Comprehensive Loss - USD ($)
    shares in Thousands, $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Operating expenses:      
    Research and development $ 66,360 $ 36,359 $ 22,649
    General and administrative 33,327 8,013 4,165
    Total operating expenses 99,687 44,372 26,814
    Loss from operations (99,687) (44,372) (26,814)
    Interest income 583 1,087 669
    Change in fair value of warrant liability (520)
    Loss before income tax benefit (99,104) (43,285) (26,665)
    Income tax benefit 523 187
    Net loss (98,581) (43,285) (26,478)
    Accretion on Series A Convertible Redeemable Preferred Stock (276)
    Net loss attributable to common stockholders $ (98,581) $ (43,285) $ (26,754)
    Net loss per common share, basic and diluted $ (1.88) $ (1.06) $ (1.19)
    Weighted average common shares outstanding, basic and diluted 52,457 40,747 22,441
    Net loss $ (98,581) $ (43,285) $ (26,478)
    Other comprehensive income (loss):      
    Unrealized gain (loss) on marketable securities (15)
    Total comprehensive loss $ (98,596) $ (43,285) $ (26,478)
    XML 35 R5.htm IDEA: XBRL DOCUMENT v3.20.4
    Statement of Stockholders' Equity - USD ($)
    $ in Thousands
    Convertible Redeemable Preferred Stock [Member]
    Common Stock [Member]
    Additional Paid-in Capital [Member]
    AOCI Attributable to Parent [Member]
    Retained Earnings [Member]
    Total
    Beginning balance, value at Dec. 31, 2017 $ 26,185 $ 1 $ 3,264 $ (9,298) $ (6,033)
    Balance, shares at Dec. 31, 2017 11,382 10,000        
    Issuance of common stock upon conversion of Series A Convertible Redeemable Preferred Stock $ (26,461) $ 1 26,460 26,461
    Issuance of common stock upon conversion of Series A Convertible Redeemable Preferred Stock, shares (11,382) 11,382        
    Accretion of Series A Convertible Redeemable Preferred Stock to redemption value $ 276 (276) (276)
    Reclassification of Series A warrants liability 1,518 1,518
    Issuance of common stock in connection with initial public offering, net of issuance costs $ 2 56,281 56,283
    Issuance of common stock in connection with initial public offering, net of issuance costs, shares 15,970        
    Issuance of common stock in connection with public follow on offering, net of issuance costs
    Issuance of common stock in connection with public follow on offering, net of issuance costs, shares        
    Issuance of common stock in connection with underwritten public offering, net of issuance costs
    Issuance of common stock in connection with underwritten public offering, net of issuance costs, shares        
    Issuance of common stock in connection with private placement with Amgen          
    Issuance of common stock in connection with private placement with Amgen, shares        
    Issuance of common stock in connection with stock option exercises 25 25
    Issuance of common stock in connection with stock option exercises, shares 10        
    Issuance of common stock in connection with at-the-market stock sales, net of issuance costs, shares        
    Issuance of common stock in connection with warrant exercises          
    Issuance of common stock in connection with warrant exercises, shares        
    Fair value of warrants issued in connection with initial public offering of common stock 3,039 3,039
    Fair value of warrants issued in connection with the acquisition of product rights 3,978 3,978
    Unrealized gain (loss) on marketable securities, net of tax        
    Stock-based compensation 1,141 1,141
    Net loss (26,478) (26,478)
    Ending balance, value at Dec. 31, 2018 $ 4 95,430 (35,776) 59,658
    Shares, Outstanding, Ending Balance at Dec. 31, 2018 37,362        
    Accretion of Series A Convertible Redeemable Preferred Stock to redemption value          
    Issuance of common stock in connection with public follow on offering, net of issuance costs $ 1 42,650 42,651
    Issuance of common stock in connection with public follow on offering, net of issuance costs, shares 5,750        
    Issuance of common stock in connection with private placement with Amgen 20,000 20,000
    Issuance of common stock in connection with private placement with Amgen, shares 2,500        
    Issuance of common stock in connection with stock option exercises 290 $ 290
    Issuance of common stock in connection with stock option exercises, shares 79       79
    Issuance of common stock in connection with warrant exercises
    Issuance of common stock in connection with warrant exercises, shares 1,967        
    Unrealized gain (loss) on marketable securities, net of tax          
    Stock-based compensation 2,842 2,842
    Net loss (43,285) (43,285)
    Ending balance, value at Dec. 31, 2019 $ 5 161,212 (79,061) 82,156
    Shares, Outstanding, Ending Balance at Dec. 31, 2019 47,658        
    Accretion of Series A Convertible Redeemable Preferred Stock to redemption value          
    Issuance of common stock in connection with underwritten public offering, net of issuance costs $ 1 103,269 103,270
    Issuance of common stock in connection with underwritten public offering, net of issuance costs, shares 7,590        
    Issuance of common stock in connection with stock option exercises 1,152 $ 1,152
    Issuance of common stock in connection with stock option exercises, shares 219       219
    Issuance of common stock in connection with at-the-market stock sales, net of issuance costs 9,869 $ 9,869
    Issuance of common stock in connection with at-the-market stock sales, net of issuance costs, shares 725        
    Issuance of common stock in connection with warrant exercises
    Issuance of common stock in connection with warrant exercises, shares 326        
    Unrealized gain (loss) on marketable securities, net of tax (15) (15)
    Stock-based compensation 13,223 13,223
    Net loss (98,581) (98,581)
    Ending balance, value at Dec. 31, 2020 $ 6 $ 288,725 $ (15) $ (177,642) $ 111,074
    Shares, Outstanding, Ending Balance at Dec. 31, 2020 56,518        
    XML 36 R6.htm IDEA: XBRL DOCUMENT v3.20.4
    Statements of Cash Flows - USD ($)
    shares in Thousands, $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Operating activities      
    Net loss $ (98,581) $ (43,285) $ (26,478)
    Adjustments to reconcile net loss to net cash used in operating activities:      
    Stock-based compensation expense 13,223 2,842 1,141
    Stock-based consideration in connection with acquisition of product rights (Note 6) 3,978
    Change in fair value of warrant liability 520
    Amortization of premium and discounts on marketable securities 247 (16)
    Non-cash operating lease expense 25
    Depreciation 33
    Changes in operating assets and liabilities:      
    Prepaid expenses and other current assets (4,112) 2,367 (2,396)
    Accounts payable 5,793 1,207 109
    Accrued interest receivable 131 58
    Accrued expenses 7,025 762 484
    Other assets (120)
    Net cash used in operating activities (76,336) (36,065) (22,642)
    Investing activities      
    Purchase of marketable securities (28,715) (46,250)
    Maturities of marketable securities 55,000
    Purchase of fixed assets (1,111)
    Net cash provided by (used in) investing activities 25,174 (46,250)
    Financing activities      
    Proceeds from underwritten public offering, net 103,270 42,651
    Proceeds from private placement with Amgen 20,000
    Proceeds from initial public offering, net 59,322
    Proceeds from at-the-market stock sales, net 9,869
    Proceeds from stock option exercises 1,152 290 25
    Net cash provided by financing activities 114,291 62,941 59,347
    Net increase (decrease) in cash and cash equivalents 63,129 (19,374) 36,705
    Cash and cash equivalents at beginning of period 39,165 58,539 21,834
    Cash and cash equivalents at end of period 102,294 39,165 58,539
    Supplemental disclosure of cash flow information:      
    Right-of-use assets obtained in exchange for new operating lease liabilities $ 413
    Supplemental disclosure of non-cash financing transactions:      
    Conversion of Series A Preferred Stock to common stock upon completion of IPO 26,461
    Reclassification of Series A Preferred Stock warrant liability to stockholders’ equity $ 1,518
    Accretion of Series A Convertible Redeemable Preferred Stock $ 276
    XML 37 R7.htm IDEA: XBRL DOCUMENT v3.20.4
    DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION
    		 12 Months Ended
    Dec. 31, 2020
    Accounting Policies [Abstract]  
    DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

    1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

     

    Business

     

    Provention Bio, Inc. (the “Company”) was incorporated on October 4, 2016 under the laws of the State of Delaware. The Company is a clinical stage biopharmaceutical company, focused on the development and commercialization of novel therapeutics and innovative approaches to intercept and prevent immune-mediated diseases. Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. The Company’s business is subject to significant risks and uncertainties and will be dependent on raising substantial additional capital before it becomes profitable and it may never achieve profitability.

     

    Basis of presentation

     

    The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented.

     
    XML 38 R8.htm IDEA: XBRL DOCUMENT v3.20.4
    LIQUIDITY
    		 12 Months Ended
    Dec. 31, 2020
    Liquidity  
    LIQUIDITY

    2. LIQUIDITY

     

    The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has incurred recurring losses since inception and as of December 31, 2020, the Company had an accumulated deficit of $177.6 million. To date, the Company has not generated any revenues and has financed its operations primarily through equity offerings.

     

    In April 2017, the Company completed its private placement of 11,381,999 shares of Series A Convertible Redeemable Preferred Stock at $2.50 per share (the “Series A Offering”). The Company received net proceeds of $26.7 million. In connection with the sale of Series A Convertible Redeemable Preferred Stock, the Company issued warrants to purchase 558,740 shares of Series A Convertible Redeemable Preferred Stock with an exercise price of $2.50 per share with a seven-year term.

     

    In July 2018, the Company issued and sold an aggregate of 15,969,563 shares of common stock in its initial public offering (“IPO”) at a public offering price of $4.00 per share. In connection with the IPO, the Company issued to MDB Capital Group, LLC (“MDB”), the underwriter in the IPO, and its designees warrants to purchase 1,596,956 shares of common stock at an exercise price of $5.00 per share. The Company received net proceeds from the IPO of $59.3 million, after deducting underwriting discounts and commissions of approximately $3.7 million and other offering expenses of approximately $0.8 million. Upon the closing of the IPO, all of the Company’s shares of redeemable convertible preferred stock outstanding at the time of the offering were automatically converted into 11,381,999 shares of common stock. In addition, the warrants issued in connection with the Series A Convertible Redeemable Preferred Stock also converted to warrants for the purchase of 558,740 shares of the Company’s common stock.

     

    In September 2019, the Company completed an underwritten public offering in which it sold 5,750,000 shares of common stock at a public offering price of $8.00 per share. The 5,750,000 shares sold included the full exercise of the underwriters’ option to purchase 750,000 shares at a price of $8.00 per share. Concurrent with the underwritten public offering, the Company sold 2,500,000 shares of common stock to Amgen, Inc. at the public offering price of $8.00 per share in a private placement, pursuant to the terms of the Company’s License and Collaboration Agreement with Amgen Inc, dated as of November 5, 2018. Aggregate net proceeds from the underwritten public offering and the concurrent private placement were $62.7 million, net of approximately $2.8 million in underwriting discounts and commissions and other offering expenses of $0.5 million.

     

     

    In August 2019, the Company established an at-the-market (“ATM”) program through which the Company may sell, from time to time at its sole discretion, up to $50.0 million of shares of its common stock. The Company has sold 725,495 shares of common stock for aggregate net proceeds of approximately $9.9 million, net of $0.3 million in sales commissions, under the ATM program, all of which occurred during the quarter ended June 30, 2020.

     

    In June 2020, the Company completed an underwritten public offering in which it sold 7,590,000 shares of common stock at a public offering price of $14.50 per share. The 7,590,000 shares sold included the full exercise of the underwriters’ option to purchase 990,000 shares at a price of $14.50 per share. The Company received net proceeds from the underwritten public offering of $103.3 million, after deducting underwriting discounts and commissions of approximately $6.6 million and other offering expenses of $0.2 million.

     

    In January 2021, the Company completed an underwritten public offering in which it sold 6,250,000 shares of common stock at a public offering price of $16.00 per share. In February 2021, the underwriters partially exercised their option to purchase an additional 587,500 shares at a price of $16.00 per share. In the aggregate, total net proceeds from the underwritten public offering was $102.3 million, after deducting underwriting discounts and commissions of approximately $6.6 million and other offering expenses of $0.5 million.

     

    The Company has devoted substantially all of its financial resources and efforts to research and development and expects to continue to incur significant expenses and increasing operating losses over the next several years due to, among other things, costs related to research funding, development of its product candidates and its preclinical programs, strategic alliances, the development of its administrative and commercial organization and pre-commercial activities for teplizumab. The Company’s net losses may fluctuate significantly from quarter to quarter and year to year.

     

    The Company will require substantial additional financing to fund its operations and to continue to execute its strategy. The Company may raise capital through public or private equity or debt financings. The sale of equity or other securities may result in dilution to the Company’s stockholders and certain of those securities may have rights senior to those of the Company’s existing shares. If the Company raises additional funds through the issuance of preferred stock, convertible debt securities or other debt financing, these securities or other debt could contain covenants that would restrict the Company’s operations. Any other third-party funding arrangement could require the Company to relinquish valuable rights. The source, timing and availability of any future financing will depend principally upon market conditions, and, more specifically, on the progress of the Company’s clinical development programs. Funding may not be available when needed, at all, or on terms acceptable to the Company. Lack of necessary funds may require the Company, among other things, to delay, scale back or eliminate some or all of the Company’s planned operations.

     

    The Company’s cash requirements for 2021 will be impacted by a number of factors, the most significant of which are expenses related to teplizumab, including costs to build out the Company’s commercial infrastructure and pre-commercial activities for teplizumab, the PROTECT clinical trial, manufacturing activities for teplizumab and any potential milestone payments that may become due upon a potential regulatory approval of teplizumab by the FDA. Other factors include costs related to the Company’s Phase 2b clinical study of PRV-015 and first-in-human safety study of PRV-101.

     

    Based on the Company’s current business plans, management believes that its cash, cash equivalents and marketable securities on hand at December 31, 2020, coupled with net proceeds from the Company’s follow on offering in January 2021 and partial exercise by the underwriters to purchase additional shares in February 2021, are sufficient to meet the Company’s obligations for at least the next 12 months from the issuance of these financial statements.

     
    XML 39 R9.htm IDEA: XBRL DOCUMENT v3.20.4
    SIGNIFICANT ACCOUNTING POLICIES
    		 12 Months Ended
    Dec. 31, 2020
    Accounting Policies [Abstract]  
    SIGNIFICANT ACCOUNTING POLICIES

    3. SIGNIFICANT ACCOUNTING POLICIES

     

    A summary of the significant accounting policies followed by the Company in the preparation of the financial statements is as follows:

     

    Use of estimates

     

    The process of preparing financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates and changes in estimates may occur.

     

     

    Segment and geographic information

     

    Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating and reporting segment.

     

    Cash, cash equivalents and concentration of credit risk

     

    The Company considers only those investments which are highly liquid, readily convertible to cash, or that mature within 90 days from the date of purchase to be cash equivalents. Marketable securities are those investments with original maturities in excess of 90 days. The carrying amounts reported in the balance sheets for cash and cash equivalents are valued at cost, which approximates their fair value.

     

    The Company has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements. The Company holds cash and cash equivalents in banks in excess of FDIC insurance limits. However, the Company believes risk of loss is minimal as the cash and cash equivalents are held by large, highly-rated financial institutions.

     

    Marketable securities

     

    The Company considers securities with original maturities of greater than 90 days to be available for sale securities. Available for sale securities are classified as either current or non-current assets based on the nature of the securities and their availability for use in current operations. Available for sale securities are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity.

     

    On a quarterly basis, the Company reviews the status of each security in an unrealized loss position, to evaluate the existence of potential credit losses. The Company first considers whether it intends to sell, or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through income. For securities that do not meet this criteria, the Company considers a number of factors to determine if the decline in fair value has resulted from credit losses or other factors, including but not limited to: (1) the extent of the decline; (2) changes to the rating of the security by a rating agency; (3) any adverse conditions specific to the security; and (4) other market conditions that may affect the fair value of the security. If this assessment indicates that a credit loss exists and the present value of cash flows expected to be collected is less than the amortized cost basis, an allowance for credit losses is required for the credit loss. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. As of December 31, 2020, the Company has not recognized any impairment or credit losses on its available for sale securities.

     

    Financial instruments

     

    Cash, cash equivalents and marketable securities are reflected in the accompanying financial statements at fair value. The carrying amount of accounts payable and accrued expenses, including accrued research and development expenses, approximates fair value due to the short-term nature of those instruments.

     

    Net loss per common share

     

    Net loss per share information is determined using the two-class method, which includes the weighted-average number of shares of common stock outstanding during the period and other securities that participate in dividends (a participating security). The Company considered the Series A Preferred Stock, all of which were automatically converted to common stock upon the Company’s IPO, to be participating securities because they included rights to participate in dividends, if any, with the common stock.

     

     

    Under the two-class method, basic net loss per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. The net loss attributable to common stockholders is calculated by adjusting the net loss of the Company for the accretion on the Preferred Stock. Net losses are not allocated to preferred stockholders as they do not have an obligation to share in the Company’s net losses. In periods with net income attributable to common stockholders, the Company would allocate net income first to preferred stockholders based on dividend rights under the Company’s certificate of incorporation and then to preferred and common stockholders based on ownership interests. Diluted net loss per share attributable to common stockholders is computed using the more dilutive of (1) the two-class method or (2) the if-converted method.

     

    Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders for all periods presented since the effect of potentially dilutive securities are anti-dilutive given the net loss of the Company.

     

    Fixed assets, net

     

    Fixed assets, which consists primarily of leasehold improvements, furniture and fixtures, software, office equipment and certain clinical equipment, are carried at cost less accumulated depreciation. Depreciation is computed over the estimated useful lives of the respective assets, generally three to seven years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset.

     

    Leases

     

    The Company determines if an arrangement is a lease at contract inception. A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company classifies its leases as operating or financing by considering factors such as the length of the lease term, the present value of the lease payments, the specialized nature of the asset being leased and the potential for ownership of the asset to transfer during the lease term.

     

    Leases with terms greater than one-year are recognized on the Company’s balance sheets as right-of-use (“ROU”) assets and lease liabilities and are measured at the present value of the fixed payments due over the lease term minus the present value of any incentives, rebates or abatements expected to be received from the lessor. Options to extend a lease are typically excluded from the expected lease term as the exercise of the option is typically not reasonably certain. Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee’s incremental borrowing rate. As the implicit rate is not typically readily determinable, the Company uses an incremental borrowing rate, which is established based upon the information available at the lease commencement date, to determine the present value of lease payments due under an arrangement. The incremental borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments.

     

    ROU assets are amortized on a straight-line basis over the term of the lease. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are recognized in the statements of comprehensive loss in the same line item as expenses arising from fixed lease payments at the time when the event giving rise to the payment occurs.

     

    Foreign currency translation

     

    The Company considers the U.S. dollar to be its functional currency. Expenses denominated in foreign currencies are translated at the exchange rate on the date the expense is incurred. The effect of exchange rate fluctuations on translating foreign currency assets and liabilities into U.S. dollars is included in the Statements of Comprehensive Loss. Foreign exchange transaction gains and losses are included in the results of operations and are not material in the Company’s financial statements.

     

     

    Research and development expenses

     

    Research and development expenses primarily consist of costs associated with the preclinical and clinical development of the Company’s product candidate portfolio, including the following:

     

      ● external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”) and other vendors and contract manufacturing organizations (“CMOs”) for the production of drug substance and drug product; and

     

      ● employee-related expenses, including salaries, benefits and share-based compensation expense.

     

    Research and development expenses also include costs of acquired product licenses and related technology rights where there is no alternative future use, costs of prototypes used in research and development, consultant fees and amounts paid to certain of our collaborative partners.

     

    All research and development expenses are charged to operations as incurred in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic (“ASC”) 730, Research and Development. The Company accounts for non-refundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received, rather than when the payment is made.

     

    Accrued research and development expenses

     

    As part of the process of preparing our financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company’s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and make adjustments if necessary. The significant estimates in the Company’s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.

     

    The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on the Company’s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company’s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company’s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.

     

    Stock-based compensation expense

     

    The Company follows the provisions of ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and non-employees, including stock options. Stock-based compensation expense is based on the grant date fair value estimated in accordance with the provisions of ASC 718 and is generally recognized as an expense over the requisite service period. For grants containing performance-based vesting provisions, the grant-date fair value of the performance-based stock options is recognized as compensation expense once it is probable that the performance condition will be achieved. The Company accounts for actual forfeitures in the period the forfeiture occurs.

     

     

    Stock Options

     

    The Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. Due to the lack of trading history, the Company’s computation of stock-price volatility is based on the volatility rates of comparable publicly held companies over a period equal to the expected term of the options granted by the Company. The Company’s computation of expected term is determined using the “simplified” method, which is the midpoint between the vesting date and the end of the contractual term. The Company believes that it does not have sufficient reliable exercise data in order to justify the use of a method other than the “simplified” method of estimating the expected exercise term of employee stock option grants. The Company utilizes a dividend yield of zero based on the fact that the Company has never paid cash dividends to stockholders and has no current intentions to pay cash dividends. The risk-free interest rate is based on the zero-coupon United States Treasury yield at the date of grant for a term equivalent to the expected term of the option.

     

    In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, (“ASU 2018-07”) which supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payments arrangements related to the acquisition of goods and services from both employees and nonemployees. During the third quarter of 2018, the Company early adopted ASU 2018-07. After the adoption of ASU 2018-07, the measurement date for non-employee awards is the date of grant. Compensation expense for non-employees is recognized, without changes to the fair value of the award, over the requisite service period, which is the vesting period of the respective award. The adoption of ASU 2018-07 did not have a material impact the Company’s financial statements or footnote disclosures.

     

    Prior to the third quarter of 2018, the Company accounted for awards of equity instruments issued to non-employees in accordance with ASC Topic 505-50, Equity-Based Payment to Non-Employees, (“ASC 505-50”) and accordingly the value of the stock compensation to non-employees was based upon the measurement date as determined at either a) the date at which a performance commitment was reached, or b) at the date at which the necessary performance to earn the equity instruments was completed, which was normally the end of the vesting period. At the end of each financial reporting period prior to completion of the service, the fair value of these awards was remeasured using updated assumption inputs in the Black-Scholes option-pricing model.

     

    Stock-based compensation expense is included in both research and development expenses and general and administrative expenses in the Statements of Comprehensive Loss.

     

    Warrant liability

     

    In April 2017, the Company issued warrants to purchase shares of Series A Convertible Redeemable Preferred Stock in connection with the issuance of the Series A Preferred Stock. The Company accounted for these warrants as a liability in the financial statements because the underlying instrument into which the warrants were exercisable contained redemption provisions that were outside the Company’s control.

     

    Upon the completion of the IPO in July 2018, the warrants issued in connection with the Series A Convertible Redeemable Preferred Stock converted to warrants for the purchase of 558,740 shares of our common stock and the warrants no longer contain redemption provisions that are outside the Company’s control. The liability associated with these warrants was revalued just prior to the completion of the IPO, with the change in the fair value of the warrant liability charged to earnings. The warrant liability was then reclassified to additional paid-in capital upon the completion of the IPO in July 2018.

     

    The fair value of the warrants was determined using the Black-Scholes option-pricing model and were re-measured to fair value at each financial reporting period date with any changes in fair value recognized in the statements of operations. See Note 11 to our financial statements for further information.

     

     

    Income taxes

     

    The Company utilizes the liability method of accounting for deferred income taxes, as set forth in ASC 740, Income Taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. A valuation allowance is established against deferred tax assets when, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense.

     

    Recent accounting pronouncements

     

    The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”). ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s financial statements.

     

    In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. Effective January 1, 2019, the Company adopted ASU 2016-02. The adoption had no impact on the Company’s financial statements and related disclosures as the Company did not have any lease agreements at the time of adoption. In July 2020, the Company entered into an agreement to lease its new corporate headquarters in Red Bank, NJ. Upon commencement of the lease, which occurred in October 2020, the lease was accounted for as an operating lease. Refer to Note 13 - Leases for details about the Company’s lease portfolio, including Topic 842 required disclosures.

     

    In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Effective January 1, 2020, the Company adopted ASU 2016-13 using the modified retrospective method for all financial assets measured at amortized cost. Results for reporting periods beginning after January 1, 2020 are presented under ASC 326 (Financial Instruments - Credit Losses), while prior period amounts continue to be reported in accordance with previously applicable GAAP. The adoption of this ASU had no impact on the Company’s financial statements and related disclosures.

     

    In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820), which modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, including, among other changes, the consideration of costs and benefits when evaluating disclosure requirements. Effective January 1, 2020, the Company adopted ASU 2018-13. The adoption had no impact on the Company’s financial statements and related disclosures.

     

    In August 2018, the FASB issued ASU No. 2018-15, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Effective January 1, 2020, the Company adopted ASU 2018-15. The adoption had no impact on the Company’s financial statements and related disclosures.

     

     

    In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808), which clarifies the interaction between the guidance for collaborative arrangements (Topic 808) and the new revenue recognition standard (Topic 606). Effective January 1, 2020, the Company adopted ASU 2018-18. The adoption had no impact on the Company’s financial statements and related disclosures.

     
    XML 40 R10.htm IDEA: XBRL DOCUMENT v3.20.4
    CAPITALIZATION
    		 12 Months Ended
    Dec. 31, 2020
    Capitalization  
    CAPITALIZATION

    4. CAPITALIZATION

     

    As of December 31, 2020 and 2019, the Company had authorized 100,000,000 shares of common stock, $0.0001 par value per share, of which 56,517,891 and 47,658,361 shares, respectively, were issued and outstanding. In addition, as of December 31, 2020 and 2019, the Company had authorized 25,000,000 shares of preferred stock, $0.0001 par value per share, of which, none were issued and outstanding.
    XML 41 R11.htm IDEA: XBRL DOCUMENT v3.20.4
    CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES
    		 12 Months Ended
    Dec. 31, 2020
    Cash and Cash Equivalents [Abstract]  
    CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES

    5. CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES

     

    The Company considers all highly liquid investments purchased with original maturities of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents as of December 31, 2020 and 2019 were $102.3 million and $39.2 million, respectively, and included cash, investments in money market funds, and United States Treasury securities with original maturities of 90 days or less.

     

    The Company considers securities with original maturities of greater than 90 days at the date of purchase to be available for sale securities. The Company held available for sale securities with a fair value totaling $19.5 million and $46.2 million at December 31, 2020 and 2019, respectively. These available for sale securities consisted solely of investment-grade corporate debt securities and United States Treasury securities and had expected maturities of less than one year. The Company may sell certain of its marketable securities prior to their stated maturities for reasons including, but not limited to, managing liquidity, credit risk, duration and asset allocation.

     

    The Company evaluates securities with unrealized losses, if any, to determine whether the decline in fair value has resulted from credit loss or other factors. As of December 31, 2020, the Company has not recognized any impairment or credit losses on the Company’s available for sale securities. While the Company classifies these securities as available for sale, the Company does not currently intend to sell its investments and the Company currently believes it has the ability to hold these investments until maturity.

     

    The following table summarizes the amortized cost, fair value and allowance for credit losses of the Company’s available for sale securities:

     

       December 31, 2020 
       Amortized Cost   Gross Unrealized Gains   Gross Unrealized Losses   Fair Value 
                     
    Corporate debt securities  $19,545   $—   $(15)  $19,530 
    Total  $19,545   $—   $(15)  $19,530 

     

       December 31, 2019 
       Amortized Cost   Gross Unrealized Gains   Gross Unrealized Losses   Fair Value 
                     
    U.S. Treasury securities  $46,208   $—   $—   $46,208 
    Total  $46,208   $—   $—   $46,208 

     

     

    The Company’s available for sale securities are reported at fair value on the Company’s balance sheets. Unrealized gains (losses) are reported within accumulated other comprehensive income (loss) in the Statements of Comprehensive Loss. The cost of securities sold and any realized gains/losses from the sale of available for sale securities are based on the specific identification method. The changes in accumulated other comprehensive income (loss) associated with the unrealized gain (loss) on available for sale securities for the years ended December 31, 2020, 2019 and 2018, were as follows:

     

       For the Years Ended December 31, 
       2020   2019   2018 
                 
    Beginning balance  $—   $—   $— 
    Current period changes in fair value before reclassifications, net of tax   (15)   —    — 
    Amounts reclassified from accumulated other comprehensive income (loss), net of tax   —    —    — 
    Other comprehensive income (loss)   (15)   —    — 
    Ending balance  $(15)  $—   $— 

     
    XML 42 R12.htm IDEA: XBRL DOCUMENT v3.20.4
    LICENSE AND OTHER AGREEMENTS
    		 12 Months Ended
    Dec. 31, 2020
    License And Other Agreements  
    LICENSE AND OTHER AGREEMENTS

    6. LICENSE AND OTHER AGREEMENTS

     

    In May 2018, the Company entered into an Asset Purchase Agreement with MacroGenics (the “MacroGenics Asset Purchase Agreement”) pursuant to which the Company acquired MacroGenics’ interest in teplizumab (renamed PRV-031), a humanized mAb for the treatment of Type 1 Diabetes (“T1D”). As partial consideration for the MacroGenics Asset Purchase Agreement, the Company granted MacroGenics a warrant to purchase 2,162,389 shares of the Company’s common stock at an exercise price of $2.50 per share. The Company is obligated to pay MacroGenics contingent milestone payments totaling $170.0 million upon the achievement of certain regulatory approval milestones, including $60.0 million payable within 90 days of an approval of a Biologics License Application (“BLA”) in the United States. In addition, the Company is obligated to make contingent milestone payments to MacroGenics totaling $225.0 million upon the achievement of certain sales milestones. The Company has also agreed to pay MacroGenics a single-digit royalty on net sales of the product. The Company has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to MacroGenics, aggregate milestone payments of up to approximately $0.7 million and other consideration, for certain third-party intellectual property under agreements the Company assumed pursuant to the MacroGenics Asset Purchase Agreement. Further, the Company is required to pay MacroGenics a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to teplizumab by the Company to a third party. The Company is obligated to use reasonable commercial efforts to develop and seek regulatory approval for teplizumab.

     

    In May 2018, the Company entered into a License Agreement with MacroGenics, Inc. (the “MacroGenics License Agreement”), pursuant to which MacroGenics, Inc. (“MacroGenics”) granted the Company exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a humanized protein and a potential treatment for systemic lupus erythematosus (“SLE”) and other similar diseases. As partial consideration for the MacroGenics License Agreement, the Company granted MacroGenics a warrant to purchase 270,299 shares of the Company’s common stock at an exercise price of $2.50 per share. The Company is obligated to make contingent milestone payments to MacroGenics totaling $42.5 million upon the achievement of certain developmental and approval milestones for the first indication, and an additional $22.5 million upon the achievement of certain regulatory approvals for a second indication. In addition, the Company is obligated to make contingent milestone payments to MacroGenics totaling $225.0 million upon the achievement of certain sales milestones. The Company has also agreed to pay MacroGenics a single-digit royalty on net sales of the product. Further, the Company is required to pay MacroGenics a low double-digit percentage of certain consideration to the extent received in connection with a future grant of rights to PRV-3279 by the Company to a third party. The Company is obligated to use commercially reasonable efforts to develop and seek regulatory approval for PRV-3279. The license agreement may also be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to MacroGenics, and by MacroGenics in the event that the Company challenges the validity of any licensed patent under the agreement.

     

    As of December 31, 2020, the Company has not achieved any milestones that would trigger payments to MacroGenics.

     

    The Company recorded the warrants issued under the MacroGenics Asset Purchase Agreement and the MacroGenics License Agreement at an estimated fair value of $1.64 per share, approximately $4.0 million in the aggregate, as license fee expense included as part of Research & development expense during the second quarter of 2018.

     

    In July 2019, MacroGenics elected to exercise its warrants for an aggregate of 2,432,688 shares on a cashless basis, resulting in the Company’s net issuance of 1,948,474 shares. Following the MacroGenics’ July 2019 warrant exercises, there were no additional warrants outstanding in connection with the MacroGenics License Agreement and the MacroGenics Asset Purchase Agreement.

     

     

    In November 2018, the Company entered into a License and Collaboration Agreement (the “Amgen Agreement”) with Amgen, Inc. (“Amgen”) for PRV-015 (formerly AMG 714), a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease (“NRCD”). Under the terms of the agreement, the Company will conduct and fund a Phase 2b trial in NRCD and lead the development and regulatory activities for the program. Amgen agreed to make an equity investment of up to $20.0 million in the Company, subject to certain terms and conditions set forth in the agreement. Amgen is also responsible for the manufacturing of PRV-015. Upon completion of the Phase 2b trial, a $150.0 million milestone payment is due from Amgen to the Company, plus an additional regulatory milestone payment, and single digit royalties on future sales; provided, however, that Amgen has the right to elect not to pay the $150.0 million milestone, in which case we will have an option to negotiate for the transfer to the Company of rights to AMG 714 pursuant to a termination license agreement between Amgen and the Company. The material terms of the termination license agreement have been negotiated and agreed and form part of the Amgen Agreement. Under the terms of the termination license agreement, the Company would be obligated to make certain contingent milestone payments to Amgen and other third parties totaling up to $70.0 million upon the achievement of certain clinical and regulatory milestones and a low double-digit royalty on net sales of any approved product based on the IL-15 technology. The agreement may be terminated by either party upon a material breach or upon an insolvency event and by Amgen if we are not able to fund our clinical development obligations (among other termination triggers). The agreement expires upon the expiration of Amgen’s last obligation to make royalty payments to Provention. In September 2019, in a private placement completed concurrently with the Company’s underwritten public offering, Amgen purchased 2,500,000 shares of the Company’s common stock at the underwritten public offering price of $8.00 per share, for a total investment of $20.0 million.

     

    In April 2017, the Company entered into a License Agreement with Vactech Ltd. (the “Vactech License Agreement”), pursuant to which Vactech Ltd. (“Vactech”) granted the Company exclusive global rights for the purpose of developing and commercializing the group B coxsackie virus vaccine (“CVB”) platform technology. In consideration of the licenses and other rights granted by Vactech, the Company issued two million shares of its common stock to Vactech. The Company recorded the issuance of the shares at their estimated fair value of approximately $1.70 per share for a total of $3.4 million as a license fee expense included as part of Research & development expense for the year ended December 31, 2017. Provention paid Vactech a total of approximately $0.5 million for transition and advisory services during the first 18 months of the term of the agreement. In addition, Provention may be obligated to make a series of contingent milestone payments to Vactech totaling up to an additional $24.5 million upon the achievement of certain clinical development and regulatory filing milestones, of which, $0.5 million became payable to Vactech in January 2021 upon the dosing of the first patient in the Phase 1 PROVENT study. In addition, the Company has agreed to pay Vactech tiered single-digit royalties on net sales of any approved product based on the CVB platform technology and three additional payments totaling $19.0 million upon the achievement of certain annual net sales levels. The Vactech License Agreement may be terminated by the Company on a country by country basis without cause (in which case the exclusive global rights to the technology will transfer back to Vactech) and by either party upon a material breach or insolvency of the other party. If the Company terminates the agreement with respect to two or more specified European countries, the agreement will be deemed terminated with respect to all of the EU, and if the Company terminates the agreement with respect to the United States, the agreement will be deemed terminated with respect to all of North America. The agreement expires upon the expiration of the Company’s last obligation to make royalty payments to Vactech. As of December 31, 2020, the Company has not achieved any milestones that would trigger payments to Vactech.

     

    In March 2018, the Company entered into a Development Services Agreement with The Institute of Translational Vaccinology (the “Intravacc Development Services Agreement”), pursuant to which The Institute of Translational Vaccinology (“Intravacc”) will provide services related to process development, non-GMP and GMP manufacturing of the Company’s polyvalent CVB vaccine, including providing proprietary technology for manufacturing purposes. The Company will pay Intravacc approximately 10 million euros for their services over the development and manufacturing period. Each party retains its existing intellectual property and will share newly developed intellectual property via a fully-paid non-exclusive license between the parties for all development work through phase 1 clinical trials. Any future use, including commercial use, of Intravacc’s technology will be subject to a separate nonexclusive license agreement. The Intravacc Development Services Agreement may be terminated by us with ninety days’ notice without cause and by either party upon a material breach or insolvency of the other party. As of December 31, 2020, the Company had paid Intravacc a total of approximately 9.0 million euros, or approximately $10.5 million, for services provided by Intravacc under the Intravacc Development Services Agreement.

     

     

    In April 2017, the Company entered into the Janssen CSF-1R License Agreement, pursuant to which Janssen Pharmaceutica NV (“Janssen”) granted the Company exclusive global rights to technology owned or controlled by Janssen Pharmaceutica NV for the purpose of developing and commercializing a colony stimulating factor 1 receptor (“CSF-1R”) inhibitor named JNJ-40346527 (renamed PRV-6527) for inflammatory bowel diseases including Crohn’s disease and UC. The Company evaluated PRV-6527 for Crohn’s disease in a recently completed Phase 2a clinical trial (the PRINCE study). In December 2019, Janssen declined its option to buy back the rights to PRV-6527 and as such, all rights will remain with the Company. The Company will be obligated to make contingent milestone payments to Janssen totaling $35.0 million upon the achievement of certain clinical and regulatory milestones for the first indication and an additional $20.0 million upon the achievement of certain clinical and regulatory milestones for a second indication. In addition, the Company has agreed to pay Janssen tiered single-digit royalties on net sales of any approved product based on the CSF-1R technology and three additional payments totaling $100.0 million upon the achievement of certain annual net sales levels. As of December 31, 2020, no milestones have been achieved that would trigger payments to Janssen under the CSF-1R License Agreement. The Company is not actively developing PRV-6527.

     
    XML 43 R13.htm IDEA: XBRL DOCUMENT v3.20.4
    NET LOSS PER SHARE OF COMMON STOCK
    		 12 Months Ended
    Dec. 31, 2020
    Earnings Per Share [Abstract]  
    NET LOSS PER SHARE OF COMMON STOCK

    7. NET LOSS PER SHARE OF COMMON STOCK

     

    The following table sets forth the computation of basic and diluted loss per share for the years ended December 31, 2020, 2019, and 2018:

     

       For the Years Ended December 31, 
       2020   2019   2018 
                 
    Net loss, basic  $(98,581)  $(43,285)  $(26,478)
    Accretion of Series A Convertible Redeemable Preferred Stock   —    —    (276)
    Net loss attributable to common stockholders  $(98,581)  $(43,285)  $(26,754)
                    
    Weighted average shares of common stock outstanding - basic and diluted   52,457    40,747    22,441 
    Net loss per share of common stock, basic and diluted  $(1.88)  $(1.06)  $(1.19)

     

     

    The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as they would be antidilutive:

     

       For the Years Ended December 31, 
       2020   2019   2018 
                 
    Stock options   9,503    5,894    3,476 
    Warrants   1,705    2,125    4,588 

     

     
    XML 44 R14.htm IDEA: XBRL DOCUMENT v3.20.4
    ACCRUED EXPENSES
    		 12 Months Ended
    Dec. 31, 2020
    Payables and Accruals [Abstract]  
    ACCRUED EXPENSES

    8. ACCRUED EXPENSES

     

    Accrued expenses consisted of the following:

     

       As of December 31, 
       2020   2019 
             
    Accrued research and development costs  $5,165   $1,700 
    Accrued compensation   1,443    54 
    Accrued professional fees   1,197    221 
    Accrued pre-commercial costs   1,191    — 
    Other accrued liabilities   166    90 
    Total accrued expenses  $9,162   $2,065 

     
    XML 45 R15.htm IDEA: XBRL DOCUMENT v3.20.4
    FAIR VALUE OF ASSETS AND LIABILITIES
    		 12 Months Ended
    Dec. 31, 2020
    Fair Value Disclosures [Abstract]  
    FAIR VALUE OF ASSETS AND LIABILITIES

    9. FAIR VALUE OF ASSETS AND LIABILITIES

     

    The carrying amounts reported in the balance sheet for cash and cash equivalents, accounts payable and accrued expenses approximate fair value based on the short-term nature of these items.

     

    In accordance with accounting principles generally accepted in the United States, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level hierarchy prioritizes the inputs used to measure fair value as follows:

     

    Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.

     

    Level 2 – Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

     

    Level 3 – Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

     

     

    The following is a summary of assets and their related classifications under the fair value hierarchy:

     

       December 31, 2020 
       Financial Instruments Carried at Fair Value 
      

    Quoted prices
    in active markets for

    identical items

    		  

    Significant
    other observable
    inputs

    		  

    Significant

    unobservable
    inputs

    		     
       (Level 1)   (Level 2)   (Level 3)   Total 
    Assets:                    
    Cash and cash equivalents1  $102,294   $—   $—   $102,294 
    Investments in Corporate debt securities2   —    19,530    —    19,530 

     

       December 31, 2019 
       Financial Instruments Carried at Fair Value 
      

    Quoted prices
    in active markets for

    identical items

    		  

    Significant

    other observable

    inputs

    		  

    Significant

    unobservable
    inputs

    		     
       (Level 1)   (Level 2)   (Level 3)   Total 
    Assets:                    
    Cash and cash equivalents 1  $39,165   $—   $—   $39,165 
    Investments in U.S. Treasury securities2   46,208    —    —    46,208 

     

     

    1 Cash and cash equivalents primarily include investments in money market funds and United States Treasury securities with maturity dates within 90 days from the purchase date
    2 Investments in United States Treasury and investment-grade corporate debt securities are classified as available for sale securities

     

     
    XML 46 R16.htm IDEA: XBRL DOCUMENT v3.20.4
    STOCK OPTIONS
    		 12 Months Ended
    Dec. 31, 2020
    Share-based Payment Arrangement [Abstract]  
    STOCK OPTIONS

    10. STOCK OPTIONS

     

    In 2017, the Company adopted the Provention Bio, Inc. 2017 Equity Incentive Plan (the “2017 Plan”). Pursuant to the 2017 Plan, the Company’s Board of Directors may grant incentive stock options, nonqualified stock options, and restricted stock to employees, officers, directors, consultants and advisors. As of December 31, 2020, there were options to purchase an aggregate of 9,503,228 shares of common stock outstanding under the 2017 Plan. Options issued under the 2017 Plan are exercisable for up to 10 years from the date of issuance.

     

    In 2018, the Company amended and restated its 2017 Plan to, among other things, include an evergreen provision, which would automatically increase the number of shares available for issuance under the 2017 Plan in an amount equal to (1) the difference between (x) 18% of the total shares of the Company’s common stock outstanding, on a fully diluted basis, on December 31st of the preceding calendar year, and (y) the total number of shares of the Company’s common stock reserved under the 2017 Plan on December 31st of such preceding calendar year or (2) an amount less than this calculated increase as determined by the board of directors.

     

    In connection with the evergreen provisions of the 2017 Plan, the number of shares available for issuance under the 2017 Plan was increased by 2,270,353 shares, as determined by the board of directors under the provisions described above, effective as of January 1, 2021. As of December 31, 2020, there were 109,499 shares available for future grants.

     

    In October 2020, the Company adopted the Provention Bio, Inc. 2020 Inducement Plan (the “2020 Inducement Plan”). Pursuant to the terms of the 2020 Inducement Plan, the Company may grant nonstatutory stock options, stock appreciation rights, restricted stock unit awards and restricted stock for up to a total of 2,000,000 shares of common stock to individuals that were not previously an employee or director of the Company or individuals returning to employment after a bona fide period of non-employment with the Company. As of December 31, 2020, there were no options to purchase shares of common stock outstanding under the 2020 Inducement Plan. Options issued under the 2020 Inducement Plan are exercisable for up to 10 years from the date of issuance.

     

     

    Stock-based compensation

     

    Total stock-based compensation expense recognized for both employees and non-employees was as follows:

     

       Years Ended December 31, 
       2020   2019   2018 
                 
    General and administrative  $7,611   $1,546   $512 
    Research and development   5,612    1,296    629 
    Total stock-based compensation expense  $13,223   $2,842   $1,141 

     

    Option activity

     

    The Company grants options with service-based vesting requirements as well as options with performance-based vesting requirements. Generally, the service-based requirements vest over a four-year period in multiple tranches. Each tranche of the performance-based component vests upon the achievement of a specific milestone. These milestones are related to the Company’s clinical trials, manufacturing activities, regulatory activities, commercial activities and certain other performance metrics.

     

    A summary of option activity for the years ended December 31, 2020 and 2019 are presented below:

     

               Weighted-    
           Weighted-   Average    
           Average   Remaining    
       Underlying   Exercise   Contractual  Intrinsic 
    Stock Option Awards  Shares   Price   Term  Value 
                    
    Outstanding at December 31, 2018   3,476   $2.85         
    Granted   2,797   $10.34         
    Exercised   (79)  $3.66         
    Forfeited or expired   (300)  $4.19         
    Outstanding at December 31, 2019   5,894   $6.33   8.5 years  $— 
    Outstanding at January 1, 2020   5,894    6.33       
    Granted   4,126   $12.87         
    Exercised   (219)  $5.28         
    Forfeited or expired   (298)  $9.39         
    Outstanding at December 31, 2020   9,503   $9.10   8.3 years  $74,536 
    Exercisable at December 31, 2020   3,730   $5.88   7.4 years  $41,263 

     

    The weighted average grant-date fair value of options granted during the year ended December 31, 2020 was $8.32 per share. As of December 31, 2020, there were approximately 1,869,000 unvested options subject to performance-based vesting criteria with approximately $13.2 million of unrecognized compensation expense. This expense will be recognized when each milestone becomes probable of occurring. In addition, as of December 31, 2020, there were approximately 3,904,000 unvested options outstanding subject to time-based vesting with approximately $25.1 million of unrecognized compensation expense which will be recognized over a period of 3.2 years.

     

     

    Cash proceeds from, and the aggregate intrinsic value of, stock options exercised during the periods presented below were as follows:

     

       Years Ended December 31, 
       2020   2019   2018 
                 
    Cash proceeds from options exercised  $1,152   $290   $25 
    Aggregate intrinsic value of options exercised  $1,615   $551   $5 

     

    The Company uses the Black-Scholes option-pricing model to estimate the fair value of option awards with the following weighted-average assumptions for the period indicated:

     

       Years Ended December 31, 
       2020   2019   2018 
                 
    Exercise price  $12.87   $10.34   $3.93 
    Expected volatility   74%   72%   61%
    Expected dividends   —    —    — 
    Expected term (in years)   6.2    6.3    6.2 
    Risk-free interest rate   0.59%   1.90%   2.78%

     

    The weighted-average valuation assumptions were determined as follows:

     

      ● Risk-free interest rate: The Company bases the risk-free interest rate on the interest rate payable on United States Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected option term.
         
      ● Expected annual dividends: The estimate for annual dividends is 0%, because the Company has not historically paid, and does not expect for the foreseeable future to pay, a dividend.
         
      ● Expected stock price volatility: The expected volatility used is based on historical volatilities of similar entities within the Company’s industry which were commensurate with the Company’s expected term assumption.
         
      ● Expected term of options: The expected term of options represents the period of time options are expected to be outstanding. The expected term of the options granted to employees is derived from the “simplified” method as described in Staff Accounting Bulletin 107 relating to stock-based compensation, whereby the expected term is an average between the vesting period and contractual period due to the limited operating history.

     
    XML 47 R17.htm IDEA: XBRL DOCUMENT v3.20.4
    WARRANTS
    		 12 Months Ended
    Dec. 31, 2020
    Warrants and Rights Note Disclosure [Abstract]  
    WARRANTS

    11. WARRANTS

     

    In connection with the April 2017 sale of Series A Convertible Redeemable Preferred Stock, the Company issued warrants to MDB, the Placement Agent, and its designees to purchase 558,740 shares of Series A Convertible Redeemable Preferred Stock with an exercise price of $2.50 per share with a seven-year term. Upon completion of the IPO in July 2018, the warrants automatically became warrants for the purchase of 558,740 shares of the Company’s common stock. During the year ended December 31, 2020, certain warrant holders from the Series A offering elected to exercise warrants for an aggregate of 312,689 shares, on a cashless basis, resulting in the Company’s net issuance of 259,542 shares. As of December 31, 2020, a total of 316,754 warrants have been exercised on a cashless basis and there were 241,986 warrants outstanding related to the Series A Offering.

     

    In May 2018, in connection with the MacroGenics License Agreement and the MacroGenics Asset Purchase Agreement, the Company issued warrants to MacroGenics to purchase 2,432,688 shares of the Company’s common stock at an exercise price of $2.50 per share. These warrants had a seven-year term. The Company recorded the warrants issued under MacroGenics License Agreement and the MacroGenics Asset Purchase Agreement at an estimated fair value of $1.64 per share, approximately $4.0 million in the aggregate, as license fee expense included as part of Research & development expense during the year ended December 31, 2018.

     

     

    The Company used valuation methods and assumptions that consider, among other factors, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants issued to MacroGenics. The fair values of these instruments were determined using models based on inputs that require management judgment and estimates.

     

    The fair value of the warrants issued to MacroGenics was measured at issuance on May 7, 2018 using the Black-Scholes option pricing model based on the following assumptions:

     

    Equity value upon issuance on May 7, 2018  $2.58 
    Exercise price  $2.50 
    Expected volatility   62.0%
    Expected dividends   — 
    Contractual term (in years)   7.0 
    Risk-free interest rate   2.86%

     

    The MacroGenics warrants were evaluated under ASC 480, Distinguishing Liabilities from Equity, (“ASC 480”) and ASC 815, Derivatives and Hedging, (“ASC 815”) and the Company determined that equity classification was appropriate.

     

    In July 2019, MacroGenics elected to exercise its warrants for an aggregate of 2,432,688 shares on a cashless basis, resulting in the Company’s net issuance of 1,948,474 shares. Following the MacroGenics’ July 2019 warrant exercises, there were no additional warrants outstanding in connection with the MacroGenics License Agreement and the MacroGenics Asset Purchase Agreement.

     

    In connection with the Company’s completion of its IPO, in July 2018, the Company issued to MDB, the underwriter in the IPO, and its designees warrants to purchase 1,596,956 shares of the Company’s common stock at an exercise price of $5.00 per share. These warrants have a five-year term.

     

    The Company used valuation methods and assumptions that consider, among other factors, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants. The fair values of these instruments were determined using models based on inputs that require management judgment and estimates.

     

    The fair value of the warrants issued to MDB were measured at issuance on July 19, 2018 using the Black-Scholes option-pricing model based on the following assumptions:

     

    Equity value upon issuance on July 19, 2018  $4.00 
    Exercise price  $5.00 
    Expected volatility   60.0%
    Expected dividends   — 
    Contractual term (in years)   5.0 
    Risk-free interest rate   2.74%

     

    The Company estimated the fair value of the warrants issued to MDB to be $1.90 per share, approximately $3.0 million in the aggregate, which was recorded as a cost of the IPO. The MDB warrants were evaluated under ASC 480 and ASC 815 and the Company determined that equity classification was appropriate.

     

    During the year ended December 31, 2020, certain warrant holders from the IPO elected to exercise warrants for an aggregate of 107,051 shares, on a cashless basis, resulting in the Company’s net issuance of 66,316 shares. As of December 31, 2020, a total of 134,114 warrants have been exercised on a cashless basis and there were 1,462,842 warrants outstanding related to the IPO.

     

     
    XML 48 R18.htm IDEA: XBRL DOCUMENT v3.20.4
    FIXED ASSETS
    		 12 Months Ended
    Dec. 31, 2020
    Property, Plant and Equipment [Abstract]  
    FIXED ASSETS

    12. FIXED ASSETS

     

    Fixed assets consisted of the following:

     

       As of December 31, 
       2020   2019 
             
    Leasehold improvements  $828   $— 
    Furniture and fixtures   149    — 
    Office equipment   35    — 
    Clinical equipment   27    — 
    Construction in progress   431    — 
        1,470    — 
    Less accumulated depreciation   (33)   — 
    Fixed assets, net  $1,437   $— 

     

    Depreciation expense was $33 thousand for the year ended December 31, 2020. The Company had no depreciation expense for the year ended December 31, 2019.

     
    XML 49 R19.htm IDEA: XBRL DOCUMENT v3.20.4
    LEASES
    		 12 Months Ended
    Dec. 31, 2020
    Lessee Disclosure [Abstract]  
    LEASES

    13. LEASES

     

    The Company’s lease portfolio consists of one office lease located in Red Bank, NJ. This lease is classified as an operating lease and has an initial term of 64 months from the lease commencement date, which began in October 2020. The Company has the option to renew or terminate the current term of a lease agreement at the end of the lease term. In its initial assessment of the lease term of the Red Bank, NJ office lease, the Company concluded that it is not reasonably certain to exercise the option to renew or terminate and therefore, this option was not considered in its lease assessment. The Company does not separate lease and non-lease components for all classes of underlying assets. The Company’s leases do not contain residual value guarantees and the Company does not sublease any of its leased assets. The Company does not record leases with an initial lease term of one-year or less on its balance sheets. As of December 31, 2020, the Company has not entered into any short-term leases.

     

    The components of lease costs from continuing operations were as follows:

     

       Year Ended
    December 31, 2020    		 
         
    Operating lease costs  $25 
    Variable lease costs   3 
    Total lease costs  $28 

     

    During the year ended December 31, 2020, the Company did not have any operating cash outflows that were used in connection to its operating leases.

     

     

    Supplemental balance sheet information related to leases are as follows:

     

       Classification  As of December 31, 2020 
            
    Operating leases        
    Lease right-of-use assets        
    Non-current  Operating lease right-of-use assets  $408 
    Lease liabilities        
    Current  Accrued expenses  $72 
    Non-current  Operating lease liabilities, long-term  $715 
             
    Weighted average remaining lease term        
    Operating leases      5.2 years 
             
    Weighted average discount rate        
    Operating leases      15.0%

     

    As of December 31, 2020, maturities of lease liabilities on an annual basis for the remaining years of the Company’s commenced lease agreements were as follows:

     

       Operating Leases 
         
    Year ending December 31,     
    2021  $185 
    2022   221 
    2023   227 
    2024   232 
    2025   238 
    Thereafter   41 
    Total lease payments   1,144 
    Less: present value discount   357 
    Present value of lease liabilities  $787 

     
    XML 50 R20.htm IDEA: XBRL DOCUMENT v3.20.4
    INCOME TAXES
    		 12 Months Ended
    Dec. 31, 2020
    Income Tax Disclosure [Abstract]  
    INCOME TAXES

    14. INCOME TAXES

     

    The Company recorded no provision or benefit for federal income taxes, as the Company has incurred a net loss for all periods presented, and the Company has provided a full valuation allowance against its deferred tax assets. The Company recorded a benefit from state income taxes of approximately $0.5 million for the year ended December 31, 2020. The benefit from state income taxes solely reflects the reversal of valuation allowances previously recorded against the Company’s New Jersey State net operating losses (‘NOLs”) that resulted from the Company’s sale of approximately $6.8 million of its New Jersey state NOLs under the State of New Jersey’s Technology Business Tax Certificate Transfer Program (the “Program”) for cash proceeds of $0.5 million. The Program allows qualified technology and biotechnology businesses in New Jersey to sell unused amounts of NOLs and defined research and development tax credits. For the year ended December 31, 2019, the Company recorded no provision or benefit for state income taxes.

     

    At December 31, 2020, the Company had Federal net operating loss carryforwards of approximately $139.1 million, of which approximately $5.4 million will expire in varying amounts beginning in 2036. The balance of the Federal net operating loss carryforwards generated in 2018 and prospectively can be carried forward indefinitely. The Company has state NOLs in various jurisdictions of approximately $129.8 million, certain of which begin to expire beginning in 2036. Utilization of net operating losses may be subject to substantial annual limitations due to the “change in ownership” provisions of the Internal Revenue Code, and similar state provisions. The Company has not yet completed a study to determine if an ownership change has occurred to date or determined the Company’s ability to utilize the aforementioned carryforwards. The Company had research and development tax credit carryforwards, including orphan drug tax credits, of approximately $16.3 million at December 31, 2020.

     

     

    Income tax benefits computed using the federal statutory income tax rate differs from the Company’s effective tax rate primarily due to the following:

     

       For the Years Ended December 31, 
       2020   2019   2018 
                 
    Tax Provision at statutory tax rate   21.0%   21.0%   21.0%
    Change in valuation allowance   (34.6)   (36.5)   (26.9)
    Orphan drug credits   10.4    10.4    — 
    State income taxes, net of federal benefit   5.2    6.5    6.2 
    Sale of NJ net operating losses   0.4    —    0.7 
    Permanent items   (2.2)   (2.1)   (0.5)
    Other   0.3    0.7    0.2 
    Effective Tax Rate   0.5%   —%   0.7%

     

    The components of income tax benefit are as follows:

     

       For the Years Ended December 31, 
       2020   2019   2018 
                 
    Current:            
    Federal  $—   $—   $— 
    State   (523)   —    (187)
    Deferred:               
    Federal   —    —    — 
    State   —    —    — 
    Income tax benefit  $(523)  $—   $(187)

     

    The income tax benefit recognized for the years ended December 31, 2020 and 2018 represent sales by the Company of its 2017 and 2018 New Jersey state net operating losses, from which the Company realized $0.5 million $0.2 million, respectively.

     

    Significant components of the Company’s net deferred tax assets are as follows:

     

           
       As of December 31, 
       2020   2019 
             
    Deferred tax assets:          
    NOL Carryforward  $37,773   $17,520 
    Federal research and development credits   15,819    5,045 
    Equity compensation   4,245    1,018 
    Product License   1,598    1,768 
    Other   390    213 
    Total deferred tax assets   59,825    25,564 
    Less valuation allowance   (59,825)   (25,564)
    Net deferred tax assets  $—   $— 

     

    The Company’s gross deferred tax assets of $59.8 million and $25.6 million at December 31, 2020 and 2019, respectively, primarily consist of net operating loss carryforwards for income tax purposes. A valuation allowance is required to be recorded when it is not more likely than not that some portion or all of the net deferred tax assets will be realized. Since the Company cannot be assured of generating taxable income and thereby realizing the net deferred tax assets, a full valuation allowance has been recorded. The Company has no uncertain tax positions at December 31, 2020. Since the Company is in a loss carryforward position, the Company is generally subject to US federal and state income tax examinations by tax authorities for all years for which a loss carryforward is available. The Company has never been, nor is currently under audit. The Company’s policy is to recognize interest accrued related to unrecognized tax benefits and penalties in income tax expense, however the Company has recorded no such expense to date.

     

     

    In March 2020, the US government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) which includes numerous modifications to income tax provisions, including a limitation on business interest expense and net operating loss provisions and the acceleration of alternative minimum tax credits. Given the Company’s history of losses, the CARES Act did not have a material impact on its income tax positions.

     
    XML 51 R21.htm IDEA: XBRL DOCUMENT v3.20.4
    RELATED PARTY TRANSACTIONS
    		 12 Months Ended
    Dec. 31, 2020
    Related Party Transactions [Abstract]  
    RELATED PARTY TRANSACTIONS

    15. RELATED PARTY TRANSACTIONS

     

    In connection with the MacroGenics Asset Purchase Agreement, the Company made payments of approximately $0.1 million and $0.3 million to Tolerance Therapeutics, Inc. during the years ended December 31, 2020 and 2018, respectively. The Company did not make any payments to Tolerance Therapeutics Inc. during the year ended December 31, 2019. Dr. Jeffrey Bluestone, who was appointed to the Company’s board of directors in March 2019, is a majority stockholder in Tolerance Therapeutics, Inc.

     

    In July 2018, MDB served as the underwriter for the Company’s IPO and the Company paid MDB cash underwriters’ fees and expenses of $3.6 million. Further, the Company issued to MDB underwriter warrants to purchase 1,596,956 shares of the Company’s common stock. The warrants are exercisable, beginning July 3, 2019 for five years at $5.00 per share. At the time of the IPO, MDB and affiliated parties beneficially owned greater than 5% of the Company’s common stock and two employees of MDB were members of the Board of Directors of the Company. See Notes 3 and 11 for further information. These MDB employees are no longer members of the Board of Directors of the Company.

     
    XML 52 R22.htm IDEA: XBRL DOCUMENT v3.20.4
    RETIREMENT SAVINGS PLAN
    		 12 Months Ended
    Dec. 31, 2020
    Payment for Pension and Other Postretirement Benefits [Abstract]  
    RETIREMENT SAVINGS PLAN

    16. RETIREMENT SAVINGS PLAN

     

    The Company has an employee savings and retirement plan which is qualified under Section 401(k) of the Internal Revenue Code. The Company matches 100% of eligible employee contributions on the first 4% of employee salary (up to the IRS maximum). Employer contributions for the years ended December 31, 2020, 2019 and 2018 were $0.2 million, $0.1 million, and $0.1 million, respectively.

     
    XML 53 R23.htm IDEA: XBRL DOCUMENT v3.20.4
    SUBSEQUENT EVENTS
    		 12 Months Ended
    Dec. 31, 2020
    Subsequent Events [Abstract]  
    SUBSEQUENT EVENTS

    17. SUBSEQUENT EVENTS

     

    In January 2021, the Company completed an underwritten public offering in which it sold 6,250,000 shares of common stock at a public offering price of $16.00 per share. In February 2021, the underwriters partially exercised their option to purchase an additional 587,500 shares at a price of $16.00 per share. In the aggregate, total net proceeds from the underwritten public offering was $102.3 million, after deducting underwriting discounts and commissions of approximately $6.6 million and other offering expenses of $0.5 million.

     

    On February 17, 2021, the Company entered into a License Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”), a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (the “Huadong License Agreement”), pursuant to which the Company granted Huadong exclusive rights for the purpose of developing and commercializing PRV-3279, a DART® (bispecific antibody-based molecule) targeting the B cell surface proteins CD32B and CD79B, in Greater China (mainland China, Hong Kong, Macau and Taiwan). Provention Bio will retain exclusive worldwide rights to develop PRV-3279 for combination uses to reduce the immunogenicity of biotherapeutics, but Huadong will have the exclusive right to distribute PRV-3279 in that field in Greater China. In consideration of the license and other rights granted as part of the Huadong License Agreement, the Company will receive and upfront payment of $6.0 million and up to $11.5 million in research, development and manufacturing funding over the next three years. If Huadong successfully develops, obtains regulatory approval for, and commercializes PRV-3279 in Greater China, the Company is eligible to receive up to $37.0 million in regulatory milestones and up to $135.0 million in commercial milestones based on aggregate net sales in a calendar year in Greater China. If commercialized, the Company would also be eligible to receive low double-digit royalties on net sales of PRV-3279 by Huadong in Greater China. The License Agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Huadong without cause upon at least 12 months prior notice to the Company and by the Company in the event Huadong challenges a licensed patent or in the event that the Company’s upstream license terminates. The Company may also terminate the License Agreement if Huadong ceases commercialization of PRV-3279 for a consecutive period of six months after first commercial sale. The Company is generally responsible for the manufacturing of PRV-3279 at least through regulatory approval in Greater China and Huadong will exclusively purchase all clinical and commercial supply requirements of PRV-3279 from the Company until Huadong exercises its option to assume manufacturing responsibilities, which may be triggered after regulatory approval in China. The Company will retain all rights to PRV-3279 in the rest of the world. The Company plans to begin a Phase 2a trial of PRV-3279 in systemic lupus erythematosus in the second half of 2021 and expects a portion of such trial to be conducted in Hong Kong.
    XML 54 R24.htm IDEA: XBRL DOCUMENT v3.20.4
    SIGNIFICANT ACCOUNTING POLICIES (Policies)
    		 12 Months Ended
    Dec. 31, 2020
    Accounting Policies [Abstract]  
    Use of estimates

    Use of estimates

     

    The process of preparing financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates and changes in estimates may occur.

     

     
    Segment and geographic information

    Segment and geographic information

     

    Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating and reporting segment.

     
    Cash, cash equivalents and concentration of credit risk

    Cash, cash equivalents and concentration of credit risk

     

    The Company considers only those investments which are highly liquid, readily convertible to cash, or that mature within 90 days from the date of purchase to be cash equivalents. Marketable securities are those investments with original maturities in excess of 90 days. The carrying amounts reported in the balance sheets for cash and cash equivalents are valued at cost, which approximates their fair value.

     

    The Company has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements. The Company holds cash and cash equivalents in banks in excess of FDIC insurance limits. However, the Company believes risk of loss is minimal as the cash and cash equivalents are held by large, highly-rated financial institutions.

     
    Marketable securities

    Marketable securities

     

    The Company considers securities with original maturities of greater than 90 days to be available for sale securities. Available for sale securities are classified as either current or non-current assets based on the nature of the securities and their availability for use in current operations. Available for sale securities are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity.

     

    On a quarterly basis, the Company reviews the status of each security in an unrealized loss position, to evaluate the existence of potential credit losses. The Company first considers whether it intends to sell, or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through income. For securities that do not meet this criteria, the Company considers a number of factors to determine if the decline in fair value has resulted from credit losses or other factors, including but not limited to: (1) the extent of the decline; (2) changes to the rating of the security by a rating agency; (3) any adverse conditions specific to the security; and (4) other market conditions that may affect the fair value of the security. If this assessment indicates that a credit loss exists and the present value of cash flows expected to be collected is less than the amortized cost basis, an allowance for credit losses is required for the credit loss. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. As of December 31, 2020, the Company has not recognized any impairment or credit losses on its available for sale securities.

     
    Financial instruments

    Financial instruments

     

    Cash, cash equivalents and marketable securities are reflected in the accompanying financial statements at fair value. The carrying amount of accounts payable and accrued expenses, including accrued research and development expenses, approximates fair value due to the short-term nature of those instruments.

     
    Net loss per common share

    Net loss per common share

     

    Net loss per share information is determined using the two-class method, which includes the weighted-average number of shares of common stock outstanding during the period and other securities that participate in dividends (a participating security). The Company considered the Series A Preferred Stock, all of which were automatically converted to common stock upon the Company’s IPO, to be participating securities because they included rights to participate in dividends, if any, with the common stock.

     

     

    Under the two-class method, basic net loss per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. The net loss attributable to common stockholders is calculated by adjusting the net loss of the Company for the accretion on the Preferred Stock. Net losses are not allocated to preferred stockholders as they do not have an obligation to share in the Company’s net losses. In periods with net income attributable to common stockholders, the Company would allocate net income first to preferred stockholders based on dividend rights under the Company’s certificate of incorporation and then to preferred and common stockholders based on ownership interests. Diluted net loss per share attributable to common stockholders is computed using the more dilutive of (1) the two-class method or (2) the if-converted method.

     

    Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders for all periods presented since the effect of potentially dilutive securities are anti-dilutive given the net loss of the Company.

     
    Fixed assets, net

    Fixed assets, net

     

    Fixed assets, which consists primarily of leasehold improvements, furniture and fixtures, software, office equipment and certain clinical equipment, are carried at cost less accumulated depreciation. Depreciation is computed over the estimated useful lives of the respective assets, generally three to seven years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset.

     
    Leases

    Leases

     

    The Company determines if an arrangement is a lease at contract inception. A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company classifies its leases as operating or financing by considering factors such as the length of the lease term, the present value of the lease payments, the specialized nature of the asset being leased and the potential for ownership of the asset to transfer during the lease term.

     

    Leases with terms greater than one-year are recognized on the Company’s balance sheets as right-of-use (“ROU”) assets and lease liabilities and are measured at the present value of the fixed payments due over the lease term minus the present value of any incentives, rebates or abatements expected to be received from the lessor. Options to extend a lease are typically excluded from the expected lease term as the exercise of the option is typically not reasonably certain. Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee’s incremental borrowing rate. As the implicit rate is not typically readily determinable, the Company uses an incremental borrowing rate, which is established based upon the information available at the lease commencement date, to determine the present value of lease payments due under an arrangement. The incremental borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments.

     

    ROU assets are amortized on a straight-line basis over the term of the lease. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are recognized in the statements of comprehensive loss in the same line item as expenses arising from fixed lease payments at the time when the event giving rise to the payment occurs.

     
    Foreign currency translation

    Foreign currency translation

     

    The Company considers the U.S. dollar to be its functional currency. Expenses denominated in foreign currencies are translated at the exchange rate on the date the expense is incurred. The effect of exchange rate fluctuations on translating foreign currency assets and liabilities into U.S. dollars is included in the Statements of Comprehensive Loss. Foreign exchange transaction gains and losses are included in the results of operations and are not material in the Company’s financial statements.

     

     
    Research and development expenses

    Research and development expenses

     

    Research and development expenses primarily consist of costs associated with the preclinical and clinical development of the Company’s product candidate portfolio, including the following:

     

      ● external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”) and other vendors and contract manufacturing organizations (“CMOs”) for the production of drug substance and drug product; and

     

      ● employee-related expenses, including salaries, benefits and share-based compensation expense.

     

    Research and development expenses also include costs of acquired product licenses and related technology rights where there is no alternative future use, costs of prototypes used in research and development, consultant fees and amounts paid to certain of our collaborative partners.

     

    All research and development expenses are charged to operations as incurred in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic (“ASC”) 730, Research and Development. The Company accounts for non-refundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received, rather than when the payment is made.

     
    Accrued research and development expenses

    Accrued research and development expenses

     

    As part of the process of preparing our financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company’s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and make adjustments if necessary. The significant estimates in the Company’s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.

     

    The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on the Company’s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company’s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company’s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.

     
    Stock-based compensation expense

    Stock-based compensation expense

     

    The Company follows the provisions of ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and non-employees, including stock options. Stock-based compensation expense is based on the grant date fair value estimated in accordance with the provisions of ASC 718 and is generally recognized as an expense over the requisite service period. For grants containing performance-based vesting provisions, the grant-date fair value of the performance-based stock options is recognized as compensation expense once it is probable that the performance condition will be achieved. The Company accounts for actual forfeitures in the period the forfeiture occurs.

     

     

    Stock Options

     

    The Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. Due to the lack of trading history, the Company’s computation of stock-price volatility is based on the volatility rates of comparable publicly held companies over a period equal to the expected term of the options granted by the Company. The Company’s computation of expected term is determined using the “simplified” method, which is the midpoint between the vesting date and the end of the contractual term. The Company believes that it does not have sufficient reliable exercise data in order to justify the use of a method other than the “simplified” method of estimating the expected exercise term of employee stock option grants. The Company utilizes a dividend yield of zero based on the fact that the Company has never paid cash dividends to stockholders and has no current intentions to pay cash dividends. The risk-free interest rate is based on the zero-coupon United States Treasury yield at the date of grant for a term equivalent to the expected term of the option.

     

    In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, (“ASU 2018-07”) which supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payments arrangements related to the acquisition of goods and services from both employees and nonemployees. During the third quarter of 2018, the Company early adopted ASU 2018-07. After the adoption of ASU 2018-07, the measurement date for non-employee awards is the date of grant. Compensation expense for non-employees is recognized, without changes to the fair value of the award, over the requisite service period, which is the vesting period of the respective award. The adoption of ASU 2018-07 did not have a material impact the Company’s financial statements or footnote disclosures.

     

    Prior to the third quarter of 2018, the Company accounted for awards of equity instruments issued to non-employees in accordance with ASC Topic 505-50, Equity-Based Payment to Non-Employees, (“ASC 505-50”) and accordingly the value of the stock compensation to non-employees was based upon the measurement date as determined at either a) the date at which a performance commitment was reached, or b) at the date at which the necessary performance to earn the equity instruments was completed, which was normally the end of the vesting period. At the end of each financial reporting period prior to completion of the service, the fair value of these awards was remeasured using updated assumption inputs in the Black-Scholes option-pricing model.

     

    Stock-based compensation expense is included in both research and development expenses and general and administrative expenses in the Statements of Comprehensive Loss.

     
    Warrant liability

    Warrant liability

     

    In April 2017, the Company issued warrants to purchase shares of Series A Convertible Redeemable Preferred Stock in connection with the issuance of the Series A Preferred Stock. The Company accounted for these warrants as a liability in the financial statements because the underlying instrument into which the warrants were exercisable contained redemption provisions that were outside the Company’s control.

     

    Upon the completion of the IPO in July 2018, the warrants issued in connection with the Series A Convertible Redeemable Preferred Stock converted to warrants for the purchase of 558,740 shares of our common stock and the warrants no longer contain redemption provisions that are outside the Company’s control. The liability associated with these warrants was revalued just prior to the completion of the IPO, with the change in the fair value of the warrant liability charged to earnings. The warrant liability was then reclassified to additional paid-in capital upon the completion of the IPO in July 2018.

     

    The fair value of the warrants was determined using the Black-Scholes option-pricing model and were re-measured to fair value at each financial reporting period date with any changes in fair value recognized in the statements of operations. See Note 11 to our financial statements for further information.

     

     
    Income taxes

    Income taxes

     

    The Company utilizes the liability method of accounting for deferred income taxes, as set forth in ASC 740, Income Taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. A valuation allowance is established against deferred tax assets when, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense.

     
    Recent accounting pronouncements

    Recent accounting pronouncements

     

    The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”). ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s financial statements.

     

    In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. Effective January 1, 2019, the Company adopted ASU 2016-02. The adoption had no impact on the Company’s financial statements and related disclosures as the Company did not have any lease agreements at the time of adoption. In July 2020, the Company entered into an agreement to lease its new corporate headquarters in Red Bank, NJ. Upon commencement of the lease, which occurred in October 2020, the lease was accounted for as an operating lease. Refer to Note 13 - Leases for details about the Company’s lease portfolio, including Topic 842 required disclosures.

     

    In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Effective January 1, 2020, the Company adopted ASU 2016-13 using the modified retrospective method for all financial assets measured at amortized cost. Results for reporting periods beginning after January 1, 2020 are presented under ASC 326 (Financial Instruments - Credit Losses), while prior period amounts continue to be reported in accordance with previously applicable GAAP. The adoption of this ASU had no impact on the Company’s financial statements and related disclosures.

     

    In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820), which modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, including, among other changes, the consideration of costs and benefits when evaluating disclosure requirements. Effective January 1, 2020, the Company adopted ASU 2018-13. The adoption had no impact on the Company’s financial statements and related disclosures.

     

    In August 2018, the FASB issued ASU No. 2018-15, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Effective January 1, 2020, the Company adopted ASU 2018-15. The adoption had no impact on the Company’s financial statements and related disclosures.

     

     

    In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808), which clarifies the interaction between the guidance for collaborative arrangements (Topic 808) and the new revenue recognition standard (Topic 606). Effective January 1, 2020, the Company adopted ASU 2018-18. The adoption had no impact on the Company’s financial statements and related disclosures.
    XML 55 R25.htm IDEA: XBRL DOCUMENT v3.20.4
    CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES (Tables)
    		 12 Months Ended
    Dec. 31, 2020
    Cash and Cash Equivalents [Abstract]  
    SCHEDULE OF AVAILABLE FOR SALE SECURITIES

     

       December 31, 2020 
       Amortized Cost   Gross Unrealized Gains   Gross Unrealized Losses   Fair Value 
                     
    Corporate debt securities  $19,545   $—   $(15)  $19,530 
    Total  $19,545   $—   $(15)  $19,530 

     

       December 31, 2019 
       Amortized Cost   Gross Unrealized Gains   Gross Unrealized Losses   Fair Value 
                     
    U.S. Treasury securities  $46,208   $—   $—   $46,208 
    Total  $46,208   $—   $—   $46,208 
    SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

     

       For the Years Ended December 31, 
       2020   2019   2018 
                 
    Beginning balance  $—   $—   $— 
    Current period changes in fair value before reclassifications, net of tax   (15)   —    — 
    Amounts reclassified from accumulated other comprehensive income (loss), net of tax   —    —    — 
    Other comprehensive income (loss)   (15)   —    — 
    Ending balance  $(15)  $—   $— 
    XML 56 R26.htm IDEA: XBRL DOCUMENT v3.20.4
    NET LOSS PER SHARE OF COMMON STOCK (Tables)
    		 12 Months Ended
    Dec. 31, 2020
    Earnings Per Share [Abstract]  
    SCHEDULE OF COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE

     

       For the Years Ended December 31, 
       2020   2019   2018 
                 
    Net loss, basic  $(98,581)  $(43,285)  $(26,478)
    Accretion of Series A Convertible Redeemable Preferred Stock   —    —    (276)
    Net loss attributable to common stockholders  $(98,581)  $(43,285)  $(26,754)
                    
    Weighted average shares of common stock outstanding - basic and diluted   52,457    40,747    22,441 
    Net loss per share of common stock, basic and diluted  $(1.88)  $(1.06)  $(1.19)
    SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE

     

       For the Years Ended December 31, 
       2020   2019   2018 
                 
    Stock options   9,503    5,894    3,476 
    Warrants   1,705    2,125    4,588 
    XML 57 R27.htm IDEA: XBRL DOCUMENT v3.20.4
    ACCRUED EXPENSES (Tables)
    		 12 Months Ended
    Dec. 31, 2020
    Payables and Accruals [Abstract]  
    SCHEDULE OF ACCRUED EXPENSES

     

       As of December 31, 
       2020   2019 
             
    Accrued research and development costs  $5,165   $1,700 
    Accrued compensation   1,443    54 
    Accrued professional fees   1,197    221 
    Accrued pre-commercial costs   1,191    — 
    Other accrued liabilities   166    90 
    Total accrued expenses  $9,162   $2,065 
    XML 58 R28.htm IDEA: XBRL DOCUMENT v3.20.4
    FAIR VALUE OF ASSETS AND LIABILITIES (Tables)
    		 12 Months Ended
    Dec. 31, 2020
    Fair Value Disclosures [Abstract]  
    SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS

     

       December 31, 2020 
       Financial Instruments Carried at Fair Value 
      

    Quoted prices
    in active markets for

    identical items

    		  

    Significant
    other observable
    inputs

    		  

    Significant

    unobservable
    inputs

    		     
       (Level 1)   (Level 2)   (Level 3)   Total 
    Assets:                    
    Cash and cash equivalents1  $102,294   $—   $—   $102,294 
    Investments in Corporate debt securities2   —    19,530    —    19,530 

     

       December 31, 2019 
       Financial Instruments Carried at Fair Value 
      

    Quoted prices
    in active markets for

    identical items

    		  

    Significant

    other observable

    inputs

    		  

    Significant

    unobservable
    inputs

    		     
       (Level 1)   (Level 2)   (Level 3)   Total 
    Assets:                    
    Cash and cash equivalents 1  $39,165   $—   $—   $39,165 
    Investments in U.S. Treasury securities2   46,208    —    —    46,208 

     

     

    1 Cash and cash equivalents primarily include investments in money market funds and United States Treasury securities with maturity dates within 90 days from the purchase date
    2 Investments in United States Treasury and investment-grade corporate debt securities are classified as available for sale securities

     
    XML 59 R29.htm IDEA: XBRL DOCUMENT v3.20.4
    STOCK OPTIONS (Tables)
    		 12 Months Ended
    Dec. 31, 2020
    Share-based Payment Arrangement [Abstract]  
    SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE

     

       Years Ended December 31, 
       2020   2019   2018 
                 
    General and administrative  $7,611   $1,546   $512 
    Research and development   5,612    1,296    629 
    Total stock-based compensation expense  $13,223   $2,842   $1,141 
    SUMMARY OF STOCK OPTION ACTIVITY

     

               Weighted-    
           Weighted-   Average    
           Average   Remaining    
       Underlying   Exercise   Contractual  Intrinsic 
    Stock Option Awards  Shares   Price   Term  Value 
                    
    Outstanding at December 31, 2018   3,476   $2.85         
    Granted   2,797   $10.34         
    Exercised   (79)  $3.66         
    Forfeited or expired   (300)  $4.19         
    Outstanding at December 31, 2019   5,894   $6.33   8.5 years  $— 
    Outstanding at January 1, 2020   5,894    6.33       
    Granted   4,126   $12.87         
    Exercised   (219)  $5.28         
    Forfeited or expired   (298)  $9.39         
    Outstanding at December 31, 2020   9,503   $9.10   8.3 years  $74,536 
    Exercisable at December 31, 2020   3,730   $5.88   7.4 years  $41,263 
    SCHEDULE OF AGGREGATED INTRINSIC VALUE OF STOCK OPTION EXERCISED

     

       Years Ended December 31, 
       2020   2019   2018 
                 
    Cash proceeds from options exercised  $1,152   $290   $25 
    Aggregate intrinsic value of options exercised  $1,615   $551   $5 
    SCHEDULE OF SHARE-BASED COMPENSATION VALUATION OF ASSUMPTIONS

     

       Years Ended December 31, 
       2020   2019   2018 
                 
    Exercise price  $12.87   $10.34   $3.93 
    Expected volatility   74%   72%   61%
    Expected dividends   —    —    — 
    Expected term (in years)   6.2    6.3    6.2 
    Risk-free interest rate   0.59%   1.90%   2.78%
    XML 60 R30.htm IDEA: XBRL DOCUMENT v3.20.4
    WARRANTS (Tables)
    		 12 Months Ended
    Dec. 31, 2020
    Macro Genics Inc [Member]  
    Entity Listings [Line Items]  
    SCHEDULE OF FAIR VALUE OF WARRANTS ISSUED

     

    Equity value upon issuance on May 7, 2018  $2.58 
    Exercise price  $2.50 
    Expected volatility   62.0%
    Expected dividends   — 
    Contractual term (in years)   7.0 
    Risk-free interest rate   2.86%
    MDB Capital Group, LLC [Member]  
    Entity Listings [Line Items]  
    SCHEDULE OF FAIR VALUE OF WARRANTS ISSUED

     

    Equity value upon issuance on July 19, 2018  $4.00 
    Exercise price  $5.00 
    Expected volatility   60.0%
    Expected dividends   — 
    Contractual term (in years)   5.0 
    Risk-free interest rate   2.74%
    XML 61 R31.htm IDEA: XBRL DOCUMENT v3.20.4
    FIXED ASSETS (Tables)
    		 12 Months Ended
    Dec. 31, 2020
    Property, Plant and Equipment [Abstract]  
    SCHEDULE OF FIXED ASSETS

     

       As of December 31, 
       2020   2019 
             
    Leasehold improvements  $828   $— 
    Furniture and fixtures   149    — 
    Office equipment   35    — 
    Clinical equipment   27    — 
    Construction in progress   431    — 
        1,470    — 
    Less accumulated depreciation   (33)   — 
    Fixed assets, net  $1,437   $— 
    XML 62 R32.htm IDEA: XBRL DOCUMENT v3.20.4
    LEASES (Tables)
    		 12 Months Ended
    Dec. 31, 2020
    Lessee Disclosure [Abstract]  
    SCHEDULE OF LEASE COSTS

     

    The components of lease costs from continuing operations were as follows:

     

       Year Ended
    December 31, 2020    		 
         
    Operating lease costs  $25 
    Variable lease costs   3 
    Total lease costs  $28 
    SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION

    Supplemental balance sheet information related to leases are as follows:

     

       Classification  As of December 31, 2020 
            
    Operating leases        
    Lease right-of-use assets        
    Non-current  Operating lease right-of-use assets  $408 
    Lease liabilities        
    Current  Accrued expenses  $72 
    Non-current  Operating lease liabilities, long-term  $715 
             
    Weighted average remaining lease term        
    Operating leases      5.2 years 
             
    Weighted average discount rate        
    Operating leases      15.0%
    SCHEDULE OF MATURITIES OF LEASE LIABILITIES

    As of December 31, 2020, maturities of lease liabilities on an annual basis for the remaining years of the Company’s commenced lease agreements were as follows:

     

       Operating Leases 
         
    Year ending December 31,     
    2021  $185 
    2022   221 
    2023   227 
    2024   232 
    2025   238 
    Thereafter   41 
    Total lease payments   1,144 
    Less: present value discount   357 
    Present value of lease liabilities  $787 
    XML 63 R33.htm IDEA: XBRL DOCUMENT v3.20.4
    INCOME TAXES (Tables)
    		 12 Months Ended
    Dec. 31, 2020
    Income Tax Disclosure [Abstract]  
    SCHEDULE OF EFFECTIVE TAX RATE

    Income tax benefits computed using the federal statutory income tax rate differs from the Company’s effective tax rate primarily due to the following:

     

       For the Years Ended December 31, 
       2020   2019   2018 
                 
    Tax Provision at statutory tax rate   21.0%   21.0%   21.0%
    Change in valuation allowance   (34.6)   (36.5)   (26.9)
    Orphan drug credits   10.4    10.4    — 
    State income taxes, net of federal benefit   5.2    6.5    6.2 
    Sale of NJ net operating losses   0.4    —    0.7 
    Permanent items   (2.2)   (2.1)   (0.5)
    Other   0.3    0.7    0.2 
    Effective Tax Rate   0.5%   —%   0.7%
    SCHEDULE OF COMPONENTS OF INCOME TAX BENEFITS

    The components of income tax benefit are as follows:

     

       For the Years Ended December 31, 
       2020   2019   2018 
                 
    Current:            
    Federal  $—   $—   $— 
    State   (523)   —    (187)
    Deferred:               
    Federal   —    —    — 
    State   —    —    — 
    Income tax benefit  $(523)  $—   $(187)
    SCHEDULE OF DEFERRED TAX ASSETS

    Significant components of the Company’s net deferred tax assets are as follows:

     

           
       As of December 31, 
       2020   2019 
             
    Deferred tax assets:          
    NOL Carryforward  $37,773   $17,520 
    Federal research and development credits   15,819    5,045 
    Equity compensation   4,245    1,018 
    Product License   1,598    1,768 
    Other   390    213 
    Total deferred tax assets   59,825    25,564 
    Less valuation allowance   (59,825)   (25,564)
    Net deferred tax assets  $—   $— 
    XML 64 R34.htm IDEA: XBRL DOCUMENT v3.20.4
    LIQUIDITY (Details Narrative) - USD ($)
    $ / shares in Units, $ in Thousands
    		 1 Months Ended 2 Months Ended 3 Months Ended 12 Months Ended
    Jun. 30, 2020
    Feb. 28, 2021
    Jan. 31, 2021
    Jun. 30, 2020
    Sep. 30, 2019
    Aug. 31, 2019
    Jul. 31, 2018
    Apr. 30, 2017
    Feb. 28, 2021
    Jun. 30, 2020
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Jul. 19, 2018
    Schedule of Capitalization, Equity [Line Items]                            
    Retained Earnings (Accumulated Deficit)                     $ 177,642 $ 79,061    
    Sale of Stock, Number of Shares Issued in Transaction         5,750,000                  
    Sale of Stock, Price Per Share         $ 8.00                  
    Proceeds from Issuance Initial Public Offering                     $ 59,322  
    Underwriting discounts and commissions       $ 6,600 $ 2,800                  
    Other offering expenses       200 500                  
    Aggregate net proceeds from underwritten public offering and Amgen private placement         $ 62,700                  
    Proceeds from Issuance or Sale of Equity       $ 103,300                    
    Subsequent Event [Member]                            
    Schedule of Capitalization, Equity [Line Items]                            
    Underwriting discounts and commissions   $ 6,600                        
    At The Market [Member]                            
    Schedule of Capitalization, Equity [Line Items]                            
    Sale of Stock, Number of Shares Issued in Transaction                   725,495        
    Sale of Stock, Consideration Received on Transaction                   $ 9,900        
    Sales Commissions and Fees                   $ 300        
    At The Market [Member] | Maximum [Member]                            
    Schedule of Capitalization, Equity [Line Items]                            
    Sale of Stock, Consideration Received on Transaction           $ 50,000                
    Options Held [Member]                            
    Schedule of Capitalization, Equity [Line Items]                            
    Sale of Stock, Number of Shares Issued in Transaction         750,000                  
    Sale of Stock, Price Per Share         $ 8.00                  
    MDB Capital Group, LLC [Member]                            
    Schedule of Capitalization, Equity [Line Items]                            
    Class of Warrant or Right, Exercise Price of Warrants or Rights                           $ 5.00
    IPO [Member]                            
    Schedule of Capitalization, Equity [Line Items]                            
    Sale of Stock, Number of Shares Issued in Transaction             15,969,563              
    Sale of Stock, Price Per Share             $ 4.00              
    Proceeds from Issuance Initial Public Offering             $ 59,300              
    Underwriting discounts and commissions             3,700              
    Other offering expenses             $ 800              
    Conversion of Stock, Shares Converted             11,381,999              
    IPO [Member] | MDB Capital Group, LLC [Member]                            
    Schedule of Capitalization, Equity [Line Items]                            
    Class of Warrant or Right, Number of Securities Called by Each Warrant or Right             1,596,956              
    Class of Warrant or Right, Exercise Price of Warrants or Rights             $ 5.00              
    Private Placement [Member] | Amgen Inc [Member]                            
    Schedule of Capitalization, Equity [Line Items]                            
    Sale of Stock, Number of Shares Issued in Transaction         2,500,000                  
    Sale of Stock, Price Per Share         $ 8.00                  
    Underwritten Public Offering [Member]                            
    Schedule of Capitalization, Equity [Line Items]                            
    Sale of Stock, Number of Shares Issued in Transaction 7,590,000                          
    Sale of Stock, Price Per Share $ 14.50     $ 14.50           $ 14.50        
    Underwriter's Option [Member]                            
    Schedule of Capitalization, Equity [Line Items]                            
    Stock Issued During Period, Shares, New Issues 990,000                          
    Shares Issued, Price Per Share $ 14.50     $ 14.50           $ 14.50        
    Underwriter's Option [Member] | Subsequent Event [Member]                            
    Schedule of Capitalization, Equity [Line Items]                            
    Stock Issued During Period, Shares, New Issues   587,500                        
    Shares Issued, Price Per Share   $ 16.00             $ 16.00          
    Sale of Stock, Number of Shares Issued in Transaction     6,250,000                      
    Sale of Stock, Price Per Share     $ 16.00                      
    Underwriting discounts and commissions                 $ 6,600          
    Other offering expenses   $ 500             500          
    Proceeds from Issuance or Sale of Equity   $ 102,300             $ 102,300          
    Series A Convertible Redeemable Preferred Stock [Member]                            
    Schedule of Capitalization, Equity [Line Items]                            
    Stock Issued During Period, Shares, New Issues               11,381,999            
    Shares Issued, Price Per Share               $ 2.50            
    Proceeds from Issuance of Redeemable Convertible Preferred Stock               $ 26,700            
    Class of Warrant or Right, Number of Securities Called by Each Warrant or Right               558,740            
    Class of Warrant or Right, Exercise Price of Warrants or Rights               $ 2.50            
    Series A Convertible Redeemable Preferred Stock [Member] | IPO [Member]                            
    Schedule of Capitalization, Equity [Line Items]                            
    Class of Warrant or Right, Number of Securities Called by Each Warrant or Right             558,740              
    XML 65 R35.htm IDEA: XBRL DOCUMENT v3.20.4
    SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)
    		 12 Months Ended
    Dec. 31, 2020
    Segment
    Jul. 31, 2018
    shares
    Apr. 30, 2017
    shares
    Property, Plant and Equipment [Line Items]      
    Number of operating segments | Segment 1    
    Series A Convertible Redeemable Preferred Stock [Member]      
    Property, Plant and Equipment [Line Items]      
    Warrants to purchase     558,740
    IPO [Member] | Series A Convertible Redeemable Preferred Stock [Member]      
    Property, Plant and Equipment [Line Items]      
    Warrants to purchase   558,740  
    Minimum [Member]      
    Property, Plant and Equipment [Line Items]      
    Fixed assets estimated useful life years three    
    Maximum [Member]      
    Property, Plant and Equipment [Line Items]      
    Fixed assets estimated useful life years seven    
    XML 66 R36.htm IDEA: XBRL DOCUMENT v3.20.4
    CAPITALIZATION (Details Narrative) - $ / shares
    Dec. 31, 2020
    Dec. 31, 2019
    Capitalization    
    Common Stock, Shares Authorized 100,000,000 100,000,000
    Common Stock, Par or Stated Value Per Share $ 0.0001 $ 0.0001
    Common Stock, Shares, Issued 56,517,891 47,658,361
    Common Stock, Shares, Outstanding 56,517,891 47,658,361
    Preferred Stock, Shares Authorized 25,000,000 25,000,000
    Preferred Stock, Par or Stated Value Per Share $ 0.0001 $ 0.0001
    Preferred Stock, Shares Issued 0 0
    Preferred Stock, Shares Outstanding 0 0
    XML 67 R37.htm IDEA: XBRL DOCUMENT v3.20.4
    SCHEDULE OF AVAILABLE FOR SALE SECURITIES (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2020
    Dec. 31, 2019
    Cash and Cash Equivalents [Line Items]    
    Amortized Cost $ 19,545 $ 46,208
    Gross Unrealized Gains
    Gross Unrealized Losses (15)
    Fair Value 19,530 46,208
    Corporate Debt Securities [Member]    
    Cash and Cash Equivalents [Line Items]    
    Amortized Cost 19,545  
    Gross Unrealized Gains  
    Gross Unrealized Losses (15)  
    Fair Value $ 19,530  
    US Treasury Securities [Member]    
    Cash and Cash Equivalents [Line Items]    
    Amortized Cost   46,208
    Gross Unrealized Gains  
    Gross Unrealized Losses  
    Fair Value   $ 46,208
    XML 68 R38.htm IDEA: XBRL DOCUMENT v3.20.4
    SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Cash and Cash Equivalents [Abstract]      
    Beginning balance
    Current period changes in fair value before reclassifications, net of tax (15)
    Amounts reclassified from accumulated other comprehensive income (loss), net of tax
    Other comprehensive income (loss) (15)
    Ending balance $ (15)
    XML 69 R39.htm IDEA: XBRL DOCUMENT v3.20.4
    CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES (Details Narrative) - USD ($)
    $ in Thousands
    Dec. 31, 2020
    Dec. 31, 2019
    Cash and Cash Equivalents [Abstract]    
    Cash and Cash Equivalents, at Carrying Value $ 102,294 $ 39,165
    Available-for-sale Securities and Held-to-maturity Securities $ 19,500 $ 46,200
    XML 70 R40.htm IDEA: XBRL DOCUMENT v3.20.4
    LICENSE AND OTHER AGREEMENTS (Details Narrative)
    $ / shares in Units, $ in Thousands, € in Millions
    		 1 Months Ended 12 Months Ended
    Jan. 31, 2021
    USD ($)
    Sep. 30, 2019
    USD ($)
    $ / shares
    shares
    Jul. 31, 2019
    shares
    Nov. 30, 2018
    USD ($)
    May 31, 2018
    USD ($)
    $ / shares
    shares
    Apr. 30, 2017
    USD ($)
    $ / shares
    Dec. 31, 2020
    USD ($)
    shares
    Dec. 31, 2020
    EUR (€)
    shares
    Dec. 31, 2019
    USD ($)
    Dec. 31, 2018
    USD ($)
    May 07, 2018
    $ / shares
    Entity Listings [Line Items]                      
    Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares             316,754 316,754      
    Sale of Stock, Number of Shares Issued in Transaction | shares   5,750,000                  
    Sale of Stock, Price Per Share | $ / shares   $ 8.00                  
    Proceeds from Issuance of Private Placement               $ 20,000  
    Macro Genics Asset Purchase Agreement and Macro Genics License Agreement [Member]                      
    Entity Listings [Line Items]                      
    Fair Value per share of each warrant | $ / shares         $ 1.64            
    Warrants issued during period, fair value         $ 4,000            
    Intravacc Development Services Agreement [Member]                      
    Entity Listings [Line Items]                      
    Payments made for develpoment and manufacturing services             $ 10,500        
    Intravacc Development Services Agreement [Member] | Euro [Member]                      
    Entity Listings [Line Items]                      
    Payments made for develpoment and manufacturing services | €               € 9.0      
    Macro Genics Inc [Member]                      
    Entity Listings [Line Items]                      
    Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                     $ 2.50
    Amount payable by the entity on achievement of various milestones         $ 225,000            
    Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares     2,432,688                
    Number of warrants issuance shares | shares     1,948,474                
    Macro Genics Inc [Member] | Asset Purchase Agreement [Member]                      
    Entity Listings [Line Items]                      
    Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares         2,162,389            
    Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares         $ 2.50            
    Amount payable by the entity on achievement of various milestones         $ 170,000            
    Macro Genics Inc [Member] | Asset Purchase Agreement [Member] | Maximum [Member]                      
    Entity Listings [Line Items]                      
    Amount payable by the entity on achievement of various milestones         700            
    Macro Genics Inc [Member] | Asset Purchase Agreement [Member] | Biologics License Application [Member]                      
    Entity Listings [Line Items]                      
    Amount payable by the entity on achievement of various milestones         $ 60,000            
    Macro Genics Inc [Member] | License Agreement [Member]                      
    Entity Listings [Line Items]                      
    Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares         270,299            
    Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares         $ 2.50            
    Amount payable by the entity on achievement of various milestones         $ 225,000            
    Macro Genics Inc [Member] | License Agreement [Member] | First Indication [Member]                      
    Entity Listings [Line Items]                      
    Amount payable by the entity on achievement of various milestones         42,500            
    Macro Genics Inc [Member] | License Agreement [Member] | Second Indication [Member]                      
    Entity Listings [Line Items]                      
    Amount payable by the entity on achievement of various milestones         $ 22,500            
    Amgen Inc [Member]                      
    Entity Listings [Line Items]                      
    Amount payable by the entity on achievement of various milestones       $ 70,000              
    Amgen Inc [Member] | Private Placement [Member]                      
    Entity Listings [Line Items]                      
    Sale of Stock, Number of Shares Issued in Transaction | shares   2,500,000                  
    Sale of Stock, Price Per Share | $ / shares   $ 8.00                  
    Proceeds from Issuance of Private Placement   $ 20,000                  
    Amgen Inc [Member] | License and Collaboration Agreement [Member]                      
    Entity Listings [Line Items]                      
    Potential proceeds from investment by collaborator       20,000              
    Amount payable by the entity on achievement of various milestones       $ 150,000              
    Vactech [Member] | License Agreement [Member]                      
    Entity Listings [Line Items]                      
    Amount payable by the entity on achievement of various milestones           $ 24,500          
    Shares Issued, Price Per Share | $ / shares           $ 1.70          
    Payments made on tiered single-digit royalties           $ 19,000          
    Vactech [Member] | License Agreement [Member] | Research and Development Expense [Member]                      
    Entity Listings [Line Items]                      
    Warrants issued during period, fair value           3,400          
    Vactech [Member] | License Agreement [Member] | First Eighteen Months [Member]                      
    Entity Listings [Line Items]                      
    Payments made for develpoment and manufacturing services           500          
    Vactech [Member] | License Agreement [Member] | Dosing Of First Patient In Phase 1 PROVENT Study [Member] | Subsequent Event [Member]                      
    Entity Listings [Line Items]                      
    Amount payable by the entity on achievement of various milestones $ 500                    
    Janssen Pharmaceutica NV [Member] | License Developmentand Commercialization Agreement [Member]                      
    Entity Listings [Line Items]                      
    Payments made on tiered single-digit royalties           100,000          
    Janssen Pharmaceutica NV [Member] | License Developmentand Commercialization Agreement [Member] | First Indication [Member]                      
    Entity Listings [Line Items]                      
    Amount payable by the entity on achievement of various milestones           35,000          
    Janssen Pharmaceutica NV [Member] | License Developmentand Commercialization Agreement [Member] | Second Indication [Member]                      
    Entity Listings [Line Items]                      
    Amount payable by the entity on achievement of various milestones           $ 20,000          
    XML 71 R41.htm IDEA: XBRL DOCUMENT v3.20.4
    SCHEDULE OF COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE (Details) - USD ($)
    $ / shares in Units, shares in Thousands, $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Earnings Per Share [Abstract]      
    Net loss, basic $ (98,581) $ (43,285) $ (26,478)
    Accretion of Series A Convertible Redeemable Preferred Stock to redemption value (276)
    Net loss attributable to common stockholders $ (98,581) $ (43,285) $ (26,754)
    Weighted average common shares outstanding, basic and diluted 52,457 40,747 22,441
    Net loss per common share, basic and diluted $ (1.88) $ (1.06) $ (1.19)
    XML 72 R42.htm IDEA: XBRL DOCUMENT v3.20.4
    SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares
    shares in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Stock Options [Member]      
    Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
    Antidilutive securities excluded from computation of earnings per share 9,503 5,894 3,476
    Warrants [Member]      
    Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
    Antidilutive securities excluded from computation of earnings per share 1,705 2,125 4,588
    XML 73 R43.htm IDEA: XBRL DOCUMENT v3.20.4
    SCHEDULE OF ACCRUED EXPENSES (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2020
    Dec. 31, 2019
    Payables and Accruals [Abstract]    
    Accrued research and development costs $ 5,165 $ 1,700
    Accrued compensation 1,443 54
    Accrued professional fees 1,197 221
    Accrued pre-commercial costs 1,191
    Other accrued liabilities 166 90
    Total accrued expenses $ 9,162 $ 2,065
    XML 74 R44.htm IDEA: XBRL DOCUMENT v3.20.4
    SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2020
    Dec. 31, 2019
    Cash and Cash Equivalents [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Fair value of assets [1] $ 102,294 $ 39,165
    Investments In Corporate Debt Securities [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Fair value of assets [2] 19,530  
    Investments In US Treasury Securities [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Fair value of assets [2]   46,208
    Fair Value, Inputs, Level 1 [Member] | Cash and Cash Equivalents [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Fair value of assets [1] 102,294 39,165
    Fair Value, Inputs, Level 1 [Member] | Investments In Corporate Debt Securities [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Fair value of assets [2]  
    Fair Value, Inputs, Level 1 [Member] | Investments In US Treasury Securities [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Fair value of assets [2]   46,208
    Fair Value, Inputs, Level 2 [Member] | Cash and Cash Equivalents [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Fair value of assets [1]
    Fair Value, Inputs, Level 2 [Member] | Investments In Corporate Debt Securities [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Fair value of assets [2] 19,530  
    Fair Value, Inputs, Level 2 [Member] | Investments In US Treasury Securities [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Fair value of assets [2]  
    Fair Value, Inputs, Level 3 [Member] | Cash and Cash Equivalents [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Fair value of assets [1]
    Fair Value, Inputs, Level 3 [Member] | Investments In Corporate Debt Securities [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Fair value of assets [2]  
    Fair Value, Inputs, Level 3 [Member] | Investments In US Treasury Securities [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Fair value of assets [2]  
    [1] Cash and cash equivalents primarily include investments in money market funds and United States Treasury securities with maturity dates within 90 days from the purchase date
    [2] Investments in United States Treasury and investment-grade corporate debt securities are classified as available for sale securities
    XML 75 R45.htm IDEA: XBRL DOCUMENT v3.20.4
    SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
    Total stock-based compensation expense $ 13,223 $ 2,842 $ 1,141
    General and Administrative Expense [Member]      
    Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
    Total stock-based compensation expense 7,611 1,546 512
    Research and Development Expense [Member]      
    Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
    Total stock-based compensation expense $ 5,612 $ 1,296 $ 629
    XML 76 R46.htm IDEA: XBRL DOCUMENT v3.20.4
    SUMMARY OF STOCK OPTION ACTIVITY (Details) - USD ($)
    $ / shares in Units, $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Share-based Payment Arrangement [Abstract]      
    Stock Options Underlying Shares, Outstanding beginning 5,894 3,476  
    Weighted-Average Exercise Price, Outstanding beginning balance $ 6.33 $ 2.85  
    Stock Options Underlying Shares, Granted 4,126 2,797  
    Weighted-Average Exercise Price, Granted $ 12.87 $ 10.34 $ 3.93
    Stock Options Underlying Shares, Exercised (219) (79)  
    Weighted-Average Exercise Price, Exercised $ 5.28 $ 3.66  
    Stock Options Underlying Shares, Forfeited or expired (298) (300)  
    Weighted-Average Exercise Price, Forfeited or expired $ 9.39 $ 4.19  
    Stock Options Underlying Shares, Outstanding ending balance 9,503 5,894 3,476
    Weighted-Average Exercise Price, Outstanding ending balance $ 9.10 $ 6.33 $ 2.85
    Weighted-Average Remaining Contractual Term, Outstanding Ending 8 years 3 months 18 days 8 years 6 months  
    Intrinsic Value, Outstanding Beginning $ 74,536  
    Stock Options Underlying Shares, Exercisable 3,730    
    Weighted-Average Exercise Price, Exercisable $ 5.88    
    Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term 7 years 4 months 24 days    
    Intrinsic Value, Exercisable $ 41,263    
    XML 77 R47.htm IDEA: XBRL DOCUMENT v3.20.4
    SCHEDULE OF AGGREGATED INTRINSIC VALUE OF STOCK OPTION EXERCISED (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Share-based Payment Arrangement [Abstract]      
    Cash proceeds from options exercised $ 1,152 $ 290 $ 25
    Aggregate intrinsic value of options exercised $ 1,615 $ 551 $ 5
    XML 78 R48.htm IDEA: XBRL DOCUMENT v3.20.4
    SCHEDULE OF SHARE-BASED COMPENSATION VALUATION OF ASSUMPTIONS (Details) - $ / shares
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Share-based Payment Arrangement [Abstract]      
    Exercise price $ 12.87 $ 10.34 $ 3.93
    Expected volatility 74.00% 72.00% 61.00%
    Expected dividends 0.00% 0.00% 0.00%
    Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term 6 years 2 months 12 days 6 years 3 months 18 days 6 years 2 months 12 days
    Risk-free interest rate 0.59% 1.90% 2.78%
    XML 79 R49.htm IDEA: XBRL DOCUMENT v3.20.4
    STOCK OPTIONS (Details Narrative) - USD ($)
    $ / shares in Units, $ in Millions
    		 1 Months Ended 12 Months Ended
    Oct. 31, 2020
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Jan. 02, 2021
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
    Number of options outstanding   9,503 5,894 3,476  
    Expected dividends   0.00% 0.00% 0.00%  
    Share-based Payment Arrangement, Option [Member]          
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
    Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value   $ 8.32      
    Stock Option One [Member]          
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
    Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares   1,869,000      
    Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount   $ 13.2      
    Stock Option Two [Member]          
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
    Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares   3,904,000      
    Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount   $ 25.1      
    Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition   3 years 2 months 12 days      
    Two Thousand Seventeen Plan [Member]          
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
    Number of options outstanding   9,503,228      
    Option exercisable expiration period   10 years      
    Number of shares, description   the number of shares available for issuance under the 2017 Plan in an amount equal to (1) the difference between (x) 18% of the total shares of the Company’s common stock outstanding, on a fully diluted basis, on December 31st of the preceding calendar year, and (y) the total number of shares of the Company’s common stock reserved under the 2017 Plan on December 31st of such preceding calendar year or (2) an amount less than this calculated increase as determined by the board of directors.      
    Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant   109,499      
    Two Thousand Seventeen Plan [Member] | Subsequent Event [Member] | Maximum [Member]          
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
    Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant         2,270,353
    Two Thousand and Twenty Inducement Plan [Member]          
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
    Option exercisable expiration period 10 years        
    Number of options authorized 2,000,000        
    XML 80 R50.htm IDEA: XBRL DOCUMENT v3.20.4
    SCHEDULE OF FAIR VALUE OF WARRANTS ISSUED (Details)
    Dec. 31, 2020
    Jul. 19, 2018
    Segment
    $ / shares
    May 07, 2018
    Segment
    $ / shares
    Entity Listings [Line Items]      
    Fair value assumptions measurement input term 5 years    
    Macro Genics Inc [Member]      
    Entity Listings [Line Items]      
    Equity value upon issuance     $ 2.58
    Exercise price     $ 2.50
    Macro Genics Inc [Member] | Measurement Input, Option Volatility [Member]      
    Entity Listings [Line Items]      
    Fair value assumptions measurement input percentage     62.0
    Macro Genics Inc [Member] | Measurement Input, Expected Dividend Rate [Member]      
    Entity Listings [Line Items]      
    Fair value assumptions measurement input percentage | Segment    
    Macro Genics Inc [Member] | Measurement Input, Expected Term [Member]      
    Entity Listings [Line Items]      
    Fair value assumptions measurement input term     7 years
    Macro Genics Inc [Member] | Measurement Input, Risk Free Interest Rate [Member]      
    Entity Listings [Line Items]      
    Fair value assumptions measurement input percentage     2.86
    MDB Capital Group, LLC [Member]      
    Entity Listings [Line Items]      
    Equity value upon issuance   $ 4.00  
    Exercise price   $ 5.00  
    MDB Capital Group, LLC [Member] | Measurement Input, Option Volatility [Member]      
    Entity Listings [Line Items]      
    Fair value assumptions measurement input percentage   60.0  
    MDB Capital Group, LLC [Member] | Measurement Input, Expected Dividend Rate [Member]      
    Entity Listings [Line Items]      
    Fair value assumptions measurement input percentage | Segment    
    MDB Capital Group, LLC [Member] | Measurement Input, Expected Term [Member]      
    Entity Listings [Line Items]      
    Fair value assumptions measurement input term   5 years  
    MDB Capital Group, LLC [Member] | Measurement Input, Risk Free Interest Rate [Member]      
    Entity Listings [Line Items]      
    Fair value assumptions measurement input percentage   2.74  
    XML 81 R51.htm IDEA: XBRL DOCUMENT v3.20.4
    WARRANTS (Details Narrative) - USD ($)
    $ / shares in Units, $ in Millions
    		 1 Months Ended 12 Months Ended
    Dec. 31, 2020
    Jul. 31, 2019
    Dec. 31, 2020
    Dec. 31, 2018
    Jul. 31, 2018
    Jul. 19, 2018
    May 31, 2018
    May 07, 2018
    Apr. 30, 2017
    Schedule of Capitalization, Equity [Line Items]                  
    Class of Warrant or Right, Number of Securities Called by Warrants or Rights 316,754   316,754            
    Warrants term 5 years   5 years            
    Macro Genics Inc [Member]                  
    Schedule of Capitalization, Equity [Line Items]                  
    Class of Warrant or Right, Number of Securities Called by Warrants or Rights   2,432,688              
    Class of Warrant or Right, Exercise Price of Warrants or Rights               $ 2.50  
    Number of warrants issuance shares   1,948,474              
    Fair value of warrants for MDB               $ 2.58  
    MDB Capital Group, LLC [Member]                  
    Schedule of Capitalization, Equity [Line Items]                  
    Class of Warrant or Right, Exercise Price of Warrants or Rights           $ 5.00      
    Fair value of warrants for MDB           $ 4.00      
    Series A Offering [Member]                  
    Schedule of Capitalization, Equity [Line Items]                  
    Class of Warrant or Right, Number of Securities Called by Warrants or Rights 312,689   312,689            
    Number of warrants issuance shares     259,542            
    Warrants outstanding, shares 241,986   241,986            
    MacroGenics License Agreement & MacroGenics Asset Purchase Agreement [Member]                  
    Schedule of Capitalization, Equity [Line Items]                  
    Class of Warrant or Right, Number of Securities Called by Warrants or Rights             2,432,688    
    Class of Warrant or Right, Exercise Price of Warrants or Rights             $ 2.50    
    Warrants term             7 years    
    MacroGenics License Agreement & MacroGenics Asset Purchase Agreement [Member] | Macro Genics Inc [Member] | Research and Development Expense [Member]                  
    Schedule of Capitalization, Equity [Line Items]                  
    Fair value per share of each warrant       $ 1.64          
    Fair value of warrant issued       $ 4.0          
    IPO [Member] | MDB Capital Group, LLC [Member]                  
    Schedule of Capitalization, Equity [Line Items]                  
    Class of Warrant or Right, Number of Securities Called by Warrants or Rights         1,596,956        
    Class of Warrant or Right, Exercise Price of Warrants or Rights         $ 5.00        
    Warrants term         5 years        
    Fair value of warrant issued $ 3.0                
    Fair value of warrants for MDB $ 1.90   $ 1.90            
    IPO [Member] | Warrant [Member]                  
    Schedule of Capitalization, Equity [Line Items]                  
    Class of Warrant or Right, Number of Securities Called by Warrants or Rights         558,740        
    Warrants outstanding, shares 1,462,842   1,462,842            
    IPO [Member] | Warrant [Member] | Cashless Basis [Member]                  
    Schedule of Capitalization, Equity [Line Items]                  
    Class of Warrant or Right, Number of Securities Called by Warrants or Rights 134,114   134,114            
    Number of warrants issuance shares     66,316            
    Number of warrants exercised 107,051   107,051            
    Series A Convertible Redeemable Preferred Stock [Member]                  
    Schedule of Capitalization, Equity [Line Items]                  
    Class of Warrant or Right, Exercise Price of Warrants or Rights                 $ 2.50
    Series A Convertible Redeemable Preferred Stock [Member] | Placement Agent [Member]                  
    Schedule of Capitalization, Equity [Line Items]                  
    Class of Warrant or Right, Number of Securities Called by Warrants or Rights                 558,740
    Class of Warrant or Right, Exercise Price of Warrants or Rights                 $ 2.50
    Warrants term                 7 years
    XML 82 R52.htm IDEA: XBRL DOCUMENT v3.20.4
    SCHEDULE OF FIXED ASSETS (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2020
    Dec. 31, 2019
    Property, Plant and Equipment [Line Items]    
    Fixed assets, net $ 1,470
    Less accumulated depreciation (33)
    Fixed assets, net 1,437
    Leasehold Improvements [Member]    
    Property, Plant and Equipment [Line Items]    
    Fixed assets, net 828
    Furniture and Fixtures [Member]    
    Property, Plant and Equipment [Line Items]    
    Fixed assets, net 149
    Office Equipment [Member]    
    Property, Plant and Equipment [Line Items]    
    Fixed assets, net 35
    Clinical Equipment [Member]    
    Property, Plant and Equipment [Line Items]    
    Fixed assets, net 27
    Construction in Progress [Member]    
    Property, Plant and Equipment [Line Items]    
    Fixed assets, net $ 431
    XML 83 R53.htm IDEA: XBRL DOCUMENT v3.20.4
    FIXED ASSETS (Details Narrative) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Property, Plant and Equipment [Abstract]      
    Depreciation expense $ 33
    XML 84 R54.htm IDEA: XBRL DOCUMENT v3.20.4
    SCHEDULE OF LEASE COSTS (Details)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    USD ($)
    Lessee Disclosure [Abstract]  
    Operating lease costs $ 25
    Variable lease costs 3
    Total lease costs $ 28
    XML 85 R55.htm IDEA: XBRL DOCUMENT v3.20.4
    SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2020
    Dec. 31, 2019
    Lessee, Lease, Description [Line Items]    
    Lease right-of-use assets Non-current $ 408
    Lease liabilities Non-Current $ 715
    Weighted average remaining lease term Operating leases 5 years 2 months 12 days  
    Weighted average discount rate Operating leases 15.00%  
    Accrued Expenses [Member]    
    Lessee, Lease, Description [Line Items]    
    Lease liabilities Current $ 72  
    XML 86 R56.htm IDEA: XBRL DOCUMENT v3.20.4
    SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details)
    $ in Thousands
    Dec. 31, 2020
    USD ($)
    Lessee Disclosure [Abstract]  
    2021 $ 185
    2022 221
    2023 227
    2024 232
    2025 238
    Thereafter 41
    Total lease payments 1,144
    Less: present value discount 357
    Present value of lease liabilities $ 787
    XML 87 R57.htm IDEA: XBRL DOCUMENT v3.20.4
    LEASES (Details Narrative)
    		 12 Months Ended
    Dec. 31, 2020
    Lessee Disclosure [Abstract]  
    Description on lease The Company’s lease portfolio consists of one office lease located in Red Bank, NJ. This lease is classified as an operating lease and has an initial term of 64 months from the lease commencement date, which began in October 2020.
    XML 88 R58.htm IDEA: XBRL DOCUMENT v3.20.4
    SCHEDULE OF EFFECTIVE TAX RATE (Details)
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Income Tax Disclosure [Abstract]      
    Tax Provision at statutory tax rate 21.00% 21.00% 21.00%
    Change in valuation allowance (34.60%) (36.50%) (26.90%)
    Orphan drug credits 10.40% 10.40%
    State income taxes, net of federal benefit 5.20% 6.50% 6.20%
    Sale of NJ net operating losses 0.40% 0.70%
    Permanent items (2.20%) (2.10%) (0.50%)
    Other 0.30% 0.70% 0.20%
    Effective Tax Rate 0.50% 0.70%
    XML 89 R59.htm IDEA: XBRL DOCUMENT v3.20.4
    SCHEDULE OF COMPONENTS OF INCOME TAX BENEFITS (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Income Tax Disclosure [Abstract]      
    Current: Federal
    Current: State (523) (187)
    Deferred: Federal
    Deferred: State
    Income tax benefit $ (523) $ (187)
    XML 90 R60.htm IDEA: XBRL DOCUMENT v3.20.4
    SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2020
    Dec. 31, 2019
    Income Tax Disclosure [Abstract]    
    NOL Carryforward $ 37,773 $ 17,520
    Federal research and development credits 15,819 5,045
    Equity compensation 4,245 1,018
    Product License 1,598 1,768
    Other 390 213
    Total deferred tax assets 59,825 25,564
    Less valuation allowance (59,825) (25,564)
    Net deferred tax assets
    XML 91 R61.htm IDEA: XBRL DOCUMENT v3.20.4
    INCOME TAXES (Details Narrative) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Operating Loss Carryforwards [Line Items]      
    Income tax benefit from state income taxes
    Deferred tax assets, gross 59,825 $ 25,564  
    Research and Development Expense [Member]      
    Operating Loss Carryforwards [Line Items]      
    Tax Credit Carryforward, Amount 16,300    
    New Jersey's Technology Business Tax Certificate Transfer Program [Member]      
    Operating Loss Carryforwards [Line Items]      
    Proceeds from NJ NOL sale 500    
    State and Local Jurisdiction [Member]      
    Operating Loss Carryforwards [Line Items]      
    Income tax benefit from state income taxes $ 500    
    [custom:OperatingLossCarryforwardsExpireDescription] begin to expire beginning in 2036    
    Deferred Tax Assets, Operating Loss Carryforwards, State and Local $ 129,800    
    State and Local Jurisdiction [Member] | NEW JERSEY      
    Operating Loss Carryforwards [Line Items]      
    Income tax benefit from state income taxes 500   $ 200
    NEW JERSEY      
    Operating Loss Carryforwards [Line Items]      
    Net operating loss 6,800    
    Domestic Tax Authority [Member]      
    Operating Loss Carryforwards [Line Items]      
    Deferred Tax Assets, Operating Loss Carryforwards, Domestic 139,100    
    [custom:OperatingLossCarryforwardsExpireAmount-0] $ 5,400    
    [custom:OperatingLossCarryforwardsExpireDescription] beginning in 2036    
    XML 92 R62.htm IDEA: XBRL DOCUMENT v3.20.4
    RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
    $ / shares in Units, $ in Millions
    		 1 Months Ended 12 Months Ended
    Jul. 31, 2018
    Dec. 31, 2020
    Dec. 31, 2018
    Jul. 19, 2018
    Related Party Transaction [Line Items]        
    Warrant term   5 years    
    MDB Capital Group, LLC [Member]        
    Related Party Transaction [Line Items]        
    Warrant exercise price       $ 5.00
    MDB Capital Group, LLC [Member] | Directors [Member] | Common Stock [Member]        
    Related Party Transaction [Line Items]        
    Ownership percentage 5.00%      
    MDB Capital Group, LLC [Member] | IPO [Member]        
    Related Party Transaction [Line Items]        
    Underwriter's fee $ 3.6      
    Number of warrants to purchase common stock 1,596,956      
    Warrant term 5 years      
    Warrant exercise price $ 5.00      
    Asset Purchase Agreement [Member] | Tolerance Therapeutics, Inc. [Member]        
    Related Party Transaction [Line Items]        
    Related party transaction, amounts of transaction   $ 0.1 $ 0.3  
    XML 93 R63.htm IDEA: XBRL DOCUMENT v3.20.4
    RETIREMENT SAVINGS PLAN (Details Narrative) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Payment for Pension and Other Postretirement Benefits [Abstract]      
    Employee contribution description The Company matches 100% of eligible employee contributions on the first 4% of employee salary (up to the IRS maximum).    
    Retirement plan contributions $ 0.2 $ 0.1 $ 0.1
    XML 94 R64.htm IDEA: XBRL DOCUMENT v3.20.4
    SUBSEQUENT EVENTS (Details Narrative) - USD ($)
    $ / shares in Units, $ in Thousands
    		 1 Months Ended 2 Months Ended
    Jun. 30, 2020
    Feb. 28, 2021
    Feb. 25, 2021
    Jan. 31, 2021
    Jun. 30, 2020
    Sep. 30, 2019
    Feb. 28, 2021
    Subsequent Event [Line Items]              
    Sale of Stock, Number of Shares Issued in Transaction           5,750,000  
    Sale of Stock, Price Per Share           $ 8.00  
    Proceeds from Issuance or Sale of Equity         $ 103,300    
    Underwriting discounts and commissions         6,600 $ 2,800  
    Other offering expenses         $ 200 $ 500  
    Underwriter's Option [Member]              
    Subsequent Event [Line Items]              
    Stock Issued During Period, Shares, New Issues 990,000            
    Shares Issued, Price Per Share $ 14.50       $ 14.50    
    Subsequent Event [Member]              
    Subsequent Event [Line Items]              
    Underwriting discounts and commissions   $ 6,600          
    Subsequent Event [Member] | License Agreement [Member] | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd [Member] | Maximum [Member]              
    Subsequent Event [Line Items]              
    Future development and regulatory milestones receivable     $ 37,000        
    Future commercial milestones receivable     135,000        
    Subsequent Event [Member] | License Agreement [Member] | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd [Member] | Research Development and Manufacturing Funding [Member]              
    Subsequent Event [Line Items]              
    Upfront payment receivable     6,000        
    Subsequent Event [Member] | License Agreement [Member] | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd [Member] | Research Development and Manufacturing Funding [Member] | Maximum [Member]              
    Subsequent Event [Line Items]              
    Future research and development funding receivable     $ 11,500        
    Subsequent Event [Member] | Underwriter's Option [Member]              
    Subsequent Event [Line Items]              
    Sale of Stock, Number of Shares Issued in Transaction       6,250,000      
    Sale of Stock, Price Per Share       $ 16.00      
    Stock Issued During Period, Shares, New Issues   587,500          
    Shares Issued, Price Per Share   $ 16.00         $ 16.00
    Proceeds from Issuance or Sale of Equity   $ 102,300         $ 102,300
    Underwriting discounts and commissions             6,600
    Other offering expenses   $ 500         $ 500
    EXCEL 95 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�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�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end XML 96 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 97 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 98 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 187 361 1 true 73 0 false 6 false false R1.htm 00000001 - Document - Cover Sheet http://proventionbio.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Balance Sheets Sheet http://proventionbio.com/role/BalanceSheets Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://proventionbio.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statements of Comprehensive Loss Sheet http://proventionbio.com/role/StatementsOfComprehensiveLoss Statements of Comprehensive Loss Statements 4 false false R5.htm 00000005 - Statement - Statement of Stockholders' Equity Sheet http://proventionbio.com/role/StatementOfStockholdersEquity Statement of Stockholders' Equity Statements 5 false false R6.htm 00000006 - Statement - Statements of Cash Flows Sheet http://proventionbio.com/role/StatementsOfCashFlows Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Sheet http://proventionbio.com/role/DescriptionOfBusinessAndBasisOfPresentation DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Notes 7 false false R8.htm 00000008 - Disclosure - LIQUIDITY Sheet http://proventionbio.com/role/Liquidity LIQUIDITY Notes 8 false false R9.htm 00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://proventionbio.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 00000010 - Disclosure - CAPITALIZATION Sheet http://proventionbio.com/role/Capitalization CAPITALIZATION Notes 10 false false R11.htm 00000011 - Disclosure - CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES Sheet http://proventionbio.com/role/CashCashEquivalentsAndMarketableSecurities CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES Notes 11 false false R12.htm 00000012 - Disclosure - LICENSE AND OTHER AGREEMENTS Sheet http://proventionbio.com/role/LicenseAndOtherAgreements LICENSE AND OTHER AGREEMENTS Notes 12 false false R13.htm 00000013 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK Sheet http://proventionbio.com/role/NetLossPerShareOfCommonStock NET LOSS PER SHARE OF COMMON STOCK Notes 13 false false R14.htm 00000014 - Disclosure - ACCRUED EXPENSES Sheet http://proventionbio.com/role/AccruedExpenses ACCRUED EXPENSES Notes 14 false false R15.htm 00000015 - Disclosure - FAIR VALUE OF ASSETS AND LIABILITIES Sheet http://proventionbio.com/role/FairValueOfAssetsAndLiabilities FAIR VALUE OF ASSETS AND LIABILITIES Notes 15 false false R16.htm 00000016 - Disclosure - STOCK OPTIONS Sheet http://proventionbio.com/role/StockOptions STOCK OPTIONS Notes 16 false false R17.htm 00000017 - Disclosure - WARRANTS Sheet http://proventionbio.com/role/Warrants WARRANTS Notes 17 false false R18.htm 00000018 - Disclosure - FIXED ASSETS Sheet http://proventionbio.com/role/FixedAssets FIXED ASSETS Notes 18 false false R19.htm 00000019 - Disclosure - LEASES Sheet http://proventionbio.com/role/Leases LEASES Notes 19 false false R20.htm 00000020 - Disclosure - INCOME TAXES Sheet http://proventionbio.com/role/IncomeTaxes INCOME TAXES Notes 20 false false R21.htm 00000021 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://proventionbio.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 21 false false R22.htm 00000022 - Disclosure - RETIREMENT SAVINGS PLAN Sheet http://proventionbio.com/role/RetirementSavingsPlan RETIREMENT SAVINGS PLAN Notes 22 false false R23.htm 00000023 - Disclosure - SUBSEQUENT EVENTS Sheet http://proventionbio.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 23 false false R24.htm 00000024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://proventionbio.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 24 false false R25.htm 00000025 - Disclosure - CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES (Tables) Sheet http://proventionbio.com/role/CashCashEquivalentsAndMarketableSecuritiesTables CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES (Tables) Tables http://proventionbio.com/role/CashCashEquivalentsAndMarketableSecurities 25 false false R26.htm 00000026 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Tables) Sheet http://proventionbio.com/role/NetLossPerShareOfCommonStockTables NET LOSS PER SHARE OF COMMON STOCK (Tables) Tables http://proventionbio.com/role/NetLossPerShareOfCommonStock 26 false false R27.htm 00000027 - Disclosure - ACCRUED EXPENSES (Tables) Sheet http://proventionbio.com/role/AccruedExpensesTables ACCRUED EXPENSES (Tables) Tables http://proventionbio.com/role/AccruedExpenses 27 false false R28.htm 00000028 - Disclosure - FAIR VALUE OF ASSETS AND LIABILITIES (Tables) Sheet http://proventionbio.com/role/FairValueOfAssetsAndLiabilitiesTables FAIR VALUE OF ASSETS AND LIABILITIES (Tables) Tables http://proventionbio.com/role/FairValueOfAssetsAndLiabilities 28 false false R29.htm 00000029 - Disclosure - STOCK OPTIONS (Tables) Sheet http://proventionbio.com/role/StockOptionsTables STOCK OPTIONS (Tables) Tables http://proventionbio.com/role/StockOptions 29 false false R30.htm 00000030 - Disclosure - WARRANTS (Tables) Sheet http://proventionbio.com/role/WarrantsTables WARRANTS (Tables) Tables http://proventionbio.com/role/Warrants 30 false false R31.htm 00000031 - Disclosure - FIXED ASSETS (Tables) Sheet http://proventionbio.com/role/FixedAssetsTables FIXED ASSETS (Tables) Tables http://proventionbio.com/role/FixedAssets 31 false false R32.htm 00000032 - Disclosure - LEASES (Tables) Sheet http://proventionbio.com/role/LeasesTables LEASES (Tables) Tables http://proventionbio.com/role/Leases 32 false false R33.htm 00000033 - Disclosure - INCOME TAXES (Tables) Sheet http://proventionbio.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://proventionbio.com/role/IncomeTaxes 33 false false R34.htm 00000034 - Disclosure - LIQUIDITY (Details Narrative) Sheet http://proventionbio.com/role/LiquidityDetailsNarrative LIQUIDITY (Details Narrative) Details http://proventionbio.com/role/Liquidity 34 false false R35.htm 00000035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://proventionbio.com/role/SignificantAccountingPoliciesDetailsNarrative SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://proventionbio.com/role/SignificantAccountingPoliciesPolicies 35 false false R36.htm 00000036 - Disclosure - CAPITALIZATION (Details Narrative) Sheet http://proventionbio.com/role/CapitalizationDetailsNarrative CAPITALIZATION (Details Narrative) Details http://proventionbio.com/role/Capitalization 36 false false R37.htm 00000037 - Disclosure - SCHEDULE OF AVAILABLE FOR SALE SECURITIES (Details) Sheet http://proventionbio.com/role/ScheduleOfAvailableForSaleSecuritiesDetails SCHEDULE OF AVAILABLE FOR SALE SECURITIES (Details) Details 37 false false R38.htm 00000038 - Disclosure - SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Details) Sheet http://proventionbio.com/role/ScheduleOfAccumulatedOtherComprehensiveIncomeLossDetails SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Details) Details 38 false false R39.htm 00000039 - Disclosure - CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES (Details Narrative) Sheet http://proventionbio.com/role/CashCashEquivalentsAndMarketableSecuritiesDetailsNarrative CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES (Details Narrative) Details http://proventionbio.com/role/CashCashEquivalentsAndMarketableSecuritiesTables 39 false false R40.htm 00000040 - Disclosure - LICENSE AND OTHER AGREEMENTS (Details Narrative) Sheet http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative LICENSE AND OTHER AGREEMENTS (Details Narrative) Details http://proventionbio.com/role/LicenseAndOtherAgreements 40 false false R41.htm 00000041 - Disclosure - SCHEDULE OF COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE (Details) Sheet http://proventionbio.com/role/ScheduleOfComputationOfBasicAndDilutedLossPerShareDetails SCHEDULE OF COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE (Details) Details 41 false false R42.htm 00000042 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) Sheet http://proventionbio.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) Details 42 false false R43.htm 00000043 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details) Sheet http://proventionbio.com/role/ScheduleOfAccruedExpensesDetails SCHEDULE OF ACCRUED EXPENSES (Details) Details 43 false false R44.htm 00000044 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details) Sheet http://proventionbio.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details) Details 44 false false R45.htm 00000045 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details) Sheet http://proventionbio.com/role/ScheduleOfStock-basedCompensationExpenseDetails SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details) Details 45 false false R46.htm 00000046 - Disclosure - SUMMARY OF STOCK OPTION ACTIVITY (Details) Sheet http://proventionbio.com/role/SummaryOfStockOptionActivityDetails SUMMARY OF STOCK OPTION ACTIVITY (Details) Details 46 false false R47.htm 00000047 - Disclosure - SCHEDULE OF AGGREGATED INTRINSIC VALUE OF STOCK OPTION EXERCISED (Details) Sheet http://proventionbio.com/role/ScheduleOfAggregatedIntrinsicValueOfStockOptionExercisedDetails SCHEDULE OF AGGREGATED INTRINSIC VALUE OF STOCK OPTION EXERCISED (Details) Details 47 false false R48.htm 00000048 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION VALUATION OF ASSUMPTIONS (Details) Sheet http://proventionbio.com/role/ScheduleOfShare-basedCompensationValuationOfAssumptionsDetails SCHEDULE OF SHARE-BASED COMPENSATION VALUATION OF ASSUMPTIONS (Details) Details 48 false false R49.htm 00000049 - Disclosure - STOCK OPTIONS (Details Narrative) Sheet http://proventionbio.com/role/StockOptionsDetailsNarrative STOCK OPTIONS (Details Narrative) Details http://proventionbio.com/role/StockOptionsTables 49 false false R50.htm 00000050 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANTS ISSUED (Details) Sheet http://proventionbio.com/role/ScheduleOfFairValueOfWarrantsIssuedDetails SCHEDULE OF FAIR VALUE OF WARRANTS ISSUED (Details) Details 50 false false R51.htm 00000051 - Disclosure - WARRANTS (Details Narrative) Sheet http://proventionbio.com/role/WarrantsDetailsNarrative WARRANTS (Details Narrative) Details http://proventionbio.com/role/WarrantsTables 51 false false R52.htm 00000052 - Disclosure - SCHEDULE OF FIXED ASSETS (Details) Sheet http://proventionbio.com/role/ScheduleOfFixedAssetsDetails SCHEDULE OF FIXED ASSETS (Details) Details 52 false false R53.htm 00000053 - Disclosure - FIXED ASSETS (Details Narrative) Sheet http://proventionbio.com/role/FixedAssetsDetailsNarrative FIXED ASSETS (Details Narrative) Details http://proventionbio.com/role/FixedAssetsTables 53 false false R54.htm 00000054 - Disclosure - SCHEDULE OF LEASE COSTS (Details) Sheet http://proventionbio.com/role/ScheduleOfLeaseCostsDetails SCHEDULE OF LEASE COSTS (Details) Details 54 false false R55.htm 00000055 - Disclosure - SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION (Details) Sheet http://proventionbio.com/role/ScheduleOfSupplementalBalanceSheetInformationDetails SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION (Details) Details 55 false false R56.htm 00000056 - Disclosure - SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) Sheet http://proventionbio.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) Details 56 false false R57.htm 00000057 - Disclosure - LEASES (Details Narrative) Sheet http://proventionbio.com/role/LeasesDetailsNarrative LEASES (Details Narrative) Details http://proventionbio.com/role/LeasesTables 57 false false R58.htm 00000058 - Disclosure - SCHEDULE OF EFFECTIVE TAX RATE (Details) Sheet http://proventionbio.com/role/ScheduleOfEffectiveTaxRateDetails SCHEDULE OF EFFECTIVE TAX RATE (Details) Details 58 false false R59.htm 00000059 - Disclosure - SCHEDULE OF COMPONENTS OF INCOME TAX BENEFITS (Details) Sheet http://proventionbio.com/role/ScheduleOfComponentsOfIncomeTaxBenefitsDetails SCHEDULE OF COMPONENTS OF INCOME TAX BENEFITS (Details) Details 59 false false R60.htm 00000060 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details) Sheet http://proventionbio.com/role/ScheduleOfDeferredTaxAssetsDetails SCHEDULE OF DEFERRED TAX ASSETS (Details) Details 60 false false R61.htm 00000061 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://proventionbio.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://proventionbio.com/role/IncomeTaxesTables 61 false false R62.htm 00000062 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://proventionbio.com/role/RelatedPartyTransactions 62 false false R63.htm 00000063 - Disclosure - RETIREMENT SAVINGS PLAN (Details Narrative) Sheet http://proventionbio.com/role/RetirementSavingsPlanDetailsNarrative RETIREMENT SAVINGS PLAN (Details Narrative) Details http://proventionbio.com/role/RetirementSavingsPlan 63 false false R64.htm 00000064 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://proventionbio.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://proventionbio.com/role/SubsequentEvents 64 false false All Reports Book All Reports form10-k.htm ex23-1.htm ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm ex4-4.htm prvb-20201231.xsd prvb-20201231_cal.xml prvb-20201231_def.xml prvb-20201231_lab.xml prvb-20201231_pre.xml form10-k_001.jpg form10-k_002.jpg form10-k_003.jpg form10-k_004.jpg form10-k_005.jpg form10-k_006.jpg form10-k_007.jpg form10-k_008.jpg form10-k_009.jpg form10-k_010.jpg form10-k_011.jpg form10-k_012.jpg image_001.jpg image_002.jpg image_003.jpg image_004.jpg image_005.jpg http://xbrl.sec.gov/dei/2020-01-31 http://xbrl.sec.gov/stpr/2018-01-31 http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 true true JSON 101 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-k.htm": { "axisCustom": 0, "axisStandard": 21, "contextCount": 187, "dts": { "calculationLink": { "local": [ "prvb-20201231_cal.xml" ] }, "definitionLink": { "local": [ "prvb-20201231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "form10-k.htm" ] }, "labelLink": { "local": [ "prvb-20201231_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "prvb-20201231_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "prvb-20201231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 496, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 183, "http://proventionbio.com/20201231": 61, "http://xbrl.sec.gov/dei/2020-01-31": 6, "total": 250 }, "keyCustom": 47, "keyStandard": 314, "memberCustom": 41, "memberStandard": 31, "nsprefix": "PRVB", "nsuri": "http://proventionbio.com/20201231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://proventionbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "PRVB:CapitalizationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - CAPITALIZATION", "role": "http://proventionbio.com/role/Capitalization", "shortName": "CAPITALIZATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "PRVB:CapitalizationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES", "role": "http://proventionbio.com/role/CashCashEquivalentsAndMarketableSecurities", "shortName": "CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "PRVB:LicenseAndOtherAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - LICENSE AND OTHER AGREEMENTS", "role": "http://proventionbio.com/role/LicenseAndOtherAgreements", "shortName": "LICENSE AND OTHER AGREEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "PRVB:LicenseAndOtherAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK", "role": "http://proventionbio.com/role/NetLossPerShareOfCommonStock", "shortName": "NET LOSS PER SHARE OF COMMON STOCK", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - ACCRUED EXPENSES", "role": "http://proventionbio.com/role/AccruedExpenses", "shortName": "ACCRUED EXPENSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - FAIR VALUE OF ASSETS AND LIABILITIES", "role": "http://proventionbio.com/role/FairValueOfAssetsAndLiabilities", "shortName": "FAIR VALUE OF ASSETS AND LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - STOCK OPTIONS", "role": "http://proventionbio.com/role/StockOptions", "shortName": "STOCK OPTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "PRVB:WarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - WARRANTS", "role": "http://proventionbio.com/role/Warrants", "shortName": "WARRANTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "PRVB:WarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - FIXED ASSETS", "role": "http://proventionbio.com/role/FixedAssets", "shortName": "FIXED ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - LEASES", "role": "http://proventionbio.com/role/Leases", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Balance Sheets", "role": "http://proventionbio.com/role/BalanceSheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - INCOME TAXES", "role": "http://proventionbio.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://proventionbio.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - RETIREMENT SAVINGS PLAN", "role": "http://proventionbio.com/role/RetirementSavingsPlan", "shortName": "RETIREMENT SAVINGS PLAN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - SUBSEQUENT EVENTS", "role": "http://proventionbio.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://proventionbio.com/role/SignificantAccountingPoliciesPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES (Tables)", "role": "http://proventionbio.com/role/CashCashEquivalentsAndMarketableSecuritiesTables", "shortName": "CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - NET LOSS PER SHARE OF COMMON STOCK (Tables)", "role": "http://proventionbio.com/role/NetLossPerShareOfCommonStockTables", "shortName": "NET LOSS PER SHARE OF COMMON STOCK (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - ACCRUED EXPENSES (Tables)", "role": "http://proventionbio.com/role/AccruedExpensesTables", "shortName": "ACCRUED EXPENSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - FAIR VALUE OF ASSETS AND LIABILITIES (Tables)", "role": "http://proventionbio.com/role/FairValueOfAssetsAndLiabilitiesTables", "shortName": "FAIR VALUE OF ASSETS AND LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - STOCK OPTIONS (Tables)", "role": "http://proventionbio.com/role/StockOptionsTables", "shortName": "STOCK OPTIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Balance Sheets (Parenthetical)", "role": "http://proventionbio.com/role/BalanceSheetsParenthetical", "shortName": "Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "PRVB:WarrantsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31_custom_MacroGenicsIncMember", "decimals": null, "first": true, "lang": "en-US", "name": "PRVB:ScheduleOfFairValueOfWarrantsIssuedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - WARRANTS (Tables)", "role": "http://proventionbio.com/role/WarrantsTables", "shortName": "WARRANTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "PRVB:WarrantsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31_custom_MacroGenicsIncMember", "decimals": null, "first": true, "lang": "en-US", "name": "PRVB:ScheduleOfFairValueOfWarrantsIssuedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - FIXED ASSETS (Tables)", "role": "http://proventionbio.com/role/FixedAssetsTables", "shortName": "FIXED ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - LEASES (Tables)", "role": "http://proventionbio.com/role/LeasesTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - INCOME TAXES (Tables)", "role": "http://proventionbio.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - LIQUIDITY (Details Narrative)", "role": "http://proventionbio.com/role/LiquidityDetailsNarrative", "shortName": "LIQUIDITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "PRVB:LiquidityTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2019-09-012019-09-30", "decimals": "-5", "lang": null, "name": "PRVB:NetProceedsFromNewSharesIssuedTransactionPlusAmgenPrivatePlacement", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://proventionbio.com/role/SignificantAccountingPoliciesDetailsNarrative", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Segment", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - CAPITALIZATION (Details Narrative)", "role": "http://proventionbio.com/role/CapitalizationDetailsNarrative", "shortName": "CAPITALIZATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - SCHEDULE OF AVAILABLE FOR SALE SECURITIES (Details)", "role": "http://proventionbio.com/role/ScheduleOfAvailableForSaleSecuritiesDetails", "shortName": "SCHEDULE OF AVAILABLE FOR SALE SECURITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Details)", "role": "http://proventionbio.com/role/ScheduleOfAccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES (Details Narrative)", "role": "http://proventionbio.com/role/CashCashEquivalentsAndMarketableSecuritiesDetailsNarrative", "shortName": "CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-5", "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAndHeldToMaturitySecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Statements of Comprehensive Loss", "role": "http://proventionbio.com/role/StatementsOfComprehensiveLoss", "shortName": "Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "p", "PRVB:WarrantsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - LICENSE AND OTHER AGREEMENTS (Details Narrative)", "role": "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "shortName": "LICENSE AND OTHER AGREEMENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "PRVB:LicenseAndOtherAgreementsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2018-05-31_custom_MacroGenicsAssetPurchaseAgreementAndMacroGenicsLicenseAgreementMember", "decimals": "INF", "lang": null, "name": "PRVB:FairValuePerShareOfEachWarrant", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - SCHEDULE OF COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE (Details)", "role": "http://proventionbio.com/role/ScheduleOfComputationOfBasicAndDilutedLossPerShareDetails", "shortName": "SCHEDULE OF COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31_custom_StockOptionsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)", "role": "http://proventionbio.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "shortName": "SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31_custom_StockOptionsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "PRVB:AccruedResearchAndDevelopmentCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details)", "role": "http://proventionbio.com/role/ScheduleOfAccruedExpensesDetails", "shortName": "SCHEDULE OF ACCRUED EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "PRVB:AccruedResearchAndDevelopmentCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_CashAndCashEquivalentsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details)", "role": "http://proventionbio.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_CashAndCashEquivalentsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)", "role": "http://proventionbio.com/role/ScheduleOfStock-basedCompensationExpenseDetails", "shortName": "SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - SUMMARY OF STOCK OPTION ACTIVITY (Details)", "role": "http://proventionbio.com/role/SummaryOfStockOptionActivityDetails", "shortName": "SUMMARY OF STOCK OPTION ACTIVITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromStockOptionsExercised", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - SCHEDULE OF AGGREGATED INTRINSIC VALUE OF STOCK OPTION EXERCISED (Details)", "role": "http://proventionbio.com/role/ScheduleOfAggregatedIntrinsicValueOfStockOptionExercisedDetails", "shortName": "SCHEDULE OF AGGREGATED INTRINSIC VALUE OF STOCK OPTION EXERCISED (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION VALUATION OF ASSUMPTIONS (Details)", "role": "http://proventionbio.com/role/ScheduleOfShare-basedCompensationValuationOfAssumptionsDetails", "shortName": "SCHEDULE OF SHARE-BASED COMPENSATION VALUATION OF ASSUMPTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Percentage", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - STOCK OPTIONS (Details Narrative)", "role": "http://proventionbio.com/role/StockOptionsDetailsNarrative", "shortName": "STOCK OPTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2017-12-31_custom_ConvertibleRedeemablePreferredStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Statement of Stockholders' Equity", "role": "http://proventionbio.com/role/StatementOfStockholdersEquity", "shortName": "Statement of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2017-12-31_custom_ConvertibleRedeemablePreferredStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "PRVB:ScheduleOfFairValueOfWarrantsIssuedTableTextBlock", "PRVB:WarrantsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2018-05-07_custom_MacroGenicsIncMember", "decimals": "INF", "first": true, "lang": null, "name": "PRVB:FairValueOfWarrantsIssuedPerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANTS ISSUED (Details)", "role": "http://proventionbio.com/role/ScheduleOfFairValueOfWarrantsIssuedDetails", "shortName": "SCHEDULE OF FAIR VALUE OF WARRANTS ISSUED (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "PRVB:ScheduleOfFairValueOfWarrantsIssuedTableTextBlock", "PRVB:WarrantsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2018-05-07_custom_MacroGenicsIncMember_us-gaap_MeasurementInputOptionVolatilityMember", "decimals": "INF", "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Percentage", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "p", "PRVB:WarrantsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - WARRANTS (Details Narrative)", "role": "http://proventionbio.com/role/WarrantsDetailsNarrative", "shortName": "WARRANTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "PRVB:WarrantsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31_custom_SeriesAOfferingMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesOther", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - SCHEDULE OF FIXED ASSETS (Details)", "role": "http://proventionbio.com/role/ScheduleOfFixedAssetsDetails", "shortName": "SCHEDULE OF FIXED ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - FIXED ASSETS (Details Narrative)", "role": "http://proventionbio.com/role/FixedAssetsDetailsNarrative", "shortName": "FIXED ASSETS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - SCHEDULE OF LEASE COSTS (Details)", "role": "http://proventionbio.com/role/ScheduleOfLeaseCostsDetails", "shortName": "SCHEDULE OF LEASE COSTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION (Details)", "role": "http://proventionbio.com/role/ScheduleOfSupplementalBalanceSheetInformationDetails", "shortName": "SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "PRVB:ScheduleOfSupplementalBalanceSheetInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details)", "role": "http://proventionbio.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails", "shortName": "SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - LEASES (Details Narrative)", "role": "http://proventionbio.com/role/LeasesDetailsNarrative", "shortName": "LEASES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Percentage", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000058 - Disclosure - SCHEDULE OF EFFECTIVE TAX RATE (Details)", "role": "http://proventionbio.com/role/ScheduleOfEffectiveTaxRateDetails", "shortName": "SCHEDULE OF EFFECTIVE TAX RATE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Percentage", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000059 - Disclosure - SCHEDULE OF COMPONENTS OF INCOME TAX BENEFITS (Details)", "role": "http://proventionbio.com/role/ScheduleOfComponentsOfIncomeTaxBenefitsDetails", "shortName": "SCHEDULE OF COMPONENTS OF INCOME TAX BENEFITS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Statements of Cash Flows", "role": "http://proventionbio.com/role/StatementsOfCashFlows", "shortName": "Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2018-01-012018-12-31", "decimals": "-3", "lang": null, "name": "PRVB:StockbasedConsiderationInConnectionWithAcquisitionOfProductRights", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000060 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)", "role": "http://proventionbio.com/role/ScheduleOfDeferredTaxAssetsDetails", "shortName": "SCHEDULE OF DEFERRED TAX ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000061 - Disclosure - INCOME TAXES (Details Narrative)", "role": "http://proventionbio.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember", "decimals": "-5", "lang": null, "name": "us-gaap:TaxCreditCarryforwardAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "PRVB:ScheduleOfFairValueOfWarrantsIssuedTableTextBlock", "PRVB:WarrantsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2018-07-19_custom_MDBCapitalGroupLLCMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000062 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "role": "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2018-07-31_custom_MDBCapitalGroupLLCMember_custom_DirectorsMember_us-gaap_CommonStockMember", "decimals": "INF", "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "Percentage", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000063 - Disclosure - RETIREMENT SAVINGS PLAN (Details Narrative)", "role": "http://proventionbio.com/role/RetirementSavingsPlanDetailsNarrative", "shortName": "RETIREMENT SAVINGS PLAN (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "p", "PRVB:LiquidityTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2019-09-012019-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000064 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "role": "http://proventionbio.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-02-25_us-gaap_SubsequentEventMember_custom_LicenseAgreementMember_custom_HangzhouZhongmeiHuadongPharmaceuticalCoLtdMember_srt_MaximumMember", "decimals": "-5", "lang": null, "name": "PRVB:FutureDevelopmentAndRegulatoryMilestonesReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION", "role": "http://proventionbio.com/role/DescriptionOfBusinessAndBasisOfPresentation", "shortName": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "PRVB:LiquidityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - LIQUIDITY", "role": "http://proventionbio.com/role/Liquidity", "shortName": "LIQUIDITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "PRVB:LiquidityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "role": "http://proventionbio.com/role/SignificantAccountingPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 73, "tag": { "PRVB_AccruedExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued Expenses [Member].", "label": "Accrued Expenses [Member]" } } }, "localname": "AccruedExpensesMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/ScheduleOfSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "PRVB_AccruedPrecommercialCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued pre-commercial costs.", "label": "Accrued pre-commercial costs" } } }, "localname": "AccruedPrecommercialCosts", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "PRVB_AccruedResearchAndDevelopmentCostsCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development costs, current.", "label": "Accrued research and development costs" } } }, "localname": "AccruedResearchAndDevelopmentCostsCurrent", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "PRVB_AccruedResearchAndDevelopmentExpensesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued research and development expenses" } } }, "localname": "AccruedResearchAndDevelopmentExpensesPolicyTextBlock", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "PRVB_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Reclassification of Series A warrants liability" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "PRVB_AmgenIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Amgen Inc [Member]" } } }, "localname": "AmgenIncMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/LiquidityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_AmountPayableByEntityOnAchievementOfVariousMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount payable by the entity on achievement of various milestones.", "label": "Amount payable by the entity on achievement of various milestones" } } }, "localname": "AmountPayableByEntityOnAchievementOfVariousMilestones", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRVB_AmountPayableByEntityOnAchievementOfVariousSalesMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments made on tiered single-digit royalties.", "label": "Payments made on tiered single-digit royalties" } } }, "localname": "AmountPayableByEntityOnAchievementOfVariousSalesMilestones", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRVB_AmountReceivablebytheentityonachievementofvariousmilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount payable by the entity on achievement of various milestones.", "label": "Amount payable by the entity on achievement of various milestones [Default Label]", "verboseLabel": "Amount payable by the entity on achievement of various milestones" } } }, "localname": "AmountReceivablebytheentityonachievementofvariousmilestones", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRVB_AssetPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asset Purchase Agreement [Member]" } } }, "localname": "AssetPurchaseAgreementMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_AtTheMarketMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "At The Market [Member]" } } }, "localname": "AtTheMarketMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_BiologicsLicenseApplicationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Biologics License Application [Member].", "label": "Biologics License Application [Member]" } } }, "localname": "BiologicsLicenseApplicationMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_CapitalizationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CAPITALIZATION" } } }, "localname": "CapitalizationTextBlock", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/Capitalization" ], "xbrltype": "textBlockItemType" }, "PRVB_CashlessBasisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cashless Basis [Member].", "label": "Cashless Basis [Member]" } } }, "localname": "CashlessBasisMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of warrants exercised" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrants", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "PRVB_ClinicalEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clinical Equipment [Member].", "label": "Clinical Equipment [Member]" } } }, "localname": "ClinicalEquipmentMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "PRVB_ConvertibleRedeemablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Redeemable Preferred Stock [Member].", "label": "Convertible Redeemable Preferred Stock [Member]" } } }, "localname": "ConvertibleRedeemablePreferredStockMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "PRVB_DeferredTaxAssetsProductLicense": { "auth_ref": [], "calculation": { "http://proventionbio.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets, Product License.", "label": "Product License" } } }, "localname": "DeferredTaxAssetsProductLicense", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "PRVB_DirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Directors [Member]", "label": "Directors [Member]" } } }, "localname": "DirectorsMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_DisclosureCapitalizationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capitalization" } } }, "localname": "DisclosureCapitalizationAbstract", "nsuri": "http://proventionbio.com/20201231", "xbrltype": "stringItemType" }, "PRVB_DisclosureLicenseAndOtherAgreementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License And Other Agreements" } } }, "localname": "DisclosureLicenseAndOtherAgreementsAbstract", "nsuri": "http://proventionbio.com/20201231", "xbrltype": "stringItemType" }, "PRVB_DisclosureLiquidityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liquidity" } } }, "localname": "DisclosureLiquidityAbstract", "nsuri": "http://proventionbio.com/20201231", "xbrltype": "stringItemType" }, "PRVB_DosingOfFirstPatientInPhaseOnePROVENTStudyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dosing Of First Patient In Phase 1 PROVENT Study [Member]", "label": "Dosing Of First Patient In Phase 1 PROVENT Study [Member]" } } }, "localname": "DosingOfFirstPatientInPhaseOnePROVENTStudyMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation permanent differences amount.", "label": "Permanent items" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/ScheduleOfEffectiveTaxRateDetails" ], "xbrltype": "percentItemType" }, "PRVB_EuroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Euro [Member].", "label": "Euro [Member]" } } }, "localname": "EuroMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_FairValueOfWarrantsIssuedPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value of warrants for MDB.", "label": "Equity value upon issuance", "verboseLabel": "Fair value of warrants for MDB" } } }, "localname": "FairValueOfWarrantsIssuedPerShare", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/ScheduleOfFairValueOfWarrantsIssuedDetails", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "PRVB_FairValuePerShareOfEachWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair Value per share of each warrant.", "label": "Fair Value per share of each warrant", "verboseLabel": "Fair value per share of each warrant" } } }, "localname": "FairValuePerShareOfEachWarrant", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "PRVB_FirstEighteenMonthsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First Eighteen Months [Member].", "label": "First Eighteen Months [Member]" } } }, "localname": "FirstEighteenMonthsMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_FirstIndicationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First Indication [Member]", "label": "First Indication [Member]" } } }, "localname": "FirstIndicationMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_FutureCommercialMilestonesReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future commercial milestones receivable.", "label": "Future commercial milestones receivable" } } }, "localname": "FutureCommercialMilestonesReceivable", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRVB_FutureDevelopmentAndRegulatoryMilestonesReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future development and regulatory milestones receivable.", "label": "Future development and regulatory milestones receivable" } } }, "localname": "FutureDevelopmentAndRegulatoryMilestonesReceivable", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRVB_FutureResearchAndDevelopmentFundingReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Future research and development funding receivable.", "label": "Future research and development funding receivable" } } }, "localname": "FutureResearchAndDevelopmentFundingReceivable", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRVB_HangzhouZhongmeiHuadongPharmaceuticalCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd [Member].", "label": "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd [Member]" } } }, "localname": "HangzhouZhongmeiHuadongPharmaceuticalCoLtdMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_IntravaccDevelopmentServicesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intravacc Development Services Agreement [Member].", "label": "Intravacc Development Services Agreement [Member]" } } }, "localname": "IntravaccDevelopmentServicesAgreementMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_InvestmentsInCorporateDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments In Corporate Debt Securities [Member]" } } }, "localname": "InvestmentsInCorporateDebtSecuritiesMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "PRVB_InvestmentsInUSTreasurySecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investments In US Treasury Securities [Member].", "label": "Investments In US Treasury Securities [Member]" } } }, "localname": "InvestmentsInUSTreasurySecuritiesMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "PRVB_JanssenPharmaceuticaNVMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Janssen Pharmaceutica NV [Member].", "label": "Janssen Pharmaceutica NV [Member]" } } }, "localname": "JanssenPharmaceuticaNVMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement [Member]", "label": "License Agreement [Member]" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_LicenseAndCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License and Collaboration Agreement [Member].", "label": "License and Collaboration Agreement [Member]" } } }, "localname": "LicenseAndCollaborationAgreementMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_LicenseAndOtherAgreementsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LICENSE AND OTHER AGREEMENTS" } } }, "localname": "LicenseAndOtherAgreementsTextBlock", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreements" ], "xbrltype": "textBlockItemType" }, "PRVB_LicenseDevelopmentandCommercializationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Developmentand Commercialization Agreement [Member].", "label": "License Developmentand Commercialization Agreement [Member]" } } }, "localname": "LicenseDevelopmentandCommercializationAgreementMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_LiquidityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIQUIDITY" } } }, "localname": "LiquidityTextBlock", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/Liquidity" ], "xbrltype": "textBlockItemType" }, "PRVB_MDBCapitalGroupLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MDB Capital Group, LLC [Member].", "label": "MDB Capital Group, LLC [Member]" } } }, "localname": "MDBCapitalGroupLLCMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://proventionbio.com/role/ScheduleOfFairValueOfWarrantsIssuedDetails", "http://proventionbio.com/role/WarrantsDetailsNarrative", "http://proventionbio.com/role/WarrantsTables" ], "xbrltype": "domainItemType" }, "PRVB_MacroGenicsAssetPurchaseAgreementAndMacroGenicsLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Macro Genics Asset Purchase Agreement and Macro Genics License Agreement [Member]", "label": "Macro Genics Asset Purchase Agreement and Macro Genics License Agreement [Member]" } } }, "localname": "MacroGenicsAssetPurchaseAgreementAndMacroGenicsLicenseAgreementMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_MacroGenicsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Macro Genics Inc [Member].", "label": "Macro Genics Inc [Member]" } } }, "localname": "MacroGenicsIncMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/ScheduleOfFairValueOfWarrantsIssuedDetails", "http://proventionbio.com/role/WarrantsDetailsNarrative", "http://proventionbio.com/role/WarrantsTables" ], "xbrltype": "domainItemType" }, "PRVB_MacroGenicsLicenseAgreementAndMacroGenicsAssetPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MacroGenics License Agreement & MacroGenics Asset Purchase Agreement [Member].", "label": "MacroGenics License Agreement & MacroGenics Asset Purchase Agreement [Member]" } } }, "localname": "MacroGenicsLicenseAgreementAndMacroGenicsAssetPurchaseAgreementMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_NetProceedsFromNewSharesIssuedTransactionPlusAmgenPrivatePlacement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate net proceeds from underwritten public offering and Amgen private placement.", "label": "Aggregate net proceeds from underwritten public offering and Amgen private placement" } } }, "localname": "NetProceedsFromNewSharesIssuedTransactionPlusAmgenPrivatePlacement", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRVB_NewJerseysTechnologyBusinessTaxCertificateTransferProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Jersey's Technology Business Tax Certificate Transfer Program [Member].", "label": "New Jersey's Technology Business Tax Certificate Transfer Program [Member]" } } }, "localname": "NewJerseysTechnologyBusinessTaxCertificateTransferProgramMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_NumberOfSharesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares, description.", "label": "Number of shares, description" } } }, "localname": "NumberOfSharesDescription", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "PRVB_OperatingLossCarryforwardsExpireAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards expire amount.", "label": "[custom:OperatingLossCarryforwardsExpireAmount-0]" } } }, "localname": "OperatingLossCarryforwardsExpireAmount", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRVB_OperatingLossCarryforwardsExpireDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards expire description.", "label": "[custom:OperatingLossCarryforwardsExpireDescription]" } } }, "localname": "OperatingLossCarryforwardsExpireDescription", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "PRVB_OtherOfferingExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other offering expenses.", "label": "Other offering expenses" } } }, "localname": "OtherOfferingExpenses", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRVB_PaymentsMadeForDevelpomentAndManufacturingServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments made for develpoment and manufacturing services.", "label": "Payments made for develpoment and manufacturing services" } } }, "localname": "PaymentsMadeForDevelpomentAndManufacturingServices", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRVB_PlacementAgentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Placement Agent [Member].", "label": "Placement Agent [Member]" } } }, "localname": "PlacementAgentMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_PotentialProceedsFromInvestmentByCollaborator": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential proceeds from investment by collaborator.", "label": "Potential proceeds from investment by collaborator" } } }, "localname": "PotentialProceedsFromInvestmentByCollaborator", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRVB_ProceedsFromAtthemarketStockSales": { "auth_ref": [], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from at-the-market stock sales, net" } } }, "localname": "ProceedsFromAtthemarketStockSales", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PRVB_ProceedsFromIssuanceSaleOfEquity": { "auth_ref": [], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from underwritten public offering, net.", "label": "Proceeds from underwritten public offering, net" } } }, "localname": "ProceedsFromIssuanceSaleOfEquity", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PRVB_ProceedsFromNetOperatingLossSale": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from New Jersey NOL sale.", "label": "Proceeds from NJ NOL sale" } } }, "localname": "ProceedsFromNetOperatingLossSale", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRVB_ReclassificationOfPreferredStockWarrantLiabilityToStockholdersEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification of Series A Preferred Stock warrant liability to stockholders&#8217; equity.", "label": "Reclassification of Series A Preferred Stock warrant liability to stockholders\u2019 equity" } } }, "localname": "ReclassificationOfPreferredStockWarrantLiabilityToStockholdersEquity", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PRVB_ResearchDevelopmentAndManufacturingFundingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research Development and Manufacturing Funding [Member].", "label": "Research Development and Manufacturing Funding [Member]" } } }, "localname": "ResearchDevelopmentAndManufacturingFundingMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_ScheduleOfFairValueOfWarrantsIssuedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of fair value of warrants issued [Table Text Block]", "label": "SCHEDULE OF FAIR VALUE OF WARRANTS ISSUED" } } }, "localname": "ScheduleOfFairValueOfWarrantsIssuedTableTextBlock", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "PRVB_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Supplemental Balance Sheet Information [Table Text Block]", "label": "SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION" } } }, "localname": "ScheduleOfSupplementalBalanceSheetInformationTableTextBlock", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "PRVB_SecondIndicationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second Indication [Member]", "label": "Second Indication [Member]" } } }, "localname": "SecondIndicationMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_SeriesAConvertibleRedeemablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Convertible Redeemable Preferred Stock [Member]" } } }, "localname": "SeriesAConvertibleRedeemablePreferredStockMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_SeriesAOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Offering [Member]" } } }, "localname": "SeriesAOfferingMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock in connection with private placement with Amgen, shares.", "label": "Issuance of common stock in connection with private placement with Amgen, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConnectionWithPrivatePlacement", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "PRVB_StockIssuedDuringPeriodSharesInitialPublicOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock in connection with initial public offering, net of issuance costs, shares.", "label": "Issuance of common stock in connection with initial public offering, net of issuance costs, shares" } } }, "localname": "StockIssuedDuringPeriodSharesInitialPublicOffering", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "PRVB_StockIssuedDuringPeriodSharesPublicFollowOnOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock in connection with public follow on offering, net of issuance costs, shares" } } }, "localname": "StockIssuedDuringPeriodSharesPublicFollowOnOffering", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "PRVB_StockIssuedDuringPeriodSharesWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share warrants (or share units) exercised during the current period.", "label": "Issuance of common stock in connection with warrant exercises, shares" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "PRVB_StockIssuedDuringPeriodValueConnectionWithPrivatePlacement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock in connection with private placement with Amgen.", "label": "Issuance of common stock in connection with private placement with Amgen" } } }, "localname": "StockIssuedDuringPeriodValueConnectionWithPrivatePlacement", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "PRVB_StockIssuedDuringPeriodValueInitialPublicOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock in connection with initial public offering, net of issuance costs.", "label": "Issuance of common stock in connection with initial public offering, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueInitialPublicOffering", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "PRVB_StockIssuedDuringPeriodValuePublicFollowOnOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock in connection with public follow on offering, net of issuance costs.", "label": "Issuance of common stock in connection with public follow on offering, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValuePublicFollowOnOffering", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "PRVB_StockIssuedDuringPeriodValueWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock warrants.", "label": "Issuance of common stock in connection with warrant exercises" } } }, "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "PRVB_StockOptionOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Option One [Member].", "label": "Stock Option One [Member]" } } }, "localname": "StockOptionOneMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_StockOptionTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Option Two [Member].", "label": "Stock Option Two [Member]" } } }, "localname": "StockOptionTwoMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_StockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options [Member]" } } }, "localname": "StockOptionsMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "PRVB_StockbasedConsiderationInConnectionWithAcquisitionOfProductRights": { "auth_ref": [], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Stock-based consideration in connection with acquisition of product rights (Note 6)" } } }, "localname": "StockbasedConsiderationInConnectionWithAcquisitionOfProductRights", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PRVB_ToleranceTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tolerance Therapeutics, Inc [Member].", "label": "Tolerance Therapeutics, Inc. [Member]" } } }, "localname": "ToleranceTherapeuticsIncMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_TwoThousandAndTwentyInducementPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand and Twenty Inducement Plan [Member].", "label": "Two Thousand and Twenty Inducement Plan [Member]" } } }, "localname": "TwoThousandAndTwentyInducementPlanMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_TwoThousandSeventeenPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Seventeen Plan [Member].", "label": "Two Thousand Seventeen Plan [Member]" } } }, "localname": "TwoThousandSeventeenPlanMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_UnderwritersFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "underwriters' fees and expenses.", "label": "Underwriter's fee" } } }, "localname": "UnderwritersFees", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRVB_UnderwritersOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriter's Option [Member]", "label": "Underwriter's Option [Member]" } } }, "localname": "UnderwritersOptionMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_UnderwrittenPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwritten Public Offering [Member]", "label": "Underwritten Public Offering [Member]" } } }, "localname": "UnderwrittenPublicOfferingMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_UpfrontPaymentReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront payment receivable.", "label": "Upfront payment receivable" } } }, "localname": "UpfrontPaymentReceivable", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRVB_VactechMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vactech [Member].", "label": "Vactech [Member]" } } }, "localname": "VactechMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PRVB_WarrantLiabilityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant liability" } } }, "localname": "WarrantLiabilityPolicyTextBlock", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "PRVB_WarrantsIssuedDuringPeriodFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrants issued during period, fair value.", "label": "Warrants issued during period, fair value", "verboseLabel": "Fair value of warrant issued" } } }, "localname": "WarrantsIssuedDuringPeriodFairValue", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PRVB_WarrantsIssuedDuringPeriodValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Fair value of warrants issued in connection with initial public offering of common stock" } } }, "localname": "WarrantsIssuedDuringPeriodValue", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "PRVB_WarrantsIssuedInConnectionWithAcquisitionOfProductRights": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrants issued in connection with acquisition of product rights.", "label": "Fair value of warrants issued in connection with the acquisition of product rights" } } }, "localname": "WarrantsIssuedInConnectionWithAcquisitionOfProductRights", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "PRVB_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "PRVB_WarrantsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants [Text Block]", "label": "WARRANTS" } } }, "localname": "WarrantsTextBlock", "nsuri": "http://proventionbio.com/20201231", "presentation": [ "http://proventionbio.com/role/Warrants" ], "xbrltype": "textBlockItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r399", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://proventionbio.com/role/ScheduleOfFairValueOfWarrantsIssuedDetails", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative", "http://proventionbio.com/role/WarrantsDetailsNarrative", "http://proventionbio.com/role/WarrantsTables" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/ScheduleOfFairValueOfWarrantsIssuedDetails", "http://proventionbio.com/role/WarrantsTables" ], "xbrltype": "stringItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r399", "r401", "r402" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://proventionbio.com/role/ScheduleOfFairValueOfWarrantsIssuedDetails", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative", "http://proventionbio.com/role/WarrantsDetailsNarrative", "http://proventionbio.com/role/WarrantsTables" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_MaximumMember": { "auth_ref": [ "r182", "r183", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r365", "r367" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://proventionbio.com/role/StockOptionsDetailsNarrative", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r182", "r183", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r365", "r367" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://proventionbio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r162", "r182", "r183", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r365", "r367" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://proventionbio.com/role/StockOptionsDetailsNarrative", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r162", "r182", "r183", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r365", "r367" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://proventionbio.com/role/StockOptionsDetailsNarrative", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r135", "r136", "r160", "r161", "r366", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r135", "r136", "r160", "r161", "r366", "r375", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r137", "r313" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "stpr_NJ": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW JERSEY" } } }, "localname": "NJ", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "ACCRUED EXPENSES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://proventionbio.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r68" ], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization of premium and discounts on marketable securities" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r6", "r7", "r32" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued compensation" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://proventionbio.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses and other current liabilities", "verboseLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets", "http://proventionbio.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r6", "r7", "r32" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r26", "r150" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r17", "r40", "r41", "r42", "r355", "r372", "r373" ], "calculation": { "http://proventionbio.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets", "http://proventionbio.com/role/ScheduleOfAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r39", "r42", "r45", "r81", "r82", "r83", "r262", "r368", "r369" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r15", "r218" ], "calculation": { "http://proventionbio.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r81", "r82", "r83", "r215", "r216", "r217" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r185", "r187", "r221", "r222" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive securities excluded from computation of earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative", "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r77", "r121", "r129", "r133", "r145", "r258", "r263", "r283", "r344", "r354" ], "calculation": { "http://proventionbio.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r37", "r77", "r145", "r258", "r263", "r283" ], "calculation": { "http://proventionbio.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r274" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Fair value of assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Fair Value" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r140" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAndHeldToMaturitySecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt and equity financial instruments classified as either held-to-maturity or available-for-sale.", "label": "Available-for-sale Securities and Held-to-maturity Securities" } } }, "localname": "AvailableForSaleSecuritiesAndHeldToMaturitySecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/CashCashEquivalentsAndMarketableSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r188", "r213" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r268", "r269" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position)." } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r1", "r80", "r118" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/DescriptionOfBusinessAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r23", "r69" ], "calculation": { "http://proventionbio.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "verboseLabel": "Cash and Cash Equivalents, at Carrying Value" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets", "http://proventionbio.com/role/CashCashEquivalentsAndMarketableSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://proventionbio.com/role/ScheduleOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Cash and Cash Equivalents [Line Items]" } } }, "localname": "CashAndCashEquivalentsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r9", "r70", "r75" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash, cash equivalents and concentration of credit risk" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).", "label": "CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES" } } }, "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/CashCashEquivalentsAndMarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r64", "r69", "r74" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r64", "r284" ], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r76", "r77", "r95", "r96", "r97", "r100", "r102", "r108", "r109", "r110", "r145", "r283" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrant exercise price", "verboseLabel": "Exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://proventionbio.com/role/ScheduleOfFairValueOfWarrantsIssuedDetails", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of warrants to purchase common stock", "verboseLabel": "Warrants to purchase" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://proventionbio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Warrants outstanding, shares" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r34", "r154", "r346", "r359" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies (Note 6)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r81", "r82" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheetsParenthetical", "http://proventionbio.com/role/CapitalizationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheetsParenthetical", "http://proventionbio.com/role/CapitalizationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheetsParenthetical", "http://proventionbio.com/role/CapitalizationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r14", "r157" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheetsParenthetical", "http://proventionbio.com/role/CapitalizationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r14" ], "calculation": { "http://proventionbio.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.0001 par value; 100,000,000 shares authorized; 56,517,891 shares issued and outstanding at December 31, 2020; 47,658,361 shares issued and outstanding at December 31, 2019" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r48", "r50", "r51", "r57", "r350", "r362" ], "calculation": { "http://proventionbio.com/role/StatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r71", "r72", "r73" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r163", "r178", "r374" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r78", "r242", "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current: Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfComponentsOfIncomeTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r78", "r242", "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current: State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfComponentsOfIncomeTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r71", "r73" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Conversion of Series A Preferred Stock to common stock upon completion of IPO" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "sharesItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r78", "r243", "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred: Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfComponentsOfIncomeTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r78", "r243", "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred: State", "verboseLabel": "Income tax benefit from state income taxes" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative", "http://proventionbio.com/role/ScheduleOfComponentsOfIncomeTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r233" ], "calculation": { "http://proventionbio.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred tax assets, gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative", "http://proventionbio.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r235" ], "calculation": { "http://proventionbio.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r240", "r241" ], "calculation": { "http://proventionbio.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "NOL Carryforward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "auth_ref": [ "r240", "r241" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r240", "r241" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r240", "r241" ], "calculation": { "http://proventionbio.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "verboseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r238", "r240", "r241" ], "calculation": { "http://proventionbio.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Federal research and development credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r240", "r241" ], "calculation": { "http://proventionbio.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Equity compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r234" ], "calculation": { "http://proventionbio.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r181" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Retirement plan contributions" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/RetirementSavingsPlanDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r67", "r148" ], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/FixedAssetsDetailsNarrative", "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of defined contribution pension and other postretirement plans.", "label": "Employee contribution description" } } }, "localname": "DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/RetirementSavingsPlanDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "STOCK OPTIONS" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StockOptions" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per common share, basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfComputationOfBasicAndDilutedLossPerShareDetails", "http://proventionbio.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r75", "r103", "r104" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net loss per common share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r103", "r104", "r105", "r106" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "NET LOSS PER SHARE OF COMMON STOCK" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/NetLossPerShareOfCommonStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Tax Rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfEffectiveTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r228", "r250" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Tax Provision at statutory tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfEffectiveTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r228", "r250" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfEffectiveTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": { "auth_ref": [ "r228", "r250" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.", "label": "Orphan drug credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfEffectiveTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r228", "r250" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Sale of NJ net operating losses" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfEffectiveTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.", "label": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfEffectiveTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r228", "r250" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "State income taxes, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfEffectiveTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfStock-basedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r212" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r81", "r82", "r83", "r85", "r90", "r92", "r107", "r146", "r157", "r159", "r215", "r216", "r217", "r245", "r246", "r285", "r286", "r287", "r288", "r289", "r291", "r368", "r369", "r370" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://proventionbio.com/role/StatementOfStockholdersEquity", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r67", "r155" ], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://proventionbio.com/role/StatementsOfComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Change in fair value of warrant liability", "negatedLabel": "Change in fair value of warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows", "http://proventionbio.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r274", "r275", "r276", "r280" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r163", "r165", "r166", "r167", "r168", "r169", "r170", "r178", "r275", "r320", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "FAIR VALUE OF ASSETS AND LIABILITIES" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/FairValueOfAssetsAndLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r163", "r165", "r170", "r178", "r275", "r320" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r163", "r165", "r170", "r178", "r275", "r321" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r163", "r165", "r166", "r167", "r168", "r169", "r170", "r178", "r275", "r322" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r163", "r165", "r166", "r167", "r168", "r169", "r170", "r178", "r320", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r75", "r281", "r282" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Financial instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r75", "r293" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign currency translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r59" ], "calculation": { "http://proventionbio.com/role/StatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfStock-basedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://proventionbio.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r54", "r121", "r128", "r131", "r132", "r134", "r343", "r347", "r351", "r363" ], "calculation": { "http://proventionbio.com/role/StatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income tax benefit" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative", "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/ScheduleOfStock-basedCompensationExpenseDetails", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative", "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/ScheduleOfStock-basedCompensationExpenseDetails", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r229", "r231", "r237", "r247", "r251", "r253", "r254", "r255" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r78", "r91", "r92", "r120", "r227", "r248", "r252", "r364" ], "calculation": { "http://proventionbio.com/role/StatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax benefit", "negatedLabel": "Income tax benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfComponentsOfIncomeTaxBenefitsDetails", "http://proventionbio.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r52", "r75", "r225", "r226", "r231", "r232", "r236", "r244", "r376" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r66" ], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "auth_ref": [ "r66" ], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.", "label": "Increase (Decrease) in Accrued Interest Receivable, Net", "negatedLabel": "Accrued interest receivable" } } }, "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r66" ], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r66" ], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r66" ], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndOtherIncome": { "auth_ref": [], "calculation": { "http://proventionbio.com/role/StatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).", "label": "Interest income" } } }, "localname": "InterestAndOtherIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r304", "r306" ], "calculation": { "http://proventionbio.com/role/ScheduleOfLeaseCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease costs" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "SCHEDULE OF LEASE COSTS" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee Disclosure [Abstract]" } } }, "localname": "LesseeDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDescription": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's operating lease.", "label": "Description on lease" } } }, "localname": "LesseeOperatingLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "SCHEDULE OF MATURITIES OF LEASE LIABILITIES" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r305" ], "calculation": { "http://proventionbio.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r305" ], "calculation": { "http://proventionbio.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r305" ], "calculation": { "http://proventionbio.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r305" ], "calculation": { "http://proventionbio.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r305" ], "calculation": { "http://proventionbio.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r305" ], "calculation": { "http://proventionbio.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r305" ], "calculation": { "http://proventionbio.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r305" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Less: present value discount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r30", "r77", "r130", "r145", "r259", "r263", "r264", "r283" ], "calculation": { "http://proventionbio.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r20", "r77", "r145", "r283", "r345", "r357" ], "calculation": { "http://proventionbio.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r33", "r77", "r145", "r259", "r263", "r264", "r283" ], "calculation": { "http://proventionbio.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r3", "r31" ], "calculation": { "http://proventionbio.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "verboseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfFairValueOfWarrantsIssuedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfFairValueOfWarrantsIssuedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputOptionVolatilityMember": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns.", "label": "Measurement Input, Option Volatility [Member]" } } }, "localname": "MeasurementInputOptionVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfFairValueOfWarrantsIssuedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfFairValueOfWarrantsIssuedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfFairValueOfWarrantsIssuedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfFairValueOfWarrantsIssuedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r64" ], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r64" ], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r64", "r65", "r68" ], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r46", "r49", "r55", "r68", "r77", "r84", "r86", "r87", "r88", "r89", "r91", "r92", "r98", "r121", "r128", "r131", "r132", "r134", "r145", "r283", "r348", "r360" ], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://proventionbio.com/role/StatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "verboseLabel": "Net loss, basic" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfComputationOfBasicAndDilutedLossPerShareDetails", "http://proventionbio.com/role/StatementOfStockholdersEquity", "http://proventionbio.com/role/StatementsOfCashFlows", "http://proventionbio.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r86", "r87", "r88", "r89", "r93", "r94", "r99", "r102", "r121", "r128", "r131", "r132", "r134" ], "calculation": { "http://proventionbio.com/role/StatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net loss attributable to common stockholders", "totalLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfComputationOfBasicAndDilutedLossPerShareDetails", "http://proventionbio.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash financing transactions:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "integerItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://proventionbio.com/role/StatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r121", "r128", "r131", "r132", "r134" ], "calculation": { "http://proventionbio.com/role/StatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r299", "r306" ], "calculation": { "http://proventionbio.com/role/ScheduleOfLeaseCostsDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r296" ], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Non-cash operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r295" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r295" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Lease liabilities Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r295" ], "calculation": { "http://proventionbio.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liabilities, long-term", "verboseLabel": "Lease liabilities Non-Current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets", "http://proventionbio.com/role/ScheduleOfSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r294" ], "calculation": { "http://proventionbio.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets", "verboseLabel": "Lease right-of-use assets Non-current" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets", "http://proventionbio.com/role/ScheduleOfSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r303", "r306" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted average discount rate Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfSupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r302", "r306" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining lease term Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfSupplementalBalanceSheetInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r238" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Net operating loss" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeAxis": { "auth_ref": [ "r156", "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.", "label": "Option Indexed to Issuer's Equity, Type [Axis]" } } }, "localname": "OptionIndexedToIssuersEquityTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding." } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_OptionMember": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).", "label": "Options Held [Member]" } } }, "localname": "OptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r6", "r7", "r8", "r32" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r27" ], "calculation": { "http://proventionbio.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r47", "r50", "r53", "r56", "r157", "r285", "r290", "r291", "r349", "r361" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": { "auth_ref": [ "r40", "r43", "r44", "r141" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.", "label": "Current period changes in fair value before reclassifications, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodAfterTax": { "auth_ref": [ "r44", "r143" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for unrealized gain (loss) of investment classified as available-for-sale transferred to equity method.", "label": "Amounts reclassified from accumulated other comprehensive income (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodAfterTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r38", "r40" ], "calculation": { "http://proventionbio.com/role/StatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Unrealized gain (loss) on marketable securities", "verboseLabel": "Unrealized gain (loss) on marketable securities, net of tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity", "http://proventionbio.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r62" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Underwriting discounts and commissions" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r139" ], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchase of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r60" ], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of fixed assets" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payment for Pension and Other Postretirement Benefits [Abstract]" } } }, "localname": "PensionAndOtherPostretirementBenefitContributionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r162", "r164", "r170", "r171", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r184" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "RETIREMENT SAVINGS PLAN" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/RetirementSavingsPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r188", "r213" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheetsParenthetical", "http://proventionbio.com/role/CapitalizationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheetsParenthetical", "http://proventionbio.com/role/CapitalizationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheetsParenthetical", "http://proventionbio.com/role/CapitalizationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheetsParenthetical", "http://proventionbio.com/role/CapitalizationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r13" ], "calculation": { "http://proventionbio.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.0001 par value; 25,000,000 shares authorized; no shares issued or outstanding at December 31, 2020 and December 31, 2019" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r21", "r22" ], "calculation": { "http://proventionbio.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/LiquidityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r61" ], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from initial public offering, net", "verboseLabel": "Proceeds from Issuance Initial Public Offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r61" ], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from private placement with Amgen", "verboseLabel": "Proceeds from Issuance of Private Placement" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.", "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock" } } }, "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r61", "r214" ], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from stock option exercises", "verboseLabel": "Cash proceeds from options exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAggregatedIntrinsicValueOfStockOptionExercisedDetails", "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r0", "r46", "r49", "r63", "r77", "r84", "r91", "r92", "r121", "r128", "r131", "r132", "r134", "r145", "r257", "r260", "r261", "r265", "r266", "r283", "r351" ], "calculation": { "http://proventionbio.com/role/StatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r26", "r151" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r153", "r377", "r378", "r379" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "FIXED ASSETS" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/FixedAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r75", "r147" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Fixed assets estimated useful life years" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r25", "r149" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "verboseLabel": "Fixed assets, net" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfFixedAssetsDetails", "http://proventionbio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r10", "r11", "r151", "r358" ], "calculation": { "http://proventionbio.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Fixed assets, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets", "http://proventionbio.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r24", "r75", "r151", "r377", "r378" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Fixed assets, net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r10", "r151" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "SCHEDULE OF FIXED ASSETS" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/FixedAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r10", "r149" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r172", "r310", "r311" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r310", "r314" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related party transaction, amounts of transaction" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r172", "r310", "r314", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r308", "r309", "r311", "r315", "r316" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r224", "r389" ], "calculation": { "http://proventionbio.com/role/StatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative", "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/ScheduleOfStock-basedCompensationExpenseDetails", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r75", "r224" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://proventionbio.com/role/ScheduleOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r159", "r218", "r356", "r371", "r373" ], "calculation": { "http://proventionbio.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets", "http://proventionbio.com/role/LiquidityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r81", "r82", "r83", "r85", "r90", "r92", "r146", "r215", "r216", "r217", "r245", "r246", "r368", "r370" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r301", "r306" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-use assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://proventionbio.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesCommissionsAndFees": { "auth_ref": [ "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).", "label": "Sales Commissions and Fees" } } }, "localname": "SalesCommissionsAndFees", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "SCHEDULE OF ACCRUED EXPENSES" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r42", "r290", "r291" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/CashCashEquivalentsAndMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/NetLossPerShareOfCommonStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "SCHEDULE OF AVAILABLE FOR SALE SECURITIES" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/CashCashEquivalentsAndMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCapitalizationEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Capitalization, Equity [Line Items]" } } }, "localname": "ScheduleOfCapitalizationEquityLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.", "label": "Schedule of Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "SCHEDULE OF COMPONENTS OF INCOME TAX BENEFITS" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "SCHEDULE OF DEFERRED TAX ASSETS" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "SCHEDULE OF COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/NetLossPerShareOfCommonStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "SCHEDULE OF EFFECTIVE TAX RATE" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r187", "r211", "r220" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfStock-basedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r274", "r275" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/FairValueOfAssetsAndLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r26", "r151" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfFixedAssetsDetails", "http://proventionbio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r79", "r312", "r314" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r199", "r200", "r203" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StockOptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year.", "label": "SCHEDULE OF AGGREGATED INTRINSIC VALUE OF STOCK OPTION EXERCISED" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StockOptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r188", "r213" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r193", "r200", "r203" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "SUMMARY OF STOCK OPTION ACTIVITY" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StockOptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "SCHEDULE OF SHARE-BASED COMPENSATION VALUATION OF ASSUMPTIONS" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StockOptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r75", "r122", "r123", "r124", "r125", "r126", "r127", "r135" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment and geographic information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r66" ], "calculation": { "http://proventionbio.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation expense", "verboseLabel": "Total stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfStock-basedCompensationExpenseDetails", "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividends" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfShare-basedCompensationValuationOfAssumptionsDetails", "http://proventionbio.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfShare-basedCompensationValuationOfAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfShare-basedCompensationValuationOfAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Number of options authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Stock Options Underlying Shares, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r202" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Aggregate intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAggregatedIntrinsicValueOfStockOptionExercisedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Stock Options Underlying Shares, Forfeited or expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Weighted-Average Exercise Price, Forfeited or expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Stock Options Underlying Shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r213" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Intrinsic Value, Outstanding Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r195", "r213" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Number of options outstanding", "periodEndLabel": "Stock Options Underlying Shares, Outstanding ending balance", "periodStartLabel": "Stock Options Underlying Shares, Outstanding beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StockOptionsDetailsNarrative", "http://proventionbio.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price, Outstanding ending balance", "periodStartLabel": "Weighted-Average Exercise Price, Outstanding beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r186", "r191" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted-Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted-Average Exercise Price, Granted", "verboseLabel": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfShare-basedCompensationValuationOfAssumptionsDetails", "http://proventionbio.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r75", "r188", "r192" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Option exercisable expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r206", "r219" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfShare-basedCompensationValuationOfAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r213" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Intrinsic Value, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted-Average Remaining Contractual Term, Outstanding Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Shares, Outstanding, Ending Balance", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r12", "r13", "r14", "r76", "r77", "r95", "r96", "r97", "r100", "r102", "r108", "r109", "r110", "r145", "r157", "r283" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r36", "r81", "r82", "r83", "r85", "r90", "r92", "r107", "r146", "r157", "r159", "r215", "r216", "r217", "r245", "r246", "r285", "r286", "r287", "r288", "r289", "r291", "r368", "r369", "r370" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://proventionbio.com/role/StatementOfStockholdersEquity", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r81", "r82", "r83", "r107", "r330" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/ScheduleOfFairValueOfWarrantsIssuedDetails", "http://proventionbio.com/role/ScheduleOfSupplementalBalanceSheetInformationDetails", "http://proventionbio.com/role/StatementOfStockholdersEquity", "http://proventionbio.com/role/WarrantsDetailsNarrative", "http://proventionbio.com/role/WarrantsTables" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r35", "r157", "r158", "r159" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Issuance of common stock upon conversion of Series A Convertible Redeemable Preferred Stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r13", "r14", "r157", "r159" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of common stock in connection with underwritten public offering, net of issuance costs, shares", "verboseLabel": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/StatementOfStockholdersEquity", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Issuance of common stock in connection with at-the-market stock sales, net of issuance costs, shares", "verboseLabel": "Number of warrants issuance shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/StatementOfStockholdersEquity", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r13", "r14", "r157", "r159", "r197" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Issuance of common stock in connection with stock option exercises, shares", "negatedLabel": "Stock Options Underlying Shares, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity", "http://proventionbio.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r36", "r157", "r159" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Issuance of common stock upon conversion of Series A Convertible Redeemable Preferred Stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r13", "r14", "r157", "r159" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of common stock in connection with underwritten public offering, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Issuance of common stock in connection with at-the-market stock sales, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r36", "r157", "r159" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Issuance of common stock in connection with stock option exercises" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r14", "r18", "r19", "r77", "r138", "r145", "r283" ], "calculation": { "http://proventionbio.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets", "http://proventionbio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r292", "r318" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/StockOptionsDetailsNarrative", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r292", "r318" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r292", "r318" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/StockOptionsDetailsNarrative", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r292", "r318" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/StockOptionsDetailsNarrative", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r317", "r319" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/LiquidityDetailsNarrative", "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://proventionbio.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r238" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": { "auth_ref": [], "calculation": { "http://proventionbio.com/role/StatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.", "label": "Accretion of Series A Convertible Redeemable Preferred Stock", "negatedLabel": "Accretion on Series A Convertible Redeemable Preferred Stock", "negatedTerseLabel": "Accretion of Series A Convertible Redeemable Preferred Stock to redemption value" } } }, "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfComputationOfBasicAndDilutedLossPerShareDetails", "http://proventionbio.com/role/StatementOfStockholdersEquity", "http://proventionbio.com/role/StatementsOfCashFlows", "http://proventionbio.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/IncomeTaxesDetailsNarrative", "http://proventionbio.com/role/LicenseAndOtherAgreementsDetailsNarrative", "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://proventionbio.com/role/SubsequentEventsDetailsNarrative", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r163", "r178", "r352" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r111", "r112", "r113", "r114", "r115", "r116", "r117" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r300", "r306" ], "calculation": { "http://proventionbio.com/role/ScheduleOfLeaseCostsDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable lease costs" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants and Rights Note Disclosure [Abstract]" } } }, "localname": "WarrantsAndRightsNoteDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Fair value assumptions measurement input percentage" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfFairValueOfWarrantsIssuedDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Fair value assumptions measurement input term", "terseLabel": "Warrant term", "verboseLabel": "Warrants term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/RelatedPartyTransactionsDetailsNarrative", "http://proventionbio.com/role/ScheduleOfFairValueOfWarrantsIssuedDetails", "http://proventionbio.com/role/WarrantsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted average common shares outstanding, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://proventionbio.com/role/ScheduleOfComputationOfBasicAndDilutedLossPerShareDetails", "http://proventionbio.com/role/StatementsOfComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r106": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r118": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=121548190&loc=d3e32804-111569" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r223": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r255": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "83", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121636179&loc=d3e34841-113949" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90193-114008" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90198-114008" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90205-114008" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519491&loc=d3e90476-114009" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r293": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r307": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r316": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r319": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r390": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r391": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r392": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r393": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r394": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r395": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r396": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r397": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r398": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r399": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r400": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r401": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r402": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r403": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r404": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r405": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r406": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r407": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r408": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724391-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r80": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" } }, "version": "2.1" } ZIP 102 0001493152-21-004781-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-004781-xbrl.zip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�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

    9$ M,Y_ )L5EO,;237,@B,CZRN_P_X!BHHQR\S\3&N5CTEY 6!VC2DPI=FBEFFLQ MAMIO+/ZOD/J/4RQ,^6G7W'Q__6_.$9D$I\?D='A$\%LVR8]/^B92NRS3+1'G M=0X>+%0=7?2]1,6*,+T M>!#SW\] 1V &S1,017H<.Q_$*;SN*S'P I7;MN/!^M3T[GVP 19VVOD)?VZK MC) J+=^KGDG>6UU[J(YM&?U8*4H44$E7UJ-&+MFNS(_MP3Q&3,6UELK=9ZU[Y29ZUE MQIPOMIBR"Z%7-1C'C,Y7OI3 MZV<"V<:EW4;7X!(#\S2[151$.@_/Z#N-E(CF:5M&BZ%Y>Q=SC^FQFH; F4$W MV."0+="0 AY@9]?;*GX\16BXI4@-YR _('[G4 M7&IX0 "_%AP<"41M#TM*AKYU!RY^V\$C7EE3\Q+^LO>CUX8<.>8KCW=')]77 MQVY6/:N>_F^*W8TL?>@?>%#AW/8]UAL6%O9 .7"R=(542HXUCC,P-2+^<0VY M^XYT\@$*+GH<$V73.I6(&K:O7$F6*8RO]:I=GIC;J;A_L=(7)0L1H' MZ^X0$MNG^6 "_O'/3V1-P:.F?/33DG,2ZRP&\'SBM/K4:^.AT1&K,\M79SO= MD2B"@3YD5BRP]-8NV\=+35B.,?#C=:\!ZPK4',5KVS"J"U%X&Z:REZ,&>UJB ML3/0:1'C/(TL&O!DOK_@BM+NWN4TON[?'?DEVNP Z"(.X.9#E;K9T_(A<\[8 M1E49TAPHA\_GQBLBF4_,T$BPQ9.XB?M4[FGV0ZOT<6H)Z57O<.!FIG91S9)\ MPG,USY;RZTQ*YP5O@2W0=G!%*)P;Y79N4MV'V'V<!+)_^2THKFHBUFZU$[=4 L-C)&$A]K " 7 M$D7^+-O0.HW/R#GB;_).63V7#LLFL5_8IX]K."VKL)+$7G: #RP4>Z=R_#& M8W;MI<.R/FO>IDR[90>>D]F2XV&(-U5ZGNU[%S2?$2?Q5=EA@J6()3_';S>, MYUBEPV4Z0P ^P_K5IPFE]KYTC)6NECJ9?>I(**Y9YNQ?HK?E668,>B=S"ZQ< MM5NF=W032"E94/GAX$M=,HC'VRJ/9&.AKALD1I_;GT]N)^<5@@XOHUN@$C9P MV;AV3HF*96><\5_C5[4&O)*5EM:6WN/YR#XASSXAA"@E\P+24T2E+5$ [$]K MTZ%HRYB*T,K*X)<$7UM4Z,V2CIB[-55S)TO?>^^6@U$.(AX;UL-?[S>*!,V) M:_;@?C15^]W#H'1]&GLVO/>?KRI42)TUS#Q61G,S3OQ0J7P+_@M0@$ M"#P->Q-9GD7*2X*YV76"E804R:,U ;Q0W>ZOQ:/%*WI\T<6A"]HQ\>>4PFLX M58UM%)S\UU<"37N3K_L4'KZ8W[W5_N(E=IIVVU.!02*%E7@7>K<<$R1.[F3D MS6VW;O-Z%XU"L\+K^FT9,-VBVQYV@T6.T/\I$*Y5<1Y-D59IF2)I*>J^&/VQ M2 ]K,=.P*5-+R8!)Y]9?N_H%+WCKWPO>V!(\6DNC!0O0UU+8UO ^2!=! $.J M#SB+B6(W M%Y!<5O M$, ,E=VFI2>W"_7<8,5NM0:!W9E"!]L&3ZP(<*^$23#72N=VH1-'\]QY$$/! M+([YHEN!_O#ESTX#Z4RB'?WVI+-5EX!BRH:-*B>\G;KQ[>XLB0A460>1?,?. MD]A5=!-[&SGD&=E0MD\C*FCFXIA0U&J.EWK$; MP,!YM(A/*-[H?D\XZ,OM@&B)GX>=L\^X(+@S^'8@SAXKFZ8$:JDM#SLJ^MEQ M^,JN', ]PF+7IV9<\"O?)^0,'3=C]:4CJRX?0Z/:ZDS_#.ZI'*2GB,_9_";- M]K@D08SWRNB=K\S7'.NX0#\%D+R8,N62^53*1# 8?532>O7O'&876Q9"KFGY XWFD4*):I)[S, 4E^?\7CORDI M:"85Z^6 E7QC\9RD#EM.EW]V2L3J<+B=4M5H9TY _Z8WP MO4;RK0O_NV5FE#Z^A03/;$P7\#YXF/*5Z&>7X/2F0-2UKSA\3B!E$.@ MSLX3B-J&FL\6[0"L(H]8/'=C>NLR D]5-<$.M?<_!^2(5CY3L#7@B+A_K/NJ M98VK[5=-)=-5364-G"C6R%XAJ6%^G$)ZNMI;SK4*>;Z_//GG-LY+&H7R8O>4 MCL-D/T3_MK@/_?8/<@+$3=9 M_U=7DQ^!#F8DT\49\.SI9Y+BF\0<9_SET(POF .F2J;I;KN&]#9W_19.L#I& M"0*0,Q1]_%K&$ZI;7)ZF83S.^,SN%L'@/MWH!0&HFCZ+US ^1>+A+<= MQ/\B&=*(-@NVR( #[: B@H%13X/VMO!',H"L< M<">WX3D9E$E+I\<5L_?QWFAE7? ;DWV5;JVRIU2#8%*I-1!]-]'M00!D_,Z3 ML6/G;F: 2.S=%'_0ELP<&8_D S2W<9P9-U9O4=K$P2;"=LK;I+P$5L'Z+6"\ MI&X ;7)G)ZTI\WY*59J(("3 M6'\=->P*['*5OP1< MF1_]S5JOX3A&*=V-E(#]]>L+U2ZBTD MU8#/NS4]YGBP+K9AEJK QLG-3YF_ELHDDS>F4T6.:D_+H*^:88^?OBQDT%[7 ML1F)81C;<&#ET'>U&[YAJT])U]R.61X?5NW9^6HDT,_0.[- Q>)0J-F.P;#-WX\U[56CKA(2K_B7#6CS+C%/?8L%6(UX<=S-#H&&] M(5:./)/^^*7LP8)$9854OHZ6""@3HSDF4&M,1)/GK$=!5LU\K/IVBQ;9<;G/ M"(=%F+!):]T%BKM7L8%ZG_[U@5)C4P37MC,MWF)119&?&QX781I4?X%MF6ES M/=O(0@XI\E< !D 6$565O+NRGI(9Q<@ B_/PYO7O],224")"AJ>VZJ L76Y M&=6?+3K)LV3&P/V104LIDZ#.2>"'JT!HG-X) 93JCG#EL#NTK@T\I-OL!!UI MCZHU"7R*>9<.5KPCH5BE!1ABL*WPMW<[8%;'@2TLV?^V=93U+2?W]UXA62Y[ MX%=\G]-'BQ^_@<3??(FTJ,Q+\.7:*?-%O.3SQ@73=%^2D-!1DX<3++%]RG@K M^'+P6W-35/ QP\]P$'E(1['DV5=HWW8!\^5>PAE2JT_.K'/\*>5O>$/P1,(J MB%@]5CV<"NVG-[F:%O=!?!SYOVA8=/2DO4*(>8T_S#'A24,M1.!F)I)N^$^7 M++JY*B3VC\]\ '-T+9'6)U11<7PM?B MHBL#K?2?BM9W1U._!]!3!@A_)D;ENG/;"+-_F1R/F5X4_E8$7"96W$TTH*7; MF'D$E^XBEBQ]]SF_7M=S

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end

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form10-k_005.jpg begin 644 form10-k_005.jpg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end GRAPHIC 13 form10-k_006.jpg begin 644 form10-k_006.jpg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